FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Gach, J Venzon, D Monica, V Brandon, K Franchini, G Forthal, D AF Gach, Johannes Venzon, David Monica, Vaccari Brandon, Keele Franchini, Genoveffa Forthal, Donald TI Vaccine-induced Antibody that Captures but Does Not Neutralize SIVmac251 Increases the Rate of Infection after Low-dose, Repeated Rectal Challenge SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Gach, Johannes; Forthal, Donald] Univ Calif Irvine, Irvine, CA USA. [Venzon, David; Monica, Vaccari; Franchini, Genoveffa] NCI, Bethesda, MD 20892 USA. [Brandon, Keele] Leidos Biomed Res Inc, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA14.02 BP 75 EP 75 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600129 ER PT J AU Huang, Y Tomaras, G Andersen-Nissen, E Dintwe, O Morris, L Grunenberg, N Issacs, A DiazGranados, C Sinangil, F Laher, F Swann, E DeRosa, S Ferrari, G Montefiori, D Gilbert, P McElrath, J Corey, L Gray, G AF Huang, Ying Tomaras, Georgia Andersen-Nissen, Erica Dintwe, One Morris, Lynn Grunenberg, Nicole Issacs, Abby DiazGranados, Carlos Sinangil, Faruk Laher, Fatima Swann, Edith DeRosa, Stephen Ferrari, Guido Montefiori, David Gilbert, Peter McElrath, Julie Corey, Lawrence Gray, Glenda CA HVTN097 TI The Relationship between Immune Responses to Tetanus Vaccine, Hepatitis B Vaccine and a Pox-protein HIV Vaccine Regimen SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Huang, Ying; Andersen-Nissen, Erica; Grunenberg, Nicole; Issacs, Abby; DeRosa, Stephen; Gilbert, Peter; McElrath, Julie; Corey, Lawrence] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Tomaras, Georgia; Ferrari, Guido; Montefiori, David] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Andersen-Nissen, Erica] Hutchinson Ctr Res Inst South Africa, Cape Town, South Africa. [Dintwe, One] Univ Cape Town, Rondebosch, South Africa. [Morris, Lynn] Univ KwaZulu Natal, Durban, South Africa. [Morris, Lynn; Laher, Fatima; Gray, Glenda] Univ Witwatersrand, ZA-2050 Johannesburg, South Africa. [DiazGranados, Carlos] Sanofi Pasteur, Swiftwater, PA USA. [Sinangil, Faruk] Global Solut Infect Dis, Princeton, NJ USA. [Swann, Edith] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Gray, Glenda] South African Med Res Council, Tygerberg, South Africa. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA14.04 BP 76 EP 76 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600131 ER PT J AU Janes, H Cohen, K Sobieszczyk, M Frahm, N Karuna, S Sanchez, B Magaret, C Adams, E Hammer, S Gilbert, P McElrath, J AF Janes, Holly Cohen, Kristen Sobieszczyk, Magda Frahm, Nicole Karuna, Shelly Sanchez, Brittany Magaret, Craig Adams, Elizabeth Hammer, Scott Gilbert, Peter McElrath, Juliana TI Vaccine-induced CD8+T Cell Immunity Strongly Predicts Lower HIV Infection Risk in HVTN 505 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Janes, Holly; Cohen, Kristen; Frahm, Nicole; Karuna, Shelly; Sanchez, Brittany; Magaret, Craig; Gilbert, Peter; McElrath, Juliana] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Sobieszczyk, Magda; Hammer, Scott] Columbia Univ, Med Ctr, New York, NY 10027 USA. [Adams, Elizabeth] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA17.03 BP 85 EP 85 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600148 ER PT J AU Parsons, M Lloyd, S Center, R Swiderek, K LaBranche, C Montefiori, D Keele, B Lifson, J Venturi, V Davenport, M Amarasena, T Kent, S AF Parsons, Matthew Lloyd, Sarah Center, Robert Swiderek, Katherine LaBranche, Celia Montefiori, David Keele, Brandon Lifson, Jeffrey Venturi, Vanessa Davenport, Miles Amarasena, Thakshila Kent, Stephen TI Partial Efficacy of a Broadly Neutralizing Antibody against Cell-associated SHIV Infection SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Parsons, Matthew; Lloyd, Sarah; Amarasena, Thakshila; Kent, Stephen] Univ Melbourne, Melbourne, Vic 3010, Australia. [Center, Robert] Burnet Inst, Melbourne, Vic, Australia. [Swiderek, Katherine] Theraclone, Seattle, WA USA. [LaBranche, Celia; Montefiori, David] Duke Univ, Durham, NC 27706 USA. [Keele, Brandon; Lifson, Jeffrey] NCI, Bethesda, MD 20892 USA. [Venturi, Vanessa; Davenport, Miles] UNSW, Sydney, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA19.02 BP 90 EP 90 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600159 ER PT J AU Steinhardt, J Guenaga, J Mckee, K Louder, M O'Dell, S Chiang, CI Lei, L Doria-Rose, N Mascola, J Li, YX AF Steinhardt, James Guenaga, Javier McKee, Krisha Louder, Mark O'Dell, Sijy Chiang, Chi-I Lei, Lin Doria-Rose, Nicole Mascola, John Li, Yuxing TI Rational Design of Bispecific Antibodies Targeting HIV-1 Env to Achieve Enhanced Anti-viral Potency and Breadth SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Steinhardt, James; Chiang, Chi-I; Lei, Lin; Li, Yuxing] Inst Biosci & Biotechnol Res, Rockville, MD USA. [Guenaga, Javier] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, San Diego, CA USA. [McKee, Krisha; Louder, Mark; O'Dell, Sijy; Doria-Rose, Nicole; Mascola, John] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA19.01 BP 90 EP 90 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600158 ER PT J AU Hessell, AJ Jaworski, JP Pandey, S Kahl, C Reed, J Sutton, WF Stanton, JJ Pegu, A Chen, XJ Axthelm, MK Lewis, A Graham, BS Mascola, JR Sacha, JB Haigwood, NL AF Hessell, Ann J. Jaworski, J. Pablo Pandey, Shilpi Kahl, Christoph Reed, Jason Sutton, William F. Stanton, Jeffrey J. Pegu, Amarendra Chen, Xuejun Axthelm, Michael K. Lewis, Anne Graham, Barney S. Mascola, John R. Sacha, Jonah B. Haigwood, Nancy L. CA Passive Immunotherapy TI Durable Marked Attenuation and Clearance of SHIV Infection in Infant Macaques with Human Neutralizing mAbs as Post-exposure Treatment Within 48 Hours SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Hessell, Ann J.; Jaworski, J. Pablo; Pandey, Shilpi; Kahl, Christoph; Sutton, William F.; Stanton, Jeffrey J.; Axthelm, Michael K.; Lewis, Anne; Sacha, Jonah B.; Haigwood, Nancy L.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Portland, OR 97201 USA. [Hessell, Ann J.; Reed, Jason; Axthelm, Michael K.; Sacha, Jonah B.; Haigwood, Nancy L.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA. [Pegu, Amarendra; Chen, Xuejun; Graham, Barney S.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA19.03 BP 91 EP 91 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600160 ER PT J AU Lynch, R Madden, P Boritz, E Coates, E Dezure, A Koup, R Graham, B Douek, D Ledgerwood, J Mascola, J AF Lynch, Rebecca Madden, Patrick Boritz, Eli Coates, Emily Dezure, Adam Koup, Richard Graham, Barney Douek, Daniel Ledgerwood, Julie Mascola, John CA VRC 601 Study Team TI Virus Fitness after Infusion with Broadly Neutralizing Antibody VRC01 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Lynch, Rebecca] George Washington Univ, Washington, DC 20052 USA. [Lynch, Rebecca; Madden, Patrick; Boritz, Eli; Coates, Emily; Dezure, Adam; Koup, Richard; Graham, Barney; Douek, Daniel; Ledgerwood, Julie; Mascola, John] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA19.04 BP 91 EP 91 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600161 ER PT J AU Astronomo, RD Lemos, MP Narpala, S Czartoski, J Westerberg, K Fleming, L Gross, M Hural, J Tieu, HV Baden, L Rodriguez, B Hammer, S Frank, I Ochsenbauer, C Grunenberg, N Ledgerwood, JE McDermott, A Mayer, K McElrath, MJ AF Astronomo, Rena D. Lemos, Maria P. Narpala, Sandeep Czartoski, Julie Westerberg, Katharine Fleming, Lamar Gross, Mary Hural, John Hong Van Tieu Baden, Lindsey Rodriguez, Benigno Hammer, Scott Frank, Ian Ochsenbauer, Christina Grunenberg, Nicole Ledgerwood, Julie E. McDermott, Adrian Mayer, Kenneth McElrath, M. Juliana TI Rectal and Vaginal Biopsies from Men and Women Infused Intravenously with VRC01 Show Protection in Ex Vivo HIV-1 Challenge SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Astronomo, Rena D.; Lemos, Maria P.; Czartoski, Julie; Westerberg, Katharine; Fleming, Lamar; Gross, Mary; Hural, John; Grunenberg, Nicole; McElrath, M. Juliana] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Narpala, Sandeep; Ledgerwood, Julie E.; McDermott, Adrian] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Hong Van Tieu] New York Blood Ctr, New York, NY 10021 USA. [Baden, Lindsey] Brigham & Womens Hosp, Boston, MA 02115 USA. [Rodriguez, Benigno] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Hammer, Scott] Columbia Univ, Med Ctr, New York, NY 10027 USA. [Frank, Ian] Univ Penn, Philadelphia, PA 19104 USA. [Ochsenbauer, Christina] Univ Alabama Birmingham, Birmingham, AL USA. [Mayer, Kenneth] Fenway Hlth, Boston, MA USA. [Mayer, Kenneth] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Mayer, Kenneth] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA19.05 BP 92 EP 92 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600162 ER PT J AU Carballo-Dieguez, A Balan, IC Giguere, R Dolezal, C Leu, CS Brown, W Ho, T Tuswa-Haynes, C Lama, J Piper, J Richardson, B McGowan, I Cranston, RD AF Carballo-Dieguez, Alex Balan, Ivan C. Giguere, Rebecca Dolezal, Curtis Leu, Cheng-Shiun Brown, William, III Ho, Titcha Tuswa-Haynes, Camagu Lama, Javier Piper, Jeanna Richardson, Barbra McGowan, Ian Cranston, Ross D. CA MTN-017 Protocol Team TI High Levels of Adherence to a Rectal Microbicide Gel and to Oral PrEP Achieved in MTN-017 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Carballo-Dieguez, Alex; Balan, Ivan C.; Giguere, Rebecca; Dolezal, Curtis; Leu, Cheng-Shiun; Brown, William, III; Ho, Titcha; Tuswa-Haynes, Camagu] New York State Psychiat Inst & Hosp, HIV Ctr Clin & Behav Studies, New York, NY 10032 USA. [Carballo-Dieguez, Alex; Balan, Ivan C.; Giguere, Rebecca; Dolezal, Curtis; Leu, Cheng-Shiun; Brown, William, III; Ho, Titcha; Tuswa-Haynes, Camagu] Columbia Univ, New York, NY 10027 USA. [Lama, Javier] Asociac Civil Impacta Salud & Educ, Lima, Peru. [Piper, Jeanna] NIAID, Div AIDS, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Richardson, Barbra] Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. [McGowan, Ian; Cranston, Ross D.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA20.01 BP 93 EP 93 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600164 ER PT J AU Palanee-Phillips, T Roberts, S Montgomery, E Reddy, K Govender, V Naidoo, L Siva, S Gaffoor, Z Pather, A Kiweewa, FM Hlahla, K Makinini, B Bunge, K Schwartz, K Torjesen, K Brown, E Soto-Torres, L Baeten, J AF Palanee-Phillips, Thesla Roberts, Sarah Montgomery, Elizabeth Reddy, Krishnaveni Govender, Vaneshree Naidoo, Logashvari Siva, Samantha Gaffoor, Zakir Pather, Arendevi Kiweewa, Flavia Matovo Hlahla, Kudzai Makinini, Bonus Bunge, Katie Schwartz, Katie Torjesen, Kristine Brown, Elizabeth Soto-Torres, Lydia Baeten, Jared CA ASPIRE Study Team TI Frequency of Partner-related Social Harms and their Impact on Adherence to the Dapivirine Vaginal Ring during the MTN020/ASPIRE HIV Prevention Trial SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Palanee-Phillips, Thesla; Reddy, Krishnaveni] Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa. [Roberts, Sarah; Baeten, Jared] Univ Washington, Seattle, WA 98195 USA. [Montgomery, Elizabeth] RTI Int, Womens Global Hlth Imperat, Res Triangle Pk, NC USA. [Govender, Vaneshree; Naidoo, Logashvari; Siva, Samantha; Gaffoor, Zakir; Pather, Arendevi] MRC, Tygerberg, South Africa. [Kiweewa, Flavia Matovo] MU JHU Res Collaborat, Kampala, Uganda. [Hlahla, Kudzai] UC UCSF Collaborat Res Programme, Harare, Zimbabwe. [Makinini, Bonus] John Hopkins Univ Res Project, Coll Med, Blantyre, Malawi. [Bunge, Katie] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schwartz, Katie; Torjesen, Kristine] FHI 360, Durham, NC USA. [Brown, Elizabeth] FHCRC SCHARP, Seattle, WA USA. [Soto-Torres, Lydia] NIAID, Div AIDS, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA20.03 BP 94 EP 94 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600166 ER PT J AU Husnik, MJ Brown, ER Marzinke, M Livant, E Palanee-Phillips, T Hendrix, C Kiweewa, FM Nair, G Soto-Torres, LE Schwartz, K Hillier, SL Baeten, JM AF Husnik, Marla J. Brown, Elizabeth R. Marzinke, Mark Livant, Edward Palanee-Phillips, Thesla Hendrix, Craig Kiweewa, Flavia Matovu Nair, Gonasagrie Soto-Torres, Lydia E. Schwartz, Katie Hillier, Sharon L. Baeten, Jared M. TI Novel Implementation of a Real-time Adherence Monitoring Strategy within a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Husnik, Marla J.; Brown, Elizabeth R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Marzinke, Mark; Hendrix, Craig] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Livant, Edward] Magee Womens Res Inst & Fdn, Pittsburgh, PA USA. [Palanee-Phillips, Thesla] Univ Witwatersrand, ZA-2050 Johannesburg, South Africa. [Kiweewa, Flavia Matovu] MUJHU Res Collaborat, Kampala, Uganda. [Nair, Gonasagrie] Ctr AIDS Programme Res South Africa, Durban, South Africa. [Soto-Torres, Lydia E.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Schwartz, Katie] FHI 360, Durham, NC USA. [Hillier, Sharon L.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Baeten, Jared M.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA20.05 BP 95 EP 95 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600168 ER PT J AU Kwong, PD Stewart-Jones, GBE Xu, K Zhou, TQ AF Kwong, Peter D. Stewart-Jones, Guillaume B. E. Xu, Kai Zhou, Tongqing TI Targeted Deglycosylation as a Means of Vaccine Focusing SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Kwong, Peter D.; Stewart-Jones, Guillaume B. E.; Xu, Kai; Zhou, Tongqing] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA21.02 BP 96 EP 96 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600171 ER PT J AU Chen, XJ Duan, HY Cheng, C Boyington, J Tian, M Cheng, KL Wang, LS Zhang, Y Frederick, A Mascola, J AF Chen, Xuejun Duan, Hongying Cheng, Cheng Boyington, Jeffery Tian, Ming Cheng, Kwei-Ling Wang, Lingshu Zhang, Yi Frederick, Alt Mascola, John TI Glycan-masking Improves the CD4bs-specificity of Antibodies Elicited by eOD-GT8 60mer SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Chen, Xuejun; Duan, Hongying; Cheng, Cheng; Boyington, Jeffery; Wang, Lingshu; Zhang, Yi; Mascola, John] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA. [Tian, Ming; Cheng, Kwei-Ling; Frederick, Alt] Harvard Med Sch, Boston, MA USA. [Tian, Ming; Cheng, Kwei-Ling; Frederick, Alt] Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA21.06LB BP 98 EP 98 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600175 ER PT J AU Xu, K Zhou, TQ Mascola, JR Kwong, PD AF Xu, Kai Zhou, Tongqing Mascola, John R. Kwong, Peter D. TI Development of a Soluble HIV-1 Env Trimer Immunogen Stabilized in the Pre-fusion Closed State from Strain CH505 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Xu, Kai; Zhou, Tongqing; Mascola, John R.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA21.05 BP 98 EP 98 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600174 ER PT J AU Huang, J Kang, B Ishida, E Griesman, T Wheatley, AK Khurana, S Narpala, SR McDermott, AB Poole, A Bailer, RT Koup, RA Alexander, J Smith, J Migueles, SA Golding, H Wohlbold, TJ Chromikova, V Krammer, F Gurwith, M Connors, M AF Huang, Jinghe Kang, Byong Ishida, Elise Griesman, Trevor Wheatley, Adam K. Khurana, Surender Narpala, Sandeep R. McDermott, Adrian B. Poole, April Bailer, Robert T. Koup, Richard A. Alexander, Jeffrey Smith, Jonathan Migueles, Stephen A. Golding, Hana Wohlbold, Teddy John Chromikova, Veronika Krammer, Florian Gurwith, Marc Connors, Mark TI Upper Respiratory Tract (URT) Administration of a Replication Competent Ad4-H5-Vtn Vaccine Induces Durable Neutralizing Antibody Responses in Humans SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Huang, Jinghe; Kang, Byong; Ishida, Elise; Griesman, Trevor; Poole, April; Migueles, Stephen A.; Connors, Mark] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Wheatley, Adam K.; Narpala, Sandeep R.; McDermott, Adrian B.; Bailer, Robert T.; Koup, Richard A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Khurana, Surender; Golding, Hana] US FDA, Rockville, MD 20857 USA. [Alexander, Jeffrey; Smith, Jonathan; Gurwith, Marc] PaxVax Inc, San Diego, CA USA. [Wohlbold, Teddy John; Chromikova, Veronika; Krammer, Florian] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA22.05 BP 101 EP 101 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600180 ER PT J AU Hural, J Metch, B Grunenberg, N Allen, M Coombs, R Dragavon, J Puren, A Singh, B Maenza, J AF Hural, John Metch, Barbara Grunenberg, Nicole Allen, Mary Coombs, Robert Dragavon, Joan Puren, Adrian Singh, Beverly Maenza, Janine TI HIV Vaccine Trials Network (HVTN) 910: Long-term Follow-up of HIV Vaccine-induced Seropositivity (VISP) among HIV Vaccinees SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Hural, John; Metch, Barbara; Grunenberg, Nicole] Fred Hutchinson Canc Res Ctr, HIV Vaccine Trials Network, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA. [Allen, Mary] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. [Coombs, Robert; Dragavon, Joan; Maenza, Janine] Univ Washington, Seattle, WA 98195 USA. [Puren, Adrian; Singh, Beverly] NICD, NHLS, Johannesburg, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA OA22.06 BP 101 EP 101 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600181 ER PT J AU Richardson, SI Lambson, BL Scheepers, C Bhiman, JN Garrett, N Abdool-Karim, S Carrington, M Moore, PL Mkhize, NN Morris, L AF Richardson, Simone Irene Lambson, Bronwen L. Scheepers, Cathrine Bhiman, Jinal N. Garrett, Nigel Abdool-Karim, Salim Carrington, Mary Moore, Penny L. Mkhize, Nonhlanhla N. Morris, Lynn TI Enhanced Effector Functionality of a V2 Broadly Neutralizing Antibody with a Novel IgG3 Fc Allotype SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Richardson, Simone Irene; Lambson, Bronwen L.; Scheepers, Cathrine; Bhiman, Jinal N.; Moore, Penny L.; Mkhize, Nonhlanhla N.; Morris, Lynn] Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa. [Richardson, Simone Irene; Lambson, Bronwen L.; Scheepers, Cathrine; Bhiman, Jinal N.; Moore, Penny L.; Mkhize, Nonhlanhla N.; Morris, Lynn] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Garrett, Nigel; Abdool-Karim, Salim; Moore, Penny L.] Univ KwaZulu Natal, CAPRISA, Durban, South Africa. [Carrington, Mary] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA. [Carrington, Mary] Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, Canc & Inflammat Program, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD02.05LB BP 113 EP 113 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600203 ER PT J AU Chakrabarti, BK Boliar, S Shukla, B Ghobeh, A Chen, WZ Patil, S Guenaga, J Dimitrov, D Wyatt, R AF Chakrabarti, Bimal K. Boliar, Saikat Shukla, Brihaspati Ghobeh, Ali Chen Weizao Patil, Shilpa Guenaga, Javier Dimitrov, Dimiter Wyatt, Richard TI Direct Access to the Co-receptor Binding Site in Virus Is Dependent on Mass of the Inhibitory Molecule and the Length of Variable Loops, V1/V2 of Env SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Chakrabarti, Bimal K.; Boliar, Saikat; Shukla, Brihaspati; Patil, Shilpa] THSTI, Faridabad, Haryana, India. [Ghobeh, Ali; Guenaga, Javier; Wyatt, Richard] IAVI, New York, NY USA. [Chen Weizao; Dimitrov, Dimiter] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD05.02 BP 120 EP 120 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600214 ER PT J AU DeKosky, BJ Normandin, E Cheng, C Duan, HY Chen, XJ Kong, R Ransier, A Darko, S Tian, M Cheng, HL Menis, S Kwong, PD Douek, DC Schief, WR Alt, FW Mascola, JR AF DeKosky, Brandon J. Normandin, Erica Cheng, Cheng Duan, Hongying Chen, Xuejun Kong, Rui Ransier, Amy Darko, Sam Tian, Ming Cheng, Hwei-Ling Menis, Sergey Kwong, Peter D. Douek, Daniel C. Schief, William R. Alt, Frederick W. Mascola, John R. TI High-throughput Paired Heavy: Light Antibody Sequencing Enables Genetic Analyses of Broadly Neutralizing Antibody Lineage Development SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [DeKosky, Brandon J.; Normandin, Erica; Cheng, Cheng; Duan, Hongying; Chen, Xuejun; Kong, Rui; Ransier, Amy; Darko, Sam; Kwong, Peter D.; Douek, Daniel C.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Tian, Ming; Cheng, Hwei-Ling; Alt, Frederick W.] Boston Children s Hosp, HHMI, Boston, MA USA. [Menis, Sergey; Schief, William R.] Scripps Res Inst, IAVI, La Jolla, CA 92037 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD05.03 BP 121 EP 121 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600215 ER PT J AU Shen, CH Soto, C Stewart-Jones, GB Lemmin, T Kwong, PD AF Shen, Chen-Hsiang Soto, Cinque Stewart-Jones, Guillaume B. Lemmin, Thomas Kwong, Peter D. TI N-linked Glycan Taxonomy and the HIV-1 Glycan Shield SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Shen, Chen-Hsiang; Soto, Cinque; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Stewart-Jones, Guillaume B.] Univ Oxford, Oxford, England. [Lemmin, Thomas] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD05.04 BP 121 EP 121 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600216 ER PT J AU Asokan, M Pegu, A Gorman, J Doria-Rose, N Ko, SY Schmidt, S Narpala, S Del Prete, G Chen, XJ Choe, M Li, H Todd, JP Hatziiannou, T McDermott, A Koup, R Keele, B Shaw, G Lifson, J Kwong, P Mascola, J AF Asokan, Mangaiarkarasi Pegu, Amarendra Gorman, Jason Doria-Rose, Nicole Ko, Sung-Youl Schmidt, Stephen Narpala, Sandeep Del Prete, Gregory Chen, Xuejun Choe, Misook Li, Hui Todd, John-Paul Hatziiannou, Theodora McDermott, Adrian Koup, Richard Keele, Brandon Shaw, George Lifson, Jeffrey Kwong, Peter Mascola, John TI Construction and Characterization of Chimeric SHIVs Displaying V1V2 Epitopes that Bind Germline Precursors of Broadly Neutralizing Human Antibodies SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Asokan, Mangaiarkarasi; Pegu, Amarendra; Gorman, Jason; Doria-Rose, Nicole; Ko, Sung-Youl; Schmidt, Stephen; Narpala, Sandeep; Chen, Xuejun; Choe, Misook; Todd, John-Paul; McDermott, Adrian; Koup, Richard; Kwong, Peter; Mascola, John] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Del Prete, Gregory; Keele, Brandon; Lifson, Jeffrey] NCI, ACVP, Leidos Biomed Inc, NIH, Bethesda, MD 20892 USA. [Li, Hui; Shaw, George] Perelman Sch Med, Philadelphia, PA USA. [Hatziiannou, Theodora] Aaron Diamond AIDS Res Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD06.01LB BP 123 EP 123 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600217 ER PT J AU Yacoob, C Pancera, M Vigdorovich, V Oliver, BG Sather, DN Glenn, J Feng, JL McGuire, AT Stamatatos, L AF Yacoob, Christina Pancera, Marie Vigdorovich, Vladimir Oliver, Brian G. Sather, D. Noah Glenn, Jolene Feng, Junli McGuire, Andrew T. Stamatatos, Leonidas TI Interactions of Germline VRC01-Class Antibodies with HIV-1 Env: The Role of CDRH3 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Yacoob, Christina; Pancera, Marie; Glenn, Jolene; Feng, Junli; McGuire, Andrew T.; Stamatatos, Leonidas] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Vigdorovich, Vladimir; Oliver, Brian G.; Sather, D. Noah] Ctr Infect Dis Res, Bethesda, MD USA. Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD06.02LB BP 123 EP 123 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600218 ER PT J AU Duan, HY Tian, M Cheng, C Chen, XJ Cheng, HL Dekosky, BJ Joyce, MG Dao, M Kimble, M Lin, S Du, Z Chen, YW Chen, YM Cantor, E Huang, PY Jain, S Schief, WR Haynes, BF Alt, FW Mascola, JR AF Duan, Hongying Tian, Ming Cheng, Cheng Chen, Xuejun Cheng, Hwei-Ling Dekosky, Brandon J. Joyce, M. Gordon Dao, Mai Kimble, Michael Lin, Sherry Du, Zhou Chen, Yiwei Chen, Yimin Cantor, Elizabeth Huang, Pei-Yi Jain, Suvi Schief, William R. Haynes, Barton F. Alt, Frederick W. Mascola, John R. TI Selective Activation of VRC01-class Germline Antibodies in Knock-in Mice with Diverse Precursor Repertoires SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Duan, Hongying; Cheng, Cheng; Chen, Xuejun; Dekosky, Brandon J.; Joyce, M. Gordon; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Tian, Ming; Cheng, Hwei-Ling; Dao, Mai; Kimble, Michael; Lin, Sherry; Du, Zhou; Chen, Yiwei; Chen, Yimin; Cantor, Elizabeth; Huang, Pei-Yi; Jain, Suvi; Alt, Frederick W.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA. [Schief, William R.] Scripps Res Inst, La Jolla, CA 92037 USA. [Haynes, Barton F.] Duke Human Vaccine Inst, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD06.03LB BP 124 EP 124 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600219 ER PT J AU Soumana, D Pancera, M Chen, GY Soto, C Kwong, PD AF Soumana, Djade Pancera, Marie Chen, Gwo-Yu Soto, Cinque Kwong, Peter D. TI Structural Characterization of HIV-1 Entry Inhibitors SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Soumana, Djade; Pancera, Marie; Chen, Gwo-Yu; Soto, Cinque; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD08.02 BP 128 EP 128 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600227 ER PT J AU Francis, JN Nishimura, Y Smith, A Welch, B Martin, M Kay, M AF Francis, J. Nicholas Nishimura, Yoshiaki Smith, Amanda Welch, Brett Martin, Malcolm Kay, Michael TI Preclinical Characterization of a Potent D-peptide Inhibitor of HIV Entry: Cholesterol-conjugated PIE12-trimer SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Francis, J. Nicholas; Welch, Brett; Kay, Michael] Navigen, Salt Lake City, UT USA. [Francis, J. Nicholas; Smith, Amanda; Welch, Brett; Kay, Michael] Univ Utah, Salt Lake City, UT 84112 USA. [Nishimura, Yoshiaki; Martin, Malcolm] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD08.04LB BP 129 EP 129 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600229 ER PT J AU Mason, R Biris, K Doria-Rose, N Welles, H Nguyen, R O'Dell, S Bailer, R Mascola, J Roederer, M AF Mason, Rosemarie Biris, Kristin Doria-Rose, Nicole Welles, Hugh Nguyen, Richard O'Dell, Sijy Bailer, Robert Mascola, John Roederer, Mario TI Next Generation SIV Broadly Neutralizing Antibodies Mediate Complete Neutralization of SIVmac239 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Mason, Rosemarie; Biris, Kristin; Doria-Rose, Nicole; Welles, Hugh; Nguyen, Richard; O'Dell, Sijy; Bailer, Robert; Mascola, John; Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA PD08.05LB BP 130 EP 130 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600230 ER PT J AU Lee, A Donofrio, G Dussupt, V Kong, R Georgiev, I Doria-Rose, N Slike, B Grande, R Bryson, M Mascola, J Robb, M Polonis, V Michael, N Krebs, S AF Lee, Anna Donofrio, Gina Dussupt, Vincent Kong, Rui Georgiev, Ivelin Doria-Rose, Nicole Slike, Bonnie Grande, Rebecca Bryson, Mary Mascola, John Robb, Merlin Polonis, Victoria Michael, Nelson Krebs, Shelly TI Isolation of HIV Specific Monoclonal Antibodies Using a Combined Antigen-specific and B Cell Culture Supernatant Method SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Lee, Anna; Donofrio, Gina; Dussupt, Vincent; Slike, Bonnie; Grande, Rebecca; Bryson, Mary; Robb, Merlin; Polonis, Victoria; Michael, Nelson; Krebs, Shelly] Walter Reed Army Inst Res, US Mil HIV Res Program, Washington, DC USA. [Lee, Anna; Donofrio, Gina; Dussupt, Vincent; Slike, Bonnie; Grande, Rebecca; Bryson, Mary; Robb, Merlin; Krebs, Shelly] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Kong, Rui; Doria-Rose, Nicole; Mascola, John] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Georgiev, Ivelin] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.01 BP 132 EP 132 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600231 ER PT J AU Cale, E Gorman, J Radakovich, N Crooks, E Osawa, K Ozorowski, G Asokan, M Doria-Rose, N Ward, A Kwong, P Mascola, J Binley, J AF Cale, Evan Gorman, Jason Radakovich, Nathan Crooks, Ema Osawa, Keiko Ozorowski, Gabriel Asokan, Mangai Doria-Rose, Nicole Ward, Andrew Kwong, Peter Mascola, John Binley, James TI A Broadly Neutralizing HIV-1 Antibody with a Non-projecting CDRH3 Loop Engages the V1V2 Apex of Native Envelope Glycoprotein Trimers SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Cale, Evan; Gorman, Jason; Radakovich, Nathan; Asokan, Mangai; Doria-Rose, Nicole; Kwong, Peter; Mascola, John] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Crooks, Ema; Osawa, Keiko; Binley, James] San Diego Biomed Res Inst, San Diego, CA USA. [Ozorowski, Gabriel; Ward, Andrew] Scripps Res Inst, La Jolla, CA 92037 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.07 BP 135 EP 135 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600237 ER PT J AU Gorman, J Geng, H Joyce, MG Zhou, TQ Kwong, PD AF Gorman, Jason Geng, Hui Joyce, M. Gordon Zhou, Tongqing Kwong, Peter D. TI Combining Env Trimer Engagement with Germline V1V2-and CD4bs-directed Antibodies SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Gorman, Jason; Geng, Hui; Joyce, M. Gordon; Zhou, Tongqing; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.09 BP 136 EP 136 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600239 ER PT J AU Duerr, R Soni, S Banin, A Tuen, M Courtney, C Nanfack, A Mayr, L Redd, A Ding, SL Finzi, A Meli, J Ngai, J Kong, XP Gorny, MK Nyambi, P AF Duerr, Ralf Soni, Sonal Banin, Andrew Tuen, Michael Courtney, Colleen Nanfack, Aubin Mayr, Luzia Redd, Andrew Ding, Shilei Finzi, Andres Meli, Josephine Ngai, Johnson Kong, Xiangpeng Gorny, Miroslaw K. Nyambi, Phillipe TI Three Related HIV-1 Cross-superinfected Individuals Exchange Similar Viral Strains, but Evolve Different Immunological Responses SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Duerr, Ralf; Soni, Sonal; Banin, Andrew; Tuen, Michael; Courtney, Colleen; Nanfack, Aubin; Mayr, Luzia; Kong, Xiangpeng; Gorny, Miroslaw K.; Nyambi, Phillipe] NYU, Sch Med, New York, NY 10003 USA. [Redd, Andrew] NIAID, NIH, Bethesda, MD USA. [Ding, Shilei; Finzi, Andres] Univ Montreal, Montreal, PQ, Canada. [Meli, Josephine; Ngai, Johnson] Med Diagnost Ctr, Yaounde, Cameroon. [Nyambi, Phillipe] Manhattan Vet Affairs Harbor Healthcare Syst, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.20 BP 141 EP 141 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600249 ER PT J AU Wang, YM Dell, SO Guenaga, J Chiang, CI Lei, L Wilson, R Doria-Rose, N Mascola, J Wyatt, R Hedestam, GK Li, YX AF Wang, Yimeng Dell, Sijy O. Guenaga, Javier Chiang, Chi-I Lei, Lin Wilson, Richard Doria-Rose, Nicole Mascola, John Wyatt, Richard Hedestam, Gunilla Karlsson Li, Yuxing TI HIV-1 Env Immunogen-elicited Cross-reactive Tier 2 Virus Neutralizing Antibody Response in Non-human Primates SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Wang, Yimeng; Wyatt, Richard; Li, Yuxing] Scripps Res Inst, La Jolla, CA 92037 USA. [Wang, Yimeng; Chiang, Chi-I; Lei, Lin; Li, Yuxing] Univ Maryland, College Pk, MD 20742 USA. [Dell, Sijy O.; Doria-Rose, Nicole; Mascola, John] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Guenaga, Javier; Wilson, Richard; Wyatt, Richard; Li, Yuxing] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA USA. [Hedestam, Gunilla Karlsson] Karolinska Inst, Stockholm, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.24 BP 143 EP 143 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600253 ER PT J AU Gift, SK Wieczorek, L Krebs, SJ Molnar, S Donofrio, G Chenine, AL Sanders-Buell, E Kijak, G Chang, D Doria-Rose, N Rolland, M Tovanabutra, S Sriplienchan, S Nitayapan, S Connell, RJO Eller, LA Mascola, J Michael, NL Robb, ML Polonis, VR AF Gift, Syna K. Wieczorek, Lindsay Krebs, Shelly J. Molnar, Sebastian Donofrio, Gina Chenine, Agnes-Laurence Sanders-Buell, Eric Kijak, Gustavo Chang, David Doria-Rose, Nicole Rolland, Morgane Tovanabutra, Sodsai Sriplienchan, Somchai Nitayapan, Sorachai Connell, Robert J. O. Eller, Leigh-Anne Mascola, John Michael, Nelson L. Robb, Merlin L. Polonis, Victoria R. TI Development of Autologous Neutralizing Antibodies in HIV-1 CRF01_AE-infected Patients Spanning the First Three Years of Infection SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Gift, Syna K.; Wieczorek, Lindsay; Krebs, Shelly J.; Molnar, Sebastian; Donofrio, Gina; Chenine, Agnes-Laurence; Sanders-Buell, Eric; Kijak, Gustavo; Chang, David; Rolland, Morgane; Tovanabutra, Sodsai; Eller, Leigh-Anne; Michael, Nelson L.; Robb, Merlin L.; Polonis, Victoria R.] US Mil HIV Res Program, Bethesda, MD USA. [Gift, Syna K.; Wieczorek, Lindsay; Krebs, Shelly J.; Molnar, Sebastian; Donofrio, Gina; Chenine, Agnes-Laurence; Sanders-Buell, Eric; Kijak, Gustavo; Chang, David; Tovanabutra, Sodsai; Eller, Leigh-Anne; Robb, Merlin L.] Henry M Jackson Fdn Advancement Mil Med, Bethesda, MD USA. [Doria-Rose, Nicole; Mascola, John] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Sriplienchan, Somchai; Nitayapan, Sorachai; Connell, Robert J. O.] Armed Forces Res Inst Med Sci, Bangkok, Thailand. [Michael, Nelson L.; Polonis, Victoria R.] Walter Reed Army Inst Res, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.30 BP 146 EP 146 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600259 ER PT J AU Lei, L Tran, K Chiang, CI Wang, YM Arendt, HE DeStefano, J Xiao, YL Wyatt, RT Li, YX AF Lei, Lin Tran, Karen Chiang, Chi-I Wang, Yimeng Arendt, Heather E. DeStefano, Joanne Xiao, Yongli Wyatt, Richard T. Li, Yuxing TI Antibody Responses Elicited by Cleaved Soluble HIV-1 Envelope Trimers in Guinea Pigs Revealed by Single B Cell Sorting and Cloning SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Lei, Lin; Chiang, Chi-I; Wang, Yimeng; Li, Yuxing] Univ Maryland, Inst Biosci & Biotechnol Res, College Pk, MD 20742 USA. [Tran, Karen; Wyatt, Richard T.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA. [Arendt, Heather E.; DeStefano, Joanne] Int AIDS Vaccine Initiat, New York, NY USA. [Xiao, Yongli] NIAID, Lab Infect Dis, NIH, Rockville, MD USA. Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.34LB BP 148 EP 148 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600263 ER PT J AU Montefiori, D Seaman, M Korber, B Wagh, K Morris, L Zolla-Pazner, S Lu, S Corey, L Scarlatti, G D'Souza, P AF Montefiori, David Seaman, Michael Korber, Bette Wagh, Kshitij Morris, Lynn Zolla-Pazner, Susan Lu, Shan Corey, Larry Scarlatti, Gabriella D'Souza, Patricia TI Tier 1 Strains of HIV-1: Time to Break an Old Habit? SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Montefiori, David] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Seaman, Michael] Harvard, Beth Isreal Deaconess Med Ctr, Cambridge, MA USA. [Korber, Bette; Wagh, Kshitij] Los Alamos Natl Lab, Los Alamos, NM USA. [Korber, Bette; Wagh, Kshitij] New Mexico Consortium, Los Alamos, NM USA. [Morris, Lynn] Natl Inst Communicable Dis, Johannesburg, South Africa. [Zolla-Pazner, Susan] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lu, Shan] Univ Massachusetts, Sch Med, Amherst, MA 01003 USA. [Corey, Larry] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Scarlatti, Gabriella] Global HIV Vaccine Enterprise, New York, NY USA. [D'Souza, Patricia] NIAID, NIH, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.33LB BP 148 EP 148 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600262 ER PT J AU Levendosky, K Barnable, P Mizenina, O Zydowsky, TM O'Keefe, BR Derby, N Teleshova, N Fernandez-Romero, JA AF Levendosky, Keith Barnable, Patrick Mizenina, Olga Zydowsky, Thomas M. O'Keefe, Barry R. Derby, Nina Teleshova, Natalia Fernandez-Romero, Jose A. TI Comparative Assessment of the Potency and Breadth of Activity of Griffithsin and Broad Neutralizing Antibodies Against HIV SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Levendosky, Keith; Barnable, Patrick; Mizenina, Olga; Zydowsky, Thomas M.; Derby, Nina; Teleshova, Natalia; Fernandez-Romero, Jose A.] Populat Council, 1230 York Ave, New York, NY 10021 USA. [O'Keefe, Barry R.] NCI, Mol Targets Lab, Ctr Canc Res, Frederick, MD 21701 USA. Borough Manhattan Community Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P01.35LB BP 149 EP 149 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600264 ER PT J AU Teigler, JE Eller, MA Bolton, D Marovich, M Robb, ML Martin, JN Deeks, SG Michael, NL Streeck, H AF Teigler, Jeffrey E. Eller, Michael A. Bolton, Diane Marovich, Mary Robb, Merlin L. Martin, Jeffrey N. Deeks, Steven G. Michael, Nelson L. Streeck, Hendrik TI Differential Impact of Inhibitory Receptors and Inhibitory Receptor Blockade on Cytokine-producing CD4 T Cell Subsets SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Teigler, Jeffrey E.; Eller, Michael A.; Bolton, Diane; Robb, Merlin L.; Michael, Nelson L.; Streeck, Hendrik] Henry M Jackson Fdn Advancement Mil Med, Bethesda, MD USA. [Teigler, Jeffrey E.; Eller, Michael A.; Bolton, Diane; Robb, Merlin L.; Michael, Nelson L.; Streeck, Hendrik] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Marovich, Mary] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Martin, Jeffrey N.] Dept Epidemiol & Biostat, Bethesda, MD USA. [Deeks, Steven G.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Streeck, Hendrik] Inst HIV Res, Essen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P03.08 BP 169 EP 169 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600303 ER PT J AU Hu, XT Valentin, A Dayton, F Kulkarni, V Alicea, C Rosati, M Chowdhury, B Gautam, R Broderick, KE Sardesai, NY Martin, MA Mullins, JI Pavlakis, GN Felber, BK AF Hu, Xintao Valentin, Antonio Dayton, Frances Kulkarni, Viraj Alicea, Candido Rosati, Margherita Chowdhury, Bhabadeb Gautam, Rajeev Broderick, Kate E. Sardesai, Niranjan Y. Martin, Malcolm A. Mullins, James I. Pavlakis, George N. Felber, Barbara K. TI Novel pDNA Prime-boost Vaccine Regimen to Augment Magnitude, Breadth, and Cytotoxicity of Cellular Immunity to Subdominant Gag Epitope of HIV and SIV SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Hu, Xintao; Valentin, Antonio; Dayton, Frances; Kulkarni, Viraj; Alicea, Candido; Rosati, Margherita; Chowdhury, Bhabadeb; Pavlakis, George N.; Felber, Barbara K.] NCI, Frederick, MD 21701 USA. [Gautam, Rajeev; Martin, Malcolm A.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Broderick, Kate E.; Sardesai, Niranjan Y.] Inovio Pharmaceut, Plymouth Meeting, PA USA. [Mullins, James I.] Univ Washington, Seattle, WA 98195 USA. RI bebarta, vikhyat/K-3476-2015 NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P03.13 BP 172 EP 172 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600308 ER PT J AU Mhlanga, F Singh, D Kamira, B Bunge, K Harkoo, I Chappell, C Mukaka, S Palanee-Phillips, T Crida, D Nakabiito, C Szydlo, D Kachipapa, E Pather, A Baeten, J Mvelase, S Mdlala, B Piper, J Balkus, J Hillier, S AF Mhlanga, Felix Singh, Devika Kamira, Betty Bunge, Katherine Harkoo, Ishana Chappell, Catherine Mukaka, Shorai Palanee-Phillips, Thesla Crida, Danielle Nakabiito, Clemensia Szydlo, Danny Kachipapa, Emma Pather, Aren Baeten, Jared Mvelase, Samkelisiwe Mdlala, Bernadette Piper, Jeanna Balkus, Jen Hillier, Sharon TI Uptake of Non-hormonal Intrauterine Contraceptive Devices (IUDs) among Women Participating in MTN-020, a Clinical Trial for HIV Prevention in Africa SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Mhlanga, Felix] Univ Zimbabwe, Coll Hlth Sci, Harare, Zimbabwe. [Singh, Devika; Bunge, Katherine; Hillier, Sharon] Microbicides Trials Network, Durham, NC USA. [Kamira, Betty; Nakabiito, Clemensia] Makerere Univ Johns Hopkins Univ, Kampala, Uganda. [Harkoo, Ishana] CAPRISA, Durban, South Africa. [Chappell, Catherine] Magee Womens Res Inst, Pittsburgh, PA USA. [Mukaka, Shorai] Univ Zimbabwe Univ Calif, San Francisco Collaborat Res Program, Harare, Zimbabwe. [Palanee-Phillips, Thesla] Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa. [Crida, Danielle] Desmond Tutu HIV Ctr, Cape Town, South Africa. [Szydlo, Danny; Balkus, Jen] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Kachipapa, Emma] UNC Project, Lilongwe, Malawi. [Pather, Aren; Mvelase, Samkelisiwe; Mdlala, Bernadette] Med Res Council South Africa, Tygerberg, South Africa. [Baeten, Jared] Global Hlth Univ Washington, Seattle, WA USA. [Piper, Jeanna] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P05.06 BP 190 EP 190 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600345 ER PT J AU Lowry, A Walker, CM O'Neill, CI Swartz, GM Turpin, JA Cummins, JE AF Lowry, Anabel Walker, Cattlena M. O'Neill, Cynthia I. Swartz, Glenn M. Turpin, Jim A. Cummins, James E., Jr. TI Best Practices for Use of the Rabbit Rectal Irritation (RRI) Model for Assessing the Safety and Systemic Exposure of Rectal Gel Microbicides SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Lowry, Anabel; Turpin, Jim A.; Cummins, James E., Jr.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. [Walker, Cattlena M.; O'Neill, Cynthia I.; Swartz, Glenn M.] Adv BioSci Labs Inc, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P06.01 BP 199 EP 199 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600361 ER PT J AU Marshall, LJ O'Neill, CI Desai, R Goykhman, D Madsen, TJ Polsky-Fisher, S Sanchez, RI Strizki, J Turpin, JA van Laarhoven, H Veronese, F Swartz, GM Cummins, JE AF Marshall, Leslie J. O'Neill, Cynthia I. Desai, Rajesh Goykhman, Dina Madsen, Timothy J. Polsky-Fisher, Stacey Sanchez, Rosa I. Strizki, Julie Turpin, Jim A. van Laarhoven, Hans Veronese, Fulvia Swartz, Glenn M. Cummins, James E. TI Utility of the Sheep Model for Testing the 28-day MK-2048A Intravaginal Ring and Determining the Correlates of Exposure for Vicriviroc and MK-2048 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Marshall, Leslie J.; Turpin, Jim A.; Veronese, Fulvia; Cummins, James E.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. [O'Neill, Cynthia I.; Swartz, Glenn M.] Adv Biosci Labs Inc, Rockville, MD USA. [Desai, Rajesh; Goykhman, Dina; Polsky-Fisher, Stacey; Sanchez, Rosa I.; Strizki, Julie] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ USA. [Madsen, Timothy J.] Sinclair Res Ctr LLC, Auxvasse, MO USA. [van Laarhoven, Hans] Merck & Co Inc, Schiphol Rijk, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P06.07 BP 202 EP 202 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600367 ER PT J AU Spreen, W Lowry, A Pal, R Yueh, YL Ford, S Richardson-Harman, N Turpin, JA Veronese, F Cummins, J AF Spreen, William Lowry, Anabel Pal, Ranajit Yueh, Yun Lan Ford, Susan Richardson-Harman, Nicola Turpin, Jim A. Veronese, Fulvia Cummins, James CA ABL BIOQUAL NHP Team TI Use of a "Lead-in" Pharmacokinetic (PK) Study to Predict the Tissue Concentration of Cabotegravir that Protects Macaques against SIV Infection SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Spreen, William; Yueh, Yun Lan; Ford, Susan] GlaxoSmithKline, Philadelphia, PA USA. [Lowry, Anabel; Turpin, Jim A.; Veronese, Fulvia; Cummins, James] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. [Pal, Ranajit] Adv BioSci Labs Inc, Rockville, MD USA. [Richardson-Harman, Nicola] Alpha StatConsult LLC, Damascus, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P06.13 BP 205 EP 205 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600373 ER PT J AU Patamawenu, AA Connors, M AF Patamawenu, Apisit A. Connors, Mark TI Truncated HIV Envelope Expressed by Synthetic Recombinant Replication-competent (SRRC) Human Ad4 Recognized by Conformation-dependent Antibodies SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Patamawenu, Apisit A.; Connors, Mark] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.04 BP 209 EP 209 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600381 ER PT J AU Calenda, G Barnable, P Levendosky, K Kleinbeck, K Fernandez-Romero, JA Keefe, BO Zydowsky, TM Teleshova, N AF Calenda, Giulia Barnable, Patrick Levendosky, Keith Kleinbeck, Kyle Fernandez-Romero, Jose A. Keefe, Barry O. Zydowsky, Thomas M. Teleshova, Natalia TI GRFT/Carrageenan Gel Inhibits HIV and HSV-2 in Human Cervical Mucosa SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Calenda, Giulia; Barnable, Patrick; Levendosky, Keith; Kleinbeck, Kyle; Fernandez-Romero, Jose A.; Zydowsky, Thomas M.; Teleshova, Natalia] Populat Council, 1230 York Ave, New York, NY 10021 USA. [Keefe, Barry O.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.19 BP 217 EP 217 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600396 ER PT J AU Francica, J Lynn, G Laga, R Aussedat, B Meyerhoff, R Alam, M Danishefsky, S Haynes, B Seder, R AF Francica, Joseph Lynn, Geoffrey Laga, Richard Aussedat, Baptiste Meyerhoff, Ryan Alam, Munir Danishefsky, Samuel Haynes, Barton Seder, Robert TI Synthetic Biocompatible Polymers Are an Effective Delivery Platform That Elicits Potent Antibody Responses Against HIV-1 Glycopeptide Immunogens SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Francica, Joseph; Lynn, Geoffrey; Seder, Robert] NIH, Bldg 10, Bethesda, MD 20892 USA. [Laga, Richard] Inst Macromol Chem, Prague, Czech Republic. [Aussedat, Baptiste; Danishefsky, Samuel] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Meyerhoff, Ryan; Alam, Munir; Haynes, Barton] Duke Human Vaccine Inst, Durham, NC USA. RI Laga, Richard/G-3627-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.27 BP 221 EP 221 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600404 ER PT J AU Jhunjhunwala, K Sant, V Wang, L Graebing, P Marshall, L Cummins, J Walker, C Swartz, G Rohan, L AF Jhunjhunwala, Kunal Sant, Vinayak Wang, Lin Graebing, Phil Marshall, Leslie Cummins, James, Jr. Walker, Cattlena Swartz, Glenn Rohan, Lisa TI Development of a Suppository Dosage Form for the Integrase Inhibitor, MK-2048 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Jhunjhunwala, Kunal; Sant, Vinayak; Rohan, Lisa] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA. [Jhunjhunwala, Kunal; Wang, Lin; Graebing, Phil; Rohan, Lisa] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15260 USA. [Marshall, Leslie; Cummins, James, Jr.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. [Walker, Cattlena; Swartz, Glenn] Adv Biosci Labs Inc, Rockville, MD USA. [Rohan, Lisa] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P07.33 BP 224 EP 224 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600410 ER PT J AU Lai, YT Pancera, M Stewart-Jones, G Druz, A Kwong, P AF Lai, Yen-Ting Pancera, Marie Stewart-Jones, Guillaume Druz, Alex Kwong, Peter TI Improving Structural Accuracy of HIV-1 env Trimeric Structure by Crystal Lattice Engineering and the Potential Application in Drug Discovery SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Lai, Yen-Ting; Pancera, Marie; Stewart-Jones, Guillaume; Druz, Alex; Kwong, Peter] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P08.07 BP 235 EP 235 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600431 ER PT J AU Chambers, MJ Narpala, SR Prabhakaran, MS Acharya, P Pancera, M Kwon, YD Cheng, C Zhou, TQ Gorman, J Joyce, GM Georgiev, IS Zhang, BS Mascola, JR Koup, RA Kwong, PD McDermott, AB AF Chambers, Michael J. Narpala, Sandeep R. Prabhakaran, Madhu S. Acharya, Priyamvada Pancera, Marie Kwon, Young D. Cheng, Cheng Zhou, Tongqing Gorman, Jason Joyce, Gordon M. Georgiev, Ivelin S. Zhang, Baoshan Mascola, John R. Koup, Richard A. Kwong, Peter D. McDermott, Adrian B. TI Antigenic Characterization of HIV-1 Trimers Using Meso Scale Discovery ECLIA SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Chambers, Michael J.; Narpala, Sandeep R.; Prabhakaran, Madhu S.; Acharya, Priyamvada; Pancera, Marie; Kwon, Young D.; Cheng, Cheng; Zhou, Tongqing; Gorman, Jason; Joyce, Gordon M.; Georgiev, Ivelin S.; Zhang, Baoshan; Mascola, John R.; Koup, Richard A.; Kwong, Peter D.; McDermott, Adrian B.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA. [Pancera, Marie] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. Vanderbilt Univ, Sch Med, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P08.11 BP 237 EP 237 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600435 ER PT J AU Kleinbeck, K Bonnaire, T Kizima, L Rodriguez, A Grecky, S Levendosky, K Katzen, L O'Keefe, BR Makovec, T Peet, M Creasy, G Zydowsky, TM Fernandez-Romero, JA AF Kleinbeck, Kyle Bonnaire, Thierry Kizima, Larisa Rodriguez, Aixa Grecky, Susanna Levendosky, Keith Katzen, Lauren O'Keefe, Barry R. Makovec, Tracy Peet, Melissa Creasy, George Zydowsky, Thomas M. Fernandez-Romero, Jose A. TI Toxicology Profile of a Topical Multipurpose Prevention Technology that Combines Griffithsin and Carrageenan SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Kleinbeck, Kyle; Bonnaire, Thierry; Kizima, Larisa; Rodriguez, Aixa; Grecky, Susanna; Levendosky, Keith; Katzen, Lauren; Creasy, George; Zydowsky, Thomas M.; Fernandez-Romero, Jose A.] Populat Council, New York, NY USA. [O'Keefe, Barry R.] NCI, Mol Targets Lab, Ctr Canc Res, Frederick, MD 21701 USA. [Makovec, Tracy; Peet, Melissa] MPI Res Inc, Mattawan, MI USA. Borough Manhattan Community Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P08.18LB BP 240 EP 240 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600442 ER PT J AU Levendosky, K Mizenina, O Aravantinou, M Kleinbeck, K Bonnaire, T Derby, N Zydowsky, TM O'Keefe, BR Fernandez-Romero, JA AF Levendosky, Keith Mizenina, Olga Aravantinou, Meropi Kleinbeck, Kyle Bonnaire, Thierry Derby, Nina Zydowsky, Thomas M. O'Keefe, Barry R. Fernandez-Romero, Jose A. TI Preclinical Evaluation of a Griffithsin/Carrageenan Formulation to Prevent HIV Infection SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Levendosky, Keith; Mizenina, Olga; Aravantinou, Meropi; Kleinbeck, Kyle; Bonnaire, Thierry; Derby, Nina; Zydowsky, Thomas M.; Fernandez-Romero, Jose A.] Populat Council, New York, NY USA. [O'Keefe, Barry R.] NCI, Mol Targets Lab, Ctr Canc Res, Frederick, MD USA. Borough Manhattan Community Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P08.17LB BP 240 EP 240 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600441 ER PT J AU Dawson, L AF Dawson, Liza TI Ethical Issues in Design of Prevention Trials: Grappling with Changing Standards of Prevention SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Dawson, Liza] NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P10.01 BP 255 EP 255 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600469 ER PT J AU deCamp, AC Rolland, M Edlefsen, PT Sanders-Buell, E Hall, B Magaret, C Fiore-Gartland, AJ Juraska, M Graham, BS Roederer, M Michael, NL Robb, ML McElrath, J Tovanabutra, S Sobieszczyk, ME Hammer, SM Kim, JH Mullins, JI Gilbert, PB AF deCamp, Allan C. Rolland, Morgane Edlefsen, Paul T. Sanders-Buell, Eric Hall, Breana Magaret, Craig Fiore-Gartland, Andrew J. Juraska, Michal Graham, Barney S. Roederer, Mario Michael, Nelson L. Robb, Merlin L. McElrath, Juliana Tovanabutra, Sodsai Sobieszczyk, Magdalena E. Hammer, Scott M. Kim, Jerome H. Mullins, James I. Gilbert, Peter B. CA HVTN505 Sieve Anal Team TI Sieve Pressure toward the CD4 Binding Site of Env in HVTN 505 Breakthrough Infections SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [deCamp, Allan C.; Edlefsen, Paul T.; Magaret, Craig; Fiore-Gartland, Andrew J.; Juraska, Michal; McElrath, Juliana; Gilbert, Peter B.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Rolland, Morgane; Sanders-Buell, Eric; Michael, Nelson L.; Robb, Merlin L.; Tovanabutra, Sodsai] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Rolland, Morgane; Sanders-Buell, Eric; Michael, Nelson L.; Robb, Merlin L.; Tovanabutra, Sodsai] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Edlefsen, Paul T.; Hall, Breana; Mullins, James I.; Gilbert, Peter B.] Univ Washington, Seattle, WA 98195 USA. [Graham, Barney S.; Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Sobieszczyk, Magdalena E.; Hammer, Scott M.] Columbia Univ, Med Ctr, New York, NY 10027 USA. [Kim, Jerome H.] Int Vaccine Inst, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P12.03 BP 260 EP 260 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600477 ER PT J AU Rolland, M Tovanabutra, S Krebs, S Sanders-Buell, E Bose, M Kijak, G Sullivan, AMO Harbolick, E Bonar, L Owen, C Slike, B Dussupt, V Doria-Rose, N Mascola, J Nitayaphan, S Polonis, V Eller, LA Kim, J Michael, N Robb, M AF Rolland, Morgane Tovanabutra, Sodsai Krebs, Shelly Sanders-Buell, Eric Bose, Meera Kijak, Gustavo Sullivan, Anne Marie O. Harbolick, Elizabeth Bonar, Lydia Owen, Christopher Slike, Bonnie Dussupt, Vincent Doria-Rose, Nicole Mascola, John Nitayaphan, Sorachai Polonis, Vicky Eller, Leigh Anne Kim, Jerome Michael, Nelson Robb, Merlin TI Super-infection and Development of MPER-specific Neutralization Breadth in Subject 40512 from the Acute Infection Cohort RV217 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Rolland, Morgane; Tovanabutra, Sodsai; Krebs, Shelly; Sanders-Buell, Eric; Bose, Meera; Kijak, Gustavo; Sullivan, Anne Marie O.; Harbolick, Elizabeth; Bonar, Lydia; Owen, Christopher; Slike, Bonnie; Dussupt, Vincent; Eller, Leigh Anne; Robb, Merlin] Henry M Jackson Fdn Adv Mil Med, US Mil HIV Res Program, Bethesda, MD USA. [Doria-Rose, Nicole; Mascola, John] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Nitayaphan, Sorachai] Armed Forces Res Inst Med Sci AFRIMS, Bangkok, Thailand. [Polonis, Vicky; Michael, Nelson] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Kim, Jerome] Int Vaccine Inst, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P12.20 BP 268 EP 268 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600494 ER PT J AU Houzet, L Perez-Losada, M Matusali, G Deleage, C Dereuddre-Bosquet, N Satie, AP Jegou, B Le Grand, R Keele, BF Crandall, KA Dejucq-Rainsford, N AF Houzet, Laurent Perez-Losada, Marcos Matusali, Giulia Deleage, Claire Dereuddre-Bosquet, Nathalie Satie, Anne-Pascale Jegou, Bernard Le Grand, Roger Keele, Brandon F. Crandall, Keith A. Dejucq-Rainsford, Nathalie TI Origin of AIDS Virus in Semen SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Houzet, Laurent; Matusali, Giulia; Deleage, Claire; Satie, Anne-Pascale; Jegou, Bernard; Dejucq-Rainsford, Nathalie] INSERM U 1085 IRSET, Rennes, France. [Perez-Losada, Marcos; Crandall, Keith A.] George Washington Univ, Computat Biol Inst, Washington, DC 20052 USA. [Dereuddre-Bosquet, Nathalie] CEA, DSV iMETI, Div Immunovirol, IDMIT, Fontenay Aux Roses, France. [Keele, Brandon F.] Frederick Natl Lab Canc Res, Leidos Biomed Res Inc, AIDS & Canc Virus Program, Frederick, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P12.22LB BP 269 EP 269 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600496 ER PT J AU Trainor, N Cohen, S Vittinghoff, E Bacon, O Doblecki-Lewis, S Matheson, T Blue, RW Estrada, Y Coleman, ME Elion, R Chege, W Philip, SS Buchbinder, S Kolber, MA Liu, AY AF Trainor, Nikole Cohen, Stephanie Vittinghoff, Eric Bacon, Oliver Doblecki-Lewis, Susanne Matheson, Tim Blue, Robert Wilder Estrada, Yannine Coleman, Megan E. Elion, Richard Chege, Wairimu Philip, Susan S. Buchbinder, Susan Kolber, Michael A. Liu, Albert Y. TI Social Harms and Social Benefits among Participants Taking Prep in the US PrEP Demo Project SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Trainor, Nikole; Cohen, Stephanie; Matheson, Tim; Blue, Robert Wilder; Philip, Susan S.; Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Cohen, Stephanie; Vittinghoff, Eric; Bacon, Oliver; Philip, Susan S.; Buchbinder, Susan; Liu, Albert Y.] Univ Calif San Francisco, San Francisco, CA USA. [Doblecki-Lewis, Susanne; Estrada, Yannine; Kolber, Michael A.] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA. [Coleman, Megan E.] Whitman Walker Hlth, Washington, DC USA. [Elion, Richard] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Chege, Wairimu] NIAID, Div AIDS, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P15.18 BP 291 EP 291 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600537 ER PT J AU Sastry, M Xu, L Bhattacharya, S Nabel, GJ Bewley, CA Kwong, PD AF Sastry, Mallika Xu, Ling Bhattacharya, Shibani Nabel, Gary J. Bewley, Carole A. Kwong, Peter D. TI NMR Assignments and Dynamics of Ligand-free HIV-1 gp120 Outer Domain SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Sastry, Mallika; Xu, Ling; Nabel, Gary J.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD USA. [Bhattacharya, Shibani] New York Struct Biol Ctr, New York, NY USA. [Bewley, Carole A.] NIDDK, Lab Bioorgan Chem, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P16.04 BP 296 EP 296 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600547 ER PT J AU Arrode-Bruses, G Goode, D Frank, I Kleinbeck, K Byrareddy, S Arthos, J Grasperge, B Blanchard, J Gettie, A Zydowsky, T Martinelli, E AF Arrode-Bruses, Geraldine Goode, Diana Frank, Ines Kleinbeck, Kyle Byrareddy, Siddappa Arthos, James Grasperge, Brooke Blanchard, James Gettie, Agegnehu Zydowsky, Thomas Martinelli, Elena TI Inhibition of alpha(4)beta(7) Activation May be Necessary to Reduce Susceptibility to SIV: Differential Effect of an Agonist and an Allosteric Inhibitor SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Arrode-Bruses, Geraldine; Goode, Diana; Frank, Ines; Kleinbeck, Kyle; Zydowsky, Thomas; Martinelli, Elena] Populat Council, New York, NY USA. [Byrareddy, Siddappa] Univ Nebraska Med Ctr, Omaha, NE USA. [Arthos, James] NIAID, NIH, Bethesda, MD USA. [Grasperge, Brooke; Blanchard, James] Tulane Natl Primate Res Ctr, Covington, LA USA. [Gettie, Agegnehu] Aaron Diamond AIDS Res Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P18.12 BP 310 EP 310 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600574 ER PT J AU Soto, C Lemmin, T Stewart-Jones, GBE Kwong, PD AF Soto, Cinque Lemmin, Thomas Stewart-Jones, Guillaume B. E. Kwong, Peter D. TI Dynamics of the HIV-1 Glycan Shield SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Soto, Cinque; Stewart-Jones, Guillaume B. E.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Rockville, MD USA. [Lemmin, Thomas] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.09 BP 326 EP 326 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600605 ER PT J AU Matyas, GR Torres, OB Jalah, R Antoline, JFG Peachman, KK Beck, Z Rao, M Jacobson, AE Michael, NL Rice, KC Alving, CR AF Matyas, Gary R. Torres, Oscar B. Jalah, Rashmi Antoline, Joshua F. G. Peachman, Kristina K. Beck, Zoltan Rao, Mangala Jacobson, Arthur E. Michael, Nelson L. Rice, Kenner C. Alving, Carl R. TI Development of a Combination HIV-heroin Vaccine SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Matyas, Gary R.; Rao, Mangala; Michael, Nelson L.; Alving, Carl R.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Torres, Oscar B.; Jalah, Rashmi; Peachman, Kristina K.; Beck, Zoltan] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Antoline, Joshua F. G.; Jacobson, Arthur E.; Rice, Kenner C.] NIDA, NIH, Bethesda, MD 20892 USA. [Antoline, Joshua F. G.; Jacobson, Arthur E.; Rice, Kenner C.] NIAAA, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.13 BP 328 EP 328 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600608 ER PT J AU Chuang, GY Geng, H Pancera, M Acharya, P Chambers, M Druz, A Tsybovsky, Y Yang, YP Georgiev, I Gorman, J Joyce, MG McDermott, A Mascola, JR Kwong, PD AF Chuang, Gwo-Yu Geng, Hui Pancera, Marie Acharya, Priyamvada Chambers, Michael Druz, Aliaksandr Tsybovsky, Yaroslav Yang, Yongping Georgiev, Ivelin Gorman, Jason Joyce, M. Gordon McDermott, Adrian Mascola, John R. Kwong, Peter D. TI Increased Thermostability and Reduced CD4 Affinity of Structure-based Stabilized Prefusion Closed HIV-1 Env Trimer SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Chuang, Gwo-Yu; Geng, Hui; Pancera, Marie; Acharya, Priyamvada; Chambers, Michael; Druz, Aliaksandr; Tsybovsky, Yaroslav; Yang, Yongping; Georgiev, Ivelin; Gorman, Jason; Joyce, M. Gordon; McDermott, Adrian; Mascola, John R.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Rockville, MD USA. [Georgiev, Ivelin] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.16 BP 329 EP 329 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600611 ER PT J AU Stewart-Jones, GBE Soto, C Zhou, TQ Kwong, PD AF Stewart-Jones, Guillaume B. E. Soto, Cinque Zhou, Tongqing Kwong, Peter D. TI Identification of Dispersed Glycans on HIV-1 Env Trimer and Design of Related Immunogens SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Stewart-Jones, Guillaume B. E.; Soto, Cinque; Zhou, Tongqing; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.15 BP 329 EP 329 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600610 ER PT J AU Lagenaur, L Marcobal, A Nilsen, T Parks, T AF Lagenaur, Laurel Marcobal, Angela Nilsen, Trine Parks, Thomas TI Safety Evaluation of Live Biotherapeutics for Prevention of BV and HIV-1 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Lagenaur, Laurel; Marcobal, Angela; Nilsen, Trine; Parks, Thomas] Osel Inc, Mountain View, CA USA. [Lagenaur, Laurel] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.27 BP 335 EP 335 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600622 ER PT J AU Joyce, MG Georgiev, I Yang, YP Sastry, M Zhang, BS Cheng, C Chambers, M Tsybovsky, Y Aliaksandr, D Xu, K Zhou, TQ Chuang, GY Gorman, J Pancera, M Geng, H Kwon, YD Stewart-Jones, G Mc Dermott, A Mascola, J Kwong, P AF Joyce, M. Gordon Georgiev, Ivelin Yang, Yongping Sastry, Mallika Zhang Baoshan Cheng, Cheng Chambers, Michael Tsybovsky, Yaroslav Aliaksandr, Druz Xu, Kai Zhou, Tongqing Chuang Gwo-Yu Gorman, Jason Pancera, Marie Geng, Hui Kwon, Young-Do Stewart-Jones, Guillaume Mc Dermott, Adrian Mascola, John Kwong, Peter TI Designed HIV-1 Env Molecules from Multiple Clades That Display Structural and Antigenic Characteristics of the Mature Prefusion HIV-1 Env SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Joyce, M. Gordon; Georgiev, Ivelin; Yang, Yongping; Sastry, Mallika; Zhang Baoshan; Cheng, Cheng; Chambers, Michael; Tsybovsky, Yaroslav; Aliaksandr, Druz; Xu, Kai; Zhou, Tongqing; Chuang Gwo-Yu; Gorman, Jason; Pancera, Marie; Geng, Hui; Kwon, Young-Do; Stewart-Jones, Guillaume; Mc Dermott, Adrian; Mascola, John; Kwong, Peter] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.30 BP 336 EP 336 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600625 ER PT J AU Galkin, A Chen, YJ Guenaga, J O'Dell, S Chiang, CI Doria-Rose, N Mascola, JR Li, YX AF Galkin, Andrey Chen, Yajing Guenaga, Javier O'Dell, Sijy Chiang, Chi-I Doria-Rose, Nicole Mascola, John R. Li, Yuxing TI gp120-CD4i Antibody Complex as Immunogen SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Galkin, Andrey] Univ Maryland, Inst Biosci & Biotechnol Res, College Pk, MD 20742 USA. [Chen, Yajing] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [Guenaga, Javier] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA. [O'Dell, Sijy; Doria-Rose, Nicole; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Chiang, Chi-I; Li, Yuxing] Univ Maryland, Inst Biosci & Biotechnol Res, College Pk, MD 20742 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.47LB BP 345 EP 345 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600642 ER PT J AU Welles, H Bailer, R Mason, R Doria-Rose, N Nguyen, R O'Dell, S Hoxie, J Mascola, J Roederer, M AF Welles, Hugh Bailer, Robert Mason, Rosemarie Doria-Rose, Nicole Nguyen, Richard O'Dell, Siji Hoxie, James Mascola, John Roederer, Mario TI Isolation of SIV Env-specific Tier 2 Neutralizing Antibody from iMac-Delta D Immunized Macaque SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Welles, Hugh; Mason, Rosemarie; Doria-Rose, Nicole; Nguyen, Richard; O'Dell, Siji; Mascola, John; Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. George Washington Univ, Washington, DC 20052 USA. [Bailer, Robert] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Hoxie, James] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.50LB BP 346 EP 346 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600645 ER PT J AU Cheng, C Wanninger, T Joyce, MG Georgiev, I Chen, R Yang, YP Kong, WP Kwong, P Mascola, J AF Cheng, Cheng Wanninger, Timothy Joyce, M. Gordon Georgiev, Ivelin Chen, Rita Yang, Yongping Kong, Wing-Pui Kwong, Peter Mascola, John TI Membrane-anchored HIV-1 Envelope Immunogens with Native Trimer Antigenicity for DNA Vaccine SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Cheng, Cheng; Wanninger, Timothy; Joyce, M. Gordon; Georgiev, Ivelin; Chen, Rita; Yang, Yongping; Kong, Wing-Pui; Kwong, Peter; Mascola, John] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.52LB BP 347 EP 347 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600647 ER PT J AU Acharya, P Liu, QB Lusso, P Chuang, GY Druz, A Zhou, TQ Rice, WJ Wigge, C Carragher, B Potter, CS Kwong, PD AF Acharya, Priyamvada Liu, Qingbo Lusso, Paolo Chuang, Gwo-Yu Druz, Aliaksandr Zhou, Tongqing Rice, William J. Wigge, Christoph Carragher, Bridget Potter, Clinton S. Kwong, Peter D. TI Cryo-EM Structure of the First Contact of CD4 Receptor with HIV-1 Env SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Acharya, Priyamvada; Liu, Qingbo; Lusso, Paolo; Chuang, Gwo-Yu; Druz, Aliaksandr; Zhou, Tongqing; Kwong, Peter D.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Acharya, Priyamvada; Rice, William J.; Wigge, Christoph; Carragher, Bridget; Potter, Clinton S.] New York Struct Biol Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.54LB BP 348 EP 348 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600649 ER PT J AU Xu, K Liu, K Acharya, P Kong, R Druz, A Carragher, B Potter, CS Mascola, JR Kwong, PD AF Xu, Kai Liu, Kevin Acharya, Priyamvada Kong, Rui Druz, Alex Carragher, Bridget Potter, Clinton S. Mascola, John R. Kwong, Peter D. TI Study of Vaccine-Elicited HIV-1 Fusion Peptide-Targeting Antibody SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Xu, Kai; Liu, Kevin; Acharya, Priyamvada; Kong, Rui; Druz, Alex; Mascola, John R.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Carragher, Bridget; Potter, Clinton S.] Simons Electron Microscopy Ctr, Natl Resource Automated Mol Microscopy, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P19.55LB BP 349 EP 349 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600650 ER PT J AU van der Straten, A Cheng, H Brown, ER Reddy, K Scheckter, R Soto-Torres, L Phillips-Palanee, T Baeten, J Mensch, B AF van der Straten, Ariane Cheng, Helen Brown, Elizabeth R. Reddy, Krishnaveni Scheckter, Rachel Soto-Torres, Lydia Phillips-Palanee, Thesla Baeten, Jared Mensch, Barbara CA MTN-020 ASPIRE Study Team TI Are Ring Worries Affecting Use? Findings from the MTN-020/ASPIRE Phase III Dapivirine Ring Trial SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [van der Straten, Ariane; Cheng, Helen] RTI Int, Womens Global Hlth Imperat, Res Triangle Pk, NC USA. [van der Straten, Ariane] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Brown, Elizabeth R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Reddy, Krishnaveni; Phillips-Palanee, Thesla] Univ Witwatersrand, ZA-2050 Johannesburg, South Africa. [Scheckter, Rachel] FHI 360, Durham, NC USA. [Soto-Torres, Lydia] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. [Baeten, Jared] Univ Washington, Seattle, WA 98195 USA. [Mensch, Barbara] Populat Council, 1230 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P24.03 BP 376 EP 376 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600700 ER PT J AU Scheckter, R McKinstry, L Balkus, J Beigi, R Kabwigu, S Noguchi, L Ndase, P Panchia, R Kintu, K Taljaard, M Mhlanga, F Nair, G Palanee-Phillips, T Moodley, J Piper, J Watts, H Pan, J Torjesen, K AF Scheckter, Rachel McKinstry, Laura Balkus, Jennifer Beigi, Rich Kabwigu, Samuel Noguchi, Lisa Ndase, Patrick Panchia, Ravindre Kintu, Kenneth Taljaard, Marthinette Mhlanga, Felix Nair, Gonasagrie Palanee-Phillips, Thesla Moodley, Jothi Piper, Jeanna Watts, Heather Pan, Jason Torjesen, Kristine TI Growth and Development of Infants Born to Women Enrolled in a Clinical Trial of Tenofovir-based Pre-exposure Prophylaxis for HIV Prevention SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Scheckter, Rachel; Torjesen, Kristine] FHI 360, Durham, NC USA. [McKinstry, Laura; Balkus, Jennifer; Pan, Jason] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Beigi, Rich] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Kabwigu, Samuel; Kintu, Kenneth] MU JHU, Kampala, Uganda. [Noguchi, Lisa] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Ndase, Patrick] PSI, Washington, DC USA. [Panchia, Ravindre] Perinatal HIV Res Unit, Soweto, South Africa. [Taljaard, Marthinette] Aurum Inst, Johannesburg, South Africa. [Mhlanga, Felix] UZ UCSF, Harare, Zimbabwe. [Nair, Gonasagrie] CAPRISA, Durban, South Africa. [Palanee-Phillips, Thesla] Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa. [Moodley, Jothi] South African Med Res Council, Cape Town, South Africa. [Piper, Jeanna] NIH, Bldg 10, Bethesda, MD 20892 USA. [Watts, Heather] US Dept State, Washington, DC 20520 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P25.13 BP 395 EP 395 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600738 ER PT J AU Yang, YP Kwong, PD AF Yang, Yongping Kwong, Peter D. TI Throughput Screening of HIV-1 Broad Neutralizing Antibodies and Env Immunogens SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Meeting Abstract CT Conference on HIV Research for Prevention (HIV R4P) CY OCT 17-20, 2016 CL Chicago, IL C1 [Yang, Yongping; Kwong, Peter D.] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2016 VL 32 SU 1 MA P26.02 BP 400 EP 400 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EA6YH UT WOS:000386774600748 ER PT J AU Perkins, NJ Schisterman, EF AF Perkins, Neil J. Schisterman, Enrique F. TI RE: "RECEIVER OPERATING CHARACTERISTIC CURVE INFERENCE FROM A SAMPLE WITH A LIMIT OF DETECTION" Reply SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Letter C1 [Perkins, Neil J.; Schisterman, Enrique F.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, Bethesda, MD 20892 USA. RP Schisterman, EF (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, Bethesda, MD 20892 USA. EM schistee@mail.nih.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD OCT 1 PY 2016 VL 184 IS 7 BP 554 EP 554 DI 10.1093/aje/kww092 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA4AY UT WOS:000386552000009 PM 27620451 ER PT J AU Yoon, SS Dillon, CF Illoh, K Carroll, M AF Yoon, Sung Sug (Sarah) Dillon, Charles F. Illoh, Kachi Carroll, Margaret TI Trends in the Prevalence of Coronary Heart Disease in the US National Health and Nutrition Examination Survey, 2001-2012 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES; BLOOD-PRESSURE; SELF-REPORTS; HYPERTENSION; ADULTS; MORTALITY; RISK; LIPOPROTEINS; POPULATION; VALIDITY AB Introduction: This study evaluated recent trends in the prevalence of coronary heart disease in the U.S. population aged >= 40 years. Methods: A total of 21,472 adults aged >= 40 years from the 2001-2012 National Health and Nutrition Examination Survey were included in the analysis. The analysis was conducted in 2015. Coronary heart disease included myocardial infarction, angina, and any other type of coronary heart disease, which were defined as a history of medical diagnosis of these specific conditions. Angina was also defined as currently taking anti-angina medication or having Rose Angina Questionnaire responses that scored with a Grade >= 1. Trends from 2001 to 2012 were analyzed overall, within demographic subgroups, and by major coronary heart disease risk factors. Results: Between 2001 and 2012, the overall prevalence of coronary heart disease significantly decreased from 10.3% to 8.0% (p-trend<0.05). The prevalence of angina significantly decreased from 7.8% to 5.5% and myocardial infarction prevalence decreased from 5.5% to 4.7% (p-trend <0.05 for both groups). Overall coronary heart disease prevalence significantly decreased among women, adults aged >60 years, non-Hispanic whites, non-Hispanic blacks, adults who did not complete high school, adults with more than a high school education, and adults who had health insurance (p-trend <0.05 for all groups). Conclusions: The overall prevalence of coronary heart disease including angina and myocardial infarction decreased significantly over the 12-year survey period. However, this reduction was seen mainly among persons without established coronary heart disease risk factors. There was no change in coronary heart disease prevalence among those with specific coronary heart disease risk factors. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Yoon, Sung Sug (Sarah)] NIH, Healthcare Delivery & Methodol IRG, Div AIDS Behav & Populat Sci, Ctr Sci Review, 6701 Rockledge Dr,Room 3152,MSC 7770, Bethesda, MD 20892 USA. [Dillon, Charles F.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Illoh, Kachi] US FDA, Off New Drugs Immediate Off, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Carroll, Margaret] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Yoon, SS (reprint author), NIH, Healthcare Delivery & Methodol IRG, Div AIDS Behav & Populat Sci, Ctr Sci Review, 6701 Rockledge Dr,Room 3152,MSC 7770, Bethesda, MD 20892 USA. EM sarah.yoon@nih.gov NR 39 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 437 EP 445 DI 10.1016/j.amepre.2016.02.023 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200008 PM 27113539 ER PT J AU Choi, K Bernat, D AF Choi, Kelvin Bernat, Debra TI E-Cigarette Use Among Florida Youth With and Without Asthma SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID BRAIN-DEVELOPMENT; SMOKING; NICOTINE; TOBACCO AB Introduction: Although prevalence of youth e-cigarette use has increased dramatically, little is known about e-cigarette use among youth with asthma and how it differs by metropolitan status. This study assessed the prevalence of e-cigarette use among youth by asthma and metropolitan status and examined the associations between e-cigarette use, susceptibility to cigarette smoking, and asthma attack. Methods: High school student participants from the 2012 Florida Youth Tobacco Survey were included (N=36,085). Information on demographics, asthma status, ever and past 30-day use of e-cigarettes, cigarette smoking susceptibility, and having asthma attacks in the past 12 months were collected. Data were weighted to be representative of Florida high school students. Analyses were conducted in 2015. Results: Overall, prevalence of ever and past 30-day e-cigarette use among students who reported having asthma were 10.4% and 5.3%, respectively, higher than those without asthma (7.2% and 2.5%, respectively, p<0.01). Among students with asthma, e-cigarette use was more common among those in non-metropolitan and rural counties than those in metropolitan counties (p<0.05). Ever and past 30-day e-cigarette use was associated with cigarette smoking susceptibility among participants with asthma and those who never tried cigarettes (n=2,410; ever use, AOR=3.96, 95% CI=1.49, 10.56; past 30-day use, AOR=422.10, 95% CI=50.29, > 999.99). Past 30-day e-cigarette use was associated with having an asthma attack in the past 12 months among participants with asthma (n=5,865, p<0.01). Conclusions: E-cigarette use is more common among Florida high school youth with asthma and is associated with susceptibility to cigarette smoking. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Choi, Kelvin] Natl Inst Minor Hlth & Hlth Dispar, Div Intramural Res, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Bernat, Debra] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA. RP Choi, K (reprint author), Natl Inst Minor Hlth & Hlth Dispar, Div Intramural Res, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM kelvin.choi@nih.gov FU Division of Intramural Research, National Institute on Minority Health and Health Disparities, NIH; National Cancer Institute [R03 CA168411] FX Dr. Choi's effort is funded by the Division of Intramural Research, National Institute on Minority Health and Health Disparities, NIH. Dr. Bernat's effort is supported with a grant from the National Cancer Institute (R03 CA168411; D. Bernat, Principal Investigator). NR 26 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 446 EP 453 DI 10.1016/j.amepre.2016.03.010 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200009 PM 27085691 ER PT J AU McCarthy, AM Kim, JJ Beaber, EF Zheng, YY Burnett-Hartman, A Chubak, J Ghai, NR McLerran, D Breen, N Conant, EF Geller, BM Green, BB Klabunde, CN Inrig, S Skinner, CS Quinn, VP Haas, JS Schnall, M Rutter, CM Barlow, WE Corley, DA Armstrong, K Doubeni, CA AF McCarthy, Anne Marie Kim, Jane J. Beaber, Elisabeth F. Zheng, Yingye Burnett-Hartman, Andrea Chubak, Jessica Ghai, Nirupa R. McLerran, Dale Breen, Nancy Conant, Emily F. Geller, Berta M. Green, Beverly B. Klabunde, Carrie N. Inrig, Stephen Skinner, Celette Sugg Quinn, Virginia P. Haas, Jennifer S. Schnall, Mitchell Rutter, Carolyn M. Barlow, William E. Corley, Douglas A. Armstrong, Katrina Doubeni, Chyke A. CA PROSPR Consortium TI Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID OCCULT BLOOD-TEST; LOW-INCOME WOMEN; UNITED-STATES; CARE; MAMMOGRAPHY; DIAGNOSIS; QUALITY; PREDICTORS; TIME; IMPROVEMENT AB Introduction: Timely follow-up of abnormal tests is critical to the effectiveness of cancer screening, but may vary by screening test, healthcare system, and sociodemographic group. Methods: Timely follow-up of abnormal mammogram and fecal occult blood testing or fecal immunochemical tests (FOBT/FIT) were compared by race/ethnicity using Population-Based Research Optimizing Screening through Personalized Regimens consortium data. Participants were women with an abnormal mammogram (aged 40-75 years) or FOBT/FIT (aged 50-75 years) in 2010-2012. Analyses were performed in 2015. Timely follow-up was defined as colonoscopy <= 3 months following positive FOBT/ FIT; additional imaging or biopsy <= 3 months following Breast Imaging Reporting and Data System Category 0, 4, or 5 mammograms; or <= 9 months following Category 3 mammograms. Logistic regression was used to model receipt of timely follow-up adjusting for study site, age, year, insurance, and income. Results: Among 166,602 mammograms, 10.7% were abnormal; among 566,781 FOBT/FITs, 4.3% were abnormal. Nearly 96% of patients with abnormal mammograms received timely follow-up versus 68% with abnormal FOBT/FIT. There was greater variability in receipt of follow-up across healthcare systems for positive FOBT/FIT than for abnormal mammograms. For mammography, black women were less likely than whites to receive timely follow-up (91.8% vs 96.0%, OR=0.71, 95% CI=0.51, 0.97). For FOBT/FIT, Hispanics were more likely than whites to receive timely follow-up than whites (70.0% vs 67.6%, OR=1.12, 95% CI=1.04, 1.21). Conclusions: Timely follow-up among women was more likely for abnormal mammograms than FOBT/FITs, with small variations in follow-up rates by race/ethnicity and larger variation across healthcare systems. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [McCarthy, Anne Marie; Armstrong, Katrina] Massachusetts Gen Hosp, Dept Med, 50 Staniford St,940F, Boston, MA 02114 USA. [Kim, Jane J.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Beaber, Elisabeth F.; McLerran, Dale] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Zheng, Yingye] Fred Hutchinson Canc Res Ctr, Dept Biostat, 1124 Columbia St, Seattle, WA 98104 USA. [Burnett-Hartman, Andrea] Fred Hutchinson Canc Res Ctr, Div Epidemiol, 1124 Columbia St, Seattle, WA 98104 USA. [Burnett-Hartman, Andrea] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Chubak, Jessica; Green, Beverly B.] Grp Hlth Res Inst, Seattle, WA USA. [Ghai, Nirupa R.; Quinn, Virginia P.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Breen, Nancy] NCI, Hlth Syst & Intervent Res Branch, Bethesda, MD 20892 USA. [Conant, Emily F.; Schnall, Mitchell] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Geller, Berta M.] Univ Vermont, Dept Family Med, Burlington, VT USA. [Klabunde, Carrie N.] NIH, Off Dis Prevent, Bldg 10, Bethesda, MD 20892 USA. [Inrig, Stephen] Univ Texas Southwestern Med Ctr Dallas, Dept Hlth Policy & Hist Med, Dallas, TX 75390 USA. [Inrig, Stephen] Mt St Marys Univ, Dept Hlth Policy & Management, Los Angeles, CA USA. [Skinner, Celette Sugg] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Skinner, Celette Sugg] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA. [Haas, Jennifer S.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Rutter, Carolyn M.] RAND Corp, Santa Monica, CA USA. [Barlow, William E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Corley, Douglas A.] Kaiser Permanente Northern Calif, Dept Gastroenterol, Oakland, CA USA. [Doubeni, Chyke A.] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. RP McCarthy, AM (reprint author), Massachusetts Gen Hosp, Dept Med, 50 Staniford St,940F, Boston, MA 02114 USA. EM amccarthy8@partners.org OI Inrig, Stephen/0000-0003-2091-5841 FU NIH/National Cancer Institute PROSPR program [U54CA163262, U54CA163261, U54CA163308, U54CA163313, U54CA163303, U54CA163307, U54CA164336, U01CA163304] FX This work was funded by the NIH/National Cancer Institute PROSPR program, grant numbers: Kaiser Foundation Research Institute U54CA163262, Group Health Research Institute U54CA163261, Parkland UT Southwestern U54CA163308, University of Pennsylvania U54CA163313, University of Vermont U54CA163303, Geisel School of Medicine at Dartmouth and Brigham and Women's Hospital U54CA163307, University of New Mexico U54CA164336, Fred Hutchinson Cancer Research Center U01CA163304. NR 32 TC 1 Z9 1 U1 8 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 507 EP 512 DI 10.1016/j.amepre.2016.03.017 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200016 PM 27132628 ER PT J AU Sandhu, PK Elder, R Patel, M Saraiya, M Holman, DM Perna, F Smith, RA Buller, D Sinclair, C Reeder, A Makin, J McNoe, B Glanz, K AF Sandhu, Paramjit K. Elder, Randy Patel, Mona Saraiya, Mona Holman, Dawn M. Perna, Frank Smith, Robert A. Buller, David Sinclair, Craig Reeder, Anthony Makin, Jennifer McNoe, Bronwen Glanz, Karen CA Community Preventive Serv TI Community-wide Interventions to Prevent Skin Cancer Two Community Guide Systematic SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PROMOTE SUN PROTECTION; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; ULTRAVIOLET-RADIATION; DYSPLASTIC NEVI; UNITED-STATES; RISK-FACTORS; AUSTRALIA; METAANALYSIS; PREVALENCE AB Context: Skin cancer is a preventable and commonly diagnosed cancer in the U.S. Excessive ultraviolet radiation exposure is a known cause of skin cancer. This article presents updated results of two types of interventions evaluated in a previously published Community Guide systematic review: multicomponent community-wide interventions and mass media interventions when used alone. Evidence acquisition: Studies assessing multicomponent community-wide and mass media interventions to prevent skin cancer by reducing ultraviolet radiation exposure were evaluated using Community Guide systematic review methods. Relevant studies published between 1966 and 2013 were included and analyzed for this review. Evidence synthesis: Seven studies evaluating the effectiveness of multicomponent community-wide interventions showed a median increase in sunscreen use of 10.8 (interquartile interval=7.3, 23.2) percentage points, a small decrease in ultraviolet radiation exposure, a decrease in indoor tanning device use of 4.0 (95% CI=2.5, 5.5) percentage points, and mixed results for other protective behaviors. Four studies evaluating the effectiveness of mass media interventions found that they generally led to improved ultraviolet protection behaviors among children and adults. Conclusions: The available evidence showed that multicomponent community-wide interventions are effective in reducing the deleterious effects of ultraviolet radiation exposure by increasing sunscreen use. There was, however, insufficient evidence to determine the effectiveness of mass media interventions alone in reducing ultraviolet radiation exposure and increasing ultraviolet protection behaviors, indicating a continuing need for more research in this field to improve assessment of effectiveness. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Sandhu, Paramjit K.; Elder, Randy; Patel, Mona] Ctr Dis Control & Prevent CDC, Community Guide Branch, Div Publ Hlth Informat Disseminat, Atlanta, GA USA. [Saraiya, Mona; Holman, Dawn M.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Perna, Frank] NCI, NIH, Bethesda, MD 20892 USA. [Smith, Robert A.] Amer Canc Soc, Atlanta, GA 30329 USA. [Buller, David] Klein Buendel, Lakewood, CO USA. [Sinclair, Craig] Canc Council Victoria, Ctr Behav Res Canc, Melbourne, Vic, Australia. [Reeder, Anthony; McNoe, Bronwen] Univ Otago, Dept Prevent & Social Med, Canc Soc Social & Behav Res Unit, Dunedin, New Zealand. [Makin, Jennifer] Univ Tasmania, Menzies Res Inst, Hobart, Tas 7001, Australia. [Glanz, Karen] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. RP Sandhu, PK (reprint author), Ctr Dis Control & Prevent CDC, Lab Res & Evaluat Branch, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30329 USA. EM psandhu@cdc.gov FU Intramural CDC HHS [CC999999] NR 43 TC 1 Z9 1 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 531 EP 539 DI 10.1016/j.amepre.2016.03.020 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200021 PM 27647053 ER PT J AU Rigotti, NA Stoney, CM AF Rigotti, Nancy A. Stoney, Catherine M. TI CHARTing the Future Course of Tobacco-Cessation Interventions for Hospitalized Smokers SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article C1 [Rigotti, Nancy A.] Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Rigotti, Nancy A.] Harvard Med Sch, Boston, MA USA. [Stoney, Catherine M.] NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA. RP Rigotti, NA (reprint author), Massachusetts Gen Hosp, 50 Staniford St,914, Boston, MA 02114 USA. EM nrigotti@partners.org FU NIH/National Heart, Lung, and Blood Institute [R01-HL11821] FX Dr. Rigotti was supported by NIH/National Heart, Lung, and Blood Institute grant number R01-HL11821, receives royalties from UpToDate, Inc., and has received travel expenses from Pfizer, Inc., to attend consultant meetings for which she received no honorarium. No other financial disclosures were reported by the authors of this paper. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH or the U.S. Government. NR 10 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 549 EP 550 DI 10.1016/j.amepre.2016.07.012 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200024 PM 27647055 ER PT J AU Fellows, JL Mularski, RA Leo, MC Bentz, CJ Waiwaiole, LA Francisco, MC Funkhouser, K Stoney, CM AF Fellows, Jeffrey L. Mularski, Richard A. Leo, Michael C. Bentz, Charles J. Waiwaiole, Lisa A. Francisco, Melanie C. Funkhouser, Kimberly Stoney, Catherine M. TI Referring Hospitalized Smokers to Outpatient Quit Services A Randomized Trial SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SMOKING-CESSATION INTERVENTION; CIGARETTE-SMOKING; HEART-DISEASE; SYSTEM; CARE; PERFORMANCE; MODEL AB Introduction: Linking outpatient cessation services to bedside counseling for hospitalized smokers can improve long-run quit rates. Adding an assisted referral (AR) offer to a tobacco treatment specialist consult service fits the team approach to care in U.S. hospitals. Design: A two-arm patient-randomized trial tested the effectiveness of adding an AR offer to outpatient smoking-cessation services and interactive voice recognition (AR+IVR) follow-up to a usual care (UC) tobacco-cessation consult for hospitalized smokers. Setting/participants: Over 24 months (November 2011-November 2013), 898 hospitalized adult smokers interested in quitting smoking were recruited from three large hospitals in the Portland, Oregon, area: an integrated group model HMO (n=622), a community hospital (n=195), and an academic health center (n=81). Intervention: Tobacco treatment specialists identified smokers and provided an intensive bedside tobacco use assessment and cessation consultation (UC). AR+IVR recipients also received proactive ARs to available outpatient counseling programs and medications, and linked patients to a tailored IVR telephone follow-up system. Main outcome measures: The primary outcome was self-reported 30-day abstinence at 6-month follow-up. Secondary outcomes included self-reported and continuous abstinence and biochemically confirmed 7-day abstinence at 6 months. Follow-up was completed in September 2014; data were analyzed in 2015. Results: A total of 597 and 301 hospitalized smokers were randomized to AR+IVR and UC, respectively. AR+IVR and UC recipients received 19.3 and 17.0 minutes of bedside counseling (p=0.372), respectively. Most (58%) AR+IVR patients accepted referrals for counseling, 43% accepted medications, and 28% accepted both. Self-reported 30-day abstinence for AR+IVR (17.9%) and UC (17.3%) were not statistically significant (p=0.569). Differences in 7-day, continuous, and biochemically confirmed abstinence by treatment group also were insignificant, overall and adjusting for site. Conclusions: Adding an AR to outpatient counseling and medications did not increase cigarette abstinence at 6 months compared to UC alone. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [Fellows, Jeffrey L.; Mularski, Richard A.; Leo, Michael C.; Waiwaiole, Lisa A.; Francisco, Melanie C.; Funkhouser, Kimberly] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Bentz, Charles J.] Legacy Hlth Syst, Tobacco Cessat & Prevent, Portland, OR USA. [Stoney, Catherine M.] NHLBI, Div Cardiovasc Sci, NIH, Bldg 10, Bethesda, MD 20892 USA. RP Fellows, JL (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM jeffrey.fellows@kpchr.org FU National Heart, Lung, and Blood Institute [U01 HL105231, NCT01236079] FX Funding was provided by the National Heart, Lung, and Blood Institute (U01 HL105231; clinical trials registration, NCT01236079). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH or the U.S. Government. NR 35 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 609 EP 619 DI 10.1016/j.amepre.2016.06.014 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200030 PM 27647061 ER PT J AU Cruvinel, E Richter, KP Stoney, C Duffy, S Fellows, J Harrington, KF Rigotti, NA Sherman, S Tindle, HA Shireman, TI Shelley, D Waiwaiole, L Cummins, S AF Cruvinel, Erica Richter, Kimber P. Stoney, Catherine Duffy, Sonia Fellows, Jeffrey Harrington, Kathleen F. Rigotti, Nancy A. Sherman, Scott Tindle, Hilary A. Shireman, Theresa I. Shelley, Donna Waiwaiole, Lisa Cummins, Sharon TI CHARTing a Path to Pragmatic Tobacco Treatment Research SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID TRIALS; PRECIS AB Introduction: It is important to consider the degree to which studies are explanatory versus pragmatic to understand the implications of their findings for patients, healthcare professionals, and policymakers. Pragmatic trials test the effectiveness of interventions in real-world conditions; explanatory trials test for efficacy under ideal conditions. The Consortium of Hospitals Advancing Research on Tobacco (CHART) is a network of seven NIH-funded trials designed to identify effective programs that can be widely implemented in routine clinical practice. Methods: A cross-sectional analysis of CHART trial study designs was conducted to place each study on the pragmatic-explanatory continuum. After reliability training, six raters independently scored each CHART study according to ten PRagmatic Explanatory Continuum Indicator Summary (PRECIS) dimensions, which covered participant eligibility criteria, intervention flexibility, practitioner expertise, follow-up procedures, participant compliance, practitioner adherence, and outcome analyses. Means and SDs were calculated for each dimension of each study, with lower scores representing more pragmatic elements. Results were plotted on "spoke and wheel" diagrams. The rating process and analyses were performed in October 2014 to September 2015. Results: All seven CHART trials tended toward the pragmatic end of the spectrum, although there was a range from 0.76 (SD = 0.23) to 1.85 (SD = 0.58). Most studies included some explanatory design elements. Conclusions: CHART findings should be relatively applicable to clinical practice. Funders and reviewers could integrate PRECIS criteria into their guidelines to better facilitate pragmatic research. CHART study protocols, coupled with scores reported here, may help readers improve the design of their own pragmatic trials. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [Cruvinel, Erica] Univ Fed Juiz de Fora, Dept Psychol, Juiz De Fora, MG, Brazil. [Richter, Kimber P.] Univ Kansas, Med Ctr, Dept Prevent Med & Publ Hlth, Kansas City, KS 66103 USA. [Richter, Kimber P.] Univ Kansas, Med Ctr, Ctr Canc, Kansas City, KS 66103 USA. [Stoney, Catherine] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Duffy, Sonia] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA. [Duffy, Sonia] Dept Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Fellows, Jeffrey; Waiwaiole, Lisa] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Harrington, Kathleen F.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Rigotti, Nancy A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA USA. [Rigotti, Nancy A.] Harvard Med Sch, Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA USA. [Sherman, Scott] NYU, Sch Med, Dept Populat Hlth Med, New York, NY USA. [Sherman, Scott] NYU, Sch Med, Dept Med, New York, NY USA. [Sherman, Scott] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Tindle, Hilary A.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Shireman, Theresa I.] Brown Univ, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. [Shelley, Donna] NYU, Sch Med, Dept Populat Med, New York, NY USA. [Cummins, Sharon] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA. RP Cruvinel, E (reprint author), Univ Fed Juiz de Fora, Dept Psychol, Ctr Res Intervent & Evaluat Alcohol & Other Drugs, Juiz De Fora, MG, Brazil. EM ecruvinel@yahoo.com.br OI Sherman, Scott/0000-0003-1752-7303 FU Foundation for Research Support of Minas Gerais (FAPEMIG); National Council for Scientific and Technological Development (CNPq); Coordination for the Improvement of Higher Education Personnel (CAPES) of Brazil; National Heart, Lung, and Blood Institute [U01 HL105232-01] FX The authors thank Niaman Nazir, MBBS, MPH, for assistance with formatting the spoke and wheel diagrams. This work was supported by the National Heart, Lung, and Blood Institute (U01 HL105232-01) and the Foundation for Research Support of Minas Gerais (FAPEMIG), National Council for Scientific and Technological Development (CNPq), and Coordination for the Improvement of Higher Education Personnel (CAPES) of Brazil. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute; NIH; or the government of Brazil. The study sponsor had no role in study design; collection, analysis, or interpretation of data; writing the report; or the decision to submit the report for publication. NR 18 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 BP 630 EP 636 DI 10.1016/j.amepre.2016.05.025 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BX UT WOS:000386784200032 PM 27647063 ER PT J AU Chambers, DA Norton, WE AF Chambers, David A. Norton, Wynne E. TI The Adaptome Advancing the Science of Intervention Adaptation SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PREVENTION INTERVENTIONS; THERAPIST ADHERENCE; MENTAL-HEALTH; IMPLEMENTATION; FIDELITY; TECHNOLOGIES; BEHAVIOR; OUTCOMES AB In the past few decades, prevention scientists have developed and tested a range of interventions with demonstrated benefits on child and adolescent cognitive, affective, and behavioral health. These evidence-based interventions offer promise of population-level benefit if accompanied by findings of implementation science to facilitate adoption, widespread implementation, and sustainment. Though there have been notable examples of successful efforts to scale up interventions, more work is needed to optimize benefit. Although the traditional pathway from intervention development and testing to implementation has served the research community well-allowing for a systematic advance of evidence-based interventions that appear ready for implementation-progress has been limited by maintaining the hypothesis that evidence generation must be complete prior to implementation. This sets up the challenging dichotomy between fidelity and adaptation and limits the science of adaptation to findings from randomized trials of adapted interventions. The field can do better. This paper argues for the development of strategies to advance the science of adaptation in the context of implementation that would more comprehensively describe the needed fit between interventions and their settings, and embrace opportunities for ongoing learning about optimal intervention delivery over time. Efforts to build the resulting adaptome (pronounced "adapt-ohm") will include the construction of a common data platform to house systematically captured information about variations in delivery of evidence-based interventions across multiple populations and contexts, and provide feedback to intervention developers, as well as the implementation research and practice communities. Finally, the article identifies next steps to jumpstart adaptome data platform development. Published by Elsevier Inc. C1 [Chambers, David A.; Norton, Wynne E.] NCI, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Bethesda, MD 20850 USA. RP Chambers, DA (reprint author), NCI, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Bethesda, MD 20850 USA. EM dchamber@mail.nih.gov FU Intramural NIH HHS [Z99 CA999999] NR 35 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 SU 2 BP S124 EP S131 DI 10.1016/j.amepre.2016.05.011 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BM UT WOS:000386783100004 PM 27371105 ER PT J AU Harding, FM Hingson, RW Klitzner, M Mosher, JF Brown, J Vincent, RM Dahl, E Cannon, CL AF Harding, Frances M. Hingson, Ralph W. Klitzner, Michael Mosher, James F. Brown, Jorielle Vincent, Robert M. Dahl, Elizabeth Cannon, Carol L. TI Underage Drinking A Review of Trends and Prevention Strategies SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID ALCOHOL-RELATED MORTALITY; KEG REGISTRATION LAWS; STUDENTS AGES 18-24; COLLEGE-STUDENTS; CONTROL POLICIES; COMMUNITY TRIAL; BINGE DRINKING; UNITED-STATES; FATAL CRASHES; YOUTH ACCESS AB Underage drinking and its associated problems have profound negative consequences for underage drinkers themselves, their families, their communities, and society as a whole, and contribute to a wide range of costly health and social problems. There is increased risk of negative consequences with heavy episodic or binge drinking. Alcohol is a factor related to approximately 4,300 deaths among underage youths in the U.S. every year. Since the mid-1980s, the nation has launched aggressive underage drinking prevention efforts at the federal, state, and local levels, and national epidemiologic data suggest that these efforts are having positive effects. For example, since 1982, alcohol-related traffic deaths among youth aged 16-20 years have declined by 79%. Evidence-based or promising strategies for reducing underage drinking include those that limit the physical, social, and economic availability of alcohol to youth, make it illegal for drivers aged <21 years to drive after drinking, and provide mechanisms for early identification of problem drinkers. Strategies may be implemented through a comprehensive prevention approach including policies and their enforcement, public awareness and education, action by community coalitions, and early brief alcohol intervention and referral programs. This paper focuses on underage drinking laws and their enforcement because these constitute perhaps the most fundamental component of efforts to limit youth access to and use of alcohol. Published by Elsevier Inc. C1 [Harding, Frances M.; Brown, Jorielle; Vincent, Robert M.] SAMHSA, CSAP, Rockville, MD USA. [Hingson, Ralph W.] NIAAA, Div Epidemiol & Prevent Res, Bethesda, MD USA. [Klitzner, Michael; Dahl, Elizabeth; Cannon, Carol L.] CDM Grp Inc, Bethesda, MD USA. [Mosher, James F.] Alcohol Policy Consultat, Felton, CA USA. RP Vincent, RM (reprint author), Subst Abuse & Mental Hlth Serv Adm, CSAP, 5600 Fishers Lane, Rockville, MD 20857 USA. EM robert.vincent@samhsa.hhs.gov FU Substance Abuse and Mental Health Services Administration [HHSS28320070008I/HHSS28342001T] FX This work was funded by the Substance Abuse and Mental Health Services Administration under Contract number HHSS28320070008I/HHSS28342001T. NR 96 TC 1 Z9 1 U1 17 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2016 VL 51 IS 4 SU 2 BP S148 EP S157 DI 10.1016/j.amepre.2016.05.020 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EA7BM UT WOS:000386783100007 PM 27476384 ER PT J AU Bissa, M Quaglino, E Zanotto, C Illiano, E Rolih, V Pacchioni, S Cavallo, F Morghen, CD Radaelli, A AF Bissa, Massimiliano Quaglino, Elena Zanotto, Carlo Illiano, Elena Rolih, Valeria Pacchioni, Sole Cavallo, Federica Morghen, Carlo De Giuli Radaelli, Antonia TI Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity SO ANTIVIRAL RESEARCH LA English DT Article DE Recombinant vaccines; Fowlpox virus; Prime/boost; OPXV vaccine; L1R, A27L, A33R, B5R VV genes; Intranasal mucosal vaccination ID PRIME-BOOST IMMUNIZATION; SMALLPOX VACCINE; ANTIBODY-RESPONSES; NONHUMAN-PRIMATES; VIRUS CHALLENGE; T-CELLS; MONKEYPOX VIRUS; MUCOSAL; IMMUNITY; INFECTION AB The control of smallpox was achieved using live vaccinia virus (VV) vaccine, which successfully eradicated the disease worldwide. As the variola virus no longer exists as a natural infection agent, mass vaccination was discontinued after 1980. However, emergence of smallpox outbreaks caused by accidental or deliberate release of variola virus has stimulated new research for second-generation vaccine development based on attenuated VV strains. Considering the closely related animal poxviruses that also arise as zoonoses, and the increasing number of unvaccinated or immunocompromised people, a safer and more effective vaccine is still required. With this aim, new vectors based on avian poxviruses that cannot replicate in mammals should improve the safety of conventional vaccines, and protect from zoonotic orthopoxvirus diseases, such as cowpox and monkeypox. In this study, DNA and fowlpox (FP) recombinants that expressed the VV L1R, A27L, A33R, and B5R genes were generated (4DNAmix, 4FPmix, respectively) and tested in mice using novel administration routes. Mice were primed with 4DNAmix by electroporation, and boosted with 4FPmix applied intranasally. The lethal VVIHD-J strain was then administered by intranasal challenge. All of the mice receiving 4DNAmix followed by 4FPmix, and 20% of the mice immunized only with 4FPmix, were protected. The induction of specific humoral and cellular immune responses directly correlated with this protection. In particular, higher anti-A27 antibodies and IFN gamma-producing T lymphocytes were measured in the blood and spleen of the protected mice, as compared to controls. VVIHD-J neutralizing antibodies in sera from the protected mice suggest that the prime/boost vaccination regimen with 4DNAmix plus 4FPmix may be an effective and safe mode to induce protection against smallpox and poxvirus zoonotic infections. The electroporation/intranasal administration routes contributed to effective immune responses and mouse survival. (C) 2016 Elsevier B.V. All rights reserved. C1 [Bissa, Massimiliano; Illiano, Elena; Pacchioni, Sole; Radaelli, Antonia] Univ Milan, Dept Pharmacol & Biomol Sci, Via Balzaretti 9, I-20133 Milan, Italy. [Quaglino, Elena; Rolih, Valeria; Cavallo, Federica] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Ctr Mol Biotechnol, Via Nizza 52, I-10126 Turin, Italy. [Zanotto, Carlo; Morghen, Carlo De Giuli] Univ Milan, Dept Med Biotechnol & Translat Med, Via Vanvitelli 32, I-20129 Milan, Italy. [Morghen, Carlo De Giuli] Catholic Univ Our Lady Good Counsel, Tirana, Albania. [Radaelli, Antonia] Univ Milan, Inst Neurosci, Cellular & Mol Pharmacol Sect, CNR, Via Vanvitelli 32, I-20129 Milan, Italy. [Bissa, Massimiliano] NCI, NIH, Basic Res Labs, Bethesda, MD 20892 USA. RP Morghen, CD; Radaelli, A (reprint author), Univ Milan, Lab Mol Virol & Recombinant Vaccine Dev, Dept Pharmacol & Biomol Sci, Via Vanvitelli 32, I-20129 Milan, Italy. EM massimiliano.bissa@nih.gov; elena.quaglino@unito.it; carlo.zanotto@unimi.it; elena.illiano@unimi.it; valeria.rolih@unito.it; sol83@libero.it; federica.cavallo@unito.it; carlo.degiulimorghen@unimi.it; antonia.radaelli@unimi.it RI Cavallo, Federica/C-5666-2011; OI Cavallo, Federica/0000-0003-4571-1060; Quaglino, Elena/0000-0002-8151-9124 FU University of Milano Transition Grant [18498, CUP G42I14001030001]; Fondazione Ricerca Molinette Onlus and Fondazione CRT, Torino, Italy [2015-2518] FX This work was partially founded by the University of Milano Transition Grant, code no. 18498, CUP G42I14001030001 and by grants to FC from Fondazione Ricerca Molinette Onlus and Fondazione CRT, Torino, Italy, grant no. 2015-2518. The following reagents were obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, (NIAID, NIH): vaccinia virus (WR) L1R protein with C-terminal histidine tag, recombinant from baculovirus, NR-2625; vaccinia virus (WR) A27L protein with C-terminal histidine tag, recombinant from baculovirus, NR-2622; vaccinia virus (WR) A33R protein with C-terminal histidine tag, recombinant from baculovirus, NR-545; vaccinia virus (WR) B5R protein with N-terminal histidine tag, recombinant from baculovirus, NR-546. The authors also thank Dr. Christopher P. Berrie for editorial assistance with the manuscript. NR 66 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD OCT PY 2016 VL 134 BP 182 EP 191 DI 10.1016/j.antiviral.2016.09.002 PG 10 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA EA9SA UT WOS:000386983800021 PM 27637905 ER PT J AU Hartman, TL Yang, L Helfrick, AN Hassink, M Shank, NI Rosenker, KG Scerba, MT Saha, M Hughes, E Wang, AQ Xu, X Gupta, P Buckheit, RW Appella, DH AF Hartman, T. L. Yang, L. Helfrick, A. N. Hassink, M. Shank, N. I. Rosenker, K. George Scerba, M. T. Saha, M. Hughes, E. Wang, A. Q. Xu, X. Gupta, P. Buckheit, R. W., Jr. Appella, D. H. TI Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus SO ANTIVIRAL RESEARCH LA English DT Article ID TYPE-1 NUCLEOCAPSID PROTEIN; ZINC-FINGER INHIBITORS; ANTI-HIV AGENTS; VIRAL-DNA; REPLICATION; TARGET; BINDING; NCP7; RNA; INACTIVATION AB Although the effective use of highly active antiretroviral therapy results in the suppression of virus production in infected individuals, it does not eliminate the infection and low level virus production in cells harboring virus in sanctuary sites. Thus, the continued search for new antiretroviral agents with unique and different mechanisms of HIV inhibition remains critical, and compounds that can reduce the level of virus production from cells already infected with HIV, as opposed to preventing de novo infection, would be of great benefit. A mercaptobenzamide (MDH-1-38) and its prodrug (NS1040) are being developed as potential therapeutic compounds targeting the zinc finger of HIV nucleocapsid. In the presence of esterase enzymes, NS1040 is designed to be converted to MDH-1-38 which has antiviral activity. While we presume that NS1040 is rapidly converted to MDH-1-38 in all experiments, the two compounds were tested side-by-side to determine whether the presence of a prodrug affects the antiviral activity or mechanism of action. The two compounds were evaluated against a panel of HIV-1 clinical isolates in human PBMCs and monocyte-macrophages and yielded EC50 values ranging from 0.7 to 13 mu M with no toxicity up to 100 mu M. MDH-1-38 and NS1040 remained equally active in human PBMCs in the presence of added serum proteins as well as against HIV-1 isolates resistant to reverse transcriptase, integrase or protease inhibitors. Cell-based and biochemical mechanism of antiviral action assays demonstrated MDH-1-38 and NS1040 were virucidal at concentrations of 15 and 50 mu M, respectively. Cell to cell transmission of HIV in multiple passages was significantly reduced in CEM-SS and human PBMCs by reducing progeny virus infectivity at compound concentrations greater than 2 mu M. The combination of either MDH-1-38 or NS1040 with other FDA-approved HIV drugs yielded additive to synergistic antiviral interactions with no evidence of antiviral antagonism or synergistic toxicity. Serial dose escalation was used in attempts to select for HIV strains resistant to MDH-1-38 and NS1040. Virus at several passages failed to replicate in cells treated at increased compound concentrations, which is consistent with the proposed mechanism of action of the virus inactivating compounds. Through 14 passages, resistance to the compounds has not been achieved. Most HIV inhibitors with mechanism of antiviral action targeting a viral protein would have selected for a drug resistant virus within 14 passages. These studies indicate that these NCp7-targeted compounds represent new potent anti-HIV drug candidates which could be effectively used in combination with all approved anti-HIV drugs. (C) 2016 Published by Elsevier B.V. C1 [Hartman, T. L.; Yang, L.; Helfrick, A. N.; Buckheit, R. W., Jr.] ImQuest Biosci Inc, 7340 Execut Way,Suite R, Frederick, MD 21704 USA. [Hassink, M.; Shank, N. I.; Rosenker, K. George; Scerba, M. T.; Saha, M.; Gupta, P.; Appella, D. H.] NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA. [Hughes, E.; Wang, A. Q.; Xu, X.] NIH, NCATS, Bldg 10, Bethesda, MD 20892 USA. RP Buckheit, RW (reprint author), ImQuest Biosci Inc, 7340 Execut Way,Suite R, Frederick, MD 21704 USA.; Appella, DH (reprint author), NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA. EM rbuckheit@imquestbio.com; appellad@niddk.nih.gov FU Intramural Research Program of NIDDK, NIH [DK075135-01] FX This work was supported in part by funding from the Intramural Research Program of NIDDK (DK075135-01), NIH. Toxicity studies in rats were performed under contract by Pharmaron (Irvine, CA). NR 34 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD OCT PY 2016 VL 134 BP 216 EP 225 DI 10.1016/j.antiviral.2016.08.022 PG 10 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA EA9SA UT WOS:000386983800024 PM 27568924 ER PT J AU Levin, GV Straat, PA AF Levin, Gilbert V. Straat, Patricia Ann TI The Case for Extant Life on Mars and Its Possible Detection by the Viking Labeled Release Experiment SO ASTROBIOLOGY LA English DT Review ID D-AMINO ACIDS; GALE CRATER; MARTIAN SOIL; PERCHLORATE; LANDER; MICROORGANISMS; ENVIRONMENTS; METABOLISM; REACTIVITY; BACTERIA AB The 1976 Viking Labeled Release (LR) experiment was positive for extant microbial life on the surface of Mars. Experiments on both Viking landers, 4000 miles apart, yielded similar, repeatable, positive responses. While the authors eventually concluded that the experiment detected martian life, this was and remains a highly controversial conclusion. Many believe that the martian environment is inimical to life and the LR responses were nonbiological, attributed to an as-yet-unidentified oxidant (or oxidants) in the martian soil. Unfortunately, no further metabolic experiments have been conducted on Mars. Instead, follow-on missions have sought to define the martian environment, mostly searching for signs of water. These missions have collected considerable data regarding Mars as a habitat, both past and present. The purpose of this article is to consider recent findings about martian water, methane, and organics that impact the case for extant life on Mars. Further, the biological explanation of the LR and recent nonbiological hypotheses are evaluated. It is concluded that extant life is a strong possibility, that abiotic interpretations of the LR data are not conclusive, and that, even setting our conclusion aside, biology should still be considered as an explanation for the LR experiment. Because of possible contamination of Mars by terrestrial microbes after Viking, we note that the LR data are the only data we will ever have on biologically pristine martian samples. Key Words: Extant life on MarsViking Labeled Release experimentAstrobiologyExtraterrestrial lifeMars. Astrobiology 16, 798-810. C1 [Levin, Gilbert V.] Arizona State Univ, Tempe, AZ USA. [Straat, Patricia Ann] NIH, Bldg 10, Bethesda, MD 20892 USA. [Levin, Gilbert V.; Straat, Patricia Ann] Biospherics Inc, Rockville, MD USA. RP Levin, GV (reprint author), 10709 Blossom Dr, Goodyear, AZ 85338 USA. EM gilvlevin@gmail.com FU National Aeronautics and Space Administration [NAS1-9690, NASW-3162, NASW-3249] FX The Viking Labeled Release results reported herein were supported by Contracts NAS1-9690, NASW-3162, and NASW-3249 from the National Aeronautics and Space Administration. NR 54 TC 0 Z9 0 U1 38 U2 38 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1531-1074 EI 1557-8070 J9 ASTROBIOLOGY JI Astrobiology PD OCT PY 2016 VL 16 IS 10 BP 798 EP 810 DI 10.1089/ast.2015.1464 PG 13 WC Astronomy & Astrophysics; Biology; Geosciences, Multidisciplinary SC Astronomy & Astrophysics; Life Sciences & Biomedicine - Other Topics; Geology GA DZ8QR UT WOS:000386136400007 PM 27626510 ER PT J AU Betsou, F Bulla, A Cho, SY Clements, J Chuaqui, R Coppola, D De Souza, Y De Wilde, A Grizzle, W Guadagni, F Gunter, E Heil, S Hodgkinson, V Kessler, J Kiehntopf, M Kim, HS Koppandi, I Shea, K Singh, R Sobel, M Somiari, S Spyropoulos, D Stone, M Tybring, G Valyi-Nagy, K Van den Eynden, G Wadhwa, L AF Betsou, Fay Bulla, Alexandre Cho, Sang Yun Clements, Judith Chuaqui, Rodrigo Coppola, Domenico De Souza, Yvonne De Wilde, Annemieke Grizzle, William Guadagni, Fiorella Gunter, Elaine Heil, Stacey Hodgkinson, Verity Kessler, Joseph Kiehntopf, Michael Kim, Hee Sung Koppandi, Iren Shea, Katheryn Singh, Rajeev Sobel, Marc Somiari, Stella Spyropoulos, Demetri Stone, Mars Tybring, Gunnel Valyi-Nagy, Klara Van den Eynden, Gert Wadhwa, Lalita TI Assays for Qualification and Quality Stratification of Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen Science Working Group SO BIOPRESERVATION AND BIOBANKING LA English DT Article DE quality control; biospecimen; qualification; tissue; cells; biological fluid ID CEREBROSPINAL-FLUID; HUMAN PLASMA; SERUM-PROTEINS; CYSTATIN-C; P-SELECTIN; STORAGE; STABILITY; BIOMARKER; BLOOD; EXPRESSION AB This technical report presents quality control (QC) assays that can be performed in order to qualify clinical biospecimens that have been biobanked for use in research. Some QC assays are specific to a disease area. Some QC assays are specific to a particular downstream analytical platform. When such a qualification is not possible, QC assays are presented that can be performed to stratify clinical biospecimens according to their biomolecular quality. C1 [Betsou, Fay] Integrated BioBank Luxemburg, 6 Rue Nicolas Ernest Barble, L-1210 Luxembourg, Luxembourg. [Bulla, Alexandre] Univ Hosp Geneva, Biotheque SML, Div Genet & Lab Med DMGL, Geneva, Switzerland. [Cho, Sang Yun] Natl Biobank Korea, Cheongju, South Korea. [Clements, Judith] Queensland Univ Technol, Australian Prostate Canc Bioresource, Brisbane, Qld, Australia. [Chuaqui, Rodrigo] NCI, Canc Diag Program, Div Canc Treatment & Diag DCTD, Rockville, MD USA. [Coppola, Domenico] Univ S Florida, Moffitt Canc Ctr, Dept Anat Pathol, Tampa, FL USA. [De Souza, Yvonne] Univ Calif San Francisco, AIDS Specimen Bank, San Francisco, CA 94143 USA. [De Wilde, Annemieke] Univ Ziekenhuis Antwerpen, Edegem, Belgium. [Grizzle, William] Univ Alabama Birmingham, Birmingham, AL USA. [Guadagni, Fiorella] San Raffaele Rome Univ, IRCCS San Raffaele Pisana, Rome, Italy. [Gunter, Elaine] Specimen Solut LLC, Tucker, Rep of Georgia. [Heil, Stacey] Coriell Inst Med Res, Camden, NJ USA. [Hodgkinson, Verity] NSW Canc Council, Canc Res Div, Woolloomooloo, NSW, Australia. [Kessler, Joseph] Medpace Reference Labs, Cincinnati, OH USA. [Kiehntopf, Michael] Univ Klinikum Jena, Jena, Germany. [Kim, Hee Sung] Chung Ang Univ, Coll Med, Dept Pathol, Dongjak Gu, South Korea. [Koppandi, Iren] Cellular Technol Ltd, Shaker Hts, OH USA. [Shea, Katheryn] Precis Med Inc, Frederick, MD USA. [Singh, Rajeev] Houston Methodist Res Inst, Biorepository, Houston, TX USA. [Sobel, Marc] Amer Soc Invest Pathol, Bethesda, MD USA. [Somiari, Stella] Windber Res Inst, Biobank & Biospecimen Sci Res, Windber, PA USA. [Spyropoulos, Demetri] Med Univ South Carolina, Childrens Res Inst, Dept Pathol & Lab Med, Charleston, SC USA. [Stone, Mars] Blood Syst Res Inst, San Francisco, CA USA. [Tybring, Gunnel] Karolinska Inst, Stockholm, Sweden. [Valyi-Nagy, Klara] Univ Illinois, Coll Med, Dept Pathol, Univ Illinois Biorepository, Chicago, IL 60612 USA. [Van den Eynden, Gert] GZA Hosp, Dept Pathol & Cytol, Antwerp, Belgium. [Wadhwa, Lalita] Baylor Coll Med, Houston, TX 77030 USA. RP Betsou, F (reprint author), Integrated BioBank Luxemburg, 6 Rue Nicolas Ernest Barble, L-1210 Luxembourg, Luxembourg. EM fay.betsou@ibbl.lu OI Clements, Judith/0000-0001-6026-1964 FU NCI NIH HHS [UM1 CA183728] NR 53 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1947-5535 EI 1947-5543 J9 BIOPRESERV BIOBANK JI Biopreserv. Biobank. PD OCT PY 2016 VL 14 IS 5 BP 398 EP 409 DI 10.1089/bio.2016.0018 PG 12 WC Cell Biology; Chemistry, Applied; Medical Laboratory Technology SC Cell Biology; Chemistry; Medical Laboratory Technology GA EA3BQ UT WOS:000386473600007 PM 27046294 ER PT J AU Bledsoe, MJ Henderson, M Tasse, AM Knoppers, BM AF Bledsoe, Marianna J. Henderson, Marianne Tasse, Anne-Marie Knoppers, Bartha M. TI International Biobanking Summit V: Harmonizing Privacy Laws to Enable International Biobank Research SO BIOPRESERVATION AND BIOBANKING LA English DT Editorial Material C1 [Bledsoe, Marianna J.] ISBER Sci Policy Comm, Silver Spring, MD 20993 USA. [Henderson, Marianne] NCI, Ctr Global Hlth, Bethesda, MD 20892 USA. [Tasse, Anne-Marie] Publ Populat Project Genom & Soc P3G, Montreal, PQ, Canada. [Knoppers, Bartha M.] McGill Univ, Ctr Genom & Policy, Montreal, PQ, Canada. RP Bledsoe, MJ (reprint author), ISBER Sci Policy Comm, Silver Spring, MD 20993 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1947-5535 EI 1947-5543 J9 BIOPRESERV BIOBANK JI Biopreserv. Biobank. PD OCT PY 2016 VL 14 IS 5 BP 452 EP 453 DI 10.1089/bio.2016.29012.mjb PG 2 WC Cell Biology; Chemistry, Applied; Medical Laboratory Technology SC Cell Biology; Chemistry; Medical Laboratory Technology GA EA3BQ UT WOS:000386473600015 PM 27749136 ER PT J AU Anderson, C Milne, GL Sandler, DP Nichols, HB AF Anderson, Chelsea Milne, Ginger L. Sandler, Dale P. Nichols, Hazel B. TI Oxidative stress in relation to diet and physical activity among premenopausal women SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Oxidative stress; F-2-isoprostanes; Diet; Physical activity; Premenopausal women ID MAJOR URINARY METABOLITE; MASS-SPECTROMETRIC ASSAY; BREAST-CANCER RISK; N-3 FATTY-ACIDS; PLASMA F-2-ISOPROSTANES; CARDIOVASCULAR-DISEASE; DOCOSAHEXAENOIC ACID; ZINC SUPPLEMENTATION; ESTROGEN METABOLISM; LIPID-PEROXIDATION AB Higher levels of oxidative stress, as measured by F-2-isoprostanes, have been associated with chronic diseases such as CVD and some cancers. Improvements in diet and physical activity may help reduce oxidative stress; however, previous studies regarding associations between lifestyle factors and F-2-isoprostane concentrations have been inconsistent. The aim of this cross-sectional study was to investigate whether physical activity and intakes of fruits/vegetables, antioxidant nutrients, dietary fat subgroups and alcohol are associated with concentrations of F-2-isoprostane and the major F-2-isoprostane metabolite. Urinary F-2-isoprostane and its metabolite were measured in urine samples collected at enrolment from 912 premenopausal women (aged 35-54 years) participating in the Sister Study. Physical activity, alcohol consumption and dietary intakes were self-reported via questionnaires. With adjustment for potential confounders, the geometric means of F-2-isoprostane and its metabolite were calculated according to quartiles of dietary intakes, alcohol consumption and physical activity, and linear regression models were used to evaluate trends. Significant inverse associations were found between F-2-isoprostane and/or its metabolite and physical activity, vegetables, fruits, vitamin C, -carotene, vitamin E, -carotene, vitamin A, Se, lutein+zeaxanthin and long-chain n-3 fatty acids. Although trans fats were positively associated with both F-2-isoprostane and its metabolite, other dietary fat subgroups including SFA, n-6 fatty acids, n-3 fatty acids, MUFA, PUFA, short-chain n-3 fatty acids, long-chain n-3 fatty acids and total fat were not associated with either F-2-isoprostane or its metabolite. Our findings suggest that lower intake of antioxidant nutrients and higher intake of trans fats may be associated with greater oxidative stress among premenopausal women. C1 [Anderson, Chelsea; Nichols, Hazel B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Milne, Ginger L.] Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Nashville, TN 37232 USA. [Sandler, Dale P.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA. RP Nichols, HB (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. EM hazel.nichols@unc.edu RI Milne, Ginger/D-7648-2014; OI Milne, Ginger/0000-0003-3890-151X; Sandler, Dale/0000-0002-6776-0018 FU Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences [Z01-ES044005]; Avon Foundation [02-2012-085]; National Center for Advancing Translational Sciences [KL2-TR001109] FX This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01-ES044005), the Avon Foundation (02-2012-085) and by the National Center for Advancing Translational Sciences (KL2-TR001109). NR 63 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 EI 1475-2662 J9 BRIT J NUTR JI Br. J. Nutr. PD OCT PY 2016 VL 116 IS 8 BP 1416 EP 1424 DI 10.1017/S0007114516003226 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA EA8TQ UT WOS:000386912200011 PM 27725001 ER PT J AU Yang, XP Sethi, A Yanek, LR Knapper, C Nordestgaard, BG Tybjaerg-Hansen, A Becker, DM Mathias, RA Remaley, AT Becker, LC AF Yang, Xiaoping Sethi, Amar Yanek, Lisa R. Knapper, Cathy Nordestgaard, Borge G. Tybjaerg-Hansen, Anne Becker, Diane M. Mathias, Rasika A. Remaley, Alan T. Becker, Lewis C. TI SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a) SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE Copenhagen City Heart Study; GeneSTAR; high-density lipoprotein cholesterol; lipids and lipoproteins; lipoprotein (a); SCARB1 gene variants; SR-B1 receptor ID SCAVENGER RECEPTOR-BI; CORONARY-HEART-DISEASE; SR-BI; LDL RECEPTOR; TARGETED MUTATION; SELECTIVE UPTAKE; DEFICIENT MICE; I GENE; POPULATION; LOCUS AB Background SR-B1 (scavenger receptor class B type 1), encoded by the gene SCARB1, is a lipoprotein receptor that binds both high-density lipoprotein (HDL) and low-density lipoprotein. We reported that SR-B1 is also a receptor for lipoprotein (a) (Lp(a)), mediating cellular uptake of Lp(a) in vitro and promoting clearance of Lp(a) in vivo. Although genetic variants in SCARB1 are associated with variations in HDL level, no SCARB1 variants affecting Lp(a) have been reported. Methods and Results In an index subject with high levels of HDL cholesterol and Lp(a), SCARB1 was sequenced and demonstrated a missense mutation resulting in an S129L substitution in exon 3. To follow up, 2 cohorts (GeneSTAR, the family-based Genetic Study of Atherosclerosis Risk [n=543], and CCHS, the population-based Copenhagen City Heart Study [n=5835]) were screened for combined HDL cholesterol and Lp(a) elevations. Subjects with the extreme phenotype (HDL >80 mg/dL and Lp(a) >100 nmol/L in GeneSTAR, n=8, and >100 mg/dL in CCHS, n=9) underwent sequencing of SCARB1 exons; 15 of 18 from the combined population demonstrated genetic variants, including rare or uncommon missense or splice site mutations in 9 and homozygous synonymous variants in 6. Functional studies with 4 of the SCARB1 variants (c.386C>T, c.631-14T>G, c.4G>A, and c.631-53(m)C>T & c.726+55(m)CG>CA) showed decreased receptor function in vitro. Conclusions Human SCARB1 gene variants are associated with a new lipid phenotype, characterized by high levels of both HDL cholesterol and Lp(a). SCARB1 exonic variants often result in diminished function of translated SR-B1 via reduced binding/intracellular transport of Lp(a). C1 [Yang, Xiaoping; Yanek, Lisa R.; Becker, Diane M.; Mathias, Rasika A.; Becker, Lewis C.] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA. [Sethi, Amar; Knapper, Cathy; Remaley, Alan T.] NHLBI, Lipoprotein Metab Sect, Pulm & Vasc Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA. [Nordestgaard, Borge G.; Tybjaerg-Hansen, Anne] Univ Copenhagen, Copenhagen Univ Hosp, Fac Hlth Sci, DK-1168 Copenhagen, Denmark. RP Becker, LC (reprint author), Johns Hopkins Univ Hosp, Div Cardiol, Halsted 500,600 N Wolfe St, Baltimore, MD 21287 USA. EM lbecker@jhmi.edu FU National Heart, Lung, and Blood Institute [HL72518, NR08153, HL59684, HL65608]; National Heart, Lung, and Blood Institute; National Human Genome Research Institute FX Supported by grants HL72518 (Dr L.C. Becker), NR08153 (Dr D.M. Becker), HL59684 (Dr L.C. Becker), and HL65608 (Dr L.C. Becker) from the National Heart, Lung, and Blood Institute and intramural research funding of National Heart, Lung, and Blood Institute and National Human Genome Research Institute. NR 50 TC 1 Z9 1 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD OCT PY 2016 VL 9 IS 5 BP 408 EP 418 DI 10.1161/CIRCGENETICS.116.001402 PG 11 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA EA4OY UT WOS:000386593700004 PM 27651445 ER PT J AU Joehanes, R Just, AC Marioni, RE Pilling, LC Reynolds, LM Mandaviya, PR Guan, WH Xu, T Elks, CE Aslibekyan, S Moreno-Macias, H Smith, JA Brody, JA Dhingra, R Yousefi, P Pankow, JS Kunze, S Shah, SH McRae, AF Lohman, K Sha, J Absher, DM Ferrucci, L Zhao, W Demerath, EW Bressler, J Grove, ML Huan, TX Liu, CY Mendelson, MM Yao, C Kiel, DP Peters, A Wang-Sattler, R Visscher, PM Wray, NR Starr, JM Ding, JZ Rodriguez, CJ Wareham, NJ Irvin, MR Zhi, DG Barrdahl, M Vineis, P Ambatipudi, S Uitterlinden, AG Hofman, A Schwartz, J Colicino, E Hou, LF Vokonas, PS Hernandez, DG Singleton, AB Bandinelli, S Turner, ST Ware, EB Smith, AK Klengel, T Binder, EB Psaty, BM Taylor, KD Gharib, SA Swenson, BR Liang, LM DeMeo, DL O'Connor, GT Herceg, Z Ressler, KJ Conneely, KN Sotoodehnia, N Kardia, SLR Melzer, D Baccarelli, AA van Meurs, JBJ Romieu, I Arnett, DK Ong, KK Liu, YM Waldenberger, M Deary, IJ Fornage, M Levy, D London, SJ AF Joehanes, Roby Just, Allan C. Marioni, Riccardo E. Pilling, Luke C. Reynolds, Lindsay M. Mandaviya, Pooja R. Guan, Weihua Xu, Tao Elks, Cathy E. Aslibekyan, Stella Moreno-Macias, Hortensia Smith, Jennifer A. Brody, Jennifer A. Dhingra, Radhika Yousefi, Paul Pankow, James S. Kunze, Sonja Shah, Sonia H. McRae, Allan F. Lohman, Kurt Sha, Jin Absher, Devin M. Ferrucci, Luigi Zhao, Wei Demerath, Ellen W. Bressler, Jan Grove, Megan L. Huan, Tianxiao Liu, Chunyu Mendelson, Michael M. Yao, Chen Kiel, Douglas P. Peters, Annette Wang-Sattler, Rui Visscher, Peter M. Wray, Naomi R. Starr, John M. Ding, Jingzhong Rodriguez, Carlos J. Wareham, Nicholas J. Irvin, Marguerite R. Zhi, Degui Barrdahl, Myrto Vineis, Paolo Ambatipudi, Srikant Uitterlinden, Andre G. Hofman, Albert Schwartz, Joel Colicino, Elena Hou, Lifang Vokonas, Pantel S. Hernandez, Dena G. Singleton, Andrew B. Bandinelli, Stefania Turner, Stephen T. Ware, Erin B. Smith, Alicia K. Klengel, Torsten Binder, Elisabeth B. Psaty, Bruce M. Taylor, Kent D. Gharib, Sina A. Swenson, Brenton R. Liang, Liming DeMeo, Dawn L. O'Connor, George T. Herceg, Zdenko Ressler, Kerry J. Conneely, Karen N. Sotoodehnia, Nona Kardia, Sharon L. R. Melzer, David Baccarelli, Andrea A. van Meurs, Joyce B. J. Romieu, Isabelle Arnett, Donna K. Ong, Ken K. Liu, Yongmei Waldenberger, Melanie Deary, Ian J. Fornage, Myriam Levy, Daniel London, Stephanie J. TI Epigenetic Signatures of Cigarette Smoking SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE biomarkers; genome-wide association study; meta-analysis; methylation; smoking ID DIFFERENTIAL DNA METHYLATION; EPIGENOME-WIDE ASSOCIATION; F2RL3 METHYLATION; HUMAN GENOME; METAANALYSIS; NUTRITION; EXPRESSION; BIOMARKERS; DISCOVERY; EXPOSURE AB Background DNA methylation leaves a long-term signature of smoking exposure and is one potential mechanism by which tobacco exposure predisposes to adverse health outcomes, such as cancers, osteoporosis, lung, and cardiovascular disorders. Methods and Results To comprehensively determine the association between cigarette smoking and DNA methylation, we conducted a meta-analysis of genome-wide DNA methylation assessed using the Illumina BeadChip 450K array on 15907 blood-derived DNA samples from participants in 16 cohorts (including 2433 current, 6518 former, and 6956 never smokers). Comparing current versus never smokers, 2623 cytosine-phosphate-guanine sites (CpGs), annotated to 1405 genes, were statistically significantly differentially methylated at Bonferroni threshold of P<1x10(-7) (18760 CpGs at false discovery rate <0.05). Genes annotated to these CpGs were enriched for associations with several smoking-related traits in genome-wide studies including pulmonary function, cancers, inflammatory diseases, and heart disease. Comparing former versus never smokers, 185 of the CpGs that differed between current and never smokers were significant P<1x10(-7) (2623 CpGs at false discovery rate <0.05), indicating a pattern of persistent altered methylation, with attenuation, after smoking cessation. Transcriptomic integration identified effects on gene expression at many differentially methylated CpGs. Conclusions Cigarette smoking has a broad impact on genome-wide methylation that, at many loci, persists many years after smoking cessation. Many of the differentially methylated genes were novel genes with respect to biological effects of smoking and might represent therapeutic targets for prevention or treatment of tobacco-related diseases. Methylation at these sites could also serve as sensitive and stable biomarkers of lifetime exposure to tobacco smoke. C1 [Joehanes, Roby; Kiel, Douglas P.] Hebrew SeniorLife, Inst Aging Res, Boston, MA USA. [Joehanes, Roby; Kiel, Douglas P.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [DeMeo, Dawn L.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Ressler, Kerry J.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Joehanes, Roby; Huan, Tianxiao; Liu, Chunyu; Mendelson, Michael M.; Yao, Chen; Levy, Daniel] NHLBI, Populat Sci Branch, NIH, Bldg 10, Bethesda, MD 20892 USA. [Hernandez, Dena G.; Singleton, Andrew B.] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. [Joehanes, Roby; Huan, Tianxiao; Liu, Chunyu; Mendelson, Michael M.; Yao, Chen; Levy, Daniel] Framingham Heart Dis Epidemiol Study, Framingham, MA USA. [Just, Allan C.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Marioni, Riccardo E.; Visscher, Peter M.; Starr, John M.; Deary, Ian J.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland. [Marioni, Riccardo E.] Univ Edinburgh, Ctr Genom & Expt Med, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland. [Starr, John M.] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland. [Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland. [Marioni, Riccardo E.; Shah, Sonia H.; McRae, Allan F.; Visscher, Peter M.; Wray, Naomi R.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia. [McRae, Allan F.; Visscher, Peter M.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia. [Pilling, Luke C.; Melzer, David] Univ Exeter, Sch Med, Inst Biomed & Clin Sci, Epidemiol & Publ Hlth Grp, Exeter, Devon, England. [Reynolds, Lindsay M.; Rodriguez, Carlos J.; Liu, Yongmei] Wake Forest Sch Med, Dept Epidemiol & Prevent, Div Publ Hlth Sci, Winston Salem, NC USA. [Lohman, Kurt] Wake Forest Sch Med, Dept Biostat Sci, Div Publ Hlth Sci, Winston Salem, NC USA. [Ding, Jingzhong] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. [Mandaviya, Pooja R.; Uitterlinden, Andre G.; van Meurs, Joyce B. J.] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands. [Mandaviya, Pooja R.] Erasmus Univ, Med Ctr, Dept Clin Chem, Rotterdam, Netherlands. [Hofman, Albert] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Guan, Weihua] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN USA. [Pankow, James S.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Xu, Tao; Kunze, Sonja; Peters, Annette; Wang-Sattler, Rui; Waldenberger, Melanie] Helmhotz Zentrum Muenchen, Inst Epidemiol 2, Res Unit Mol Epidemiol, Munich, Germany. [Elks, Cathy E.; Wareham, Nicholas J.; Ong, Ken K.] Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England. [Aslibekyan, Stella; Sha, Jin; Irvin, Marguerite R.; Arnett, Donna K.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Moreno-Macias, Hortensia] Autonomous Metropolitan Univ Iztapalapa, Mexico City, DF, Mexico. [Moreno-Macias, Hortensia; Ambatipudi, Srikant; Herceg, Zdenko; Romieu, Isabelle] Int Agcy Res Canc, Lyon, France. [Smith, Jennifer A.; Zhao, Wei; Ware, Erin B.; Kardia, Sharon L. R.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Ware, Erin B.] Univ Michigan, Inst Social Res, Res Ctr Grp Dynam, Ann Arbor, MI USA. [Brody, Jennifer A.; Psaty, Bruce M.; Swenson, Brenton R.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Gharib, Sina A.] Univ Washington, Dept Med, Ctr Lung Biol, Div Pulm & Crit Care Med, Seattle, WA USA. [Sotoodehnia, Nona] Univ Washington, Dept Epidemiol, Div Cardiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Dhingra, Radhika] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Yousefi, Paul; Demerath, Ellen W.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Absher, Devin M.] HudsonAlpha Inst Biotechnol, Huntsville, AL USA. [Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA. [Bressler, Jan; Grove, Megan L.; Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA. [Zhi, Degui] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA. [Mendelson, Michael M.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA. [Barrdahl, Myrto] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Vineis, Paolo] Imperial Coll London, Sch Publ Hlth, MRC PHE Ctr Environm & Hlth, London, England. [Vineis, Paolo] HuGeF Fdn, Turin, Italy. [Sha, Jin; Baccarelli, Andrea A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Baccarelli, Andrea A.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Hou, Lifang] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Hou, Lifang] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Vokonas, Pantel S.] VA Boston Healthcare Syst, VA Normat Aging Study, Boston, MA USA. [Vokonas, Pantel S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Bandinelli, Stefania] Azienda Sanit Firenze, Geriatr Unit, Florence, Italy. [Turner, Stephen T.] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA. [Smith, Alicia K.; Binder, Elisabeth B.; Ressler, Kerry J.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. [Conneely, Karen N.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA. [Klengel, Torsten; Binder, Elisabeth B.] Max Planck Inst Psychiat, Dept Translat Res Psychiat, Munich, Germany. [Klengel, Torsten; Ressler, Kerry J.] McLean Hosp, Div Depress & Anxiety Disorders, 115 Mill St, Belmont, MA 02178 USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Taylor, Kent D.] Los Angeles BioMed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA USA. [Taylor, Kent D.] Harbor UCLA Med Ctr, Div Genom Outcomes, Dept Pediat, Torrance, CA 90509 USA. [Taylor, Kent D.] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. [Taylor, Kent D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Taylor, Kent D.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA. [Liang, Liming] Harvard Sch Publ Hlth, Boston, MA USA. [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02118 USA. [London, Stephanie J.] NIEHS, Epidemiol Branch, US Dept HHS, NIH, POB 12233,Room A306, Res Triangle Pk, NC 27709 USA. RP London, SJ (reprint author), NIEHS, Epidemiol Branch, US Dept HHS, NIH, POB 12233,Room A306, Res Triangle Pk, NC 27709 USA. EM london2@niehs.nih.gov RI Shah, Sonia/N-7547-2013; OI Mendelson, Michael/0000-0001-7590-3958; Shah, Sonia/0000-0001-5860-4526; London, Stephanie/0000-0003-4911-5290; Colicino, Elena/0000-0002-1875-8448; Smith, Jennifer/0000-0002-3575-5468; Just, Allan/0000-0003-4312-5957; Pankow, James/0000-0001-7076-483X; AMBATIPUDI, SRIKANT/0000-0003-3102-3603 FU National Heart, Lung, and Blood Institute [R01HL105756]; NIH; National Institute of Environmental Health Sciences; National Heart Lung and Blood Institute FX Infrastructure for the CHARGE consortium is provided by the National Heart, Lung, and Blood Institute grant R01HL105756. This work was supported in part by the Intramural Research Program of the NIH; National Institute of Environmental Health Sciences; and the National Heart Lung and Blood Institute. Additional funding sources for each cohort can be found in the Data Supplement. NR 43 TC 6 Z9 6 U1 9 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD OCT PY 2016 VL 9 IS 5 BP 436 EP 447 DI 10.1161/CIRCGENETICS.116.001506 PG 12 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA EA4OY UT WOS:000386593700007 PM 27651444 ER PT J AU Mital, S Musunuru, K Garg, V Russell, MW Lanfear, DE Gupta, RM Hickey, KT Ackerman, MJ Perez, MV Roden, DM Woo, D Fox, CS Ware, S AF Mital, Seema Musunuru, Kiran Garg, Vidu Russell, Mark W. Lanfear, David E. Gupta, Rajat M. Hickey, Kathleen T. Ackerman, Michael J. Perez, Marco V. Roden, Dan M. Woo, Daniel Fox, Caroline S. Ware, Stephanie TI Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE AHA Scientific Statements; aneurysm; arrhythmia; cardiomyopathy; channelopathy; congenital heart defects; genetic testing; genetics; pharmacogenetics; pharmacology ID LONG QT SYNDROME; OF-FUNCTION POLYMORPHISM; PRIMARY-CARE; MEDICAL GENETICS; DILATED CARDIOMYOPATHY; MUSCULAR-DYSTROPHIES; CLINICAL MANAGEMENT; CONSENSUS STATEMENT; PRACTICE GUIDELINES; INCIDENTAL FINDINGS AB Advances in genomics are enhancing our understanding of the genetic basis of cardiovascular diseases, both congenital and acquired, and stroke. These advances include finding genes that cause or increase the risk for childhood and adult-onset diseases, finding genes that influence how patients respond to medications, and the development of genetics-guided therapies for diseases. However, the ability of cardiovascular and stroke clinicians to fully understand and apply this knowledge to the care of their patients has lagged. This statement addresses what the specialist caring for patients with cardiovascular diseases and stroke should know about genetics; how they can gain this knowledge; how they can keep up-to-date with advances in genetics, genomics, and pharmacogenetics; and how they can apply this knowledge to improve the care of patients and families with cardiovascular diseases and stroke. C1 [Mital, Seema] Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. [Musunuru, Kiran] Univ Penn, Cardiovasc Inst, Philadelphia, PA 19104 USA. [Ackerman, Michael J.] Mayo Clin, Rochester, MN USA. [Fox, Caroline S.] NHLBI, Bldg 10, Bethesda, MD 20892 USA. [Garg, Vidu] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA. [Gupta, Rajat M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hickey, Kathleen T.] Columbia Univ, Med Ctr, New York, NY 10027 USA. [Lanfear, David E.] Henry Ford Hosp, Detroit, MI 48202 USA. [Perez, Marco V.] Stanford Univ, Stanford, CA 94305 USA. [Roden, Dan M.] Vanderbilt Univ, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA. [Russell, Mark W.] Univ Michigan, Ann Arbor, MI 48109 USA. [Ware, Stephanie] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Woo, Daniel] Univ Cincinnati, Cincinnati, OH 45221 USA. RP Mital, S (reprint author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. RI Garg, Vidu/D-8240-2012 OI Garg, Vidu/0000-0002-3778-5927 FU NIH; Janssen; Portola; HeartWare; BioControl; Amgen; AHA; Burroughs Wellcome; March of Dimes FX David E. Lanfear Henry Ford Hospital NIH dagger; Janssen dagger; Portolastar; HeartWare dagger; BioControlstar; Amgen dagger; Stephanie Ware Indiana University School of Medicine AHA dagger; Burroughs Wellcome dagger; March of Dimes dagger; NIH dagger NR 126 TC 2 Z9 2 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD OCT PY 2016 VL 9 IS 5 BP 448 EP 467 DI 10.1161/HCG.0000000000000031 PG 20 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA EA4OY UT WOS:000386593700008 PM 27672144 ER PT J AU Kendall, BJ Rubenstein, JH Cook, MB Vaughan, TL Anderson, LA Murray, LJ Shaheen, NJ Corley, DA Chandar, AK Li, L Greer, KB Chak, A El-Serag, HB Whiteman, DC Thrift, AP AF Kendall, Bradley J. Rubenstein, Joel H. Cook, Michael B. Vaughan, Thomas L. Anderson, Lesley A. Murray, Liam J. Shaheen, Nicholas J. Corley, Douglas A. Chandar, Apoorva K. Li, Li Greer, Katarina B. Chak, Amitabh El-Serag, Hashem B. Whiteman, David C. Thrift, Aaron P. TI Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE BEACON; Obesity; Esophageal Cancer; Epidemiology; Risk Factors ID BODY-MASS INDEX; ABDOMINAL OBESITY; GASTROESOPHAGEAL-REFLUX; CENTRAL ADIPOSITY; ADENOCARCINOMA; DISEASE; CANCER; SEX; METAANALYSIS; INSULIN AB BACKGROUND & AIMS: Gluteofemoral obesity (determined by measurement of subcutaneous fat in the hip and thigh regions) could reduce risks of cardiovascular and diabetic disorders associated with abdominal obesity. We evaluated whether gluteofemoral obesity also reduces the risk of Barrett's esophagus (BE), a premalignant lesion associated with abdominal obesity. METHODS: We collected data from non-Hispanic white participants in 8 studies in the Barrett's and Esophageal Adenocarcinoma Consortium. We compared measures of hip circumference (as a proxy for gluteofemoral obesity) from cases of BE (n = 1559) separately with 2 control groups: 2557 population-based controls and 2064 individuals with gastroesophageal reflux disease (GERD controls). Study-specific odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated using individual participant data and multivariable logistic regression and combined using a random-effects meta-analysis. RESULTS: We found an inverse relationship between hip circumference and BE (OR per 5-cmincrease, 0.88; 95% CI, 0.81-0.96), compared with population-based controls in a multivariable model that included waist circumference. This association was not observed in models that did not include waist circumference. Similar results were observed in analyses stratified by frequency of GERD symptoms. The inverse association with hip circumference was statistically significant only among men (vs population-based controls: OR, 0.85; 95% CI, 0.76-0.96 for men; OR, 0.93; 95% CI, 0.74-1.16 for women). For men, within each category of waist circumference, a larger hip circumference was associated with a decreased risk of BE. Increasing waist circumference was associated with an increased risk of BE in the mutually adjusted population-based and GERD control models. CONCLUSIONS: Although abdominal obesity is associated with an increased risk of BE, there is an inverse association between gluteofemoral obesity and BE, particularly among men. C1 [Kendall, Bradley J.; Whiteman, David C.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia. [Kendall, Bradley J.] Univ Queensland, Sch Med, Brisbane, Qld, Australia. [Rubenstein, Joel H.] Ann Arbor Vet Affairs Med Ctr, Ctr Clin Management Res, Ann Arbor, MI USA. [Rubenstein, Joel H.] Univ Michigan, Sch Med, Dept Internal Med, Barretts Esophagus Program,Div Gastroenterol, Ann Arbor, MI USA. [Cook, Michael B.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Vaughan, Thomas L.] Fred Hutchinson Canc Res Ctr, Program Epidemiol, Seattle, WA 98104 USA. [Anderson, Lesley A.; Murray, Liam J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland. [Shaheen, Nicholas J.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. [Corley, Douglas A.] Kaiser Permanente, Div Res, Oakland, CA USA. [Corley, Douglas A.] San Francisco Med Ctr, San Francisco, CA USA. [Chandar, Apoorva K.; Greer, Katarina B.; Chak, Amitabh] Case Western Reserve Univ, Div Gastroenterol & Liver Dis, Cleveland, OH 44106 USA. [Li, Li] Case Western Reserve Univ, Swetland Ctr Environm Hlth, Dept Family Med, Cleveland, OH 44106 USA. [El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston VA Hlth Serv Res & Dev, Dept Med, Houston, TX USA. [Whiteman, David C.; Thrift, Aaron P.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Thrift, Aaron P.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, One Baylor Plaza,MS BCM305, Houston, TX 77030 USA. RP Thrift, AP (reprint author), Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.; Thrift, AP (reprint author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, One Baylor Plaza,MS BCM305, Houston, TX 77030 USA. EM aaron.thrift@bcm.edu OI Anderson, Lesley/0000-0002-1000-3649; Whiteman, David/0000-0003-2563-9559 FU National Institutes of Health [RO1 DK63616, 1R21DK077742, K23DK59311, R03 DK75842, K23DK079291, R01 CA116845, K24-04-107]; NCI [U54CA163060]; Intramural Program of the National Institutes of Health; Ireland-Northern Ireland cooperation research project grant - Northern Ireland Research and Development Office; Health Research Board, Ireland [RES/1699/01N/S]; Study of Digestive Health grant [NCI RO1 CA 001833]; Study of Reflux Disease grant [NCI R01 CA72866]; Established Investigator Award in Cancer Prevention and Control grant [K05 CA124911]; US Department of Veterans Affairs [I01-CX000899]; US Public Health Service [R21 CA135692] FX This work was supported by the National Institutes of Health RO1 DK63616 (D.A.C.), 1R21DK077742 (N.J.S. and D.A.C.), K23DK59311 (N.J.S.), R03 DK75842 (N.J.S.), K23DK079291 (J.H.R.), R01 CA116845 (H.B.E.-S.), K24-04-107 (H.B.E.-S.); NCI grant U54CA163060 (A.C.); the Intramural Program of the National Institutes of Health (M.B.C.); an Ireland-Northern Ireland cooperation research project grant sponsored by the Northern Ireland Research and Development Office and the Health Research Board, Ireland (Factors Influencing the Barrett's/Adenocarcinoma Relationship) (RES/1699/01N/S to L.J.M.); the Study of Digestive Health grant NCI RO1 CA 001833 (D.C.W.); the Study of Reflux Disease grant NCI R01 CA72866 (T.L.V.); the Established Investigator Award in Cancer Prevention and Control grant K05 CA124911 (T.L.V.); the US Department of Veterans Affairs grant CSRD Merit I01-CX000899 (J.H.R.); and US Public Health Service research grant R21 CA135692 (A.C.). NR 37 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD OCT PY 2016 VL 14 IS 10 BP 1412 EP + DI 10.1016/j.cgh.2016.05.032 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA6SO UT WOS:000386759500011 PM 27264393 ER PT J AU Papadakis, GZ Millo, C Stratakis, CA AF Papadakis, Georgios Z. Millo, Corina Stratakis, Constantine A. TI Benign hormone-secreting adenoma within a larger adrenocortical mass showing intensely increased activity on F-18-FDG PET/CT SO ENDOCRINE LA English DT Article DE F-18-FDG PET/CT; Computed Tomography (CT); Adrenal glands; Adenoma(s) ID LESIONS AB Adrenal adenomas usually show F-18-FDG activity less than that of the liver parenchyma. However, lipid-poor and hormone-secreting adenomas have been reported to show mild F-18-FDG avidity. We report on a 51-year-old female with clinical symptoms of hypercortisolemia and a large right adrenal mass detected on CT. Post-contrast CT images showed an enhancing focus in the lower pole of the mass, with corresponding markedly increased activity on F-18-FDG PET/CT. Right adrenalectomy was performed and histology revealed a benign adenoma, indicating that functioning benign adenomas can show intensely increased metabolic activity on F-18-FDG mimicking malignancy. C1 [Papadakis, Georgios Z.] NIH, Radiol & Imaging Sci, Warren Grant Magnuson Clin Ctr CC, Bldg 10, Bethesda, MD 20892 USA. [Millo, Corina] RAD&IS, Div Nucl Med, Bethesda, MD 20892 USA. [Millo, Corina] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, CRC, Bldg 10,Room 1-3330,MSC1103, Bethesda, MD 20892 USA. RP Stratakis, CA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, CRC, Bldg 10,Room 1-3330,MSC1103, Bethesda, MD 20892 USA. EM stratakc@mail.nih.gov FU Intramural NIH HHS [ZIA HD008920-04] NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD OCT PY 2016 VL 54 IS 1 BP 269 EP 270 DI 10.1007/s12020-016-0969-7 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA4WL UT WOS:000386616300031 PM 27154873 ER PT J AU Chang, FE Beall, SA Cox, JM Richter, KS DeCherney, AH Levy, MJ AF Chang, Frank E. Beall, Stephanie A. Cox, Jeris M. Richter, Kevin S. DeCherney, Alan H. Levy, Michael J. TI Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response SO FERTILITY AND STERILITY LA English DT Article DE Gonadotropin-releasing hormone (GnRH) agonist; leuprolide acetate; human chorionic gonadotropin (hCG); retrigger; in vitro fertilization (IVF) ID OVARIAN HYPERSTIMULATION SYNDROME; IN-VITRO FERTILIZATION; HIGH-RISK PATIENTS; GNRH AGONIST; PREGNANCY RATES; LUTEAL SUPPORT; HCG; ANTAGONIST; MULTICENTER; COTREATMENT AB Objective: To compare outcomes of in vitro fertilization (IVF) cycles with adequate versus inadequate response to the gonadotropin-releasing hormone (GnRH) agonist trigger rescued with the use of human chorionic gonadotropin (hCG) retrigger, and to identify risk factors associated with an inadequate trigger. Design: Retrospective cohort study. Setting: Private practice. Patient(s): Women at high risk for ovarian hyperstimulation syndrome who underwent an autologous IVF cycle and used GnRH agonist to trigger oocyte maturation before oocyte retrieval. Intervention(s): Patients were triggered with GnRH agonist for final oocyte maturation before retrieval. Patients with an inadequate response, defined by low post-trigger serum LH and P concentrations or failure to recover oocytes after aspiration of several follicles, were retriggered with hCG. Main Outcome Measure(s): Number of oocytes retrieved, fertilization rate, clinical pregnancy, and live birth. Result(s): Two percent of patients triggered with GnRH agonist had an inadequate response and were retriggered with hCG. There was no statistically significant difference in clinical outcomes between the cycles that were retriggered with hCG and successful GnRH agonist triggers. Low body mass index, low baseline LH, and higher total dosage of gonadotropins required for stimulation were associated with an increased risk of having an inadequate response to the GnRH agonist trigger. Conclusion(s): A small minority of patients triggered with GnRH agonist had an inadequate response. Rescheduling of oocyte retrieval after hCG retrigger yielded similar IVF outcomes. Evaluation of trigger response based on serum LH and P concentrations is time dependent. Patient characteristics suggestive of hypothalamic hypofunction were predictive of an inadequate response to the GnRH agonist trigger. (C) 2016 by American Society for Reproductive Medicine. C1 [Chang, Frank E.; Beall, Stephanie A.; Richter, Kevin S.; Levy, Michael J.] Shady Grove Fertil Reprod Sci Ctr, 15001 Shady Grove Rd, Rockville, MD 20850 USA. [Beall, Stephanie A.; Cox, Jeris M.; DeCherney, Alan H.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA. RP Chang, FE (reprint author), Shady Grove Fertil Reprod Sci Ctr, 15001 Shady Grove Rd, Rockville, MD 20850 USA. EM frank.chang@integramed.com NR 21 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2016 VL 106 IS 5 BP 1093 EP + DI 10.1016/j.fertnstert.2016.06.013 PG 11 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA EA7RG UT WOS:000386828800022 PM 27341988 ER PT J AU Owen, CM Pal, L Mumford, SL Freeman, R Isaac, B McDonald, L Santoro, N Taylor, HS Wolff, EF AF Owen, Carter M. Pal, Lubna Mumford, Sunni L. Freeman, Ruth Isaac, Barbara McDonald, Linda Santoro, Nanette Taylor, Hugh S. Wolff, Erin F. TI Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study SO FERTILITY AND STERILITY LA English DT Article DE Menopause; hormone therapy; skin wrinkles; skin rigidity; race ID POSTMENOPAUSAL WOMEN; ETHNIC-DIFFERENCES; COLLAGEN CONTENT; THERAPY; ESTRADIOL AB Objective: To measure skin wrinkles and rigidity in menopausal women of varying race/ethnicity with or without hormone therapy (HT) for up to four years. Design: Randomized, double-blind, placebo-controlled trial. Setting: Academic medical centers. Patient(s): Women (42-58 years of age) within 36 months of last menstrual period and enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Intervention(s): Treatment with 0.45 mg oral conjugated equine estrogens (CEE), transdermal E-2 (50 mu g/d) with micronized P (200 mg daily), or placebo for 4 years. Main Outcome Measure(s): Skin wrinkles were assessed at 11 locations on the face and neck, and skin rigidity was assessed at the forehead and cheek at baseline and yearly for 4 years. Result(s): Neither total wrinkle score nor total rigidity score was significantly different at baseline or over the 4-year follow-up among patients randomized to CEE, E-2, or placebo. Skin wrinkle and rigidity scores were primarily affected by race/ethnicity, with scores being significantly different between races for almost all of the wrinkle parameters and for all of the rigidity measures. There was no association between race and response to HT for total wrinkle or rigidity scores. Black women had the lowest wrinkle scores compared with white women across all 4 years. In general, skin rigidity decreased in all groups over time, but black women had significantly reduced total facial rigidity compared with white women after 4 years. Conclusion(s): Race is the strongest predictor of the advancement of skin aging in the 4 years following menopause. HT does not appear to affect skin wrinkles or rigidity at most facial locations. Clinical Trial Registration Number: NCT00154180. (Fertil Steril (R) 2016;106:1170-5. (C) 2016 by American Society for Reproductive Medicine.) C1 [Owen, Carter M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA. [Pal, Lubna; McDonald, Linda; Taylor, Hugh S.] Yale Univ, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA. [Mumford, Sunni L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, Bethesda, MD USA. [Freeman, Ruth; Isaac, Barbara] Albert Einstein Coll Med, Obstet & Gynecol & Womens Hlth, Div Reprod Endocrinol & Infertil, Bronx, NY 10467 USA. [Santoro, Nanette] Univ Colorado, Dept Obstet & Gynecol & Womens Hlth, Denver Sch Med, Aurora, CO USA. [Wolff, Erin F.] Celmatix, New York, NY USA. RP Owen, CM (reprint author), Program Reprod & Adult Endocrinol, 10 CRC,Room 1E-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA. EM carter.owen@mail.nih.gov FU Bayer Women's Healthcare; Pfizer; Bayer; Abbvie; Euroscreen; Kronos Longevity Research Institute Reproductive Scientist Development Program [NIH K12HD00849]; Berlex Foundation; National Institutes of Health [U54 HD052668]; Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland FX C.M.O. has nothing to disclose. L.P. has nothing to disclose. S.L.M. has nothing to disclose. R.F. has nothing to disclose. B.I. has nothing to disclose. L.M. has nothing to disclose. N.S. reports stock options in Menogenix and investigator-initiated grant support from Bayer Women's Healthcare. H.S.T. reports grants and personal fees from Pfizer, Bayer, and Abbvie and personal fees from Euroscreen. E.F.W. has nothing to disclose.; Supported by the Kronos Longevity Research Institute Reproductive Scientist Development Program (NIH K12HD00849) and the Berlex Foundation (E.F.W.), the National Institutes of Health (U54 HD052668, H.S.T.), and the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. NR 17 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD OCT PY 2016 VL 106 IS 5 BP 1170 EP + DI 10.1016/j.fertnstert.2016.06.023 PG 9 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA EA7RG UT WOS:000386828800033 PM 27393520 ER PT J AU Rupert, CB Heltzel, JMH Taylor, DJ Rusche, LN AF Rupert, Christopher B. Heltzel, Justin M. H. Taylor, Derek J. Rusche, Laura N. TI Sporadic Gene Loss After Duplication Is Associated with Functional Divergence of Sirtuin Deacetylases Among Candida Yeast Species SO G3-GENES GENOMES GENETICS LA English DT Article DE Sir2; Hst1; specifically retained ancestral gene; CTG clade ID SACCHAROMYCES-CEREVISIAE; PHYLOGENETIC ANALYSIS; ALBICANS; EXPRESSION; SIR2; DNA; HETEROCHROMATIN; BIODIVERSITY; SELECTION; GENOMICS AB Gene duplication promotes the diversification of protein functions in several ways. Ancestral functions can be partitioned between the paralogs, or a new function can arise in one paralog. These processes are generally viewed as unidirectional. However, paralogous proteins often retain related functions and can substitute for one another. Moreover, in the event of gene loss, the remaining paralog might regain ancestral functions that had been shed. To explore this possibility, we focused on the sirtuin deacetylase SIR2 and its homolog HST1 in the CTG clade of yeasts. HST1 has been consistently retained throughout the clade, whereas SIR2 is only present in a subset of species. These NAD(+)-dependent deacetylases generate condensed chromatin that represses transcription and stabilizes tandemly repeated sequences. By analyzing phylogenetic trees and gene order, we found that a single duplication of the SIR2/HST1 gene occurred, likely prior to the emergence of the CTG clade. This ancient duplication was followed by at least two independent losses of SIR2. Functional characterization of Sir2 and Hst1 in three species revealed that these proteins have not maintained consistent functions since the duplication. In particular, the rDNA locus is deacetylated by Sir2 in Candida albicans, by Hst1 in C. lusitaniae, and by neither paralog in C. parapsilosis. In addition, the subtelomeres in C. albicans are deacetylated by Sir2 rather than by Hst1, which is orthologous to the sirtuin associated with Saccharomyces cerevisiae subtelomeres. These differences in function support the model that sirtuin deacetylases can regain ancestral functions to compensate for gene loss. C1 [Rupert, Christopher B.; Heltzel, Justin M. H.; Taylor, Derek J.; Rusche, Laura N.] SUNY Buffalo, Dept Biol Sci, 109 Cooke Hall, Buffalo, NY 14260 USA. [Heltzel, Justin M. H.] NIA, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA. RP Rusche, LN (reprint author), SUNY Buffalo, Dept Biol Sci, 109 Cooke Hall, Buffalo, NY 14260 USA. EM lrusche@buffalo.edu FU National Science Foundation [MCB-1121569, ARC-1023334] FX We thank G. Butler and S. Noble for strains and plasmids, and the members of the Rusche lab for helpful discussion. This research was supported by grants from the National Science Foundation to L.N.R. (MCB-1121569) and D.J.T. (ARC-1023334). NR 48 TC 0 Z9 0 U1 0 U2 0 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 2160-1836 J9 G3-GENES GENOM GENET JI G3-Genes Genomes Genet. PD OCT PY 2016 VL 6 IS 10 BP 3297 EP 3305 DI 10.1534/g3.116.033845 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA EA4KM UT WOS:000386581200023 PM 27543294 ER PT J AU Bolte, FJ O'Keefe, A Serti, E Rivera, E Liang, TJ Ghany, MG Rehermann, B AF Bolte, Fabian J. O'Keefe, Ashley Serti, Elisavet Rivera, Elenita Liang, T. Jake Ghany, Marc G. Rehermann, Barbara TI Monocyte-dependent activation of intrahepatic mucosal associated invariant T cells resolves within weeks of antiviral therapy for hepatitis C SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Bolte, Fabian J.; O'Keefe, Ashley; Serti, Elisavet; Rivera, Elenita; Liang, T. Jake; Ghany, Marc G.; Rehermann, Barbara] NIDDK, Liver Dis Branch, NIH, DHHS, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 10 BP 5A EP 5A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800011 ER PT J AU Uchida, T Walsh, K Hiraga, N Imamura, M Koh, C Glenn, J Uprichard, SL Heller, T Dahari, H Chayama, K AF Uchida, Takuro Walsh, Kevin Hiraga, Nobuhiko Imamura, Michio Koh, Christopher Glenn, Jeffrey Uprichard, Susan L. Heller, Theo Dahari, Harel Chayama, Kazuaki TI Characterization of HDV and HBV kinetics during acute co-infection and interferon-alpha treatment in uPA/SCID chimeric mice with humanized livers SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Walsh, Kevin; Uprichard, Susan L.; Dahari, Harel] Loyola Univ, Med Ctr, Program Expt & Theoret Modeling, Div Hepatol,Dept Med, 2160 S 1st Ave, Maywood, IL 60153 USA. [Uchida, Takuro; Hiraga, Nobuhiko; Imamura, Michio; Chayama, Kazuaki] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab, Appl Life Sci, Hiroshima, Japan. [Koh, Christopher; Heller, Theo] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Glenn, Jeffrey] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA USA. [Uprichard, Susan L.] Loyola Univ, Med Ctr, Dept Microbiol & Immunol, 2160 S 1st Ave, Maywood, IL 60153 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 18 BP 9A EP 10A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800019 ER PT J AU Emmanuel, B Gross, C Masur, H Kottilil, S Kattakuzhy, S AF Emmanuel, Benjamin Gross, Chloe Masur, Henry Kottilil, Shyam Kattakuzhy, Sarah TI High Efficacy in Real-World Treatment of Cirrhotic Patients by Non-Specialist Providers SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Emmanuel, Benjamin; Gross, Chloe; Kottilil, Shyam; Kattakuzhy, Sarah] Univ Maryland, Sch Med, Inst Human Virol, Div Clin Care & Res, Baltimore, MD 21201 USA. [Masur, Henry] NIH, Crit Care, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 22 BP 11A EP 12A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800023 ER PT J AU Ajmera, VH Belt, PH Wilson, L Gill, RM Loomba, R Kleiner, DE Tetri, BA Terrault, N AF Ajmera, Veeral H. Belt, Patricia H. Wilson, Laura Gill, Ryan M. Loomba, Rohit Kleiner, David E. Tetri, Brent A. Terrault, Norah TI No Benefit from Modest Alcohol Use in Nonalcoholic Fatty Liver Disease (NAFLD) SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ajmera, Veeral H.; Terrault, Norah] UCSF, Gastroenterol, San Francisco, CA USA. [Belt, Patricia H.; Wilson, Laura] Johns Hopkins Univ, Baltimore, MD USA. [Gill, Ryan M.] UCSF, Pathol, San Francisco, CA USA. [Loomba, Rohit] Univ Calif San Diego, San Diego, CA USA. [Kleiner, David E.] NCI, Pathol, Bethesda, MD 20892 USA. [Tetri, Brent A.] St Luis Univ, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 31 BP 16A EP 16A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800032 ER PT J AU Kleiner, DE Brunt, EM Belt, PH Wilson, L Guy, CD Yeh, MM Gill, RM Kowdley, KV Tetri, BA Sanyal, AJ AF Kleiner, David E. Brunt, Elizabeth M. Belt, Patricia H. Wilson, Laura Guy, Cynthia D. Yeh, Matthew M. Gill, Ryan M. Kowdley, Kris V. Tetri, Brent A. Sanyal, Arun J. TI Diagnostic Pattern and Disease Activity Are Related To Disease Progression and Regression in Nonalcoholic Fatty Liver Disease SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Sanyal, Arun J.] Virginia Commonwealth Univ, Richmond, VA USA. [Kleiner, David E.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Brunt, Elizabeth M.] Washington Univ, St Louis, MO USA. [Belt, Patricia H.; Wilson, Laura] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. [Guy, Cynthia D.] Duke Univ, Durham, NC USA. [Yeh, Matthew M.] Univ Washington, Seattle, WA USA. [Gill, Ryan M.] Univ Calif San Francisco, San Francisco, CA USA. [Kowdley, Kris V.] Swedish Med Ctr, Seattle, WA USA. [Tetri, Brent A.] St Louis Univ, St Louis, MO 63103 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 BP 19A EP 19A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800038 ER PT J AU Puri, P Mirshahi, F Daita, K Vincent, R Liangpunsakul, S Chalasani, NP Crabb, DW Shah, V Kamath, PS Gores, GJ Katz, BP Radaeva, S Sanyal, AJ AF Puri, Puneet Mirshahi, Faridoddin Daita, Kalyani Vincent, Robert Liangpunsakul, Suthat Chalasani, Naga P. Crabb, David W. Shah, Vijay Kamath, Patrick S. Gores, Gregory J. Katz, Barry P. Radaeva, Svetlana Sanyal, Arun J. TI Quantitative and Qualitative Changes in the Circulating Microbiome Are Associated With the Development and Severity of Alcoholic Hepatitis SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Puri, Puneet; Mirshahi, Faridoddin; Daita, Kalyani; Vincent, Robert; Sanyal, Arun J.] Virginia Commonwealth Univ, Richmond, VA USA. [Liangpunsakul, Suthat; Chalasani, Naga P.; Crabb, David W.; Katz, Barry P.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Shah, Vijay; Kamath, Patrick S.; Gores, Gregory J.] Mayo Clin, Rochester, MN USA. [Radaeva, Svetlana] NIAAA, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 48 BP 25A EP 25A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800049 ER PT J AU Alao, H Cam, M Zhang, F Suarez, DF Henderson, WA Fourie, NI Li, QS Liang, TJ Ghany, MG AF Alao, Hawwa Cam, Margaret Zhang, Fang Suarez, Daniel F. Henderson, Wendy A. Fourie, N. I. Li, Qisheng Liang, T. Jake Ghany, Marc G. TI Role Of MiRNAs In Hepatitis C Virus Clearance In Prior Non-Responders During Therapy With DAAs SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Alao, Hawwa; Zhang, Fang; Suarez, Daniel F.; Li, Qisheng; Liang, T. Jake; Ghany, Marc G.] NIDDK, NIH, Baltimore, MD USA. [Cam, Margaret] NCI, NIH, Bethesda, MD 20892 USA. [Henderson, Wendy A.; Fourie, N. I.] NINR, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 66 BP 34A EP 35A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800067 ER PT J AU Asselah, T Shiha, G Feld, JJ Abergel, A Kohli, A Kottilil, S Ruane, PJ Naggie, S Letterio, C Hahambis, TA Llewellyn, J Natha, M Kersey, K McNally, J Brainard, DM Esmat, GE AF Asselah, Tarik Shiha, Gamal Feld, Jordan J. Abergel, Armando Kohli, Anita Kottilil, Shyam Ruane, Peter J. Naggie, Susanna Letterio, Cathleen Hahambis, Thomas A. Llewellyn, Joseph Natha, Macky Kersey, Kathryn McNally, John Brainard, Diana M. Esmat, Gamal E. TI Integrated Analysis of SOF plus RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Letterio, Cathleen; Hahambis, Thomas A.; Llewellyn, Joseph; Natha, Macky; Kersey, Kathryn; McNally, John; Brainard, Diana M.] Gilead Sci, Foster City, CA USA. [Kohli, Anita] Creighton Univ, Sch Med, Phoenix, AZ USA. [Feld, Jordan J.] Toronto Western Hosp, Toronto, ON, Canada. [Ruane, Peter J.] Ruane Med & Liver Hlth Inst, Los Angeles, CA USA. [Shiha, Gamal] Almansoura Univ Hosp, Mansoura, Egypt. [Abergel, Armando] Beaujon Hosp, Clermont Ferrand, France. [Asselah, Tarik] Hop Beaujon, Serv Hepatol, Clichy, France. [Asselah, Tarik] Hop Beaujon, INSERM, U773, CRB3, Clichy, France. [Naggie, Susanna] Duke Clin Res Inst, Durham, NC USA. [Kottilil, Shyam] NIAID, Baltimore, MD USA. [Esmat, Gamal E.] Cairo Univ, Cairo, Egypt. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 75 BP 40A EP 41A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800076 ER PT J AU Alonso, EM Ye, W Hawthorne, K Venkat, VL Loomes, KM Mack, CL Hertel, PM Karpen, SJ Kerkar, N Molleston, JP Murray, KF Romero, R Rosenthal, P Schwarz, KB Shneider, B Suchy, FJ Turmelle, YP Wang, KS Whitington, PF Sherker, AH Sokol, RJ Bezerra, JA Magee, JC AF Alonso, Estella M. Ye, Wen Hawthorne, Kieran Venkat, Veena L. Loomes, Kathleen M. Mack, Cara L. Hertel, Paula M. Karpen, Saul J. Kerkar, Nanda Molleston, Jean P. Murray, Karen F. Romero, Rene Rosenthal, Phil Schwarz, Kathleen B. Shneider, Benjamin Suchy, Frederick J. Turmelle, Yumirle P. Wang, Kasper S. Whitington, Peter F. Sherker, Averell H. Sokol, Ronald J. Bezerra, Jorge A. Magee, John C. TI Impact of Steroid Therapy on Early Growth in Infants with Biliary Atresia SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Alonso, Estella M.; Whitington, Peter F.] Ann & Robert H Lurie Childrens Hosp, Div Pediat Gastroenterol Hepatol & Nutr, Chicago, IL USA. [Ye, Wen] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Hawthorne, Kieran] Arbor Res Collaborat Hlth, Ann Arbor, MI USA. [Venkat, Veena L.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. [Loomes, Kathleen M.] Childrens Hosp Philadelphia, Pediat Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA. [Mack, Cara L.; Suchy, Frederick J.; Sokol, Ronald J.] Univ Colorado, Sch Med, Sect Pediat Gastroenterol Hepatol & Nutr, Aurora, CO USA. [Hertel, Paula M.; Shneider, Benjamin] Baylor Coll Med, Pediat Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA. [Karpen, Saul J.; Romero, Rene] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Pediat Gastroenterol Hepatol & Nutr, Atlanta, GA USA. [Kerkar, Nanda; Wang, Kasper S.] Childrens Hosp Los Angeles, Div Pediat Surg, Los Angeles, CA 90027 USA. [Molleston, Jean P.] Indiana Univ Sch Med, Riley Hosp Children, Pediat Gastroenterol Hepatol & Nutr, Indianapolis, IN 46202 USA. [Murray, Karen F.] Univ Washington, Med Ctr, Seattle Childrens, Div Gastroenterol & Hepatol, Seattle, WA 98195 USA. [Rosenthal, Phil] Univ Calif San Francisco, Dept Pediat, Div Gastroenterol Hepatol & Nutr, San Francisco, CA USA. [Schwarz, Kathleen B.] Johns Hopkins Sch Med, Baltimore, MD USA. [Turmelle, Yumirle P.] Washington Univ, Sch Med, St Louis, MO USA. [Sherker, Averell H.] NIDDKD, NIH, Bethesda, MD USA. [Bezerra, Jorge A.] Cincinnati Childrens Hosp Med, Div Pediat Gastroenterol Hepatol & Nutr, Cincinnati, OH USA. [Magee, John C.] Univ Michigan, Sch Med, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 79 BP 43A EP 43A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800080 ER PT J AU Murray, KF Rodriguez-Baez, N Kleiner, DE Shaffer, M Cooper, KL Ling, SC Rosenthal, P Schwarz, KB Schwarzenberg, SJ AF Murray, Karen F. Rodriguez-Baez, Norberto Kleiner, David E. Shaffer, Michele Cooper, Kara L. Ling, Simon C. Rosenthal, Philip Schwarz, Kathleen B. Schwarzenberg, Sarah J. TI Liver Histology in North American Children with Immune-active Chronic Hepatitis B Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Murray, Karen F.; Shaffer, Michele; Cooper, Kara L.] Univ Washington, Med Ctr, Div Pediat GI & Hepatol, Seattle, WA 98195 USA. [Rodriguez-Baez, Norberto] Univ Texas Dallas, Pediatr Gastroenterol, Dallas, TX USA. [Kleiner, David E.] NCI, Pathol, Washington, DC USA. [Ling, Simon C.] Hosp Sick Kids, Pediat Gastroenterol & Hepatol, Toronto, ON, Canada. [Rosenthal, Philip] Univ Calif San Fransisco, Pediat Gastroenterol, San Francisco, CA USA. [Schwarz, Kathleen B.] Johns Hopkins Sch Med, Pediat Gastroenterol, Baltimore, MD USA. [Schwarzenberg, Sarah J.] Univ Minnesota, Pediat Gastroenterol, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 105 BP 57A EP 57A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800106 ER PT J AU Chalasani, NP Ghabril, M Fontana, RJ Barnhart, HX Hayashi, PH Ahmad, J Stolz, A Navarro, VJ Hoofnagle, JH AF Chalasani, Naga P. Ghabril, Marwan Fontana, Robert J. Barnhart, Huiman X. Hayashi, Paul H. Ahmad, Jawad Stolz, Andrew Navarro, Victor J. Hoofnagle, Jay H. TI Idiosyncratic drug induced liver injury in African Americans: Causes, Clinical Features and Outcomes SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Chalasani, Naga P.; Ghabril, Marwan] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Fontana, Robert J.] Univ Michigan, Ann Arbor, MI 48109 USA. [Barnhart, Huiman X.] Duke Univ, Med Ctr, Durham, NC USA. [Hayashi, Paul H.] Univ N Carolina, Chapel Hill, NC USA. [Ahmad, Jawad] Icahn Sch Med Mt Sinai, Med Ctr, New York, NY 10029 USA. [Stolz, Andrew] Univ Southern Calif, Los Angeles, CA USA. [Navarro, Victor J.] Einstein Healthcare Network, Philadelphia, PA USA. [Hoofnagle, Jay H.] NIDDK, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 116 BP 64A EP 64A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800117 ER PT J AU Ahmad, J Rossi, S Rodgers, SK Fontana, RJ Chalasani, NP Stolz, A Hayashi, PH Barnhart, HX Kleiner, DE Bjornsson, E AF Ahmad, Jawad Rossi, Simona Rodgers, Shuchi K. Fontana, Robert J. Chalasani, Naga P. Stolz, Andrew Hayashi, Paul H. Barnhart, Huiman X. Kleiner, David E. Bjornsson, Einar TI Drug Induced Liver Injury Associated with Sclerosing Cholangitis Like Changes on Magnetic Resonance Cholangiography Imaging SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ahmad, Jawad] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA. [Rossi, Simona] Einstein Med Ctr, Philadelphia, PA USA. [Rodgers, Shuchi K.] Einstein Med Ctr, Dept Radiol, Philadelphia, PA USA. [Fontana, Robert J.] Univ Michigan, Ann Arbor, MI 48109 USA. [Chalasani, Naga P.] Indiana Univ, Indianapolis, IN 46204 USA. [Stolz, Andrew] Univ Southern Calif, Los Angeles, CA USA. [Hayashi, Paul H.] Univ N Carolina, Chapel Hill, NC USA. [Barnhart, Huiman X.] Duke Univ, Durham, NC USA. [Kleiner, David E.] NCI, Bethesda, MD 20892 USA. [Bjornsson, Einar] Landspitali Univ Hosp, Reykjavik, Iceland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 118 BP 65A EP 65A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800119 ER PT J AU Chalasani, NP Xu, YF de Boer, YS Raman, I Lian, Y Eckert, G Li, QZ Hoofnagle, JH AF Chalasani, Naga P. Xu, Yuanfang de Boer, Ynto S. Raman, Indu Lian, Yun Eckert, George Li, Quanzhen Hoofnagle, Jay H. TI Serum Ig M autoantibody profiling using autoantigen arrays identifies Histone H4 Ig M antibody as highly specific to patients with autoimmune like drug induced liver injury SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Chalasani, Naga P.; Xu, Yuanfang; Eckert, George] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Raman, Indu; Lian, Yun; Li, Quanzhen] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [de Boer, Ynto S.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. [Hoofnagle, Jay H.] NIDDK, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 119 BP 65A EP 66A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800120 ER PT J AU Gawrieh, S Karns, R Kleiner, DE Goldblatt, MI Olivier, M Chalasani, NP Xanthakos, S AF Gawrieh, Samer Karns, Rebekah Kleiner, David E. Goldblatt, Matthew I. Olivier, Michael Chalasani, Naga P. Xanthakos, Stavra TI Comparative analysis of global hepatic gene expression profiles in adolescents and adults with NAFLD SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Gawrieh, Samer; Chalasani, Naga P.] Indiana Univ Sch Med, Div Gastroenterol & Hepatol, Indianapolis, IN 46202 USA. [Olivier, Michael] Texax Biomed Inst, Genet, San Antonio, TX USA. [Karns, Rebekah] Cincinnati Children Hosp, Bioinformat, Cincinnati, OH USA. [Kleiner, David E.] NCI, Pathol Lab, Bldg 10, Bethesda, MD 20892 USA. [Goldblatt, Matthew I.] Med Coll Wisconsin, Surg, Milwaukee, WI 53226 USA. [Xanthakos, Stavra] Cincinnati Children Hosp, Div Gastroenterol & Hepatol, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 199 BP 105A EP 105A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800200 ER PT J AU Chen, JG Odena, G Xu, MJ Rodrigo, D Altamirano, J Massey, VL Affo, S Cabezas, J Gines, P Caballeria, J Sancho-Bru, P Gao, B Bataller, R AF Chen, Jiegen Odena, Gemma Xu, Ming-Jiang Rodrigo, Daniel Altamirano, Jose Massey, Veronica L. Affo, Silvia Cabezas, Joaquin Gines, Pere Caballeria, Juan Sancho-Bru, Pau Gao, Bin Bataller, Ramon TI Lipocalin-2 overexpression is mediated by LPS-TL4 pathway and mediates liver fibrosis in alcoholic hepatitis SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Chen, Jiegen; Odena, Gemma; Massey, Veronica L.; Cabezas, Joaquin; Bataller, Ramon] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Chen, Jiegen; Odena, Gemma; Massey, Veronica L.; Cabezas, Joaquin; Bataller, Ramon] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Chen, Jiegen; Odena, Gemma; Massey, Veronica L.; Cabezas, Joaquin; Bataller, Ramon] Univ N Carolina, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. [Xu, Ming-Jiang; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD USA. [Rodrigo, Daniel; Affo, Silvia; Gines, Pere; Caballeria, Juan; Sancho-Bru, Pau] CIBER Enfermedades Hepat & Digest CIBERehd, Inst INvest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, Barcelona, Spain. [Altamirano, Jose] Univ Autonoma Barcelona, Vall dHebron Hosp, Dept Internal Med, Liver Unit, Barcelona, Spain. [Altamirano, Jose] Univ Autonoma Barcelona, Vall dHebron Inst Recerca VHIR, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 219 BP 116A EP 116A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493800220 ER PT J AU Han, MAT Samala, N Rizvi, BS Etzion, O Wright, EC Patel, R Samala-Venkata, V Kleiner, DE Koh, C Pavletic, S Williams, K Heller, T AF Han, Ma Ai Thanda Samala, Niharika Rizvi, Bisharah S. Etzion, Ohad Wright, Elizabeth C. Patel, Ruchi Samala-Venkata, Vikramaditya Kleiner, David E. Koh, Christopher Pavletic, Steven Williams, Kirsten Heller, Theo TI Abnormal Liver Tests Are Inaccurate For Diagnosis Of Chronic Hepatic Graft Versus Host Disease In Critically Ill Patients SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Han, Ma Ai Thanda; Samala, Niharika; Rizvi, Bisharah S.; Etzion, Ohad; Patel, Ruchi; Samala-Venkata, Vikramaditya; Koh, Christopher; Heller, Theo] NIDDK, Liver Dis Branch, NIH, Rockville, MD USA. [Wright, Elizabeth C.] NIDDK, NIH, Bethesda, MD 20892 USA. [Kleiner, David E.; Pavletic, Steven; Williams, Kirsten] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 356 BP 182A EP 182A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801098 ER PT J AU Bae, H Hodge, D Yang, GX Leung, PS Valencia, J Tsuneyama, K Gershwin, ME Young, HA AF Bae, Heekyong Hodge, Deborah Yang, Guo-Xiang Leung, Patrick S. Valencia, Julio Tsuneyama, Koichi Gershwin, M. Eric Young, Howard A. TI The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Bae, Heekyong; Hodge, Deborah; Valencia, Julio; Young, Howard A.] NCI, Canc & Inflammat Program, Frederick, MD 21701 USA. [Yang, Guo-Xiang; Leung, Patrick S.; Gershwin, M. Eric] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA. [Tsuneyama, Koichi] Univ Tokushima, Grad Sch, Dept Pathol & Lab Med, Tokushima, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 364 BP 186A EP 186A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801106 ER PT J AU Roberts, LR Farshidfar, F Zheng, SY Gingras, MC Newton, Y Shih, J Robertson, AG Hinoue, T Hoadley, KA Gibbs, R Roszik, J Covington, K Wu, CC Shinbrot, E Stransky, N Hegde, AM Yang, JD Reznik, E Sadeghi, S Pedamallu, CS Ojesina, AI Hess, J Auman, JT Rhie, SK Bowlby, R Borad, MJ Stuart, J Sander, C Akbani, R Cherniack, AD Laird, PW Deshpande, V Mounajjed, T Foo, WC Torbenson, M Kleiner, DE Wheeler, DA Mcree, AJ Bathe, OF Andersen, JB Bardeesy, N Kwong, LN AF Roberts, Lewis R. Farshidfar, Farshad Zheng, Siyuan Gingras, Marie-Claude Newton, Yulia Shih, Juliann Robertson, A. Gordon Hinoue, Toshinori Hoadley, Katherine A. Gibbs, Richard Roszik, Jason Covington, Kyle Wu, Chia-Chin Shinbrot, Eve Stransky, Nicolas Hegde, Apurva M. Yang, Ju Dong Reznik, Ed Sadeghi, Sara Pedamallu, Chandra Sekhar Ojesina, Akinyemi I. Hess, Julian Auman, J. Todd Rhie, Suhn K. Bowlby, Reanne Borad, Mitesh J. Stuart, Josh Sander, Chris Akbani, Rehan Cherniack, Andrew D. Laird, Peter W. Deshpande, Vikram Mounajjed, Taofic Foo, Wai Chin Torbenson, Michael Kleiner, David E. Wheeler, David A. Mcree, Autumn J. Bathe, Oliver F. Andersen, Jesper B. Bardeesy, Nabeel Kwong, Lawrence N. TI Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Roberts, Lewis R.; Yang, Ju Dong; Mounajjed, Taofic; Torbenson, Michael] Mayo Clin, Coll Med, Rochester, MN USA. [Farshidfar, Farshad] Univ Calgary, Calgary, AB, Canada. [Zheng, Siyuan; Roszik, Jason; Wu, Chia-Chin; Hegde, Apurva M.; Akbani, Rehan; Foo, Wai Chin; Kwong, Lawrence N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Gingras, Marie-Claude; Gibbs, Richard; Covington, Kyle; Shinbrot, Eve; Wheeler, David A.] Baylor Coll Med, Houston, TX 77030 USA. [Newton, Yulia; Stuart, Josh] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA. [Shih, Juliann; Cherniack, Andrew D.] Eli & Edythe L Broad Inst Massachusetts Inst Tech, Cambridge, MA USA. [Robertson, A. Gordon; Sadeghi, Sara; Bowlby, Reanne] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada. [Hinoue, Toshinori; Laird, Peter W.] Van Andel Res Inst, Grand Rapids, MI USA. [Hoadley, Katherine A.; Auman, J. Todd; Mcree, Autumn J.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA. [Stransky, Nicolas] Blueprint Med, Cambridge, MA USA. [Reznik, Ed] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Pedamallu, Chandra Sekhar; Sander, Chris] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ojesina, Akinyemi I.] Univ Alabama Birmingham, Birmingham, AL USA. [Rhie, Suhn K.] Univ Southern Calif, Los Angeles, CA USA. [Borad, Mitesh J.] Mayo Clin, Scottsdale, AZ USA. [Kleiner, David E.] NCI, Bethesda, MD 20892 USA. [Bathe, Oliver F.] Tom Baker Canc Clin, Calgary, AB, Canada. [Andersen, Jesper B.] Univ Copenhagen, DK-1168 Copenhagen, Denmark. [Bardeesy, Nabeel] Harvard Med Sch, Ctr Canc, Gen Hosp 1Massachusetts, Boston, MA USA. [Hess, Julian] Broad Inst, Cambridge, MA USA. [Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 447 BP 227A EP 227A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801189 ER PT J AU Castven, D Czauderna, C Becker, D Worns, MA Grimminger, P Lang, H Thorgeirsson, SS Galle, PR Marquardt, JU AF Castven, Darko Czauderna, Carolin Becker, Diana Worns, Marcus A. Grimminger, Peter Lang, Hauke Thorgeirsson, Snorri S. Galle, Peter R. Marquardt, Jens U. TI Importance of Stem-like Tumor-initiating Cells for the Development of Chemoresistance During Anti-angiogenic Therapies in Hepatocellular Carcinoma SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Castven, Darko; Czauderna, Carolin; Becker, Diana; Worns, Marcus A.; Galle, Peter R.; Marquardt, Jens U.] Johannes Gutenberg Univ Mainz, Dept Internal Med, Mainz, Germany. [Thorgeirsson, Snorri S.] NCI, CCR, NIH, Bethesda, MD 20892 USA. [Grimminger, Peter] Johannes Gutenberg Univ Mainz, Dept Surg, Mainz, Germany. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 494 BP 250A EP 250A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801236 ER PT J AU An, P Zeng, Z Winkler, CA AF An, Ping Zeng, Zheng Winkler, Cheryl A. TI The loss-of-function S267F variant in the HBV receptor NTCP reduces human risk to HBV infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [An, Ping; Winkler, Cheryl A.] NCI, Basic Res Lab, Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA. [Zeng, Zheng] Peking Univ, Dept Infect Dis, Hosp 1, Beijing, Peoples R China. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 602 BP 300A EP 300A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801342 ER PT J AU Zhang, Q Matsuura, K Kleiner, DE Zamboni, F Alter, HJ Farci, P AF Zhang, Quan Matsuura, Kentaro Kleiner, David E. Zamboni, Fausto Alter, Harvey J. Farci, Patrizia TI Identification of Long Noncoding RNA Associated with Hepatocellular Carcinoma of Different Viral Etiology SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Zhang, Quan; Farci, Patrizia] NIH, Infect Dis Lab, Bldg 10, Bethesda, MD 20892 USA. [Matsuura, Kentaro; Alter, Harvey J.] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA. [Kleiner, David E.] NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA. [Zamboni, Fausto] Brotzu Hosp, Liver Transplantat Ctr, Cagliari, Italy. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 609 BP 303A EP 304A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801349 ER PT J AU Townsend, EC Moon, MS Zhang, G Firke, M Han, MAT Kleiner, DE Koh, C Heller, T AF Townsend, Elizabeth C. Moon, Mi Sun Zhang, Grace Firke, Marian Han, Ma Ai Thanda Kleiner, David E. Koh, Christopher Heller, Theo TI Microbial Translocation in the Context of Hepatitis B and Hepatitis D infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Townsend, Elizabeth C.; Moon, Mi Sun; Zhang, Grace; Firke, Marian; Han, Ma Ai Thanda; Koh, Christopher; Heller, Theo] NIH, Liver Dis Branch, Bldg 10, Bethesda, MD 20892 USA. [Kleiner, David E.] NCI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 627 BP 312A EP 313A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801367 ER PT J AU Tillmann, HL Barnhart, HX Serrano, J Rockey, DC AF Tillmann, Hans L. Barnhart, Huiman X. Serrano, Jose Rockey, Don C. TI A Novel Computerized Drug Induced Liver Injury Causality Assessment Tool (DILI-CAT) SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Tillmann, Hans L.] East Carolina Univ, Dept Med, Div Gastroenterol Hepatol & Nutr, Greenville, NC USA. [Barnhart, Huiman X.] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Serrano, Jose] NIDDK, Digest Dis Branch, Bethesda, DC USA. [Rockey, Don C.] Med Univ South Carolina, Med, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 645 BP 320A EP 321A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801385 ER PT J AU Amet, T Li, W Yang, D Liangpunsakul, S Puri, P Kamath, PS Sanyal, AJ Shah, V Radaeva, S Crabb, DW Chalasani, NP Yu, QA AF Amet, Tohti Li, Wei Yang, Dennis Liangpunsakul, Suthat Puri, Puneet Kamath, Patrick S. Sanyal, Arun J. Shah, Vijay Radaeva, Svetlana Crabb, David W. Chalasani, Naga P. Yu, Qigui A. TI Profiles of inflammatory cytokines/chemokines and immune cell activation in patients with alcoholic hepatitis SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Amet, Tohti; Li, Wei; Yang, Dennis; Yu, Qigui A.] Indiana Univ Sch Med, Microbiol & Immunol, Indianapolis, IN 46202 USA. [Liangpunsakul, Suthat; Crabb, David W.; Chalasani, Naga P.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Puri, Puneet; Sanyal, Arun J.] Virginia Commonwealth Univ, Richmond, VA USA. [Kamath, Patrick S.; Shah, Vijay] Mayo Clin, Rochester, MN USA. [Radaeva, Svetlana] NIAAA, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 689 BP 341A EP 342A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801429 ER PT J AU Vatsalya, V Song, M Schwandt, M Cave, M Barve, S George, D Ramchandani, VA McClain, C AF Vatsalya, Vatsalya Song, Ming Schwandt, Melanie Cave, Matthew Barve, Shirish George, David Ramchandani, Vijay A. McClain, Craig TI Effects of sex, drinking history and omega-3 and omega-6 fatty acids dysregulation on the onset of liver injury in very heavy drinking alcohol dependent patients SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Vatsalya, Vatsalya; Song, Ming; Cave, Matthew; Barve, Shirish; McClain, Craig] Univ Louisville, Med, Louisville, KY 40292 USA. [Schwandt, Melanie; George, David; Ramchandani, Vijay A.] NIAAA, DICBR LCTS, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 688 BP 341A EP 341A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801428 ER PT J AU Li, W Amet, T Yang, K Liangpunsakul, S Puri, P Kamath, PS Sanyal, AJ Shah, V Radaeva, S Crabb, DW Chalasani, NP Yu, QA AF Li, Wei Amet, Tohti Yang, Kai Liangpunsakul, Suthat Puri, Puneet Kamath, Patrick S. Sanyal, Arun J. Shah, Vijay Radaeva, Svetlana Crabb, David W. Chalasani, Naga P. Yu, Qigui A. TI Monocyte/macrophage activation and IL-22 dysregulation in patients with alcoholic hepatitis SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Li, Wei; Amet, Tohti; Yang, Kai; Yu, Qigui A.] Indiana Univ Sch Med, Microbiol & Immunol, Indianapolis, IN 46202 USA. [Liangpunsakul, Suthat; Crabb, David W.; Chalasani, Naga P.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Puri, Puneet; Sanyal, Arun J.] Virginia Commonwealth Univ, Richmond, VA USA. [Kamath, Patrick S.; Shah, Vijay] Mayo Clin, Rochester, MN USA. [Radaeva, Svetlana] NIAAA, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 696 BP 344A EP 345A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493801436 ER PT J AU Etzion, O Ali, R Koh, C Levy, E Kleiner, DE Rampertaap, S Rosenzweig, S Takyar, VK Han, MAT Lingala, S Fryzek, N Haynes-Williams, V Heller, T AF Etzion, Ohad Ali, Rabab Koh, Christopher Levy, Elliot Kleiner, David E. Rampertaap, Shakuntala Rosenzweig, Sergio Takyar, Varun K. Han, Ma Ai Thanda Lingala, Shilpa Fryzek, Nancy Haynes-Williams, Vanessa Heller, Theo TI Disparate Changes in Adaptive Immunity in Systemic vs. Portal Venous Circulation, Across the Spectrum of HCV Associated Liver Disease SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Kleiner, David E.] NCI, Pathol Lab, Bldg 10, Bethesda, MD 20892 USA. [Etzion, Ohad; Ali, Rabab; Koh, Christopher; Levy, Elliot; Kleiner, David E.; Rampertaap, Shakuntala; Rosenzweig, Sergio; Takyar, Varun K.; Han, Ma Ai Thanda; Lingala, Shilpa; Fryzek, Nancy; Haynes-Williams, Vanessa; Heller, Theo] NIH, Bldg 10, Bethesda, MD 20892 USA. [Etzion, Ohad; Ali, Rabab; Koh, Christopher; Takyar, Varun K.; Han, Ma Ai Thanda; Lingala, Shilpa; Fryzek, Nancy; Haynes-Williams, Vanessa; Heller, Theo] NIDDK, Liver Dis Branch, Bethesda, MD 20892 USA. [Levy, Elliot] Ctr Clin, Intervent Radiol, Bethesda, MD USA. [Rampertaap, Shakuntala; Rosenzweig, Sergio] Ctr Clin, Immunol Serv, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 731 BP 362A EP 362A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802003 ER PT J AU Unalp-Arida, A Ruhl, CE AF Unalp-Arida, Aynur Ruhl, Constance E. TI The Burden of Viral Hepatitis B and C Infection in the United States Population SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Unalp-Arida, Aynur] NIDDK, Bethesda, MD 20892 USA. [Ruhl, Constance E.] Social & Sci Syst Inc, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 793 BP 391A EP 391A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802062 ER PT J AU Naggie, S Rosenthal, E Kattakuzhy, S McGinnis, J Naik, S Natha, M Llewellyn, J Haubrich, R Osinusi, AO Stamm, LM Cooper, C Dieterich, DT Sulkowski, MS AF Naggie, Susanna Rosenthal, Eric Kattakuzhy, Sarah McGinnis, Justin Naik, Sarjita Natha, Macky Llewellyn, Joseph Haubrich, Richard Osinusi, Anu O. Stamm, Luisa M. Cooper, Curtis Dieterich, Douglas T. Sulkowski, Mark S. TI Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Naggie, Susanna] Duke Univ, Durham, NC USA. [Rosenthal, Eric] Univ Hosp Archet, Nice, France. [Kattakuzhy, Sarah] NIH, Rockville, MD USA. [McGinnis, Justin] Univ Southern Calif, Los Angeles, CA USA. [Naik, Sarjita; Natha, Macky; Llewellyn, Joseph; Haubrich, Richard; Osinusi, Anu O.; Stamm, Luisa M.] Gilead Sci, Foster City, CA USA. [Cooper, Curtis] Ottawa Hosp, Ottawa, ON, Canada. [Dieterich, Douglas T.] Mt Sinai Sch Med, New York, NY USA. [Sulkowski, Mark S.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 892 BP 445A EP 445A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802159 ER PT J AU Tran, NJQ Kovalic, AJ Kleiner, DE Bridges, D Satapathy, SK AF Tran, Nhu Josephine Q. Kovalic, Alexander J. Kleiner, David E. Bridges, Dave Satapathy, Sanjaya K. TI The use of calcineurin inhibitors post-liver transplantation and the donor SOD2 C47T polymorphism influence recurrent NAFLD after liver transplantation SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Tran, Nhu Josephine Q.] Univ Tennessee, Ctr Hlth Sci, Prevent Med, Memphis, TN 38163 USA. [Bridges, Dave] Univ Tennessee, Ctr Hlth Sci, Physiol, Memphis, TN 38163 USA. [Satapathy, Sanjaya K.] Univ Tennessee, Ctr Hlth Sci, Surg, Memphis, TN 38163 USA. [Satapathy, Sanjaya K.] Methodist Univ Hosp, Transplant Inst, Memphis, TN USA. [Kovalic, Alexander J.] Univ Tennessee, Ctr Hlth Sci, Med, Memphis, TN 38163 USA. [Kleiner, David E.] NIH, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 990 BP 502A EP 502A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802257 ER PT J AU Bolte, FJ O'Keefe, A Etzion, O Ali, R Serti, E Liang, TJ Heller, T Rehermann, B AF Bolte, Fabian J. O'Keefe, Ashley Etzion, Ohad Ali, Rabab Serti, Elisavet Liang, T. Jake Heller, Theo Rehermann, Barbara TI Innate immune cell phenotype and function in different compartments of the gut-liver-axis in chronic liver diseas SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Bolte, Fabian J.; O'Keefe, Ashley; Etzion, Ohad; Ali, Rabab; Serti, Elisavet; Liang, T. Jake; Heller, Theo; Rehermann, Barbara] NIDDK, Liver Dis Branch, NIH, DHHS, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1029 BP 520A EP 520A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802296 ER PT J AU Ouyang, XS Han, SN Lau, G Feng, DC Cardone, R Cai, SY Hoque, R Chen, YL Yang, WH Garcia-Martinez, I Wang, FS Gao, B Torok, NJ Kibbey, R Mehal, WZ AF Ouyang, Xinshou Han, Sheng-Na Lau, George Feng, Dechun Cardone, Rebecca Cai, Shi-Ying Hoque, Rafaz Chen, Yonglin Yang, Wei-Hong Garcia-Martinez, Irma Wang, Fu-Sheng Gao, Bin Torok, Natalie J. Kibbey, Richard Mehal, Wajahat Z. TI Digoxin protects from sterile inflammation in the liver by targeting pyruvate kinase M2 (PKM2) promoted HIF-1 alpha transactivation SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Ouyang, Xinshou; Han, Sheng-Na; Lau, George; Cardone, Rebecca; Cai, Shi-Ying; Hoque, Rafaz; Chen, Yonglin; Yang, Wei-Hong; Garcia-Martinez, Irma; Kibbey, Richard; Mehal, Wajahat Z.] Yale Univ, New Haven, CT USA. [Feng, Dechun; Gao, Bin] NIAAA, NIH, Bethesda, MD USA. [Wang, Fu-Sheng] Beijing 302 Hosp, Inst Translat Hepatol, Beijing, Peoples R China. [Torok, Natalie J.] Univ Calif Davis, Dept Med, Sacramento, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1035 BP 522A EP 523A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802302 ER PT J AU Samala, N Hallinan, EK Kleiner, DE Hoofnagle, JH Loomba, R AF Samala, Niharika Hallinan, Erin K. Kleiner, David E. Hoofnagle, Jay H. Loomba, Rohit TI Race and Ethnicity in Patients with Nonalcoholic Fatty Liver Disease SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Hoofnagle, Jay H.] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Samala, Niharika] Indiana Univ Sch Med, Med, Indianapolis, IN 46202 USA. [Hallinan, Erin K.] John Hopkins Univ Bloomberg Sch Publ Hlth, Stat, Indianapolis, IN USA. [Kleiner, David E.] NCI, Pathol, NIH, Indianapolis, IN USA. [Loomba, Rohit] Univ Calif San Diego, Med, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1055 BP 532A EP 532A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802322 ER PT J AU Unalp-Arida, A Ruhl, CE AF Unalp-Arida, Aynur Ruhl, Constance E. TI The US Fatty Liver Index and Fatty Liver Index as Potential Steatosis Markers Predict Liver Disease Mortality in the US Population SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Unalp-Arida, Aynur] NIDDK, Bethesda, MD 20892 USA. [Ruhl, Constance E.] Social & Sci Syst Inc, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1059 BP 533A EP 534A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802326 ER PT J AU Unalp-Arida, A Ruhl, CE AF Unalp-Arida, Aynur Ruhl, Constance E. TI The Burden of Liver Disease in the United States Population SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Unalp-Arida, Aynur] NIDDK, Bethesda, MD 20892 USA. [Ruhl, Constance E.] Social & Sci Syst Inc, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1115 BP 563A EP 563A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802382 ER PT J AU Rotman, Y Lingala, S Morris, N AF Rotman, Yaron Lingala, Shilpa Morris, Nevitt TI Subtle Iron Deficiency is Common During Vitamin E Treatment For NAFLD SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Rotman, Yaron; Lingala, Shilpa; Morris, Nevitt] NIDDK, Liver & Energy Metab Unit, Liver Dis Branch, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1133 BP 571A EP 572A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802400 ER PT J AU Takyar, VK Nath, A Beri, A Rotman, Y AF Takyar, Varun K. Nath, Anand Beri, Andrea Rotman, Yaron TI How Healthy are "Healthy Volunteers"? Prevalence and Potential Impact of Fatty Liver Disease in Volunteers to Clinical Trials SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Takyar, Varun K.; Nath, Anand; Rotman, Yaron] NIDDK, Liver & Energy Metab Unit, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Nath, Anand] Georgetown Univ, Sch Med, Medstar Washington Hosp Ctr, Dept Internal Med, Washington, DC USA. [Beri, Andrea] NIH, BTRIS, Lab Informat Dev, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1157 BP 583A EP 583A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802424 ER PT J AU Serti, E Werner, JM Keane, M Bolte, FJ Lingala, S Morris, N Liang, TJ Rotman, Y Rehermann, B AF Serti, Elisavet Werner, Jens M. Keane, Meghan Bolte, Fabian J. Lingala, Shilpa Morris, Nevitt Liang, T. Jake Rotman, Yaron Rehermann, Barbara TI Natural killer T cells and mucosal associated invariant T cells share phenotypic and functional alterations in patients with non-alcoholic fatty liver disease SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Serti, Elisavet; Werner, Jens M.; Keane, Meghan; Bolte, Fabian J.; Lingala, Shilpa; Morris, Nevitt; Liang, T. Jake; Rotman, Yaron; Rehermann, Barbara] NIDDK, Liver Dis Branch, NIH, DHHS, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1160 BP 584A EP 584A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802427 ER PT J AU Sampaziotis, F de Brito, MC Sawiak, S Gomez-Vazquez, MJ Berntsen, NL Tysoe, OC Ortmann, D Bertero, A Bargehr, J Zonneveld, MC Pedersen, MT Pawlowski, M Georgakopoulos, N Yiangou, L Godfrey, EM Upponi, SS Gieseck, R Rimland, C Simonic, I Davies, S Jensen, KB Sinha, S Gelson, W Alexander, GJ Melum, E Hannan, NR Saeb-Parsy, K Vallier, L AF Sampaziotis, Fotios de Brito, Miguel Cardoso Sawiak, Steve Gomez-Vazquez, Maria J. Berntsen, Natalie L. Tysoe, Olivia C. Ortmann, Daniel Bertero, Alessandro Bargehr, Johannes Zonneveld, Marielle C. Pedersen, Marianne T. Pawlowski, Matthias Georgakopoulos, Nikitas Yiangou, Loukia Godfrey, Edmund M. Upponi, Sara S. Gieseck, Richard Rimland, Casey Simonic, Ingrid Davies, Susan Jensen, Kim B. Sinha, Sanjay Gelson, William Alexander, Graeme J. Melum, Espen Hannan, Nicholas R. Saeb-Parsy, Kourosh Vallier, Ludovic TI Reconstruction of the biliary tree using primary in vitro propagated extra-hepatic cholangiocytes and biode-gradable scaffolds SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Sampaziotis, Fotios] Cambridge Univ Hosp NHS Fdn Trust, Hepatol, Hitchin, England. [Sampaziotis, Fotios; de Brito, Miguel Cardoso; Tysoe, Olivia C.; Ortmann, Daniel; Bertero, Alessandro; Zonneveld, Marielle C.; Georgakopoulos, Nikitas; Yiangou, Loukia; Rimland, Casey; Saeb-Parsy, Kourosh; Vallier, Ludovic] Univ Cambridge, Surg, Cambridge, England. [Sawiak, Steve] Univ Cambridge, Clin Neurosci, Cambridge, England. [Gomez-Vazquez, Maria J.] Univ Cambridge, Pathol, Cambridge, England. [Bargehr, Johannes; Pawlowski, Matthias; Sinha, Sanjay; Alexander, Graeme J.] Univ Cambridge, Med, Cambridge, England. [Pedersen, Marianne T.; Jensen, Kim B.] Univ Copenhagen, Biotech Res & Innovat Ctr, Copenhagen, Denmark. [Godfrey, Edmund M.; Upponi, Sara S.] Cambridge Univ Hosp NHS Fdn Trust, Radiol, Cambridge, England. [Gieseck, Richard] NIAID, Parasit Dis Lab, Bethesda, MD USA. [Simonic, Ingrid] Cambridge Univ Hosp NHS Fdn Trust, Med Genet Labs, Cambridge, England. [Davies, Susan] Cambridge Univ Hosp NHS Fdn Trust, Histopathol, Cambridge, England. [Gelson, William] Cambridge Univ Hosp NHS Fdn Trust, Hepatol, Cambridge, England. [Melum, Espen] Natl Hosp Norway, Oslo Univ Hosp, Clin Specialized Med & Surg, Norwegian PSC Res Ctr, Oslo, Norway. [Hannan, Nicholas R.] Univ Nottingham, Ctr Biomol Sci, Nottingham, England. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1187 BP 597A EP 598A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493802454 ER PT J AU Puri, P Daita, K Mirshahi, F Liangpunsakul, S Chalasani, NP Crabb, DW Shah, V Kamath, PS Gores, GJ Katz, BP Sikaroodi, M Radaeva, S Gillevet, PM Sanyal, AJ AF Puri, Puneet Daita, Kalyani Mirshahi, Faridoddin Liangpunsakul, Suthat Chalasani, Naga P. Crabb, David W. Shah, Vijay Kamath, Patrick S. Gores, Gregory J. Katz, Barry P. Sikaroodi, Masoumeh Radaeva, Svetlana Gillevet, Patrick M. Sanyal, Arun J. TI Alcoholic Hepatitis and Disease Severity Are Associated With Distinct Shifts in Fecal Microbial Ecology SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Puri, Puneet; Daita, Kalyani; Mirshahi, Faridoddin; Sanyal, Arun J.] Virginia Commonwealth Univ, Richmond, VA USA. [Liangpunsakul, Suthat; Chalasani, Naga P.; Crabb, David W.; Katz, Barry P.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Shah, Vijay; Kamath, Patrick S.; Gores, Gregory J.] Mayo Clin, Rochester, MN USA. [Sikaroodi, Masoumeh; Gillevet, Patrick M.] George Mason Univ, Manassas, VA USA. [Radaeva, Svetlana] NIAAA, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1212 BP 609A EP 609A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803019 ER PT J AU Unalp-Arida, A Ruhl, CE AF Unalp-Arida, Aynur Ruhl, Constance E. TI The Burden of Liver Cancer in the United States Population SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Unalp-Arida, Aynur] NIDDK, Bethesda, MD 20892 USA. [Ruhl, Constance E.] Social & Sci Syst Inc, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1278 BP 641A EP 642A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803085 ER PT J AU Tang, MM Alao, H Morris, N Walter, M Rolman, Y AF Tang, Michele M. Alao, Hawwa Morris, Nevitt Walter, Mary Rolman, Yaron TI The Fatigue of Chronic Liver Disease is Associated with Altered Circadian Rhythm of Cortisol SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Tang, Michele M.; Alao, Hawwa; Morris, Nevitt; Rolman, Yaron] NIDDK, Liver & Energy Metab Unit, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Tang, Michele M.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA USA. [Tang, Michele M.] Univ Calif San Francisco, UCSF Liver Transplant Ctr, San Francisco, CA 94143 USA. [Walter, Mary] NIDDK, Clin Res Core Lab, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1446 BP 723A EP 724A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803253 ER PT J AU Ramirez, T Lie, YM Yin, S Xu, MJ Feng, DC Zang, MW Pacher, P Gao, B Wang, H AF Ramirez, Teresa Lie, Yongmei Yin, Shi Xu, Ming-Jiang Feng, Dechun Zang, Mengwei Pacher, Pal Gao, Bin Wang, Hua TI Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating Sirtuin 1 expressionin the liver SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Wang, Hua] Anhui Med Univ, Affiliated Prov Hosp, Dept Oncol, Hefei, Anhui, Peoples R China. [Ramirez, Teresa; Lie, Yongmei; Yin, Shi; Xu, Ming-Jiang; Feng, Dechun; Gao, Bin; Wang, Hua] NIAAA, Lab Liver Dis, NIH, Rockville, MD 20852 USA. [Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Pacher, Pal] NIAAA, Lab Cardiovasc Physiol & Tissue Injury, Rockville, MD 20852 USA. RI Zhou, Zhou/R-7788-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1513 BP 755A EP 755A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803320 ER PT J AU Chen, HQ Li, Y Sherban, A Nocon, A Luo, T Wang, H Bin Gao, Zang, MW AF Chen, Hanqing Li, Yu Sherban, Alex Nocon, Allison Luo, Ting Wang, Hua Bin Gao Zang, Mengwei TI Pharmacological and Molecular inhibition of mTORC1 Activation Reduces Ethanol-Induced ER Stress and Ameliorates Alcoholic Liver Injury in Mice SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Chen, Hanqing; Li, Yu; Sherban, Alex; Nocon, Allison; Luo, Ting] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Wang, Hua; Bin Gao] NIAAA, Lab Liver Dis, NIH, Bethesda, MD USA. [Chen, Hanqing; Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Ctr Hlth Aging, San Antonio, TX 78229 USA. [Chen, Hanqing; Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Zang, Mengwei] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1515 BP 756A EP 756A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803322 ER PT J AU Abdelmegeed, M Choi, YS Song, BJ AF Abdelmegeed, Mohamed Choi, Youngshim Song, Byoung-Joon TI The role of cytochrome P450-2E1 in fast food-induced hepatic fibrosis SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Abdelmegeed, Mohamed; Choi, Youngshim; Song, Byoung-Joon] NIH, Membrane Biochem & Biophys, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1546 BP 769A EP 770A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803353 ER PT J AU Naguib, G Morris, N Bernstein, S Rotman, Y AF Naguib, Gihan Morris, Nevitt Bernstein, Shanna Rotman, Yaron TI NAFLD is Associated with Decreased Oxidation of Orally-Delivered Fatty Acids - a Palmitate Breath Test Study SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Naguib, Gihan; Morris, Nevitt; Rotman, Yaron] NIDDK, Liver & Energy Metab Unit, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Naguib, Gihan] Univ Maryland, Pediat Gastroenterol, Baltimore, MD 21201 USA. [Bernstein, Shanna] NIH, Dept Nutr, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1562 BP 776A EP 776A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803369 ER PT J AU Samala, N Ted, H Maloney, D Nadler, JL Chalasani, NP Mirmira, R Anderson, R AF Samala, Niharika Ted, Holman Maloney, David Nadler, Jerry L. Chalasani, Naga P. Mirmira, Raghavendra Anderson, Ryan TI Role of 12-Lipoxygenase in a Zebrafish Model of Non Alcoholic Fatty Liver Disease (NAFLD) SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Samala, Niharika; Chalasani, Naga P.; Mirmira, Raghavendra] Indiana Univ Sch Med, Med, Indianapolis, IN 46202 USA. [Ted, Holman] Univ Calif Santa Cruz, PBSci Chem & Biochem, Santa Cruz, CA 95064 USA. [Maloney, David] NIH, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA. [Anderson, Ryan] Indiana Univ Sch Med, Pediat, Indianapolis, IN 46202 USA. [Nadler, Jerry L.] Eastern Virginia Med Sch, Internal Med, Norfolk, VA 23501 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1566 BP 778A EP 778A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493803373 ER PT J AU Suarez, DF Loria, A Ferreira, M Raziuddin, A Ghany, MG AF Suarez, Daniel F. Loria, Anthony Ferreira, Michelle Raziuddin, Arati Ghany, Marc G. TI Proportion of Pre-Core Mutation Determines HBV Phenotype after HBeAg Seroconversion SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Suarez, Daniel F.; Loria, Anthony; Ferreira, Michelle; Ghany, Marc G.] NIH, Liver Dis Branch, Bldg 10, Bethesda, MD 20892 USA. [Raziuddin, Arati] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1831 BP 903A EP 903A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804192 ER PT J AU Yurdaydin, C Idilman, R Kalkan, C Karakaya, F Kartal, AC Keskin, O Karatayli, E Karatayli, SC Bozdayi, AM Koh, C Heller, T Glenn, J AF Yurdaydin, Cihan Idilman, Ramazan Kalkan, Cagdas Karakaya, Fatih Kartal, Aysun Caliskan Keskin, Onur Karatayli, Ersin Karatayli, Senem C. Bozdayi, A. Mithat Koh, Christopher Heller, Theo Glenn, Jeffrey TI Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis-Interim Results From The Lowr Hdv-2 Study SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Yurdaydin, Cihan; Idilman, Ramazan; Kalkan, Cagdas; Karakaya, Fatih; Kartal, Aysun Caliskan; Keskin, Onur; Karatayli, Ersin; Karatayli, Senem C.; Bozdayi, A. Mithat] Ankara Univ, Sch Med, Gastroenterol Sect, Ankara, Turkey. [Koh, Christopher; Heller, Theo] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. [Glenn, Jeffrey] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1845 BP 910A EP 911A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804206 ER PT J AU Li, Y Xia, YC Han, MF Chen, G Zhang, DK Thasler, WE Protzer, U Ning, Q AF Li, Yong Xia, Yuchen Han, Meifang Chen, Guang Zhang, Dake Thasler, Wolfgang E. Protzer, Ulrike Ning, Qin TI IFN-alpha-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Li, Yong; Han, Meifang; Chen, Guang; Ning, Qin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China. [Xia, Yuchen; Protzer, Ulrike] Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, D-81675 Munich, Germany. [Xia, Yuchen] NIDDK, Liver Dis Branch, NIH, Bethesda, MD USA. [Zhang, Dake] Chinese Acad Sci, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China. [Thasler, Wolfgang E.] Univ Munich, Dept Gen Visceral Transplantat Vasc Surg Grossula, Munich, Germany. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1864 BP 921A EP 921A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804225 ER PT J AU Yurdaydin, C Idilman, R Kalkan, C Karakaya, F Kartal, AC Keskin, O Karatayli, E Karatayli, SC Bozdayi, AM Koh, C Heller, T Glenn, J AF Yurdaydin, Cihan Idilman, Ramazan Kalkan, Cagdas Karakaya, Fatih Kartal, Aysun Caliskan Keskin, Onur Karatayli, Ersin Karatayli, Senem C. Bozdayi, A. Mithat Koh, Christopher Heller, Theo Glenn, Jeffrey TI The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis SO HEPATOLOGY LA English DT Meeting Abstract CT 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 11-15, 2016 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Yurdaydin, Cihan; Idilman, Ramazan; Kalkan, Cagdas; Karakaya, Fatih; Kartal, Aysun Caliskan; Keskin, Onur; Karatayli, Ersin; Karatayli, Senem C.; Bozdayi, A. Mithat] Ankara Univ, Sch Med, Gastroenterol Sect, Ankara, Turkey. [Koh, Christopher; Heller, Theo] NIDDK, Liver Dis Branch, Bethesda, MD USA. [Glenn, Jeffrey] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 SU 1 MA 1875 BP 927A EP 927A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY9YT UT WOS:000385493804236 ER PT J AU Haut, LH Gill, AL Kurupati, RK Bian, A Li, Y Giles-Davis, W Xiang, ZQ Zhou, XY Ertl, HCJ AF Haut, Larissa H. Gill, Amanda L. Kurupati, Raj K. Bian, Ang Li, Yan Giles-Davis, Wynetta Xiang, Zhiquan Zhou, Xiang Yang Ertl, Hildegund C. J. TI A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products SO HUMAN GENE THERAPY METHODS LA English DT Article DE HIV-1; vaccine; genetic stability; immune responses ID CD8(+) T-CELLS; CHIMPANZEE ADENOVIRUS; PROTECTIVE EFFICACY; TRANSCRIPTION UNIT; NONHUMAN-PRIMATES; RHESUS MACAQUES; FUSION PROTEIN; DOUBLE-BLIND; VACCINE; HIV-1 AB Adenovirus (Ad) is used extensively for construction of viral vectors, most commonly with deletion in its E1 and/or E3 genomic regions. Previously, our attempts to insert envelope proteins (Env) of HIV-1 into such vectors based on chimpanzee-derived Ad (AdC) viruses were thwarted. Here, we describe that genetic instability of an E1- and E3-deleted AdC vector of serotype C6 expressing Env of HIV-1 can be overcome by reinsertion of E3 sequences with anti-apoptotic activities. This partial E3 deletion presumably delays premature death of HEK-293 packaging cell lines due to Env-induced cell apoptosis. The same partial E3 deletion also allows for the generation of stable glycoprotein 140 (gp140)- and gp160-expressing Ad vectors based on AdC7, a distinct AdC serotype. Env-expressing AdC vectors containing the partial E3 deletion are genetically stable upon serial cell culture passaging, produce yields comparable to those of other AdC vectors, and induce transgene product-specific antibody responses in mice. A partial E3 deletion thereby allows expansion of the repertoire of transgenes that can be expressed by Ad vectors. C1 [Haut, Larissa H.; Gill, Amanda L.; Kurupati, Raj K.; Bian, Ang; Li, Yan; Giles-Davis, Wynetta; Xiang, Zhiquan; Zhou, Xiang Yang; Ertl, Hildegund C. J.] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA. [Gill, Amanda L.] NIAID, Clin Mol Regulat Sect, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Ertl, HCJ (reprint author), Wistar Inst Anat & Biol, Dept Immunol, 3601 Spruce St,Room 283, Philadelphia, PA 19104 USA. EM ertl@wistar.upenn.edu FU NIAID/IPCAVD [U19 AI074078] FX We wish to thank C. Cole for help with preparing the manuscript. Funding for this project was provided by the NIAID/IPCAVD U19 AI074078. NR 44 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1946-6536 EI 1946-6544 J9 HUM GENE THER METHOD JI Hum. Gene Ther. Methods PD OCT PY 2016 VL 27 IS 5 BP 187 EP 196 DI 10.1089/hgtb.2016.044 PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine GA EA6YT UT WOS:000386775800003 PM 27604324 ER PT J AU Teratani-Ota, Y Yamamizu, K Piao, Y Sharova, L Amano, M Yu, H Schlessinger, D Ko, MSH Sharov, AA AF Teratani-Ota, Yusuke Yamamizu, Kohei Piao, Yulan Sharova, Lioudmila Amano, Misa Yu, Hong Schlessinger, David Ko, Minoru S. H. Sharov, Alexei A. TI Induction of specific neuron types by overexpression of single transcription factors SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL LA English DT Article DE GABAergic neurons; Dopaminergic neurons; Cholinergic neurons; Ascl1; ESCs; Gene expression profiling; miRNA ID EMBRYONIC STEM-CELLS; DOPAMINERGIC-NEURONS; HUMAN FIBROBLASTS; IN-VIVO; CORTICOFUGAL NEURONS; PARKINSONS-DISEASE; TISSUE-SPECIFICITY; FUNCTIONAL-NEURONS; GABAERGIC NEURONS; DIRECT CONVERSION AB Specific neuronal types derived from embryonic stem cells (ESCs) can facilitate mechanistic studies and potentially aid in regenerative medicine. Existing induction methods, however, mostly rely on the effects of the combined action of multiple added growth factors, which generally tend to result in mixed populations of neurons. Here, we report that overexpression of specific transcription factors (TFs) in ESCs can rather guide the differentiation of ESCs towards specific neuron lineages. Analysis of data on gene expression changes 2 d after induction of each of 185 TFs implicated candidate TFs for further ESC differentiation studies. Induction of 23 TFs (out of 49 TFs tested) for 6 d facilitated neural differentiation of ESCs as inferred from increased proportion of cells with neural progenitor marker PSA-NCAM. We identified early activation of the Notch signaling pathway as a common feature of most potent inducers of neural differentiation. The majority of neuron-like cells generated by induction of Ascl1, Smad7, Nr2f1, Dlx2, Dlx4, Nr2f2, Barhl2, and Lhx1 were GABA-positive and expressed other markers of GABAergic neurons. In the same way, we identified Lmx1a and Nr4a2 as inducers for neurons bearing dopaminergic markers and Isl1, Fezf2, and St18 for cholinergic motor neurons. A time-course experiment with induction of Ascl1 showed early upregulation of most neural-specific messenger RNA (mRNA) and microRNAs (miRNAs). Sets of Ascl1-induced mRNAs and miRNAs were enriched in Ascl1 targets. In further studies, enrichment of cells obtained with the induction of Ascl1, Smad7, and Nr2f1 using microbeads resulted in essentially pure population of neuron-like cells with expression profiles similar to neural tissues and expressed markers of GABAergic neurons. In summary, this study indicates that induction of transcription factors is a promising approach to generate cultures that show the transcription profiles characteristic of specific neural cell types. C1 [Teratani-Ota, Yusuke; Yamamizu, Kohei; Piao, Yulan; Sharova, Lioudmila; Amano, Misa; Yu, Hong; Schlessinger, David; Sharov, Alexei A.] NIA, Genet Lab, NIH, Baltimore, MD 21224 USA. [Teratani-Ota, Yusuke] Univ Calif Davis, Dept Psychol, Ctr Neurosci, Davis, CA 95616 USA. [Yamamizu, Kohei] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Lab Stem Cell Differentiat, Kyoto 6068507, Japan. [Amano, Misa; Yu, Hong] Elixirgen LLC, Baltimore, MD 21205 USA. [Ko, Minoru S. H.] Keio Univ, Dept Syst Med, Sakaguchi Lab, Sch Med, Tokyo 1608582, Japan. RP Sharov, AA (reprint author), NIA, Genet Lab, NIH, Baltimore, MD 21224 USA. EM sharoval@mail.nih.gov FU Intramural Research Program of the NIH, National Institute on Aging [Z01 AG000656-09]; Post-Baccalaureate Intramural Research Training Award; Kanae Foundation, Japan; Uehara Memorial Foundation, Japan; Naito Foundation, Japan; Japan Society for Promotion of Science (JSPS); Japan Science and Technology Agency (JST), CREST program FX This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging, project Z01 AG000656-09. Y.T-O. was funded by Post-Baccalaureate Intramural Research Training Award. K.Y. was supported by the postdoctoral fellowships from the Kanae Foundation, Japan, Uehara Memorial Foundation, Japan, Naito Foundation, Japan, and the Japan Society for Promotion of Science (JSPS). This research was also supported in part by the Japan Science and Technology Agency (JST), CREST program. The authors declare no competing financial interests. Y.T-O., K.Y., Y.P., and L.S. performed experiments; M.A. made new ES clones; H.Y. carried out vector construction for ES clones and synthetic mRNA; D.S. and M.S.H.K supervised the project and edited the manuscript; and A.A.S. performed statistical analysis and wrote the manuscript. NR 74 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-2690 EI 1543-706X J9 IN VITRO CELL DEV-AN JI In Vitro Cell. Dev. Biol.-Anim. PD OCT PY 2016 VL 52 IS 9 BP 961 EP 973 DI 10.1007/s11626-016-0056-7 PG 13 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA EA5KE UT WOS:000386658200008 PM 27251161 ER PT J AU Park, YM Steck, SE Fung, TT Zhang, J Hazlett, LJ Han, K Merchant, AT AF Park, Y-M Steck, S. E. Fung, T. T. Zhang, J. Hazlett, L. J. Han, K. Merchant, A. T. TI Mediterranean diet and mortality risk in metabolically healthy obese and metabolically unhealthy obese phenotypes SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID NUTRITION EXAMINATION SURVEY; CORONARY-HEART-DISEASE; KOREA NATIONAL-HEALTH; CARDIOVASCULAR-DISEASE; RECOVERY BIOMARKERS; ALCOHOL-CONSUMPTION; PHYSICAL-ACTIVITY; ADIPOSE-TISSUE; US POPULATION; WEIGHT-LOSS AB BACKGROUND: The Mediterranean diet has been consistently associated with reduced mortality risk. Few prospective studies have examined whether the benefits from a Mediterranean diet are equally shared by obese individuals with varying metabolic health. OBJECTIVE: The objective of this study was to investigate the association between Mediterranean diet, metabolic phenotypes and mortality risk in a representative obese US population. METHODS: Data from 1739 adults aged 20-88 years were analyzed from participants of the National Health and Nutrition Examination Survey III, 1988-1994 followed up for deaths until 31 December 2011 in a prospective cohort analysis. Mediterranean Diet Scores (MDS) were created to assess the adherence to Mediterranean diet. Participants were classified as metabolically healthy obese (MHO) phenotype (0 or 1 metabolic abnormality) or metabolically unhealthy obese (MUO) phenotype (two or more metabolic abnormalities), based on high glucose, insulin resistance, blood pressure, triglycerides, C-reactive protein and low high-density lipoprotein cholesterol. RESULTS: The MHO phenotype (n = 598) was observed in 34.8% (s.e., 1.7%) of those who were obese (mean body mass index was 33.4 and 34.8 in MHO and MUO phenotypes, respectively). During a median follow-up of 18.5 years, there were 77 (12.9%) and 309 (27.1%) deaths in MHO and MUO individuals, respectively. In MHO individuals, the multivariable-adjusted hazard ratio (HR) of all-cause mortality in the highest tertile compared with the first tertile of MDS was 0.44 (95% confidence interval (CI), 0.26-0.75; P for trend < 0.001), after adjustment for potential confounders. A five-point (1 s.d.) increment in the adherence to MDS was associated with a 41% reduction in the risk of all-cause mortality (HR, 0.59; 95% CI, 0.37-0.94). Similar findings were obtained when we restricted our analyses to those with or without prevalent diabetes mellitus and hypertension. We did not observe mortality risk reduction in either individuals with MUO phenotype or all obese participants combined. CONCLUSIONS: Adherence to a Mediterranean dietary pattern appears to reduce mortality in the MHO phenotype, but not among the MUO phenotype in an obese population. C1 [Park, Y-M; Steck, S. E.; Zhang, J.; Hazlett, L. J.; Merchant, A. T.] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St, Columbia, SC 29208 USA. [Park, Y-M] NIEHS, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Fung, T. T.] Simmons Coll, Dept Nutr, Boston, MA 02115 USA. [Fung, T. T.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Han, K.] Catholic Univ Korea, Coll Med, Dept Biostat, Seoul, South Korea. RP Merchant, AT (reprint author), Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St, Columbia, SC 29208 USA. EM merchant@mailbox.sc.edu OI PARK, YONG-MOON/0000-0002-5879-6879 NR 54 TC 1 Z9 1 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD OCT PY 2016 VL 40 IS 10 BP 1541 EP 1549 DI 10.1038/ijo.2016.114 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EA4JZ UT WOS:000386579500011 PM 27339604 ER PT J AU Zhang, Y Ji, G Xu, M Cai, W Zhu, Q Qian, L Zhang, YE Yuan, K Liu, J Li, Q Cui, G Wang, H Zhao, Q Wu, K Fan, D Gold, MS Tian, J Tomasi, D Liu, Y Nie, Y Wang, GJ AF Zhang, Y. Ji, G. Xu, M. Cai, W. Zhu, Q. Qian, L. Zhang, Y. E. Yuan, K. Liu, J. Li, Q. Cui, G. Wang, H. Zhao, Q. Wu, K. Fan, D. Gold, M. S. Tian, J. Tomasi, D. Liu, Y. Nie, Y. Wang, G-J TI Recovery of brain structural abnormalities in morbidly obese patients after bariatric surgery SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID GASTRIC BYPASS-SURGERY; FOOD ADDICTION SCALE; HIGH-CALORIE FOODS; BODY-MASS INDEX; WEIGHT-LOSS; COGNITIVE CONTROL; FUTURE INCREASES; NETWORK; MRI; ACTIVATION AB BACKGROUND/OBJECTIVES: Obesity-related brain structural abnormalities have been reported extensively, and bariatric surgery (BS) is currently the most effective intervention to produce sustained weight reduction in overtly obese (OB) people. It is unknown whether BS can repair the brain circuitry abnormalities concomitantly with long-term weight loss. SUBJECTS/ METHODS: In order to investigate whether BS promotes neuroplastic structural recovery in morbidly OB patients, we quantified fractional anisotropy (FA), mean diffusivity (MD) and gray (GM) and white (WM) matter densities in 15 morbidly OB patients and in 18 normal weight (NW) individuals. OB patients were studied at baseline and also 1 month after laparoscopic sleeve gastrectomy surgery. RESULTS: Two-sample t-test between OB (baseline) and NW groups showed decreased FA values, GM/WM densities and increased MD value in brain regions associated with food intake control (that is, caudate, orbitofrontal cortex, body and genu of corpus callosum) and cognitive-emotion regulation (that is, inferior frontal gyrus, hippocampus, insula, external capsule) (P < 0.05, familywise error correction). Paired t-test in the OB group between before and after surgery showed that BS generated partial neuroplastic structural recovery in the OB group, but the differences had relative less strength and smaller volume (P < 0.001). CONCLUSIONS: This study provides the first anatomical evidence for BS-induced acute neuroplastic recovery that might in part mediate the long-term benefit of BS in weight reduction. It also highlights the importance of this line of gut-brain axis research employing the combined BS and neuroimaging model for identifying longitudinal changes in brain structure that correlated with obesity status. C1 [Zhang, Y.; Cai, W.; Zhu, Q.; Yuan, K.; Liu, J.; Tian, J.] Xidian Univ, Sch Life Sci & Technol, Ctr Brain Imaging, Xian 710071, Shaanxi, Peoples R China. [Zhang, Y.; Zhang, Y. E.; Gold, M. S.; Liu, Y.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Zhang, Y.; Zhang, Y. E.; Gold, M. S.; Liu, Y.] Univ Florida, McKnight Brain Inst, Gainesville, FL USA. [Ji, G.; Zhao, Q.; Wu, K.; Fan, D.; Nie, Y.] Fourth Mil Med Univ, Xijing Gastrointestinal Hosp, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. [Xu, M.; Qian, L.; Liu, Y.] Peking Univ, Dept Biomed Engn, Beijing, Peoples R China. [Zhang, Y. E.] Malcom Randall Vet Affairs Med Ctr, Gainesville, FL USA. [Li, Q.; Cui, G.] Fourth Mil Med Univ, Tangdu Hosp, Dept Radiol, Xian, Peoples R China. [Wang, H.] Fourth Mil Med Univ, Xijing Hosp, Dept Psychiat, Xian, Peoples R China. [Tian, J.] Chinese Acad Sci, Inst Automat, Beijing, Peoples R China. [Tomasi, D.; Wang, G-J] NIAAA, Lab Neuroimaging, 10 Ctr Dr,MSC1013,Bldg 10,Room B2L304, Bethesda, MD 20892 USA. RP Zhang, Y (reprint author), Xidian Univ, Sch Life Sci & Technol, Ctr Brain Imaging, Xian 710071, Shaanxi, Peoples R China.; Nie, Y (reprint author), Fourth Mil Med Univ, Xijing Gastrointestinal Hosp, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Wang, GJ (reprint author), NIAAA, Lab Neuroimaging, 10 Ctr Dr,MSC1013,Bldg 10,Room B2L304, Bethesda, MD 20892 USA. EM zhangyiuf@gmail.com; yongznie@fmmu.edu.cn; gene-jack.wang@nih.gov FU National Natural Science Foundation of China [81271549, 81470816, 61131003, 61431013, 81201081, 81227901, 81120108005, 81501543, 81371530, 81571751, 81571753]; Shaanxi Provincial Natural Science Foundation [2015JM3117]; Project for the National Key Basic Research and Development Program (973) [2011CB707700] FX This work is supported by the National Natural Science Foundation of China under Grant Nos. 81271549, 81470816, 61131003, 61431013, 81201081, 81227901, 81120108005, 81501543, 81371530, 81571751 and 81571753; the Shaanxi Provincial Natural Science Foundation under Grant No. 2015JM3117; and the Project for the National Key Basic Research and Development Program (973) under Grant No. 2011CB707700. We thank Dr Samantha Cunningham of NIAAA and Dr Jiayu Liu of Yale University for proofreading. NR 46 TC 0 Z9 0 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD OCT PY 2016 VL 40 IS 10 BP 1558 EP 1565 DI 10.1038/ijo.2016.98 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EA4JZ UT WOS:000386579500013 PM 27200505 ER PT J AU Wu, J Peters, BA Dominianni, C Zhang, YL Pei, ZH Yang, LY Ma, YF Purdue, MP Jacobs, EJ Gapstur, SM Li, HL Alekseyenko, AV Hayes, RB Ahn, JY AF Wu, Jing Peters, Brandilyn A. Dominianni, Christine Zhang, Yilong Pei, Zhiheng Yang, Liying Ma, Yingfei Purdue, Mark P. Jacobs, Eric J. Gapstur, Susan M. Li, Huilin Alekseyenko, Alexander V. Hayes, Richard B. Ahn, Jiyoung TI Cigarette smoking and the oral microbiome in a large study of American adults SO ISME JOURNAL LA English DT Article ID CANCER SCREENING TRIAL; POLYMORPHONUCLEAR LEUKOCYTES; TOBACCO SMOKING; PERIODONTITIS; CESSATION; BACTERIA; SMOKERS; SALIVA; LUNG; METAANALYSIS AB Oral microbiome dysbiosis is associated with oral disease and potentially with systemic diseases; however, the determinants of these microbial imbalances are largely unknown. In a study of 1204 US adults, we assessed the relationship of cigarette smoking with the oral microbiome. 16S rRNA gene sequencing was performed on DNA from oral wash samples, sequences were clustered into operational taxonomic units (OTUs) using QIIME and metagenomic content was inferred using PICRUSt. Overall oral microbiome composition differed between current and non-current (former and never) smokers (Po0.001). Current smokers had lower relative abundance of the phylum Proteobacteria (4.6%) compared with never smokers (11.7%) (false discovery rate q= 5.2 x 10(-7)), with no difference between former and never smokers; the depletion of Proteobacteria in current smokers was also observed at class, genus and OTU levels. Taxa not belonging to Proteobacteria were also associated with smoking: the genera Capnocytophaga, Peptostreptococcus and Leptotrichia were depleted, while Atopobium and Streptococcus were enriched, in current compared with never smokers. Functional analysis from inferred metagenomes showed that bacterial genera depleted by smoking were related to carbohydrate and energy metabolism, and to xenobiotic metabolism. Our findings demonstrate that smoking alters the oral microbiome, potentially leading to shifts in functional pathways with implications for smoking-related diseases. C1 [Wu, Jing; Peters, Brandilyn A.; Dominianni, Christine; Hayes, Richard B.; Ahn, Jiyoung] NYU, Sch Med, Dept Populat Hlth, Div Epidemiol, New York, NY USA. [Wu, Jing; Pei, Zhiheng; Hayes, Richard B.; Ahn, Jiyoung] NYU, Perlmutter Canc Ctr, New York, NY USA. [Zhang, Yilong; Li, Huilin] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA. [Pei, Zhiheng; Ma, Yingfei] NYU, Sch Med, Dept Pathol, New York, NY USA. [Pei, Zhiheng] New York Harbor Healthcare Syst, Dept Vet Affairs, New York, NY USA. [Yang, Liying] NYU, Sch Med, Dept Med, Div Translat Med, New York, NY USA. [Purdue, Mark P.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Purdue, Mark P.] Ontario Inst Canc Res, Toronto, ON, Canada. [Jacobs, Eric J.; Gapstur, Susan M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Alekseyenko, Alexander V.] Med Univ South Carolina, Biomed Informat Ctr, Charleston, SC 29425 USA. [Alekseyenko, Alexander V.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Alekseyenko, Alexander V.] Med Univ South Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA. RP Ahn, JY (reprint author), NYU, Sch Med, Dept Populat Hlth, 650 Ist Ave,5th Floor, New York, NY 10016 USA. EM Jiyoung.Ahn@nyumc.org OI Alekseyenko, Alexander/0000-0002-5748-2085; Yang, Liying/0000-0003-1442-4915; Peters, Brandilyn/0000-0002-1534-2578; Pei, Zhiheng/0000-0001-8570-6747; Hayes, Richard/0000-0002-0918-661X FU US National Cancer Institute [R01CA159036, U01CA182370, U01CA170948-01A1, R01CA164964, R03CA159414, P30CA016087, R21CA183887]; AACR/Pancreas Cancer Action Network Career Development Award; American Cancer Society (ACS) FX Research reported in this publication was supported in part by the US National Cancer Institute under award numbers R01CA159036, U01CA182370, U01CA170948-01A1, R01CA164964, R03CA159414, P30CA016087, R21CA183887, and by AACR/Pancreas Cancer Action Network Career Development Award. ZP is a Staff Physician at the Department of Veterans Affairs New York Harbor Healthcare System. The American Cancer Society (ACS) funds the creation, maintenance and updating of the Cancer Prevention Study II cohort. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Department of Veterans Affairs or the United States Government. NR 55 TC 3 Z9 3 U1 17 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1751-7362 EI 1751-7370 J9 ISME J JI ISME J. PD OCT PY 2016 VL 10 IS 10 BP 2435 EP 2446 DI 10.1038/ismej.2016.37 PG 12 WC Ecology; Microbiology SC Environmental Sciences & Ecology; Microbiology GA EB0LN UT WOS:000387035400008 PM 27015003 ER PT J AU Maas, P Barrdahl, M Joshi, AD Auer, PL Gaudet, MM Milne, RL Schumacher, FR Anderson, WF Check, D Chattopadhyay, S Baglietto, L Berg, CD Chanock, SJ Cox, DG Figueroa, JD Gail, MH Graubard, BI Haiman, CA Hankinson, SE Hoover, RN Isaacs, C Kolonel, LN Le Marchand, L Lee, IM Lindstrom, S Overvad, K Romieu, I Sanchez, MJ Southey, MC Stram, DO Tumino, R VanderWeele, TJ Willett, WC Zhang, SM Buring, JE Canzian, F Gapstur, SM Henderson, BE Hunter, DJ Giles, GG Prentice, RL Ziegler, RG Kraft, P Garcia-Closas, M Chatterjee, N AF Maas, Paige Barrdahl, Myrto Joshi, Amit D. Auer, Paul L. Gaudet, Mia M. Milne, Roger L. Schumacher, Fredrick R. Anderson, William F. Check, David Chattopadhyay, Subham Baglietto, Laura Berg, Christine D. Chanock, Stephen J. Cox, David G. Figueroa, Jonine D. Gail, Mitchell H. Graubard, Barry I. Haiman, Christopher A. Hankinson, Susan E. Hoover, Robert N. Isaacs, Claudine Kolonel, Laurence N. Le Marchand, Loic Lee, I-Min Lindstrom, Sara Overvad, Kim Romieu, Isabelle Sanchez, Maria-Jose Southey, Melissa C. Stram, Daniel O. Tumino, Rosario VanderWeele, Tyler J. Willett, Walter C. Zhang, Shumin Buring, Julie E. Canzian, Federico Gapstur, Susan M. Henderson, Brian E. Hunter, David J. Giles, Graham G. Prentice, Ross L. Ziegler, Regina G. Kraft, Peter Garcia-Closas, Montse Chatterjee, Nilanjan TI Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States SO JAMA ONCOLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; SINGLE-NUCLEOTIDE POLYMORPHISMS; GENE-ENVIRONMENT INTERACTIONS; SUSCEPTIBILITY LOCI; COHORT CONSORTIUM; MODELS; PREDICTION; INDIVIDUALS; INFORMATION; VARIANTS AB IMPORTANCE An improved model for risk stratification can be useful for guiding public health strategies of breast cancer prevention. OBJECTIVE To evaluate combined risk stratification utility of common low penetrant single nucleotide polymorphisms (SNPs) and epidemiologic risk factors. DESIGN, SETTING, AND PARTICIPANTS Using a total of 17 171 cases and 19 862 controls sampled from the Breast and Prostate Cancer Cohort Consortium (BPC3) and 5879 women participating in the 2010 National Health Interview Survey, a model for predicting absolute risk of breast cancer was developed combining information on individual level data on epidemiologic risk factors and 24 genotyped SNPs from prospective cohort studies, published estimate of odds ratios for 68 additional SNPs, population incidence rate from the National Cancer Institute-Surveillance, Epidemiology, and End Results Program cancer registry and data on risk factor distribution from nationally representative health survey. The model is used to project the distribution of absolute risk for the population of white women in the United States after adjustment for competing cause of mortality. EXPOSURES Single nucleotide polymorphisms, family history, anthropometric factors, menstrual and/ or reproductive factors, and lifestyle factors. MAIN OUTCOMES AND MEASURES Degree of stratification of absolute risk owing to nonmodifiable (SNPs, family history, height, and some components of menstrual and/ or reproductive history) and modifiable factors (body mass index [BMI; calculated as weight in kilograms divided by height in meters squared], menopausal hormone therapy [MHT], alcohol, and smoking). RESULTS The average absolute risk for a 30-year-old white woman in the United States developing invasive breast cancer by age 80 years is 11.3%. A model that includes all risk factors provided a range of average absolute risk from 4.4% to 23.5% for women in the bottom and top deciles of the risk distribution, respectively. For women who were at the lowest and highest deciles of nonmodifiable risks, the 5th and 95th percentile range of the risk distribution associated with 4 modifiable factors was 2.9% to 5.0% and 15.5% to 25.0%, respectively. For women in the highest decile of risk owing to nonmodifiable factors, those who had low BMI, did not drink or smoke, and did not use MHT had risks comparable to an average woman in the general population. CONCLUSIONS AND RELEVANCE This model for absolute risk of breast cancer including SNPs can provide stratification for the population of white women in the United States. The model can also identify subsets of the population at an elevated risk that would benefit most from risk-reduction strategies based on altering modifiable factors. The effectiveness of this model for individual risk communication needs further investigation. C1 [Maas, Paige; Anderson, William F.; Check, David; Chattopadhyay, Subham; Chanock, Stephen J.; Figueroa, Jonine D.; Gail, Mitchell H.; Graubard, Barry I.; Hoover, Robert N.; Ziegler, Regina G.; Garcia-Closas, Montse; Chatterjee, Nilanjan] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Barrdahl, Myrto] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Joshi, Amit D.; Lindstrom, Sara; Hunter, David J.; Kraft, Peter] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Program Genet Epidemiol & Stat Genet, Boston, MA USA. [Auer, Paul L.; Prentice, Ross L.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Auer, Paul L.] Univ Wisconsin, Sch Publ Hlth, Milwaukee, WI 53201 USA. [Gaudet, Mia M.; Gapstur, Susan M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Milne, Roger L.; Baglietto, Laura; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [Milne, Roger L.; Baglietto, Laura; Giles, Graham G.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia. [Schumacher, Fredrick R.; Haiman, Christopher A.; Stram, Daniel O.; Henderson, Brian E.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Berg, Christine D.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [Cox, David G.] Ctr Leon Berard, INSERM, U1052, Canc Res Ctr Lyon, Lyon, France. [Cox, David G.] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England. [Hankinson, Susan E.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Biostat & Epidemiol, Amherst, MA 01003 USA. [Hankinson, Susan E.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Hankinson, Susan E.; Lee, I-Min; Zhang, Shumin; Buring, Julie E.] Harvard Med Sch, Boston, MA USA. [Isaacs, Claudine] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA. [Kolonel, Laurence N.] Univ Hawaii, Canc Res Ctr, Program Epidemiol, Honolulu, HI 96813 USA. [Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. [Lee, I-Min; Zhang, Shumin; Buring, Julie E.] Brigham & Womens Hosp, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Overvad, Kim] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark. [Romieu, Isabelle] Int Agcy Res Canc, Nutr & Metab Sect, Lyon, France. [Sanchez, Maria-Jose] Univ Granada, Hosp Univ Granada, Inst Invest Biosanitaria Ibs GRANADA, Escuela Andaluza Salud Publ, Granada, Spain. [Sanchez, Maria-Jose] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain. [Southey, Melissa C.] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Melbourne, Vic, Australia. [Tumino, Rosario] Civ MP Arezzo Hosp, ASP Ragusa, Canc Registry & Histopathol Unit, Ragusa, Italy. [VanderWeele, Tyler J.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [VanderWeele, Tyler J.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Canzian, Federico] German Canc Res Ctr, Heidelberg, Germany. [Giles, Graham G.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia. [Prentice, Ross L.] Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. [Garcia-Closas, Montse] Inst Canc Res, Breakthrough Breast Canc Res Ctr, Div Genet & Epidemiol, London, England. [Chatterjee, Nilanjan] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, 615 N Wolfe St, Baltimore, MD 21205 USA. [Chatterjee, Nilanjan] Johns Hopkins Univ, Sch Med, Dept Oncol, 615 N Wolfe St, Baltimore, MD 21205 USA. RP Chatterjee, N (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, 615 N Wolfe St, Baltimore, MD 21205 USA. EM nilanjan@jhu.edu FU US National Institutes of Health, National Cancer Institute [U01-CA98233-07, U01-CA98710-06, U01-CA98216-06, U01-CA98758-07]; Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services; National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Hellenic Health Association; Stavros Niarchos Foundation FX Design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication was supported by US National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233-07 to Dr Hunter, U01-CA98710-06 to M.J.T., U01-CA98216-06 to E.R. and R.K., and U01-CA98758-07 to Dr Henderson) and Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. EPIC Greece is funded by the Hellenic Health Association and the Stavros Niarchos Foundation. NR 37 TC 6 Z9 6 U1 9 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA EI 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD OCT 1 PY 2016 VL 2 IS 10 BP 1295 EP 1302 DI 10.1001/jamaoncol.2016.1025 PG 8 WC Oncology SC Oncology GA EA3GB UT WOS:000386488600012 PM 27228256 ER PT J AU Journy, NMY Morton, LM Kleinerman, RA Bekelman, JE de Gonzalez, AB AF Journy, Neige M. Y. Morton, Lindsay M. Kleinerman, Ruth A. Bekelman, Justin E. de Gonzalez, Amy Berrington TI Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer SO JAMA ONCOLOGY LA English DT Letter C1 [Journy, Neige M. Y.; Morton, Lindsay M.; Kleinerman, Ruth A.; de Gonzalez, Amy Berrington] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Room 7E556,MSC 9778,9609 Med Ctr Dr, Bethesda, MD 20892 USA. [Bekelman, Justin E.] Abramson Canc Ctr, Dept Radiat Oncol, Philadelphia, PA USA. [Bekelman, Justin E.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bekelman, Justin E.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Journy, NMY (reprint author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Room 7E556,MSC 9778,9609 Med Ctr Dr, Bethesda, MD 20892 USA. EM neige.journy@nih.gov NR 6 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA EI 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD OCT 1 PY 2016 VL 2 IS 10 BP 1368 EP 1370 DI 10.1001/jamaoncol.2016.1368 PG 3 WC Oncology SC Oncology GA EA3GB UT WOS:000386488600024 PM 27415446 ER PT J AU Quinn, GE Ying, GS Repka, MX Siatkowski, RM Hoffman, R Mills, MD Morrison, D Daniel, E Baumritter, A Hildebrand, PL Schron, EB Ells, AL Wade, K Kemper, AR AF Quinn, Graham E. Ying, Gui-shuang Repka, Michael X. Siatkowski, R. Michael Hoffman, Robert Mills, Monte D. Morrison, David Daniel, Ebenezer Baumritter, Agnieshka Hildebrand, P. Lloyd Schron, Eleanor B. Ells, Anna L. Wade, Kelly Kemper, Alex R. TI Timely implementation of a retinopathy of prematurity telemedicine system SO JOURNAL OF AAPOS LA English DT Article ID ACUTE-PHASE RETINOPATHY; INFANTS; CARE; ROP AB PURPOSE To examine the feasibility of a retinopathy of prematurity (ROP) telemedicine evaluation system of providing timely feedback to a neonatal intensive care unit (NICU) with at-risk premature infants. METHODS This was a prospective observational study of premature infants with birth weights of <1251 g in five NICUs in the United States. Infants scheduled for clinically indicated ROP evaluations underwent indirect ophthalmoscopic examinations and digital imaging on the same day. Imaging was performed by nonphysician retinal imagers. Times required were determined from obtaining digital images of both eyes to submission via web-based system to a secure server for grading by trained readers at a central reading center to sending back grading results to the clinical center. RESULTS A total of 1,642 image sets of eyes of 292 infants were obtained, from 823 imaging sessions. The mean turnaround time from submission of image sets of both eyes to return of the grading results to the clinical center was 10.1 +/- 11.3 hours (standard deviation), with a median of 12.0 hours (1st quartile, 0.9 hours; 3rd quartile, 16 hours). Overall, 95.5% of gradings (95% CI, 93.9%-96.7%) were returned within 24 hours. Subgroup analyses found, for image sets submitted to the reading center before 2 p.m. Eastern Standard Time, median time to report was 1.7 hours (1st quartile, 0.7 hours; 3rd quartile, 15.5 hours) compared with those submitted after 2pm (median, 14.1 hours; 1st quartile, 11.2, hours; 3rd quartile, 16.3 hours). CONCLUSIONS An ROP telemedicine approach can provide timely feedback to the NICU regarding the detection of potentially serious ROP and thus referral to an ophthalmologist for examination and consideration of treatment. C1 [Quinn, Graham E.; Ying, Gui-shuang; Mills, Monte D.; Daniel, Ebenezer; Wade, Kelly] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA. [Quinn, Graham E.; Mills, Monte D.; Baumritter, Agnieshka; Wade, Kelly] Childrens Hosp Philadelphia, Div Pediat Ophthalmol, Philadelphia, PA 19104 USA. [Repka, Michael X.; Hildebrand, P. Lloyd] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA. [Siatkowski, R. Michael] Univ Oklahoma, Dean McGee Eye Inst, Oklahoma City, OK USA. [Hoffman, Robert] Univ Utah, Dept Ophthalmol, Salt Lake City, UT USA. [Morrison, David] Vanderbilt Univ, Dept Ophthalmol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Schron, Eleanor B.] NEI, Bethesda, MD 20892 USA. [Ells, Anna L.] Univ Calgary, Dept Ophthalmol, Calgary, AB T2N 1N4, Canada. [Kemper, Alex R.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA. RP Quinn, GE (reprint author), Childrens Hosp Philadelphia, Div Ophthalmol, Wood Ctr, 1st Floor, Philadelphia, PA 19104 USA. EM quinn@email.chop.edu FU National Eye Institute of the National Institutes of Health, Department of Health and Human Services [U10 EY017014] FX Funded by National Eye Institute of the National Institutes of Health, Department of Health and Human Services. U10 EY017014. NR 13 TC 0 Z9 0 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-8531 EI 1528-3933 J9 J AAPOS JI J. AAPOS PD OCT PY 2016 VL 20 IS 5 BP 425 EP 430 DI 10.1016/j.jaapos.2016.06.007 PG 6 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA EA5FL UT WOS:000386644700010 PM 27651231 ER PT J AU Revell, AD Wang, DC Wood, R Morrow, C Tempelman, H Hamers, RL Reiss, P van Sighem, AI Nelson, M Montaner, JSG Lane, HC Larder, BA AF Revell, Andrew D. Wang, Dechao Wood, Robin Morrow, Carl Tempelman, Hugo Hamers, Raph L. Reiss, Peter van Sighem, Ard I. Nelson, Mark Montaner, Julio S. G. Lane, H. Clifford Larder, Brendan A. CA RDI Data Study Grp TI An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article ID RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL THERAPY; GUIDELINES; RESISTANCE; ADULTS AB Optimizing antiretroviral drug combination on an individual basis in resource-limited settings is challenging because of the limited availability of drugs and genotypic resistance testing. Here, we describe our latest computational models to predict treatment responses, with or without a genotype, and compare the potential utility of global and local models as a treatment tool for South Africa. Global random forest models were trained to predict the probability of virological response to therapy following virological failure using 29aEuroS574 treatment change episodes (TCEs) without a genotype, 3179 of which were from South Africa and were used to develop local models. In addition, 15aEuroS130 TCEs including genotypes were used to develop another set of models. The 'no-genotype' models were tested with an independent global test set (naEuroS=aEuroS1700) plus a subset from South Africa (naEuroS=aEuroS222). The genotype models were tested with 750 independent cases. The global no-genotype models achieved area under the receiver-operating characteristic curve (AUC) values of 0.82 and 0.79 with the global and South African tests sets, respectively, and the South African models achieved AUCs of 0.70 and 0.79. The genotype models achieved an AUC of 0.84. The global no-genotype models identified more alternative, locally available regimens that were predicted to be effective for cases that failed their new regimen in the South African clinics than the local models. Both sets of models were significantly more accurate predictors of outcomes than genotyping with rules-based interpretation. These latest global models predict treatment responses accurately even without a genotype, out-performed the local South African models and have the potential to help optimize therapy, particularly in resource-limited settings. C1 [Revell, Andrew D.; Wang, Dechao; Larder, Brendan A.] HIV Resistance Response Database Initiat RDI, London, England. [Wood, Robin; Morrow, Carl] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa. [Tempelman, Hugo] Ndlovu Care Grp, Elandsdoorn, South Africa. [Hamers, Raph L.; Reiss, Peter] Univ Amsterdam, Amsterdam Inst Global Hlth & Dev, Acad Med Ctr, Dept Internal Med, Amsterdam, Netherlands. [Hamers, Raph L.; Reiss, Peter] Univ Amsterdam, Amsterdam Inst Global Hlth & Dev, Acad Med Ctr, Dept Global Hlth, Amsterdam, Netherlands. [Reiss, Peter; van Sighem, Ard I.] Stichting HIV Monitoring, Amsterdam, Netherlands. [Nelson, Mark] Chelsea & Westminster Hosp, London, England. [Montaner, Julio S. G.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Lane, H. Clifford] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Revell, AD (reprint author), HIV Resistance Response Database Initiat RDI, London, England. EM andrewrevell@hivrdi.org FU National Cancer Institute, National Institutes of Health [HHSN261200800001E]; National Institute of Allergy and Infectious Diseases FX This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. This research was supported by the National Institute of Allergy and Infectious Diseases. NR 14 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD OCT PY 2016 VL 71 IS 10 BP 2928 EP 2937 DI 10.1093/jac/dkw217 PG 10 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA EA2VO UT WOS:000386453900030 PM 27330070 ER PT J AU Aresh, W Liu, Y Sine, J Thayer, D Puri, A Huang, YK Wang, Y Nieh, MP AF Aresh, Wafa Liu, Ying Sine, Jessica Thayer, Derek Puri, Anu Huang, Yike Wang, Yong Nieh, Mu-Ping TI The Morphology of Self-Assembled Lipid-Based Nanoparticles Affects Their Uptake by Cancer Cells SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY LA English DT Article DE Cancer Cellular Internalization; Spontaneous Formation; Morphology-Targeting; Bicelles; Vesicles; SANS ID FORMED UNILAMELLAR VESICLES; CELLULAR UPTAKE; ENGINEERED NANOPARTICLES; MAMMALIAN-CELLS; DRUG-DELIVERY; SIZE; SHAPE; LIPOSOMES; NANODISCS; INTERNALIZATION AB The morphology of nanoparticles (NPs) has been presumed to play an important role in cellular uptake and in vivo stability. This report experimentally demonstrates such dependence by using two types of uniform-sized self-assembled lipid-based NPs, namely nanodiscs and nanovesicles, composed of identical lipid composition. The morphology is characterized by small angle neutron scattering, dynamic light scattering and transmission electron microscopy. Both NPs have similar bio-stability in serum and cellular cytotoxicity. However, cellular uptake of the nanodiscs at 37 degrees C is consistently and significantly higher than that of the vesicles according to the uptake results of several human cancer cell lines, i.e., CCRF-CEM, KB, and OVCAR-8, indicating a strong morphological dependence of cellular internalization. Further studies on such morphological dependence using CCRF-CEM reveals that vesicles only use Clathrin-and caveolae-mediated endocytic pathways, while nanodiscs also take the additional routes of macropinocytosis and microtubule-mediated endocytosis. C1 [Aresh, Wafa; Nieh, Mu-Ping] Univ Connecticut, Dept Biomed Engn, Storrs, CT 06269 USA. [Liu, Ying; Nieh, Mu-Ping] Univ Connecticut, Dept Chem & Biomol Engn, Storrs, CT 06269 USA. [Sine, Jessica; Thayer, Derek; Puri, Anu] NCI, Basic Res Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA. [Huang, Yike; Wang, Yong] Penn State Univ, Dept Biomed Engn, University Pk, PA 16802 USA. [Nieh, Mu-Ping] Univ Connecticut, Inst Mat Sci, Polymer Program, Storrs, CT 06269 USA. RP Nieh, MP (reprint author), Univ Connecticut, Dept Biomed Engn, Storrs, CT 06269 USA.; Nieh, MP (reprint author), Univ Connecticut, Dept Chem & Biomol Engn, Storrs, CT 06269 USA.; Nieh, MP (reprint author), Univ Connecticut, Inst Mat Sci, Polymer Program, Storrs, CT 06269 USA. EM mu-ping.nieh@uconn.edu FU Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; [NSF-CMMI 1131587] FX Mu-Ping Nieh, Yong Wang, Ying Liu, and Yike Huang would like to acknowledge the financial support by NSF-CMMI 1131587 and the assistance from the staff and scientist at the Spallation Neutron Source at the Oak Ridge National Laboratory. This research was also supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. We would like to thank Mr. Patrick Hall and Mr. Joseph Bergman for their assistance in the stability of the nanoparticles. We also thank Dr. Carol Norris for the training and her assistance in the use of Flow Cytometry/Confocal Microscope at the UConn Biotechnology-Bioservice Center as well as Dr. William Heller for his help with the experiment on EQ-SANS. NR 42 TC 0 Z9 0 U1 8 U2 8 PU AMER SCIENTIFIC PUBLISHERS PI VALENCIA PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA SN 1550-7033 EI 1550-7041 J9 J BIOMED NANOTECHNOL JI J. Biomed. Nanotechnol. PD OCT PY 2016 VL 12 IS 10 BP 1852 EP 1863 DI 10.1166/jbn.2016.2292 PG 12 WC Nanoscience & Nanotechnology; Materials Science, Biomaterials SC Science & Technology - Other Topics; Materials Science GA EA3FN UT WOS:000386486800002 ER PT J AU Ostrom, QT Gittleman, H Kruchko, C Louis, DN Brat, DJ Gilbert, MR Petkov, VI Barnholtz-Sloan, JS AF Ostrom, Quinn T. Gittleman, Haley Kruchko, Carol Louis, David N. Brat, Daniel J. Gilbert, Mark R. Petkov, Valentina I. Barnholtz-Sloan, Jill S. TI Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying) SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE WHO grade; Brain tumors; Cancer registration; MGMT methylation; 1p/19q codeletion ID MGMT PROMOTER METHYLATION; CENTRAL-NERVOUS-SYSTEM; DNA-REPAIR GENE; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ANAPLASTIC OLIGODENDROGLIOMAS; GRADE GLIOMAS; TEMOZOLOMIDE; MUTATIONS; CLASSIFICATION; TRIAL AB Cancer registries are an important source of population-level information on brain tumor incidence and survival. Surveillance, Epidemiology, and End Results (SEER) registries currently collect data on specific required factors related to brain tumors as defined by the American Joint Commission on Cancer, including World Health Organization (WHO) grade, MGMT methylation and 1p/19q codeletion status. We assessed 'completeness', defined as having valid values over the time periods that they have been collected, overall, by year, histology, and registry. Data were obtained through a SEER custom data request for four factors related to brain tumors for the years 2004-2012 (3/4 factors were collected only from 2010 to 2012). SEER*Stat was used to generate frequencies of 'completeness' for each factor overall, and by year, histology and registry. The four factors varied in completeness, but increased over time. WHO grade has been collected the longest, and showed significant increases in completeness. Completeness of MGMT and 1p/19q codeletion was highest for glioma subtypes for which testing is recommended by clinical practice guidelines. Completeness of all factors varied by histology and cancer registry. Overall, several of the factors had high completeness, and all increased in completeness over time. With increasing focus on 'precision medicine' and the incorporation of molecular parameters into the 2016 WHO CNS tumor classification, it is critical that the data are complete, and factors collected at the population level are fully integrated into cancer reporting. It is critical that cancer registries continue to collect established and emerging prognostic and predictive factors. C1 [Ostrom, Quinn T.; Gittleman, Haley; Barnholtz-Sloan, Jill S.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, 11100 Euclid Ave,Wearn 152, Cleveland, OH 44106 USA. [Ostrom, Quinn T.; Gittleman, Haley; Kruchko, Carol; Barnholtz-Sloan, Jill S.] CBTRUS, Hinsdale, IL 60521 USA. [Louis, David N.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA. [Brat, Daniel J.] Emory Univ, Dept Pathol & Lab Med, Winship Canc Inst, Atlanta, GA 30322 USA. [Gilbert, Mark R.] NIH, Neurooncol Branch, Bldg 10, Bethesda, MD 20892 USA. [Petkov, Valentina I.] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Barnholtz-Sloan, JS (reprint author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, 11100 Euclid Ave,Wearn 152, Cleveland, OH 44106 USA.; Barnholtz-Sloan, JS (reprint author), CBTRUS, Hinsdale, IL 60521 USA. EM jsb42@case.edu FU National Cancer Institute Case Comprehensive Cancer Center [P30CA043703]; CBTRUS database: the Centers for Disease Control and Prevention (CDC) [5U58DP00383]; Sontag Foundation, Genentech, Novocure, Inc; Celldex Therapeutics, Inc; AbbVie, Inc; Musella Foundation; Voices Against Brain Cancer, Elekta FX QTO, HG, and JSB-S were supported by the National Cancer Institute Case Comprehensive Cancer Center Support Grant (P30CA043703). CBTRUS is honored to be included among the research grant recipients of the following organizations, which have contributed to the maintenance of the CBTRUS database: the Centers for Disease Control and Prevention (CDC) under Agreement 5U58DP00383, the Sontag Foundation, Genentech, Novocure, Inc., Celldex Therapeutics, Inc., AbbVie, Inc., along with the Musella Foundation, Voices Against Brain Cancer, Elekta, the Zelda Dorin Memorial Fund, as well as private and in kind donations. NR 42 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD OCT PY 2016 VL 130 IS 1 BP 31 EP 42 DI 10.1007/s11060-016-2217-7 PG 12 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA EA4FH UT WOS:000386565200004 PM 27418206 ER PT J AU Nesvick, CL Zhang, C Edwards, NA Montgomery, BK Lee, M Yang, CZ Wang, HR Zhu, DW Heiss, JD Merrill, MJ Ray-Chaudhury, A Zhuang, ZP AF Nesvick, Cody L. Zhang, Chao Edwards, Nancy A. Montgomery, Blake K. Lee, Michaela Yang, Chunzhang Wang, Herui Zhu, Dongwang Heiss, John D. Merrill, Marsha J. Ray-Chaudhury, Abhik Zhuang, Zhengping TI ZEB1 expression is increased in IDH1-mutant lower-grade gliomas SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE IDH; Lower-grade glioma; Epithelial-mesenchymal transition; ZEB1 ID EPITHELIAL-MESENCHYMAL TRANSITION; INTEGRATED GENOMIC ANALYSIS; GENE-EXPRESSION; GLIOBLASTOMA-MULTIFORME; TUMOR INITIATION; STEM-CELLS; MUTATIONS; INVASION; IDH1; TRANSCRIPTION AB Transcription factors that induce epithelial-mesenchymal transition (EMT) promote invasion, chemoresistance and a stem-cell phenotype in epithelial tumors, but their roles in central nervous system tumors are not well-understood. We hypothesized these transcription factors have a functional impact in grades II-III gliomas. Using the National Cancer Institute (NCI) Repository for Molecular Brain Neoplasia Data (REMBRANDT) and the Cancer Genome Atlas (TCGA) Lower-Grade Glioma (LGG) data, we determined the impact of EMT-promoting transcription factors (EMT-TFs) on overall survival in grades II-III gliomas, compared their expression across common genetic subtypes and subsequently validated these findings in a set of 31 tumors using quantitative real-time polymerase chain reaction (PCR) and immunohistochemistry. Increased expression of the gene coding for the transcriptional repressor Zinc Finger E box-binding Homeobox 1 (ZEB1) was associated with a significant increase in overall survival (OS) on Kaplan-Meier analysis. Genetic subtype analysis revealed that ZEB1 expression was relatively increased in IDH1/2-mutant gliomas, and IDH1/2-mutant gliomas expressed significantly lower levels of many ZEB1 transcriptional targets. Similarly, IDH1/2-mutant tumors expressed significantly higher levels of targets of microRNA 200C (MIR200C), a key regulator of ZEB1. In a validation study, ZEB1 mRNA was significantly increased in IDH1-mutant grades II-III gliomas, and ZEB1 protein expression was more pronounced in these tumors. Our findings demonstrate a novel relationship between IDH1/2 mutations and expression of ZEB1 and its transcriptional targets. Therapy targeting ZEB1-associated pathways may represent a novel therapeutic avenue for this class of tumors. C1 [Nesvick, Cody L.; Zhang, Chao; Edwards, Nancy A.; Montgomery, Blake K.; Lee, Michaela; Yang, Chunzhang; Wang, Herui; Zhu, Dongwang; Heiss, John D.; Merrill, Marsha J.; Ray-Chaudhury, Abhik; Zhuang, Zhengping] NINDS, Surg Neurol Branch, 9000 Rockville Pike,Bldg 10 Room 3D17, Bethesda, MD 20892 USA. [Nesvick, Cody L.] Mayo Clin, Dept Neurol Surg, 200 1st St SW, Rochester, MN 55905 USA. [Montgomery, Blake K.] Stanford Univ, Dept Orthopaed Surg, 450 Broadway St,Pavil C,4th Floor, Redwood City, CA 94063 USA. [Lee, Michaela] George Washington Univ, Dept Neurol Surg, 2150 Penn Ave NW,Suite 7-420, Washington, DC 20037 USA. [Yang, Chunzhang] NCI, Neurooncol Branch, Bldg 37,Room 1142E, Bethesda, MD 20892 USA. RP Nesvick, CL; Zhuang, ZP (reprint author), NINDS, Surg Neurol Branch, 9000 Rockville Pike,Bldg 10 Room 3D17, Bethesda, MD 20892 USA.; Nesvick, CL (reprint author), Mayo Clin, Dept Neurol Surg, 200 1st St SW, Rochester, MN 55905 USA. EM Cody.Nesvick@gmail.com; ZhuangP@ninds.nih.gov FU Intramural Research Program at the National Institute of Neurological Disorders and Stroke; National Institutes of Health Medical Research Scholars Program FX This research was supported by the Intramural Research Program at the National Institute of Neurological Disorders and Stroke and the National Institutes of Health Medical Research Scholars Program. NR 56 TC 1 Z9 1 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD OCT PY 2016 VL 130 IS 1 BP 111 EP 122 DI 10.1007/s11060-016-2240-8 PG 12 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA EA4FH UT WOS:000386565200012 PM 27568035 ER PT J AU Jacobson, KA Civan, MM AF Jacobson, Kenneth A. Civan, Mortimer M. TI Ocular Purine Receptors as Drug Targets in the Eye SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS LA English DT Review DE adenosine receptor; P2Y receptor; P2X receptor; ATP ID RETINAL GANGLION-CELLS; DIQUAFOSOL OPHTHALMIC SOLUTION; A(3) ADENOSINE RECEPTOR; MOUSE INTRAOCULAR-PRESSURE; TRAUMATIC OPTIC NEUROPATHY; TRABECULAR MESHWORK CELLS; AQUEOUS-HUMOR; DRY-EYE; A(2A) RECEPTOR; GLAUCOMA TREATMENT AB Agonists and antagonists of various subtypes of G protein coupled adenosine receptors (ARs), P2Y receptors (P2YRs), and ATP-gated P2X receptor ion channels (P2XRs) are under consideration as agents for the treatment of ocular diseases, including glaucoma and dry eye. Numerous nucleoside and nonnucleoside modulators of the receptors are available as research tools and potential therapeutic molecules. Three of the 4 subtypes of ARs have been exploited with clinical candidate molecules for treatment of the eye: A(1), A(2A), and A(3). An A(1)AR agonist is in clinical trials for glaucoma, A(2A)AR reduces neuroinflammation, A(3)AR protects retinal ganglion cells from apoptosis, and both A(3)AR agonists and antagonists had been reported to lower intraocular pressure (IOP). Extracellular concentrations of endogenous nucleotides, including dinucleoside polyphosphates, are increased in pathological states, activating P2Y and P2XRs throughout the eye. P2YR agonists, including P2Y(2) and P2Y(6), lower IOP. Antagonists of the P2X7R prevent the ATP-induced neuronal apoptosis in the retina. Thus, modulators of the purinome in the eye might be a source of new therapies for ocular diseases. C1 [Jacobson, Kenneth A.] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA. [Civan, Mortimer M.] Univ Penn, Dept Physiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Civan, Mortimer M.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Jacobson, KA (reprint author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA. EM kennethj@helix.nih.gov FU NIDDK, NIH Intramural Research Program FX K.A.J. thanks the NIDDK, NIH Intramural Research Program for support. NR 123 TC 0 Z9 0 U1 4 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1080-7683 EI 1557-7732 J9 J OCUL PHARMACOL TH JI J. Ocular Pharmacol. Ther. PD OCT PY 2016 VL 32 IS 8 SI SI BP 534 EP 547 DI 10.1089/jop.2016.0090 PG 14 WC Ophthalmology; Pharmacology & Pharmacy SC Ophthalmology; Pharmacology & Pharmacy GA EA4NJ UT WOS:000386589200011 PM 27574786 ER PT J AU Louis, GMB Backonja, U Schliep, KC Sun, LP Peterson, CM Chen, Z AF Louis, Germaine M. Buck Backonja, Uba Schliep, Karen C. Sun, Liping Peterson, C. Matthew Chen, Zhen TI Women's Reproductive History Before the Diagnosis of Incident Endometriosis SO JOURNAL OF WOMENS HEALTH LA English DT Article DE endometriosis; epidemiology; fertility ID PREDICTIVE-VALUE; INFERTILE WOMEN; BODY-SIZE; PREGNANCY; POPULATION; RISK; RECURRENCE; CLASSIFICATION; ASSOCIATION; PERFORMANCE AB Background: Endometriosis is a gynecologic disease reported to be associated with infertility and, possibly, adverse pregnancy outcomes. While considerable research focuses on pregnancy outcomes following diagnosis and/or treatment, few data actually describe women's reproductive history before diagnosis for a more complete understanding of endometriosis and reproduction. Materials and Methods: The study sample comprised 473 women (aged 18-44 years) undergoing laparoscopies or laparotomies, irrespective of surgical indication at 14 clinical sites, during the period 2007-2009. Upon enrollment and before surgery, women were queried about pregnancy intentions and the time required to become pregnant for planned pregnancies. Endometriosis was defined as surgically visualized disease. Using discrete time survival analysis, we estimated fecundability odds ratios (FORs) and 95% confidence intervals (CIs) to assess time to pregnancy (TTP) after adjusting for potential confounders (age, body composition, cigarette smoking, site). Generalized estimating equations accounted for multiple pregnancy attempts per woman. FORs <1.0 denote a longer TTP or diminished fecundity. Results: Approximately 66% and 69% of women with and without endometriosis, respectively, reported having a planned pregnancy before surgery, respectively. After adjustment, an endometriosis diagnosis was associated with approximate to 29% reduction in fecundity or a longer TTP across all pregnancy-trying attempts (adjusted FOR=0.71; 95% CI 0.46-1.10). While FORs were consistently <1.0, irrespective of endometriosis staging, CIs included 1. Conclusions: Women with endometriosis had a longer TTP than unaffected women, irrespective of disease severity, although the findings did not achieve significance. Prior reproductive history may be informative for predicting fecundity and pregnancy outcomes following diagnosis/treatment. C1 [Louis, Germaine M. Buck; Backonja, Uba] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth, Rockville, MD USA. [Backonja, Uba] Univ Washington, Sch Med, Dept Biomed Informat & Med Educ, Div Biomed & Hlth Informat, Seattle, WA USA. [Schliep, Karen C.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Intramural Populat Hlth, Rockville, MD USA. [Schliep, Karen C.] Univ Utah, Sch Med, Dept Family & Prevent Med, Div Publ Hlth, Salt Lake City, UT 84112 USA. [Sun, Liping] Glotech Corp, Rockville, MD USA. [Peterson, C. Matthew] Univ Utah, Sch Med, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Salt Lake City, UT 84132 USA. [Chen, Zhen] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Div Intramural Populat Hlth, Rockville, MD USA. RP Louis, GMB (reprint author), 6710B Rockledge Blvd, Rockville, MD 20852 USA. EM louisg@mail.nih.gov OI Buck Louis, Germaine/0000-0002-1774-4490 FU Intramural Research Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development [NO1-DK-6-3428, NO1-DK-6-3427, 10001406-02]; National Institutes of Health, National Library of Medicine (NLM) Biomedical and Health Informatics Training Program at the University of Washington [T15LM007442] FX This research was supported by the Intramural Research Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development (contracts NO1-DK-6-3428; NO1-DK-6-3427; 10001406-02). Dr. U.B. was supported as a predoctoral fellow by the National Institute for Nursing Research's Graduate Partnership Program during the course of this research and is now supported, in part, by the National Institutes of Health, National Library of Medicine (NLM) Biomedical and Health Informatics Training Program at the University of Washington (Grant Nr. T15LM007442). NR 52 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2016 VL 25 IS 10 BP 1021 EP 1029 DI 10.1089/jwh.2015.5712 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA EA3BH UT WOS:000386472300008 ER PT J AU Lerin, C Goldfine, AB Boes, T Liu, M Kasif, S Dreyfuss, JM De Sousa-Coelho, AL Daher, G Manoli, I Sysol, JR Isganaitis, E Jessen, N Goodyear, LJ Beebe, K Gall, W Venditti, CP Patti, ME AF Lerin, Carles Goldfine, Allison B. Boes, Tanner Liu, Manway Kasif, Simon Dreyfuss, Jonathan M. De Sousa-Coelho, Ana Luisa Daher, Grace Manoli, Irini Sysol, Justin R. Isganaitis, Elvira Jessen, Niels Goodyear, Laurie J. Beebe, Kirk Gall, Walt Venditti, Charles P. Patti, Mary-Elizabeth TI Defects in muscle branched-chain amino acid oxidation contribute to impaired lipid metabolism SO MOLECULAR METABOLISM LA English DT Article DE Insulin sensitivity; BCAA; Fatty acid oxidation; TCA cycle ID TYPE-2 DIABETES-MELLITUS; VISCERAL ADIPOSE-TISSUE; CIRCULATING BCAA LEVELS; INSULIN-RESISTANCE; SKELETAL-MUSCLE; METHYLMALONIC ACIDEMIA; GENE-EXPRESSION; ENZYME-ACTIVITY; WEIGHT-LOSS; OBESITY AB Objective: Plasma levels of branched-chain amino acids (BCAA) are consistently elevated in obesity and type 2 diabetes (T2D) and can also prospectively predict T2D. However, the role of BCAA in the pathogenesis of insulin resistance and T2D remains unclear. Methods: To identify pathways related to insulin resistance, we performed comprehensive gene expression and metabolomics analyses in skeletal muscle from 41 humans with normal glucose tolerance and 11 with T2D across a range of insulin sensitivity (SI, 0.49 to 14.28). We studied both cultured cells and mice heterozygous for the BCAA enzyme methylmalonyl-CoA mutase (Mut) and assessed the effects of altered BCAA flux on lipid and glucose homeostasis. Results: Our data demonstrate perturbed BCAA metabolism and fatty acid oxidation in muscle from insulin resistant humans. Experimental alterations in BCAA flux in cultured cells similarly modulate fatty acid oxidation. Mut heterozygosity in mice alters muscle lipid metabolism in vivo, resulting in increased muscle triglyceride accumulation, increased plasma glucose, hyperinsulinemia, and increased body weight after high-fat feeding. Conclusions: Our data indicate that impaired muscle BCAA catabolism may contribute to the development of insulin resistance by perturbing both amino acid and fatty acid metabolism and suggest that targeting BCAA metabolism may hold promise for prevention or treatment of T2D. (C) 2016 The Authors. Published by Elsevier GmbH. C1 [Lerin, Carles; Goldfine, Allison B.; Boes, Tanner; Dreyfuss, Jonathan M.; De Sousa-Coelho, Ana Luisa; Daher, Grace; Isganaitis, Elvira; Jessen, Niels; Goodyear, Laurie J.; Patti, Mary-Elizabeth] Joslin Diabet Ctr, Res Div, Boston, MA 02215 USA. [Lerin, Carles; Goldfine, Allison B.; De Sousa-Coelho, Ana Luisa; Isganaitis, Elvira; Patti, Mary-Elizabeth] Harvard Med Sch, Boston, MA 02215 USA. [Lerin, Carles] Hosp St Joan Deu, Inst Recerca Pediat, Endocrinol Dept, Barcelona 08950, Spain. [Liu, Manway; Kasif, Simon; Dreyfuss, Jonathan M.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Manoli, Irini; Sysol, Justin R.; Venditti, Charles P.] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA. [Beebe, Kirk; Gall, Walt] Metabolon Inc, Durham, NC 27723 USA. [Gall, Walt] Saffron Technol, Cary, NC 27513 USA. RP Patti, ME (reprint author), Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA.; Lerin, C (reprint author), Hosp St Joan Deu, Inst Recerca Pediat, Barcelona 08950, Spain. EM clerin@fsjd.org; mary.elizabeth.patti@joslin.harvard.edu OI Jessen, Niels/0000-0001-5613-7274 FU NICHD NIH HHS [K99 HD064793]; NIDDK NIH HHS [K23 DK002795, P30 DK036836, R01 DK101043]; NLM NIH HHS [U54 LM008748] NR 64 TC 0 Z9 0 U1 10 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2212-8778 J9 MOL METAB JI Mol. Metab. PD OCT PY 2016 VL 5 IS 10 BP 926 EP 936 DI 10.1016/j.molmet.2016.08.001 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA8KC UT WOS:000386882700012 PM 27689005 ER PT J AU Bachis, A Wenzel, E Boelk, A Becker, J Mocchetti, I AF Bachis, Alessia Wenzel, Erin Boelk, Allyssia Becker, Jodi Mocchetti, Italo TI The neurotrophin receptor p75 mediates gp120-induced loss of synaptic spines in aging mice SO NEUROBIOLOGY OF AGING LA English DT Article DE Aging; Hippocampus; HIV; p75NTR; proBDNF; TrkB ID HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; ENVELOPE PROTEIN GP120; LONG-TERM POTENTIATION; ANTIRETROVIRAL THERAPY; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; HIV-1 ENCEPHALITIS; AXONAL-TRANSPORT; DENDRITIC GROWTH AB Human immunodeficiency virus 1 and its envelope protein gp120 reduce synaptodendritic complexity. However, the mechanisms contributing to this pathological feature are still not understood. The proneurotrophin brain-derived neurotrophic factor promotes synaptic simplification through the activation of the p75 neurotrophin receptor (p75NTR). Here, we have used gp120 transgenic (gp120tg) mice to investigate whether p75NTR has a role in gp120-mediated neurotoxicity. Old (similar to 10 months) gp120tg mice exhibited an increase in proneurotrophin brain-derived neurotrophic factor levels in the hippocampus as well as a decrease in the number of dendritic spines when compared to age-matched wild type. These effects were not observed in 3-or 6-month-old mice. To test if the reduction in spine density and morphology is caused by the activation of p75NTR, we crossed gp120tg mice with p75NTR null mice. We found that deletion of only 1 copy of the p75NTR gene in gp120tg mice is sufficient to normalize the number of hippocampal spines, strongly suggesting that the neurotoxic effect of gp120 is mediated by p75NTR. These data indicate that p75NTR antagonists could provide an adjunct therapy against synaptic simplification caused by human immunodeficiency virus 1. (C) 2016 Elsevier Inc. All rights reserved. C1 [Bachis, Alessia; Wenzel, Erin; Boelk, Allyssia; Mocchetti, Italo] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Preclin Neurobiol, Washington, DC 20007 USA. [Wenzel, Erin] Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA. [Becker, Jodi] NCI, Ctr Canc Res, Frederick, MD 21701 USA. RP Mocchetti, I (reprint author), Georgetown Univ, Med Ctr, EP09 New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA. EM moccheti@georgetown.edu FU HHS [NS079172, NS074916] FX This work was supported by HHS grants NS079172 and NS074916. Special thanks to Dr. Eliezer Masliah (University of California San Diego, San Diego, CA) for the breading pairs of gp120tg mice, to Dr. Bruce Carter (Vanderbilt University, Nashville, TE) for the gift of the p75NTR antibody, and Lino Tessarollo (NCI-Frederick, MD) for discussions and advice with the animal studies. The authors are grateful to the National NeuroAIDS Tissue Consortium for providing human brain tissues. NR 57 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD OCT PY 2016 VL 46 BP 160 EP 168 DI 10.1016/j.neurobiolaging.2016.07.001 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA EA9OP UT WOS:000386973900017 PM 27498053 ER PT J AU Bras, J Djaldetti, R Alves, AM Mead, S Darwent, L Lleo, A Molinuevo, JL Blesa, R Singleton, A Hardy, J Clarimon, J Guerreiro, R AF Bras, Jose Djaldetti, Ruth Alves, Ana Margarida Mead, Simon Darwent, Lee Lleo, Alberto Luis Molinuevo, Jose Blesa, Rafael Singleton, Andrew Hardy, John Clarimon, Jordi Guerreiro, Rita TI Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation SO NEUROBIOLOGY OF AGING LA English DT Article DE Early onset Alzheimer's disease; Kufs disease; Recessive; Exome sequencing; Homozygosity; CTSF ID NEURONAL CEROID-LIPOFUSCINOSIS; B KUFS-DISEASE; EXTENDED TRACTS; CANDIDATE GENES; GENOME ANALYSIS; FRAMEWORK; DEMENTIA AB We have previously reported the whole genome genotyping analysis of 2 consanguineous siblings clinically diagnosed with early onset Alzheimer's disease (AD). In this analysis, we identified several large regions of homozygosity shared between both affected siblings, which we suggested could be candidate loci for a recessive genetic lesion underlying the early onset AD in these cases. We have now performed exome sequencing in one of these siblings and identified the potential cause of disease: the CTSF c.1243G>A:p. Gly415Arg mutation in homozygosity. Biallelic mutations in this gene have been shown to cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis with some cases resembling the impairment seen in AD. (C) 2016 Elsevier Inc. All rights reserved. C1 [Bras, Jose; Alves, Ana Margarida; Darwent, Lee; Hardy, John; Guerreiro, Rita] UCL, Inst Neurol, Dept Mol Neurosci, 1 Wakefield St 1st Floor, London WC1N 1PJ, England. [Bras, Jose; Guerreiro, Rita] Univ Aveiro, Dept Med Sci, Aveiro, Portugal. [Bras, Jose; Guerreiro, Rita] Univ Aveiro, Inst Biomed iBiMED, Aveiro, Portugal. [Djaldetti, Ruth] Rabin Med Ctr, Dept Neurol, Beilinson Campus, Petah Tiqwa, Israel. [Djaldetti, Ruth] Felsenstein Res Ctr, Petah Tiqwa, Israel. [Djaldetti, Ruth] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel. [Mead, Simon] UCL, Inst Neurol, Dept Neurodegenerat Dis, MRC Prion Unit, London, England. [Lleo, Alberto; Blesa, Rafael; Clarimon, Jordi] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Memory Unit, Barcelona, Spain. [Lleo, Alberto; Blesa, Rafael; Clarimon, Jordi] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, St Pau Biomed Res Inst, Barcelona, Spain. [Lleo, Alberto] Ctr Networked Biomed Res Neurodegenerat Dis, CIBERNED, Madrid, Spain. [Luis Molinuevo, Jose] Hosp Clin Barcelona, Inst Neurosci, Dept Neurol, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain. [Luis Molinuevo, Jose] Univ Barcelona, IDIBAPS, Barcelona, Spain. [Singleton, Andrew] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. RP Guerreiro, R (reprint author), UCL, Inst Neurol, Dept Mol Neurosci, 1 Wakefield St 1st Floor, London WC1N 1PJ, England. EM r.guerreiro@ucl.ac.uk RI Hardy, John/C-2451-2009 FU Medical Research Council (UK); National Institute of Health Research's Biomedical Research Centre and Biomedical Research Unit (Dementia) at UCL Hospitals NHS Foundation Trust; Alzheimer's Society; European Grand Prix for Young Researcher-SCOR - Fondation pour la Recherche sur Alzheimer FX This work was supported in part by an anonymous donor; the Medical Research Council (UK) and by the National Institute of Health Research's Biomedical Research Centre and Biomedical Research Unit (Dementia) at UCL Hospitals NHS Foundation Trust; fellowships from the Alzheimer's Society to Jose Bras and Rita Guerreiro, and by the 2014 European Grand Prix for Young Researcher-SCOR awarded by the Fondation pour la Recherche sur Alzheimer to Rita Guerreiro. The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about. NR 22 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD OCT PY 2016 VL 46 AR 236.e1 DI 10.1016/j.neurobiolaging.2016.06.018 PG 6 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA EA9OP UT WOS:000386973900025 PM 27524508 ER PT J AU Sassi, C Nalls, MA Ridge, PG Gibbs, JR Ding, JH Lupton, MK Troakes, C Lunnon, K Al-Sarraj, S Brown, KS Medway, C Clement, N Lord, J Turton, J Bras, J Almeida, MR Holstege, H Louwersheimer, E Van Der Flier, WM Scheltens, P Van Swieten, JC Santana, I Oliveira, C Morgan, K Powell, JF Kauwe, JS Cruchaga, C Goate, AM Singleton, AB Guerreiro, R Hardy, J AF Sassi, Celeste Nalls, Michael A. Ridge, Perry G. Gibbs, Jesse R. Ding, Jinhui Lupton, Michelle K. Troakes, Claire Lunnon, Katie Al-Sarraj, Safa Brown, Kristelle S. Medway, Christopher Clement, Naomi Lord, Jenny Turton, James Bras, Jose Almeida, Maria R. Holstege, Henne Louwersheimer, Eva van der Flier, Wiesje M. Scheltens, Philip Van Swieten, John C. Santana, Isabel Oliveira, Catarina Morgan, Kevin Powell, John F. Kauwe, John S. Cruchaga, Carlos Goate, Alison M. Singleton, Andrew B. Guerreiro, Rita Hardy, John CA ARUK Consortium TI ABCA7 p.G215S as potential protective factor for Alzheimer's disease SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimer's disease (AD); Genome-wide association studies (GWASs); ABCA7; Whole exome sequencing (WES); Whole genome sequencing (WGS); Protective variant ID GENOME-WIDE ASSOCIATION; IDENTIFIES VARIANTS; APOLIPOPROTEIN-E; COMMON VARIANTS; SEQUENCING DATA; RARE VARIANTS; RISK; LOCI; EXPRESSION; SUSCEPTIBILITY AB Genome-wide association studies (GWASs) have been effective approaches to dissect common genetic variability underlying complex diseases in a systematic and unbiased way. Recently, GWASs have led to the discovery of over 20 susceptibility loci for Alzheimer's disease (AD). Despite the evidence showing the contribution of these loci to AD pathogenesis, their genetic architecture has not been extensively investigated, leaving the possibility that low frequency and rare coding variants may also occur and contribute to the risk of disease. We have used exome and genome sequencing data to analyze the single independent and joint effect of rare and low-frequency protein coding variants in 9 AD GWAS loci with the strongest effect sizes after APOE (BIN1, CLU, CR1, PICALM, MS4A6A, ABCA7, EPHA1, CD33, and CD2AP) in a cohort of 332 sporadic AD cases and 676 elderly controls of British and North-American ancestry. We identified coding variability in ABCA7 as contributing to AD risk. This locus harbors a low-frequency coding variant (p. G215S, rs72973581, minor allele frequency = 4.3%) conferring a modest but statistically significant protection against AD (p-value = 0.024, odds ratio = 0.57, 95% confidence interval = 0.41-0.80). Notably, our results are not driven by an enrichment of loss of function variants in ABCA7, recently reported as main pathogenic factor underlying AD risk at this locus. In summary, our study confirms the role of ABCA7 in AD and provides new insights that should address functional studies. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license. C1 [Sassi, Celeste; Bras, Jose; Guerreiro, Rita; Hardy, John] UCL Inst Neurol, Dept Mol Neurosci, Weston Res Labs, Reta Lila, London, England. [Sassi, Celeste; Nalls, Michael A.; Gibbs, Jesse R.; Ding, Jinhui; Singleton, Andrew B.] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. [Sassi, Celeste] Charite, Ctr Stroke Res Berlin CSB, Dept Expt Neurol, Berlin, Germany. [Sassi, Celeste] German Ctr Neurodegenerat Dis DZNE, Berlin Site, Germany. [Ridge, Perry G.; Kauwe, John S.] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA. [Lupton, Michelle K.; Troakes, Claire; Lunnon, Katie; Al-Sarraj, Safa; Powell, John F.] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England. [Lupton, Michelle K.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia. [Lunnon, Katie] Univ Exeter, Sch Med, Inst Biomed & Clin Sci, Exeter, Devon, England. [Brown, Kristelle S.; Medway, Christopher; Clement, Naomi; Lord, Jenny; Turton, James; Morgan, Kevin] Univ Nottingham, Queens Med Ctr, Sch Life Sci, Translat Cell Sci Human Genet, Nottingham, England. [Almeida, Maria R.] Univ Coimbra, Ctr Neurosci & Cell Biol, Neurogenet Lab, Coimbra, Portugal. [Holstege, Henne; Louwersheimer, Eva; van der Flier, Wiesje M.; Scheltens, Philip; Van Swieten, John C.] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Dept Neurol, Neurosci Campus Amsterdam, Amsterdam, Netherlands. [Van Swieten, John C.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands. [Santana, Isabel] Ctr Hosp & Univ Coimbra, Neurol Dept, Coimbra, Portugal. [Santana, Isabel] Univ Coimbra, Fac Med, Coimbra, Portugal. [Oliveira, Catarina] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal. [Oliveira, Catarina] Univ Coimbra, Fac Med, Biochem Lab, Coimbra, Portugal. [Powell, John F.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA. [Cruchaga, Carlos] Washington Univ, Div Biol & Biomed Sci, St Louis, MO USA. [Goate, Alison M.] Icahn Sch Med Mt Sinai, Icahn Med Inst, New York, NY 10029 USA. RP Hardy, J (reprint author), UCL Inst Neurol, Dept Mol Neurosci, Weston Res Labs, Reta Lila, London, England. EM j.hardy@ucl.ac.uk RI Powell, John/G-4412-2011; Hardy, John/C-2451-2009; OI Powell, John/0000-0001-6124-439X; Todd, Stephen/0000-0002-2312-9195 FU Alzheimer's Research UK; Medical Research Council (MRC); Wellcome Trust/MRC Joint Call in Neurodegeneration award [WT089698]; National Institute for Health Research Biomedical Research Unit in Dementia at University College London Hospitals, University College London; Intramural Research Programs of the National Institute on Aging; National Institute of Neurological Disease and Stroke; National Institutes of Health (Department of Health and Human Services) [ZO1 AG000950-10]; ARUK; AS; Intramural Research Program of the National Institute on Aging; National Institutes of Health; Department of Health and Human Services [ZO1 AG000950-10]; National Institute on Aging (NIA) [U24 AG21886]; NIH [R01 AG042611]; [P50 AG016574]; [U01 AG006786]; [R01 AG18023] FX This study was supported by the Alzheimer's Research UK, the Medical Research Council (MRC), the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium (whose members are from the University College London Institute of Neurology, the University of Sheffield, and the MRC Protein Phosphorylation Unit at the University of Dundee), grants (P50 AG016574, U01 AG006786, and R01 AG18023), the National Institute for Health Research Biomedical Research Unit in Dementia at University College London Hospitals, University College London; an anonymous donor, the Big Lottery (to Dr. Morgan); a fellowship from Alzheimer's Research UK (to Dr. Guerreiro); and the Intramural Research Programs of the National Institute on Aging and the National Institute of Neurological Disease and Stroke, National Institutes of Health (Department of Health and Human Services Project number, ZO1 AG000950-10). The MRC London Neurodegenerative Diseases Brain Bank and the Manchester Brain Bank from Brains for Dementia Research are jointly funded from ARUK and AS. This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services, project number ZO1 AG000950-10. Samples from the National Cell Repository for Alzheimer's Disease (NCRAD), which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA), were used in this study. NIH grant R01 AG042611 to Kauwe J. NR 37 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD OCT PY 2016 VL 46 AR 235.e1 DI 10.1016/j.neurobiolaging.2016.04.004 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA EA9OP UT WOS:000386973900023 PM 27289440 ER PT J AU Knittel, G Liedgens, P Korovkina, D Seeger, JM Al-Baldawi, Y Al-Maarri, M Fritz, C Vlantis, K Bezhanova, S Scheel, AH Wolz, OO Reimann, M Moller, P Lopez, C Staudt, LM Ortmann, M Pasparakis, M Siebert, R Schmitt, CA Klatt, AR Wunderlich, FT Schafer, SC Persigehl, T Montesinos-Rongen, M Odenthal, M Buttner, R Frenzel, LP Kashkar, H Reinhardt, HC AF Knittel, G. Liedgens, P. Korovkina, D. Seeger, J. M. Al-Baldawi, Y. Al-Maarri, M. Fritz, C. Vlantis, K. Bezhanova, S. Scheel, A. H. Wolz, O. -O. Reimann, M. Moeller, P. Lopez, C. Staudt, L. M. Ortmann, M. Pasparakis, M. Siebert, R. Schmitt, C. A. Klatt, A. R. Wunderlich, F. T. Schaefer, S. C. Persigehl, T. Montesinos-Rongen, M. Odenthal, M. Buettner, R. Frenzel, L. P. Kashkar, H. Reinhardt, H. C. TI B cell-specific conditional expression of Myd88 p.L252P leads to the development of diffuse large B cell lymphoma in mice SO ONCOLOGY RESEARCH AND TREATMENT LA English DT Meeting Abstract C1 [Knittel, G.; Liedgens, P.; Korovkina, D.; Fritz, C.; Frenzel, L. P.; Reinhardt, H. C.] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany. [Seeger, J. M.; Kashkar, H.] Univ Hosp Cologne, Inst Microbiol & Hyg, Cologne, Germany. [Al-Baldawi, Y.; Persigehl, T.] Univ Hosp Cologne, Dept Radiol, Cologne, Germany. [Al-Maarri, M.; Wunderlich, F. T.] Max Planck Inst Metab Res, Cologne, Germany. [Vlantis, K.; Pasparakis, M.] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany. [Bezhanova, S.] NN Blokhin Russian Canc Res Ctr, Moscow, Russia. [Scheel, A. H.; Ortmann, M.; Schaefer, S. C.; Odenthal, M.; Buettner, R.] Univ Hosp Cologne, Inst Pathol, Cologne, Germany. [Wolz, O. -O.] Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Tubingen, Germany. [Reimann, M.; Schmitt, C. A.] Charite Univ Med Ctr, Dept Hematol Oncol, Berlin, Germany. [Moeller, P.] Univ Ulm, Fac Med, Inst Pathol, Ulm, Germany. [Lopez, C.; Siebert, R.] Univ Kiel, Kiel, Germany. [Lopez, C.; Siebert, R.] Univ Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany. [Staudt, L. M.] NCI, NIH, Metab Branch, Ctr Canc Res, Bethesda, MD 20892 USA. [Klatt, A. R.] Univ Hosp Cologne, Inst Clin Chem, Cologne, Germany. [Montesinos-Rongen, M.] Univ Hosp Cologne, Inst Neuropathol, Cologne, Germany. NR 0 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 2296-5270 EI 2296-5262 J9 ONCOL RES TREAT JI Oncol. Res. Treat. PD OCT PY 2016 VL 39 SU 3 MA V717 BP 218 EP 219 PG 2 WC Oncology SC Oncology GA DZ2SK UT WOS:000385691300538 ER PT J AU Smit, RAJ Postmus, I Trompet, S Barnes, MR Warren, H Arsenault, BJ Chasman, DI Cupples, LA Hitman, GA Krauss, RM Li, XH Psaty, BM Stein, CM Rotter, JI Jukema, JW AF Smit, Roelof A. J. Postmus, Iris Trompet, Stella Barnes, Michael R. Warren, Helen Arsenault, Benoit J. Chasman, Daniel I. Cupples, L. Adrienne Hitman, Graham A. Krauss, Ronald M. Li, Xiaohui Psaty, Bruce M. Stein, Charles M. Rotter, Jerome I. Jukema, J. Wouter TI Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment SO PHARMACOGENOMICS LA English DT Article DE MR-Egger; pharmacogenetics; statin therapy ID MENDELIAN RANDOMIZATION; LDL-CHOLESTEROL; HEART-DISEASE; NPC1L1; METAANALYSIS; EZETIMIBE; THERAPY; BIAS AB Aims: To utilize previously reported lead SNPs for low-density lipoprotein cholesterol (LDL-c) levels to find additional loci of importance to statin response, and examine whether genetic predisposition to LDL-c levels associates with differential statin response. Methods: We investigated effects on statin response of 59 LDL-c SNPs, by combining summary level statistics from the Global Lipids Genetics and Genomic Investigation of Statin Therapy consortia. Results: Lead SNPs for APOE, SORT1 and NPC1L1 were associated with a decreased LDL-c response to statin treatment, as was overall genetic predisposition for increased LDL-c levels as quantified with 59 SNPs, with a 5.4% smaller statin response per standard deviation increase in genetically raised LDL-c levels. Conclusion: Genetic predisposition for increased LDL-c level may decrease efficacy of statin therapy. C1 [Smit, Roelof A. J.; Trompet, Stella; Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands. [Smit, Roelof A. J.; Postmus, Iris; Trompet, Stella] Leiden Univ, Med Ctr, Dept Internal Med, Sect Gerontol & Geriatr, Leiden, Netherlands. [Barnes, Michael R.; Warren, Helen] Queen Mary Univ London, William Harvey Res Inst, Barts & London Sch Med, London EC1M 6BQ, England. [Barnes, Michael R.; Warren, Helen] Queen Mary Univ London, Barts & London Sch Med, NIHR Barts Cardiovasc Biomed Res Unit, London EC1M 6BQ, England. [Arsenault, Benoit J.] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada. [Chasman, Daniel I.] Brigham & Womens Hosp, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Chasman, Daniel I.] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA. [Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Cupples, L. Adrienne] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA. [Hitman, Graham A.] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London EC1M 6BQ, England. [Krauss, Ronald M.] Childrens Hosp Oakland, Res Inst, Dept Atherosclerosis Res, Oakland, CA 94609 USA. [Li, Xiaohui; Rotter, Jerome I.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90502 USA. [Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA. [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA. [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA. [Psaty, Bruce M.] Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA 98101 USA. [Stein, Charles M.] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA. [Stein, Charles M.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA. [Jukema, J. Wouter] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Leiden, Netherlands. [Jukema, J. Wouter] Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands. RP Smit, RAJ (reprint author), Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands.; Smit, RAJ (reprint author), Leiden Univ, Med Ctr, Dept Internal Med, Sect Gerontol & Geriatr, Leiden, Netherlands. EM r.a.j.smit@lumc.nl FU Steering Committee of the Yale Open Data Access Project by Johnson Johnson; JUPITER from AstraZeneca; Netherlands Heart Foundation [2001 D 032] FX BM Psaty serves on the Data and Safety Monitoring Board of a clinical trial funded by the manufacturer, and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. DI Chasman received research support for independent genetic analysis in JUPITER from AstraZeneca. JW Jukema is an Established Clinical Investigator of The Netherlands Heart Foundation (grant no. 2001 D 032). RM Krauss serves on the Merck Global Atherosclerosis Advisory Board. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 26 TC 0 Z9 0 U1 0 U2 0 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1462-2416 EI 1744-8042 J9 PHARMACOGENOMICS JI Pharmacogenomics PD OCT PY 2016 VL 17 IS 15 BP 1621 EP 1628 DI 10.2217/pgs-2016-0091 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EA3UD UT WOS:000386529900003 PM 27648687 ER PT J AU Pereira, TA Syn, WK Amancio, FF Cunha, PHD Caporali, JFM Trindade, GVD Santos, ET Souza, MM Andrade, ZA Witek, RP Secor, WE Pereira, FEL Lambertucci, JR Diehl, AM AF Pereira, Thiago Almeida Syn, Wing-Kin Amancio, Frederico Figueiredo Diniz Cunha, Pedro Henrique Morais Caporali, Julia Fonseca de Melo Trindade, Guilherme Vaz Santos, Elisangela Trindade Souza, Marcia Maria Andrade, Zilton Araujo Witek, Rafal P. Secor, William Evan Lima Pereira, Fausto Edmundo Lambertucci, Jose Roberto Diehl, Anna Mae TI Osteopontin Is Upregulated in Human and Murine Acute Schistosomiasis Mansoni SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID GRANULOMA-FORMATION; LIVER; INFLAMMATION; INFECTION; RESPONSES; FIBROSIS; INJURY; CELLS AB Background Symptomatic acute schistosomiasis mansoni is a systemic hypersensitivity reaction against the migrating schistosomula and mature eggs after a primary infection. The mechanisms involved in the pathogenesis of acute schistosomiasis are not fully elucidated. Osteopontin has been implicated in granulomatous reactions and in acute hepatic injury. Our aims were to evaluate if osteopontin plays a role in acute Schistosoma mansoni infection in both human and experimentally infected mice and if circulating OPN levels could be a novel biomarker of this infection. Methodology/Principal Findings Serum/plasma osteopontin levels were measured by ELISA in patients with acute (n = 28), hepatointestinal (n = 26), hepatosplenic (n = 39) schistosomiasis and in uninfected controls (n = 21). Liver osteopontin was assessed by immunohistochemistry in needle biopsies of 5 patients. Sera and hepatic osteopontin were quantified in the murine model of schistosomiasis mansoni during acute (7 and 8 weeks post infection, n = 10) and chronic (30 weeks post infection, n = 8) phase. Circulating osteopontin levels are increased in patients with acute schistosomiasis (p = 0.0001). The highest levels of OPN were observed during the peak of clinical symptoms (7-11 weeks post infection), returning to baseline level once the granulomas were modulated (>12 weeks post infection). The plasma levels in acute schistosomiasis were even higher than in hepatosplenic patients. The murine model mirrored the human disease. Macrophages were the major source of OPN in human and murine acute schistosomiasis, while the ductular reaction maintains OPN production in hepatosplenic disease. Soluble egg antigens from S. mansoni induced OPN expression in primary human kupffer cells. Conclusions/Significance S. mansoni egg antigens induce the production of OPN by macrophages in the necroticexudative granulomas characteristic of acute schistosomiasis mansoni. Circulating OPN levels are upregulated in human and murine acute schistosomiasis and could be a noninvasive biomarker of this form of disease. C1 [Pereira, Thiago Almeida; Diehl, Anna Mae] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA. [Pereira, Thiago Almeida; Amancio, Frederico Figueiredo; Diniz Cunha, Pedro Henrique; Morais Caporali, Julia Fonseca; de Melo Trindade, Guilherme Vaz; Lambertucci, Jose Roberto] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Doencas Infecciosas & Parasitarias, Belo Horizonte, MG, Brazil. [Pereira, Thiago Almeida; Santos, Elisangela Trindade; Souza, Marcia Maria; Andrade, Zilton Araujo] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Patol Expt, Salvador, BA, Brazil. [Pereira, Thiago Almeida] NIAID, Immunopathogesis Sect, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Syn, Wing-Kin] Ralph H Johnson Vet Affairs Med Ctr, Gastroenterol Sect, Charleston, SC USA. [Syn, Wing-Kin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC USA. [Syn, Wing-Kin] Fdn Liver Res, Inst Hepatol, Liver Regenerat & Repair Res Grp, London, England. [de Melo Trindade, Guilherme Vaz] Natl Univ Ireland, Sch Med, Dept Physiol, Galway, Ireland. [Witek, Rafal P.] Thermo Fisher Sci, Frederick, MD USA. [Secor, William Evan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lima Pereira, Fausto Edmundo] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, Vitoria, ES, Brazil. RP Diehl, AM (reprint author), Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA.; Lambertucci, JR (reprint author), Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Lab Doencas Infecciosas & Parasitarias, Belo Horizonte, MG, Brazil. EM jrlambertu@gmail.com; annamae.diehl@duke.edu FU National Institutes of Health [R01-DK-077794]; National Institutes of Health (Division of Intramural Research, NIAID, NIH); Duke University; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Ministry of Science, Technology and Innovation of Brazil (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) FX This work was supported by National Institutes of Health (grant number R01-DK-077794 (to AMD); Division of Intramural Research, NIAID, NIH (to TAP)); the Duke University Endowment (the Florence McAlister Professorship) (to AMD), the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Ministry of Science, Technology and Innovation of Brazil (CNPq) (to TAP, FELP, JRL and ZAA); and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) (to JRL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005057 DI 10.1371/journal.pntd.0005057 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200038 PM 27755536 ER PT J AU Tomashek, KM Rivera, A Torres-Velasquez, B Hunsperger, EA Munoz-Jordan, JL Sharp, TM Rivera, I Sanabria, D Blau, DM Galloway, R Torres, J Rodriguez, R Serrano, J Chavez, C Davila, F Perez-Padilla, J Ellis, EM Caballero, G Wright, L Zaki, SR Deseda, C Rodriguez, E Margolis, HS AF Tomashek, Kay M. Rivera, Aidsa Torres-Velasquez, Brenda Hunsperger, Elizabeth A. Munoz-Jordan, Jorge L. Sharp, Tyler M. Rivera, Irma Sanabria, Dario Blau, Dianna M. Galloway, Renee Torres, Jose Rodriguez, Rosa Serrano, Javier Chavez, Carlos Davila, Francisco Perez-Padilla, Janice Ellis, Esther M. Caballero, Gladys Wright, Laura Zaki, Sherif R. Deseda, Carmen Rodriguez, Edda Margolis, Harold S. TI Enhanced Surveillance for Fatal Dengue-Like Acute Febrile Illness in Puerto Rico, 2010-2012 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; CONSENSUS CONFERENCE; HEMORRHAGIC-FEVER; CASE-MANAGEMENT; SHOCK SYNDROME; PCR ASSAY; RT-PCR; DIAGNOSIS; VIRUS; EPIDEMIC AB Background Dengue is a leading cause of morbidity throughout the tropics; however, accurate population- based estimates of mortality rates are not available. Methods/Principal Findings We established the Enhanced Fatal Acute Febrile Illness Surveillance System (EFASS) to estimate dengue mortality rates in Puerto Rico. Healthcare professionals submitted serum and tissue specimens from patients who died from a dengue-like acute febrile illness, and death certificates were reviewed to identify additional cases. Specimens were tested for markers of dengue virus (DENV) infection by molecular, immunologic, and immunohistochemical methods, and were also tested for West Nile virus, Leptospira spp., and other pathogens based on histopathologic findings. Medical records were reviewed and clinical data abstracted. A total of 311 deaths were identified, of which 58 (19%) were DENV laboratory-positive. Dengue mortality rates were 1.05 per 100,000 population in 2010, 0.16 in 2011 and 0.36 in 2012. Dengue mortality was highest among adults 19-64 years and seniors >= 65 years (1.17 and 1.66 deaths per 100,000, respectively). Other pathogens identified included 34 Leptospira spp. cases and one case of Burkholderia pseudomallei and Neisseria meningitidis. Conclusions/Significance EFASS showed that dengue mortality rates among adults were higher than reported for influenza, and identified a leptospirosis outbreak and index cases of melioidosis and meningitis. C1 [Tomashek, Kay M.; Rivera, Aidsa; Torres-Velasquez, Brenda; Hunsperger, Elizabeth A.; Munoz-Jordan, Jorge L.; Sharp, Tyler M.; Perez-Padilla, Janice; Ellis, Esther M.; Margolis, Harold S.] Ctr Dis Control & Prevent CDC, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA. [Rivera, Irma; Sanabria, Dario; Torres, Jose; Rodriguez, Rosa; Serrano, Javier; Chavez, Carlos; Davila, Francisco; Rodriguez, Edda] Puerto Rico Inst Forens Sci, San Juan, PR USA. [Blau, Dianna M.; Zaki, Sherif R.] CDC, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Galloway, Renee] CDC, Bacterial Special Pathogens Branch, Div High Consequence Pathogens, Atlanta, GA 30333 USA. [Caballero, Gladys] Demog Registry Puerto Rico, San Juan, PR USA. [Wright, Laura] ATSDR, Geospatial Res Anal & Serv Program, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. [Deseda, Carmen] Puerto Rico Dept Hlth, San Juan, PR USA. [Tomashek, Kay M.] NIAID, Off Clin Res Resources, Div Microbiol & Infect Dis, NIH, Rockville, MD USA. RP Tomashek, KM (reprint author), Ctr Dis Control & Prevent CDC, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA.; Tomashek, KM (reprint author), NIAID, Off Clin Res Resources, Div Microbiol & Infect Dis, NIH, Rockville, MD USA. EM kay.tomashek@nih.gov FU CDC Dengue Branch programmatic FX The authors received CDC Dengue Branch programmatic funding for this project. No additional sources of funding were received. The funders had no role in the system design, data collection and analysis, decision to publish or preparation of the manuscript. NR 61 TC 0 Z9 0 U1 3 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2016 VL 10 IS 10 AR e0005025 DI 10.1371/journal.pntd.0005025 PG 19 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EA5QH UT WOS:000386676200018 PM 27727271 ER PT J AU Meacham, E Orem, J Nakigudde, G Zujewski, JA Rao, D AF Meacham, Elizabeth Orem, Jackson Nakigudde, Gertrude Zujewski, Jo Anne Rao, Deepa TI Exploring stigma as a barrier to cancer service engagement with breast cancer survivors in Kampala, Uganda SO PSYCHO-ONCOLOGY LA English DT Article DE cancer; oncology; qualitative; stigma; Uganda AB ObjectiveTo understand the role of stigma in the delay of cancer service engagement by women with breast cancer in Kampala, Uganda. BackgroundWomen in Sub-Saharan African countries are twice as likely to die from cancer as women in high-income countries, which is largely attributable to late diagnosis. While breast cancer-related stigma has been identified in Sub-Saharan Africa, limited research focuses on how stigma impacts the behavior of breast cancer patients in Uganda. MethodsThis qualitative study used a grounded theory approach to examine illness narratives from 20 breast cancer survivors in Uganda, gathered through semistructured interviews. ResultsThematic analysis showed that perceived and internalized stigma associated with breast cancer influenced care engagement throughout illness, delaying engagement and inhibiting treatment completion. Women identified key factors for overcoming stigma including acceptance of diagnosis, social support, and understanding of breast cancer. ConclusionThe growing burden of mortality associated with breast cancer in Uganda can be mitigated by improving early detection and treatment engagement through interventions which account for key psychosocial barriers such as stigma. C1 [Meacham, Elizabeth] Univ Washington, Dept Global Hlth, Seattle, WA USA. [Orem, Jackson] Uganda Canc Inst, Kampala, Uganda. [Nakigudde, Gertrude] Uganda Womens Canc Support Org UWOCASO, Kampala, Uganda. [Zujewski, Jo Anne] NCI, Rockville, MD USA. [Rao, Deepa] Univ Washington, Dept Global Hlth, Dept Psychiat & Behav Sci, Seattle, WA USA. RP Meacham, E (reprint author), Univ Washington, Dept Global Hlth, Seattle, WA USA. EM elizabeth.meacham@gmail.com FU National Cancer Institute - Center for Global Health FX We are indebted to all of the breast cancer survivors in Uganda who were willing to share their illness experiences. This project was funded through a contract from the National Cancer Institute - Center for Global Health. NR 13 TC 1 Z9 1 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD OCT PY 2016 VL 25 IS 10 SI SI BP 1206 EP 1211 DI 10.1002/pon.4215 PG 6 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA DZ3CA UT WOS:000385720300011 PM 27421234 ER PT J AU Blair, KS Otero, M Teng, C Geraci, M Lewis, E Hollon, N Blair, RJR Ernst, M Grillon, C Pine, DS AF Blair, K. S. Otero, M. Teng, C. Geraci, M. Lewis, E. Hollon, N. Blair, R. J. R. Ernst, Monique Grillon, C. Pine, D. S. TI Learning from other people's fear: amygdala-based social reference learning in social anxiety disorder SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Amygdala; emotions; imaging; medial prefrontal cortex; social anxiety ID EMOTIONAL EXPRESSIONS; FACIAL EXPRESSIONS; FRONTAL-CORTEX; PHOBIA; FACES; BRAIN; ACTIVATION; ANGRY; SELF; MECHANISMS AB Background Social anxiety disorder involves fear of social objects or situations. Social referencing may play an important role in the acquisition of this fear and could be a key determinant in future biomarkers and treatment pathways. However, the neural underpinnings mediating such learning in social anxiety are unknown. Using event-related functional magnetic resonance imaging, we examined social reference learning in social anxiety disorder. Specifically, would patients with the disorder show increased amygdala activity during social reference learning, and further, following social reference learning, show particularly increased response to objects associated with other people's negative reactions? Method A total of 32 unmedicated patients with social anxiety disorder and 22 age-, intelligence quotient- and gender-matched healthy individuals responded to objects that had become associated with others' fearful, angry, happy or neutral reactions. Results During the social reference learning phase, a significant group x social context interaction revealed that, relative to the comparison group, the social anxiety group showed a significantly greater response in the amygdala, as well as rostral, dorsomedial and lateral frontal and parietal cortices during the social, relative to non-social, referencing trials. In addition, during the object test phase, relative to the comparison group, the social anxiety group showed increased bilateral amygdala activation to objects associated with others' fearful reactions, and a trend towards decreased amygdala activation to objects associated with others' happy and neutral reactions. Conclusions These results suggest perturbed observational learning in social anxiety disorder. In addition, they further implicate the amygdala and dorsomedial prefrontal cortex in the disorder, and underscore their importance in future biomarker developments. C1 [Blair, K. S.; Otero, M.; Teng, C.; Geraci, M.; Lewis, E.; Hollon, N.; Blair, R. J. R.; Ernst, Monique; Grillon, C.; Pine, D. S.] NIMH, Dept Hlth & Human Serv, NIH, 15K North Dr,Room 115A,MSC 2670, Bethesda, MD 20892 USA. RP Blair, KS (reprint author), NIMH, Dept Hlth & Human Serv, NIH, 15K North Dr,Room 115A,MSC 2670, Bethesda, MD 20892 USA. EM peschark@mail.nih.gov FU National Institutes of Health, National Institute of Mental Health FX This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Mental Health. The authors have no financial disclosures to report. Further, the authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. NR 35 TC 0 Z9 0 U1 4 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD OCT PY 2016 VL 46 IS 14 BP 2943 EP 2953 DI 10.1017/S0033291716001537 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA EA5DN UT WOS:000386639700006 PM 27476529 ER PT J AU Carlson, BA Tobe, R Yefremova, E Tsuji, PA Hoffmann, VJ Schweizer, U Gladyshev, VN Hatfield, DL Conrad, M AF Carlson, Bradley A. Tobe, Ryuta Yefremova, Elena Tsuji, Petra A. Hoffmann, Victoria J. Schweizer, Ulrich Gladyshev, Vadim N. Hatfield, Dolph L. Conrad, Marcus TI Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration SO REDOX BIOLOGY LA English DT Article DE Selenoprotein; Ferroptosis; Lipid peroxidation ID THIOREDOXIN REDUCTASE; CELL-DEATH; TARGETED DISRUPTION; EMBRYONIC LETHALITY; MOUSE DEVELOPMENT; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; GENE-EXPRESSION; UGA CODONS; SELENOCYSTEINE AB The selenoenzyme glutathione peroxidase 4 (Gpx4) is an essential mammalian glutathione peroxidase, which protects cells against detrimental lipid peroxidation and governs a novel form of regulated necrotic cell death, called ferroptosis. To study the relevance of Gpx4 and of another vitally important selenoprotein, cytosolic thioredoxin reductase (Txnrd1), for liver function, mice with conditional deletion of Gpx4 in hepatocytes were studied, along with those lacking Txnrd1 and selenocysteine (Sec) tRNA (Trsp) in hepatocytes. Unlike Txnrd1- and Trsp-deficient mice, Gpx4(-/-) mice died shortly after birth and presented extensive hepatocyte degeneration. Similar to Txnrd1-deficient livers, Gpx4(-/-) livers manifested upregulation of nuclear factor (erythroid-derived)-like 2 (Nrf2) response genes. Remarkably, Gpx4(-/-) pups born from mothers fed a vitamin E-enriched diet survived, yet this protection was reversible as subsequent vitamin E deprivation caused death of Gpx4-deficient mice similar to 4 weeks thereafter. Abrogation of selenoprotein expression in Gpx4(-/-) mice did not result in viable mice, indicating that the combined deficiency aggravated the loss of Gpx4 in liver. By contrast, combined Trsp/Txnrd1-deficient mice were born, but had significantly shorter lifespans than either single knockout, suggesting that Txnrd1 plays an important role in supporting liver function of mice lacking Trsp. In sum our study demonstrates that the ferroptosis regulator Gpx4 is critical for hepatocyte survival and proper liver function, and that vitamin E can compensate for its loss by protecting cells against deleterious lipid peroxidation. Published by Elsevier B.V. C1 [Carlson, Bradley A.; Tobe, Ryuta; Hatfield, Dolph L.] NCI, Mol Biol Selenium Sect, Mouse Canc Genet Program, NIH, 37 Convent Dr,Bldg 37,Room 5016, Bethesda, MD 20892 USA. [Yefremova, Elena; Conrad, Marcus] Helmholtz Zentrum Munchen, Inst Dev Genet, Neuherberg, Germany. [Tsuji, Petra A.] Towson Univ, Dept Biol Sci, Towson, MD USA. [Hoffmann, Victoria J.] NIH, Off Director Diagnost & Res Serv Branch, Bldg 10, Bethesda, MD 20892 USA. [Schweizer, Ulrich] Univ Bonn, Inst Biochem & Mol Biol, Bonn, Germany. [Gladyshev, Vadim N.] Harvard Med Sch, Dept Med, Div Genet, Brigham & Womens Hosp, Boston, MA USA. RP Hatfield, DL (reprint author), NCI, Mol Biol Selenium Sect, Mouse Canc Genet Program, NIH, 37 Convent Dr,Bldg 37,Room 5016, Bethesda, MD 20892 USA.; Conrad, M (reprint author), Helmholtz Zentrum Munchen, Inst Dev Genet, Neuherberg, Germany. EM hatfield@mail.nih.gov; marcus.conrad@helmholtz-muenchen.de OI Conrad, Marcus/0000-0003-1140-5612; Schweizer, Ulrich/0000-0003-1380-4780 FU Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research; Deutsche Forschungsgemeinschaft [CO 291/2-3, CO 291/5-1]; Human Frontier Science Program [RGP0013/14] FX We are grateful to Jose Pedro Friedmann Angeli for critical reading of the manuscript. DLH was funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. MC received funding from the Deutsche Forschungsgemeinschaft (CO 291/2-3; CO 291/5-1) and the Human Frontier Science Program (RGP0013/14). NR 39 TC 6 Z9 6 U1 10 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD OCT PY 2016 VL 9 BP 22 EP 31 DI 10.1016/j.redox.2016.05.003 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EA6RQ UT WOS:000386757000003 PM 27262435 ER PT J AU Childs, R Blaise, D AF Childs, Richard Blaise, Didier TI Alternative Donor Allogeneic Transplants: Introduction SO SEMINARS IN HEMATOLOGY LA English DT Editorial Material C1 [Childs, Richard] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Blaise, Didier] Ctr Rech Cancerol Marseille, Marseille, France. RP Childs, R (reprint author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. EM childsr@nhlbi.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0037-1963 EI 1532-8686 J9 SEMIN HEMATOL JI Semin. Hematol. PD OCT PY 2016 VL 53 IS 4 BP 219 EP 220 DI 10.1053/j.seminhematol.2016.08.003 PG 2 WC Hematology SC Hematology GA EB1FL UT WOS:000387094900001 PM 27788758 ER PT J AU van Besien, K Childs, R AF van Besien, Koen Childs, Richard TI Haploidentical cord transplantation-The best of both worlds SO SEMINARS IN HEMATOLOGY LA English DT Article DE Alternative donor transplant; Umbilical cord blood; Third-party progenitors ID HEMATOPOIETIC-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; ALTERNATIVE DONOR TRANSPLANTATION; RELAPSE-FREE SURVIVAL; HOST DISEASE-FREE; BLOOD TRANSPLANTATION; BONE-MARROW; OUTCOMES; UNIT; ENGRAFTMENT AB Haploidentical (haplo)-cord transplantation combines infusion of an umbilical cord blood (UCB) unit with CD34-selected cells usually from human leukocyte antigen (HLA) mismatched donors. Initial rapid count recovery from the haplo-hematopoietic progenitors, is gradually replaced by durable engraftment from UCB progenitors. UCB grafts used for haplo-cord are smaller, but better matched than those required for single or double UCB stem cell transplant (SCT). More than 200 patients with hematological malignancies have been transplanted. Median age was 54 years (range 17-74) and 77 were over age 60. One-year survival was 64% for patients with intermediate- and low-risk disease, with no deaths beyond 2 years. In high-risk disease, 1-year survival was 44%. In a comparison with patients undergoing double UCB SCT, haplo-cord transplant resulted in faster hematopoietic recovery, lower rates of acute and chronic graft-versus-host disease (GVHD), lower rates of disease recurrence, and improved GVHD- and relapse-free survival (GRFS). Excellent results were also reported for patients with aplastic anemia where 18 of 21 patients had sustained cord blood engraftment. Rates of GVHD and of disease recurrence after haplo-cord are encouraging. However, in the approximately 10% of patients with failure of the UCB graft disease recurrence is high, supporting the important role of UCB-mediated graft-versus-leukemia (GVL). Ongoing efforts are aimed at identifying determinants of UCB engraftment, at reducing rates of disease recurrence in high risk patients and at optimizing dose and schedule of ATG -necessary to avoid early haplo-graft rejection, but also contributing to early post-transplant immunocompromise. For those lacking haploidentical donors, unrelated donors have been successfully utilized. (C) 2016 Elsevier Inc. All rights reserved. C1 [van Besien, Koen] Weill Cornell Med, Div Hematol Oncol, 520 E 70th St, New York, NY 10021 USA. [Childs, Richard] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. RP van Besien, K (reprint author), Weill Cornell Med, Div Hematol Oncol, 520 E 70th St, New York, NY 10021 USA. EM kov9001@med.cornell.edu FU Miltenyi Biotec (Germany) FX Dr. van Besien's research was supported by an unrestricted grant from Miltenyi Biotec (Germany). NR 38 TC 1 Z9 1 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0037-1963 EI 1532-8686 J9 SEMIN HEMATOL JI Semin. Hematol. PD OCT PY 2016 VL 53 IS 4 BP 257 EP 266 DI 10.1053/j.seminhematol.2016.07.004 PG 10 WC Hematology SC Hematology GA EB1FL UT WOS:000387094900007 PM 27788764 ER PT J AU Truog, WE Higgins, RD AF Truog, William E. Higgins, Rosemary D. TI The Neonatal Research Network Introduction SO SEMINARS IN PERINATOLOGY LA English DT Editorial Material C1 [Truog, William E.] Univ Missouri, Sch Med, Childrens Mercy Hosp, Kansas City, MO 64108 USA. [Higgins, Rosemary D.] Eunice Kennedy Shriner Natl Inst Child Hlth, Human Dev, NIH, Bethesda, MD USA. RP Truog, WE (reprint author), Univ Missouri, Sch Med, Childrens Mercy Hosp, Kansas City, MO 64108 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0146-0005 EI 1558-075X J9 SEMIN PERINATOL JI Semin. Perinatol. PD OCT PY 2016 VL 40 IS 6 BP 335 EP 336 DI 10.1053/j.semperi.2016.05.001 PG 2 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA EA3XX UT WOS:000386543700001 PM 27344191 ER PT J AU Higgins, RD Shankaran, S AF Higgins, Rosemary D. Shankaran, Seetha TI The Neonatal Research Network: History since 2003, future directions and challenges SO SEMINARS IN PERINATOLOGY LA English DT Review DE Neonatal; Research; Infant; Trial; Study ID EXTREMELY PRETERM INFANTS; NEURODEVELOPMENTAL OUTCOMES; EARLY CPAP; ENCEPHALOPATHY; HYPOTHERMIA; MORTALITY; DISEASE; GROWTH; AGE AB The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neontal Research Network (NRN) was established in 1986 in response to the need for rigorous studies to guide care and management of sick and premature newborns. The network is comprise of clinical centers that perform clinical protocols to investigate the safety and efficay of treatment and management strategies for newborn infants as well as a data cordinating center. Infrastructure is set up for observational and interventional studies as well as neurodevelopmental follow-up of patients. The network has conducted trials and observational studies on major neonatal problems including pulmonary disease, neuroprotection, sepsis and infection, necrotizing enterocolitis, vaccine administration to preterm infants, retinopathy of prematurity, cardiovascular issues including blood pressure, human milk, growth and nutrition, hematologic issues, resuscitation, pulmonary hypertension, and neurodevelopmental outcome. This mechanism of clinical research for newborns has led to changes in care practices leading to improved outcomes for high-risk infants. Published by Elsevier Inc. C1 [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pregnancy & Perinatol Branch, NIH, 6710B Rockledge Dr,Room 2233,MSC 7002, Bethesda, MD 20892 USA. [Shankaran, Seetha] Wayne State Univ, Sch Med, Dept Pediat, Div Neonatal Perinatal Med, Detroit, MI 48201 USA. RP Higgins, RD (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pregnancy & Perinatol Branch, NIH, 6710B Rockledge Dr,Room 2233,MSC 7002, Bethesda, MD 20892 USA. EM higginsr@mail.nih.gov FU Intramural NIH HHS [Z99 HD999999]; NICHD NIH HHS [U10 HD021385, UG1 HD027853] NR 18 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0146-0005 EI 1558-075X J9 SEMIN PERINATOL JI Semin. Perinatol. PD OCT PY 2016 VL 40 IS 6 BP 337 EP 340 DI 10.1053/j.semperi.2016.05.002 PG 4 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA EA3XX UT WOS:000386543700002 PM 27371959 ER PT J AU Das, A Tyson, J Pedroza, C Schmidt, B Gantz, M Wallace, D Truog, WE Higgins, RD AF Das, Abhik Tyson, Jon Pedroza, Claudia Schmidt, Barbara Gantz, Marie Wallace, Dennis Truog, William E. Higgins, Rosemary D. TI Methodological issues in the design and analyses of neonatal research studies: Experience of the NICHD Neonatal Research Network SO SEMINARS IN PERINATOLOGY LA English DT Review DE Statistical methodology; Trial design; Competing outcomes; Randomization of multiples; Causal inference ID LOW-BIRTH-WEIGHT; EXTREMELY PRETERM INFANTS; CLUSTER-RANDOMIZED-TRIAL; SEMICOMPETING RISKS DATA; WEEKS GESTATIONAL-AGE; CLINICAL-TRIALS; MULTIPLE BIRTHS; NEURODEVELOPMENTAL OUTCOMES; BRONCHOPULMONARY DYSPLASIA; PROPENSITY SCORE AB Impressive advances in neonatology have occurred over the 30 years of life of The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN). However, substantial room for improvement remains in investigating and further developing the evidence base for improving outcomes among the extremely premature. We discuss some of the specific methodological challenges in the statistical design and analysis of randomized trials and observational studies in this population. Challenges faced by the NRN include designing trials for unusual or rare outcomes, accounting for and explaining center variations, identifying other subgroup differences, and balancing safety and efficacy concerns between short-term hospital outcomes and longer-term neurodevelopmental outcomes. In conclusion, the constellation of unique patient characteristics in neonates calls for broad understanding and careful consideration of the issues identified in this article for conducting rigorous studies in this population. (C) 2016 Elsevier Inc. All rights reserved. C1 [Das, Abhik] RTI Int, Biostat & Epidemiol Div, 6110 Execut Blvd,Suite 902, Rockville, MD 20852 USA. [Tyson, Jon; Pedroza, Claudia] Univ Texas Hlth Sci Ctr Houston, Ctr Clin Res & Evidence Based Med, Houston, TX 77030 USA. [Schmidt, Barbara] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA. [Gantz, Marie; Wallace, Dennis] RTI Int, Biostat & Epidemiol Div, Res Triangle Pk, NC USA. [Truog, William E.] Univ Missouri, Sch Med, Childrens Mercy Hosp & Clin, Kansas City, MO 64108 USA. [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Hlth & Human Dev, Pregnancy & Perinatol Branch, NIH, Bethesda, MD USA. RP Das, A (reprint author), RTI Int, Biostat & Epidemiol Div, 6110 Execut Blvd,Suite 902, Rockville, MD 20852 USA. EM adas@rti.org FU NICHD NIH HHS [U10 HD021373, UG1 HD027853, U10 HD036790, UG1 HD068244, UG1 HD068284, UG1 HD087229] NR 80 TC 1 Z9 1 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0146-0005 EI 1558-075X J9 SEMIN PERINATOL JI Semin. Perinatol. PD OCT PY 2016 VL 40 IS 6 BP 374 EP 384 DI 10.1053/j.semperi.2016.05.005 PG 11 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA EA3XX UT WOS:000386543700007 PM 27344192 ER PT J AU Archer, SW Carlo, WA Truog, WE Stevenson, DK Van Meurs, KP Sanchez, PJ Das, A Devaskar, U Nelin, LD Huitema, CMP Crawford, MM Higgins, RD AF Archer, Stephanie Wilson Carlo, Waldemar A. Truog, William E. Stevenson, David K. Van Meurs, Krisa P. Sanchez, Pablo J. Das, Abhik Devaskar, Uday Nelin, Leif D. Huitema, Carolyn M. Petrie Crawford, Margaret M. Higgins, Rosemary D. CA Eunice Kennedy Shriver Natl Inst TI Improving publication rates in a collaborative clinical trials research network SO SEMINARS IN PERINATOLOGY LA English DT Review DE Publication rates; Network collaboration; Authorship policies AB Unpublished results can bias biomedical literature, favoring positive over negative findings, primary over secondary analyses, and can lead to duplicate studies that unnecessarily endanger subjects and waste resources. The Neonatal Research Network's (NRN) publication policies for approving, reviewing, and tracking abstracts and papers work to combat these problems. In 2003, the NRN restricted investigators with unfinished manuscripts from proposing new ones and in 2010, urged authors to complete long-outstanding manuscripts. Data from 1991 to 2015 were analyzed to determine effectiveness of these policy changes. The NRN has achieved an overall publication rate of 78% for abstracts. For 1990-2002, of 137 abstracts presented, 43 (31%) were published within 2 years; for 2003-2009, after the manuscript completion policy was instituted, of 140 abstracts presented, 68 (49%) were published within 2 years. Following the effort in 2010, the rate increased to 64%. The NRN surpassed reported rates by developing a comprehensive process, holding investigators accountable and tracking abstracts from presentation to publication. (C) 2016 Published by Elsevier Inc. C1 [Archer, Stephanie Wilson; Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, NICHD Pregnancy & Perinatol Branch, 6710B Rockledge Dr,2321B, Bethesda, MD 20817 USA. [Carlo, Waldemar A.] Univ Alabama Birmingham, Div Neonatol, Birmingham, AL USA. [Truog, William E.] Univ Missouri, Sch Med, Dept Pediat, Childrens Mercy Hosp, Kansas City, MO 64108 USA. [Stevenson, David K.; Van Meurs, Krisa P.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA. [Stevenson, David K.; Van Meurs, Krisa P.] Lucile Packard Childrens Hosp, Palo Alto, CA USA. [Sanchez, Pablo J.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA. [Sanchez, Pablo J.; Nelin, Leif D.] Nationwide Childrens Hosp, Div Neonatol, Columbus, OH USA. [Das, Abhik; Huitema, Carolyn M. Petrie; Crawford, Margaret M.] RTI Int, Social Stat & Environm Sci Unit, Rockville, MD USA. [Devaskar, Uday] Univ Calif Los Angeles, David Geffen Sch Med, Div Neonatol & Dev Biol, Los Angeles, CA 90095 USA. RP Archer, SW (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, NICHD Pregnancy & Perinatol Branch, 6710B Rockledge Dr,2321B, Bethesda, MD 20817 USA. EM archerst@mail.nih.gov FU National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources; National Center for Advancing Translational Sciences FX The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Center for Research Resources, and the National Center for Advancing Translational Sciences provided grant support for the Neonatal Research Network. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 9 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0146-0005 EI 1558-075X J9 SEMIN PERINATOL JI Semin. Perinatol. PD OCT PY 2016 VL 40 IS 6 BP 410 EP 417 DI 10.1053/j.semperi.2016.05.003 PG 8 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA EA3XX UT WOS:000386543700011 PM 27423510 ER PT J AU Ginexi, EM Vollinger, RE AF Ginexi, Elizabeth M. Vollinger, Robert E., Jr. TI National Cancer Institute's leadership role in promoting State and Community Tobacco Control research SO TOBACCO CONTROL LA English DT Editorial Material DE Environment; Media; Prevention; Public policy; Secondhand smoke ID UNITED-STATES; SMOKING; DISPARITIES; ADULTS; US AB The National Cancer Institute (NCI) has been at the vanguard of funding tobacco control research for decades with major efforts such as the Community Intervention Trial for Smoking Cessation (COMMIT) in 1988 and the American Stop Smoking Intervention Study (ASSIST) in 1991, followed by the Tobacco Research Initiative for State and Community Interventions in 1999. Most recently, in 2011, the NCI launched the State and Community Tobacco Control (SCTC) Research Initiative to address gaps in secondhand smoke policies, tax and pricing policies, mass media countermeasures, community and social norms and tobacco marketing. The initiative supported large scale research projects and time-sensitive ancillary pilot studies in response to expressed needs of state and community partners. This special issue of Tobacco Control showcases exciting findings from the SCTC. In this introductory article, we provide a brief account of NCI's historical commitment to promoting research to inform tobacco control policy. C1 [Ginexi, Elizabeth M.; Vollinger, Robert E., Jr.] NCI, Tobacco Control Res Branch, 9609 Med Ctr Dr,Room 3E564,MSC 9761, Bethesda, MD 20892 USA. RP Ginexi, EM (reprint author), NCI, Tobacco Control Res Branch, 9609 Med Ctr Dr,Room 3E564,MSC 9761, Bethesda, MD 20892 USA. EM LGinexi@mail.nih.gov NR 21 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 EI 1468-3318 J9 TOB CONTROL JI Tob. Control PD OCT PY 2016 VL 25 SU 1 BP i4 EP i5 DI 10.1136/tobaccocontrol-2016-053153 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA2ZF UT WOS:000386465600002 PM 27697941 ER PT J AU Williams, B Mirmonsef, P Boucher, CA Bushman, F Carrington-Lawrence, S Collman, RG Dandekar, S Dang, Q Malaspina, A Paredes, R Stone, A Landay, A AF Williams, Brett Mirmonsef, Paria Boucher, Charles A. B. Bushman, Frederic Carrington-Lawrence, Stacy Collman, Ronald G. Dandekar, Satya Que Dang Malaspina, Angela Paredes, Roger Stone, Arthur Landay, Alan TI A Summary of the First HIV Microbiome Workshop 2015 SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article DE HIV; microbiome; immune activation; microbial translocation ID IMMUNODEFICIENCY-VIRUS-INFECTION; EPITHELIAL BARRIER DYSFUNCTION; SYSTEMIC IMMUNE ACTIVATION; TRIMETHYLAMINE-N-OXIDE; BACTERIAL VAGINOSIS; GUT MICROBIOTA; VAGINAL MICROBIOTA; GENITAL-TRACT; T-CELLS; MUCOSAL AB The role of microbiota in the pathogenesis of HIV infection has become the subject of intense research in recent years. A rapidly growing amount of data suggest that microbial dysbiosisin the gut or the genital tractcan influence HIV transmission and/or disease progression; however, a deeper understanding of the mechanisms involved is lacking. To better understand the relationship between the microbiome and HIV infection, investigators from a wide variety of disciplines, including those working in basic and clinical HIV studies, cardiovascular disease, reproductive health, and bioinformatics, gathered at the first International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment, at NIH on 7 and 8 April, 2015. C1 [Williams, Brett] Rush Univ, Med Ctr, Div Infect Dis, 600 South Paulina Suite 143, Chicago, IL 60612 USA. [Mirmonsef, Paria; Landay, Alan] Rush Univ, Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA. [Boucher, Charles A. B.] Erasmus Univ, Dept Virosci, Erasmus Med Ctr, Rotterdam, Netherlands. [Bushman, Frederic] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Carrington-Lawrence, Stacy] US Natl Inst Hlth, Off AIDS Res, Div Program Coordinat Planning & Strateg Initiat, Off Director,US Dept Hlth & Human Serv, Philadelphia, PA USA. [Collman, Ronald G.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Dandekar, Satya] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA. [Que Dang; Malaspina, Angela] NIAID, Vaccine Res Program, Div AIDS, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Paredes, Roger] Univ Vic, Univ Autonoma Barcelona, Inst Recerca, SIDA IrsiCaixa, Catalonia, Spain. [Paredes, Roger] Univ Vic, Univ Autonoma Barcelona, Unitat VIH, Catalonia, Spain. [Stone, Arthur] NIAID, HJF DAIDS, NIH, DHHS, Bethesda, MD USA. RP Williams, B (reprint author), Rush Univ, Med Ctr, Div Infect Dis, 600 South Paulina Suite 143, Chicago, IL 60612 USA. EM brett_williams@rush.edu FU NHLBI NIH HHS [R01 HL113252, U01 HL098957, U01 HL112712]; NIAID NIH HHS [P30 AI045008]; NIMH NIH HHS [R01 MH061139] NR 56 TC 0 Z9 0 U1 2 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT-NOV PY 2016 VL 32 IS 10-11 BP 935 EP 941 DI 10.1089/aid.2016.0034 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DZ9RL UT WOS:000386216200001 PM 27267576 ER PT J AU Porter, KA Turpin, J Begg, L Brown, G Chakhtoura, N Church, E Grossman, C Wira, C Veronese, F AF Porter, Kristen A. Turpin, Jim Begg, Lisa Brown, Gina Chakhtoura, Nahida Church, Elizabeth Grossman, Cynthia Wira, Charles Veronese, Fulvia TI Understanding the Intersection of Young Age, Mucosal Injury, and HIV Susceptibility SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Review DE HIV; HIV; AIDS pathogenesis; HIV transmission; HIV prevention; mucosal ID INTIMATE PARTNER VIOLENCE; FEMALE REPRODUCTIVE-TRACT; GENITOANAL INJURY; MENSTRUAL-CYCLE; VAGINAL TRANSMISSION; SEXUAL VIOLENCE; WOMEN; ADOLESCENT; RISK; METAANALYSIS AB Adolescent boys and girls are disproportionately affected in the current HIV epidemic. Numerous sociobehavioral studies have addressed the indirect drivers surrounding this vulnerabilityfor example, socioeconomic, geographical locale, and all forms of violence. However, the direct factors that may influence infection, such as the anatomical and physiological maturation of the anogenital tracts of adolescents or the trauma and wound-healing processes of injured mucosal tissue, are understudied and represent a gap within the HIV prevention field. This article reviews the epidemiology of HIV infection and violence in adolescents and the available basic science knowledge attending this research area. More importantly, this review highlights the most critical gaps that need to be addressed to design preventive interventions that are safe and effective for this population, which is key to ending the HIV pandemic. C1 [Porter, Kristen A.; Turpin, Jim; Church, Elizabeth; Veronese, Fulvia] NIAID, Div Aids, NIH, Room 8B53,MSC9831,5601 Fishers Lane, Bethesda, MD 20852 USA. [Begg, Lisa] NIH, Off Res Womens Hlth, Bldg 10, Bethesda, MD 20892 USA. [Brown, Gina] NIH, Off AIDS Res, Bldg 10, Bethesda, MD 20892 USA. [Chakhtoura, Nahida] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. [Grossman, Cynthia] NIMH, Div AIDS Res, NIH, Rockville, MD 20857 USA. [Wira, Charles] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA. [Porter, Kristen A.] Westfield State Univ, Dept Biol, Westfield, MA USA. [Grossman, Cynthia] FasterCures, Washington, DC USA. RP Veronese, F (reprint author), NIAID, Div Aids, NIH, Room 8B53,MSC9831,5601 Fishers Lane, Bethesda, MD 20852 USA. EM fv10x@nih.gov FU NIAID NIH HHS [R01 AI117739] NR 52 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT-NOV PY 2016 VL 32 IS 10-11 BP 1149 EP 1158 DI 10.1089/aid.2016.0206 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DZ9RL UT WOS:000386216200026 PM 27726428 ER PT J AU Opitz, JM Biesecker, LG Hennekam, RC AF Opitz, John M. Biesecker, Leslie G. Hennekam, Raoul C. TI GAUDEAMUS IGITUR...In gratitude to John Carey for his stewardship of the American Journal of Medical Genetics 2001-2016 SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Editorial Material C1 [Opitz, John M.] Univ Utah, Sch Med, Dept Pediat Med Genet, Salt Lake City, UT USA. [Opitz, John M.] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA. [Opitz, John M.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA. [Opitz, John M.] Univ Utah, Sch Med, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA. [Biesecker, Leslie G.] NHGRI, NIH, Bethesda, MD 20892 USA. [Hennekam, Raoul C.] Acad Med Ctr, Dept Pediat, Amsterdam, Netherlands. RP Opitz, JM (reprint author), Univ Utah, Sch Med, Dept Pediat, Div Med Genet, 295 Chipeta Way, Salt Lake City, UT 84108 USA. EM john.opitz@hsc.utah.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD OCT PY 2016 VL 170 IS 10 SI SI BP 2501 EP 2502 DI 10.1002/ajmg.a.37760 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA DW4KQ UT WOS:000383612200003 PM 27540900 ER PT J AU Gripp, KW Baker, L Kandula, V Conard, K Scavina, M Napoli, JA Griffin, GC Thacker, M Knox, RG Clark, GR Parker, VER Semple, R Mirzaa, G Keppler-Noreuil, KM AF Gripp, Karen W. Baker, Laura Kandula, Vinay Conard, Katrina Scavina, Mena Napoli, Joseph A. Griffin, Gregory C. Thacker, Mihir Knox, Rachel G. Clark, Graeme R. Parker, Victoria E. R. Semple, Robert Mirzaa, Ghayda Keppler-Noreuil, Kim M. TI Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE Wilms tumor; nephroblastomatosis; PIK3CA-related overgrowth; hemihyperplasia; hemihypertrophy; CLOVES; lipoma; somatic mutation ID MARMORATA-TELANGIECTATICA-CONGENITA; PIK3CA-RELATED OVERGROWTH SPECTRUM; KLIPPEL-TRENAUNAY-SYNDROME; NEVI CLOVE-SYNDROME; VASCULAR MALFORMATIONS; LIPOMATOUS OVERGROWTH; ACTIVATING MUTATIONS; CHILDREN; RISK; HEMIHYPERTROPHY AB Wilms tumor and nephroblastomatosis are associated with syndromic conditions including hemihyperplasia. Hemihyperplasia is genetically heterogeneous and may be the result of genomic abnormalities seen in Beckwith-Wiedemann syndrome, mosaic chromosome or genomic abnormalities, or somatic point mutations. Somatic missense mutations affecting the PI3K-AKT-MTOR pathway result in segmental overgrowth and are present in numerous benign and malignant tumors. Here, we report a fourth patient with asymmetric overgrowth due to a somatic PIK3CA mutation who had nephroblastomatosis or Wilms tumor. Similar to two of three reported patients with a somatic PIK3CA mutation and renal tumors, he shared a PIK3CA mutation affecting codon 1047, presented at birth with asymmetric overgrowth, and had fibroadipose overgrowth. Codon 1047 is most commonly affected by somatic mutations in PIK3CA-related overgrowth spectrum (PROS). While the fibroadipose overgrowth phenotype appears to be common in individuals with PIK3CA mutations at codon 1047, individuals with a clinical diagnosis of Klippel-Trenaunay syndrome or isolated lymphatic malformation also had mutations affecting this amino acid. Screening for Wilms tumor in individuals with PROS-related hemihyperplasia may be considered and, until the natural history is fully elucidated in larger cohort studies, may follow guidelines for Beckwith-Wiedemann syndrome, or isolated hemihyperplasia. It is not known if the specific PIK3CA mutation, the mosaic distribution, or the clinical presentation affect the Wilms tumor or nephroblastomatosis risk in individuals with PROS. (c) 2016 Wiley Periodicals, Inc. C1 [Gripp, Karen W.; Baker, Laura; Kandula, Vinay; Conard, Katrina; Scavina, Mena; Napoli, Joseph A.; Griffin, Gregory C.; Thacker, Mihir] AI du Pont Hosp Children Nemours, Wilmington, DE 19803 USA. [Knox, Rachel G.; Clark, Graeme R.; Parker, Victoria E. R.; Semple, Robert] Univ Cambridge, Metab Res Labs, Inst Metab Sci, Cambridge, MA USA. [Mirzaa, Ghayda] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA USA. [Keppler-Noreuil, Kim M.] NHGRI, NIH, Bethesda, MD 20892 USA. RP Gripp, KW (reprint author), AI du Pont Hosp Children Nemours, Wilmington, DE 19803 USA. EM kgripp@nemours.org FU US National Institutes of Health under NINDS [K08NS092898]; Intramural Research Program of the National Human Genome Research Institute; Wellcome Trust [WT097721, WT098498]; Medical Research Council [MRC_MC_UU_12012/5]; United Kingdom National Institute for Health Research Rare Diseases Translational Research Collaboration FX Grant sponsor: US National Institutes of Health under NINDS; Grant number: K08NS092898; Grant sponsor: Intramural Research Program of the National Human Genome Research Institute; Grant sponsor: Wellcome Trust; Grant numbers: WT097721, WT098498; Grant sponsor: Medical Research Council; Grant number: MRC_MC_UU_12012/5; Grant sponsor: United Kingdom National Institute for Health Research Rare Diseases Translational Research Collaboration. NR 36 TC 2 Z9 2 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD OCT PY 2016 VL 170 IS 10 SI SI BP 2559 EP 2569 DI 10.1002/ajmg.a.37758 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA DW4KQ UT WOS:000383612200009 PM 27191687 ER PT J AU Keppler-Noreuil, KM Baker, EH Sapp, JC Lindhurst, MJ Biesecker, LG AF Keppler-Noreuil, Kim M. Baker, Eva H. Sapp, Julie C. Lindhurst, Marjorie J. Biesecker, Leslie G. TI Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE AKT1 mutations; cranial hyperostosis; hemimegalencephaly; meningiomas; Proteus syndrome ID PROTEUS-SYNDROME; MOLECULAR-GENETICS; DIAGNOSTIC-CRITERIA; EN PLAQUE; SECONDARY; SKULL; BASE AB Somatic genetic mutations in meningiomas are associated with histologic subtypes, anatomical location, and grade. Concomitant hyperostosis occurs with some meningiomas and the pathogenesis is not well understood. Cranial hyperostosis and meningiomas are common in patients with Proteus syndrome, which is caused by a somatic activating mutation in AKT1 c.49G>A. This same mutation has also been found in 6-9% of sporadic non-syndromic meningiomas. Sixty-one patients with Proteus syndrome meeting clinical diagnostic criteria were evaluated at the NIH from 1997 to 2014. Of these 61, 52 had a somatic activating mutation (c.49G>A, p.Glu17Lys) in AKT1 confirmed from affected tissue samples. Photographs, physical examination and/or autopsy, X-rays, CT, and/or MRI scan of the head were reviewed in 29/52 patients. Of the 29 patients, the most common intracranial tumor was meningioma, all co-localizing with cranial hyperostosis, and diagnosed at younger ages than typical for isolated, non-syndromic meningiomas. These patients had progressive cranial overgrowth that consisted primarily of diploic space expansion, and was characterized by unilateral, parasagittal, and frontal bone involvement. We hypothesize that sporadic meningothelial and transitional subtype meningiomas are a forme fruste or microform of Proteus syndrome, and activation of the AKT/PI3K pathway drives hyperostosis in both non-syndromic, and Proteus-related meningiomas. (c) 2016 The Authors. American Journal of Medical Genetics Part A Published by Wiley Periodicals, Inc. C1 [Keppler-Noreuil, Kim M.; Sapp, Julie C.; Lindhurst, Marjorie J.; Biesecker, Leslie G.] NHGRI, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA. [Baker, Eva H.] NIH, Dept Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA. RP Keppler-Noreuil, KM (reprint author), NHGRI, NIH, 49 Convent Dr,4A83, Bethesda, MD 20892 USA. EM kim.keppler-noreuil@nih.gov FU National Human Genome Research Institute FX Grant sponsor: National Human Genome Research Institute. NR 22 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD OCT PY 2016 VL 170 IS 10 SI SI BP 2605 EP 2610 DI 10.1002/ajmg.a.37737 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA DW4KQ UT WOS:000383612200017 PM 27550858 ER PT J AU AuYoung, M Linke, SE Pagoto, S Buman, MP Craft, LL Richardson, CR Hutber, A Marcus, BH Estabrooks, P Gorin, SS AF AuYoung, Mona Linke, Sarah E. Pagoto, Sherry Buman, Matthew P. Craft, Lynette L. Richardson, Caroline R. Hutber, Adrian Marcus, Bess H. Estabrooks, Paul Gorin, Sherri Sheinfeld TI Integrating Physical Activity in Primary Care Practice SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE Physical activity; Primary care; Socioecologic model ID HEALTH-CARE; ACTIVITY INTERVENTIONS; ACTIVITY PROMOTION; SOCIAL ECOLOGY; OBESITY PREVENTION; RANDOMIZED-TRIAL; ACTIVITY ADVICE; UNITED-STATES; WEIGHT-LOSS; EXERCISE AB Based on a collaborative symposium in 2014 hosted by the Society of Behavioral Medicine (SBM) and the American College of Sports Medicine (ACSM), this paper presents a model for physical activity counseling for primary care physicians (PCPs). Most US adults do not meet national recommendations for physical activity levels. Socioecological factors drive differences in physical activity levels by geography, sex, age, and racial/ethnic group. The recent Patient Protection and Affordable Care Act incentivizes PCPs to offer patients physical activity counseling. However, PCPs have reported socioecological barriers to physical activity counseling and also patient barriers to physical activity, spanning from the individual to the environmental (eg, lack of safe spaces for physical activity), policy (eg, reimbursement policies), and organizational (eg, electronic medical record protocols, worksite norms/policies) levels. The aims of this paper are to: 1) discuss barriers to PCP counseling for physical activity; 2) provide evidence-based strategies and techniques to help PCPs address these counseling barriers; and 3) suggest practical steps for PCPs to counsel patients on physical activity using strategies and supports from policy, the primary care team, and other support networks. (C) 2016 Elsevier Inc. All rights reserved. C1 [AuYoung, Mona] Ann Arbor VA Ctr Clin Management Res, Ann Arbor, MI USA. [Linke, Sarah E.; Marcus, Bess H.] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA. [Pagoto, Sherry] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Buman, Matthew P.] Arizona State Univ, Sch Nutr & Hlth Promot, Phoenix, AZ USA. [Craft, Lynette L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Richardson, Caroline R.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Hutber, Adrian] ACSM, Indianapolis, IN USA. [Estabrooks, Paul] Univ Nebraska Med Ctr, Dept Hlth Promot Social & Behav Hlth, Omaha, NE USA. [Gorin, Sherri Sheinfeld] NYPAC, New York, NY USA. [Gorin, Sherri Sheinfeld] NIH, Leidos Biomed Res SAIC, Frederick, MD USA. RP Gorin, SS (reprint author), NYPAC, New York, NY USA.; Gorin, SS (reprint author), NCI, Leidos Biomed Res Inc, NIH, 3167 Fairbury Ln, Fairfax, VA 22031 USA. EM sherri.gorin@gmail.com FU Society of Behavioral Medicine (SBM); American College of Sports Medicine FX This paper resulted from an American College of Sports Medicine and Society of Behavioral Medicine (SBM) co-sponsored symposium for the SBM Annual Meeting, April 2014. NR 64 TC 1 Z9 1 U1 16 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD OCT PY 2016 VL 129 IS 10 BP 1022 EP 1029 DI 10.1016/j.amjmed.2016.02.008 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EA1EA UT WOS:000386334100025 PM 26953063 ER PT J AU Gomez-Lopez, N Romero, R Xu, Y Miller, D Unkel, R MacKenzie, TC Frascoli, M Hassan, SS AF Gomez-Lopez, Nardhy Romero, Roberto Xu, Yi Miller, Derek Unkel, Ronald MacKenzie, Tippi C. Frascoli, Michela Hassan, Sonia S. TI Umbilical cord CD71+erythroid cells are reduced in neonates born to women in spontaneous preterm labor SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article DE cord blood; immunosuppression; neonates; parturition; placenta; pregnancy ID IMMATURE ERYTHROID-CELLS; INFECTION; NEWBORNS; BIRTH AB Problem: Preterm neonates are highly susceptible to infection. Neonatal host defense against infection seems to be maintained by the temporal presence of immunosuppressive CD71+ erythroid cells. The aim of this study was to investigate whether umbilical cord CD71+ erythroid cells are reduced in neonates born to women who undergo spontaneous preterm labor/birth. Method of study: Umbilical cord blood samples (n=155) were collected from neonates born to women who delivered preterm with (n=39) and without (n=12) spontaneous labor or at term with (n=82) and without (n=22) spontaneous labor. Time-matched maternal peripheral blood samples were also included (n=111). Mononuclear cells were isolated from these samples, and CD71+ erythroid cells were identified and quantified as CD3-CD235a+ CD71+ cells by flow cytometry. Results: (i) The proportion of CD71+ erythroid cells was 50-fold higher in cord blood than in maternal blood; (ii) a reduced number and frequency of umbilical cord CD71+ erythroid cells were found in neonates born to women who underwent spontaneous preterm labor compared to those born to women who delivered preterm without labor; (iii) umbilical cord CD71+ erythroid cells were fewer in neonates born to term pregnancies, regardless of the process of labor, than in those born to women who delivered preterm without labor; and (iv) no differences were seen in umbilical cord CD71+ erythroid cells between neonates born to women who -underwent spontaneous preterm labor and those born to women who delivered at term with labor. Conclusion: Umbilical cord CD71+ erythroid cells are reduced in neonates born to women who had undergone spontaneous preterm labor. C1 [Gomez-Lopez, Nardhy; Romero, Roberto; Xu, Yi; Miller, Derek; Unkel, Ronald; Hassan, Sonia S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Program Perinatal Res & Obstet, Div Intramural Res,NICHD,NIH,DHHS, Bethesda, MD USA. [Gomez-Lopez, Nardhy; Romero, Roberto; Xu, Yi; Miller, Derek; Unkel, Ronald; Hassan, Sonia S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, Program Perinatal Res & Obstet, Div Intramural Res,NICHD,NIH,DHHS, Detroit, MI USA. [Gomez-Lopez, Nardhy; Xu, Yi; Miller, Derek; Unkel, Ronald; Hassan, Sonia S.] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA. [Gomez-Lopez, Nardhy; Miller, Derek] Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA. [Romero, Roberto] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA. [Romero, Roberto] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA. [Romero, Roberto] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI USA. [MacKenzie, Tippi C.; Frascoli, Michela] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med, San Francisco, CA 94143 USA. [MacKenzie, Tippi C.; Frascoli, Michela] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RP Gomez-Lopez, N (reprint author), Wayne State Univ, Perinatol Res Branch, Dept Obstet & Gynecol, Sch Med,NICHD,NIH,DHHS, Detroit, MI 48202 USA.; Romero, R (reprint author), Wayne State Univ, Perinatol Res Branch, NICHD, NIH,DHHS,Hutzel Womens Hosp, Detroit, MI 48202 USA. EM nardhy.gomez-lopez@wayne.edu; romeror@mail.nih.gov RI Gomez-Lopez, Nardhy/R-7664-2016 OI Gomez-Lopez, Nardhy/0000-0002-3406-5262 FU Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U. S. Department of Health and Human Services (NICHD/NIH/DHHS); NICHD/NIH/DHHS [HHSN275201300006C]; Wayne State University Perinatal Initiative in Maternal, Perinatal and Child Health FX This research was supported, in part, by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U. S. Department of Health and Human Services (NICHD/NIH/DHHS), and, in part, with federal funds from the NICHD/NIH/DHHS under Contract No. HHSN275201300006C. This research was also supported by the Wayne State University Perinatal Initiative in Maternal, Perinatal and Child Health. We thank the physicians and nurses from the Center for Advanced Obstetrical Care and Research and the Intrapartum Unit, as well as the research assistants from the PRB Clinical Laboratory, for their help in collecting human samples. We also thank staff members of the PRB Histology and Pathology Units for their examination of the pathological sections and Tara Mial for her critical readings of the manuscript. NR 19 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1046-7408 EI 1600-0897 J9 AM J REPROD IMMUNOL JI Am. J. Reprod. Immunol. PD OCT PY 2016 VL 76 IS 4 BP 280 EP 284 DI 10.1111/aji.12556 PG 5 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA EA1CP UT WOS:000386330400004 PM 27625200 ER PT J AU Olivier, KN AF Olivier, Kenneth N. TI Lady Windermere Dissected: More Form Than Fastidious SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Editorial Material C1 [Olivier, Kenneth N.] NHLBI, Bldg 10, Bethesda, MD 20892 USA. RP Olivier, KN (reprint author), NHLBI, Cardiovasc & Pulm Branch, 10 Ctr Dr,MSC 1454,Bldg 10 CRC,Room 6-3130, Bethesda, MD 20832 USA. EM olivierk@nhlbi.nih.gov FU Intramural Research Program, National Heart, Lung and Blood Institute, National Institutes of Health FX Supported in part by the Intramural Research Program, National Heart, Lung and Blood Institute, National Institutes of Health. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD OCT PY 2016 VL 13 IS 10 BP 1674 EP 1676 DI 10.1513/AnnalsATS.201607-521ED PG 3 WC Respiratory System SC Respiratory System GA DZ8KG UT WOS:000386118700003 PM 27726444 ER PT J AU Labonte, ME Kirkpatrick, SI Bell, RC Boucher, BA Csizmadi, I Koushik, A L'Abbe, MR Massarelli, I Robson, PJ Rondeau, I Shatenstein, B Subar, AF Lamarche, B AF Labonte, Marie-Eve Kirkpatrick, Sharon I. Bell, Rhonda C. Boucher, Beatrice A. Csizmadi, Ilona Koushik, Anita L'Abbe, Mary R. Massarelli, Isabelle Robson, Paula J. Rondeau, Isabelle Shatenstein, Bryna Subar, Amy F. Lamarche, Benoit TI Dietary assessment is a critical element of health research - Perspective from the Partnership for Advancing Nutritional and Dietary Assessment in Canada SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM LA English DT Article DE dietary analysis; nutrition; dietary intake; diet ID FOOD-FREQUENCY QUESTIONNAIRE; VALIDITY; WOMEN AB Challenges and complexities associated with assessing dietary intakes are numerous, but not insurmountable. This opinion paper from Canadian researchers draws attention to the importance of building capacity and providing funding opportunities for research in dietary assessment methods in Canada and elsewhere. Such strategies would contribute to a better understanding of the roles played by diet in human health and better translation of this information into the most meaningful and effective dietary guidelines, policies, and interventions. C1 [Labonte, Marie-Eve; Lamarche, Benoit] Univ Laval, Inst Nutr & Funct Foods, Sch Nutr, Quebec City, PQ G1V 0A6, Canada. [Kirkpatrick, Sharon I.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada. [Bell, Rhonda C.] Univ Alberta, Dept Agr Food & Nutr Sci, Div Human Nutr, Li Ka Shing Ctr Hlth Res Innovat, Edmonton, AB T6G 2E1, Canada. [Boucher, Beatrice A.] Canc Care Ontario, Prevent & Canc Control, Toronto, ON M5G 2L7, Canada. [Boucher, Beatrice A.] Univ Toronto, Dept Nutr Sci, Toronto, ON M5S 3E2, Canada. [Csizmadi, Ilona] Alberta Hlth Serv, CancerControl Alberta, Canc Epidemiol & Prevent Res, Calgary, AB T2S 3C3, Canada. [Koushik, Anita] Univ Montreal, CRCHUM, Montreal, PQ H2X 0A9, Canada. [Koushik, Anita] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ H2X 0A9, Canada. [Labonte, Marie-Eve; L'Abbe, Mary R.] Univ Toronto, Dept Nutr Sci, Fac Med, Toronto, ON M5S 3E2, Canada. [Massarelli, Isabelle; Rondeau, Isabelle] Hlth Canada, Bur Food Surveillance & Sci Integrat, Food Directorate, Ottawa, ON K1A 0K9, Canada. [Robson, Paula J.] Alberta Hlth Serv, CancerControl Alberta, C MORE, Edmonton, AB T5J 3H1, Canada. [Shatenstein, Bryna] Univ Montreal, Dept Nutr, Ctr Rech, Inst Univ Geriatrie Montreal, Montreal, PQ H3W 1W5, Canada. [Subar, Amy F.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20814 USA. RP Lamarche, B (reprint author), Univ Laval, Inst Nutr & Funct Foods, Sch Nutr, Quebec City, PQ G1V 0A6, Canada.; Kirkpatrick, SI (reprint author), Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON N2L 3G1, Canada. EM sharon.kirkpatrick@uwaterloo.ca; benoit.lamarche@fsaa.ulaval.ca OI Koushik, Anita/0000-0001-5304-7660 FU Canadian Cancer Society Research Institute [702855] FX B. L. and M. E. L. have developed a Web-based FFQ that is licensed for utilization by researchers and clinicians through formal agreements with Laval University's Research Office. User fees serve solely for the maintenance and upgrade of the dietary assessment tool. S. I. K. receives financial support from the Canadian Cancer Society Research Institute (grant no. 702855). R. C. B., B. A. B., I. C., A. K., M. R. L., I. M., P. J. R., I. R., B. S., A. F. S. report no conflicts of interest. NR 24 TC 3 Z9 3 U1 2 U2 2 PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS PI OTTAWA PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA SN 1715-5312 EI 1715-5320 J9 APPL PHYSIOL NUTR ME JI Appl. Physiol. Nutr. Metab. PD OCT PY 2016 VL 41 IS 10 BP 1096 EP 1099 DI 10.1139/apnm-2016-0146 PG 4 WC Nutrition & Dietetics; Physiology; Sport Sciences SC Nutrition & Dietetics; Physiology; Sport Sciences GA DZ8NZ UT WOS:000386128400014 ER PT J AU Nakamura, Y Mochida, A Choyke, PL Kobayashi, H AF Nakamura, Yuko Mochida, Ai Choyke, Peter L. Kobayashi, Hisataka TI Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? SO BIOCONJUGATE CHEMISTRY LA English DT Review ID INTERSTITIAL FLUID PRESSURE; NEAR-INFRARED PHOTOIMMUNOTHERAPY; ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; ISOLATED LIMB PERFUSION; TEMPERATURE-SENSITIVE LIPOSOMES; INTENSITY FOCUSED ULTRASOUND; ELEVATING BLOOD-PRESSURE; TARGETED DRUG-DELIVERY; SOLID TUMORS AB Nanotechnology offers several attractive design features that have prompted its exploration for cancer diagnosis and treatment. Nanosized drugs have a large loading capacity, the ability to protect the payload from degradation, a large surface on which to conjugate targeting ligands, and controlled or sustained release. Nanosized drugs also leak preferentially into tumor tissue through permeable tumor vessels and are then retained in the tumor bed due to reduced lymphatic drainage. This process is known as the enhanced permeability and retention (EPR) effect. However, while the EPR effect is widely held to improve delivery of nanodrugs to tumors, it in fact offers less than a 2-fold increase in nanodrug delivery compared with critical normal organs, resulting in drug concentrations that are not sufficient for curing most cancers. In this Review, we first overview various barriers for nanosized drug delivery with an emphasis on the capillary wall's resistance, the main obstacle to delivering drugs. Then, we discuss current regulatory issues facing nanomedicine. Finally, we discuss how to make the delivery of nanosized drugs to tumors more effective by building on the EPR effect. C1 [Nakamura, Yuko; Mochida, Ai; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. RP Kobayashi, H (reprint author), NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. EM kobayash@mail.nih.gov FU Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research FX This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 165 TC 4 Z9 4 U1 47 U2 47 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD OCT PY 2016 VL 27 IS 10 BP 2225 EP 2238 DI 10.1021/acs.bioconjchem.6b00437 PG 14 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA DZ6SK UT WOS:000385992000001 PM 27547843 ER PT J AU Jacobson, O Kiesewetter, DO Chen, XY AF Jacobson, Orit Kiesewetter, Dale O. Chen, Xiaoyuan TI Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics SO BIOCONJUGATE CHEMISTRY LA English DT Review ID NEONATAL FC-RECEPTOR; MRI CONTRAST AGENT; IN-VIVO; RGD PEPTIDE; HALF-LIFE; POLYETHYLENE-GLYCOL; BOUND PACLITAXEL; SERUM-ALBUMIN; TUMOR-THERAPY; PLASMA-VOLUME AB One of the major design considerations for a drug is its pharmacokinetics: a drug with short blood half-life is less available at a target organ which in turn dictates treatment with either high or more frequent doses, and increases the likelihood of undesirable side effects. One method to improve drug pharmacokinetics is adding functional chemical groups to the drug molecule that can increase the half-life in the blood, hopefully, without significantly affecting its desired biological activity. Evans Blue (EB) dye reversibly binds to serum albumin with moderate affinity and has a long blood half-life. The binding of EB to albumin has been exploited to quantify protein leakage as an indicator of increased vascular permeability. Design of new chemical entities based on EB structure and coupling them to drugs, enables the usage of albumin as a reversible carrier in the blood and improves drug's half-life. This Topical Review summarizes the recent developments of various EB derivatives for molecular imaging and therapy applications. C1 [Jacobson, Orit; Kiesewetter, Dale O.; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA. RP Chen, XY (reprint author), NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA. EM shawn.chen@nih.gov NR 68 TC 0 Z9 0 U1 15 U2 15 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD OCT PY 2016 VL 27 IS 10 BP 2239 EP 2247 DI 10.1021/acs.bioconjchem.6b00487 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA DZ6SK UT WOS:000385992000002 ER PT J AU Francica, JR Lynn, GM Laga, R Joyce, MG Ruckwardt, TJ Morabito, KM Chen, M Chaudhuri, R Zhang, BS Sastry, M Druz, A Ko, K Choe, M Pechar, M Georgiev, IS Kueltzo, LA Seymour, LW Mascola, JR Kwong, PD Graham, BS Seder, RA AF Francica, Joseph R. Lynn, Geoffrey M. Laga, Richard Joyce, M. Gordon Ruckwardt, Tracy J. Morabito, Kaitlyn M. Chen, Man Chaudhuri, Rajoshi Zhang, Baoshan Sastry, Mallika Druz, Aliaksandr Ko, Kiyoon Choe, Misook Pechar, Michal Georgiev, Ivelin S. Kueltzo, Lisa A. Seymour, Leonard W. Mascola, John R. Kwong, Peter D. Graham, Barney S. Seder, Robert A. TI Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant SO BIOCONJUGATE CHEMISTRY LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; T-CELL RESPONSES; DENDRITIC CELLS; IMMUNE-RESPONSES; FUSION GLYCOPROTEIN; RATIONAL DESIGN; INNATE IMMUNITY; VACCINE DEVELOPMENT; CROSS-PRESENTATION; NONHUMAN-PRIMATES AB Structure-based vaccine design has been used to develop immunogens that display conserved neutralization sites on pathogens such as HIV-1, respiratory syncytial virus (RSV), and influenza. Improving the immunogenicity of these designed immunogens with adjuvants will require formulations that do not alter protein antigenicity. Here, we show that nanoparticle-forming thermoresponsive polymers (TRP) allow for co-delivery of RSV fusion (F) protein trimers with Toll like receptor 7 and 8 agonists (TLR-7/8a) to enhance protective immunity. Although primary amine conjugation of TLR-7/8a to F trimers severely disrupted the recognition of critical neutralizing epitopes, F trimers site-selectively coupled to TRP nanoparticles retained appropriate antigenicity and elicited high titers of prefusion-specific, T(H)1 isotype anti-RSV F antibodies following vaccination. Moreover, coupling F trimers to TRP delivering TLR-7/8a resulted in similar to 3-fold higher binding and neutralizing antibody titers than soluble F trimers admixed with TLR-7/8a and conferred protection from intranasal RSV challenge. Overall, these data show that TRP nanoparticles may provide a broadly applicable platform for eliciting neutralizing antibodies to structure-dependent epitopes on RSV, influenza, HIV-1, or other pathogens. C1 [Francica, Joseph R.; Lynn, Geoffrey M.; Joyce, M. Gordon; Ruckwardt, Tracy J.; Morabito, Kaitlyn M.; Chen, Man; Zhang, Baoshan; Sastry, Mallika; Druz, Aliaksandr; Ko, Kiyoon; Choe, Misook; Georgiev, Ivelin S.; Mascola, John R.; Kwong, Peter D.; Graham, Barney S.; Seder, Robert A.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Laga, Richard; Pechar, Michal] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague, Czech Republic. [Chaudhuri, Rajoshi; Kueltzo, Lisa A.] NIAID, Vaccine Prod Program, Vaccine Res Ctr, NIH, Gaithersburg, MD 20878 USA. [Seymour, Leonard W.] Univ Oxford, Dept Oncol, Oxford OX3 7DQ, England. RP Seder, RA (reprint author), NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. EM rseder@mail.nih.gov RI Pechar, Michal/G-6423-2014; Laga, Richard/G-3627-2014 FU Vaccine Research Center (NIAID, NIH); Czech Science Foundation [16-14957Y]; Ministry of Education, Youth and Sports of the Czech Republic [BIOCEV-FAR LQ1604] FX The authors acknowledge Marlon Dillon, Kefale Wuddie, Gloria Salbador, and Carmelo Chiedi for expert veterinary technical assistance; Azad Kumar for generously providing untagged RSV F proteins; and April Kilikelly, Joan Ngwuta, and Andrew Ishizuka for helpful discussion. This work was funded in part by the intramural research program of the Vaccine Research Center (NIAID, NIH). Further support was given by the Czech Science Foundation (project 16-14957Y) and by the Ministry of Education, Youth and Sports of the Czech Republic within the National Sustainability Program II (project BIOCEV-FAR LQ1604). NR 84 TC 0 Z9 0 U1 9 U2 9 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1043-1802 J9 BIOCONJUGATE CHEM JI Bioconjugate Chem. PD OCT PY 2016 VL 27 IS 10 BP 2372 EP 2385 DI 10.1021/acs.bioconjchem.6b00370 PG 14 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic SC Biochemistry & Molecular Biology; Chemistry GA DZ6SK UT WOS:000385992000019 PM 27583777 ER PT J AU Lesage, E Nailer, EL Miall, RC AF Lesage, Elise Nailer, Emma L. Miall, R. Chris TI Cerebellar BOLD signal during the acquisition of a new lexicon predicts its early consolidation SO BRAIN AND LANGUAGE LA English DT Article DE Cerebellum; Language; Vocabulary; Learning; Lexicon; fMRI; Word association; Non-motor ID WORKING-MEMORY; PREFRONTAL CORTEX; FUNCTIONAL TOPOGRAPHY; SEMANTIC KNOWLEDGE; EPISODIC MEMORY; INTERNAL-MODELS; COGNITIVE TASKS; HUMAN BRAIN; LANGUAGE; FMRI AB Cerebellar contributions to language are presently poorly understood, but it has been argued that the cerebellar role in motor learning can be extended to learning in cognitive and linguistic domains. Here, we used fMRI to investigate whether the cerebellum is recruited in mapping novel words onto existing semantic concepts. On separate days, participants performed a Basque vocabulary learning task and a control English synonym task in the MRI scanner. Learning-related BOLD activity was found in left inferior frontal gyrus, bilateral insula, pre-SMA, left superior parietal cortex, right caudate, the right cerebellar vermis and right cerebellar Crus II. The extent to which the cerebellar regions, but not the cerebral areas, were recruited during learning correlated positively with participants' off-line improvement in performance after the learning task. These data provide evidence for a cerebellar role in lexical learning, and suggest that the right cerebellum may contribute toward consolidation of lexico-semantic associations in the language network. (C) 2015 The Authors. Published by Elsevier Inc. C1 [Lesage, Elise; Nailer, Emma L.; Miall, R. Chris] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England. [Lesage, Elise] NIDA, Neuroimaging Res Branch, NIH, Baltimore, MD 21224 USA. [Nailer, Emma L.] Univ Birmingham, Sch Educ, Birmingham B15 2TT, W Midlands, England. RP Lesage, E (reprint author), NIDA, Neuroimaging Res Branch, NIH, Baltimore, MD 21224 USA. EM Elise.r.d.lesage@gmail.com FU Wellcome Trust [WT087554]; Marie Curie Actions Grant [EU-FP7-ITN "C7"] FX This work was supported by grants from the Wellcome Trust (WT087554) and the Marie Curie Actions Grant EU-FP7-ITN "C7". We thank the staff of the Birmingham University Imaging Centre for their help. NR 97 TC 2 Z9 2 U1 2 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0093-934X EI 1090-2155 J9 BRAIN LANG JI Brain Lang. PD OCT PY 2016 VL 161 SI SI BP 33 EP 44 DI 10.1016/j.bandl.2015.07.005 PG 12 WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology GA DZ8FA UT WOS:000386105100005 PM 26303580 ER PT J AU Thomas, RM Van Dyke, T Merlino, G Day, CP AF Thomas, Renee M. Van Dyke, Terry Merlino, Glenn Day, Chi-Ping TI Concepts in Cancer Modeling: A Brief History SO CANCER RESEARCH LA English DT Review ID ANTITUMOR IMMUNITY; MELANOMA; CHEMOTHERAPY; IMMUNOTHERAPY; KINETICS; THERAPY AB Modeling, an experimental approach to investigate complex biological systems, has significantly contributed to our understanding of cancer. Although extensive cancer research has been conducted utilizing animal models for elucidating mechanisms and developing therapeutics, the concepts in a good model design and its application have not been well elaborated. In this review, we discuss the theory underlying biological modeling and the process of producing a valuable and relevant animal model. Several renowned examples in the history of cancer research will be used to illustrate how modeling can be translatable to clinical applications. Finally, we will also discuss how the advances in cancer genomics and cancer modeling will influence each other going forward. (C) 2016 AACR. C1 [Thomas, Renee M.; Merlino, Glenn; Day, Chi-Ping] NCI, Lab Canc Biol & Genet, NIH, 37 Convent Dr,Room 5002, Bethesda, MD 20892 USA. [Thomas, Renee M.] NIH, Med Res Scholars Program, Bldg 10, Bethesda, MD 20892 USA. [Van Dyke, Terry] NCI, Ctr Adv Preclin Res, Ctr Canc Res, Frederick, MD 21701 USA. RP Merlino, G; Day, CP (reprint author), NCI, Lab Canc Biol & Genet, NIH, 37 Convent Dr,Room 5002, Bethesda, MD 20892 USA. EM gmerlino@helix.nih.gov; daychi@mail.nih.gov FU Intramural NIH HHS [Z99 CA999999, ZIA BC011167-01] NR 26 TC 0 Z9 0 U1 4 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT PY 2016 VL 76 IS 20 BP 5921 EP 5925 DI 10.1158/0008-5472.CAN-16-1293 PG 5 WC Oncology SC Oncology GA DZ1UW UT WOS:000385627600003 PM 27694601 ER PT J AU Campbell, PT Newton, CC Freedman, ND Koshiol, J Alavanja, MC Freeman, LEB Buring, JE Chan, AT Chong, DQ Datta, M Gaudet, MM Gaziano, JM Giovannucci, EL Graubard, BI Hollenbeck, AR King, L Lee, IM Linet, MS Palmer, JR Petrick, JL Poynter, JN Purdue, MP Robien, K Rosenberg, L Sahasrabuddhe, VV Schairer, C Sesso, HD Sigurdson, AJ Stevens, VL Wactawski-Wende, J Zeleniuch-Jacquotte, A Renehan, AG McGlynn, KA AF Campbell, Peter T. Newton, Christina C. Freedman, Neal D. Koshiol, Jill Alavanja, Michael C. Freeman, Laura E. Beane Buring, Julie E. Chan, Andrew T. Chong, Dawn Q. Datta, Mridul Gaudet, Mia M. Gaziano, J. Michael Giovannucci, Edward L. Graubard, Barry I. Hollenbeck, Albert R. King, Lindsey Lee, I-Min Linet, Martha S. Palmer, Julie R. Petrick, Jessica L. Poynter, Jenny N. Purdue, Mark P. Robien, Kim Rosenberg, Lynn Sahasrabuddhe, Vikrant V. Schairer, Catherine Sesso, Howard D. Sigurdson, Alice J. Stevens, Victoria L. Wactawski-Wende, Jean Zeleniuch-Jacquotte, Anne Renehan, Andrew G. McGlynn, Katherine A. TI Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for US Adults SO CANCER RESEARCH LA English DT Article ID EPIC-OXFORD PARTICIPANTS; BILIARY-TRACT CANCER; HEPATOCELLULAR-CARCINOMA; EUROPEAN COHORT; UNITED-STATES; MELLITUS; OBESITY; METAANALYSIS; ASSOCIATION; WEIGHT AB Incidence rates for liver cancer have increased 3-fold since the mid-1970s in the United States in parallel with increasing trends for obesity and type II diabetes mellitus. Weconducted an analysis of baseline body mass index (BMI), waist circumference (WC), and type II diabetes mellitus with risk of liver cancer. The Liver Cancer Pooling Project maintains harmonized data from 1.57 million adults enrolled in 14 U.S.-based prospective studies. Cox regression estimated HRs and 95% confidence intervals (CI) adjusted for age, sex, study center, alcohol, smoking, race, and BMI (for WC and type II diabetes mellitus). Stratified analyses assessed whether the BMI-liver cancer associations differed by hepatitis sera-positivity in nested analyses for a subset of cases (n = 220) and controls (n = 547). After enrollment, 2,162 incident liver cancer diagnoses were identified. BMI, per 5 kg/m(2), was associated with higher risks of liver cancer, more so for men (HR = 1.38; 95% CI, 1.30-1.46) than women (HR = 1.25; 95% CI, 1.17-1.35; P-interaction = 0.02). WC, per 5 cm, was associated with higher risks of liver cancer, approximately equally by sex (overall, HR = 1.08; 95% CI, 1.04-1.13). Type II diabetes mellitus was associated with higher risk of liver cancer (HR = 2.61; 95% CI, 2.34-2.91). In stratified analyses, there was a null association between BMI and liver cancer risk for participants who were sera-positive for hepatitis. This study suggests that high BMI, high WC, and type II diabetes mellitus are associated with higher risks of liver cancer and that the association may differ by status of viral hepatitis infection. (C) 2016 AACR. C1 [Campbell, Peter T.; Newton, Christina C.; Gaudet, Mia M.; Stevens, Victoria L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Freedman, Neal D.; Koshiol, Jill; Alavanja, Michael C.; Freeman, Laura E. Beane; Graubard, Barry I.; Linet, Martha S.; Petrick, Jessica L.; Purdue, Mark P.; Sahasrabuddhe, Vikrant V.; Schairer, Catherine; Sigurdson, Alice J.; McGlynn, Katherine A.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Buring, Julie E.; Chan, Andrew T.; Gaziano, J. Michael; King, Lindsey; Lee, I-Min; Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Buring, Julie E.; Giovannucci, Edward L.; Lee, I-Min; Sesso, Howard D.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Chan, Andrew T.; King, Lindsey] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Chan, Andrew T.; Chong, Dawn Q.; King, Lindsey] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Chan, Andrew T.; Chong, Dawn Q.; King, Lindsey] Harvard Med Sch, Boston, MA USA. [Chong, Dawn Q.] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore. [Datta, Mridul] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA. [Gaziano, J. Michael] VA Boston Healthcare Syst, Boston, MA USA. [Giovannucci, Edward L.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Hollenbeck, Albert R.] AARP, Washington, DC USA. [Palmer, Julie R.; Rosenberg, Lynn] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Poynter, Jenny N.] Univ Minnesota, Div Pediat Epidemiol & Clin Res, Minneapolis, MN USA. [Poynter, Jenny N.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA. [Robien, Kim] George Washington Univ, Milken Inst, Sch Publ Hlth, Dept Exercise & Nutr Sci, Washington, DC USA. [Wactawski-Wende, Jean] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. [Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Renehan, Andrew G.] Univ Manchester, Fac Inst Canc Sci, Manchester, Lancs, England. RP Campbell, PT (reprint author), Amer Canc Soc, 250 Williams St NW, Atlanta, GA 30303 USA. EM peter.campbell@cancer.org RI Beane Freeman, Laura/C-4468-2015; OI Beane Freeman, Laura/0000-0003-1294-4124; Robien, Kim/0000-0002-2120-2280; Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303 FU Intramural NIH HHS [Z01 CP010119-12, Z01 ES049030-11]; NCI NIH HHS [UM1 CA186107, P01 CA055075, P01 CA087969, P30 CA016087, R01 CA034944, R01 CA034944-03, R01 CA039742, R01 CA040360, R01 CA047988, R01 CA049449, R01 CA058420, R01 CA097193, R01 CA098661, UM1 CA164974, UM1 CA167552]; NHLBI NIH HHS [R01 HL026490, R01 HL026490-03, R01 HL034595, R01 HL034595-07, R01 HL043851, R01 HL080467]; NIEHS NIH HHS [P30 ES000260, Z01 ES049030] NR 37 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT PY 2016 VL 76 IS 20 BP 6076 EP 6083 DI 10.1158/0008-5472.CAN-16-0787 PG 8 WC Oncology SC Oncology GA DZ1UW UT WOS:000385627600018 PM 27742674 ER PT J AU Ali, I Hogberg, J Hsieh, JH Auerbach, S Korhonen, A Stenius, U Silins, I AF Ali, Imran Hogberg, Johan Hsieh, Jui-Hua Auerbach, Scott Korhonen, Anna Stenius, Ulla Silins, Ilona TI Gender differences in cancer susceptibility: role of oxidative stress SO CARCINOGENESIS LA English DT Article ID HEME OXYGENASE-1; SEX DISPARITIES; CHROMOSOME Y; MOSAIC LOSS; CARCINOGENESIS; RISK AB Cancer statistics indicate that compared to women, men are more susceptible to cancer. In literature analysis based on about 600000 scientific references covering male- and female-specific carcinogens, estradiol and testosterone, oxidative stress emerges as one critical factor that could offer explanation for the gender disparity observed.Cancer is a leading cause of death worldwide and environmental factors, including chemicals, have been suggested as major etiological incitements. Cancer statistics indicates that men get more cancer than women. However, differences in the known risk factors including life style or occupational exposure only offer partial explanation. Using a text mining tool, we have investigated the scientific literature concerning male- and female-specific rat carcinogens that induced tumors only in one gender in NTP 2-year cancer bioassay. Our evaluation shows that oxidative stress, although frequently reported for both male- and female-specific rat carcinogens, was mentioned significantly more in literature concerning male-specific rat carcinogens. Literature analysis of testosterone and estradiol showed the same pattern. Tox21 high-throughput assay results, although showing only weak association of oxidative stress-related processes for male- and female-specific rat carcinogens, provide additional support. We also analyzed the literature concerning 26 established human carcinogens (IARC group 1). Oxidative stress was more frequently reported for the majority of these carcinogens, and the Tox21 data resembled that of male-specific rat carcinogens. Thus, our data, based on about 600000 scientific abstracts and Tox21 screening assays, suggest a link between male-specific carcinogens, testosterone and oxidative stress. This implies that a different cellular response to oxidative stress in men and women may be a critical factor in explaining the greater cancer susceptibility observed in men. Although the IARC carcinogens are classified as human carcinogens, their classification largely based on epidemiological evidence from male cohorts, which raises the question whether carcinogen classifications should be gender specific. C1 [Ali, Imran; Hogberg, Johan; Stenius, Ulla; Silins, Ilona] Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden. [Hsieh, Jui-Hua; Auerbach, Scott] NIEHS, Div Natl Toxicol Program, NIH, POB 12233, Res Triangle Pk, NC 27709 USA. [Korhonen, Anna] Univ Cambridge, Dept Theoret & Appl Linguist, Cambridge CB3 9DA, England. RP Ali, I; Silins, I (reprint author), Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden. EM imran.ali@ki.se; ilona.silins@ki.se OI Ali, Imran/0000-0001-9274-2295 FU Swedish Research Council Formas [2013-0529]; Swedish Research Council for Health, Working Life and Welfare (FORTE) [2014-1530]; VINNOVA, Sweden [2011-01319] FX This work was supported by The Swedish Research Council Formas (Grant number 2013-0529), Swedish Research Council for Health, Working Life and Welfare (FORTE) (grant number 2014-1530) and VINNOVA (grant number 2011-01319), Sweden. NR 35 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD OCT PY 2016 VL 37 IS 10 BP 985 EP 992 DI 10.1093/carcin/bgw076 PG 8 WC Oncology SC Oncology GA DZ7IC UT WOS:000386037100008 PM 27481070 ER PT J AU Callejas-Valera, JL Iglesias-Bartolome, R Amornphimoltham, P Palacios-Garcia, J Martin, D Califano, JA Molinolo, AA Gutkind, JS AF Callejas-Valera, Juan Luis Iglesias-Bartolome, Ramiro Amornphimoltham, Panomwat Palacios-Garcia, Julia Martin, Daniel Califano, Joseph A. Molinolo, Alfredo A. Gutkind, J. Silvio TI mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model SO CARCINOGENESIS LA English DT Article ID HUMAN-PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMA; STEM-CELLS; OROPHARYNGEAL CANCER; HAIR FOLLICLE; TUMOR-GROWTH; HPV16 E6/E7; SKIN; E7; E6 AB The rising incidence of human papillomavirus (HPV)-associated malignancies, especially for oropharyngeal cancers, has highlighted the urgent need to understand how the interplay between high-risk HPV oncogenes and carcinogenic exposure results in squamous cell carcinoma (SCC) development. Here, we describe an inducible mouse model expressing high risk HPV-16 E6/E7 oncoproteins in adults, bypassing the impact of these viral genes during development. HPV-16 E6/E7 genes were targeted to the basal squamous epithelia in transgenic mice using a doxycycline inducible cytokeratin 5 promoter (cK5-rtTA) system. After doxycycline induction, both E6 and E7 were highly expressed, resulting in rapid epidermal hyperplasia with a remarkable expansion of the proliferative cell compartment to the suprabasal layers. Surprisingly, in spite of the massive growth of epithelial cells and their stem cell progenitors, HPV-E6/E7 expression was not sufficient to trigger mTOR activation, a key oncogenic driver in HPV-associated malignancies, and malignant progression to SCC. However, these mice develop SCC rapidly after a single exposure to a skin carcinogen, DMBA, which was increased by the prolonged exposure to a tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA). Thus, only few oncogenic hits may be sufficient to induce cancer in E6/E7 expressing cells. All HPV-E6/E7 expressing SCC lesions exhibited increased mTOR activation. Remarkably, rapamycin, an mTOR inhibitor, abolished tumor development when administered to HPV-E6/E7 mice prior to DMBA exposure. Our findings revealed that mTOR inhibition protects HPV-E6/E7 expressing tissues form SCC development upon carcinogen exposure, thus supporting the potential clinical use of mTOR inhibitors as a molecular targeted approach for prevention of HPV-associated malignancies. C1 [Callejas-Valera, Juan Luis; Amornphimoltham, Panomwat; Califano, Joseph A.; Molinolo, Alfredo A.; Gutkind, J. Silvio] Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA. [Iglesias-Bartolome, Ramiro] NIAMS, Dev Skin Biol Sect HNB 254, NIH, Bldg 50, Bethesda, MD 20814 USA. [Palacios-Garcia, Julia] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid 28049, Spain. [Martin, Daniel] NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bldg 30, Bethesda, MD 20892 USA. RP Gutkind, JS (reprint author), Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA. EM sgutkind@ucsd.edu NR 47 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD OCT PY 2016 VL 37 IS 10 BP 1014 EP 1025 DI 10.1093/carcin/bgw086 PG 97 WC Oncology SC Oncology GA DZ7IC UT WOS:000386037100001 PM 27538837 ER PT J AU Zhang, T Ye, YH AF Zhang, Ting Ye, Yihong TI Ever HRD a ubiquitin-gated channel? SO CELL RESEARCH LA English DT Editorial Material ID ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; ER PROTEINS; RETROTRANSLOCATION AB Elimination of misfolded proteins of the endoplasmic reticulum (ER) requires their retrotranslocation from the ER to the cytosol via membrane-bound ubiquitin ligase complexes. Baldridge and Rapoport now reconstitute a key step of retrotranslocation, demonstrating a protein conduit gated by ubiquitination. C1 [Zhang, Ting; Ye, Yihong] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. RP Ye, YH (reprint author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. EM yihongy@mail.nih.gov NR 10 TC 0 Z9 0 U1 3 U2 3 PU INST BIOCHEMISTRY & CELL BIOLOGY PI SHANGHAI PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA SN 1001-0602 EI 1748-7838 J9 CELL RES JI Cell Res. PD OCT PY 2016 VL 26 IS 10 BP 1075 EP 1076 DI 10.1038/cr.2016.92 PG 2 WC Cell Biology SC Cell Biology GA DZ8QF UT WOS:000386135200003 PM 27491350 ER PT J AU Kadri, SS Rhee, C Magda, G Strich, JR Cai, RM Sun, JF Decker, BK O'Grady, NP AF Kadri, Sameer S. Rhee, Chanu Magda, Gabriela Strich, Jeffrey R. Cai, Rongman Sun, Junfeng Decker, Brooke K. O'Grady, Naomi P. TI Synergy, Salary, and Satisfaction: Benefits of Training in Critical Care Medicine and Infectious Diseases Gleaned From a National Pilot Survey of Dually Trained Physicians SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE critical care; infectious diseases; survey ID UNITED-STATES; EMERGENCY PHYSICIANS; MORTALITY; CONSULTATIONS; SUBSPECIALTY; CHALLENGES; PREVENTION; PULMONARY; EDUCATION; THERAPY AB A survey of physicians trained in critical care medicine (CCM) and infectious diseases (ID) suggested this combination is synergistic and satisfying. However, most respondents had to train in individual specialties at separate institutions. Avenues for CCM-ID training should be considered.Methods.aEuro integral All physicians trained and/or certified in both CCM and ID to date in the United States were sent a Web-based questionnaire in 2015. Responses enabled a cross-sectional analysis of physician demographics and training and practice characteristics and satisfaction. Results.aEuro integral Of 202 CCM-ID physicians, 196 were alive and reachable. The response rate was 79%. Forty-six percent trained and 34% practice in the northeastern United States. Only 40% received dual training at the same institution. Eighty-three percent identified as either an intensivist with ID expertise (44%) or as equally an intensivist and ID physician (38%). Median salary was $265 000 (interquartile range [IQR], $215 000-$350 000). Practice settings were split between academic (45%) and community settings (42%). Two-thirds are clinicians but 62% conduct some research and 26% practice outpatient ID. Top reasons to dually specialize included clinical synergy (70%), procedural activity (50%), and less interest in pulmonology (49%). Although 38% cited less proficiency with bronchoscopy as a disadvantage, 87% seldom need pulmonary consultation in the intensive care unit. Median career satisfaction was 4 (IQR, 4-5) out of 5, and 76% would dually train again. Conclusions.aEuro integral CCM-ID graduates prefer the acute care setting, predominantly CCM or a combination of CCM and ID. They find combination training and practice to be synergistic and satisfying, but most have had to seek CCM and ID training independently at separate institutions. Given these findings, avenues for combined training in CCM-ID should be considered. C1 [Kadri, Sameer S.; Cai, Rongman; Sun, Junfeng; O'Grady, Naomi P.] NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr,B10 2C-145, Bethesda, MD 20892 USA. [Rhee, Chanu] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. [Rhee, Chanu] Harvard Med Sch, Dept Populat Med, Boston, MA USA. [Rhee, Chanu] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Magda, Gabriela] Georgetown Univ Hosp, Medstar, Dept Med, Washington, DC 20007 USA. [Strich, Jeffrey R.] NIAID, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Decker, Brooke K.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. RP Kadri, SS (reprint author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr,B10 2C-145, Bethesda, MD 20892 USA. EM sameer.kadri@nih.gov FU National Institutes of Health FX This work was supported by intramural funds from the National Institutes of Health. NR 34 TC 3 Z9 3 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2016 VL 63 IS 7 BP 868 EP 875 DI 10.1093/cid/ciw441 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ7JL UT WOS:000386041100009 PM 27358351 ER PT J AU Fwu, CW Kimmel, PL Eggers, PW Abbott, KC AF Fwu, Chyng-Wen Kimmel, Paul L. Eggers, Paul W. Abbott, Kevin C. TI Comparison of trends in colorectal cancer screening in the US end-stage renal disease population and the US Medicare population SO CLINICAL KIDNEY JOURNAL LA English DT Article DE colorectal cancer; dialysis; screening; kidney; transplant; USRDS ID TRANSPLANT CANDIDATES; KIDNEY-TRANSPLANT; DIALYSIS PATIENTS; GUIDELINES; RISK; HEMODIALYSIS; COLONOSCOPY; BENEFITS; SOCIETY; INJURY AB Background: Although patients treated with maintenance hemodialysis are at an increased risk of colorectal cancer compared with the general population, national practices for colorectal cancer screening have not been reported in this population. We assessed the performance of colorectal cancer screening in the US end-stage renal disease program in comparison with the US Medicare population. Methods: We studied the United States Renal Data System for US prevalent hemodialysis patients between 2002 and 2011 who had Medicare as their primary insurer. We assessed procedure codes for performance of common colorectal cancer screening tests, including fecal occult blood testing, sigmoidoscopy and colonoscopy. We assessed screening sigmoidoscopy and screening colonoscopy only and excluded patients who had preexisting colon cancer or gastrointestinal hemorrhage. Because colorectal cancer screening recommendations are established for hemodialysis patients who have been listed for kidney transplantation, but no general recommendations exist for patients who are not wait-listed, we assessed colorectal cancer screening separately for the two groups. Results: We found that 1-year performance of colonoscopy in wait-listed hemodialysis patients was similar to or higher than that in general Medicare patients of the same age, while performance of colonoscopy in non-wait-listed patients was significantly lower than among general Medicare patients of the same age. Conclusions: Given improved survival among hemodialysis patients in the last decade, the utility of colorectal cancer screening even among non-wait-listed hemodialysis patients should be reassessed. C1 [Fwu, Chyng-Wen] Social & Sci Syst Inc, Silver Spring, MD USA. [Kimmel, Paul L.; Eggers, Paul W.; Abbott, Kevin C.] NIDDK, Div Kidney Urol & Hematol Dis, NIH, 6707 Democracy Blvd, Bethesda, MD 20892 USA. RP Abbott, KC (reprint author), NIDDK, Div Kidney Urol & Hematol Dis, NIH, 6707 Democracy Blvd, Bethesda, MD 20892 USA. EM kevin.abbott@nih.gov OI Abbott, Kevin/0000-0003-2111-7112 NR 28 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1753-0784 EI 1753-0792 J9 CLIN KIDNEY J JI Clin. Kidney J. PD OCT PY 2016 VL 9 IS 5 BP 722 EP 728 DI 10.1093/ckj/sfw053 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DZ8OX UT WOS:000386131400011 PM 27679719 ER PT J AU Yamada, KM Mayor, R AF Yamada, Kenneth M. Mayor, Roberto TI Editorial overview: Cell dynamics in development, tissue remodelling, and cancer SO CURRENT OPINION IN CELL BIOLOGY LA English DT Editorial Material C1 [Yamada, Kenneth M.] Natl Inst Dent & Craniofacial Res, Lab Cell & Dev Biol, Cell Biol Sect, NIH, Bethesda, MD 20892 USA. [Mayor, Roberto] UCL, Dept Cell & Dev Biol, Gower St, London WC1E 6BT, England. RP Yamada, KM (reprint author), Natl Inst Dent & Craniofacial Res, Lab Cell & Dev Biol, Cell Biol Sect, NIH, Bethesda, MD 20892 USA. EM kyamada@dir.nidcr.nih.gov; r.mayor@ucl.ac.uk NR 0 TC 0 Z9 0 U1 0 U2 0 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0955-0674 EI 1879-0410 J9 CURR OPIN CELL BIOL JI Curr. Opin. Cell Biol. PD OCT PY 2016 VL 42 BP IV EP VI DI 10.1016/j.ceb.2016.09.001 PG 3 WC Cell Biology SC Cell Biology GA EA1PC UT WOS:000386363300001 PM 27725095 ER PT J AU Petrie, RJ Yamada, KM AF Petrie, Ryan J. Yamada, Kenneth M. TI Multiple mechanisms of 3D migration: the origins of plasticity SO CURRENT OPINION IN CELL BIOLOGY LA English DT Article ID 3-DIMENSIONAL CELL-MIGRATION; FUNDULUS DEEP CELLS; LEADING-EDGE; FOCAL ADHESIONS; RAC ACTIVATION; STRESS FIBERS; CONTRACTILITY; MATRIX; INVASION; DYNAMICS AB Cells migrate through 3D environments using a surprisingly wide variety of molecular mechanisms. These distinct modes of migration often rely on the same intracellular components, which are used in different ways to achieve cell motility. Recent work reveals that how a cell moves can be dictated by the relative amounts of cell-matrix adhesion and actomyosin contractility. A current concept is that the level of difficulty in squeezing the nucleus through a confining 3D environment determines the amounts of adhesion and contractility required for cell motility. Ultimately, determining how the nucleus controls the mode of cell migration will be essential for understanding both physiological and pathological processes dependent on cell migration in the body. C1 [Petrie, Ryan J.] Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA. [Yamada, Kenneth M.] Natl Inst Dent & Craniofacial Res, Lab Cell & Dev Biol, NIH, Bethesda, MD USA. RP Petrie, RJ (reprint author), Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA. EM rjp336@drexel.edu FU Department of Biology; College of Arts and Sciences of Drexel University; National Institutes of Health, National Institute of Dental and Craniofacial Research (NIH, NIDCR) FX RJP is supported by startup funds from the Department of Biology and the College of Arts and Sciences of Drexel University. Work in KMY's laboratory is supported by the Intramural Research Program of the National Institutes of Health, National Institute of Dental and Craniofacial Research (NIH, NIDCR). NR 64 TC 4 Z9 4 U1 8 U2 8 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0955-0674 EI 1879-0410 J9 CURR OPIN CELL BIOL JI Curr. Opin. Cell Biol. PD OCT PY 2016 VL 42 BP 7 EP 12 DI 10.1016/j.ceb.2016.03.025 PG 6 WC Cell Biology SC Cell Biology GA EA1PC UT WOS:000386363300003 PM 27082869 ER PT J AU Koo, H Yamada, KM AF Koo, Hyun Yamada, Kenneth M. TI Dynamic cell-matrix interactions modulate microbial biofilm and tissue 3D microenvironments SO CURRENT OPINION IN CELL BIOLOGY LA English DT Article ID VIBRIO-CHOLERAE BIOFILMS; EXTRACELLULAR-MATRIX; STREPTOCOCCUS-MUTANS; BACILLUS-SUBTILIS; PSEUDOMONAS-AERUGINOSA; CANDIDA-ALBICANS; IN-VIVO; STIFFNESS; CANCER; COLLAGEN AB Microbial biofilms and most eukaryotic tissues consist of cells embedded in a three-dimensional extracellular matrix. This matrix serves as a scaffold for cell adhesion and a dynamic milieu that provides varying chemical and physical signals to the cells. Besides a vast array of specific molecular components, an extracellular matrix can provide locally heterogeneous microenvironments differing in porosity/diffusion, stiffness, pH, oxygen and metabolites or nutrient levels. Mechanisms of matrix formation, mechanosensing, matrix remodeling, and modulation of cell-cell or cell-matrix interactions and dispersal are being revealed. This perspective article aims to identify such concepts from the fields of biofilm or eukaryotic matrix biology relevant to the other field to help stimulate new questions, approaches, and insights. C1 [Koo, Hyun] Univ Penn, Sch Dent Med, Dept Orthodont, Biofilm Res Labs,Levy Ctr Oral Hlth, Philadelphia, PA 19104 USA. [Koo, Hyun] Univ Penn, Sch Dent Med, Div Pediat Dent, Philadelphia, PA 19104 USA. [Koo, Hyun] Univ Penn, Sch Dent Med, Div Community Oral Hlth, Philadelphia, PA 19104 USA. [Yamada, Kenneth M.] Natl Inst Dent & Craniofacial Res, Lab Cell & Dev Biol, Cell Biol Sect, NIH, Bethesda, MD 20892 USA. [Koo, Hyun] Univ Penn, Sch Dent Med, 240 South 40th St,Levy Bldg Rm 417, Philadelphia, PA 19104 USA. RP Koo, H (reprint author), Univ Penn, Sch Dent Med, 240 South 40th St,Levy Bldg Rm 417, Philadelphia, PA 19104 USA. EM koohy@upenn.edu FU National Institute for Dental and Craniofacial Research (NIDCR), NIH Intramural Research Program; NIDCR [DE16139, DE18023, DE25220] FX The authors' research is supported by the National Institute for Dental and Craniofacial Research (NIDCR), NIH Intramural Research Program (KMY) and by NIDCR grants DE16139, DE18023, and DE25220 (HK). We thank Dr. Marlise Klein (State University of Sao Paulo, Brazil) and Dr. William H. Bowen (University of Rochester Medical Center, Rochester, NY, USA) for helpful suggestions and comments. We are also grateful to Jill Harunaga, Ryan Petrie, and Roumen Pankov for the fluorescence images. The diagrams and schematics were designed by Long Do and Mirae Jang (The University of Arts, Philadelphia, PA, USA; Instructor: Joel Katz). The authors regret that many studies could only be cited indirectly owing to space and reference number limitation. NR 71 TC 1 Z9 1 U1 6 U2 6 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0955-0674 EI 1879-0410 J9 CURR OPIN CELL BIOL JI Curr. Opin. Cell Biol. PD OCT PY 2016 VL 42 BP 102 EP 112 DI 10.1016/j.ceb.2016.05.005 PG 11 WC Cell Biology SC Cell Biology GA EA1PC UT WOS:000386363300014 PM 27257751 ER PT J AU Deroo, LA Wilcox, AJ Lie, RT Romitti, PA Pedersen, DA Munger, RG Uribe, LMM Wehby, GL AF DeRoo, Lisa A. Wilcox, Allen J. Lie, Rolv T. Romitti, Paul A. Pedersen, Dorthe Almind Munger, Ronald G. Uribe, Lina M. Moreno Wehby, George L. TI Maternal alcohol binge-drinking in the first trimester and the risk of orofacial clefts in offspring: a large population-based pooling study SO EUROPEAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Cleft lip; Cleft palate; Alcohol ID BIRTH-DEFECTS; ORAL CLEFTS; POOLED ANALYSES; CONSUMPTION; PREGNANCY; METAANALYSES; EPIDEMIOLOGY; NORWAY; COHORT; GENES AB Using individual participant data from six population-based case-control studies, we conducted pooled analyses to examine maternal alcohol consumption and the risk of clefts among > 4600 infants with cleft lip only, cleft lip with cleft palate, or cleft palate only and > 10,000 unaffected controls. We examined two first-trimester alcohol measures: average number of drinks/sitting and maximum number of drinks/sitting, with five studies contributing to each analysis. Study-specific odds ratios (ORs) were estimated using logistic regression and pooled to generate adjusted summary ORs. Across studies, 0.9-3.2 % of control mothers reported drinking an average of 5+ drinks/sitting, while 1.4-23.5 % reported drinking a maximum of 5+ drinks/sitting. Compared with non-drinkers, mothers who drank an average of 5+ drinks/sitting were more likely to deliver an infant with cleft lip only (pooled OR 1.48; 95 % confidence intervals 1.01, 2.18). The estimate was higher among women who drank at this level 3+ times (pooled OR 1.95; 1.23, 3.11). Ever drinking a maximum of 5+ drinks/sitting and non-binge drinking were not associated with cleft risk. Repeated heavy maternal alcohol consumption was associated with an increased risk of cleft lip only in offspring. There was little evidence of increased risk for other cleft types or alcohol measures. C1 [DeRoo, Lisa A.; Lie, Rolv T.] Univ Bergen, Dept Global Publ Hlth & Primary Care, Postboks 7804, N-5020 Bergen, Norway. [DeRoo, Lisa A.; Wilcox, Allen J.] NIEHS, Epidemiol Branch, NIH, Durham, NC 27711 USA. [Lie, Rolv T.] Med Birth Registry Norway, Norwegian Inst Publ Hlth, Bergen, Norway. [Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Pedersen, Dorthe Almind] Univ Southern Denmark, Inst Publ Hlth, Epidemiol Biostat & Biodemog, Odense, Denmark. [Munger, Ronald G.] Utah State Univ, Dept Nutr Dietet & Food Sci, Logan, UT 84322 USA. [Uribe, Lina M. Moreno] Univ Iowa, Dept Orthodont, Coll Dent & Dent Clin, Iowa City, IA USA. [Wehby, George L.] Univ Iowa, Dept Hlth Management & Policy, 105 River St, Iowa City, IA 52242 USA. RP Deroo, LA (reprint author), Univ Bergen, Dept Global Publ Hlth & Primary Care, Postboks 7804, N-5020 Bergen, Norway.; Deroo, LA (reprint author), NIEHS, Epidemiol Branch, NIH, Durham, NC 27711 USA.; Wehby, GL (reprint author), Univ Iowa, Dept Hlth Management & Policy, 105 River St, Iowa City, IA 52242 USA. EM Lisa.De.Roo@igs.uib.no; george-wehby@uiowa.edu OI Wilcox, Allen/0000-0002-3376-1311 FU National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR) [1 R01 DE020895]; Intramural Research Program of the National Institute of Environmental Health Sciences (NIEHS) [ZIA-ES-49027]; NIH [R01 HD39061]; U.S. Centers for Disease Control and Prevention (CDC) [U01-DD000492, U01-D000698, U01-DD001035]; Norwegian Ministry of Health; Ministry of Education and Research FX The main funding for this study was provided by Grant 1 R01 DE020895 from the National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR). This research was also supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (NIEHS) (ZIA-ES-49027). Additional partial funding was from NIH grant R01 HD39061, U.S. Centers for Disease Control and Prevention (CDC) grants U01-DD000492, U01-D000698, and U01-DD001035, and the Norwegian Ministry of Health and the Ministry of Education and Research. We thank Drs. Abee L. Boyles, Lorenzo D. Botto, Sonja A. Rasmussen and Donna D. Baird and for helpful comments on an earlier draft of this manuscript. NR 35 TC 1 Z9 1 U1 4 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0393-2990 EI 1573-7284 J9 EUR J EPIDEMIOL JI Eur. J. Epidemiol. PD OCT PY 2016 VL 31 IS 10 BP 1021 EP 1034 DI 10.1007/s10654-016-0171-5 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EA1SP UT WOS:000386372500006 PM 27350158 ER PT J AU Chiang, YJ Hodes, RJ AF Chiang, Y. Jeffrey Hodes, Richard J. TI T-cell development is regulated by the coordinated function of proximal and distal Lck promoters active at different developmental stages SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE Development; T cell; Thymus; Lck; Promoter ID MAMMALIAN GENOMES; EXPRESSION; P56(LCK); THYMOCYTES; DISSECTION; ACTIVATION; GENE AB Expression of Lck, a T-cell lineage-specific tyrosine kinase critical for T-cell development and activation, can be mediated by either proximal or distal lck promoter. We generated BAC transgenic mice in which BAC lck promoter was deleted and bred these transgenes to an Lck knockout background. Lck-PROX mice, in which only the proximal promoter is functional, have maximal Lck protein and normal thymic development through CD4(-)CD8(-) double negative (DN) and CD4(+)CD8(+) double positive (DP) stages, but undetectable Lck later in development and reduced mature single positive thymocytes. In contrast, Lck-DIST mice, in which only distal promoter was functional, are deficient in Lck protein in DN and DP thymocytes and severely defective in early T-cell development, with a block at the DN3-DN4 beta checkpoint equivalent to complete Lck knockouts. The ability of the proximal lck promoter to support thymic development is independent of Fyn; while, in contrast, the distal lck promoter alone is completely unable to support development in the absence of Fyn. Notably, normal thymocyte development is restored by presence of both proximal and distal promoters, even when independently expressed on different lck genes. These results define distinct and complementary requirements for proximal and distal lck promoters during T-cell development. C1 [Chiang, Y. Jeffrey; Hodes, Richard J.] NCI, Expt Immunol Branch, Bldg 10, Bethesda, MD 20892 USA. [Hodes, Richard J.] NIA, NIH, Bethesda, MD 20892 USA. RP Hodes, RJ (reprint author), NCI, Expt Immunol Branch, Bldg 10, Bethesda, MD 20892 USA.; Hodes, RJ (reprint author), NIA, NIH, Bethesda, MD 20892 USA. EM hodesr@31.nia.nih.gov FU National Institutes of Health, National Cancer Institute FX This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. NR 20 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD OCT PY 2016 VL 46 IS 10 BP 2401 EP 2408 DI 10.1002/eji.201646440 PG 8 WC Immunology SC Immunology GA DZ9VV UT WOS:000386229600013 PM 27469439 ER PT J AU Tikkanen, R Saukkonen, T Fex, M Bennet, H Rautiainen, MR Paunio, T Koskinen, M Panarsky, R Bevilacqua, L Sjoberg, RL Tiihonen, J Virkkunen, M AF Tikkanen, R. Saukkonen, T. Fex, M. Bennet, H. Rautiainen, M. -R. Paunio, T. Koskinen, M. Panarsky, R. Bevilacqua, L. Sjoberg, R. L. Tiihonen, J. Virkkunen, M. TI Influence of a HTR2B Stop Codon on Glucagon Homeostasis and Glucose Excursion in Non-Diabetic Men SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES LA English DT Article DE glucose; glucagon; serotonin 2B receptor; oral glucose tolerance test; insulin resistance; BMI ID INSULIN-SECRETION; GLYCOGEN-SYNTHESIS; SEROTONIN; PHOSPHORYLASE; DYSREGULATION; HYPERGLYCEMIA; METABOLISM; ACTIVATION; MECHANISMS; RATS AB Limited data are available about the role of the serotonin 2B (5-HT2B) receptor in the function of human islets. This study aimed to test whether the 5-HT2B receptor contributes to glucose, insulin, and glucagon homeostasis in humans, utilizing a hereditary loss-of-function gene mutation in the receptor, which causes a 50% reduction in the production of the receptor protein in heterozygotes. This clinical study enrolled participants recruited by newspaper advertisements and from mental status examinations. A cohort of participants from a young Finnish founder population composed of 68 non-diabetic males with a mean age of 30 was divided into groups for comparison based on being a 5-HT2B receptor loss-of-function gene mutation (HTR2B Q20*) heterozygote carrier (n=11) or not (n=57). Serum levels of glucose, insulin, and glucagon were measured in a 5h oral glucose tolerance test using a 75g glucose challenge. Insulin resistance, insulin sensitivity, and beta cell activity were calculated using the homeostasis model assessment (HOMA2) and whole body insulin sensitivity index (WBISI), as well as the ratio of glucagon to insulin was noted. The areas under the curves (AUCs) were also determined. Concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) were measured in cerebrospinal fluid (CSF). Covariate adjusted mean score comparisons were applied. Lower glucagon secretion and decreased glucose excursion were observed among HTR2B Q20* carriers as compared with individuals who were homozygotes for the wild-type Q20 allele (controls). No differences in insulin secretion, beta cell activity, insulin resistance, or insulin sensitivity were observed. The glucagon to insulin ratio differed between the HTR2B Q20* carriers and controls. CSF levels of 5-HIAA were similar between groups. Our findings indicate that the 5-HT2B receptor may contribute to the regulation of human glucagon and glucose homeostasis and the interplay between glucagon and insulin secretion. C1 [Tikkanen, R.; Paunio, T.; Virkkunen, M.] Univ Helsinki, Dept Psychiat, Cent Hosp, Helsinki, Finland. [Tikkanen, R.] Rinnekoti Fdn, Res & Dev, Espoo, Finland. [Saukkonen, T.] Univ Helsinki, Cent Hosp, Childrens Hosp, Helsinki, Finland. [Saukkonen, T.] Univ Helsinki, Helsinki, Finland. [Saukkonen, T.] Novo Nordisk Farma Oy, Espoo, Finland. [Fex, M.; Bennet, H.] Lund Univ, Ctr Diabet, Scania Univ Hosp, Dept Clin Sci, Malmo, Sweden. [Rautiainen, M. -R.; Paunio, T.; Tiihonen, J.] Natl Inst Hlth & Welf, Helsinki, Finland. [Koskinen, M.] Oy Aava Dev Ltd, Helsinki, Finland. [Panarsky, R.] NIAAA, Neurogenet Lab, Bethesda, MD USA. [Bevilacqua, L.] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Sjoberg, R. L.; Tiihonen, J.] Umea Univ, Dept Pharmacol & Clin Neurosci, Umea, Sweden. [Tiihonen, J.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden. [Tiihonen, J.] Univ Eastern Finland, Niuvanniemi Hosp, Dept Forens Psychiat, Kuopio, Finland. RP Tikkanen, R (reprint author), Univ Helsinki, Dept Psychiat, Valskarinkatu 12,POB 22, Helsinki 00260, Finland. EM roope.tikkanen@gmail.com FU Orion Research Foundation; Swedish Research Council [2012-1552]; Waldemar von Frenckell Foundation FX We thank for receiving the following grants: the Orion Research Foundation (R.T), Swedish Research Council (project number: 2012-1552 to M.F), and Waldemar von Frenckell Foundation (MR.R). Excellence in diabetes research (EXODIAB), Krapperup foundation, Ake Wiberg foundation, Royal Physiographic Society, Albert Pahlsson foundation, Crafoord foundation, Childhood Diabetes Foundation, and the Foundation of Sigurd and Elsa Golijes Minne. NR 30 TC 0 Z9 0 U1 0 U2 0 PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH PI STUTTGART PA RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0947-7349 EI 1439-3646 J9 EXP CLIN ENDOCR DIAB JI Exp. Clin. Endocrinol. Diabet. PD OCT PY 2016 VL 124 IS 9 BP 529 EP 534 DI 10.1055/s-0042-109263 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA0XR UT WOS:000386313300002 PM 27437919 ER PT J AU Mookherjee, S Banerjee, D Chakraborty, S Mukhopadhyay, I Sen, A Ray, K AF Mookherjee, Suddhasil Banerjee, Deblina Chakraborty, Subhadip Mukhopadhyay, Indranil Sen, Abhijit Ray, Kunal TI Evaluation of the IL1 Gene Cluster Single Nucleotide Polymorphisms in Primary Open-Angle Glaucoma Pathogenesis SO GENETIC TESTING AND MOLECULAR BIOMARKERS LA English DT Article DE genetics; glaucoma; POAG; interleukins; association study ID HEAT-SHOCK PROTEINS; AQUEOUS-HUMOR; IL-1F7 GENE; ASSOCIATION; IDENTIFICATION; POPULATION; IMMUNITY; DISEASE AB Aims: Dysregulation of the immune system has previously been implicated in glaucoma pathogenesis. In this study, we investigated the potential association of SNPs in the IL1 gene cluster, consisting of nine genes, with primary open-angle glaucoma (POAG) cases. These cases presented with low to normal intraocular pressures (<20mmHg), and are referred to as non-high tension glaucoma (non-HTG) cases. Materials and Methods: In this biphasic study, the discovery phase was conducted with 198 non-HTG cases and 112 controls from eastern India. A total of 68 single nucleotide polymorphisms (SNPs) spanning the IL1 nine-gene cluster region were genotyped using the MALDI-TOF based Sequenom platform. SNPs, which were found to be significantly associated with non-HTG cases in the first phase of the study, were further genotyped by Sanger sequencing in a replication cohort consisting of 194 non-HTG cases and 242 controls. Results: In the discovery phase, two nonsynonymous SNPs (rs3811046 and rs3811047), located in the IL1F7 gene and in an intergenic region, respectively were found to be weakly associated with non-HTG cases. However, the association was not sustained in the replication cohort. Conclusion: Our study did not reveal any reproducible association of SNPs in the IL1 gene cluster with POAG. C1 [Mookherjee, Suddhasil; Banerjee, Deblina; Chakraborty, Subhadip; Ray, Kunal] CSIR Indian Inst Chem Biol, Mol & Human Genet Div, Kolkata, India. [Mukhopadhyay, Indranil] Indian Stat Inst, Human Genet Unit, Kolkata, India. [Sen, Abhijit] Dristi Pradip, Kolkata, India. [Mookherjee, Suddhasil] NEI, NIH, 6 Ctr Dr, Bethesda, MD 20892 USA. [Banerjee, Deblina] NCI, NIH, Bethesda, MD 20892 USA. [Chakraborty, Subhadip] Univ Calcutta, SN Pradhan Ctr Neurosci, Kolkata, India. [Ray, Kunal] CSIR Cent Rd Res Inst, Acad Sci & Innovat Res, CRRI PO Delhi,Mathura Rd, New Delhi 110025, India. RP Mookherjee, S (reprint author), NEI, NIH, 6 Ctr Dr, Bethesda, MD 20892 USA.; Ray, K (reprint author), CSIR Cent Rd Res Inst, Acad Sci & Innovat Res, CRRI PO Delhi,Mathura Rd, New Delhi 110025, India. EM suddhasil.mookherjee@nih.gov; kunalray@acsir.res.in FU Council of Scientific and Industrial Research, Govt. of India [SIP-007, MLP-0016, NWP 004] FX The authors are grateful to the donors who participated in this study and to Dr. Keya Sen for helping with clinical evaluation of patients. We thank Ananya Ray-Soni for critically proofreading the article for improving the language and grammar of the article. The Council of Scientific and Industrial Research, Govt. of India supported the study through funding grants (SIP-007, MLP-0016, and NWP 004) and predoctoral fellowships to S.M., D.B., and S.C. NR 33 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1945-0265 EI 1945-0257 J9 GENET TEST MOL BIOMA JI Genet. Test. Mol. Biomark. PD OCT PY 2016 VL 20 IS 10 BP 633 EP 636 DI 10.1089/gtmb.2015.0344 PG 4 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA EA3AV UT WOS:000386470900012 PM 27533638 ER PT J AU Qian, F Feng, Y Zheng, YL Ogundiran, TO Ojengbede, O Zheng, W Blot, W Ambrosone, CB John, EM Bernstein, L Hu, JJ Ziegler, RG Nyante, S Bandera, EV Ingles, SA Press, MF Nathanson, KL Hennis, A Nemesure, B Ambs, S Kolonel, LN Olopade, OI Haiman, CA Huo, DZ AF Qian, Frank Feng, Ye Zheng, Yonglan Ogundiran, Temidayo O. Ojengbede, Oladosu Zheng, Wei Blot, William Ambrosone, Christine B. John, Esther M. Bernstein, Leslie Hu, Jennifer J. Ziegler, Regina G. Nyante, Sarah Bandera, Elisa V. Ingles, Sue A. Press, Michael F. Nathanson, Katherine L. Hennis, Anselm Nemesure, Barbara Ambs, Stefan Kolonel, Laurence N. Olopade, Olufunmilayo I. Haiman, Christopher A. Huo, Dezheng TI Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry SO HUMAN GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; ESTROGEN-RECEPTOR; SUSCEPTIBILITY LOCI; INDIGENOUS AFRICANS; AMERICAN WOMEN; HUMAN-DISEASE; POPULATION; POLYMORPHISMS; EXPRESSION; BRCA1 AB MicroRNAs (miRNA) regulate breast biology by binding to specific RNA sequences, leading to RNA degradation and inhibition of translation of their target genes. While germline genetic variations may disrupt some of these interactions between miRNAs and their targets, studies assessing the relationship between genetic variations in the miRNA network and breast cancer risk are still limited, particularly among women of African ancestry. We systematically put together a list of 822 and 10,468 genetic variants among primary miRNA sequences and 38 genes in the miRNA biogenesis pathway, respectively; and examined their association with breast cancer risk in the ROOT consortium which includes women of African ancestry. Findings were replicated in an independent consortium. Logistic regression was used to estimate the odds ratio (OR) and 95 % confidence intervals (CI). For overall breast cancer risk, three single-nucleotide polymorphisms (SNPs) in miRNA biogenesis genes DROSHA rs78393591 (OR = 0.69, 95 % CI: 0.55-0.88, P = 0.003), ESR1 rs523736 (OR = 0.88, 95 % CI: 0.82-0.95, P = 3.99 x 10(-4)), and ZCCHC11 rs114101502 (OR = 1.33, 95 % CI: 1.11-1.59, P = 0.002), and one SNP in primary miRNA sequence (rs116159732 in miR-6826, OR = 0.74, 95 % CI: 0.63-0.89, P = 0.001) were found to have significant associations in both discovery and validation phases. In a subgroup analysis, two SNPs were associated with risk of estrogen receptor (ER)-negative breast cancer, and three SNPs were associated with risk of ER-positive breast cancer. Several variants in miRNA and miRNA biogenesis pathway genes were associated with breast cancer risk. Risk associations varied by ER status, suggesting potential new mechanisms in etiology. C1 [Qian, Frank; Zheng, Yonglan; Olopade, Olufunmilayo I.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Feng, Ye; Ingles, Sue A.; Haiman, Christopher A.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Feng, Ye; Ingles, Sue A.; Press, Michael F.; Haiman, Christopher A.] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. [Ogundiran, Temidayo O.] Univ Ibadan, Dept Surg, Coll Med, Ibadan, Nigeria. [Ojengbede, Oladosu] Univ Ibadan, Coll Med, Ctr Populat & Reprod Hlth, Ibadan, Nigeria. [Zheng, Wei; Blot, William] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Vanderbilt Epidemiol Ctr, Div Epidemiol,Dept Med, Nashville, TN USA. [Ambrosone, Christine B.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [John, Esther M.] Canc Prevent Inst Calif, Fremont, CA USA. [John, Esther M.] Stanford Univ, Sch Med Stanford, Dept Hlth Res & Policy Epidemiol, Stanford, CA 94305 USA. [John, Esther M.] Stanford Univ, Sch Med Stanford, Stanford Canc Inst, Stanford, CA 94305 USA. [Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA. [Hu, Jennifer J.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA. [Hu, Jennifer J.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. [Ziegler, Regina G.] NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, Bethesda, DC USA. [Nyante, Sarah] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Nyante, Sarah] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Bandera, Elisa V.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. [Press, Michael F.] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA. [Nathanson, Katherine L.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Hennis, Anselm] Univ West Indies, Chron Dis Res Ctr, Bridgetown, Barbados. [Hennis, Anselm] Univ West Indies, Res Inst Trop Med, Bridgetown, Barbados. [Nemesure, Barbara] SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA. [Ambs, Stefan] NCI, Human Carcinogenesis Lab, Bldg 37, Bethesda, MD 20892 USA. [Kolonel, Laurence N.] Univ Hawaii, Ctr Canc, Program Epidemiol, Honolulu, HI 96822 USA. [Huo, Dezheng] Univ Chicago, Dept Publ Hlth Sci, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA. RP Huo, DZ (reprint author), Univ Chicago, Dept Publ Hlth Sci, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA. EM dhuo@health.bsd.uchicago.edu FU National Cancer Institute [R01-CA142996, P50-CA125183, R01-CA89085] FX This work was supported by National Cancer Institute Grants R01-CA142996, P50-CA125183, and R01-CA89085. NR 75 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 EI 1432-1203 J9 HUM GENET JI Hum. Genet. PD OCT PY 2016 VL 135 IS 10 BP 1145 EP 1159 DI 10.1007/s00439-016-1707-1 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA DX2UC UT WOS:000384225700004 PM 27380242 ER PT J AU Santoro, N Eisenberg, E Trussell, JC Craig, LB Gracia, C Huang, H Alvero, R Casson, P Christman, G Coutifaris, C Diamond, M Jin, SS Legro, RS Robinson, RD Schlaff, WD Zhang, HP AF Santoro, Nanette Eisenberg, Esther Trussell, J. C. Craig, LaTasha B. Gracia, Clarisa Huang, Hao Alvero, Ruben Casson, Peter Christman, Gregory Coutifaris, Christos Diamond, Michael Jin, Susan Legro, Richard S. Robinson, Randal D. Schlaff, William D. Zhang, Heping CA Reprod Med Network Investigators TI Fertility-related quality of life from two RCT cohorts with infertility: unexplained infertility and polycystic ovary syndrome SO HUMAN REPRODUCTION LA English DT Article DE quality of life; polycystic ovary syndrome; unexplained infertility; FertiQOL; infertility ID IN-VITRO FERTILIZATION; MULTIPLE INTRAUTERINE GESTATIONS; STIMULATION AMIGOS TRIAL; PSYCHOLOGICAL DISTRESS; EMOTIONAL DISTRESS; PSYCHOMETRIC PROPERTIES; PROBLEM STRESS; SOCIAL IMPACT; WOMEN; COUPLES AB Does fertility-related quality of life (FertiQOL) differ by infertility diagnosis between women with polycystic ovary syndrome (PCOS) and their partners, compared with couples with unexplained infertility (UI)? Women with PCOS report lower QOL than those with UI, whereas males with UI report lower QOL than males with PCOS partners. The fertility-specific QOL survey, FertiQOL, has been used to examine fertility-related QOL in a number of worldwide cohorts. Few data have addressed fertility-related QOL as a function of infertility diagnosis. Overall, men report better QOL than women with infertility, and there is variation in FertiQOL scores across different samples from different countries. This was a prospective, cohort study derived from two concurrent, randomized clinical trials, and designed to examine QOL in infertile females with PCOS and UI at the time of enrollment compared with each other and their male partners; to compare concordance FertiQOL scores in this study across other worldwide cohorts; and to determine if baseline FertiQOL was associated with pregnancy outcome. Women with PCOS and their partners (n = 733 and n = 641, respectively), and couples with UI (n = 865 women and 849 men) completed a validated fertility-specific QOL survey (FertiQOL) at the time of the study screening visit. PCOS women were randomized to either clomiphene citrate or letrozole treatment; couples with UI were randomized to clomiphene citrate, letrozole or gonadotrophin plus IUI. FertiQOL results were compiled by diagnosis (PCOS or UI) and compared by diagnosis and sex using Wilcoxon Rank-Sum testing. Relationships between baseline FertiQOL and pregnancy outcomes were examined using logistic regression. Multivariable models were performed to assess the association between FertiQOL scores and key participant characteristics. Women with PCOS had lower total FertiQOL scores (72.3 +/- 14.8) than those with UI (77.1 +/- 12.8; P < 0.001); this was true for each domain (except Relational). These differences were largely explained by variation in BMI, hirsutism, household income and age. Women had lower overall FertiQOL scores than their male partners. Males with PCOS partners had higher scores than males with UI (84.9 +/- 10.2 versus 83.3 +/- 10.8; P = 0.003). Scores were not consistently associated with conception or pregnancy outcome. The use of multiple tests of association may have resulted in spurious statistically significant findings. Inherent sociodemographic differences between women with PCOS and those with UI largely account for the lower QOL in women with PCOS. Our study was unable to assess if changes in QOL affected pregnancy outcome as FertiQOL data were collected prior to treatment. Finally, the participants for both studies represent their local communities, but are not a population-based sample and thus firm conclusions about how representative these couples are to the general population must be made with caution. Women with PCOS with elevated BMI and hirsutism scores and with lower socioeconomic status may require more, targeted psychosocial support than those with other diagnoses. Possible attribution of infertility to the male partner appears to result in a lower QOL. There appears to be substantial national variation in FertiQOL scores, with US-based cohorts reporting overall higher QOL. This work was supported by National Institutes of Health (NIH)/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Grants U10 HD39005 (to M.D.), U10 HD38992 (to R.S.L.), (to C.C.), U10 HD38998 (to R.A.), U10 HD055942 (to R.D.R.), HD055944 (to P.C.), U10 HD055936 (to G.C.), U10HD055925 (to H.Z.); and U10 U54-HD29834 (to the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core of the Specialized Cooperative Centers Program in Reproduction and Infertility Research). Most importantly, this research was made possible by the funding by American Recovery and Reinvestment Act. N.S., E.E., J.C.T., C.G., H.H., R.A., P.C., G.C., C.C., M.D., S.J., W.D.S. and H.Z. report no conflicts of interests/disclosures. L.B.C. reports research support from Ferring Pharmaceuticals and Roche Diagnostics; R.S.L. reports receipt of consulting fees from AstraZeneca, Euroscreen, Sprout Pharmaceuticals, Taken, Kindex, Clarus and Bayer, Inc., and research support from AstraZeneca and Ferring Pharmaceuticals. R.D.R. reports research support from AbbVie. Pregnancy in Polycystic Ovary Syndrome II (PPCOS II), NCT00719186; Assessment of Multiple Intrauterine Gestations in Ovulation Stimulation (AMIGOS) NCT01044862, clinicaltrials.gov. PPCOS II 17 July 2008; AMIGOS 7 January 2010. PPCOS II 19 February 2009; AMIGOS 2 August 2010. C1 [Santoro, Nanette; Alvero, Ruben] Univ Colorado, Dept Obstet & Gynecol, Sch Med, 12631 E 17th Ave AO,Room 4010, Aurora, CO 80045 USA. [Eisenberg, Esther] NICHD, Fertil & Infertil Branch, NIH, Bethesda, MD 20892 USA. [Trussell, J. C.] SUNY Upstate Med Univ, Dept Urol, 750 E Adams St, Syracuse, NY 13210 USA. [Craig, LaTasha B.] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, POB 26901,WP 2410, Oklahoma City, OK 73126 USA. [Gracia, Clarisa; Coutifaris, Christos] Univ Penn, Dept Obstet & Gynecol, Penn Fertil Ctr, 3701 Market St, Philadelphia, PA 19104 USA. [Huang, Hao; Jin, Susan; Zhang, Heping] Yale Sch Publ Hlth, Collaborat Ctr Stat Sci, 60 Coll St, New Haven, CT 06520 USA. [Legro, Richard S.] Penn State Coll Med, 500 Univ Dr, Hershey, PA 17033 USA. [Robinson, Randal D.] Univ Texas San Antonio, Hlth Sci Ctr, 8300 Floyd Curl Dr, San Antonio, TX 78229 USA. [Casson, Peter] Northeastern Reprod Med, 105 West View Rd Suite 305, Colchester, VT 05446 USA. [Christman, Gregory] Univ Florida, Coll Med, Dept Obstet & Gynecol, 1600 SW Archer Rd, Gainesville, FL 32611 USA. [Diamond, Michael] Georgia Regents Univ, Med Coll Georgia, 1120 15th St,BA-7300, Augusta, GA 30912 USA. [Schlaff, William D.] Thomas Jefferson Univ, Dept Obstet & Gynecol, 834 Chestnut St,Suite 400, Philadelphia, PA 19107 USA. [Alvero, Ruben] Brown Univ, Warren Alpert Med Sch, Dept Obstet & Gynecol, Providence, RI 02903 USA. RP Santoro, N (reprint author), Univ Colorado, Dept Obstet & Gynecol, Sch Med, 12631 E 17th Ave AO,Room 4010, Aurora, CO 80045 USA. EM nanette.santoro@ucdenver.edu FU National Institutes of Health (NIH)/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [U10 HD39005, U10 HD38992, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, U10HD055925, U10 U54-HD29834]; American Recovery and Reinvestment Act FX This work was supported by National Institutes of Health (NIH)/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Grants U10 HD39005 (to M.D.), U10 HD38992 (to R.S.L., to C.C.), U10 HD38998 (to R.A.), U10 HD055942 (to R.D.R.), HD055944 (to P.C.), U10 HD055936 (to G.C.), U10HD055925 (to H.Z.); and U10 U54-HD29834 (to the University of Virginia Center for Research in Reproduction Ligand Assay and AnalysisCore of the Specialized Cooperative Centers Program in Reproduction and Infertility Research). Most importantly, this research was made possible by the funding by American Recovery and Reinvestment Act. NR 62 TC 0 Z9 0 U1 9 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD OCT PY 2016 VL 31 IS 10 BP 2268 EP 2279 DI 10.1093/humrep/dew175 PG 12 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DZ7ZH UT WOS:000386087000014 PM 27402910 ER PT J AU Eisenberg, ML Sundaram, R Maisog, J Louis, GMB AF Eisenberg, Michael L. Sundaram, Rajeshwari Maisog, Jose Louis, Germaine M. Buck TI Diabetes, medical comorbidities and couple fecundity SO HUMAN REPRODUCTION LA English DT Article DE diabetes; hypertension; hyperlipidemia; hyperthyroidism; hypothyroidism; fertility ID SEMEN QUALITY DATA; TIME-TO-PREGNANCY; BODY-MASS INDEX; MALE-INFERTILITY; UNITED-STATES; LIPID CONCENTRATIONS; METABOLIC SYNDROME; LIFE; MELLITUS; INSULIN AB What is the relationship between couple's health and fecundity in a preconception cohort? Somatic health may impact fecundity in men and women as couples whose male partner had diabetes or whose female partner had two or more medical conditions had a longer time-to-pregnancy (TTP). The impact of somatic health on human fecundity is hypothesized given the reported declines in spermatogenesis and ovulation among individuals with certain medical comorbidities. A population-based prospective cohort study recruiting couples from 16 counties in Michigan and Texas (2005-2009) using sampling frameworks allowing for identification of couples planning pregnancy in the near future. Five hundred and one couples desiring pregnancy and discontinuing contraception were followed-up for 12 months or until a human chorionic gonadotropin pregnancy was detected. In all, 33 (21.4%) female and 41 (26.6%) male partners had medical conditions at baseline. Couples' medical comorbidity was associated with pregnancy status. Diabetes in either partner was associated with diminished fecundity, as measured by a longer TTP. Specifically, fecundability odds ratios (FORs) were below 1, indicating a longer TTP, for male partners with diabetes (0.35, 95% confidence interval (CI): 0.14-0.86) even in adjusted models (0.35, 95% CI: 0.13-0.88). Female partners with diabetes had comparable reductions in FORs; however, the analyses did not reach statistical significance (0.26, 95% CI: 0.03-1.98). Female partners with two or more medical conditions had a significantly longer TTP compared with women with no health problems (0.36, 95% CI: 0.14-0.92). Importantly, the presence of medical conditions was not associated with sexual frequency. We cannot rule out residual confounding, Type 2 errors for less prevalent medical conditions, or chance findings in light of the multiple comparisons made in the analysis. The findings require cautious interpretation given that medical diagnoses are subject to possible reporting errors, although we are unaware of any potential biases that may have been introduced, as participants were unaware of how long it would take to become pregnant upon enrollment. The current report suggests a relationship between male and female diabetes and fecundity, and possibly somatic health more globally. Moreover, while the mechanism is uncertain, if corroborated, our data suggest that early evaluation and treatment may be warranted for diabetics prior to attempting to conceive. Intramural research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Contract nos. #N01-HD-3-3355, N01-HD-3-3356 and N01-HD-3-3358). The authors have no conflicts of interest to declare. C1 [Eisenberg, Michael L.] Stanford Univ, Dept Urol, 300 Pasteur Dr, Stanford, CA 94305 USA. [Eisenberg, Michael L.] Stanford Univ, Dept Obstet & Gynecol, 300 Pasteur Dr, Stanford, CA 94305 USA. [Sundaram, Rajeshwari] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Biostat & Bioinformat Branch, Div Intramural Populat Hlth Res, 6100 Execut Blvd,Room 7B03, Rockville, MD 20852 USA. [Maisog, Jose] Glotech Inc, 1801 Res Blvd,Suite 605, Rockville, MD 20852 USA. [Louis, Germaine M. Buck] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, 6100 Execut Blvd,Room 7B03, Rockville, MD 20852 USA. RP Eisenberg, ML (reprint author), Stanford Univ, Sch Med, Dept Urol, Male Reprod Med & Surg, 300 Pasteur Dr, Stanford, CA 94305 USA. EM eisenberg@stanford.edu OI Sundaram, Rajeshwari/0000-0002-6918-5002; Buck Louis, Germaine/0000-0002-1774-4490 FU Intramural research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development [N01-HD-3-3355, N01-HD-3-3356, N01-HD-3-3358] FX Intramural research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Contract nos. # N01-HD-3-3355, N01-HD-3-3356 and N01-HD-3-3358). NR 41 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD OCT PY 2016 VL 31 IS 10 BP 2369 EP 2376 DI 10.1093/humrep/dew200 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA DZ7ZH UT WOS:000386087000025 PM 27591240 ER PT J AU Fleg, JL Evans, GW Margolis, KL Barzilay, J Basile, JN Bigger, JT Cutler, JA Grimm, R Pedley, C Peterson, K Pop-Busui, R Sperl-Hillen, J Cushman, WC AF Fleg, Jerome L. Evans, Gregory W. Margolis, Karen L. Barzilay, Joshua Basile, Jan N. Bigger, J. Thomas Cutler, Jeffrey A. Grimm, Richard Pedley, Carolyn Peterson, Kevin Pop-Busui, Rodica Sperl-Hillen, JoAnn Cushman, William C. TI Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance SO HYPERTENSION LA English DT Article DE cardiovascular diseases; clinical trials; randomized; diabetes mellitus; type 2; hypertension; hypotension; orthostatic ID POSTURAL HYPOTENSION; ATHEROSCLEROSIS RISK; HEART-FAILURE; PROGRAM; INSULIN; VASODILATION; HYPERTENSION; COMMUNITIES; MORTALITY AB Orthostatic hypotension (OH) is associated with hypertension and diabetes mellitus. However, in populations with both hypertension and diabetes mellitus, its prevalence, the effect of intensive versus standard systolic blood pressure (BP) targets on incident OH, and its prognostic significance are unclear. In 4266 participants in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) BP trial, seated BP was measured 3x, followed by readings every minute for 3 minutes after standing. Orthostatic BP change, calculated as the minimum standing minus the mean seated systolic BP and diastolic BP, was assessed at baseline, 12 months, and 48 months. The relationship between OH and clinical outcomes (total and cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, heart failure hospitalization or death and the primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) was assessed using proportional hazards analysis. Consensus OH, defined by orthostatic decline in systolic BP 20 mmHg or diastolic BP 10 mmHg, occurred at 1 time point in 20% of participants. Neither age nor systolic BP treatment target (intensive, <120 mmHg versus standard, <140 mmHg) was related to OH incidence. Over a median follow-up of 46.9 months, OH was associated with increased risk of total death (hazard ratio, 1.61; 95% confidence interval, 1.11-2.36) and heart failure death/hospitalization (hazard ratio, 1.85, 95% confidence interval, 1.17-2.93), but not with the primary outcome or other prespecified outcomes. In patients with type 2 diabetes mellitus and hypertension, OH was common, not associated with intensive versus standard BP treatment goals, and predicted increased mortality and heart failure events. C1 [Fleg, Jerome L.; Cutler, Jeffrey A.] NHLBI, Bldg 10, Bethesda, MD 20892 USA. [Evans, Gregory W.; Pedley, Carolyn] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Margolis, Karen L.; Sperl-Hillen, JoAnn] Hlth Partners Inst Educ & Res, Minneapolis, MN USA. [Barzilay, Joshua] Kaiser Permanente Georgia, Atlanta, GA USA. [Basile, Jan N.] Med Univ South Carolina, Charleston, SC USA. [Bigger, J. Thomas] Columbia Univ, Sch Med, New York, NY USA. [Grimm, Richard] Berman Ctr Outcomes & Clin Res, Minneapolis, MN USA. [Peterson, Kevin] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Pop-Busui, Rodica] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Cushman, William C.] Vet Affairs Med Ctr, Memphis, TN USA. RP Fleg, JL (reprint author), NHLBI, Div Cardiovasc Sci, 6701 Rockledge Dr,Room 8154, Bethesda, MD 20892 USA. EM flegj@nhlbi.nih.gov FU National Heart, Lung, and Blood Institute FX The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure trial was funded by a contract from the National Heart, Lung, and Blood Institute. NR 24 TC 3 Z9 3 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD OCT PY 2016 VL 68 IS 4 BP 888 EP 895 DI 10.1161/HYPERTENSIONAHA.116.07474 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DX1LB UT WOS:000384127800015 PM 27504006 ER PT J AU Sung, VW Borello-France, D Dunivan, G Gantz, M Lukacz, ES Moalli, P Newman, DK Richter, HE Ridgeway, B Smith, AL Weidner, AC Meikle, S AF Sung, Vivian W. Borello-France, Diane Dunivan, Gena Gantz, Marie Lukacz, Emily S. Moalli, Pamela Newman, Diane K. Richter, Holly E. Ridgeway, Beri Smith, Ariana L. Weidner, Alison C. Meikle, Susan CA Pelvic Floor Disorders Network TI Methods for a multicenter randomized trial for mixed urinary incontinence: rationale and patient-centeredness of the ESTEEM trial SO INTERNATIONAL UROGYNECOLOGY JOURNAL LA English DT Article DE Female; Mixed urinary incontinence; Clinical trials; Sling; Behavioral therapy ID QUALITY-OF-LIFE; PELVIC FLOOR DISORDERS; STRESS-INCONTINENCE; BEHAVIORAL-THERAPY; US WOMEN; OVERACTIVE BLADDER; URGE INCONTINENCE; TRACT SYMPTOMS; ORGAN PROLAPSE; PREVALENCE AB Introduction and hypothesis Mixed urinary incontinence (MUI) can be a challenging condition to manage. We describe the protocol design and rationale for the Effects of Surgical Treatment Enhanced with Exercise for Mixed Urinary Incontinence (ESTEEM) trial, designed to compare a combined conservative and surgical treatment approach versus surgery alone for improving patient-centered MUI outcomes at 12 months. Methods ESTEEM is a multisite, prospective, randomized trial of female participants with MUI randomized to a standardized perioperative behavioral/pelvic floor exercise intervention phis midurethral sling versus midurethral sling alone. We describe our methods and four challenges encountered during the design phase: defusing the study population, selecting relevant patient-centered outcomes, determining sample size estimates using a patient-reported outcome measure, and designing an analysis plan that accommodates MUI failure rates. A central theme in the design was patient centeredness, which guided many key decisions. Our primary outcome is patient reported MUI symptoms measured using the Urogenital Distress Inventory (UDI) score at 12 months. Secondary outcomes include quality of life, sexual function, cost-effectiveness, time to failure, and need for additional treatment. Results The final study design was implemented in November 2013 across eight clinical sites in the Pelvic Floor Disorders Network. As of 27 February 2016, 433 total/472 targeted participants had been randomized. Conclusions We describe the ESTEEM protocol and our methods for reaching consensus for methodological challenges in designing a trial for MUI by maintaining the patient perspective at the core of key decisions. This trial will provide information that can directly impact patient care and clinical decision making. C1 [Sung, Vivian W.] Brown Univ, Dept Obstet & Gynecol, Alpert Med Sch, Div Urogynecol & Reconstruct Pelv Surg, 101 Plain St 5th Floor, Providence, RI 02903 USA. [Sung, Vivian W.] Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp Rhode Isl, Div Urogynecol & Reconstruct Pelv Surg, 101 Plain St 5th Floor, Providence, RI 02903 USA. [Borello-France, Diane] Duquesne Univ, Dept Phys Therapy, Rangos Sch Hlth Sci, Pittsburgh, PA 15219 USA. [Dunivan, Gena] Univ New Mexico, Dept Obstet & Gynecol, Div Urogynecol, Albuquerque, NM 87131 USA. [Gantz, Marie] RTI Int, Social Stat & Environm Sci, Res Triangle Pk, NC USA. [Lukacz, Emily S.] UC San Diego Hlth Syst, Dept Reprod Med, Div Female Pelv Med & Reconstruct Surg, San Diego, CA USA. [Moalli, Pamela] Univ Pittsburgh, Med Ctr, Dept Obstet Gynecol & Reprod Sci, Womens Ctr Bladder & Pelv Hlth,Div Urogynecol & R, Pittsburgh, PA USA. [Newman, Diane K.; Smith, Ariana L.] Univ Penn Hlth Syst, Dept Surg, Div Urol, Philadelphia, PA USA. [Richter, Holly E.] Univ Alabama Birmingham, Dept Obstet & Gynecol, Div Urogynecol & Pelv Reconstruct Surg, Birmingham, AL 35294 USA. [Ridgeway, Beri] Cleveland Clin, Ctr Urogynecol & Reconstruct Pelv Surg, Obstet Gynecol & Womens Hlth Inst, Cleveland, OH 44106 USA. [Weidner, Alison C.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Urogynecol, Durham, NC 27710 USA. [Meikle, Susan] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. RP Sung, VW (reprint author), Brown Univ, Dept Obstet & Gynecol, Alpert Med Sch, Div Urogynecol & Reconstruct Pelv Surg, 101 Plain St 5th Floor, Providence, RI 02903 USA.; Sung, VW (reprint author), Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp Rhode Isl, Div Urogynecol & Reconstruct Pelv Surg, 101 Plain St 5th Floor, Providence, RI 02903 USA. EM vsung@wihri.org OI Markland, Alayne/0000-0002-6567-6744 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [U10 HD041261, U10 HD069013, U10 HD054214, U10 HD054215, U10 HD041267, U10 HD069025, U10 HD069010, U10 HD069006, U01 HD069031]; National Institutes of Health Office of Research on Women's Health FX Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10 HD041261, U10 HD069013, U10 HD054214, U10 HD054215, U10 HD041267, U10 HD069025, U10 HD069010, U10 HD069006, U01 HD069031) and the National Institutes of Health Office of Research on Women's Health. NR 60 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-3462 EI 1433-3023 J9 INT UROGYNECOL J JI Int. Urogynecol. J. PD OCT PY 2016 VL 27 IS 10 BP 1479 EP 1490 DI 10.1007/s00192-016-3031-7 PG 12 WC Obstetrics & Gynecology; Urology & Nephrology SC Obstetrics & Gynecology; Urology & Nephrology GA EA1LR UT WOS:000386354200004 PM 27287818 ER PT J AU Meyer, BJ Byrne, M Parletta, N Gow, R Hibbeln, JR AF Meyer, Barbara J. Byrne, Mitchell Parletta, Natalie Gow, Rachel Hibbeln, Joseph R. TI Fish Oil and Impulsive Aggressive Behavior SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY LA English DT Letter ID YOUNG-ADULT PRISONERS; DISORDER; CHILDREN; TRIAL C1 [Meyer, Barbara J.] Univ Wollongong, Sch Med, Northfields Ave, Wollongong, NSW 2522, Australia. [Byrne, Mitchell] Univ Wollongong, Sch Psychol, Wollongong, NSW 2522, Australia. [Parletta, Natalie] Univ S Australia, Sansom Inst Hlth Res, Sch Populat Hlth, Adelaide, SA, Australia. [Gow, Rachel; Hibbeln, Joseph R.] NIAAA, Sect Nutr Neurosci, Lab Membrane Biol & Biophys, NIH, Bethesda, MD USA. RP Meyer, BJ (reprint author), Univ Wollongong, Sch Med, Northfields Ave, Wollongong, NSW 2522, Australia. EM bmeyer@uow.edu.au OI Byrne, Mitchell/0000-0003-0823-2917 NR 5 TC 0 Z9 0 U1 4 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5463 EI 1557-8992 J9 J CHILD ADOL PSYCHOP JI J. Child Adolesc. Psychopharmacol. PD OCT PY 2016 VL 26 IS 8 BP 766 EP 766 DI 10.1089/cap.2015.0065 PG 1 WC Pediatrics; Pharmacology & Pharmacy; Psychiatry SC Pediatrics; Pharmacology & Pharmacy; Psychiatry GA DZ8QN UT WOS:000386136000017 PM 26217883 ER PT J AU da Cunha, MG Franchin, M de Paula-Eduardo, LF Freires, IA Beutler, JA de Alencar, SM Ikegaki, M Tabchoury, CPM Cunha, TM Rosalen, PL AF da Cunha, Marcos Guilherme Franchin, Marcelo de Paula-Eduardo, Laila Facin Freires, Irlan Almeida Beutler, John A. de Alencar, Severino Matias Ikegaki, Masaharu Machado Tabchoury, Cinthia Pereira Cunha, Thiago Mattar Rosalen, Pedro Luiz TI Anti-inflammatory and anti-biofilm properties of ent-nemorosone from Brazilian geopropolis SO JOURNAL OF FUNCTIONAL FOODS LA English DT Article DE Geopropolis; ent-Nemorosone; Anti-inflammatory; Anti-biofilm ID NF-KAPPA-B; MECHANICAL INFLAMMATORY HYPERNOCICEPTION; ACTIVATED PROTEIN-KINASES; STREPTOCOCCUS-MUTANS; RED PROPOLIS; MELIPONA-SCUTELLARIS; TNF-ALPHA; 7-EPICLUSIANONE; BENZOPHENONE; RECRUITMENT AB ent-Nemorosone is a benzophenone isolated from geopropolis from Melipona scutellaris whose biological properties remain unexplored. Herein, we evaluated the anti-inflammatory activity of ent-nemorosone by in vivo neutrophil migration and TNF-alpha quantification, as well as by in vitro TNF-alpha quantification, ERK 1/2 phosphorylation, NF-kB activation and nuclear translocation of p65 in stimulated macrophages. ent-Nemorosone was also tested for its antimicrobial effects against Streptococcus mutans biofilm adhesion, polysaccharide production, and viability ent-Nemorosone reduced the influx of neutrophils and TNF-alpha release into the peritoneal cavity of mice, as well as the in vitro TNF-alpha levels, ERK 1/2 phosphorylation, NF-kB activation and nuclear p65 translocation. Furthermore, this compound inhibited biofilm adhesion and reduced the amount of extra- and intracellular polysaccharides synthesized by S. mutans. Thus, ent-nemorosone showed promising anti-inflammatory activity by acting on TNF-alpha release in macrophages, as well as anti-biofilm properties by reducing S. mutans polysaccharide production. (C) 2016 Elsevier Ltd. All rights reserved. C1 [da Cunha, Marcos Guilherme; Franchin, Marcelo; de Paula-Eduardo, Laila Facin; Freires, Irlan Almeida; Machado Tabchoury, Cinthia Pereira; Rosalen, Pedro Luiz] Univ Estadual Campinas, UNICAMP, Piracicaba Dent Sch, Dept Physiol Sci, Campinas, SP, Brazil. [da Cunha, Marcos Guilherme; Beutler, John A.] NCI, Mol Targets Lab, NIH, Frederick, MD 21701 USA. [de Alencar, Severino Matias] Univ Sao Paulo, Luiz de Queiroz Coll Agr, Dept Agrifood Ind Food & Nutr, Piracicaba, SP, Brazil. [Ikegaki, Masaharu] Univ Fed Alfenas, Coll Pharmaceut Sci, Alfenas, MG, Brazil. [Cunha, Thiago Mattar] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto, SP, Brazil. RP Rosalen, PL (reprint author), Univ Estadual Campinas, UNICAMP, Piracicaba Dent Sch, Dept Physiol Sci, Campinas, SP, Brazil. EM rosalen@fop.unicamp.br RI Alencar, Severino/B-7743-2012; CEPID, CRID/J-2644-2015; Cunha, Thiago/B-7729-2012; OI Alencar, Severino/0000-0002-6637-7973; Cunha, Thiago/0000-0003-1084-0065; Freires, Irlan/0000-0002-1079-6941 FU FAPESP [2011/16501-3, 2011/23635-6, 2012/22378-2, 2012/22002-2]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research [1ZIABC011469-04] FX This research was supported by FAPESP (No. 2011/16501-3, 2011/23635-6, 2012/22378-2 and 2012/22002-2) and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (No. 1ZIABC011469-04). The authors would like to thank Mr. Jose Emidio Borges de Souza for providing the geopropolis samples. We thank Sergey Tarasov and Marzena Dyba (Biophysics Resource Core, Structural Biophysics Laboratory, CCR) for assistance with mass spectrometry. NR 33 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1756-4646 J9 J FUNCT FOODS JI J. Funct. Food. PD OCT PY 2016 VL 26 BP 27 EP 35 DI 10.1016/j.jff.2016.07.009 PG 9 WC Food Science & Technology SC Food Science & Technology GA DZ9KG UT WOS:000386193400003 ER PT J AU Mudd, JC Brenchley, JM AF Mudd, Joseph C. Brenchley, Jason M. TI Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV-1 pathognesis; gastrointestinal tract; microbiome; Th17; cART; residual inflammation; probiotics ID HUMAN-IMMUNODEFICIENCY-VIRUS; SYSTEMIC IMMUNE ACTIVATION; T-CELL-ACTIVATION; INFLAMMATORY-BOWEL-DISEASE; INFECTED RHESUS MACAQUES; INNATE LYMPHOID-CELLS; ANTIRETROVIRAL THERAPY; SIV INFECTION; INTESTINAL INFLAMMATION; VIRAL SUPPRESSION AB Distinct pathological events occur within the gastrointestinal (GI) tract of Asian macaques with progressive simian immunodeficiency virus (SIV) infection and humans with human immunodeficiency virus type 1 (HIV-1) infection that are critical in shaping disease course. These events include depletion and functional alteration of GI-resident CD4(+) T cells, loss of antigen-presenting cells, loss of innate lymphocytes, and possible alterations to the composition of the gut microbiota. These contribute to structural damage to the GI tract and systemic translocation of GI tract microbial products. These translocated microbial products directly stimulate the immune system, and there is now overwhelming evidence that this drives chronic immune activation in HIV-1 and SIV infection. While combined antiretroviral therapy (cART) in HIV-1-infected subjects generally allows for immune reconstitution in peripheral blood, reconstitution of the GI tract occurs at a much slower pace, and both immunological and structural abnormalities persist in the GI tract. Importantly, studies of large cohorts of individuals have linked suboptimal GI reconstitution to residual inflammation and heightened morbidities in HIV-1-infected cART recipients. As a result, current era treatments aimed at augmenting restoration of the GI tract hold promise in returning cART recipients to full health. C1 [Mudd, Joseph C.; Brenchley, Jason M.] NIAID, Parasit Dis Lab, NIH, 4 Mem Dr, Bethesda, MD 20814 USA. RP Brenchley, JM (reprint author), NIAID, Parasit Dis Lab, NIH, 4 Mem Dr, Bethesda, MD 20814 USA. EM jbrenchl@niaid.nih.gov FU Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health FX This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. NR 98 TC 2 Z9 2 U1 6 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2016 VL 214 SU 2 BP S58 EP S66 DI 10.1093/infdis/jiw258 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DZ8UP UT WOS:000386147600004 PM 27625432 ER PT J AU Du Toit, J Millum, J AF Du Toit, Jessica Millum, Joseph TI Are Indirect Benefits Relevant to Health Care Allocation Decisions? SO JOURNAL OF MEDICINE AND PHILOSOPHY LA English DT Article DE direct benefits; indirect benefits; resource allocation ID INFLUENZA; HEADACHES; COUNT; LIVES AB When allocating scarce healthcare resources, the expected benefits of alternative allocations matter. But, there are different kinds of benefits. Some are direct benefits to the recipient of the resource such as the health improvements of receiving treatment. Others are indirect benefits to third parties such as the economic gains from having a healthier workforce. This article considers whether only the direct benefits of alternative healthcare resource allocations are relevant to allocation decisions, or whether indirect benefits are relevant too. First, we distinguish different conceptions of direct and indirect benefits and argue that only a recipient conception could be morally relevant. We analyze four arguments for thinking that indirect benefits should not count and argue that none is successful in showing that the indirectness of a benefit is a good reason not to count it. We conclude that direct and indirect benefits should be evaluated in the same way. C1 [Du Toit, Jessica; Millum, Joseph] NIH, Bldg 10, Bethesda, MD 20892 USA. RP Du Toit, J (reprint author), NIH, Dept Bioeth, 10 Ctr Dr,Bldg 10,Room 1C118, Bethesda, MD 20892 USA. EM jess.dutoit@gmail.com FU National Institutes of Health Clinical Center; Fogarty International Center FX The authors would like to thank audiences at the NIH Clinical Center Department of Bioethics and the New Scholars in Bioethics 4th Annual Symposium for helpful comments on earlier drafts of this article. This work was supported, in part, by intramural funds from the National Institutes of Health Clinical Center and Fogarty International Center. The views expressed are the authors' own. They do not represent the position or policy of the National Institutes of Health, US Public Health Service, or the Department of Health and Human Services. NR 29 TC 2 Z9 2 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-5310 EI 1744-5019 J9 J MED PHILOS JI J. Med. Philos. PD OCT PY 2016 VL 41 IS 5 BP 540 EP 557 DI 10.1093/jmp/jhw018 PG 18 WC Ethics; Social Sciences, Biomedical SC Social Sciences - Other Topics; Biomedical Social Sciences GA DZ8WB UT WOS:000386152000007 PM 27465773 ER PT J AU Moaddel, R Fabbri, E Khadeer, MA Carlson, OD Gonzalez-Freire, M Zhang, PB Semba, RD Ferrucci, L AF Moaddel, Ruin Fabbri, Elisa Khadeer, Mohammed A. Carlson, Olga D. Gonzalez-Freire, Marta Zhang, Pingbo Semba, Richard D. Ferrucci, Luigi TI Plasma Biomarkers of Poor Muscle Quality in Older Men and Women from the Baltimore Longitudinal Study of Aging SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Sarcopenia; Muscles; Metabolomics ID SKELETAL-MUSCLE; INDOLEAMINE 2,3-DIOXYGENASE; BODY-COMPOSITION; HEALTHY-MEN; STRENGTH; MASS; MORTALITY; POLYAMINES; ADULTS; AGE AB Aging is characterized by progressive decline in muscle mass, strength, and quality all of which contribute to functional impairment, falls, mobility disability, and frailty. Circulating factors may provide clues on the mechanisms for decline in muscle quality with aging. Characterizing the metabolic profile associated with reduced muscle quality in older persons could have important translational implications for the early identification of subjects at high risk of developing sarcopenia and the identification of targets for new preventive strategies and treatments. In a pilot cross-sectional, case-control study nested in the Baltimore Longitudinal Study on Aging, we compared circulating metabolites between 79 participants with low muscle quality ratio and 79 controls with high muscle quality, matched by age, sex, and height. The concentrations of 180 metabolites were determined by LC MS/MS, using the Biocrates p180 system, a targeted metabolomics approach. Participants with low muscle quality had significantly higher levels of leucine, isoleucine, tryptophan, serotonin, and methionine, while those with high muscle quality had significantly lower levels of putrescine and the selected phophatidylcholine (PCs) and lysoPCs. The results of this study open a new road for future investigations aimed at identifying new metabolic pathways involved in the decline of muscle quality with aging. C1 [Moaddel, Ruin; Fabbri, Elisa; Khadeer, Mohammed A.; Carlson, Olga D.; Gonzalez-Freire, Marta; Ferrucci, Luigi] NIA, Intramural Res Programs, NIH, Baltimore, MD 21224 USA. [Zhang, Pingbo; Semba, Richard D.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA. RP Moaddel, R (reprint author), 251 Bayview Blvd, Baltimore, MD 21224 USA. EM moaddelru@mail.nih.gov FU Intramural Research Program of the National Institutes of Health; National Institute on Aging FX Intramural Research Program of the National Institutes of Health; National Institute on Aging. NR 46 TC 1 Z9 1 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2016 VL 71 IS 10 BP 1266 EP 1272 DI 10.1093/gerona/glw046 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DZ7WI UT WOS:000386078800003 PM 27029859 ER PT J AU Shea, MK Loeser, RF Hsu, FC Booth, SL Nevitt, M Simonsick, EM Strotmeyer, ES Vermeer, C Kritchevsky, SB AF Shea, M. Kyla Loeser, Richard F. Hsu, Fang-Chi Booth, Sarah L. Nevitt, Michael Simonsick, Eleanor M. Strotmeyer, Elsa S. Vermeer, Cees Kritchevsky, Stephen B. CA Hlth ABC Study TI Vitamin K Status and Lower Extremity Function in Older Adults: The Health Aging and Body Composition Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Physical performance; Nutrition; Physical function; Vitamin K ID MATRIX GLA PROTEIN; PHYSICAL PERFORMANCE; KNEE OSTEOARTHRITIS; MOBILITY DISABILITY; MEANINGFUL CHANGE; CLINICAL-TRIAL; ASSOCIATION; CALCIFICATION; WOMEN; INFLAMMATION AB While low vitamin K status has been associated with several chronic diseases that can lead to lower extremity disability, it is not known if low vitamin K status is associated with worse lower extremity function. Vitamin K status was measured according to plasma phylloquinone (vitamin K1) and dephosphorylated-uncarboxylated MGP (dp-ucMGP) in 1,089 community-dwelling older adults (mean +/- SD age =74 +/- 3 years; 67% female). Lower extremity function was assessed using the short physical performance battery (SPPB), gait speed, and isokinetic leg strength. Linear regression and mixed models were used to determine the cross-sectional and longitudinal associations between vitamin K status and functional outcome measures. Cross-sectionally, higher plasma phylloquinone was associated with better SPPB scores and 20-m gait speed (p a parts per thousand currency sign .05). After 4-5 years, those with a parts per thousand yen1.0nM plasma phylloquinone (the concentration achieved when recommended intakes are met) had better SPPB scores (p = .03) and 20-m gait speed (p < .05). Lower plasma dp-ucMGP (reflective of better vitamin K status) was associated with better SPPB scores and leg strength cross-sectionally (p a parts per thousand currency sign .04), but not longitudinally. Neither measure of vitamin K status was associated with walking endurance or with the rate of decline in function. Older adults with higher vitamin K status had better physical performance scores at baseline, but data are less consistent longitudinally. Since lower extremity disability is a common consequence of multiple chronic diseases for which a role of vitamin K has been suggested, future studies are needed to determine if vitamin K supplementation could improve function in those with vitamin K insufficiency and clarify underlying mechanism(s). C1 [Shea, M. Kyla; Booth, Sarah L.] Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA. [Loeser, Richard F.] Univ N Carolina, Div Rheumatol Allergy & Immunol, Chapel Hill, NC USA. [Hsu, Fang-Chi] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA. [Nevitt, Michael] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Simonsick, Eleanor M.] NIA, NIH, Baltimore, MD 21224 USA. [Strotmeyer, Elsa S.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. [Vermeer, Cees] Maastricht Univ, VitaK, NL-6200 MD Maastricht, Netherlands. [Kritchevsky, Stephen B.] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. RP Shea, MK (reprint author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA. EM kyla.shea@tufts.edu FU NIH Intramural Research Program; NIA; NINR [R01-NR012459]; NIAMS [R21AR062284, K01AR063167]; Arthritis Foundation New Investigator Grant; USDA, Agricultural Research Service Cooperative Agreement [58-1950-7-707]; [N01-AG-6-2101]; [N01-AG-6-2103]; [N01-AG-6-2106]; [R01-AG028050] FX This study was supported by the NIH Intramural Research Program, the NIA and contracts (N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; R01-AG028050); the NINR (R01-NR012459); the NIAMS (R21AR062284, K01AR063167); an Arthritis Foundation New Investigator Grant and the USDA, Agricultural Research Service Cooperative Agreement (58-1950-7-707). NR 30 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD OCT PY 2016 VL 71 IS 10 BP 1348 EP 1355 DI 10.1093/gerona/glv209 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DZ7WI UT WOS:000386078800014 PM 26576842 ER PT J AU McNeil, SE AF McNeil, Scott E. TI Evaluation of nanomedicines: stick to the basics SO NATURE REVIEWS MATERIALS LA English DT Letter ID DELIVERY; TUMORS C1 [McNeil, Scott E.] NCI, Nanotechnol Characterizat Lab, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA. RP McNeil, SE (reprint author), NCI, Nanotechnol Characterizat Lab, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA. EM ncl@mail.nih.gov NR 9 TC 0 Z9 0 U1 7 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2058-8437 J9 NAT REV MATER JI Nat. Rev. Mater. PD OCT PY 2016 VL 1 IS 10 PG 2 WC Materials Science, Multidisciplinary SC Materials Science GA EA0ET UT WOS:000386259300005 ER PT J AU Liao, Y Berghoff, AS Osswald, M Ilhan-Mutlu, A Gil, B Thome, C Ratliff, M Steeg, P Wick, W Winkler, F AF Liao, Y. Berghoff, A. S. Osswald, M. Ilhan-Mutlu, A. Gil, B. Thome, C. Ratliff, M. Steeg, P. Wick, W. Winkler, F. TI IDENTIFICATION AND CHARACTERIZATION OF BRAIN METASTASIS INITIATING CELLS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 12th Meeting of the European-Association-of-Neuro-Oncology CY OCT 12-16, 2016 CL GERMANY SP European Assoc Neuro Oncol C1 [Liao, Y.; Berghoff, A. S.; Osswald, M.; Thome, C.; Ratliff, M.; Wick, W.; Winkler, F.] German Canc Res Ctr, Clin Cooperat Unit Neurooncol, German Canc Consortium DKTK, Heidelberg, Germany. [Liao, Y.; Osswald, M.; Wick, W.; Winkler, F.] Univ Heidelberg Hosp, Neurol Clin, Heidelberg, Germany. [Liao, Y.; Osswald, M.; Wick, W.; Winkler, F.] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany. [Berghoff, A. S.; Ilhan-Mutlu, A.] Med Univ Vienna, Dept Med 1, Clin Div Oncol, Vienna, Austria. [Berghoff, A. S.; Ilhan-Mutlu, A.] Med Univ Vienna, Vienna, Austria. [Gil, B.; Steeg, P.] NCI, Womens Malignancies Branch, NIH, Bethesda, MD 20892 USA. [Gil, B.; Steeg, P.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA. [Gil, B.; Steeg, P.] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA. [Gil, B.; Steeg, P.] NCI, Lab Anim Sci Program, SAIC Frederick, NIH, Frederick, MD 21701 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD OCT PY 2016 VL 18 SU 4 MA OS7.1 BP 15 EP 16 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA DZ9MT UT WOS:000386200200053 ER PT J AU Mankodi, A Bishop, CA Auh, S Newbould, RD Fischbeck, KH Janiczek, RL AF Mankodi, Ami Bishop, Courtney A. Auh, Sungyoung Newbould, Rexford D. Fischbeck, Kenneth H. Janiczek, Robert L. TI Quantifying disease activity in fatty-infiltrated skeletal muscle by IDEAL-CPMG in Duchenne muscular dystrophy SO NEUROMUSCULAR DISORDERS LA English DT Article DE Duchenne muscular dystrophy; Magnetic resonance imaging; IDEAL-CPMG; Skeletal muscle; Apparent fat fraction; Fatty degeneration; T-2 relaxation times; Water T-2 ID STIMULATED ECHO COMPENSATION; TRANSVERSE RELAXOMETRY; QUANTIFICATION METHODS; NATURAL-HISTORY; WATER; MRI; PROGRESSION; BOYS; MULTICENTER; ACCURACY AB The purpose of this study was to explore the use of iterative decomposition of water and fat with echo asymmetry and least-squares estimation Carr-Purcell-Meiboom-Gill (IDEAL-CPMG) to simultaneously measure skeletal muscle apparent fat fraction and water T-2 (T-2,T-w) in patients with Duchenne muscular dystrophy (DMD). In twenty healthy volunteer boys and thirteen subjects with DMD, thigh muscle apparent fat fraction was measured by Dixon and IDEAL-CPMG, with the IDEAL-CPMG also providing T-2,T-w as a measure of muscle inflammatory activity. A subset of subjects with DMD was followed up during a 48-week clinical study. The study was in compliance with the Patient Privacy Act and approved by the Institutional Review Board. Apparent fat fraction in the thigh muscles of subjects with DMD was significantly increased compared to healthy volunteer boys (p < 0.001). There was a strong correlation between Dixon and IDEAL-CPMG apparent fat fraction. Muscle T-2,T-w measured by IDEAL-CPMG was independent of changes in apparent fat fraction. Muscle T-2,T-w was higher in the biceps femoris and vastus lateralis muscles of subjects with DMD (p < 0.05). There was a strong correlation (p < 0.004) between apparent fat fraction in all thigh muscles and six-minute walk distance (6MWD) in subjects with DMD. IDEAL-CPMG allowed independent and simultaneous quantification of skeletal muscle fatty degeneration and disease activity in DMD. IDEAL-CPMG apparent fat fraction and T-2,T-w may be useful as biomarkers in clinical trials of DMD as the technique disentangles two competing biological processes. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Mankodi, Ami; Auh, Sungyoung; Fischbeck, Kenneth H.] NINDS, Neurogenet Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Bishop, Courtney A.; Newbould, Rexford D.] Hammersmith Hosp, Imanova Ctr Imaging Sci, London W12 0NN, England. [Janiczek, Robert L.] GlaxoSmithKline, Expt Med Imaging, Expt Med Unit, Middlesex UB11 1BT, England. RP Mankodi, A (reprint author), NINDS, Hereditary Muscle Dis Unit, Neurogenet Branch, NIH, 35 Convent Dr,Bldg 35,Room 2A-1002, Bethesda, MD 20892 USA. EM Ami.Mankodi@nih.gov FU Intramural NIH HHS [Z99 NS999999] NR 31 TC 1 Z9 1 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 IS 10 BP 650 EP 658 DI 10.1016/j.nmd.2016.07.013 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EA2FL UT WOS:000386408100003 PM 27593185 ER PT J AU Goldstein, DS Holmes, C Sullivan, P Jinsmaa, Y Kopin, IJ Sharabi, Y AF Goldstein, David S. Holmes, Courtney Sullivan, Patricia Jinsmaa, Yunden Kopin, Irwin J. Sharabi, Yehonatan TI Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson disease; Multiple system atrophy; Aldehyde dehydrogenase ID MULTIPLE SYSTEM ATROPHY; DOPAMINE METABOLITE 3,4-DIHYDROXYPHENYLACETALDEHYDE; NEUROGENIC ORTHOSTATIC HYPOTENSION; ALDEHYDE DEHYDROGENASE-ACTIVITY; PURE AUTONOMIC FAILURE; ALPHA-SYNUCLEIN; MONOAMINE-OXIDASE; PC12 CELLS; MITOCHONDRIAL DYSFUNCTION; REACTIVE INTERMEDIATE AB Introduction: There is intense interest in identifying cerebrospinal fluid (CSF) biomarkers of Parkinson's disease (PD), both for early diagnosis and to track effects of putative treatments. Nigrostriatal dopamine depletion characterizes PD. Predictably, CSF levels of 3,4-dihydroxyphenylacetic acid (DOPAC), the main neuronal metabolite of dopamine, are decreased in PD, even in patients with recent onset of the movement disorder. Whether low CSF DOPAC is associated specifically with parkinsonism has been unclear. In the neuronal cytoplasm dopamine undergoes not only enzymatic oxidation to form DOPAC but also spontaneous oxidation to form 5-S-cysteinyl-dopamine (Cys-DA). Theoretically, oxidative stress or decreased activity of aldehyde dehydrogenase (ALDH) in the residual nigrostriatal dopaminergic neurons would increase CSF Cys-DA levels with respect to DOPAC levels. PD, parkinsonian multiple system atrophy (MSA-P), and pure autonomic failure (PAF) are synucleinopathies; however, PAF does not entail parkinsonism. We examined whether an elevated Cys-DA/DOPAC ratio provides a specific biomarker of parkinsonism in synucleinopathy patients. Methods: CSF catechols were assayed in PD (n = 24), MSA-P (n = 32), PAF (n = 18), and control subjects (n = 32). Results: Compared to controls, CSF DOPAC was decreased in PD and MSA-P (p < 0.0001 each). In both diseases Cys-DA/DOPAC ratios averaged more than twice control (0.14 +/- 0.02 and 0.13 +/- 0.02 vs. 0.05 +/- 0.01, p < 0.0001 each), whereas in PAF the mean Cys-DA/DOPAC ratio was normal (0.05 +/- 0.01). Conclusions: CSF Cys-DA/DOPAC ratios are substantially increased in PD and MSA-P and are normal in PAF. Thus, in synucleinopathies an elevated CSF Cys-DA/DOPAC ratio seems to provide a specific biomarker of parkinsonism. Published by Elsevier Ltd. C1 [Goldstein, David S.; Holmes, Courtney; Sullivan, Patricia; Jinsmaa, Yunden; Kopin, Irwin J.; Sharabi, Yehonatan] NINDS, Clin Neurocardiol Sect, NIH, 10 Ctr Dr MSC 1620,Bldg 10 Room 5N220, Bethesda, MD 20892 USA. [Sharabi, Yehonatan] Tel Aviv Univ, Tel Hashomer Affiliated Sackler Fac Med, Sheba Med Ctr, Hypertens Unit, IL-69978 Tel Aviv, Israel. RP Goldstein, DS (reprint author), NINDS, Clin Neurocardiol Sect, NIH, 10 Ctr Dr MSC 1620,Bldg 10 Room 5N220, Bethesda, MD 20892 USA. EM goldsteind@ninds.nih.gov FU Intramural Research Program of the NIH, NINDS FX This research was supported by the Intramural Research Program of the NIH, NINDS. NR 53 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD OCT PY 2016 VL 31 BP 79 EP 86 DI 10.1016/j.parkreldis.2016.07.009 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA EA1AG UT WOS:000386320100013 PM 27474472 ER PT J AU Lin, YH Brown, JA DiMartino, C Dahms, I Salem, N Hibbeln, JR AF Lin, Yu-Hong Brown, James A. DiMartino, Carmine Dahms, Irina Salem, Norman, Jr. Hibbeln, Joseph R. TI Differences in long chain polyunsaturates composition and metabolism in male and female rats SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS LA English DT Article DE Essential fatty acid; Alpha-linolenic acid; Linoleic acid; DHA; DPA; Omega-3; Omega-6; Gender; Stable isotope; GC/MS ID ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID; FATTY-ACIDS; GONADAL-HORMONES; SEX-DIFFERENCES; GENDER-DIFFERENCES; ARACHIDONIC-ACID; LIVER MICROSOMES; METHYL-ESTERS; FISH-OIL AB Human studies and some animal work have shown more docosahexaenoic acid (DHA) and arachidonic acid (ARA) was accumulated or converted from precursors in females compared to males. This study explored in-depth the effect of gender on fatty acid composition and polyunsaturated fatty acid metabolism in rats fed one of two well-defined diets containing 10% total fat. One diet contained 15% of linoleic acid (LA) and 3% of alpha-linolenic acid (ALA) of the total fatty acids (LA+ALA diet), while the other diet contained 15% LA and 0.05% ALA (LA diet). At the age of 20 weeks, all animals were orally administered a single dose of a mixture of deuterium-labeled LA and ALA. Caudal venous blood was then drawn at 0, 2, 4, 8, 12, 24, 48, 96 and 168 h. The concentrations of the deuterated precursors and their metabolites in plasma total lipids were quantified by GC/MS negative chemical ionization. Endogenous fatty acids were quantified by GC/FID analysis. When expressed as the percentage of oral dosage, female rats accumulated more precursors and more products, deuterated DHA and deuterated n-6 docosapentaenoic acid (H-2(5)-DPAn-6), in plasma than did male rats in both the LA+ALA diet and the LA diet. For the endogenous non-labeled PUFA, greater concentrations of DHA and DPAn-6 were similarly observed in female rats compared to males within each diet. A lower concentration of non-labeled ARA was observed only in female rats fed the LA+ALA diet. In summary, greater endogenous and exogenous DHA and DPAn-6 was observed in female rat plasma and this was independent of dietary ALA status. Published by Elsevier Ltd. C1 [Lin, Yu-Hong; Brown, James A.; DiMartino, Carmine; Hibbeln, Joseph R.] NIAAA, Sect Nutr Neurosci, LMBB, NIH, Bethesda, MD 20892 USA. [Dahms, Irina; Salem, Norman, Jr.] DSM Nutr Prod LLC, Nutr Lipids, Columbia, MD USA. RP Lin, YH (reprint author), NIAAA, Sect Nutr Neurosci, LMBB, NIH, Bethesda, MD 20892 USA. EM yuhong.lin@nih.gov FU Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism, NIH, United States [Z99 AA999999] FX The authors wish to acknowledge Dr. Lee Chedester and Dr. Raouf Kechrid for their expert assistance with the animal work. This project was funded by the Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism, NIH, United States (Grant no. Z99 AA999999). NR 46 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0952-3278 EI 1532-2823 J9 PROSTAG LEUKOTR ESS JI Prostaglandins Leukot. Essent. Fatty Acids PD OCT PY 2016 VL 113 BP 19 EP 27 DI 10.1016/j.plefa.2016.08.008 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology & Metabolism GA EA2ER UT WOS:000386406100003 PM 27720036 ER PT J AU Quinn, G Vadaparampil, S Kanetsky, P Simmons, V Hudson, J Sutton, S Wheldon, C Sanchez, J Schabath, M AF Quinn, Gwendolyn Vadaparampil, Susan Kanetsky, Peter Simmons, Vani Hudson, Janella Sutton, Steven Wheldon, Christopher Sanchez, Julian Schabath, Matthew TI Sexual and Gender Minorities Cancer Screening and Health Behaviours SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Quinn, Gwendolyn; Vadaparampil, Susan; Kanetsky, Peter; Simmons, Vani; Hudson, Janella; Sutton, Steven; Sanchez, Julian; Schabath, Matthew] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Wheldon, Christopher] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD OCT PY 2016 VL 25 IS SP. S3 MA 141 BP 47 EP 47 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA DZ6AA UT WOS:000385942700100 ER PT J AU Bell, C Weaver, M Dickens, D Diver, J Smythe, E Iacoboni, A Hinds, P AF Bell, Cynthia Weaver, Meaghann Dickens, David Diver, Jessica Smythe, Elizabeth Iacoboni, Alyssa Hinds, Pamela TI Assessing Adolescent and Young Adult Acceptability of a Preliminary Instrument Measuring Readiness to Engage in End-of-Life Discussions within Clinical Settings SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Bell, Cynthia] Wayne State Univ, Detroit, MI USA. [Diver, Jessica] NIH, Washington, DC USA. [Dickens, David; Iacoboni, Alyssa] Helen DeVos Childrens Hosp, Grand Rapids, MI USA. [Smythe, Elizabeth] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Hinds, Pamela] Childrens Natl Hlth Syst, Washington, DC USA. [Weaver, Meaghann] Childrens Hosp & Med Ctr, Pediat Palliat Care Program, Omaha, NE USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD OCT PY 2016 VL 25 IS SP. S3 MA 514 BP 171 EP 171 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA DZ6AA UT WOS:000385942700387 ER PT J AU Aziz, N Rahman, A AF Aziz, Noreen Rahman, A. TI Lifestyle Health Behavior Interventions among Long Term Cancer Survivors SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Aziz, Noreen] NIH, Bldg 10, Bethesda, MD 20892 USA. [Rahman, A.] Univ Maryland, College Pk, MD 20742 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD OCT PY 2016 VL 25 IS SP. S3 MA 594 BP 189 EP 189 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA DZ6AA UT WOS:000385942700432 ER PT J AU Louis, GMB Sapra, KJ Barr, DB Lu, ZH Sundaram, R AF Louis, Germaine M. Buck Sapra, Katherine J. Barr, Dana Boyd Lu, Zhaohui Sundaram, Rajeshwari TI Preconception perfluoroalkyl and polyfluoroalkyl substances and incident pregnancy loss, LIFE Study SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Cohort; Epidemiology; Miscarriage; Perfluoroalkyl; Perfluoroalkyl acids; Polyfluoroalkyl; Pregnancy loss; Reproductive toxicity ID PERFLUOROOCTANOIC ACID EXPOSURE; HUMAN SEMEN QUALITY; PERFLUORINATED CHEMICALS; SERUM-LEVELS; TIME; WOMEN; PERFLUOROCHEMICALS; FERTILITY; SULFONATE; TOXICITY AB Equivocal findings are reported for perfluoroalkyl and polyfluoroalkyl substances (PFASs) and self-reported pregnancy loss. We prospectively assessed PFASs and pregnancy loss in a cohort comprising 501 couples recruited preconception and followed daily through 7 post-conception weeks. Seven PFAS5 were quantified: 2-N-ethyl-perfluorooctane sulfonamide acetate (Et-PFOSA-AcOH); 2-N-methyl-perfluorooctane sulfonamido acetate (Me-PFOSA-AcOH); perfluorodecanoate (PFDeA); perfluorononanoate (PFNA); perfluorooctane sulfonamide (PFOSA); perfluorooctane sulfonate (PFOS); and perfluorooctanoate (PFOA). Women used home pregnancy test kits. Loss denoted conversion from a positive to a negative pregnancy test, onset of menses or clinical confirmation (n = 98; 28%). Chemicals were log transformed and rescaled by their standard deviations to estimate adjusted hazard ratios (HRs) and 95% confidence intervals. No significantly elevated HRs were observed for any PFASs suggesting no association with loss: Et-PFOSA-AcOH (1.04; 0.87, 1.23), Me-PFOSA-AcOH (0.79; 0.61, 1.00; p < 0.05), PFDeA (0.83; 0.66, 1.04), PFNA (0.86; 0.70, 1.06), PFOSA (0.74; 0.50, 1.09), PFOS (0.81; 0.65, 1.00), and PFOA (0.93; 0.75, 1.16). Published by Elsevier Inc. C1 [Louis, Germaine M. Buck; Sapra, Katherine J.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Off Director, Div Intramural Populat Hlth Res, Rockville, MD USA. [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Lu, Zhaohui] Glotech Inc, Rockville, MD USA. [Sundaram, Rajeshwari] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, Biostat & Bioinformat Branch, Rockville, MD USA. RP Louis, GMB (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Off Director, Div Intramural Populat Hlth Res, Rockville, MD USA. EM louisg@mail.nih.gov OI Buck Louis, Germaine/0000-0002-1774-4490; Sundaram, Rajeshwari/0000-0002-6918-5002 FU Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development [N01-HD-3-3355, N01-HD-3-3356, NOH-HD-3-3358] FX Supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (#N01-HD-3-3355; N01-HD-3-3356; NOH-HD-3-3358). We acknowledge the technical assistance of Antonia Calafat, Division of Laboratory Sciences, Centers for Disease Control and Prevention who performed the analytic chemistry work under a Memo of Understanding with the NICHD. NR 46 TC 0 Z9 0 U1 5 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD OCT PY 2016 VL 65 BP 11 EP 17 DI 10.1016/j.reprotox.2016.06.011 PG 7 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA DZ6RZ UT WOS:000385990900002 PM 27319395 ER PT J AU Hessel, EVS Ezendam, J van Broekhuizen, FA Hakkert, B DeWitt, J Granum, B Guzylack, L Lawrence, BP Penninks, A Rooney, AA Piersma, AH van Loveren, H AF Hessel, Ellen V. S. Ezendam, Janine van Broekhuizen, Fleur A. Hakkert, Betty DeWitt, Jamie Granum, Berit Guzylack, Laurence Lawrence, B. Paige Penninks, Andre Rooney, Andrew A. Piersma, Aldert H. van Loveren, Henk TI Assessment of recent developmental immunotoxicity studies with bisphenol A in the context of the 2015 EFSA t-TDI SO REPRODUCTIVE TOXICOLOGY LA English DT Article ID INNER-CITY CHILDREN; PRENATAL EXPOSURE; ASTHMA; INFLAMMATION; ADULTHOOD; ALLERGY; RISK; MICE AB Humans are exposed to bisphenol A (BPA) mainly through the diet, air, dust, skin contact and water. There are concerns about adverse health effects in humans due to exposure to bisphenol A (BPA). The European Food Safety Authority (EFSA) has extensively reviewed the available literature to establish a temporary Tolerable Daily Intake (t-TDI). This exposure level was based on all available literature published before the end of 2012. Since then, new experimental animal studies have emerged, including those that identified effects of BPA on the immune system after developmental exposure. These studies indicate that developmental immunotoxicity might occur at lower dose levels than previously observed and on which the current EFSA t-TDI is based. The Dutch National Institute for Public Health and the Environment (RIVM) organized an expert workshop in September 2015 to consider recently published studies on the developmental immunotoxicity of bisphenol A (BPA). Key studies were discussed in the context of other experimental studies. The workshop concluded that these new experimental studies provide credible evidence for adverse immune effects after developmental exposure to BPA at 5 mu g/kg BW/day from gestation day 15 to postnatal day 21. Supportive evidence for adverse immune effects in similar dose ranges was obtained from other publications that were discussed during the workshop. The dose level associated with adverse immune effects is considerably lower than the dose used by EFSA for deriving the t-TDI. The workshop unanimously concluded that the current EFSA t-TDI warrants reconsideration in the context of all currently available data. (C) 2016 Elsevier Inc. All rights reserved. C1 [Hessel, Ellen V. S.; Ezendam, Janine; Piersma, Aldert H.; van Loveren, Henk] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, Bilthoven, Netherlands. [van Broekhuizen, Fleur A.; Hakkert, Betty] Natl Inst Publ Hlth & Environm RIVM, Ctr Safety Subst & Prod, Bilthoven, Netherlands. [DeWitt, Jamie] East Carolina Univ, Dept Pharmacol & Toxicol, Greenville, NC USA. [Granum, Berit] Norwegian Inst Publ Hlth, Dept Toxicol & Risk Assessment, Oslo, Norway. [Guzylack, Laurence] Univ Toulouse, Dept Intestinal Dev Xenobiot & Immunotoxicol, INRA, Res Ctr Food Toxicol Toxalim, Toulouse, France. [Lawrence, B. Paige] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY USA. [Lawrence, B. Paige] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA. [Penninks, Andre] TNO Triskel BV, Dept Toxicol & Risk Assessment, Zeist, Netherlands. [Rooney, Andrew A.] NIEHS, Natl Toxicol Program, Off Hlth Assessment & Translat, POB 12233, Res Triangle Pk, NC 27709 USA. [Piersma, Aldert H.] Univ Utrecht, Inst Risk Assessment Sci, Fac Vet, Utrecht, Netherlands. [van Loveren, Henk] Maastricht Univ, Dept Toxicogen, Maastricht, Netherlands. RP Piersma, AH (reprint author), Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, Bilthoven, Netherlands. EM aldert.piersma@rivm.nl OI DeWitt, Jamie/0000-0002-0440-4059 NR 21 TC 0 Z9 0 U1 6 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD OCT PY 2016 VL 65 BP 448 EP 456 DI 10.1016/j.reprotox.2016.06.020 PG 9 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA DZ6RZ UT WOS:000385990900045 PM 27352639 ER PT J AU McFadden, WC Jaffe, AE Ye, TZ Paltan-Ortiz, JD Hyde, TM Kleinman, JE AF McFadden, Whitney C. Jaffe, Andrew E. Ye, Tianzhang Paltan-Ortiz, Jose D. Hyde, Thomas M. Kleinman, Joel E. TI Assessment of genetic risk for distribution of total interstitial white matter neurons in dorsolateral prefrontal cortex: role in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Interstitial white matter neurons; Schizophrenia; Dorsolateral prefrontal cortex; Postmortem brain ID DENSITY; EXPRESSION; BRAINS C1 [McFadden, Whitney C.; Paltan-Ortiz, Jose D.; Kleinman, Joel E.] NIMH, Clin Brain Disorders Branch, Genes Cognit & Psychosis, Div Intramural Res Programs,NIH, Bethesda, MD 20892 USA. [Jaffe, Andrew E.; Ye, Tianzhang; Hyde, Thomas M.; Kleinman, Joel E.] Lieber Inst Brain Dev, Rangos Bldg,Johns Hopkins Med Campus, Baltimore, MD 21205 USA. RP McFadden, WC (reprint author), Mt Sinai Hosp, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA. FU NIH; Intramural Research Program of the NIH, NIMH FX This research was made possible through the National Institutes of Health (NIH) Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from Pfizer Inc, The Leona M. and Harry B. Helmsley Charitable Trust, and the Howard Hughes Medical Institute, as well as other private donors. This research was supported in part by the Intramural Research Program of the NIH, NIMH. NR 17 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2016 VL 176 IS 2-3 BP 141 EP 143 DI 10.1016/j.schres.2016.04.007 PG 3 WC Psychiatry SC Psychiatry GA DX1LZ UT WOS:000384130200009 PM 27237599 ER PT J AU Luo, Z Dauter, Z AF Luo, Zhipu Dauter, Zbigniew TI Detection of twinning in macromolecular crystallography SO ZEITSCHRIFT FUR KRISTALLOGRAPHIE-CRYSTALLINE MATERIALS LA English DT Article DE macromolecular crystallography; merohedral twinning; pseudo-merohedral twinning; twinning fraction; twinning tests ID INTENSITY STATISTICS; STRUCTURE REFINEMENT; CRYSTAL-STRUCTURE; PROTEIN CRYSTALS; TWINS; MEROHEDRY AB The merohedrally or pseudo-merohedrally twinned crystals cannot be identified during diffraction pattern inspection at the stage of data collection. Several methods for identifying twinning and estimating the twin fraction are suitable for macromolecular crystals, and all are based on the statistical properties of the measured diffraction intensities. They can be based on either the overall statistical properties of the measured reflection intensities or on the comparison of reflection intensities related by the twinning operation. The application of various tests for identification of twinning and estimation of twinning fraction is discussed, with examples of diffraction data from the Protein Data Bank. Twinning makes the solution of crystal structures more difficult, but once initially solved, the atomic models can be properly refined by the existing programs. C1 [Luo, Zhipu; Dauter, Zbigniew] NCI, Argonne Natl Lab, Synchrotron Radiat Res Sect, Argonne, IL 60439 USA. RP Dauter, Z (reprint author), NCI, Argonne Natl Lab, Synchrotron Radiat Res Sect, Argonne, IL 60439 USA. EM dauter@anl.gov FU Intramural Research Program of the National Cancer Institute FX This work was supported by the Intramural Research Program of the National Cancer Institute. NR 35 TC 0 Z9 0 U1 1 U2 1 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-4946 EI 2196-7105 J9 Z KRIST-CRYST MATER JI Z. Krist.-Cryst. Mater. PD OCT PY 2016 VL 231 IS 10 SI SI BP 561 EP 571 DI 10.1515/zkri-2016-1946 PG 11 WC Crystallography SC Crystallography GA DZ7NB UT WOS:000386051600004 ER PT J AU Lin, J Chen, XY Huang, P AF Lin, Jing Chen, Xiaoyuan Huang, Peng TI Graphene-based nanomaterials for bioimaging SO ADVANCED DRUG DELIVERY REVIEWS LA English DT Review DE Graphene; Graphene oxide; Reduced graphene oxide; Graphene quantum dots; Photoacoustic imaging; PET/SPECT; MRI; Bioimaging ID ENHANCED RAMAN-SCATTERING; NEAR-INFRARED WINDOW; MESOPOROUS SILICA NANOPARTICLES; GUIDED PHOTOTHERMAL THERAPY; RAY-COMPUTED-TOMOGRAPHY; MRI CONTRAST AGENTS; DRUG-DELIVERY; IN-VIVO; NANO-GRAPHENE; QUANTUM DOTS AB Graphene-based nanomaterials, due to their unique physicochemical properties, versatile surface functionalization, ultra-high surface area, and good biocompatibility, have attracted considerable interest in biomedical applications such as biosensors, drug delivery, bioimaging, theranostics, and so on. In this review, we will summarize the current advances in bioimaging of graphene-based nanomaterials, including graphene, graphene oxide (GO), reduced graphene oxide (rGO), graphene quantum dots (GQDs), and their derivatives. There are two methods to synthesize graphene-based nanomaterials: in situ synthesis and binding method. We will highlight the molecular imaging modalities including optical imaging (fluorescence (FL), two-photon FL, and Raman imaging), PET/SPECT (positron emission tomography/single photon emission computed tomography), MM (magnetic resonance imaging), PAI (photoacoustic imaging), CT (computed tomography), and multimodal imaging. In the end, we will elaborate on the prospects and challenges of their future bioimaging applications. Published by Elsevier B.V. C1 [Lin, Jing; Huang, Peng] Shenzhen Univ, Sch Med, Dept Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasoun, Shenzhen 518060, Peoples R China. [Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA. RP Huang, P (reprint author), Shenzhen Univ, Sch Med, Dept Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasoun, Shenzhen 518060, Peoples R China.; Chen, XY (reprint author), NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA. EM shawn.chen@nih.gov; peng.huang@szu.edu.cn RI Huang, Peng/R-2480-2016 OI Huang, Peng/0000-0003-3651-7813 FU National Science Foundation of China [51573096, 81401465]; Intramural Research Program (IRP) of the NIBIB; NIH FX This work was supported by the National Science Foundation of China (51573096, 81401465), and the Intramural Research Program (IRP) of the NIBIB, NIH. NR 128 TC 6 Z9 6 U1 108 U2 108 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-409X EI 1872-8294 J9 ADV DRUG DELIVER REV JI Adv. Drug Deliv. Rev. PD OCT 1 PY 2016 VL 105 BP 242 EP 254 DI 10.1016/j.addr.2016.05.013 PN B PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DZ1LW UT WOS:000385600900009 PM 27233213 ER PT J AU Xuan, ZM Naimi, TS Kaplan, MS Bagge, CL Few, LR Maisto, S Saitz, R Freeman, R AF Xuan, Ziming Naimi, Timothy S. Kaplan, Mark S. Bagge, Courtney L. Few, Lauren R. Maisto, Stephen Saitz, Richard Freeman, Robert TI Alcohol Policies and Suicide: A Review of the Literature SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Review DE Alcohol Policies; Suicide; Blood Alcohol Content; Critical Review ID LEGAL DRINKING AGE; DEATH REPORTING SYSTEM; TIME-SERIES ANALYSIS; UNITED-STATES; PSYCHIATRIC-DISORDERS; YOUTH SUICIDE; RISK-FACTORS; MORTALITY; TAX; US AB Both intoxication and chronic heavy alcohol use are associated with suicide. There is extensive population-level evidence linking per capita alcohol consumption with suicide. While alcohol policies can reduce excessive alcohol consumption, the relationship between alcohol policies and suicide warrants a critical review of the literature. This review summarizes the associations between various types of alcohol policies and suicide, both in the United States and internationally, as presented in English-language literature published between 1999 and 2014. Study designs, methodological challenges, and limitations in ascertaining the associations are discussed. Because of the substantial between-states variation in alcohol policies, U.S.-based studies contributed substantially to the literature. Repeated cross-sectional designs at both the ecological level and decedent level were common among U.S.-based studies. Non-U.S. studies often used time series data to evaluate pre-post comparisons of a hybrid set of policy changes. Although inconsistency remained, the published literature in general supported the protective effect of restrictive alcohol policies on reducing suicide as well as the decreased level of alcohol involvement among suicide decedents. Common limitations included measurement and selection bias and a focus on effects of a limited number of alcohol policies without accounting for other alcohol policies. This review summarizes a number of studies that suggest restrictive alcohol policies may contribute to suicide prevention on a general population level and to a reduction of alcohol involvement among suicide deaths. C1 [Xuan, Ziming; Saitz, Richard] Boston Univ, Dept Community Hlth Sci, Sch Publ Hlth, 801 Massachusetts Ave,Crosstown 443, Boston, MA 02118 USA. [Naimi, Timothy S.] Boston Med Ctr, Sect Gen Internal Med, Boston, MA USA. [Kaplan, Mark S.] Univ Calif Los Angeles, Sch Publ Affairs, Dept Social Welf, Los Angeles, CA USA. [Bagge, Courtney L.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA. [Few, Lauren R.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Maisto, Stephen] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Freeman, Robert] NIAAA, NIH, Bethesda, MD USA. RP Xuan, ZM (reprint author), Boston Univ, Dept Community Hlth Sci, Sch Publ Hlth, 801 Massachusetts Ave,Crosstown 443, Boston, MA 02118 USA. EM zxuan@bu.edu FU NIAAA NIH HHS [F32 AA023693, K05 AA016928, R01 AA020063, R01 AA021335, R01 AA021791, R01 AA023376, U01 AA020784] NR 71 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2016 VL 40 IS 10 BP 2043 EP 2055 DI 10.1111/acer.13203 PG 13 WC Substance Abuse SC Substance Abuse GA DZ0PT UT WOS:000385542900002 PM 27618526 ER PT J AU Williams, EC Hahn, JA Saitz, R Bryant, K Lira, MC Samet, JH AF Williams, Emily C. Hahn, Judith A. Saitz, Richard Bryant, Kendall Lira, Marlene C. Samet, Jeffrey H. TI Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Review DE Alcohol; Alcohol Use; Substance Use; HIV; HIV-Related Comorbidities ID RANDOMIZED CONTROLLED-TRIAL; ACTIVE ANTIRETROVIRAL THERAPY; INTERACTIVE TOXICITY BELIEFS; NUTRITION EXAMINATION SURVEY; SYSTEMIC IMMUNE ACTIVATION; MULTICENTER AIDS COHORT; HEALTH-CARE-UTILIZATION; ALL-CAUSE MORTALITY; SUB-SAHARAN AFRICA; ILLICIT DRUG-USE AB Alcohol use is common among people living with human immunodeficiency virus (HIV). In this narrative review, we describe literature regarding alcohol's impact on transmission, care, coinfections, and comorbidities that are common among people living with HIV (PLWH), as well as literature regarding interventions to address alcohol use and its influences among PLWH. This narrative review identifies alcohol use as a risk factor for HIV transmission, as well as a factor impacting the clinical manifestations and management of HIV. Alcohol use appears to have additive and potentially synergistic effects on common HIV-related comorbidities. We find that interventions to modify drinking and improve HIV-related risks and outcomes have had limited success to date, and we recommend research in several areas. Consistent with Office of AIDS Research/National Institutes of Health priorities, we suggest research to better understand how and at what levels alcohol influences comorbid conditions among PLWH, to elucidate the mechanisms by which alcohol use is impacting comorbidities, and to understand whether decreases in alcohol use improve HIV-relevant outcomes. This should include studies regarding whether state-of-the-art medications used to treat common coinfections are safe for PLWH who drink alcohol. We recommend that future research among PLWH include validated self-report measures of alcohol use and/or biological measurements, ideally both. Additionally, subgroup variation in associations should be identified to ensure that the risks of particularly vulnerable populations are understood. This body of research should serve as a foundation for a next generation of intervention studies to address alcohol use from transmission to treatment of HIV. Intervention studies should inform implementation efforts to improve provision of alcohol-related interventions and treatments for PLWH in healthcare settings. By making further progress on understanding how alcohol use affects PLWH in the era of HIV as a chronic condition, this research should inform how we can mitigate transmission, achieve viral suppression, and avoid exacerbating common comorbidities of HIV and alcohol use and make progress toward the 90-90-90 goals for engagement in the HIV treatment cascade. C1 [Williams, Emily C.] Ctr Innovat Vet Ctr & Value Driven Care, Vet Hlth Adm VA Hlth Serv Res & Dev, Seattle, WA USA. [Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Hahn, Judith A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Hahn, Judith A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Saitz, Richard; Samet, Jeffrey H.] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA USA. [Saitz, Richard; Lira, Marlene C.; Samet, Jeffrey H.] Boston Univ, Sch Med, Dept Med, CARE Unit,Sect Gen Internal Med,Boston Med Ctr, Boston, MA 02118 USA. [Bryant, Kendall] NIAAA, CHAART, NIH, Bethesda, MD USA. RP Samet, JH (reprint author), Boston Univ, Boston Med Ctr, Sch Med, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA.; Samet, JH (reprint author), Boston Univ, Boston Med Ctr, Sch Publ Hlth, 801 Massachusetts Ave,2nd Floor, Boston, MA 02118 USA. EM jsamet@bu.edu FU HSRD VA [IK2 HX001161]; NIAAA NIH HHS [U24 AA020778, K24 AA022586, U01 AA020776, U01 AA020780, U01 AA020784] NR 285 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2016 VL 40 IS 10 BP 2056 EP 2072 DI 10.1111/acer.13204 PG 17 WC Substance Abuse SC Substance Abuse GA DZ0PT UT WOS:000385542900003 PM 27696523 ER PT J AU Vatsalya, V Song, M Schwandt, ML Cave, MC Barve, SS George, DT Ramchandani, VA McClain, CJ AF Vatsalya, Vatsalya Song, Ming Schwandt, Melanie L. Cave, Matthew C. Barve, Shirish S. George, David T. Ramchandani, Vijay A. McClain, Craig J. TI Effects of Sex, Drinking History, and Omega-3 and Omega-6 Fatty Acids Dysregulation on the Onset of Liver Injury in Very Heavy Drinking Alcohol-Dependent Patients SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol; Sex; Heavy Drinking Markers; Fatty Acids; Liver Injury ID DISEASE; INFLAMMATION; SUSCEPTIBILITY; STEATOSIS; MEDIATORS AB BackgroundHeavy alcohol consumption frequently causes liver inflammation/injury, and certain fatty acids (FAs) may be involved in this liver pathology. In this study, we evaluated the association of heavy drinking and the changes in the FA levels involved in the -6 (pro-inflammatory) and -3 (anti-inflammatory) state in alcohol-dependent (AD) patients who had no clinical manifestations of liver injury. We aimed to identify sex-based differences in patients with mild or no biochemical evidence of liver injury induced by heavy drinking. MethodsA total of 114 heavy drinking AD female and male patients aged 21 to 65years without clinical manifestations of liver injury, who were admitted to an alcohol dependence treatment program, were grouped by the alanine aminotransferase (ALT) levels: 40 IU/l, as no liver injury (GR.1), and >40 IU/l, as mild liver injury (GR.2). Patients were actively drinking until the day of admission. Comprehensive metabolic panel, comprehensive FA panel, and drinking history data were evaluated. ResultsElevated ALT and aspartate aminotransferase (AST) showed close association with markers of heavy alcohol intake. In the patients with mild biochemical liver injury (GR.2), females showed significantly higher AST level than males. Significant association of AST and total drinks in past 90 days (TD90) in females, and AST and heavy drinking days in past 90 days (HDD90) in males was observed. The -6:-3 ratio showed a significant pro-inflammatory response only in females with mild liver injury (GR.2) when adjusted by drinking history marker, TD90. Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) were increased in males with liver injury, while females did not show any comparable rise in EPA; and DHA levels were lower. ConclusionsMeasures of heavy drinking, TD90 and HDD90, predicted changes in liver injury. Changes in the -3 and -6 FA levels and the -6:-3 ratio showed a pro-inflammatory shift in patients with biochemical liver injury with a significant effect in females. Changes in FAs involved in the inflammatory state may represent one mechanism for liver inflammation/injury in response to heavy alcohol drinking. C1 [Vatsalya, Vatsalya; Song, Ming; Cave, Matthew C.; Barve, Shirish S.; McClain, Craig J.] Univ Louisville, Dept Med, Sch Med, 505 S Hancock St CTR Room 521A, Louisville, KY 40202 USA. [Vatsalya, Vatsalya; Cave, Matthew C.; McClain, Craig J.] Robley Rex Vet Affairs Med Ctr, Louisville, KY USA. [Vatsalya, Vatsalya; Schwandt, Melanie L.; George, David T.; Ramchandani, Vijay A.] NIAAA, Lab Clin & Translat Studies, Bethesda, MD USA. [Cave, Matthew C.; Barve, Shirish S.; McClain, Craig J.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA. RP Vatsalya, V (reprint author), Univ Louisville, Dept Med, Sch Med, 505 S Hancock St CTR Room 521A, Louisville, KY 40202 USA. EM vatsalya.vatsalya@louisville.edu OI Vatsalya, Vatsalya/0000-0001-6764-6891 FU Intramural NIH HHS [Z99 AA999999]; NIAAA NIH HHS [P50 AA024337, U01 AA021901, ZIA AA000213, ZIA AA000466]; NIGMS NIH HHS [P20 GM113226] NR 26 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2016 VL 40 IS 10 BP 2085 EP 2093 DI 10.1111/acer.13197 PG 9 WC Substance Abuse SC Substance Abuse GA DZ0PT UT WOS:000385542900006 PM 27589090 ER PT J AU Wardell, JD Ramchandani, VA Hendershot, CS AF Wardell, Jeffrey D. Ramchandani, Vijay A. Hendershot, Christian S. TI Drinking Motives Predict Subjective Effects of Alcohol and Alcohol Wanting and Liking During Laboratory Alcohol Administration: A Mediated Pathway Analysis SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Subjective Response; Craving; Liking; Coping; Alcohol Challenge ID COLLEGE-STUDENTS; PSYCHOMETRIC SUPPORT; MOTIVATED DRINKERS; ACUTE TOLERANCE; FAMILY-HISTORY; BINGE DRINKING; EFFECTS SCALE; YOUNG-PEOPLE; MODEL; RESPONSES AB BackgroundMotivational models of alcohol use suggest that individual differences in sensitivity to the acute subjective effects of alcohol play an important role in motivational pathways to alcohol use. However, few studies have examined the link between drinking motives and subjective responses to alcohol. This study investigated the associations of coping and enhancement drinking motives with subjective stimulant and sedative effects during a laboratory alcohol administration session. We also examined whether stimulation and sedation following alcohol administration mediated the relationships between drinking motives and postalcohol ratings of alcohol wanting and liking. MethodsHeavy episodic drinkers (n=147, ages 19 to 25) at 2 sites participated in an intravenous alcohol administration session in which blood alcohol concentration was raised to a target of 80mg% over 20minutes. Participants completed measures of stimulation and sedation at baseline and 20minutes and also rated alcohol liking and wanting at 20minutes. Drinking motives and alcohol use were assessed during a previous laboratory visit. ResultsA path analysis controlling for baseline stimulation and sedation showed that enhancement motives were positively associated with postalcohol stimulation and negatively associated with postalcohol sedation. In contrast, coping motives were positively associated with postalcohol sedation. In turn, postalcohol stimulation, but not sedation, was associated with alcohol wanting and liking. Further, indirect pathways from enhancement motives to postalcohol wanting and liking mediated through postalcohol stimulation were statistically significant. Coping motives, on the other hand, were directly associated with increased postalcohol wanting and liking. ConclusionsThe results demonstrate that drinking motives are linked with individual differences in sensitivity to the effects of alcohol, which may serve as a mechanism underlying alcohol reinforcement and the motivation to consume more alcohol during a drinking episode. C1 [Wardell, Jeffrey D.; Hendershot, Christian S.] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada. [Ramchandani, Vijay A.] NIAAA, Sect Human Psychopharmacol, Div Intramural Clin & Biol Res, NIH, Bethesda, MD USA. [Hendershot, Christian S.] Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, Toronto, ON, Canada. [Hendershot, Christian S.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Hendershot, Christian S.] Univ Toronto, Dept Psychol, Toronto, ON, Canada. RP Hendershot, CS (reprint author), Ctr Addict & Mental Hlth, 100 Stokes St, Toronto, ON M6J 1H4, Canada. EM christian.hendershot@utoronto.ca FU NIAAA NIH HHS [R21 AA020304, P60 AA007611] NR 49 TC 0 Z9 0 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2016 VL 40 IS 10 BP 2190 EP 2198 DI 10.1111/acer.13174 PG 9 WC Substance Abuse SC Substance Abuse GA DZ0PT UT WOS:000385542900016 PM 27527738 ER PT J AU Karlsson, C Aziz, AMA Rehman, F Pitcairn, C Barchiesi, R Barbier, E Wendel Hansen, M Gehlert, D Steensland, P Heilig, M Thorsell, A AF Karlsson, Camilla Aziz, Abdul Maruf Asif Rehman, Faazal Pitcairn, Caleb Barchiesi, Riccardo Barbier, Estelle Wendel Hansen, Mikaela Gehlert, Don Steensland, Pia Heilig, Markus Thorsell, Annika TI Melanin-Concentrating Hormone and Its MCH-1 Receptor: Relationship Between Effects on Alcohol and Caloric Intake SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcohol Escalation; Reward; Motivation; Calorie Intake; Melanin-Concentrating Hormone Receptor-1 ID VOLUNTARY ETHANOL-CONSUMPTION; APPETITE REGULATION; NUCLEUS-ACCUMBENS; DRUG-ADDICTION; RAT-BRAIN; DOPAMINE; SYSTEM; REWARD; FOOD; OBESITY AB BackgroundReward and energy homeostasis are both regulated by a network of hypothalamic neuropeptide systems. The melanin-concentrating hormone (MCH) and its MCH-1 receptor (MCH1-R) modulate alcohol intake, but it remains unknown to what extent this reflects actions on energy balance or reward. Here, we evaluated the MCH1-R in regulation of caloric intake and motivation to consume alcohol in states of escalated consumption. MethodsRats had intermittent access (IA) to alcohol and were divided into high- and low-drinking groups. Food and alcohol consumption was assessed after administration of an MCH1-R antagonist, GW803430. Next, GW803430 was evaluated on alcohol self-administration in protracted abstinence induced by IA in high-drinking rats. Finally, the effect of GW803430 was assessed on alcohol self-administration in acute withdrawal in rats exposed to alcohol vapor. Gene expression of MCH and MCH1-R was measured in the hypothalamus and nucleus accumbens (NAc) in both acute and protracted abstinence. ResultsHigh-drinking IA rats consumed more calories from alcohol than chow and GW803430 decreased both chow and alcohol intake. In low-drinking rats, only food intake was affected. In protracted abstinence from IA, alcohol self-administration was significantly reduced by pretreatment with GW803430 and gene expression of both MCH and the MCH1-R were dysregulated in hypothalamus and NAc. In contrast, during acute withdrawal from vapor exposure, treatment with GW803430 did not affect alcohol self-administration, and no changes in MCH or MCH1-R gene expression were observed. ConclusionsOur data suggest a dual role of MCH and the MCH1-R in regulation of alcohol intake, possibly through mechanisms involving caloric intake and reward motivation. A selective suppression of alcohol self-administration during protracted abstinence by GW803430 was observed and accompanied by adaptations in gene expression of MCH and MCH1-R. Selective suppression of escalated consumption renders the MCH1-R an attractive target for treatment of alcohol use disorders. C1 [Karlsson, Camilla; Aziz, Abdul Maruf Asif; Barchiesi, Riccardo; Barbier, Estelle; Wendel Hansen, Mikaela; Heilig, Markus; Thorsell, Annika] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden. [Rehman, Faazal; Pitcairn, Caleb] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD USA. [Gehlert, Don] Eli Lilly & Co, Lilly Res Labs, CNS Res, Indianapolis, IN 46285 USA. [Steensland, Pia] Karolinska Inst, Clin Neurosci, Stockholm, Sweden. RP Karlsson, C (reprint author), Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden. EM camilla.s.karlsson@liu.se NR 37 TC 1 Z9 1 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD OCT PY 2016 VL 40 IS 10 BP 2199 EP 2207 DI 10.1111/acer.13181 PG 9 WC Substance Abuse SC Substance Abuse GA DZ0PT UT WOS:000385542900017 PM 27579857 ER PT J AU Patel, VS Sampat, V Espey, MG Sitapara, R Wang, HC Yang, XJ Ashby, CR Thomas, DD Mantell, LL AF Patel, Vivek S. Sampat, Vaishali Espey, Michael Graham Sitapara, Ravikumar Wang, Haichao Yang, Xiaojing Ashby, Charles R., Jr. Thomas, Douglas D. Mantell, Lin L. TI Ascorbic Acid Attenuates Hyperoxia-Compromised Host Defense against Pulmonary Bacterial Infection SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE hyperoxia; ascorbic acid; pneumonia; high-mobility group box 1 ID NF-KAPPA-B; VENTILATOR-ASSOCIATED PNEUMONIA; OXYGEN RADICAL PRODUCTION; CHROMATIN PROTEIN HMGB1; MOBILITY GROUP BOX-1; INDUCED LUNG INJURY; VITAMIN-C; OXIDATIVE STRESS; PSEUDOMONAS-AERUGINOSA; IN-VITRO AB Supraphysiological concentrations of oxygen (hyperoxia) can compromise host defense and increase susceptibility to bacterial infections, causing ventilator-associated pneumonia. The phagocytic activity of macrophages is impaired by hyperoxia-induced increases in the levels of reactive oxygen species (ROS) and extracellular high-mobility group box protein B1 (HMGB1). Ascorbic acid (AA), an essential nutrient and antioxidant, has been shown to be beneficial in various animal models of ROS-mediated diseases. The aim of this study was to determine whether AA could attenuate hyperoxia-compromised host defense and improve macrophage functions against bacterial infections. C57BL/6 male mice were exposed to hyperoxia (>= 98% O-2, 48 h), followed by intratracheal inoculation with Pseudomonas aeruginosa, and simultaneous intraperitoneal administration of AA. AA(50mg/kg) significantly improved bacterial clearance in the lungs and airways, and significantly reduced HMGB1 accumulation in the airways. The incubation of RAW 264.7 cells (a macrophage-like cell line) with AA (0-1,000 mu M) before hyperoxic exposure (95% O-2) stabilized the phagocytic activity of macrophages in a concentration-dependent manner. The AA-enhanced macrophage function was associated with significantly decreased production of intracellular ROS and accumulation of extracellular HMGB1. These data suggest that AA supplementation can prevent or attenuate the development of ventilator-associated pneumonia in patients receiving oxygen support. C1 [Patel, Vivek S.; Sampat, Vaishali; Sitapara, Ravikumar; Yang, Xiaojing; Ashby, Charles R., Jr.; Mantell, Lin L.] St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 128 St Albert Hall,8000 Utopia Pkwy, Queens, NY 11439 USA. [Espey, Michael Graham] NCI, Bethesda, MD 20892 USA. [Wang, Haichao; Mantell, Lin L.] North Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA. [Thomas, Douglas D.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL USA. RP Mantell, LL (reprint author), St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 128 St Albert Hall,8000 Utopia Pkwy, Queens, NY 11439 USA. EM lmantell@nshs.edu OI Wang, Haichao/0000-0002-0211-9000 FU National Heart, Lung, and Blood Institute [HL093708]; St. John's University FX This work was supported by National Heart, Lung, and Blood Institute grant HL093708 (L.L.M.) and a grant from St. John's University. NR 72 TC 0 Z9 0 U1 3 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD OCT 1 PY 2016 VL 55 IS 4 BP 511 EP 520 DI 10.1165/rcmb.2015-0310OC PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA DZ2DY UT WOS:000385653700007 PM 27120084 ER PT J AU Hunter, CM AF Hunter, Christine M. TI Understanding Diabetes and the Role of Psychology in Its Prevention and Treatment SO AMERICAN PSYCHOLOGIST LA English DT Article DE diabetes; treatment; prevention; biopsychosocial model; health psychology ID LIFE-STYLE INTERVENTION; EXCHANGE CLINIC REGISTRY; HEALTH BEHAVIOR-CHANGE; FUTURE-DIRECTIONS; YOUNG-CHILDREN; MENTAL-HEALTH; OBESE ADULTS; TYPE-1; PREVALENCE; MELLITUS AB Diabetes is a common, chronic, and costly condition that currently affects millions of individuals in the United States and worldwide with even greater numbers at high risk for developing the disease. Dramatic increases in diagnosed diabetes are projected for the decades to come meaning that most people will be affected by diabetes; either personally or through a family member. This article introduces the special issue of the American Psychologist focused on diabetes by providing an overview of the scope of diabetes and the importance of psychologists for improving disease management and quality of life. This includes an overview of the contributions of the behavioral and social sciences toward improved diabetes prevention and treatment. Finally, the article will point to opportunities for psychologists to close the gaps in the research, develop practice competencies, and increase training opportunities to meet the challenges of diabetes today and in the future. C1 [Hunter, Christine M.] NIDDK, Bethesda, MD 20892 USA. RP Hunter, CM (reprint author), NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, 6707 Democracy Blvd,Room 6071, Bethesda, MD 20892 USA. EM hunterchristine@niddk.nih.gov NR 79 TC 5 Z9 5 U1 16 U2 16 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X EI 1935-990X J9 AM PSYCHOL JI Am. Psychol. PD OCT PY 2016 VL 71 IS 7 SI SI BP 515 EP 525 DI 10.1037/a0040344 PG 11 WC Psychology, Multidisciplinary SC Psychology GA DZ0YV UT WOS:000385566500001 PM 27690481 ER PT J AU Lenis, YY Wang, XQ Tang, WJ Wu, GY Bazer, FW AF Lenis, Yasser Y. Wang, Xiaoqiu Tang, Wanjin Wu, Guoyao Bazer, Fuller W. TI Effects of agmatine on secretion of interferon tau and catecholamines and expression of genes related to production of polyamines by ovine trophectoderm cells SO AMINO ACIDS LA English DT Article DE Arginine; Agmatine; Polyamines; Trophectoderm cells; Interferon tau ID NITRIC-OXIDE SYNTHASE; SELECT NUTRIENTS; AMINO-ACIDS; ARGININE SUPPLEMENTATION; PERIIMPLANTATION PERIOD; MAMMALIAN CONCEPTUSES; DEVELOPMENTAL-CHANGES; SIGNALING PATHWAYS; EARLY-PREGNANCY; TUMOR-CELLS AB Embryonic survival requires histotrophic nutrition, including molecules secreted or transported into the uterine lumen by uterine epithelia. l-Arginine (Arg) is a common substrate for synthesis of nitric oxide, ornithine, proline, glutamate, creatinine, urea, polyamines and agmatine. Agmatine (Agm) is a product of arginine decarboxylation and it is a substrate for agmatinase for synthesis of putrescine and other polyamines in the ovine conceptus. Polyamines are essential for conceptus development. Therefore, this study compared effects of Arg and Agm on the behavior of ovine trophectoderm (oTr1) cells cultured in vitro. Arg, but not Agm, increased proliferation and migration of oTr1 cells, but neither Arg nor Agm affected cell adhesion. The total amount of IFNT in culture medium of oTr1 cells was increased by Arg, but Agm increased the IFNT production per oTr1 cell. Arg and Agm plus Arg decreased secretion of dopamine and norepinephrine by oTr1 cells. Agm upregulates expression of mRNAs SLC7A1, agmatinase and OAZ2 while the combination of Arg and Agm decreased expression of mRNAs for ODC1, SLC7A1, OAZ1 and OAZ3 by oTr1 cells. Although Agm does not stimulate proliferation, migration or adhesion of oTr1 cells or their secretion of catecholamines, Agm did increase transcription of SLC7A1, agmatinase and OAZ2 genes which would increase the capacity of oTr1 cells to produce polyamines. Collectively, our findings suggest a role for Arg and Agm in the regulation of transport of basic amino acids (including Arg), polyamine synthesis, and secretion of catecholamines by oTr1 cells. C1 [Lenis, Yasser Y.; Wang, Xiaoqiu; Tang, Wanjin; Wu, Guoyao; Bazer, Fuller W.] Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA. [Lenis, Yasser Y.; Wang, Xiaoqiu; Tang, Wanjin; Wu, Guoyao; Bazer, Fuller W.] Texas A&M Univ, Ctr Anim Biotechnol & Genom, College Stn, TX 77843 USA. [Lenis, Yasser Y.] Univ Antioquia, Sch Vet Med, Fac Agr Sci, Centauro Res Grp, Calle 70 52-21, Medellin, Colombia. [Wang, Xiaoqiu] NIEHS, Res Triangle Pk, NC 27709 USA. RP Bazer, FW (reprint author), Texas A&M Univ, Dept Anim Sci, College Stn, TX 77843 USA.; Bazer, FW (reprint author), Texas A&M Univ, Ctr Anim Biotechnol & Genom, College Stn, TX 77843 USA. EM fbazer@cvm.tamu.edu FU CODI University of Antioquia (UdeA); Medellin; Colombia Scholarship "Becas Doctorado UdeA; Agriculture and Food Research Initiative Competitive Grants from the USDA National Institute of Food and Agriculture [2011-67015-20028, 2015-67015-23276] FX This work was supported by Sustainability Strategy 2013-2014, from CODI University of Antioquia (UdeA), Medellin, Colombia Scholarship "Becas Doctorado UdeA 2014" (to YYL; PhD student in Veterinary Science, Faculty of Agrarian Science, Antioquia University) and by Agriculture and Food Research Initiative Competitive Grants (2011-67015-20028 and 2015-67015-23276) from the USDA National Institute of Food and Agriculture (to FWB and GW). Yasser Lenis is also a Research Fellow in the Department of Animal Science, Texas A&M University. NR 52 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0939-4451 EI 1438-2199 J9 AMINO ACIDS JI Amino Acids PD OCT PY 2016 VL 48 IS 10 BP 2389 EP 2399 DI 10.1007/s00726-016-2216-1 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DY8XC UT WOS:000385414500011 PM 27074718 ER PT J AU Charlifue, S Tate, D Biering-Sorensen, F Burns, S Chen, YY Chun, S Jakeman, LB Kowalski, RG Noonan, VK Ullrich, P AF Charlifue, Susan Tate, Denise Biering-Sorensen, Fin Burns, Stephen Chen, Yuying Chun, Sophia Jakeman, Lyn B. Kowalski, Robert G. Noonan, Vanessa K. Ullrich, Philip TI Harmonization of Databases: A Step for Advancing the Knowledge About Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Dataset; Database; Rehabilitation; Spinal cord injuries ID POPULATION HEALTH SURVEY; QUALITY-OF-LIFE; DEVELOPING-COUNTRIES; NEUROLOGICAL DISORDERS; NATIONAL INSTITUTE; DATA SET; CLASSIFICATION; EPIDEMIOLOGY; INDIVIDUALS; INSTRUMENTS AB The objectives of this article are to (1) provide an overview of existing spinal cord injury (SCI) clinical research databases-their purposes, characteristics, and accessibility to users; and (2) present a vision for future collaborations required for cross-cutting research in SCI. This vision highlights the need for validated and relevant data for longitudinal clinical trials and observational and epidemiologic SCI-related studies. Three existing SCI clinical research databases/registries are reviewed and summarized with regard to current formats, collection methods, and uses, including major strengths and weaknesses. Efforts to provide a uniform approach to data collection are also reviewed. The databases reviewed offer different approaches to capture important clinical information on SCI. They vary on size, purpose, data points, inclusion of standard outcomes, and technical requirements. Each presents with a set of limitations including lack of population data and lack of a common platform for data comparisons and exchanges. It is clear that numerous issues need to be considered when planning to establish common ways of collecting data through data sets or patient registries, ranging from a carefully crafted implementation plan that lists purposes, cost, resources required, and policies to guide such development to establishing a framework for dissemination of data and findings. For the present, taking advantage of the vast but different data already collected over many decades may require a variety of statistical skills and epidemiologic techniques. Ultimately, our ability to speak the same language with regard to variables and assessment tools will facilitate international collaborations and enhance comparability, data pooling, and the ability to generalize findings to a broader population. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Charlifue, Susan; Kowalski, Robert G.] Craig Hosp, Rocky Mt Reg Spinal Injury Syst, Englewood, CO USA. [Tate, Denise] Univ Michigan Spinal Cord Injury Model Syst, Dept Phys Med & Rehabil, Ann Arbor, MI USA. [Biering-Sorensen, Fin] Univ Copenhagen, Clin Spinal Cord Injuries, Rigshosp, Copenhagen, Denmark. [Burns, Stephen; Ullrich, Philip] Puget Sound Vet Adm Med Ctr, Vet Adm Spinal Cord Injury & Disorder Serv, Seattle, WA USA. [Burns, Stephen; Ullrich, Philip] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Chen, Yuying] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [Chun, Sophia] Vet Adm Long Beach Healthcare Syst, Spinal Cord Injury Ctr, Long Beach, CA USA. [Jakeman, Lyn B.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Noonan, Vanessa K.] Rick Hansen Inst, Vancouver, BC, Canada. RP Charlifue, S (reprint author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80110 USA. EM susie@craighospital.org FU National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) [90S15003, 90DP0011, 90SI5000]; Health Canada; Western Economic Diversification Canada; Government of Alberta; Government of British Columbia; Government of Manitoba; Government of Ontario FX Supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR grant nos. 90S15003, 90DP0011, 90SI5000). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The Rick Hansen Spinal Cord Injury Registry is supported by funding from Health Canada, Western Economic Diversification Canada, and the Governments of Alberta, British Columbia, Manitoba, and Ontario. The contents of this manuscript do not represent the opinions or policy of NIDILRR, ACL, National Institutes of Health, National Institute of Neurological Disorders and Stroke, or HHS, and do not imply endorsement by the respective institutes, agencies, or the U.S. Federal Government. NR 45 TC 1 Z9 1 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD OCT PY 2016 VL 97 IS 10 BP 1805 EP 1818 DI 10.1016/j.apmr.2016.03.030 PG 14 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DY7TX UT WOS:000385333300027 PM 27137095 ER PT J AU Hourigan, CS Aplan, PD AF Hourigan, Christopher S. Aplan, Peter D. TI Accurate Medicine: Indirect Targeting of NPM1-Mutated AML SO CANCER DISCOVERY LA English DT Editorial Material ID ACUTE MYELOID-LEUKEMIA; CLASSIFICATION; HOXA9 AB Acute myeloid leukemia (AML) is now recognized to be an imprecise term that refers to a range of myeloid malignancies that have different genetical etiologies, clinical characteristics, and therapeutic sensitivities. Targeting the MLL1 and DOT1L histone modification complexes, both alone and in combination, showed activity against AML driven by a mutant NPM1 protein in several preclinical models and may represent a new treatment direction for this devastating disease. (C) 2016 AACR. C1 [Hourigan, Christopher S.] NHLBI, Myeloid Malignancies Sect, Hematol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA. [Aplan, Peter D.] NCI, Leukemia Biol Sect, Genet Branch, NIH, Bethesda, MD 20892 USA. RP Hourigan, CS; Aplan, PD (reprint author), NCI, NIH, 37 Convent Dr,Bldg 37 Room 6002, Bethesda, MD 20892 USA. EM christopher.hourigan@nih.gov; aplanp@mail.nih.gov RI Hourigan, Christopher/S-2476-2016 OI Hourigan, Christopher/0000-0002-6189-8067 FU Intramural Research Program of the NCI [ZIA SC 010378, ZIA BC 010982]; National Heart, Lung and Blood Institute of the NIH [ZIA HL 006163] FX This work was supported by the Intramural Research Program of the NCI (Grants ZIA SC 010378 and ZIA BC 010982 to P.D. Aplan) and the National Heart, Lung and Blood Institute of the NIH (Grant ZIA HL 006163 to C.S. Hourigan). NR 10 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2159-8274 EI 2159-8290 J9 CANCER DISCOV JI Cancer Discov. PD OCT PY 2016 VL 6 IS 10 BP 1087 EP 1089 DI 10.1158/2159-8290.CD-16-0917 PG 3 WC Oncology SC Oncology GA DZ1ZW UT WOS:000385642200019 PM 27698101 ER PT J AU Trabert, B AF Trabert, Britton TI Body Powder and Ovarian Cancer Risk-What Is the Role of Recall Bias? SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; TALC USE; INFLAMMATION; MORTALITY; EXPOSURE C1 [Trabert, Britton] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. RP Trabert, B (reprint author), NCI, 9609 Med Ctr Dr, Bethesda, MD 20892 USA. EM britton.trabert@nih.gov RI Trabert, Britton/F-8051-2015 FU Intramural NIH HHS [ZIA CP010126-21] NR 17 TC 0 Z9 0 U1 4 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2016 VL 25 IS 10 BP 1369 EP 1370 DI 10.1158/1055-9965.EPI-16-0476 PG 2 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DZ2AA UT WOS:000385642800001 PM 27697794 ER PT J AU Kennedy, AE Khoury, MJ Ioannidis, JPA Brotzman, M Miller, A Lane, C Lai, GY Rogers, SD Harvey, C Elena, JW Seminara, D AF Kennedy, Amy E. Khoury, Muin J. Ioannidis, John P. A. Brotzman, Michelle Miller, Amy Lane, Crystal Lai, Gabriel Y. Rogers, Scott D. Harvey, Chinonye Elena, Joanne W. Seminara, Daniela TI The Cancer Epidemiology Descriptive Cohort Database: A Tool to Support Population-Based Interdisciplinary Research SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GENOME-WIDE ASSOCIATION; PROSTATE-CANCER; PRECISION MEDICINE; PANCREATIC-CANCER; CLINICAL-TRIALS; PUBLIC-HEALTH; CONSORTIUM; RISK; TRANSFORMATION; BREAST AB Background: We report on the establishment of a web-based Cancer Epidemiology Descriptive Cohort Database (CEDCD). The CEDCD's goals are to enhance awareness of resources, facilitate interdisciplinary research collaborations, and support existing cohorts for the study of cancer-related outcomes. Methods: Comprehensive descriptive data were collected from large cohorts established to study cancer as primary outcome using a newly developed questionnaire. These included an inventory of baseline and follow-up data, biospecimens, genomics, policies, and protocols. Additional descriptive data extracted from publicly available sources were also collected. This information was entered in a searchable and publicly accessible database. We summarized the descriptive data across cohorts and reported the characteristics of this resource. Results: As of December 2015, the CEDCD includes data from 46 cohorts representing more than 6.5 million individuals (29% ethnic/racial minorities). Overall, 78% of the cohorts have collected blood at least once, 57% at multiple time points, and 46% collected tissue samples. Genotyping has been performed by 67% of the cohorts, while 46% have performed whole-genome or exome sequencing in subsets of enrolled individuals. Information on medical conditions other than cancer has been collected in more than 50% of the cohorts. More than 600,000 incident cancer cases and more than 40,000 prevalent cases are reported, with 24 cancer sites represented. Conclusions: The CEDCD assembles detailed descriptive information on a large number of cancer cohorts in a searchable database. Impact: Information from the CEDCD may assist the interdisciplinary research community by facilitating identification of well-established population resources and large-scale collaborative and integrative research. (C) 2016 AACR. C1 [Kennedy, Amy E.; Lai, Gabriel Y.; Rogers, Scott D.; Harvey, Chinonye; Elena, Joanne W.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Rockville, MD USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Ioannidis, John P. A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Meta Res Innovat Ctr Stanford METRICS, Stanford, CA 94305 USA. [Brotzman, Michelle; Miller, Amy] Westat Corp, Rockville, MD USA. [Lane, Crystal] US Hlth Resources & Serv Adm, Off Epidemiol & Res, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Seminara, Daniela] NCI, Div Canc Control & Populat Sci, NIH, Rockville, MD USA. RP Seminara, D (reprint author), NCI, 9609 Med Ctr Dr,Room 3E336,MSC 9763, Bethesda, MD 20850 USA. EM seminard@mail.nih.gov OI Kennedy, Amy/0000-0001-9589-5510 NR 34 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD OCT PY 2016 VL 25 IS 10 BP 1392 EP 1401 DI 10.1158/1055-9965.EPI-16-0412 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DZ2AA UT WOS:000385642800004 PM 27439404 ER PT J AU Long, AH Highfill, SL Cui, YZ Smith, JP Walker, AJ Ramakrishna, S El-Etriby, R Galli, S Tsokos, MG Orentas, RJ Mackall, CL AF Long, Adrienne H. Highfill, Steven L. Cui, Yongzhi Smith, Jillian P. Walker, Alec J. Ramakrishna, Sneha El-Etriby, Rana Galli, Susana Tsokos, Maria G. Orentas, Rimas J. Mackall, Crystal L. TI Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas SO CANCER IMMUNOLOGY RESEARCH LA English DT Article ID MODIFIED T-CELLS; CHIMERIC ANTIGEN RECEPTORS; SUPPRESSOR-CELLS; MYELOID CELLS; IMMUNE-RESPONSE; CANCER; NEUROBLASTOMA; EXPANSION; CYTOKINE; ANTIBODY AB Genetically engineered T cells expressing CD19-specific chimeric antigen receptors (CAR) have shown impressive activity against B-cell malignancies, and preliminary results suggest that T cells expressing a first-generation disialoganglioside (GD2)-specific CAR can also provide clinical benefit in patients with neuroblastoma. We sought to assess the potential of GD2-CAR therapies to treat pediatric sarcomas. We observed that 18 of 18 (100%) of osteosarcomas, 2 of 15 (13%) of rhabdomyosarcomas, and 7 of 35 (20%) of Ewing sarcomas expressed GD2. T cells engineered to express a third-generation GD2-CAR incorporating the 14g2a-scFv with the CD28, OX40, and CD3 zeta signaling domains (14g2a.CD28.OX40.zeta) mediated efficient and comparable lysis of both GD2(+) sarcoma and neuroblastoma cell lines in vitro. However, in xenograft models, GD2-CAR T cells had no antitumor effect against GD2(+) sarcoma, despite effectively controlling GD2(+) neuroblastoma. We observed that pediatric sarcoma xenografts, but not neuroblastoma xenografts, induced large populations of monocytic and granulocytic murine myeloid-derived suppressor cells (MDSC) that inhibited human CAR T-cell responses in vitro. Treatment of sarcoma-bearing mice with all-trans retinoic acid (ATRA) largely eradicated monocytic MDSCs and diminished the suppressive capacity of granulocytic MDSCs. Combined therapy using GD2-CAR T cells plus ATRA significantly improved antitumor efficacy against sarcoma xenografts. We conclude that retinoids provide a clinically accessible class of agents capable of diminishing the suppressive effects of MDSCs, and that co-administration of retinoids may enhance the efficacy of CAR therapies targeting solid tumors. (C) 2016 AACR. C1 [Long, Adrienne H.; Highfill, Steven L.; Cui, Yongzhi; Smith, Jillian P.; Walker, Alec J.; Ramakrishna, Sneha; Orentas, Rimas J.; Mackall, Crystal L.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Long, Adrienne H.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA. [El-Etriby, Rana; Galli, Susana; Tsokos, Maria G.] NCI, Pathol Lab, CCR, NIH, Bldg 10, Bethesda, MD 20892 USA. [Mackall, Crystal L.] Stanford Univ, Sch Med, Dept Pediat, 265 Campus Dr G3141A, Stanford, CA 94305 USA. [Galli, Susana] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20007 USA. [Tsokos, Maria G.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Orentas, Rimas J.] Lentigen Technol Inc, Gaithersburg, MD USA. RP Mackall, CL (reprint author), Stanford Univ, 265 Campus Dr G3141A,MC5456, Stanford, CA 94305 USA. EM cmackall@stanford.edu FU Intramural NIH HHS [ZIA BC011073-03]; NIGMS NIH HHS [T32 GM008152] NR 50 TC 1 Z9 1 U1 6 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 2326-6066 EI 2326-6074 J9 CANCER IMMUNOL RES JI Cancer Immunol. Res. PD OCT PY 2016 VL 4 IS 10 BP 869 EP 880 DI 10.1158/2326-6066.CIR-15-0230 PG 12 WC Oncology; Immunology SC Oncology; Immunology GA DZ1WR UT WOS:000385632900007 PM 27549124 ER PT J AU Cook, KL Soto-Pantoja, DR Clarke, PAG Cruz, MI Zwart, A Warri, A Hilakivi-Clarke, L Roberts, DD Clarke, R AF Cook, Katherine L. Soto-Pantoja, David R. Clarke, Pamela A. G. Cruz, M. Idalia Zwart, Alan Warri, Anni Hilakivi-Clarke, Leena Roberts, David D. Clarke, Robert TI Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer SO CANCER RESEARCH LA English DT Article ID FATTY-ACID OXIDATION; ANTIESTROGEN RESPONSIVENESS; THERAPEUTIC TARGET; HEPATIC STEATOSIS; GENE-EXPRESSION; CELL FATE; RESISTANCE; TAMOXIFEN; AUTOPHAGY; CHOLESTEROL AB The unfolded protein response is an endoplasmic reticulum stress pathway mediated by the protein chaperone glucose regulated-protein 78 (GRP78). Metabolic analysis of breast cancer cells shows that GRP78 silencing increases the intracellular concentrations of essential polyunsaturated fats, including linoleic acid. Accumulation of fatty acids is due to an inhibition of mitochondrial fatty acid transport, resulting in a reduction of fatty acid oxidation. These data suggest a novel role of GRP78-mediating cellular metabolism. We validated the effect of GRP78-regulated metabolite changes by treating tumor-bearing mice with tamoxifen and/or linoleic acid. Tumors treated with linoleic acid plus tamoxifen exhibited reduced tumor area and tumor weight. Inhibition of either GRP78 or linoleic acid treatment increased MCP-1 serum levels, decreased CD47 expression, and increased macrophage infiltration, suggesting a novel role for GRP78 in regulating innate immunity. GRP78 control of fatty acid oxidation may represent a new homeostatic function for GRP78. (C) 2016 AACR. C1 [Cook, Katherine L.; Soto-Pantoja, David R.] Wake Forest Univ, Bowman Gray Sch Med, Dept Surg, Winston Salem, NC 27103 USA. [Cook, Katherine L.; Soto-Pantoja, David R.] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC USA. [Cook, Katherine L.; Clarke, Pamela A. G.; Cruz, M. Idalia; Zwart, Alan; Warri, Anni; Hilakivi-Clarke, Leena; Clarke, Robert] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA. [Cook, Katherine L.; Clarke, Pamela A. G.; Cruz, M. Idalia; Zwart, Alan; Warri, Anni; Hilakivi-Clarke, Leena; Clarke, Robert] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA. [Roberts, David D.] NCI, Pathol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA. RP Cook, KL (reprint author), Wake Forest Univ, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM klcook@wakehealth.edu RI Clarke, Robert/A-6485-2008; Roberts, David/A-9699-2008 OI Clarke, Robert/0000-0002-9278-0854; Roberts, David/0000-0002-2481-2981 FU NCATS NIH HHS [KL2 TR001421]; NCI NIH HHS [U54 CA149147, U01 CA184902, K22 CA181274, R01 CA131465] NR 45 TC 1 Z9 1 U1 7 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT PY 2016 VL 76 IS 19 BP 5657 EP 5670 DI 10.1158/0008-5472.CAN-15-2616 PG 14 WC Oncology SC Oncology GA DZ1UD UT WOS:000385625500012 PM 27698188 ER PT J AU He, XZ Yan, B Liu, S Jia, JT Lai, WW Xin, X Tang, CE Luo, DX Tan, T Jiang, YQ Shi, Y Liu, YT Xiao, DS Chen, L Liu, S Mao, C Yin, G Cheng, Y Fan, J Cao, Y Muegge, K Tao, YG AF He, Xiaozhen Yan, Bin Liu, Shuang Jia, Jiantao Lai, Weiwei Xin, Xing Tang, Can-e Luo, Dixian Tan, Tan Jiang, Yiqun Shi, Ying Liu, Yating Xiao, Desheng Chen, Ling Liu, Shao Mao, Chao Yin, Gang Cheng, Yan Fan, Jia Cao, Ya Muegge, Kathrin Tao, Yongguang TI Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase SO CANCER RESEARCH LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; DNA METHYLATION; GENE-EXPRESSION; NASOPHARYNGEAL CARCINOMA; STEM-CELLS; IKK-ALPHA; EPIGENETICS; METABOLISM; PHOSPHORYLATION AB Chromatin modification is pivotal to the epithelial-mesenchymal transition (EMT), which confers potent metastatic potential to cancer cells. Here, we report a role for the chromatin remodeling factor lymphoid-specific helicase (LSH) in nasopharyngeal carcinoma (NPC), a prevalent cancer in China. LSH expression was increased in NPC, where it was controlled by the Epstein-Barr virus-encoded protein LMP1. In NPC cells in vitro and in vivo, LSH promoted cancer progression in part by regulating expression of fumarate hydratase (FH), a core component of the tricarboxylic acid cycle. LSH bound to the FH promoter, recruiting the epigenetic silencer factor G9a to repress FH transcription. Clinically, we found that the concentration of TCA intermediates in NPC-patient sera was deregulated in the presence of LSH. RNAi-mediated silencing of FH mimicked LSH overexpression, establishing FH as downstream mediator of LSH effects. The TCA intermediates a-KG and citrate potentiated the malignant character of NPC cells, in part by altering IKK alpha-dependent EMT gene expression. In this manner, LSH furthered malignant progression of NPC by modifying cancer cell metabolism to support EMT. (C) 2016 AACR. C1 [He, Xiaozhen; Yan, Bin; Liu, Shuang; Jia, Jiantao; Lai, Weiwei; Xin, Xing; Tang, Can-e; Jiang, Yiqun; Shi, Ying; Liu, Yating; Chen, Ling; Mao, Chao; Cao, Ya; Tao, Yongguang] Cent S Univ, Xiangya Hosp, Ctr Med Res, Changsha, Hunan, Peoples R China. [He, Xiaozhen; Yan, Bin; Jia, Jiantao; Lai, Weiwei; Xin, Xing; Jiang, Yiqun; Shi, Ying; Liu, Yating; Chen, Ling; Mao, Chao; Cao, Ya; Tao, Yongguang] Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha, Hunan, Peoples R China. [He, Xiaozhen; Yan, Bin; Jia, Jiantao; Lai, Weiwei; Xin, Xing; Jiang, Yiqun; Shi, Ying; Liu, Yating; Chen, Ling; Mao, Chao; Cao, Ya; Tao, Yongguang] Cent S Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China. [He, Xiaozhen; Yan, Bin; Xin, Xing; Shi, Ying; Liu, Yating; Chen, Ling; Cao, Ya; Tao, Yongguang] Cent S Univ, Minist Hlth, Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China. [Luo, Dixian; Tan, Tan] Univ South China, Peoples Hosp Chenzhou 1, Natl & Local Joint Engn Lab High Throughput Mol D, Translat Med Inst, Chenzhou, Hunan, Peoples R China. [Xiao, Desheng] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha, Hunan, Peoples R China. [Liu, Shao] Cent S Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China. [Yin, Gang] Cent S Univ, Sch Basic Med, Dept Pathol, Changsha, Hunan, Peoples R China. [Cheng, Yan] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Hunan, Peoples R China. [Fan, Jia] Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst, Liver Surg Dept,Zhongshan Hosp,Minist Educ, Shanghai, Peoples R China. [Fan, Jia] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China. [Muegge, Kathrin] NCI, Mouse Canc Genet Program, Basic Sci Program, Leidos Biomed Res Inc,Frederick Natl Lab Canc Res, Frederick, MD 21701 USA. RP Tao, YG (reprint author), Cent S Univ, Xiangya Hosp, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China. EM taoyong@csu.edu.cn RI Shi, Ying-Hong/B-7063-2017 NR 56 TC 1 Z9 1 U1 5 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT PY 2016 VL 76 IS 19 BP 5743 EP 5755 DI 10.1158/0008-5472.CAN-16-0268 PG 13 WC Oncology SC Oncology GA DZ1UD UT WOS:000385625500019 PM 27302170 ER PT J AU Patel, YM Park, SL Han, YH Wilkens, LR Bickeboller, H Rosenberger, A Caporaso, N Landi, MT Bruske, I Risch, A Wei, YY Christiani, DC Brennan, P Houlston, R McKay, J McLaughlin, J Hung, R Murphy, S Stram, DO Amos, C Le Marchand, L AF Patel, Yesha M. Park, Sunghim L. Han, Younghun Wilkens, Lynne R. Bickeboeller, Heike Rosenberger, Albert Caporaso, Neil Landi, Maria Teresa Brueske, Irene Risch, Angela Wei, Yongyue Christiani, David C. Brennan, Paul Houlston, Richard McKay, James McLaughlin, John Hung, Rayjean Murphy, Sharon Stram, Daniel O. Amos, Christopher Le Marchand, Loic TI Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk SO CANCER RESEARCH LA English DT Article ID GENOME-WIDE ASSOCIATION; NICOTINE METABOLISM; SUSCEPTIBILITY LOCUS; ETHNIC/RACIAL GROUPS; SMOKING-BEHAVIOR; COMPLEX TRAITS; METAANALYSIS; VARIANTS; GENOTYPE; GLUCURONIDATION AB Metabolism of nicotine by cytochrome P450 2A6 (CYP2A6) is a suspected determinant of smoking dose and, consequently, lung cancer risk. We conducted a genome-wide association study (GWAS) of CYP2A6 activity, as measured by the urinary ratio of trans-3'-hydroxycotinine and its glucuronide conjugate over cotinine (total 3HCOT/COT), among 2,239 smokers in the Multiethnic Cohort (MEC) study. We identified 248 CYP2A6 variants associated with CYP2A6 activity (P < 5 x 10(-8)). CYP2A6 activity was correlated (r = 0.32; P < 0.0001) with total nicotine equivalents (a measure of nicotine uptake). When we examined the effect of these variants on lung cancer risk in the Transdisciplinary Research in Cancer of the Lung (TRICL) consortium GWAS dataset (13,479 cases and 43,218 controls), we found that the vast majority of these individual effects were directionally consistent and associated with an increased lung cancer risk. Two hundred and twenty-six of the 248 variants associated with CYP2A6 activity in the MEC were available in TRICL. Of them, 81% had directionally consistent risk estimates, and six were globally significantly associated with lung cancer. When conditioning on nine known functional variants and two deletions, the top two SNPs (rs56113850 in MEC and rs35755165 in TRICL) remained significantly associated with CYP2A6 activity in MEC and lung cancer in TRICL. The present data support the hypothesis that a greater CYP2A6 activity causes smokers to smoke more extensively and be exposed to higher levels of carcinogens, resulting in an increased risk for lung cancer. Although the variants identified in these studies may be used as risk prediction markers, the exact causal variants remain to be identified. (C) 2016 AACR. C1 [Patel, Yesha M.; Park, Sunghim L.; Stram, Daniel O.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Patel, Yesha M.; Park, Sunghim L.; Stram, Daniel O.] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA. [Han, Younghun; Amos, Christopher] Dartmouth Coll, Dept Biomed Data Sci, Hanover, NH 03755 USA. [Wilkens, Lynne R.; Le Marchand, Loic] Univ Hawaii, Ctr Canc, Program Epidemiol, Honolulu, HI 96822 USA. [Bickeboeller, Heike; Rosenberger, Albert] Univ Gottingen, Univ Med Ctr, Dept Genet Epidemiol, Gottingen, Germany. [Caporaso, Neil; Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Brueske, Irene] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Epidemiol 1, Neuherberg, Germany. [Risch, Angela] Salzburg Univ, Dept Mol Biol, Salzburg, Austria. [Wei, Yongyue] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China. [Christiani, David C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Christiani, David C.] Harvard Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Brennan, Paul; McKay, James] Int Agcy Res Canc, Genet Epidemiol Grp, Lyon, France. [Houlston, Richard] Inst Canc Res, Div Genet & Epidemiol, London, England. [McLaughlin, John] Publ Hlth Ontario, Toronto, ON, Canada. [Hung, Rayjean] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada. [Murphy, Sharon] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN USA. [Murphy, Sharon] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA. RP Le Marchand, L (reprint author), Univ Hawaii, Ctr Canc, 701 Ilalo St,Room 530, Honolulu, HI 96813 USA. EM loic@cc.hawaii.edu RI Risch, Angela/H-2669-2013 OI Risch, Angela/0000-0002-8026-5505 FU CCR NIH HHS [N01RC37004]; NCI NIH HHS [K07 CA160753, N01 CN045165, N01 CN25404, N01 CN25476, N01 CN25511, N01 CN25512, N01 CN25513, N01 CN25514, N01 CN25515, N01 CN25516, N01 CN25518, N01 CN25522, N01 CN25524, N01 CN75022, P01 CA138338, P20 CA090578, P30 CA023108, P50 CA070907, P50 CA090578, R01 CA055769, R01 CA074386, R01 CA092039, R01 CA092824, R01 CA111703, R01 CA121197, R01 CA127219, R01 CA133996, U01 CA063673, U01 CA164973, U19 CA148127, UM1 CA167462]; NHGRI NIH HHS [HHSN268200782096C, U01 HG004438, U01 HG004446] NR 50 TC 2 Z9 2 U1 5 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT PY 2016 VL 76 IS 19 BP 5768 EP 5776 DI 10.1158/0008-5472.CAN-16-0446 PG 9 WC Oncology SC Oncology GA DZ1UD UT WOS:000385625500021 PM 27488534 ER PT J AU Murphy, B Yin, H Maris, JM Kolb, EA Gorlick, R Reynolds, CP Kang, MH Keir, ST Kurmasheva, RT Dvorchik, I Wu, JR Billups, CA Boateng, N Smith, MA Lock, RB Houghton, PJ AF Murphy, Brendan Yin, Han Maris, John M. Kolb, E. Anders Gorlick, Richard Reynolds, C. Patrick Kang, Min H. Keir, Stephen T. Kurmasheva, Raushan T. Dvorchik, Igor Wu, Jianrong Billups, Catherine A. Boateng, Nana Smith, Malcolm A. Lock, Richard B. Houghton, Peter J. TI Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis SO CANCER RESEARCH LA English DT Article ID PRECLINICAL TESTING PROGRAM; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN COLORECTAL TUMORS; IMMUNE-DEPRIVED MICE; CELL LUNG-CANCER; MONOCLONAL-ANTIBODY; XENOGRAFT MODELS; STAGE 1; BMN 673; RHABDOMYOSARCOMA AB Traditional approaches to evaluating antitumor agents using human tumor xenograft models have generally used cohorts of 8 to 10 mice against a limited panel of tumor models. An alternative approach is to use fewer animals per tumor line, allowing a greater number of models that capture greater molecular/genetic heterogeneity of the cancer type. We retrospectively analyzed 67 agents evaluated by the Pediatric Preclinical Testing Program to determine whether a single mouse, chosen randomly from each group of a study, predicted the median response for groups of mice using 83 xenograft models. The individual tumor response from a randomly chosen mouse was compared with the group median response using established response criteria. A total of 2,134 comparisons were made. The single tumor response accurately predicted the group median response in 1,604 comparisons (75.16%). The mean tumor response correct prediction rate for 1,000 single mouse random samples was 78.09%. Models had a range for correct prediction (60%-87.5%). Allowing for misprediction of +/- one response category, the overall mean correct single mouse prediction rate was 95.28%, and predicted overall objective response rates for group data in 66 of 67 drug studies. For molecularly targeted agents, occasional exceptional responder models were identified and the activity of that agent confirmed in additional models with the same genotype. Assuming that large treatment effects are targeted, this alternate experimental design has similar predictive value as traditional approaches, allowing for far greater numbers of models to be used that more fully encompass the heterogeneity of disease types. (C) 2016 AACR. C1 [Murphy, Brendan; Yin, Han; Houghton, Peter J.] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc & Blood Dis, Columbus, OH USA. [Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Maris, John M.] Abramson Family Canc Res Inst, Philadelphia, PA USA. [Kolb, E. Anders] Alfred I DuPont Hosp Children, Dept Pediat, Wilmington, DE USA. [Gorlick, Richard] Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA. [Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med & Pediat, Lubbock, TX 79430 USA. [Kang, Min H.] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA. [Keir, Stephen T.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA. [Kurmasheva, Raushan T.; Houghton, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, Dept Mol Med, San Antonio, TX 78229 USA. [Dvorchik, Igor] Nationwide Childrens Hosp, Res Inst, Biostat, Columbus, OH USA. [Wu, Jianrong; Billups, Catherine A.; Boateng, Nana] St Jude Childrens Res Hosp, Dept Biostat, 332 N Lauderdale St, Memphis, TN 38105 USA. [Smith, Malcolm A.] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Lock, Richard B.] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia. RP Houghton, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 8403 Floyd Curl Dr,Mail Code 7794, San Antonio, TX 78229 USA. EM houghtonp@uthscsa.edu RI Lock, Richard/G-4253-2013 FU NCI NIH HHS [N01 CM042216, N01CM42216, P01 CA165995, U01 CA199297] NR 48 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD OCT PY 2016 VL 76 IS 19 BP 5798 EP 5809 DI 10.1158/0008-5472.CAN-16-0122 PG 12 WC Oncology SC Oncology GA DZ1UD UT WOS:000385625500024 PM 27496711 ER PT J AU Xu, R Shimizu, F Hoyinga, K Beal, K Karimi, S Droms, L Peck, KK Gutin, P Iorgulescu, JB Kaley, T DeAngelis, L Pentsova, E Nolan, C Grommes, C Chan, T Bobrow, D Hormigo, A Cross, JR Wu, N Takebe, N Panageas, K Ivy, P Supko, JG Tabar, V Omuro, A AF Xu, Ran Shimizu, Fumiko Hoyinga, Koos Beal, Kathryn Karimi, Sasan Droms, Leif Peck, Kyung K. Gutin, Philip Iorgulescu, J. Bryan Kaley, Thomas DeAngelis, Lisa Pentsova, Elena Nolan, Craig Grommes, Christian Chan, Timothy Bobrow, Dylan Hormigo, Adilia Cross, Justin R. Wu, Nian Takebe, Naoko Panageas, Katherine Ivy, Percy Supko, Jeffrey G. Tabar, Viviane Omuro, Antonio TI Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase O/I Trial SO CLINICAL CANCER RESEARCH LA English DT Article ID GAMMA-SECRETASE INHIBITOR; ADVANCED SOLID TUMORS; NEWLY-DIAGNOSED GLIOBLASTOMA; CANCER STEM-CELLS; SIGNALING PATHWAY; INITIATING CELLS; RO4929097; ANGIOGENESIS; COMBINATION; GROWTH AB Purpose: High-grade gliomas are associated with a dismal prognosis. Notch inhibition via the gamma-secretase inhibitor RO4929097 has emerged as a potential therapeutic option based on modulation of the cancer-initiating cell (CIS) population and a presumed antiangiogenic role. Experimental Design: In this phase O/I trial, 21 patients with newly diagnosed glioblastoma or anaplastic as trocytoma received RO4929097 combined with temozolomide and radiotherapy. In addition to establishing the MTD, the study design enabled exploratory studies evaluating tumor and brain drug penetration and neuroimaging parameters. We also determined functional effects on the Notch pathway and targeting of CISs through analysis of tumor tissue sampled from areas with and without blood-brain barrier disruption. Finally, recurrent tumors were also sampled and assessed for Notch pathway responses while on treatment. Results: Treatment was well tolerated and no dose-limiting toxicities were observed. 1FIC of treated tumors showed a significant decrease in proliferation and in the expression of the Notch intracellular domain (NICD) by tumor cells and blood vessels. Patient-specific organotypic tumor explants cultures revealed a specific decrease in the CD133(+) CIS population upon treatment. Perfusion MRI demonstrated a significant decrease in relative plasma volume after drug exposure. Gene expression data in recurrent tumors suggested low Notch signaling activity, the upregulation of key mesenchymal genes, and an increase in VEGF-dependent angiogenic factors. Conclusions: The addition of RO4929097 to temozolomide and radiotherapy was well tolerated; the drug has a variable blood-brain barrier penetration. Evidence of target modulation was observed, but recurrence occurred, associated with alterations in angiogenesis signaling pathways. (C) 2016 AACR. C1 [Xu, Ran; Shimizu, Fumiko; Hoyinga, Koos; Droms, Leif; Gutin, Philip; Iorgulescu, J. Bryan; Tabar, Viviane] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, 1275 York Ave, New York, NY 10065 USA. [Xu, Ran; Shimizu, Fumiko; Hoyinga, Koos; Droms, Leif; Gutin, Philip; Iorgulescu, J. Bryan; Tabar, Viviane] Mem Sloan Kettering Canc Ctr, Ctr Stem Cell Biol, 1275 York Ave, New York, NY 10021 USA. [Xu, Ran] Charite, Dept Neurosurg, Berlin, Germany. [Beal, Kathryn; Chan, Timothy] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA. [Karimi, Sasan; Peck, Kyung K.] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA. [Kaley, Thomas; DeAngelis, Lisa; Pentsova, Elena; Nolan, Craig; Grommes, Christian; Bobrow, Dylan; Hormigo, Adilia; Omuro, Antonio] Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA. [Hormigo, Adilia] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Hormigo, Adilia] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Hormigo, Adilia] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA. [Hormigo, Adilia] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA. [Cross, Justin R.] Mem Sloan Kettering Canc Ctr, Donald B & Catherine C Marron Canc Metab Ctr, 1275 York Ave, New York, NY 10021 USA. [Wu, Nian] Mem Sloan Kettering Canc Ctr, Analyt Pharmacol Core, 1275 York Ave, New York, NY 10021 USA. [Wu, Nian] LipoSeuticals Inc, Princeton, NJ USA. [Takebe, Naoko] NCI, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. [Panageas, Katherine] Mem Sloan Kettering Canc Ctr, Epidemiol & Stat, 1275 York Ave, New York, NY 10021 USA. [Ivy, Percy] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Supko, Jeffrey G.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Iorgulescu, J. Bryan] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA. RP Tabar, V (reprint author), Mem Sloan Kettering Canc Ctr, Dept Neurosurg, 1275 York Ave, New York, NY 10065 USA. EM tabarv@mskcc.org FU NIH/NCI (NCI Cancer Clinical Investigator Team Leadership Award) [3P30CA008748-47S2, U01CA069856]; B*Cured Foundation; Philadelphia Foundation; Have a Chance Foundation FX The study was partially funded by NIH/NCI through grants 3P30CA008748-47S2 (NCI Cancer Clinical Investigator Team Leadership Award; to A.M.P. Omuro) and U01CA069856. Additional funding was provided by B*Cured Foundation, Philadelphia Foundation, and Have a Chance Foundation. NR 36 TC 5 Z9 6 U1 4 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD OCT 1 PY 2016 VL 22 IS 19 BP 4786 EP 4796 DI 10.1158/1078-0432.CCR-16-0048 PG 11 WC Oncology SC Oncology GA DZ1VV UT WOS:000385630500006 PM 27154916 ER PT J AU Muller, F Cunningham, T Liu, XF Wayne, AS Pastan, I AF Mueller, Fabian Cunningham, Tyler Liu, Xiu Fen Wayne, Alan S. Pastan, Ira TI Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design SO CLINICAL CANCER RESEARCH LA English DT Article ID PHASE-II TRIAL; RECOMBINANT IMMUNOTOXIN; ANTI-CD22 IMMUNOTOXIN; RFB4(DSFV)-PE38 BL22; MOXETUMOMAB PASUDOTOX; IN-VITRO; THERAPY; BLINATUMOMAB; MALIGNANCIES; CONJUGATE AB Purpose: Recombinant immunotoxins (rITs) targeting CD22 are highly active in hairy cell leukemia, but less so in acute lymphoblastic leukemia (ALL). This study aims to understand the variable activity of an rIT against ALL toward improving responses in clinical application. Experimental Design: We determined in vitro activity of rITs by WST-8 assays and the time needed to kill ALL cell lines and patient-derived ALL blasts by flow cytometry. The findings were translated into two systemic ALL xenograft models. Differences in time needed to kill KOPN-8 cells for distinct rITs were addressed biochemically. Results: In vitro activity (IC50) of anti-CD22 rIT varied 210-fold from 0.02 to 4.6 ng/mL. Activity also varied greatly depending on the time ALL cells were exposed to immunotoxin from < 30 minutes to > 4 days. For KOPN-8, the difference in exposure time was related to intracellular rIT processing. We showed in newly developed ALL xenograft models, where immunotoxins have a short half-life, that the needed exposure time in vitro predicted the responses in vivo. By replacing bolus dose with small doses at frequent intervals or with continuous infusion, responses were substantially improved. We confirmed exposure time variability on patient-derived ALL samples and showed a correlation between exposure time needed to reach maximal cytotoxicity in vitro and their clinical response. Conclusions: The exposure time needed for rITs targeting CD22 to kill ALL cells varies widely. Our results suggest that ALL patients would have a better response rate to anti-CD22 immunotoxins if treated by continuous infusion rather than by bolus injections. (C) 2016 AACR. C1 [Mueller, Fabian; Cunningham, Tyler; Liu, Xiu Fen; Pastan, Ira] NCI, Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA. [Wayne, Alan S.] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr,Childrens Ctr Canc & B, Childrens Hosp Los Angeles,Div Hematol Oncol & Bl, Los Angeles, CA USA. RP Pastan, I (reprint author), NCI, NIH, 37 Convent Dr,Rm 5106, Bethesda, MD 20892 USA. EM pastani@mail.nih.gov FU NCI [P30CA014089]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; Medimmune, LLC; German Research Foundation [MU 3619/1 1]; Cooperative Research and Development Agreement FX The work was supported in part by award number P30CA014089 from the NCI, the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and with a Cooperative Research and Development Agreement (#1975) with Medimmune, LLC. F. Muller was supported in part by the German Research Foundation (award number MU 3619/1 1). NR 42 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD OCT 1 PY 2016 VL 22 IS 19 BP 4913 EP 4922 DI 10.1158/1078-0432.CCR-15-2500 PG 10 WC Oncology SC Oncology GA DZ1VV UT WOS:000385630500018 PM 27114443 ER PT J AU Lozier, JN Kloos, MT Merricks, EP Lemoine, N Whitford, MH Raymer, RA Bellinger, DA Nichols, TC AF Lozier, Jay N. Kloos, Mark T. Merricks, Elizabeth P. Lemoine, Nathaly Whitford, Margaret H. Raymer, Robin A. Bellinger, Dwight A. Nichols, Timothy C. TI Severe Hemophilia A in a Male Old English Sheep Dog with a C -> T Transition that Created a Premature Stop Codon in Factor VIII SO COMPARATIVE MEDICINE LA English DT Article ID DEFICIENT MOUSE MODEL; MOLECULAR CHARACTERIZATION; INHIBITOR DEVELOPMENT; BLEEDING DISORDERS; ANIMAL-MODELS; GENE; MUTATION; SPECTRUM; DISEASE; IDENTIFICATION AB Animals with hemophilia are models for gene therapy, factor replacement, and inhibitor development in humans. We have actively sought dogs with severe hemophilia A that have novel factor VIII mutations unlike the previously described factor VIII intron 22 inversion. A male Old English Sheepdog with recurrent soft-tissue hemorrhage and hemarthrosis was diagnosed with severe hemophilia A (factor VIII activity less than 1% of normal). We purified genomic DNA from this dog and ruled out the common intron 22 inversion; we then sequenced all 26 exons. Comparing the results with the normal canine factor VIII sequence revealed a C -> T transition in exon 12 of the factor VIII gene that created a premature stop codon at amino acid 577 in the A2 domain of the protein. In addition, 2 previously described polymorphisms that do not cause hemophilia were present at amino acids 909 and 1184. The hemophilia mutation creates a new TaqI site that facilitates rapid genotyping of affected offspring by PCR and restriction endonuclease analyses. This mutation is analogous to the previously described human factor VIII mutation at Arg583, which likewise is a CpG dinucleotide transition causing a premature stop codon in exon 12. Thus far, despite extensive treatment with factor VIII, this dog has not developed neutralizing antibodies ('inhibitors') to the protein. This novel mutation in a dog gives rise to severe hemophilia A analogous to a mutation seen in humans. This model will be useful for studies of the treatment of hemophilia. C1 [Lozier, Jay N.] NIH, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA. [Kloos, Mark T.; Merricks, Elizabeth P.; Lemoine, Nathaly; Whitford, Margaret H.; Raymer, Robin A.; Bellinger, Dwight A.; Nichols, Timothy C.] Univ North Carolina Chapel Hill, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA. RP Nichols, TC (reprint author), Univ North Carolina Chapel Hill, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA. EM tnichols@med.unc.edu FU NIH Intramural Research Program; NHLBI [HL63098] FX Funded by the NIH Intramural Research Program and NHLBI grant no. HL63098. NR 50 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1532-0820 J9 COMPARATIVE MED JI Comparative Med. PD OCT PY 2016 VL 66 IS 5 BP 405 EP 411 PG 7 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA DZ1OP UT WOS:000385608000007 PM 27780008 ER PT J AU Cadena, AM Klein, EC White, AG Tomko, JA Chedrick, CL Reed, DS Via, LE Lin, PL Flynn, JL AF Cadena, Anthony M. Klein, Edwin C. White, Alexander G. Tomko, Jaime A. Chedrick, Chelsea L. Reed, Douglas S. Via, Laura E. Lin, Philana Ling Flynn, JoAnne L. TI Very Low Doses of Mycobacterium tuberculosis Yield Diverse Host Outcomes in Common Marmosets (Callithrix jacchus) SO COMPARATIVE MEDICINE LA English DT Article ID CYNOMOLGUS MACAQUES; BIOMEDICAL-RESEARCH; INFECTION; MODEL; VIRULENCE; DISEASE AB Identifying and refining small-animal models of tuberculosis that recapitulate aspects of human Mycobacterium tuberculosis infection can contribute to advancing our understanding of critical facets of the disease. To study the effects of very low-dose infections with 2 strains of M. tuberculosis on disease progression and survival in common marmosets, animals were challenged with strains Erdman and CDC1551 at doses ranging from 1 to 12 cfu. These data revealed that the susceptibility of marmosets to M. tuberculosis infection is influenced by strain virulence and initial dose. Marmoset infection with the Erdman strain, even at very low doses, resulted in rapid disease progression associated with severe weight loss, extensive pathology, and poor survival. By contrast, challenge with the less virulent CDC1551 strain resulted in slower disease progression, delayed weight loss, and prolonged survival. One marmoset infected with CDC1551 at a very low dose (approximately 1 cfu) was able to contain and control M. tuberculosis infection in a subclinical state that persisted as long as 300 d. These findings underscore the critical importance of understanding the heterogeneity in host outcome that can arise in association with different infectious doses and strains in the marmoset model of tuberculosis. C1 [Cadena, Anthony M.; White, Alexander G.; Tomko, Jaime A.; Chedrick, Chelsea L.; Flynn, JoAnne L.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA. [Klein, Edwin C.] Univ Pittsburgh, Sch Med, Dept Immunol, Ctr Vaccine Res, Pittsburgh, PA USA. [Reed, Douglas S.] Univ Pittsburgh, Div Lab Anim Res, Pittsburgh, PA USA. [Via, Laura E.] NIAID, TB Res Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Via, Laura E.] Univ Cape Town, Dept Pathol, Inst Infect Dis & Mol Med, Cape Town, South Africa. [Lin, Philana Ling] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Sch Med, Div Infect Dis,Dept Pediat, Pittsburgh, PA USA. RP Flynn, JL (reprint author), Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA. EM joanne@pitt.edu FU NIH training grant [T32 AI089443]; Bill and Melinda Gates Foundation [OPP1034408]; intramural research program of NIAID, NIH FX We thank Mark Rodgers, Carolyn Bigbee, Catherine Cochran, and Charles Scanga for technical assistance. We also thank Daniel Filmore for veterinary and animal assistance. We gratefully acknowledge Pauline Maiello and Teresa Coleman for imaging support and Danielle Weiner, Daniel Schimel, and Manny Dayao for veterinary assistance at NIAID. These studies were funded in part by a NIH training grant (T32 AI089443 [to AMC]), the Bill and Melinda Gates Foundation (grant no. OPP1034408 [to JLF]), and the intramural research program of NIAID, NIH (to LEV). NR 23 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1532-0820 J9 COMPARATIVE MED JI Comparative Med. PD OCT PY 2016 VL 66 IS 5 BP 412 EP 419 PG 8 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA DZ1OP UT WOS:000385608000008 PM 27780009 ER PT J AU Wang, XW Wang, HR Guo, B Zhang, Y Gong, Y Zhang, C Xu, H Wu, XH AF Wang, Xiaowen Wang, Herui Guo, Bin Zhang, Ya Gong, Yinv Zhang, Chi Xu, Hong Wu, Xiaohui TI Gen1 and Eme1 Play Redundant Roles in DNA Repair and Meiotic Recombination in Mice SO DNA AND CELL BIOLOGY LA English DT Article DE Gen1; Eme1; DNA repair; meiotic recombination ID HOLLIDAY JUNCTION RESOLVASE; STRUCTURE-SPECIFIC NUCLEASES; MAMMALIAN-CELLS; RESOLUTION; MUS81-EME1; SLX1-SLX4; YEN1; PATHWAYS; MEIOSIS; YEAST AB Resolution of the Holliday junction (HJ) is essential for homologous recombination and DNA repair. In Saccharomyces cerevisiae, HJ resolvase Yen1 and the Mus81-Mms4 complex are redundant in DNA damage repair. In cultured mammalian cells, such redundancy also exists between Yen1 ortholog GEN1 and the Mus81-Mms1 ortholog MUS81-EME1. In this report, we further tested if GEN1 and EME1 redundantly affect HJ-related physiological processes in mice. We found that combined homozygous mutations of Gen1 and Eme1 led to synthetic lethality during early embryonic stages. Homozygous Gen1 mutations did not cause DNA repair deficiency in mouse embryonic fibroblast (MEF) cells, but made heterozygous Eme1 mutant MEFs more sensitive to various DNA-damaging reagents. Gen1 mutations also reduced the meiotic recombination efficiency in Eme1 mutant mice. These results suggest that Gen1 and Eme1 play redundant roles in DNA repair and meiotic recombination in vivo. C1 [Wang, Xiaowen; Zhang, Ya; Gong, Yinv; Xu, Hong; Wu, Xiaohui] Fudan Univ, Childrens Hosp, Shanghai Kidney Dev & Pediat Kidney Dis Res Ctr, Shanghai, Peoples R China. [Wang, Xiaowen] Wuhan Med & Healthcare Ctr Women & Children, Dept Nephrol, Wuhan, Peoples R China. [Wang, Herui; Guo, Bin; Zhang, Chi; Wu, Xiaohui] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Inst Dev Biol & Mol Med, State Key Lab Genet Engn,Sch Life Sci, Shanghai, Peoples R China. [Wang, Herui; Guo, Bin; Zhang, Chi; Wu, Xiaohui] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Inst Dev Biol & Mol Med, Natl Ctr Int Res Dev & Dis,Sch Life Sci, Shanghai, Peoples R China. [Wang, Herui] Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD USA. [Zhang, Chi] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA. RP Wu, XH (reprint author), Fudan Univ, Inst Dev Biol & Mol Med, Shanghai 200433, Peoples R China.; Xu, H (reprint author), Fudan Univ, Childrens Hosp, Dept Nephrol & Rheumatol, Shanghai 201102, Peoples R China. EM hxu@shmu.edu.cn; xiaohui_wu@fudan.edu.cn FU National Natural Science Foundation of China [81270763]; Chinese Hi-Tech Research and Development Project [2014AA021104]; Chinese Key Projects for Basic Research [2011CB944001]; Shanghai Municipal Government [15XD1500500, 12431900100]; State Key Laboratory of Genetic Engineering, Fudan University FX The authors thank Dr. Kai Lei, Zhisheng Ye, and Xiaoqiang Zhu for helpful discussion, and Guicheng Wang, Yanyan Nie, Xiaorong Huang, and Zhiyan Xia for technical assistance. This study was supported by grants from the National Natural Science Foundation of China (81270763), Chinese Hi-Tech Research and Development Project (2014AA021104), Chinese Key Projects for Basic Research (2011CB944001), Shanghai Municipal Government (15XD1500500 and 12431900100), and the Research Fund of the State Key Laboratory of Genetic Engineering, Fudan University. NR 31 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1044-5498 EI 1557-7430 J9 DNA CELL BIOL JI DNA Cell Biol. PD OCT PY 2016 VL 35 IS 10 BP 585 EP 590 DI 10.1089/dna.2015.3022 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity GA DZ2DV UT WOS:000385653400004 PM 27383418 ER PT J AU Woloshchuk, CJ Nelson, KH Rice, KC Riley, AL AF Woloshchuk, Claudia J. Nelson, Katharine H. Rice, Kenner C. Riley, Anthony L. TI Effects of 3,4-methylenedioxypyrovalerone (MDPV) pre-exposure on the aversive effects of MDPV, cocaine and lithium chloride: Implications for abuse vulnerability SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE MDPV; Cocaine; LiCl; Conditioned taste avoidance; Drug pre-exposure ID INTRACRANIAL SELF-STIMULATION; CONDITIONED PLACE PREFERENCE; TASTE-AVERSION; BATH SALTS; CONSTITUENT 3,4-METHYLENEDIOXYPYROVALERONE; DESIGNER CATHINONES; LOCOMOTOR-ACTIVITY; RAT STRAINS; MEPHEDRONE; MICE AB Background: Drug use is thought to be a balance of the rewarding and aversive effects of drugs. Understanding how various factors impact these properties and their relative balance may provide insight into their abuse potential. In this context, the present study attempted to evaluate the effects of drug history on the aversive effects of 3,4-methylenedioxypyrovalerone (MDPV), one of a variety of synthetic cathinones (collectively known as "bath salts"). Methods: Different groups of male Sprague-Dawley rats were exposed to either vehicle or MDPV (1.8 mg/kg) once every fourth day for five total injections prior to taste avoidance conditioning in which a novel saccharin solution was repeatedly paired with either vehicle, MDPV (1.8 mg/kg), the related psychostimulant cocaine (18 mg/kg) or the emetic lithium chloride (LiCl) (13.65 mg/kg). Results: In animals pre-exposed to vehicle, all three drugs induced significant and comparable taste avoidance relative to animals injected with vehicle during conditioning. MDPV pre-exposure attenuated the avoidance induced by both MDPV and cocaine (greater attenuation for MDPV than cocaine), but had no effect on that induced by LiCl. Conclusions: These findings suggest that a history of MDPV use may reduce or attenuate MDPV and cocaine's (but not Lid 's) aversive effects. The implications for such changes in MDPV's aversive effects to its potential use and abuse were discussed. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Woloshchuk, Claudia J.; Nelson, Katharine H.; Riley, Anthony L.] Amer Univ, Ctr Behav Neurosci, Psychopharmacol Lab, 4400 Massachusetts Ave NW, Washington, DC 20016 USA. [Rice, Kenner C.] NIDA, Mol Targets & Medicat Discovery Branch, NIAAA, Bethesda, MD 20892 USA. RP Woloshchuk, CJ (reprint author), Amer Univ, Ctr Behav Neurosci, Psychopharmacol Lab, 4400 Massachusetts Ave NW, Washington, DC 20016 USA. EM cw2606a@student.american.edu; alriley@american.edu FU Mellon Foundation FX This research was supported in part by a grant from the Mellon Foundation to ALR. The Mellon Foundation had no further role in the study design, data collection, analysis and interpretation, the writing of the report or the decision to submit the manuscript for publication. NR 65 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD OCT 1 PY 2016 VL 167 BP 121 EP 127 DI 10.1016/j.drugalcdep.2016.08.008 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DY7QT UT WOS:000385325100017 PM 27520883 ER PT J AU Heinssen, R McGorry, P Nordentoft, M AF Heinssen, Robert McGorry, Patrick Nordentoft, Merete TI RAISE 2.0-Establishing a National Early Psychosis Intervention Network in the US SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Heinssen, Robert] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA. [McGorry, Patrick] Univ Melbourne, Ctr Youth Mental Hlth, Orygen, Parkville, Vic, Australia. [Nordentoft, Merete] Univ Copenhagen, Mental Hlth Serv Capital Reg Denmark, DK-1168 Copenhagen, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 BP 4 EP 4 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800004 ER PT J AU Adelsheim, S Harrison, V Heinssen, R Lowe, JI Blau, GM AF Adelsheim, Steven Harrison, Vicki Heinssen, Robert Lowe, Jane Isaacs Blau, Gary M. TI Implementation of a National Early Psychosis Clinical Support Program in the United States: The Prodrome and Early Psychosis Program Network (PEPPNET) SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Adelsheim, Steven; Harrison, Vicki] Stanford Univ, Palo Alto, CA 94304 USA. [Heinssen, Robert] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA. [Lowe, Jane Isaacs] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. [Blau, Gary M.] Subst Abuse & Mental Hlth Serv Adm, Ctr Mental Hlth Serv, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 BP 23 EP 23 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800062 ER PT J AU Addington, J Cadenhead, KS Cannon, TD Cornblatt, BA McGlashan, TH Perkins, DO Seidman, LJ Walker, EF Woods, S Bearden, CE Mathalon, D Buchy, L AF Addington, Jean Cadenhead, Kristin S. Cannon, Tyrone D. Cornblatt, Barbara A. McGlashan, Thomas H. Perkins, Diana O. Seidman, Larry J. Walker, Elaine F. Woods, Scott Bearden, Carrie E. Mathalon, Daniel Buchy, Lisa TI Cannabis Use in Individuals at Clinical High Risk of Psychosis SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Addington, Jean; Buchy, Lisa] Univ Calgary, Calgary, AB T2N 1N4, Canada. [Cadenhead, Kristin S.] Univ Calif San Diego, San Diego, CA 92103 USA. [Cannon, Tyrone D.; McGlashan, Thomas H.; Woods, Scott] Yale Univ, New Haven, CT USA. [Cornblatt, Barbara A.] Zucker Hillside Hosp, New York, NY USA. [Perkins, Diana O.] Univ N Carolina, Chapel Hill, NC 27515 USA. [Seidman, Larry J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Walker, Elaine F.] Emory Univ, Atlanta, GA 30322 USA. NIMH, Bethesda, MD 20892 USA. [Bearden, Carrie E.] Univ Calif Los Angeles, Los Angeles, CA USA. [Mathalon, Daniel] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 BP 30 EP 30 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800084 ER PT J AU Adelsheim, S Harrison, V Heinssen, R Lowe, JI Blau, GM AF Adelsheim, Steven Harrison, Vicki Heinssen, Robert Lowe, Jane Isaacs Blau, Gary M. TI Creating a National Early Psychosis Clinical Support Program in the United States: The Development of the Prodrome and Early Psychosis Program Network (PEPPNET) SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Adelsheim, Steven; Harrison, Vicki] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Heinssen, Robert] NIMH, Div Serv & Intervent Res, Bethesda, MD 20892 USA. [Lowe, Jane Isaacs] Robert Wood Johnson Fdn, Program Dev, Princeton, NJ 08540 USA. [Blau, Gary M.] Subst Abuse & Mental Hlth Serv Adm, Ctr Mental Hlth Serv, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 BP 99 EP 99 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800295 ER PT J AU Schooler, N Mueser, K Estroff, S Correll, C Robinson, D Marcy, P Severe, J Azrin, S Goldstein, A Heinssen, R Kane, J AF Schooler, Nina Mueser, Kim Estroff, Sue Correll, Christoph Robinson, Delbert Marcy, Patricia Severe, Joanne Azrin, Susan Goldstein, Amy Heinssen, Robert Kane, John TI Elements of Recovery in First Episode Psychosis: Developing Measurable Criteria SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Schooler, Nina; Kane, John] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Mueser, Kim] Boston Univ, Boston, MA 02215 USA. [Estroff, Sue] Univ N Carolina, Chapel Hill, NC USA. [Correll, Christoph; Robinson, Delbert] Zucker Hillside Hosp, New York, NY USA. [Correll, Christoph; Robinson, Delbert; Marcy, Patricia] Northwell Hlth Syst NY, Great Neck, NY USA. [Severe, Joanne; Azrin, Susan; Goldstein, Amy; Heinssen, Robert] NIMH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 MA A106 BP 149 EP 149 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800445 ER PT J AU Vyas, NS Lehrer, DS Merrill, B DeCastro, A Doninger, NA Christian, BT Buchsbaum, MS AF Vyas, Nora S. Lehrer, Douglas S. Merrill, Brian DeCastro, Alex Doninger, Nicholas A. Christian, Bradley T. Buchsbaum, Monte S. TI D2/D3 Dopamine Receptor Binding with [F-18] fallypride correlates of executive function in medication-naive patients with schizophrenia SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Vyas, Nora S.] Kingston Univ London, Kingston Upon Thames, Surrey, England. [Vyas, Nora S.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Vyas, Nora S.] Imperial Coll Healthcare NHS Trust, London, England. [Lehrer, Douglas S.; Merrill, Brian] Wright State Univ, Dayton, OH 45435 USA. [DeCastro, Alex; Buchsbaum, Monte S.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Doninger, Nicholas A.] Wright State Univ, SOM, Dayton, OH 45435 USA. [Christian, Bradley T.] Univ Wisconsin, Madison, WI 53706 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 EI 1751-7893 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2016 VL 10 SU 1 BP 246 EP 246 PG 1 WC Psychiatry SC Psychiatry GA DZ1EX UT WOS:000385582800758 ER PT J AU Hoffmann, GR Shelby, MD Zeiger, E AF Hoffmann, George R. Shelby, Michael D. Zeiger, Errol TI Remembering Heinrich Malling In Memoriam SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Biographical-Item C1 [Hoffmann, George R.] Coll Holy Cross, Dept Biol, One Coll St, Worcester, MA 01610 USA. [Shelby, Michael D.] NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA. [Zeiger, Errol] Errol Zeiger Consulting, Chapel Hill, NC 27514 USA. RP Hoffmann, GR (reprint author), Coll Holy Cross, Dept Biol, One Coll St, Worcester, MA 01610 USA. EM ghoffmann@holycross.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 EI 1098-2280 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD OCT PY 2016 VL 57 IS 8 BP 575 EP 578 DI 10.1002/em.22056 PG 4 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA DZ4OA UT WOS:000385836800001 PM 27696552 ER PT J AU Dai, YF Niu, Y Duan, HW Bassig, BA Ye, M Zhang, X Meng, T Bin, P Jia, XW Shen, ML Zhang, R Hu, W Yang, XF Vermeulen, R Silverman, D Rothman, N Lan, Q Yu, SF Zheng, YX AF Dai, Yufei Niu, Yong Duan, Huawei Bassig, Bryan A. Ye, Meng Zhang, Xiao Meng, Tao Bin, Ping Jia, Xiaowei Shen, Meili Zhang, Rong Hu, Wei Yang, Xiaofa Vermeulen, Roel Silverman, Debra Rothman, Nathaniel Lan, Qing Yu, Shanfa Zheng, Yuxin TI Effects of occupational exposure to carbon black on peripheral white blood cell counts and lymphocyte subsets SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article DE carbon black; occupational exposure; inflammation; immunotoxicity ID LUNG-CANCER; PARTICULATE MATTER; INHALED PARTICLES; COHORT MORTALITY; DIESEL EXHAUST; AIR-POLLUTION; INFLAMMATION; WORKERS; HEALTH; DISEASE AB The International Agency for Research on Cancer has classified carbon black (CB) as a possible (Group 2B) human carcinogen. Given that most CB manufacturing processes result in the emission of various types of chemicals, it is uncertain if the adverse health effects that have been observed in CB-exposed workers are related to CB specifically or are due to other exposures. To address this issue, we conducted a cross-sectional molecular epidemiology study in China of 106 male factory workers who were occupationally exposed to pure CB and 112 unexposed male workers frequency-matched by age and smoking status from the same geographic region. Repeated personal exposure measurements were taken in workers before biological sample collection. Peripheral blood from all workers was used for the complete blood cell count and lymphocyte subsets analysis. Compared to unexposed workers, eosinophil counts in workers exposed to CB were increased by 30.8% (P=0.07) after adjusting for potential confounders. When stratified by smoking status, statistically significant differences in eosinophils between CB exposed and unexposed workers were only present among never smokers (P=0.040). Smoking is associated with alterations in various cell counts; however, no significant interaction between CB exposure and smoking status for any cell counts was observed. Given that inflammation, characterized in part by elevated eosinophils in peripheral blood, may be associated with increased cancer risk, our findings provide new biologic insights into the potential relationship between CB exposure and lung carcinogenesis. Environ. Mol. Mutagen. 57:589-604, 2016. (c) 2016 Wiley Periodicals, Inc. C1 [Dai, Yufei; Niu, Yong; Duan, Huawei; Ye, Meng; Zhang, Xiao; Meng, Tao; Bin, Ping; Jia, Xiaowei; Shen, Meili; Zhang, Rong; Zheng, Yuxin] Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poison Control, Key Lab, Beijing 100050, Peoples R China. [Dai, Yufei; Bassig, Bryan A.; Hu, Wei; Silverman, Debra; Rothman, Nathaniel; Lan, Qing] NCI, Occupat & Environm Epidemiol Branch, Rockville, MD 20850 USA. [Zhang, Rong] Hebei Med Univ, Dept Toxicol, Sch Publ Hlth, Shijiazhuang, Peoples R China. [Yang, Xiaofa] Jiao Zuo Ctr Dis Control & Prevent, Jiaozuo, Peoples R China. [Vermeulen, Roel] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands. [Yu, Shanfa] Henan Prov Inst Occupat Hlth, Zhengzhou, Peoples R China. RP Lan, Q (reprint author), NCI, Occupat & Environm Epidemiol Branch, Rockville, MD 20850 USA.; Yu, SF (reprint author), Henan Prov Inst Occupat Hlth, Zhengzhou, Peoples R China.; Zheng, YX (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poison Control, Beijing 100050, Peoples R China. EM qingl@mail.nih.gov; yu-shanfa@163.com; zhengyx@chinacdc.cn RI Vermeulen, Roel/F-8037-2011 OI Vermeulen, Roel/0000-0003-4082-8163 NR 42 TC 0 Z9 0 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 EI 1098-2280 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD OCT PY 2016 VL 57 IS 8 BP 615 EP 622 DI 10.1002/em.22036 PG 8 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA DZ4OA UT WOS:000385836800005 PM 27671983 ER PT J AU Dal-Re, R Rid, A Emanuel, E Wendler, D AF Dal-Re, Rafael Rid, Annette Emanuel, Ezekiel Wendler, David TI Addressing exploitation of poor clinical trial participants in North America and the European Union SO EUROPEAN JOURNAL OF INTERNAL MEDICINE LA English DT Letter DE Clinical research; Clinical trial regulations; Fair benefits; Poor participants; Uninsured patients C1 [Dal-Re, Rafael] Univ Autonoma Madrid, BUC Biosci UAM CSIC Program, Clin Res, Int Campus Excellence, Madrid, Spain. [Rid, Annette] Kings Coll London, Dept Social Sci Hlth & Med, London, England. [Emanuel, Ezekiel] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Wendler, David] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA. RP Dal-Re, R (reprint author), Univ Autonoma Madrid, Invest Clin, Programa BUC Biociencias UAM CSIC, Campus Excelencia Int,Ciudad Univ Cantoblanco, E-28049 Madrid, Spain. EM Rafael.dalre@fuam.uam.es NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0953-6205 EI 1879-0828 J9 EUR J INTERN MED JI Eur. J. Intern. Med. PD OCT PY 2016 VL 34 BP E37 EP E38 DI 10.1016/j.ejim.2016.06.026 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DY9XG UT WOS:000385488500018 PM 27425655 ER PT J AU Mead, B Tomarev, S AF Mead, Ben Tomarev, Stanislav TI Evaluating retinal ganglion cell loss and dysfunction SO EXPERIMENTAL EYE RESEARCH LA English DT Review DE Retina; Retinal ganglion cells; Electroretinography; Visual evoked potential; Quantification; Dysfunction ID OPTIC-NERVE CRUSH; PHOTOPIC NEGATIVE RESPONSE; RETROGRADE AXONAL-TRANSPORT; OCULAR HYPERTENSION MODEL; RNA-BINDING PROTEIN; OPEN-ANGLE GLAUCOMA; MOUSE MODEL; IN-VIVO; ADULT-RATS; ELECTROPHYSIOLOGICAL ASSESSMENT AB Retinal ganglion cells (RGC) bear the sole responsibility of propagating visual stimuli to the brain. Their axons, which make up the optic nerve, project from the retina to the brain through the lamina cribrosa and in rodents, decussate almost entirely at the optic chiasm before synapsing at the superior colliculus. For many traumatic and degenerative ocular conditions, the dysfunction and/or loss of RGC is the primary determinant of visual loss and are the measurable endpoints in current research into experimental therapies. To actually measure these endpoints in rodent models, techniques must ascertain both the quantity of surviving RGC and their functional capacity. Quantification techniques include phenotypic markers of RGC, retrogradely transported fluorophores and morphological measurements of retinal thickness whereas functional assessments include electroretinography (flash and pattern) and visual evoked potential. The importance of the accuracy and reliability of these techniques cannot be understated, nor can the relationship between RGC death and dysfunction. The existence of up to 30 types of RGC complicates the measuring process, particularly as these may respond differently to disease and treatment. Since the above techniques may selectively identify and ignore particular subpopulations, their appropriateness as measures of RGC survival and function may be further limited. This review discusses the above techniques in the context of their subtype specificity. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Mead, Ben; Tomarev, Stanislav] NEI, Sect Retinal Gangl Cell Biol, Lab Retinal Cell & Mol Biol, NIH, 6 Ctr Dr,Bldg 6,Room 213B, Bethesda, MD 20892 USA. RP Mead, B (reprint author), NEI, Sect Retinal Gangl Cell Biol, Lab Retinal Cell & Mol Biol, NIH, 6 Ctr Dr,Bldg 6,Room 213B, Bethesda, MD 20892 USA. EM ben.mead@nih.gov FU National Eye Institute Intramural Research Program FX This work was funded by a grant from the National Eye Institute Intramural Research Program. NR 113 TC 1 Z9 1 U1 12 U2 12 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0014-4835 EI 1096-0007 J9 EXP EYE RES JI Exp. Eye Res. PD OCT PY 2016 VL 151 BP 96 EP 106 DI 10.1016/j.exer.2016.08.006 PG 11 WC Ophthalmology SC Ophthalmology GA DZ1OI UT WOS:000385607300014 PM 27523467 ER PT J AU Dreger, DL Davis, BW Cocco, R Sechi, S Di Cerbo, A Parker, HG Polli, M Marelli, SP Crepaldi, P Ostrander, EA AF Dreger, Dayna L. Davis, Brian W. Cocco, Raffaella Sechi, Sara Di Cerbo, Alessandro Parker, Heidi G. Polli, Michele Marelli, Stefano P. Crepaldi, Paola Ostrander, Elaine A. TI Commonalities in Development of Pure Breeds and Population Isolates Revealed in the Genome of the Sardinian Fonni's Dog SO GENETICS LA English DT Article DE dog; whole-genome sequence; demography; population structure ID BARDET-BIEDL-SYNDROME; HEREDITARY PROSTATE-CANCER; OLD ORDER AMISH; DOMESTIC DOG; LINKAGE DISEQUILIBRIUM; GENETIC-STRUCTURE; SEQUENCING DATA; WIDE SEARCH; SNP DATA; DISEASE AB The island inhabitants of Sardinia have long been a focus for studies of complex human traits due to their unique ancestral background and population isolation reflecting geographic and cultural restriction. Population isolates share decreased genomic diversity, increased linkage disequilibrium, and increased inbreeding coefficients. In many regions, dogs and humans have been exposed to the same natural and artificial forces of environment, growth, and migration. Distinct dog breeds have arisen through human-driven selection of characteristics to meet an ideal standard of appearance and function. The Fonni's Dog, an endemic dog population on Sardinia, has not been subjected to an intensive system of artificial selection, but rather has developed alongside the human population of Sardinia, influenced by geographic isolation and unregulated selection based on its environmental adaptation and aptitude for owner-desired behaviors. Through analysis of 28 dog breeds, represented with whole-genome sequences from 13 dogs and similar to 170,000 genome-wide single nucleotide variants from 155 dogs, we have produced a genomic illustration of the Fonni's Dog. Genomic patterns confirm within-breed similarity, while population and demographic analyses provide spatial identity of Fonni's Dog to other Mediterranean breeds. Investigation of admixture and fixation indices reveals insights into the involvement of Fonni's Dogs in breed development throughout the Mediterranean. We describe how characteristics of population isolates are reflected in dog breeds that have undergone artificial selection, and are mirrored in the Fonni's Dog through traditional isolating factors that affect human populations. Lastly, we show that the genetic history of Fonni's Dog parallels demographic events in local human populations. C1 [Dreger, Dayna L.; Davis, Brian W.; Parker, Heidi G.; Ostrander, Elaine A.] NHGRI, Canc Genet & Comparat Genom Branch, NIH, Bethesda, MD 20892 USA. [Cocco, Raffaella; Sechi, Sara] Univ Sassari, Dipartimento Med Vet, Sez Clin Med, I-07100 Sassari, Italy. [Di Cerbo, Alessandro] Univ G dAnnunzio, Specializzaz Biochim Clin, Dipartimento Sci Med Orali & Biotecnol, I-66100 Chieti, Italy. [Polli, Michele; Marelli, Stefano P.; Crepaldi, Paola] Univ Milan, Dipartimento Med Vet, I-20133 Milan, Italy. RP Ostrander, EA (reprint author), NHGRI, NIH, Bldg 50,Room 5351,50 South Dr, Bethesda, MD 20892 USA. EM eostrand@mail.nih.gov OI Ostrander, Elaine/0000-0001-6075-9738 FU Intramural Program of the International Human Genome Research Institute; misura 3.13 del Programma Operativo Regione (P.O.R.) Sardegna (Fondi Europep di Sviluppo Regionale (FESR)) FX The authors thank all the dog owners and their dogs for providing DNA samples. Special thanks to Sir Terence Clark, Mauricio Lima, and Robert Gennari for obtaining DNA samples from regional dog breeds from Italy, North Africa, and the Middle East. D.L.D., E.A.O, B.W.D, and H.G.P. acknowledge support from the Intramural Program of the International Human Genome Research Institute. This study is part of an Italian study "Detection of morphological, genetic, and behavioral characteristics of Fonni's Dog, aimed at selection and official recognition of this breed by ENCI", funded in part by misura 3.13 del Programma Operativo Regione (P.O.R.) Sardegna 2006-2008 (Fondi Europep di Sviluppo Regionale (FESR)). NR 76 TC 0 Z9 0 U1 14 U2 14 PU GENETICS SOCIETY AMERICA PI BETHESDA PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA SN 0016-6731 EI 1943-2631 J9 GENETICS JI Genetics PD OCT PY 2016 VL 204 IS 2 BP 737 EP 755 DI 10.1534/genetics.116.192427 PG 19 WC Genetics & Heredity SC Genetics & Heredity GA DZ4ZP UT WOS:000385871400028 PM 27519604 ER PT J AU Rehman, AU Bird, JE Faridi, R Shahzad, M Shah, S Lee, K Khan, SN Imtiaz, A Ahmed, ZM Riazuddin, S Santos-Cortez, RLP Ahmad, W Leal, SM Riazuddin, S Friedman, TB AF Rehman, Atteeq U. Bird, Jonathan E. Faridi, Rabia Shahzad, Mohsin Shah, Sujay Lee, Kwanghyuk Khan, Shaheen N. Imtiaz, Ayesha Ahmed, Zubair M. Riazuddin, Saima Santos-Cortez, Regie Lyn P. Ahmad, Wasim Leal, Suzanne M. Riazuddin, Sheikh Friedman, Thomas B. TI Mutational Spectrum of MYO15A and the Molecular Mechanisms of DFNB3 Human Deafness SO HUMAN MUTATION LA English DT Article DE DFNB3; deafness; myosin 15; MYO15A; shaker 2; giant exon; micro exon ID NONSYNDROMIC HEARING-LOSS; HAIR-CELL STEREOCILIA; MYOSIN-VIIA GENE; TARGETED GENOMIC CAPTURE; NON-SYNDROMIC DEAFNESS; RECESSIVE DEAFNESS; UNCONVENTIONAL MYOSIN; PROFOUND DEAFNESS; USHER-SYNDROME; STEM-CELLS AB Deafness in humans is a common neurosensory disorder and is genetically heterogeneous. Across diverse ethnic groups, mutations of MYO15A at the DFNB3 locus appear to be the third or fourth most common cause of autosomal-recessive, nonsyndromic deafness. In 49 of the 67 exons of MYO15A, there are currently 192 recessive mutations identified, including 14 novel mutations reported here. These mutations are distributed uniformly across MYO15A with one enigmatic exception; the alternatively spliced giant exon 2, encoding 1,233 residues, has 17 truncating mutations but no convincing deafness-causing missense mutations. MYO15A encodes three distinct isoform classes, one of which is 395 kDa (3,530 residues), the largest member of the myosin superfamily of molecular motors. Studies of Myo15 mouse models that recapitulate DFNB3 revealed two different pathogenic mechanisms of hearing loss. In the inner ear, myosin 15 is necessary both for the development and the long-term maintenance of stereocilia, mechanosensory sound-transducing organelles that extend from the apical surface of hair cells. The goal of this Mutation Update is to provide a comprehensive review of mutations and functions of MYO15A. (C) 2016 Wiley Periodicals, Inc. C1 [Rehman, Atteeq U.; Bird, Jonathan E.; Faridi, Rabia; Shah, Sujay; Imtiaz, Ayesha; Friedman, Thomas B.] Natl Inst Deafness & Other Commun Disorders, Lab Mol Genet, NIH, Bethesda, MD 20892 USA. [Faridi, Rabia; Khan, Shaheen N.] Univ Punjab, Ctr Excellence Mol Biol, Lahore 54550, Pakistan. [Shahzad, Mohsin; Ahmed, Zubair M.; Riazuddin, Saima] Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA. [Lee, Kwanghyuk; Santos-Cortez, Regie Lyn P.; Leal, Suzanne M.] Baylor Coll Med, Dept Mol & Human Genet, Ctr Stat Genet, Houston, TX 77030 USA. [Ahmad, Wasim] Quaid I Azam Univ, Fac Biol Sci, Dept Biochem, Islamabad 45320, Pakistan. [Riazuddin, Sheikh] Univ Hlth Sci, Allama Iqbal Med Res Ctr, Jinnah Hosp Complex, Lahore 54550, Pakistan. [Rehman, Atteeq U.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. RP Friedman, TB (reprint author), Natl Inst Deafness & Other Commun Disorders, Lab Mol Genet, NIH, Bethesda, MD 20892 USA. EM friedman@nidcd.nih.gov OI Bird, Jonathan/0000-0001-5531-8794 FU Intramural Research Program of the NIDCD/NIH [DC000048-19]; Higher Education Commission of Pakistan (HEC); NIDCD [R01 DC003594, R01 DC011651, R01DC012564, R01DC011803] FX Contract grant sponsors: Intramural Research Program of the NIDCD/NIH (DC000048-19); Higher Education Commission of Pakistan (HEC); NIDCD (grants R01 DC003594, R01 DC011651, R01DC012564, R01DC011803). NR 106 TC 2 Z9 2 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 EI 1098-1004 J9 HUM MUTAT JI Hum. Mutat. PD OCT PY 2016 VL 37 IS 10 BP 991 EP 1003 DI 10.1002/humu.23042 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA DZ4CQ UT WOS:000385805800013 PM 27375115 ER PT J AU Olfson, M Blanco, C Marcus, SC AF Olfson, Mark Blanco, Carlos Marcus, Steven C. TI Treatment of Adult Depression in the United States SO JAMA INTERNAL MEDICINE LA English DT Article ID COMORBIDITY SURVEY REPLICATION; SERIOUS MENTAL-ILLNESS; HEALTH-CARE; GENERAL-POPULATION; MAJOR DEPRESSION; NATIONAL TRENDS; METAANALYSIS; PSYCHOTHERAPY; DISORDER; SETTINGS AB IMPORTANCE Despite recent increased use of antidepressants in the United States, concerns persist that many adults with depression do not receive treatment, whereas others receive treatments that do not match their level of illness severity. OBJECTIVE To characterize the treatment of adult depression in the United States. DESIGN, SETTING, AND PARTICIPANTS Analysis of screen-positive depression, psychological distress, and depression treatment data from 46 417 responses to the Medical Expenditure Panel Surveys taken in US households by participants aged 18 years or older in 2012 and 2013. MAIN OUTCOME AND MEASURES Percentages of adults with screen-positive depression (Patient Health Questionnaire-2 score of > 3) and adjusted odds ratios (AORs) of the effects of sociodemographic characteristics on odds of screen-positive depression; percentages with treatment for screen-positive depression and AORs; percentages with any treatment of depression and AORs stratified by presence of serious psychological distress (Kessler 6 scale score of >= 13); and percentages with depression treatment by health care professional group (psychiatrists, other health care professionals, and general medical providers); and type of depression treatment (antidepressants, psychotherapy, and both) all stratified by distress level. RESULTS Approximately 8.4%(95% CI, 7.9-8.8) of adults screened positive for depression, of which 28.7% received any depression treatment. Conversely, among all adults treated for depression, 29.9% had screen-positive depression and 21.8% had serious psychological distress. Adults with serious compared with less serious psychological distress who were treated for depression were more likely to receive care from psychiatrists (33.4% vs 17.3%, P < .001) or other mental health specialists (16.2% vs 9.6%, P < .001), and less likely to receive depression care exclusively from general medical professionals (59.0% vs 74.4%, P < .001). They were also more likely to receive psychotherapy (32.5% vs 20.6%, P < .001), though not antidepressant medications (81.1% vs 88.6%, P < .001). CONCLUSIONS AND RELEVANCE Most US adults who screen positive for depression did not receive treatment for depression, whereas most who were treated did not screen positive. In light of these findings, it is important to strengthen efforts to align depression care with each patient's clinical needs. C1 [Olfson, Mark] Columbia Univ Coll Phys & Surg, Dept Psychiat, 722 W 168th St, New York, NY 10032 USA. [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Blanco, Carlos] NIDA, Bethesda, MD 20892 USA. [Marcus, Steven C.] Univ Penn, Sch Social Practice & Policy, Philadelphia, PA 19104 USA. RP Olfson, M (reprint author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA. EM mo49@cumc.columbia.edu FU Agency for Healthcare Quality and Research [U19 HS02112]; National Institute on Drug Abuse; AHRQ FX This work was supported by the Agency for Healthcare Quality and Research U19 HS02112. Work by Dr. Blanco was supported by the National Institute on Drug Abuse and he had no role in the grant from AHRQ. NR 50 TC 5 Z9 5 U1 10 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD OCT PY 2016 VL 176 IS 10 BP 1482 EP 1491 DI 10.1001/jamainternmed.2016.5057 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DZ1ZU UT WOS:000385642000013 PM 27571438 ER PT J AU Goedert, JJ AF Goedert, James J. TI Intestinal Microbiota and Health of Adults Who Were Born by Cesarean Delivery SO JAMA PEDIATRICS LA English DT Letter C1 [Goedert, James J.] NCI, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr,Room 6E106,MSC 9767, Bethesda, MD 20892 USA. RP Goedert, JJ (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr,Room 6E106,MSC 9767, Bethesda, MD 20892 USA. EM goedertj@mail.nih.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2016 VL 170 IS 10 BP 1027 EP 1027 DI 10.1001/jamapediatrics.2016.2310 PG 1 WC Pediatrics SC Pediatrics GA DZ2AB UT WOS:000385643000026 PM 27548071 ER PT J AU Blanco, C Compton, WM Grant, BF AF Blanco, Carlos Compton, Wilson M. Grant, Bridget F. TI Toward Precision Epidemiology SO JAMA PSYCHIATRY LA English DT Editorial Material ID COMMON PSYCHIATRIC-DISORDERS; GENERAL-POPULATION; ANXIETY DISORDERS; MENTAL-DISORDERS; DEPRESSION; ILLNESS; ALCOHOL; SAMPLE C1 [Blanco, Carlos] NIDA, Div Epidemiol Serv & Prevent Res, 6001 Execut Blvd, Bethesda, MD 20852 USA. [Compton, Wilson M.] NIDA, Off Director, Bethesda, MD 20892 USA. [Grant, Bridget F.] NIAAA, Lab Epidemiol & Biometry, Div Intramural Clin & Biol Res, Rockville, MD 20852 USA. RP Blanco, C (reprint author), NIDA, Div Epidemiol Serv & Prevent Res, 6001 Execut Blvd, Bethesda, MD 20852 USA. EM carlos.blanco2@nih.gov NR 16 TC 1 Z9 1 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD OCT PY 2016 VL 73 IS 10 BP 1008 EP 1009 DI 10.1001/jamapsychiatry.2016.1869 PG 2 WC Psychiatry SC Psychiatry GA DZ5QG UT WOS:000385916000003 PM 27603943 ER PT J AU Paksarian, D Cui, LH Angst, J Ajdacic-Gross, V Rossler, W Merikangas, KR AF Paksarian, Diana Cui, Lihong Angst, Jules Ajdacic-Gross, Vladeta Rossler, Wulf Merikangas, Kathleen R. TI Latent Trajectories of Common Mental Health Disorder Risk Across 3 Decades of Adulthood in a Population-Based Cohort SO JAMA PSYCHIATRY LA English DT Article ID EPIDEMIOLOGIC CATCHMENT-AREA; NATIONAL-COMORBIDITY-SURVEY; SUBSTANCE USE DISORDERS; OF-ONSET DISTRIBUTIONS; UNITED-STATES; LIFETIME PREVALENCE; FOLLOW-UP; PSYCHIATRIC-DISORDERS; DEPRESSIVE DISORDER; ZURICH COHORT AB IMPORTANCE Epidemiologic evidence indicates that most of the general population will experience a mental health disorder at some point in their lives. However, few prospective population-based studies have estimated trajectories of risk for mental disorders from young through middle adulthood to estimate the proportion of individuals who experience persistent mental disorder across this age period. OBJECTIVES To describe the proportion of the population who experience persistent mental disorder across adulthood and to estimate latent trajectories of disorder risk across this age period. DESIGN, SETTING, AND PARTICIPANTS A population-based, prospective cohort study was conducted between 1979 and 2008 in the canton of Zurich, Switzerland. A stratified random sample of 591 Swiss citizens was enrolled in 1978 at ages 19 years (men) and 20 years (women); 7 interviews were performed during a 29-year period. Men were sampled from military enrollment records and women from electoral records. From those initially enrolled, participants with high levels of psychiatric symptoms were oversampled for follow-up. Data analysis was performed from July 28, 2015, to June 8, 2016. MAIN OUTCOMES AND MEASURES Latent trajectories, estimated using growth mixture modeling, of past-year mood/anxiety disorder (ie, major depressive episode, phobias, panic, generalized anxiety disorder, and obsessive-compulsive disorder), substance use disorder (ie, drug abuse or dependence and alcohol abuse or dependence), and any mental disorder (ie, any of the above) assessed during in-person semistructured interviews at each wave. Diagnoses were based on DSM-III, DSM-III-R, and DSM-IV criteria. RESULTS Of the 591 participants at baseline, 299 (50.6%) were female. Persistent mental health disorder across multiple study waves was rare. Among 252 individuals (42.6%) who participated in all 7 study waves, only 1.2% met criteria for disorder every time. Growth mixture modeling identified 3 classes of risk for any disorder across adulthood: low (estimated prevalence, 40.0%; 95% CI, -8.7% to 88.9%), increasing-decreasing (estimated prevalence, 15.3%; 95% CI, 1.0% to 29.6%), and increasing (estimated prevalence, 44.7%; 95% CI, -0.9% to 90.1%). Although no classes were characterized by persistently high disorder risk, for those in the increasing-decreasing class, risk was high from the late 20s to early 40s. Sex-specific models indicated 4 trajectory classes for women but only 3 for men. CONCLUSIONS AND RELEVANCE Persistently high mental health disorder risk across 3 decades of adulthood was rare in this population-based sample. Identifying early determinants of sex-specific risk trajectories would benefit prevention efforts. C1 [Paksarian, Diana; Cui, Lihong; Merikangas, Kathleen R.] NIMH, Genet Epidemiol Res Branch, Intramural Res Program, Bethesda, MD 20892 USA. [Angst, Jules; Ajdacic-Gross, Vladeta] Univ Zurich, Hosp Psychiat, Dept Psychiat Psychotherapy & Psychosomat, Zurich, Switzerland. [Rossler, Wulf] Univ Sao Paulo, Inst Psychiat, Lab Neurosci, Sao Paulo, Brazil. [Rossler, Wulf] Univ Zurich, Coll Helveticum, Zurich, Switzerland. [Rossler, Wulf] Swiss Tech Inst, Zurich, Switzerland. RP Merikangas, KR (reprint author), NIMH, Genet Epidemiol Res Branch, 35A Convent Dr,MSC 3720, Bethesda, MD 20892 USA. EM kathleen.merikangas@nih.gov FU Intramural Research Program of the National Institute of Mental Health [ZIAMH002807]; Swiss National Science Foundation [3200-050881.97/1, 32-50881.97] FX This study was supported by project ZIAMH002807 from the Intramural Research Program of the National Institute of Mental Health and grants 3200-050881.97/1 and 32-50881.97 from the Swiss National Science Foundation. NR 59 TC 1 Z9 1 U1 14 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD OCT PY 2016 VL 73 IS 10 BP 1023 EP 1031 DI 10.1001/jamapsychiatry.2016.1921 PG 9 WC Psychiatry SC Psychiatry GA DZ5QG UT WOS:000385916000007 PM 27602550 ER PT J AU Pongracic, JA Krouse, RZ Babineau, DC Zoratti, EM Cohen, RT Wood, RA Hershey, GKK Kercsmar, CM Gruchalla, RS Kattan, M Teach, SJ Johnson, CC Bacharier, LB Gern, JE Sigelman, SM Gergen, PJ Togias, A Visness, CM Busse, WW Liu, AH AF Pongracic, Jacqueline A. Krouse, Rebecca Z. Babineau, Denise C. Zoratti, Edward M. Cohen, Robyn T. Wood, Robert A. Hershey, Gurjit K. Khurana Kercsmar, Carolyn M. Gruchalla, Rebecca S. Kattan, Meyer Teach, Stephen J. Johnson, Christine C. Bacharier, Leonard B. Gern, James E. Sigelman, Steven M. Gergen, Peter J. Togias, Alkis Visness, Cynthia M. Busse, William W. Liu, Andrew H. TI Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Child; asthma; inner-city asthma; asthma phenotype; asthma morbidity; asthma severity; asthma exacerbations; pulmonary function; rhinitis; allergen sensitization; IgE ID ALLERGIC RHINITIS; BRONCHODILATOR RESPONSIVENESS; PRESCHOOL-CHILDREN; MODERATE ASTHMA; YOUNG-ADULTS; IMPACT; CHILDHOOD; OBSTRUCTION; VALIDATION; MANAGEMENT AB Background: Treatment levels required to control asthma vary greatly across a population with asthma. The factors that contribute to variability in treatment requirements of inner-city children have not been fully elucidated. Objective: We sought to identify the clinical characteristics that distinguish difficult-to-control asthma from easy-to-control asthma. Methods: Asthmatic children aged 6 to 17 years underwent baseline assessment and bimonthly guideline-based management visits over 1 year. Difficult-to-control and easy-to-control asthma were defined as daily therapy with 500 mg of fluticasone or greater with or without a long-acting beta-agonist versus 100 mu g or less assigned on at least 4 visits. Forty-four baseline variables were used to compare the 2 groups by using univariate analyses and to identify the most relevant features of difficult-to-control asthma by using a variable selection algorithm. Nonlinear seasonal variation in longitudinal measures (symptoms, pulmonary physiology, and exacerbations) was examined by using generalized additive mixed-effects models. Results: Among 619 recruited participants, 40.9% had difficult-to-control asthma, 37.5% had easy-to-control asthma, and 21.6% fell into neither group. At baseline, FEV1 bronchodilator responsiveness was the most important characteristic distinguishing difficult-to-control asthma from easy-to-control asthma. Markers of rhinitis severity and atopy were among the other major discriminating features. Over time, difficult-tocontrol asthma was characterized by high exacerbation rates, particularly in spring and fall; greater daytime and nighttime symptoms, especially in fall and winter; and compromised pulmonary physiology despite ongoing high-dose controller therapy. Conclusions: Despite good adherence, difficult-to-control asthma showed little improvement in symptoms, exacerbations, or pulmonary physiology over the year. In addition to pulmonary physiology measures, rhinitis severity and atopy were associated with high-dose asthma controller therapy requirement. C1 [Pongracic, Jacqueline A.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. [Krouse, Rebecca Z.; Babineau, Denise C.; Visness, Cynthia M.] Rho Fed Syst Div, Chapel Hill, NC USA. [Zoratti, Edward M.; Johnson, Christine C.] Henry Ford Hlth Syst, Detroit, MI USA. [Cohen, Robyn T.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC USA. [Teach, Stephen J.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA. [Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA. [Liu, Andrew H.] Childrens Hosp Colorado, Aurora, CO USA. [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA. RP Pongracic, JA (reprint author), 225 E Chicago Av 60, Chicago, IL 60614 USA. EM jpongracic@luriechildrens.org OI Cohen, Robyn/0000-0002-6902-3118 FU National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS), NIH [NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1, NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105] FX This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (under contract nos. HHSN272200900052C and HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). GlaxoSmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication. NR 38 TC 4 Z9 4 U1 2 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD OCT PY 2016 VL 138 IS 4 BP 1030 EP 1041 DI 10.1016/j.jaci.2016.06.059 PG 12 WC Allergy; Immunology SC Allergy; Immunology GA DZ0AP UT WOS:000385499400008 PM 27720017 ER PT J AU Liu, AH Babineau, DC Krouse, RZ Zoratti, EM Pongracic, JA O'Connor, GT Wood, RA Hershey, GKK Kercsmar, CM Gruchalla, RS Kattan, M Teach, SJ Makhija, M Pillai, D Lamm, CI Gern, JE Sigelman, SM Gergen, PJ Togias, A Visness, CM Busse, WW AF Liu, Andrew H. Babineau, Denise C. Krouse, Rebecca Z. Zoratti, Edward M. Pongracic, Jacqueline A. O'Connor, George T. Wood, Robert A. Hershey, Gurjit K. Khurana Kercsmar, Carolyn M. Gruchalla, Rebecca S. Kattan, Meyer Teach, Stephen J. Makhija, Melanie Pillai, Dinesh Lamm, Carin I. Gern, James E. Sigelman, Steven M. Gergen, Peter J. Togias, Alkis Visness, Cynthia M. Busse, William W. TI Pathways through which asthma risk factors contribute to asthma severity in inner-city children SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Asthma; children; inner-city; allergy; sensitization; inflammation; lung function; pulmonary physiology; rhinitis; environmental tobacco smoke exposure ID ALLERGIC RHINITIS; ADOLESCENTS; MORBIDITY; EXACERBATIONS; VALIDATION; EXPOSURE; VALIDITY; VIOLENCE; STRESS; IMPACT AB Background: Pathway analyses can be used to determine how host and environmental factors contribute to asthma severity. Objective: To investigate pathways explaining asthma severity in inner-city children. Methods: On the basis of medical evidence in the published literature, we developed a conceptual model to describe how 8 risk-factor domains (allergen sensitization, allergic inflammation, pulmonary physiology, stress, obesity, vitamin D, environmental tobacco smoke [ETS] exposure, and rhinitis severity) are linked to asthma severity. To estimate the relative magnitude and significance of hypothesized relationships among these domains and asthma severity, we applied a causal network analysis to test our model in an Inner-City Asthma Consortium study. Participants comprised 6- to 17-year-old children (n = 561) with asthma and rhinitis from 9 US inner cities who were evaluated every 2 months for 1 year. Asthma severity was measured by a longitudinal composite assessment of day and night symptoms, exacerbations, and controller usage. Results: Our conceptual model explained 53.4% of the variance in asthma severity. An allergy pathway (linking allergen sensitization, allergic inflammation, pulmonary physiology, and rhinitis severity domains to asthma severity) and the ETS exposure pathway (linking ETS exposure and pulmonary physiology domains to asthma severity) exerted significant effects on asthma severity. Among the domains, pulmonary physiology and rhinitis severity had the largest significant standardized total effects on asthma severity (-0.51 and 0.48, respectively), followed by ETS exposure (0.30) and allergic inflammation (0.22). Although vitamin D had modest but significant indirect effects on asthma severity, its total effect was insignificant (0.01). Conclusions: The standardized effect sizes generated by a causal network analysis quantify the relative contributions of different domains and can be used to prioritize interventions to address asthma severity. C1 [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA. [Liu, Andrew H.] Childrens Hosp Colorado, 13123 East 16th Ave,Box B395, Aurora, CO 80045 USA. [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA. [Babineau, Denise C.; Krouse, Rebecca Z.; Visness, Cynthia M.] Rho Fed Syst Div, Chapel Hill, NC USA. [Zoratti, Edward M.] Henry Ford Hlth Syst, Detroit, MI USA. [Pongracic, Jacqueline A.; Makhija, Melanie] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Kattan, Meyer; Lamm, Carin I.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Teach, Stephen J.; Pillai, Dinesh] Childrens Natl Hlth Syst, Washington, DC USA. [Teach, Stephen J.; Pillai, Dinesh] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Gern, James E.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Liu, AH (reprint author), Childrens Hosp Colorado, 13123 East 16th Ave,Box B395, Aurora, CO 80045 USA. EM Andrew.liu@childrenscolorado.org FU National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS), NIH [NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105] FX This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (under contract nos. HHSN272200900052C and HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). GlaxoSmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication. NR 34 TC 2 Z9 2 U1 8 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD OCT PY 2016 VL 138 IS 4 BP 1042 EP 1050 DI 10.1016/j.jaci.2016.06.060 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA DZ0AP UT WOS:000385499400009 PM 27720018 ER PT J AU Feeney, M Du Toit, G Roberts, G Sayre, PH Lawson, K Bahnson, HT Sever, ML Radulovic, S Plaut, M Lack, G AF Feeney, Mary Du Toit, George Roberts, Graham Sayre, Peter H. Lawson, Kaitie Bahnson, Henry T. Sever, Michelle L. Radulovic, Suzana Plaut, Marshall Lack, Gideon CA Immune Tolerance Network Leap Stu TI Impact of peanut consumption in the LEAP Study: Feasibility, growth, and nutrition SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Food allergy; allergy prevention; peanut; infant feeding; breast-feeding; nutrition; growth; prospective food diary; protein homeostasis ID HIGH-RISK INFANTS; CONSENSUS COMMUNICATION; ALLERGY; CHILDREN; ADOLESCENTS; PREVENTION; PREVALENCE; ACCEPTANCE; CHILDHOOD; FRUIT AB Background: Early introduction of peanut is an effective strategy to prevent peanut allergy in high-risk infants; however, feasibility and effects on growth and nutritional intake are unknown. Objective: We sought to evaluate the feasibility of introducing peanut in infancy and explore effects on growth and nutritional intake up to age 60 months. Methods: In the Learning Early About Peanut Allergy trial, 640 atopic infants aged 4 to 11 months were randomly assigned to consume (6 g peanut protein per week) or avoid peanut until age 60 months. Peanut consumption and early feeding practices were assessed by questionnaire. Dietary intake was evaluated with prospective food diaries. Anthropometric measurements were taken at all study visits. Results: Peanut was successfully introduced and consumed until 60 months, with median peanut protein intake of 7.5 g/wk (interquartile range, 6.0-9.0 g/wk) in the consumption group compared with 0 g in the avoidance group. Introduction of peanut in breast-feeding infants did not affect the duration of breast-feeding. There were no differences in anthropometric measurements or energy intakes between groups at any visits. Regular peanut consumption led to differences in dietary intakes. Consumers had higher intakes of fat and avoiders had higher carbohydrate intakes; differences were greatest at the upper quartiles of peanut consumption. Protein intakes remained consistent between groups. Conclusions: Introduction of peanut proved feasible in infants at high risk of peanut allergy and did not affect the duration of breast-feeding nor impact negatively on growth or nutrition. Energy balance was achieved in both groups through variations in intakes from fat and carbohydrate while protein homeostasis was maintained. C1 [Feeney, Mary; Du Toit, George; Radulovic, Suzana; Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London, England. [Feeney, Mary; Du Toit, George; Roberts, Graham; Radulovic, Suzana; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London, England. [Roberts, Graham] Univ Southampton, Southampton, Hants, England. [Roberts, Graham] Natl Inst Hlth, Res Resp Biomed Res Unit, Southampton, Hants, England. [Roberts, Graham] David Hide Ctr, Isle Of Wight, England. [Sayre, Peter H.] Immune Tolerance Network, San Francisco, CA USA. [Sayre, Peter H.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA. [Lawson, Kaitie; Bahnson, Henry T.; Sever, Michelle L.] Rho Fed Syst Div, Chapel Hill, NC USA. [Plaut, Marshall] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Lack, G (reprint author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Unit, 2nd Fl,South Wing,Westminster Bridge Rd, London SE1 7EH, England. EM gideon.lack@kcl.ac.uk FU National Institute of Allergy and Infectious Diseases [UM1AI109565, NO1-AI-15416, HHSN272200800029C]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Food Allergy Research & Education (FARE), McLean, Virginia; Medical Research Council & Asthma UK Centre; UK Department of Health through the National Institute for Health Research comprehensive Biomedical Research Centre award; King's College London; King's College Hospital NHS Foundation Trust; National Peanut Board, Atlanta, Georgia; UK Food Standards Agency FX This study was funded by the National Institute of Allergy and Infectious Diseases (award nos. UM1AI109565, NO1-AI-15416, and HHSN272200800029C) and others. This research was performed as a project of the Immune Tolerance Network, an international clinical research consortium headquartered at the Benaroya Research Institute and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support came from Food Allergy Research & Education (FARE), McLean, Virginia; the Medical Research Council & Asthma UK Centre; the UK Department of Health through the National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's & St Thomas' National Health Service (NHS) Foundation Trust, in partnership with King's College London and King's College Hospital NHS Foundation Trust. The clinical trials unit is supported by the National Peanut Board, Atlanta, Georgia. The UK Food Standards Agency provided additional support for the costs of phlebotomy. NR 41 TC 9 Z9 9 U1 5 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD OCT PY 2016 VL 138 IS 4 BP 1108 EP 1118 DI 10.1016/j.jaci.2016.04.016 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA DZ0AP UT WOS:000385499400016 PM 27297994 ER PT J AU Koplin, JJ Peters, RL Dharmage, SC Gurrin, L Tang, MLK Ponsonby, AL Matheson, M Togias, A Lack, G Allen, KJ AF Koplin, Jennifer J. Peters, Rachel L. Dharmage, Shyamali C. Gurrin, Lyle Tang, Mimi L. K. Ponsonby, Anne-Louise Matheson, Melanie Togias, Alkis Lack, Gideon Allen, Katrina J. CA HealthNuts Study Investigators TI Understanding the feasibility and implications of implementing early peanut introduction for prevention of peanut allergy SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Peanut allergy; infant feeding; guidelines; skin prick test; specific IgE; prevention ID FOOD ALLERGY; EARLY CONSUMPTION; PREVALENCE; INFANTS; HEALTHNUTS; PREDICTORS; DIAGNOSIS; CRITERIA; COHORT; TIME AB Background: A recent randomized trial (the Learning Early About Peanut Allergy [LEAP] study) provided evidence that earlier dietary peanut introduction reduces peanut allergy prevalence in high-risk infants. However, questions remain as to how to identify and target the "at-risk'' population to facilitate timely introduction of peanut. Objective: We sought to use population-based infant peanut allergy data to understand feasibility and implications of implementing the LEAP trial intervention. Methods: Using the HealthNuts study cohort (n = 5276) of 1-year-old infants, we explored the impact of using various criteria to identify infants at high risk of developing peanut allergy, and the implications of skin prick test (SPT) screening before peanut introduction. Results: Screening all infants with early onset eczema and/or egg allergy could require testing 16% of the population and would still miss 23% of peanut allergy cases; 29% of screened infants would require clinical follow-up because of being SPT-positive. Around 11% of high-risk infants were excluded from the LEAP study because of an SPT wheal size of more than 4 mm to peanut at baseline; data from the HealthNuts study suggest that 80% of these would be peanut allergic on food challenge. There were no life-threatening events among either low-or high-risk infants whose parents chose to introduce peanut at home in the first year of life, or in 150 peanut-allergic infants during hospital-based challenges. Conclusions: Based on this large epidemiological study, a population program aiming to identify and screen all infants at risk of peanut allergy would pose major cost and logistic challenges that need to be carefully considered. Further research might be required to provide data for low-risk infants. C1 [Koplin, Jennifer J.; Peters, Rachel L.; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Murdoch Childrens Res Inst, Parkville, Vic, Australia. [Koplin, Jennifer J.; Peters, Rachel L.; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Clin Immunol, Parkville, Vic, Australia. [Koplin, Jennifer J.; Dharmage, Shyamali C.; Gurrin, Lyle; Matheson, Melanie] Univ Melbourne, Sch Populat & Global Hlth, Parkville, Vic, Australia. [Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Lack, Gideon] Kings Coll London, Dept Pediat Allergy, Div Asthma Allergy & Lung Biol, London, England. [Lack, Gideon] Guys & St Thomas Natl Hlth Serv Fdn Trust, London, England. [Allen, Katrina J.] Univ Manchester, Sch Inflammat & Repair, Manchester, Lancs, England. RP Allen, KJ (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia. EM katie.allen@rch.org.au RI Matheson, Melanie/O-4721-2015; OI Matheson, Melanie/0000-0002-5822-3499; Peters, Rachel/0000-0002-2411-6628; Allen, Katrina/0000-0002-1921-4493 FU National Health & Medical Research Council (NHMRC) of Australia; Australian Food Allergy Foundation; Anaphylaxi-Stop; Victorian Government's Operational Infrastructure Support Program FX This work was supported by funding from the National Health & Medical Research Council (NHMRC) of Australia, Australian Food Allergy Foundation, Anaphylaxi-Stop, and the Victorian Government's Operational Infrastructure Support Program. The study sponsors had no involvement in the study design, collection, analysis, and interpretation of data, writing of the report, or decision to submit the article for publication. NR 19 TC 7 Z9 7 U1 3 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD OCT PY 2016 VL 138 IS 4 BP 1131 EP + DI 10.1016/j.jaci.2016.04.011 PG 13 WC Allergy; Immunology SC Allergy; Immunology GA DZ0AP UT WOS:000385499400019 PM 27260320 ER PT J AU Chandrasekaran, P Zimmerman, O Paulson, M Sampaio, EP Freeman, AF Sowerwine, KJ Hurt, D Alcantara-Montiel, JC Hsu, AP Holland, SM AF Chandrasekaran, Prabha Zimmerman, Ofer Paulson, Michelle Sampaio, Elizabeth P. Freeman, Alexandra F. Sowerwine, Kathryn J. Hurt, Darell Alcantara-Montiel, Julio C. Hsu, Amy P. Holland, Steven M. TI Distinct mutations at the same positions of STAT3 cause either loss or gain of function SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Letter ID GRANULAR LYMPHOCYTIC-LEUKEMIA; HYPER-IGE SYNDROME C1 [Chandrasekaran, Prabha; Zimmerman, Ofer; Paulson, Michelle; Sampaio, Elizabeth P.; Freeman, Alexandra F.; Sowerwine, Kathryn J.; Hsu, Amy P.; Holland, Steven M.] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Chandrasekaran, Prabha] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA. [Hurt, Darell] NIAID, Bioinformat & Computat Biosci Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Alcantara-Montiel, Julio C.] CINVES TAV IPN, Dept Mol Biomed, Mexico City, DF, Mexico. RP Holland, SM (reprint author), NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM smh@nih.gov FU CCR NIH HHS [HHSN261200800001C]; Intramural NIH HHS [Z01 AI000646-16]; NCI NIH HHS [HHSN261200800001E] NR 13 TC 1 Z9 1 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD OCT PY 2016 VL 138 IS 4 BP 1222 EP 1224 DI 10.1016/j.jaci.2016.05.007 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA DZ0AP UT WOS:000385499400037 PM 27345172 ER PT J AU Weeks, J Briggs, JP AF Weeks, John Briggs, Josephine P. TI The New USA NIH Strategic Plan for Complementary and Integrative Health: Interview with Josephine Briggs, MD: Director, National Center for Complementary and Integrative Health (Part 2) SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Editorial Material C1 [Briggs, Josephine P.] NIH, NCCIH, USA Natl Inst Hlth NIH, Bldg 10, Bethesda, MD 20892 USA. [Briggs, Josephine P.] NIH, Precis Med Initiat, Cohort Program, Bldg 10, Bethesda, MD 20892 USA. [Briggs, Josephine P.] NIH, Common Fund Hlth Care Syst Res Collaboratory, Bldg 10, Bethesda, MD 20892 USA. [Briggs, Josephine P.] NIH, Steering Comm, Bldg 10, Bethesda, MD 20892 USA. [Briggs, Josephine P.] NIH, Sci Management Review Board, Bldg 10, Bethesda, MD 20892 USA. [Briggs, Josephine P.] NIH, Pain Consortium, Bldg 10, Bethesda, MD 20892 USA. [Briggs, Josephine P.] Univ Munich, Inst Physiol, Munich, Germany. [Briggs, Josephine P.] Univ Michigan, Internal Med & Physiol, Ann Arbor, MI 48109 USA. [Briggs, Josephine P.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Briggs, Josephine P.] NIH, Div Kidney Urol & Hematol Dis, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD OCT PY 2016 VL 22 IS 10 BP 765 EP 767 DI 10.1089/acm.2016.29011.jjw PG 3 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DZ5SU UT WOS:000385922600002 PM 27653499 ER PT J AU Scott, JM Robinson, SE Holroyd, T Coppola, R Sato, S Inati, SK AF Scott, Jonathan M. Robinson, Stephen E. Holroyd, Tom Coppola, Richard Sato, Susumu Inati, Sara K. TI Localization of Interictal Epileptic Spikes With MEG: Optimization of an Automated Beamformer Screening Method (SAMepi) in a Diverse Epilepsy Population SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY LA English DT Article DE Magnetoencephalography; Source localization; Epilepsy; Beamforming; Kurtosis ID INTRACRANIAL EEG; MAGNETOENCEPHALOGRAPHY AB Purpose: To describe and optimize an automated beamforming technique followed by identification of locations with excess kurtosis (g2) for efficient detection and localization of interictal spikes in patients with medically refractory epilepsy. Methods: Synthetic aperture magnetometry with g2 averaged over a sliding time window (SAMepi) was performed in seven patients with focal epilepsy and five healthy volunteers. The effect of varied window lengths on detection of spiking activity was evaluated. Results: Sliding window lengths of 0.5 to 10 seconds performed similarly, with 0.5- and 1-second windows detecting spiking activity in 1 of the 3 virtual sensor locations with highest kurtosis. These locations were concordant with the region of eventual surgical resection in these seven patients who remained seizure-free at 1 year. Average g2 values increased with increasing sliding window length in all subjects. In healthy volunteers, kurtosis values stabilized in data sets longer than 2 minutes. Conclusions: SAMepi using g2 averaged over 1-second sliding time windows in data sets of at least 2 minutes of duration reliably identified interictal spiking and the presumed seizure focus in these seven patients. Screening the five locations with highest kurtosis values for spiking activity is an efficient and accurate technique for localizing interictal activity using magnetoencephalography. Significance: SAMepi should be applied using the parameter values and procedure described for optimal detection and localization of interictal spikes. Use of this screening procedure could significantly improve the efficiency of magnetoencephalography analysis if clinically validated. C1 [Scott, Jonathan M.; Sato, Susumu; Inati, Sara K.] NINDS, EEG Sect, NIH, 10 CRC,Room 7-3753,10 Ctr Dr,MSC 1404, Bethesda, MD 20892 USA. [Robinson, Stephen E.; Holroyd, Tom; Coppola, Richard] NIMH, MEG Core Facil, NIH, Bethesda, MD 20892 USA. RP Scott, JM (reprint author), NINDS, EEG Sect, NIH, 10 CRC,Room 7-3753,10 Ctr Dr,MSC 1404, Bethesda, MD 20892 USA. EM jonathan.m.scott2013@gmail.com FU Intramural Research Program of the National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS) FX Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS). NR 18 TC 0 Z9 0 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0736-0258 EI 1537-1603 J9 J CLIN NEUROPHYSIOL JI J. Clin. Neurophysiol. PD OCT PY 2016 VL 33 IS 5 BP 414 EP 420 DI 10.1097/WNP.0000000000000255 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DZ2HP UT WOS:000385663200007 PM 27760068 ER PT J AU Clark, C Thomas, D Mejzner, N Llewellyn, D Ferrucci, L Campbell, J AF Clark, Christopher Thomas, Daniel Mejzner, Natasha Llewellyn, David Ferrucci, Luigi Campbell, John TI Can we predict who should be tested for postural hypotension? Derivation and validation of a prediction tool SO JOURNAL OF HUMAN HYPERTENSION LA English DT Meeting Abstract C1 [Clark, Christopher; Thomas, Daniel; Mejzner, Natasha; Llewellyn, David; Campbell, John] Univ Exeter, Sch Med, Exeter EX4 4QJ, Devon, England. [Ferrucci, Luigi] NIA, Baltimore, MD 21224 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9240 EI 1476-5527 J9 J HUM HYPERTENS JI J. Hum. Hypertens. PD OCT PY 2016 VL 30 IS 10 SI SI MA O-15 BP 640 EP 640 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DZ3ZY UT WOS:000385797000025 ER PT J AU Murphy, J Mark, H AF Murphy, Jeanne Mark, Hayley TI Self-Sampling as an Intervention to Promote Cervical Cancer Screening Among Women With HIV SO JOURNAL OF LOWER GENITAL TRACT DISEASE LA English DT Letter C1 [Murphy, Jeanne] NCI, Canc Prevent Fellowship Program, Canc Prevent Div, Rockville, MD 20850 USA. [Mark, Hayley] Towson Univ, Dept Nursing, Towson, MD USA. RP Murphy, J (reprint author), NCI, Canc Prevent Fellowship Program, Canc Prevent Div, Rockville, MD 20850 USA. EM jeanne.murphy@nih.gov FU Intramural NIH HHS [Z99 CA999999] NR 2 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1089-2591 EI 1526-0976 J9 J LOW GENIT TRACT DI JI J. Low. Genit. Tract. Dis. PD OCT PY 2016 VL 20 IS 4 BP e63 EP e63 DI 10.1097/LGT.0000000000000259 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DY8II UT WOS:000385372600006 PM 27556424 ER PT J AU Kim, H Sanchez, GAM Goldbach-Mansky, R AF Kim, Hanna Sanchez, Gina A. Montealegre Goldbach-Mansky, Raphaela TI Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus SO JOURNAL OF MOLECULAR MEDICINE-JMM LA English DT Review DE Type I IFN; Autoinflammatory; Autoimmune; Candle; SAVI; Interferonopathies ID AICARDI-GOUTIERES-SYNDROME; FAMILIAL CHILBLAIN LUPUS; ATYPICAL NEUTROPHILIC DERMATOSIS; INNATE IMMUNE-RESPONSE; SINGLETON-MERTEN SYNDROME; NAKAJO-NISHIMURA SYNDROME; OF-FUNCTION MUTATION; MEDIATED CELL-DEATH; I INTERFERON; EXTRACELLULAR TRAPS AB Autoinflammatory disorders are sterile inflammatory conditions characterized by episodes of early-onset fever and disease-specific patterns of organ inflammation. Recently, the discoveries of monogenic disorders with strong type I interferon (IFN) signatures caused by mutations in proteasome degradation and cytoplasmic RNA and DNA sensing pathways suggest a pathogenic role of IFNs in causing autoinflammatory phenotypes. The IFN response gene signature (IGS) has been associated with systemic lupus erythematosus (SLE) and other autoimmune diseases. In this review, we compare the clinical presentations and pathogenesis of two IFN-mediated autoinflammatory diseases, CANDLE and SAVI, with Aicardi GoutiSres syndrome (AGS) and monogenic forms of SLE (monoSLE) caused by loss-of-function mutations in complement 1 (C1q) or the DNA nucleases, DNASE1 and DNASE1L3. We outline differences in intracellular signaling pathways that fuel a pathologic type I IFN amplification cycle. While IFN amplification is caused by predominantly innate immune cell dysfunction in SAVI, CANDLE, and AGS, autoantibodies to modified RNA and DNA antigens interact with tissues and immune cells including neutrophils and contribute to IFN upregulation in some SLE patients including monoSLE, thus justifying a grouping of "autoinflammatory" and "autoimmune" interferonopathies. Understanding of the differences in the cellular sources and signaling pathways will guide new drug development and the use of emerging targeted therapies. C1 [Kim, Hanna] NIAMSD, Translat Res, Pediat Translat Res Branch, NIH, Bethesda, MD 20892 USA. [Sanchez, Gina A. Montealegre; Goldbach-Mansky, Raphaela] NIAID, Translat Autoinflammatory Dis Studies, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Sanchez, Gina A. Montealegre; Goldbach-Mansky, Raphaela] NIAMS, NIH, Bethesda, MD USA. RP Kim, H (reprint author), NIAMSD, Translat Res, Pediat Translat Res Branch, NIH, Bethesda, MD 20892 USA.; Goldbach-Mansky, R (reprint author), NIAID, Translat Autoinflammatory Dis Studies, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Goldbach-Mansky, R (reprint author), NIAMS, NIH, Bethesda, MD USA. EM hanna.kim@nih.gov; gina.montealegre@nih.gov; goldbacr@mail.nih.gov OI Kim, Hanna/0000-0002-0595-6533 FU Intramural Research Program of the NIH; NIAID; NIAMS FX This research was supported by the Intramural Research Program of the NIH, NIAID, and NIAMS. The authors would like to thank Dr. Ann Marschuk-Rothstein and Dr. Adriana Almeida de Jesus for helpful discussions. NR 120 TC 1 Z9 1 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0946-2716 EI 1432-1440 J9 J MOL MED JI J. Mol. Med. PD OCT PY 2016 VL 94 IS 10 BP 1111 EP 1127 DI 10.1007/s00109-016-1465-5 PG 17 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA DY6PP UT WOS:000385250200005 PM 27678529 ER PT J AU Akgul, G McBain, CJ AF Akguel, Guelcan McBain, Chris J. TI Diverse roles for ionotropic glutamate receptors on inhibitory interneurons in developing and adult brain SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Review ID CA2+-PERMEABLE AMPA RECEPTORS; RAT HIPPOCAMPAL-NEURONS; PARVALBUMIN-EXPRESSING INTERNEURONS; LACUNOSUM MOLECULARE INTERNEURONS; DUAL INTRACELLULAR-RECORDINGS; PRESYNAPTIC NMDA RECEPTORS; CALCIUM-PERMEABLE AMPA; LONG-TERM POTENTIATION; SUBUNIT MESSENGER-RNAS; KAINATE RECEPTORS AB Glutamate receptor-mediated recruitment of GABAergic inhibitory interneurons is a critical determinant of network processing. Early studies observed that many, but not all, interneuron glutamatergic synapses contain AMPA receptors that are GluA2-subunit lacking and Ca2+ permeable, making them distinct from AMPA receptors at most principal cell synapses. Subsequent studies demonstrated considerable alignment of synaptic AMPA and NMDA receptor subunit composition within specific subtypes of interneurons, suggesting that both receptor expression profiles are developmentally and functionally linked. Indeed glutamate receptor expression profiles are largely predicted by the embryonic origins of cortical interneurons within the medial and caudal ganglionic eminences of the developing telencephalon. Distinct complements of AMPA and NMDA receptors within different interneuron subpopulations contribute to the differential recruitment of functionally divergent interneuron subtypes by common afferent inputs for appropriate feed-forward and feedback inhibitory drive and network entrainment. In contrast, the lesser-studied kainate receptors, which are often present at both pre- and postsynaptic sites, appear to follow an independent developmental expression profile. Loss of specific ionotropic glutamate receptor (iGluR) subunits during interneuron development has dramatic consequences for both cellular and network function, often precipitating circuit inhibition-excitation imbalances and in some cases lethality. Here we briefly review recent findings highlighting the roles of iGluRs in interneuron development. C1 [Akguel, Guelcan; McBain, Chris J.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Porter Neurosci Res Ctr, Rm3C903,Lincoln Dr, Bethesda, MD 20892 USA. RP McBain, CJ (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA. EM mcbainc@mail.nih.gov FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [Z1A-HD001205-21] FX This work was funded by an Intramural research award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z1A-HD001205-21). NR 137 TC 2 Z9 2 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 EI 1469-7793 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD OCT 1 PY 2016 VL 594 IS 19 BP 5471 EP 5490 DI 10.1113/JP271764 PG 20 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA DY8DK UT WOS:000385358500011 PM 26918438 ER PT J AU Lawrence, E Fry, RJ AF Lawrence, Emily Fry, Richard J. TI Content Blocking and the Patron as Situated Knower: What Would It Take for an Internet Filter to Work? SO LIBRARY QUARTERLY LA English DT Article ID INTELLECTUAL FREEDOM; LIBRARIES AB Librarians often object to Internet filters on the grounds that filters are prone to overblocking and underblocking. This argument implies that a significant problem with contemporary filters is that they are insufficiently fine-grained. In this article, we posit that present-day filters will always be conceptually capable of failure, regardless of how granular their content analysis becomes. This is because, we argue, objections to content are best understood as objections to problematic interactions between content and particular knowers. We import the concept of the situated knower from feminist epistemology to capture the heterogeneous, socially embedded nature of patrons, about whom we cannot make blunt generalizations for filtering purposes. A successful filter would need information about these differently situated patrons, the content they seek, and the interactions between the two. We conclude that a genuinely successful Internet filter would therefore need to be both mind reading and fortune-telling. C1 [Lawrence, Emily] Univ Illinois, Grad Sch Lib & Informat Sci, Champaign, IL 61801 USA. [Lawrence, Emily] Natl Lib Med, Reference Serv, Bethesda, MD 20894 USA. [Lawrence, Emily] Natl Lib Med, Web Serv, Bethesda, MD 20894 USA. [Fry, Richard J.] Southern Illinois Univ, Edwardsville, IL USA. RP Lawrence, E (reprint author), Univ Illinois, Grad Sch Lib & Informat Sci, Champaign, IL 61801 USA.; Lawrence, E (reprint author), Natl Lib Med, Reference Serv, Bethesda, MD 20894 USA.; Lawrence, E (reprint author), Natl Lib Med, Web Serv, Bethesda, MD 20894 USA. EM elawrnc2@illinois.edu; rfry@siue.edu NR 38 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0024-2519 EI 1549-652X J9 LIBR QUART JI Libr. Q. PD OCT PY 2016 VL 86 IS 4 BP 403 EP 418 DI 10.1086/688030 PG 16 WC Information Science & Library Science SC Information Science & Library Science GA DZ2EU UT WOS:000385655900003 ER PT J AU Park, YMM Fung, TT Steck, SE Zhang, JJ Hazlett, LJ Han, K Lee, SH Merchant, AT AF Park, Yong-Moon Mark Fung, Teresa T. Steck, Susan E. Zhang, Jiajia Hazlett, Linda J. Han, Kyungdo Lee, Seung-Hwan Merchant, Anwar T. TI Diet Quality and Mortality Risk in Metabolically Obese Normal-Weight Adults SO MAYO CLINIC PROCEEDINGS LA English DT Article ID HEALTHY EATING INDEX; NONDIABETIC KOREAN POPULATION; GUIDELINES-FOR-AMERICANS; HYPERTENSION DASH DIET; MAJOR CHRONIC DISEASE; C-REACTIVE PROTEIN; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; WAIST CIRCUMFERENCE; NATIONAL-HEALTH AB Objective: To examine the associations among the Dietary Approaches to Stop Hypertension (DASH)-style diet, the Healthy Eating Index (HEI), and mortality risk in metabolically obese normal-weight (MONW) adults. Patients and Methods: Data were from normal-weight (body mass index of 18.5 to < 25) adults aged 30 to 90 years at baseline in the Third National Health and Nutrition Examination Survey, October 18, 1988, through October 15, 1994, followed up for deaths (all-cause, cardiovascular, and cancer related) until December 31, 2011. A total of 2103 participants without known cardiovascular disease and cancer at baseline were included in this prospective cohort study. Metabolic obesity was defined as having 2 or more of the following: high glucose, blood pressure, triglyceride, C-reactive protein, and insulin resistance values and low high-density lipoprotein cholesterol levels; metabolic healthy status was defined as having 0 or 1 of these metabolic derangements. Results: During median follow-up of 18.6 years, there were 344 and 296 deaths in the MONW and metabolically healthy normal-weight (MHNW) phenotypes, respectively. In MONW individuals, a 1-SD increment in adherence to a DASH diet (2 points) or HEI (14 points) was significantly associated with reductions (17% [hazard ratio (HR), 0.83; 95% CI, 0.72-0.97] and 22% [HR, 0.78; 95% CI, 0.68-0.90], respectively) in the risk of all-cause mortality, after adjustment for potential confounders. The corresponding HRs for cardiovascular disease mortality were 0.72 (95% CI, 0.55-0.94) and 0.79 (95% CI, 0.65-0.97), respectively. In addition, reduction of cancer mortality was observed with 1-SD increment of HEI (HR, 0.63; 95% CI, 0.46-0.88). However, no association was observed in the MHNW phenotype. Sensitivity analyses suggested relationships robust to different definitions of MONW and also dose responses with the number of metabolic derangements. Conclusion: Higher diet quality scores were associated with lower risk of mortality in normal-weight individuals with metabolic abnormalities. (C) 2016 Mayo Foundation for Medical Education and Research C1 [Park, Yong-Moon Mark; Steck, Susan E.; Zhang, Jiajia; Hazlett, Linda J.; Merchant, Anwar T.] Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St, Columbia, SC 29208 USA. [Park, Yong-Moon Mark] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA. [Fung, Teresa T.] Simmons Coll, Dept Nutr, Boston, MA 02115 USA. [Fung, Teresa T.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Han, Kyungdo] Catholic Univ Korea, Coll Med, Dept Biostat, Seoul, South Korea. [Lee, Seung-Hwan] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea. RP Merchant, AT (reprint author), Univ South Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, 915 Greene St, Columbia, SC 29208 USA. EM merchant@mailbox.sc.edu OI Lee, Seung-Hwan/0000-0002-3964-3877; PARK, YONG-MOON/0000-0002-5879-6879 NR 50 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD OCT PY 2016 VL 91 IS 10 BP 1372 EP 1383 DI 10.1016/j.mayocp.2016.06.022 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DZ6AQ UT WOS:000385944400011 PM 27712636 ER PT J AU Maio, N Rouault, TA AF Maio, N. Rouault, T. A. TI Mammalian Fe-S proteins: definition of a consensus motif recognized by the co-chaperone HSC20 SO METALLOMICS LA English DT Review ID IRON-SULFUR CLUSTER; MITOCHONDRIAL CYSTEINE DESULFURASE; RESONANCE EPR SPECTROSCOPY; ASSEMBLY SCAFFOLD PROTEIN; X-RAY-STRUCTURE; ESCHERICHIA-COLI; COMPLEX-I; SACCHAROMYCES-CEREVISIAE; ADENOSYLMETHIONINE ENZYMES; AZOTOBACTER-VINELANDII AB Iron-sulfur (Fe-S) clusters are inorganic cofactors that are fundamental to several biological processes in all three kingdoms of life. In most organisms, Fe-S clusters are initially assembled on a scaffold protein, ISCU, and subsequently transferred to target proteins or to intermediate carriers by a dedicated chaperone/co-chaperone system. The delivery of assembled Fe-S clusters to recipient proteins is a crucial step in the biogenesis of Fe-S proteins, and, in mammals, it relies on the activity of a multiprotein transfer complex that contains the chaperone HSPA9, the co-chaperone HSC20 and the scaffold ISCU. How the transfer complex efficiently engages recipient Fe-S target proteins involves specific protein interactions that are not fully understood. This mini review focuses on recent insights into the molecular mechanism of amino acid motif recognition and discrimination by the co-chaperone HSC20, which guides Fe-S cluster delivery. C1 [Maio, N.; Rouault, T. A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Mol Med, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Rouault, TA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Mol Med, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM rouault@mail.nih.gov FU intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD FX This work was supported by the intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD. NR 163 TC 0 Z9 0 U1 8 U2 8 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1756-5901 EI 1756-591X J9 METALLOMICS JI Metallomics PD OCT 1 PY 2016 VL 8 IS 10 BP 1032 EP 1046 DI 10.1039/c6mt00167j PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DZ1JF UT WOS:000385594000001 PM 27714045 ER PT J AU Yi, MN Yu, PP Lu, Q Geller, HM Yu, ZH Chen, HZ AF Yi, Mengni Yu, Panpan Lu, Qin Geller, Herbert M. Yu, Zhihua Chen, Hongzhuan TI KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease SO MOLECULAR AND CELLULAR NEUROSCIENCE LA English DT Article DE Astrogliosis; Alzheimer's disease; GFAP; Mouse; Culture ID ACCELERATED MOUSE SAMP8; K+ CHANNEL; REACTIVE ASTROCYTES; THERAPEUTIC TARGET; UP-REGULATION; IN-VIVO; INHIBITION; CALCIUM; MODEL; MEMORY AB Alzheimer's disease (AD) is the most common type of dementia and is characterized by a progression from decline of episodic memory to a global impairment of cognitive function. Astrogliosis is a hallmark feature of AD, and reactive gliosis has been considered as an important target for intervention in various neurological disorders. We previously found in astrocyte cultures that the expression of the intermediate conductance calcium-activated potassium channel KCa3.1 was increased in reactive astrocytes induced by TGF-beta, while pharmacological blockade or genetic deletion of KCa3.1 attenuated astrogliosis. In this study, we sought to suppress reactive gliosis in the context of AD by inhibiting KCa3.1 and evaluate its effects on the cognitive impairment using murine animal models such as the senescence-accelerated mouse prone 8 (SAMP8) model that exhibits some AD-like symptoms. We found KCa3.1 expression was increased in reactive astrocytes as well as neurons in the brains of both SAMP8 mice and Alzheimer's disease patients. Blockade of KCa3.1 with the selective inhibitor TRAM-34 in SAMP8 mice resulted in a decrease in astrogliosis as well as microglia activation, and moreover an attenuation of memory deficits. Using KCa3.1 knockout mice, we further confirmed that deletion of KCa3.1 reduced the activation of astrocytes and microglia, and rescued the memory loss induced by intrahippocampal A beta(1-42) peptide injection. We also found in astrocyte cultures that blockade of KCa3.1 or deletion of KCa3.1 suppressed A beta oligomer-induced astrogliosis. Our data suggest that KCa3.1 inhibition might represent a promising therapeutic strategy for AD treatment. (C) 2016 Elsevier Inc. All rights reserved. C1 [Yi, Mengni; Lu, Qin; Yu, Zhihua; Chen, Hongzhuan] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China. [Yu, Panpan] Jinan Univ, Guangdong Hongkong Macau Inst CNS Regenerat, Guangzhou 510632, Guangdong, Peoples R China. [Yu, Panpan] Jinan Univ, Minist Educ, Joint Int Res Lab CNS Regenerat, Guangzhou 510632, Guangdong, Peoples R China. [Geller, Herbert M.] NHLBI, Dev Neurobiol Sect, Div Intramural Res, NIH, Bldg 10, Bethesda, MD 20892 USA. RP Yu, ZH; Chen, HZ (reprint author), Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China. EM yuzhihua@shsmu.edu.cn; hongzhuan_chen@hotmail.com FU Science and Technology Commission of Shanghai Municipality [16ZR1418700]; National Natural Science Foundation of China [81102491]; Natural Science Foundation of Guangdong Province [2016A030313096]; Fundamental Research Funds for the Central Universities [21616340] FX This work was supported by Science and Technology Commission of Shanghai Municipality grant 16ZR1418700, National Natural Science Foundation of China grant 81102491, Natural Science Foundation of Guangdong Province (2016A030313096), the Fundamental Research Funds for the Central Universities (21616340). The authors declare no competing financial interests. NR 48 TC 1 Z9 1 U1 3 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1044-7431 EI 1095-9327 J9 MOL CELL NEUROSCI JI Mol. Cell. Neurosci. PD OCT PY 2016 VL 76 BP 21 EP 32 DI 10.1016/j.mcn.2016.08.008 PG 12 WC Neurosciences SC Neurosciences & Neurology GA DY9RA UT WOS:000385471600003 PM 27567685 ER PT J AU Keasey, SL Natesan, M Pugh, C Kamata, T Wuchty, S Ulrich, RG AF Keasey, Sarah L. Natesan, Mohan Pugh, Christine Kamata, Teddy Wuchty, Stefan Ulrich, Robert G. TI Cell-free Determination of Binary Complexes That Comprise Extended Protein-Protein Interaction Networks of Yersinia pestis SO MOLECULAR & CELLULAR PROTEOMICS LA English DT Article ID TANDEM AFFINITY PURIFICATION; RNA CHAPERONE HFQ; ESCHERICHIA-COLI; HELICOBACTER-PYLORI; INTERACTION MAP; III SECRETION; IN-VITRO; PSEUDOTUBERCULOSIS; INHIBITORS; BIOLOGY AB Binary protein interactions form the basic building blocks of molecular networks and dynamic assemblies that control all cellular functions of bacteria. Although these protein interactions are a potential source of targets for the development of new antibiotics, few high-confidence data sets are available for the large proteomes of most pathogenic bacteria. We used a library of recombinant proteins from the plague bacterium Yersinia pestis to probe planar microarrays of immobilized proteins that represented similar to 85% (3552 proteins) of the bacterial proteome, resulting in >77,000 experimentally determined binary interactions. Moderate (K-D similar to mu M) to high-affinity (K-D similar to nM) interactions were characterized for >1600 binary complexes by surface plasmon resonance imaging of microarrayed proteins. Core binary interactions that were in common with other gram-negative bacteria were identified from the results of both microarray methods. Clustering of proteins within the interaction network by function revealed statistically enriched complexes and pathways involved in replication, biosynthesis, virulence, metabolism, and other diverse biological processes. The interaction pathways included many proteins with no previously known function. Further, a large assembly of proteins linked to transcription and translation were contained within highly interconnected subregions of the network. The two-tiered microarray approach used here is an innovative method for detecting binary interactions, and the resulting data will serve as a critical resource for the analysis of protein interaction networks that function within an important human pathogen. C1 [Keasey, Sarah L.; Natesan, Mohan; Pugh, Christine; Kamata, Teddy; Ulrich, Robert G.] US Army Med Res Inst Infect Dis, Mol & Translat Sci Div, Frederick, MD 21702 USA. [Keasey, Sarah L.] Univ Maryland Baltimore Cty, Dept Biol Sci, Baltimore, MD 21250 USA. [Wuchty, Stefan] NIH, Natl Ctr Biotechnol Informat, Bldg 10, Bethesda, MD 20892 USA. [Wuchty, Stefan] Univ Miami, Dept Comp Sci, Coral Gables, FL 33124 USA. RP Ulrich, RG (reprint author), USAMRIID, Mol & Translat Sci, 1425 Porter St, Frederick, MD 21702 USA. EM rulrich@bhsai.org FU Defense Threat Reduction Agency (RGU) FX This work was supported in part by a grant from the Defense Threat Reduction Agency (RGU) and by appointment of SLK to the Research Participation Program for the U.S. Army Medical Research and Materiel Command, administered through an agreement between the U.S. Department of Energy and the USAMRMC. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army or the National Institutes of Health. 10.1074/mcp.M116.059337. NR 51 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 1535-9476 EI 1535-9484 J9 MOL CELL PROTEOMICS JI Mol. Cell. Proteomics PD OCT PY 2016 VL 15 IS 10 BP 3220 EP 3232 DI 10.1074/mcp.M116.059337 PG 13 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA DY8JB UT WOS:000385374800010 PM 27489291 ER PT J AU Norris, EL Headlam, MJ Dave, KA Smith, DD Bukreyev, A Singh, T Jayakody, BA Chappell, KJ Collins, PL Gorman, JJ AF Norris, Emma L. Headlam, Madeleine J. Dave, Keyur A. Smith, David D. Bukreyev, Alexander Singh, Toshna Jayakody, Buddhika A. Chappell, Keith J. Collins, Peter L. Gorman, Jeffrey J. TI Proteoform-Specific Insights into Cellular Proteome Regulation SO MOLECULAR & CELLULAR PROTEOMICS LA English DT Article ID TRANSFER-RNA-SYNTHETASE; SHOTGUN PROTEOMICS; INTERFERON-GAMMA; MASS-SPECTROMETRY; PEPTIDE IDENTIFICATION; GEL-ELECTROPHORESIS; EPITHELIAL-CELLS; GENE-EXPRESSION; VIRUS; PROTEINS AB Knowledge regarding compositions of proteomes at the proteoform level enhances insights into cellular phenotypes. A strategy is described herein for discovery of proteoform-specific information about cellular proteomes. This strategy involved analysis of data obtained by bottom-up mass spectrometry of multiple protein OGE separations on a fraction by fraction basis. The strategy was exemplified using five matched sets of lysates of uninfected and human respiratory syncytial virus-infected A549 cells. Template matching demonstrated that 67.3% of 10475 protein profiles identified focused to narrow pI windows indicative of efficacious focusing. Furthermore, correlation between experimental and theoretical pI gradients indicated reproducible focusing. Based on these observations a proteoform profiling strategy was developed to identify proteoforms, detect proteoform diversity and discover potential proteoform regulation. One component of this strategy involved examination of the focusing profiles for protein groups. A novel concordance analysis facilitated differentiation between proteoforms, including proteoforms generated by alternate splicing and proteolysis. Evaluation of focusing profiles and concordance analysis were applicable to cells from a single and/or multiple biological states. Statistical analyses identified proteoform variation between biological states. Regulation relevant to cellular responses to human respiratory syncytial virus was revealed. Western blotting and Protomap analyses validated the proteoform regulation. Discovery of STAT1, WARS, MX1, and HSPB1 proteoform regulation by human respiratory syncytial virus highlighted the impact of the profiling strategy. Novel truncated proteoforms of MX1 were identified in infected cells and phosphorylation driven regulation of HSPB1 proteoforms was correlated with infection. The proteoform profiling strategy is generally applicable to investigating interactions between viruses and host cells and the analysis of other biological systems. C1 [Norris, Emma L.; Headlam, Madeleine J.; Dave, Keyur A.; Singh, Toshna; Jayakody, Buddhika A.; Gorman, Jeffrey J.] QIMR Berghofer Med Res Inst, Prot Discovery Ctr, Herston, Qld, Australia. [Smith, David D.] QIMR Berghofer Med Res Inst, Stat Unit, Herston, Qld, Australia. [Bukreyev, Alexander; Collins, Peter L.] NIAID, Resp Virus Sect, Infect Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Chappell, Keith J.; Gorman, Jeffrey J.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia. [Bukreyev, Alexander] Univ Texas Med Branch, Galveston Natl Lab, Dept Pathol, Keiller Bldg,Room 3-145,301 Univ Blvd, Galveston, TX 77555 USA. [Bukreyev, Alexander] Univ Texas Med Branch, Galveston Natl Lab, Dept Microbiol & Immunol, Keiller Bldg,Room 3-145,301 Univ Blvd, Galveston, TX 77555 USA. RP Gorman, JJ (reprint author), Royal Brisbane Hosp, Prot Discovery Ctr, QIMR Berghofer, Locked Bag 2000, Herston, Qld 4029, Australia. EM jeff.gorman@qimr.edu.au OI Smith, David/0000-0001-9644-2353; Headlam, Madeleine/0000-0001-6812-2459 FU Bioplatforms Australia; Queensland State Government through the Australian Government National Collaborative Infrastructure Strategy (NCRIS); EIF Fund FX Access to proteomic infrastructure in the QIMR Berghofer Protein Discovery Centre was made possible by funding from Bioplatforms Australia and the Queensland State Government provided through the Australian Government National Collaborative Infrastructure Strategy (NCRIS) and EIF Fund. NR 65 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 1535-9476 EI 1535-9484 J9 MOL CELL PROTEOMICS JI Mol. Cell. Proteomics PD OCT PY 2016 VL 15 IS 10 BP 3297 EP 3320 DI 10.1074/mcp.O116.058438 PG 24 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA DY8JB UT WOS:000385374800016 PM 27451424 ER PT J AU Turkbey, B Choyke, PL AF Turkbey, Baris Choyke, Peter L. TI Birth of a standard: MET-RADS-P for metastatic prostate cancer SO NATURE REVIEWS UROLOGY LA English DT Editorial Material C1 [Turkbey, Baris; Choyke, Peter L.] NCI, Mol Imaging Program, US Natl Inst Hlth, 10 Ctr Dr,Room B3B69, Bethesda, MD 20892 USA. RP Turkbey, B (reprint author), NCI, Mol Imaging Program, US Natl Inst Hlth, 10 Ctr Dr,Room B3B69, Bethesda, MD 20892 USA. EM turkbeyi@mail.nih.gov NR 6 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4812 EI 1759-4820 J9 NAT REV UROL JI Nat. Rev. Urol. PD OCT PY 2016 VL 13 IS 10 BP 568 EP 570 DI 10.1038/nrurol.2016.163 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA DY9TH UT WOS:000385477500014 PM 27578044 ER PT J AU Cardenas, SA Kassem, L Brotman, MA Leibenluft, E McMahon, FJ AF Cardenas, Stephanie A. Kassem, Layla Brotman, Melissa A. Leibenluft, Ellen McMahon, Francis J. TI Neurocognitive functioning in euthymic patients with bipolar disorder and unaffected relatives: A review of the literature SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Bipolar disorder; Neuropsychology; Cognition; At-risk; Relatives; Review ID INCREASED INTRASUBJECT VARIABILITY; TRAUMATIC BRAIN-INJURY; 1ST-DEGREE RELATIVES; I DISORDER; NEUROPSYCHOLOGICAL DEFICITS; COGNITIVE IMPAIRMENT; MULTIGENERATIONAL FAMILIES; SUSTAINED ATTENTION; EXECUTIVE FUNCTIONS; GENETIC LIABILITY AB Background: Neurocognitive deficits are present in bipolar disorder (BD) patients and their unaffected (nonbipolar) relatives, but it is not clear which domains are most often impaired and the extent of the impairment resulting from shared genetic factors. In this literature review, we address these issues and identify specific neurocognitive tasks most sensitive to cognitive deficits in patients and unaffected relatives. Method: We conducted a systematic review in Web of Science, PubMed/Medline and PsycINFO databases. Results: Fifty-one articles assessing cognitive functioning in BD patients (23 studies) and unaffected relatives (28 studies) were examined. Patients and, less so, relatives show impairments in attention, processing speed, verbal learning/memory, and verbal fluency. Conclusion: Studies were more likely to find impairment in patients than relatives, suggesting that some neurocognitive deficits may be a result of the illness itself and/or its treatment. However, small sample sizes, differences among relatives studied (e.g., relatedness, diagnostic status, age), and differences in assessment instruments may contribute to inconsistencies in reported neurocognitive performance among relatives. Additional studies addressing these issues are needed. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Cardenas, Stephanie A.] NIH, 10 Ctr Dr,RM 3D54,MSC 1264, Bethesda, MD 20814 USA. [Kassem, Layla] NIH, 35 Convent Dr,RM 1A202,MSC 3719, Bethesda, MD 20892 USA. [Brotman, Melissa A.] NIH, 15K North Dr,Room 211, Bethesda, MD 20892 USA. [Leibenluft, Ellen] NIH, 15K North Dr,RM 210,MSC 2670, Bethesda, MD 20892 USA. [McMahon, Francis J.] NIH, 35 Convent Dr,RM 1A201,MSC 3719, Bethesda, MD 20892 USA. RP Cardenas, SA (reprint author), NIH, 10 Ctr Dr,RM 3D54,MSC 1264, Bethesda, MD 20814 USA. EM sac1@williams.edu; kasseml@mail.nih.gov; brotmanm@mail.nih.gov; leibs@mail.nih.gov; mcmahonf@mail.nih.gov RI Brotman, Melissa/H-7409-2013 FU NIMH [1Z01MH002810-11] FX This work was funded by the NIMH Intramural Research Program (1Z01MH002810-11). NR 93 TC 3 Z9 3 U1 9 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 EI 1873-7528 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD OCT PY 2016 VL 69 BP 193 EP 215 DI 10.1016/j.neubiorev.2016.08.002 PG 23 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA DY7QE UT WOS:000385323500015 PM 27502749 ER PT J AU Luo, J AF Luo, Ji TI Ji Luo elucidates the CRISPR gene editing technology, and how it may affect cancer therapy in the future SO ONCOLOGY-NEW YORK LA English DT Editorial Material C1 [Luo, Ji] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA. RP Luo, J (reprint author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD OCT PY 2016 VL 30 IS 10 BP 879 EP 879 PG 1 WC Oncology SC Oncology GA DZ2TF UT WOS:000385693800001 ER PT J AU Wentzensen, N AF Wentzensen, Nicolas TI Epidemiology, prevention and early detection of cervical cancer SO ONKOLOGE LA German DT Article DE Cervical cancer; Human papillomaviruses; Screening; Biomarker; Risk-based management ID HPV-POSITIVE WOMEN; HUMAN-PAPILLOMAVIRUS INFECTION; INTRAEPITHELIAL NEOPLASIA; AMERICAN SOCIETY; FOLLOW-UP; METHYLATION; RISK; COLPOSCOPY; PATHOLOGY; VACCINE AB Persisting infections with human papillomaviruses (HPV) are the indisputable cause of cervical cancer. The development of HPV-based preventive procedures, HPV vaccination and HPV testing are currently leading to major changes in cervical cancer prevention programs worldwide. A reduction of HPV infections and cancer precursors has been observed for young women in many countries one decade after the introduction of HPV vaccination. The focus is now on the integration of new testing approaches for screening of populations with increasing vaccination rates. A successful cervical cancer prevention program consists of various components including primary screening, triage of screening positives and colposcopy with biopsy to identify women with precursor cancer stages who require treatment. The role of primary screening is to identify a small subset of women with an increased risk of a precancerous stage, while the majority of women can be reassured that the risk is very low. Depending on the primary screening test, additional triage testing is required to decide who should be referred for colposcopy. Currently, there are three major approaches to cervical cancer screening: cervical cytology, HPV testing and HPV cytology co-testing. Several triage tests for HPV-positive women are currently being evaluated, including cytology, HPV genotyping, p16/Ki-67 cytology and various methylation tests. The increasing number of options for cervical cancer screening represent a challenge for clinical guidelines to remain up to date and comprehensible. The increasing complexity can lead to confusion among providers and women who participate in screening programs about the best approaches. Precision prevention is a novel approach to cervical cancer screening that integrates comprehensive risk data based on the individual medical history with test results for uniform, risk-based management decisions. C1 [Wentzensen, Nicolas] NCI, Div Canc Epidemiol & Genet, Med Ctr Dr,Room 7-E114,9609, Bethesda, MD 20892 USA. RP Wentzensen, N (reprint author), NCI, Div Canc Epidemiol & Genet, Med Ctr Dr,Room 7-E114,9609, Bethesda, MD 20892 USA. EM wentzenn@mail.nih.gov NR 46 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0947-8965 EI 1433-0415 J9 ONKOLOGE JI Onkologe PD OCT PY 2016 VL 22 IS 10 BP 725 EP 736 DI 10.1007/s00761-016-0092-7 PG 12 WC Oncology SC Oncology GA DY5TS UT WOS:000385166900004 PM 28265177 ER PT J AU Olivier, KN AF Olivier, Kenneth N. TI ANTIMICROBIAL THERAPY: QUESTIONS, CONCERNS AND LOOKING AHEAD SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Olivier, Kenneth N.] NHLBI, Cardiovasc & Pulm Branch, Bldg 10, Bethesda, MD 20892 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD OCT PY 2016 VL 51 SU S45 MA S04.2 BP 130 EP 131 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA DY0VW UT WOS:000384815300014 ER PT J AU Goeckeler-Fried, J Estabrooks, SK Chiang, A Chung, W Ye, Z Denny, RA Weissman, AM Camacho, CJ Sorscher, EJ Brodsky, JL AF Goeckeler-Fried, J. Estabrooks, S. K. Chiang, A. Chung, W. Ye, Z. Denny, R. A. Weissman, A. M. Camacho, C. J. Sorscher, E. J. Brodsky, J. L. TI IDENTIFICATION OF NOVEL INHIBITORS OF UBIQUITINATION THAT IMPROVE RESCUE OF F508DEL-CFTR BY VX-809 SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Goeckeler-Fried, J.; Estabrooks, S. K.; Chiang, A.; Brodsky, J. L.] Univ Pittsburgh, Biol Sci, Pittsburgh, PA USA. [Chung, W.] Univ Alabama Birmingham, Neurobiol, Birmingham, AL USA. [Ye, Z.; Camacho, C. J.] Univ Pittsburgh, Computat Biol, Pittsburgh, PA USA. [Denny, R. A.] Pfizer Worldwide Med Chem, Cambridge, MA USA. [Weissman, A. M.] NCI, Lab Prot Dynam & Signaling, Frederick, MD 21701 USA. [Sorscher, E. J.] Emory Univ, Pediat, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD OCT PY 2016 VL 51 SU S45 MA 35 BP 206 EP 206 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA DY0VW UT WOS:000384815300112 ER PT J AU Liou, TG Adler, FR Brown, P Chatfield, BA Clancy, JP Cox, DR Daines, C Elborn, JS Emmett, P Francis, J Jensen, JL Heynekamp, TR Keogh, RH Lechtzin, N Li, Y Lysinger, J Nakamura, C Olivier, KN Packer, KA Quittner, AL Radford, P Szczesniak, RD Taylor-Cousar, JL Vroom, J Sagel, SD AF Liou, T. G. Adler, F. R. Brown, P. Chatfield, B. A. Clancy, J. P. Cox, D. R. Daines, C. Elborn, J. S. Emmett, P. Francis, J. Jensen, J. L. Heynekamp, T. R. Keogh, R. H. Lechtzin, N. Li, Y. Lysinger, J. Nakamura, C. Olivier, K. N. Packer, K. A. Quittner, A. L. Radford, P. Szczesniak, R. D. Taylor-Cousar, J. L. Vroom, J. Sagel, S. D. TI MOUNTAIN WEST CF CONSORTIUM SPUTUM BIOMARKER STUDY SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Liou, T. G.; Adler, F. R.; Chatfield, B. A.; Francis, J.; Jensen, J. L.; Li, Y.; Packer, K. A.; Vroom, J.] Univ Utah, Salt Lake City, UT USA. [Nakamura, C.] Las Vegas CF Ctr, Las Vegas, NV USA. [Brown, P.] CF Ctr Idaho, Boise, ID USA. [Lysinger, J.] Billings Clin, Billings, MT USA. [Clancy, J. P.; Szczesniak, R. D.] Univ Cincinnati, Cincinnati, OH USA. [Daines, C.] Univ Arizona, Tucson, AZ USA. [Elborn, J. S.] Queens Univ Belfast, Belfast, Antrim, North Ireland. [Cox, D. R.] Univ Oxford Nuffield Coll, Oxford, England. [Emmett, P.; Sagel, S. D.] Univ Colorado, Aurora, CO USA. [Heynekamp, T. R.] Univ New Mexico, Albuquerque, NM 87131 USA. [Keogh, R. H.] London Sch Hyg & Trop Med, London, England. [Lechtzin, N.] Johns Hopkins Univ, Baltimore, MD USA. [Olivier, K. N.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Quittner, A. L.] Univ Miami, Miami, FL USA. [Radford, P.] Phoenix Childrens Hosp, Phoenix, AZ USA. [Taylor-Cousar, J. L.] Natl Jewish Hlth, Denver, CO USA. [Sagel, S. D.] Childrens Hosp Colorado, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD OCT PY 2016 VL 51 SU S45 MA 232 BP 279 EP 280 PG 2 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA DY0VW UT WOS:000384815300309 ER PT J AU Tsuchiya, M Kalurupalle, S Kumar, P Ghoshal, S Zhang, Y Lehrmann, E Becker, K Gorospe, M Biswas, R AF Tsuchiya, M. Kalurupalle, S. Kumar, P. Ghoshal, S. Zhang, Y. Lehrmann, E. Becker, K. Gorospe, M. Biswas, R. TI RPTOR, A NOVEL TARGET OF MICRORNA-155, REGULATES THE FIBROTIC PHENOTYPE OF CYSTIC FIBROSIS LUNG EPITHELIUM THROUGH UP-REGULATION OF CTGF SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Tsuchiya, M.; Kalurupalle, S.; Kumar, P.; Ghoshal, S.; Biswas, R.] USUHS, Anat Physiol & Genet, Bethesda, MD USA. [Zhang, Y.; Lehrmann, E.; Becker, K.; Gorospe, M.] NIA, Genet Lab, NIH, Baltimore, MD 21224 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD OCT PY 2016 VL 51 SU S45 MA 237 BP 281 EP 281 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA DY0VW UT WOS:000384815300314 ER PT J AU Davidson, RM Hasan, NA Epperson, LE Vasireddy, S Smith, T Elliot, B Olivier, KN Holland, SM Salfinger, ML Nick, JA Zelazny, A Wallace, RJ Daley, CL Strong, M AF Davidson, R. M. Hasan, N. A. Epperson, L. E. Vasireddy, S. Smith, T. Elliot, B. Olivier, K. N. Holland, S. M. Salfinger, M. L. Nick, J. A. Zelazny, A. Wallace, R. J. Daley, C. L. Strong, M. TI GENOMIC AND EVOLUTIONARY ANALYSES OF CLINICAL MYCOBACTERIUM ABSCESSUS SUBSP MASSILIENSE FROM PATIENTS WITH AND WITHOUT CYSTIC FIBROSIS SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Davidson, R. M.; Hasan, N. A.; Epperson, L. E.; Strong, M.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA. [Vasireddy, S.; Smith, T.; Elliot, B.; Wallace, R. J.] Univ Texas Hlth Sci Ctr, Dept Microbiol, Tyler, TX USA. [Salfinger, M. L.; Nick, J. A.; Daley, C. L.] Natl Jewish Hlth, Dept Med, Denver, CO USA. [Olivier, K. N.] NHLBI, Cardiovasc & Pulm Branch, NIH, Bldg 10, Bethesda, MD 20892 USA. [Holland, S. M.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Zelazny, A.] NIH, Dept Microbiol Serv, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 8755-6863 EI 1099-0496 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD OCT PY 2016 VL 51 SU S45 MA 392 BP 342 EP 342 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA DY0VW UT WOS:000384815300468 ER PT J AU Shiroma, EJ Schepps, MA Harezlak, J Chen, KY Matthews, CE Koster, A Caserotti, P Glynn, NW Harris, TB AF Shiroma, E. J. Schepps, M. A. Harezlak, J. Chen, K. Y. Matthews, C. E. Koster, A. Caserotti, P. Glynn, N. W. Harris, T. B. TI Daily physical activity patterns from hip- and wrist-worn accelerometers SO PHYSIOLOGICAL MEASUREMENT LA English DT Article DE physical activity; epidemiology; exercise; accelerometer; patterns; aging ID SEDENTARY BEHAVIOR; OLDER-ADULTS; AGE; CALIBRATION; MONITORS; OUTPUT; WHITE; SITES; WOMEN; MEN AB Accelerometer wear location may influence physical activity estimates. This study investigates this relationship through the examination of activity patterns throughout the day. Participants from the aging research evaluating accelerometry (AREA) study (n men = 37, n women = 47, mean age (SD) = 78.9 (5.5) years) were asked to wear accelerometers in a free-living environment for 7 d at three different wear locations; one on each wrist and one on the right hip. During waking hours, wrist-worn accelerometers consistently produced higher median activity counts, about 5 x higher, as well as wider variability compared to hip-worn monitors. However, the shape of the accrual pattern curve over the course of the day for the hip and wrist are similar; there is a spike in activity in the morning, with a prolonged tapering of activity level as the day progresses. The similar patterns of hip and wrist activity accrual provide support that each location is capable of estimating total physical activity volume. The examination of activity patterns over time may provide a more detailed way to examine differences in wear location and different subpopulations. C1 [Shiroma, E. J.; Schepps, M. A.; Harris, T. B.] NIA, Lab Epidemiol & Populat Sci, 7201 Wisconsin Ave,Gateway Bldg,Suite 3C309, Bethesda, MD 20892 USA. [Harezlak, J.] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Biostat, Bloomington, IN 47405 USA. [Harezlak, J.] Indiana Univ, Sch Med, Bloomington, IN 47405 USA. [Chen, K. Y.] NIDDK, Diabet Endocrinol & Obes Branch, Bethesda, MD 20892 USA. [Matthews, C. E.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Koster, A.] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Social Med, Maastricht, Netherlands. [Caserotti, P.] Univ Southern Denmark, Dept Sports Sci & Clin Biomech, Odense, Denmark. [Glynn, N. W.] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Aging & Populat Hlth, Pittsburgh, PA USA. RP Shiroma, EJ (reprint author), NIA, Lab Epidemiol & Populat Sci, 7201 Wisconsin Ave,Gateway Bldg,Suite 3C309, Bethesda, MD 20892 USA. EM Eric.shiroma@nih.gov RI Dey, Kamalesh/E-6568-2017; Koster, Annemarie/E-7438-2010; OI Chen, Kong/0000-0002-0306-1904 FU Intramural Research Program of the National Institutes of Health, National Institute on Aging; National Institutes of Health [AG024826, AG024827, AG036594, AG000181]; European Union Seventh Framework Programme (FP7-PEOPLE-CIG) [PCIG09-GA-2011-293621]; National Institute on Aging [HHSN271201 100605P] FX This study was supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging and by the research grants AG024826, AG024827, AG036594, and AG000181 from the National Institutes of Health. A Koster has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2011-CIG) under grant agreement PCIG09-GA-2011-293621. NW Glynn was supported in part by National Institute on Aging Professional Services Contract HHSN271201 100605P. We are grateful to the staff of the AREA and DECO studies, particularly B S Lange-Maia, M E Garcia, and J R Treinish. NR 25 TC 1 Z9 1 U1 6 U2 6 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0967-3334 EI 1361-6579 J9 PHYSIOL MEAS JI Physiol. Meas. PD OCT PY 2016 VL 37 IS 10 BP 1852 EP 1861 DI 10.1088/0967-3334/37/10/1852 PG 10 WC Biophysics; Engineering, Biomedical; Physiology SC Biophysics; Engineering; Physiology GA DY9ZW UT WOS:000385497200015 PM 27654140 ER PT J AU Karlsson, C Rehman, F Damadzic, R Atkins, AL Schank, JR Gehlert, DR Steensland, P Thorsell, A Heilig, M AF Karlsson, Camilla Rehman, Faazal Damadzic, Ruslan Atkins, Alison L. Schank, Jesse R. Gehlert, Donald R. Steensland, Pia Thorsell, Annika Heilig, Markus TI The melanin-concentrating hormone-1 receptor modulates alcohol-induced reward and DARPP-32 phosphorylation (vol 233, pg 2355, 2016) SO PSYCHOPHARMACOLOGY LA English DT Correction C1 [Karlsson, Camilla; Atkins, Alison L.; Thorsell, Annika; Heilig, Markus] Linkopings Univ, Dept Clin & Expt Med, Linkoping, Sweden. [Rehman, Faazal; Damadzic, Ruslan] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD USA. [Schank, Jesse R.] Univ Georgia, Dept Physiol & Pharmacol, Athens, GA 30602 USA. [Gehlert, Donald R.] Lilly Res Labs, Neurosci & Endocrine Discovery Res, Indianapolis, IN USA. [Steensland, Pia] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden. RP Heilig, M (reprint author), Linkopings Univ, Dept Clin & Expt Med, Linkoping, Sweden. EM markus.heilig@liu.se NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD OCT PY 2016 VL 233 IS 21-22 BP 3825 EP 3825 DI 10.1007/s00213-016-4434-3 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DZ0HM UT WOS:000385518500015 PM 27650828 ER PT J AU Murad, H Kipnis, V Freedman, LS AF Murad, Havi Kipnis, Victor Freedman, Laurence S. TI Estimating and testing interactions when explanatory variables are subject to non-classical measurement error SO STATISTICAL METHODS IN MEDICAL RESEARCH LA English DT Article DE measurement error (ME); errors in variables; interaction; regression calibration (RC); linear regression calibration; efficient regression calibration; type I error probability; power ID STRUCTURAL EQUATION MODELS; REGRESSION CALIBRATION; NUTRITIONAL EPIDEMIOLOGY AB Assessing interactions in linear regression models when covariates have measurement error (ME) is complex. We previously described regression calibration (RC) methods that yield consistent estimators and standard errors for interaction coefficients of normally distributed covariates having classical ME. Here we extend normal based RC (NBRC) and linear RC (LRC) methods to a non-classical ME model, and describe more efficient versions that combine estimates from the main study and internal sub-study. We apply these methods to data from the Observing Protein and Energy Nutrition (OPEN) study. Using simulations we show that (i) for normally distributed covariates efficient NBRC and LRC were nearly unbiased and performed well with sub-study size 200; (ii) efficient NBRC had lower MSE than efficient LRC; (iii) the naive test for a single interaction had type I error probability close to the nominal significance level, whereas efficient NBRC and LRC were slightly anti-conservative but more powerful; (iv) for markedly non-normal covariates, efficient LRC yielded less biased estimators with smaller variance than efficient NBRC. Our simulations suggest that it is preferable to use: (i) efficient NBRC for estimating and testing interaction effects of normally distributed covariates and (ii) efficient LRC for estimating and testing interactions for markedly non-normal covariates. C1 [Murad, Havi; Freedman, Laurence S.] Gertner Inst Epidemiol & Hlth Policy Res, Biostat Unit, IL-52621 Tel Hashomer, Israel. [Kipnis, Victor] NCI, Biometry Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA. RP Murad, H (reprint author), Gertner Inst Epidemiol & Hlth Policy Res, Biostat Unit, IL-52621 Tel Hashomer, Israel. EM HaviM@gertner.health.gov.il FU Marcia and Eugene Applebaum, Detroit, MI, USA; United States-Israel Educational Foundation (USIEF) FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Doctoral Fellowship of Excellence grant, awarded to Bar-Ilan University, Israel by Marcia and Eugene Applebaum, Detroit, MI, USA. Apart of this research was done during a three months visit to the National Cancer Institute, Biometry Research Division, USA supported by the Fulbright Grant for Doctoral Dissertation Students, awarded by the United States-Israel Educational Foundation (USIEF). NR 19 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0962-2802 EI 1477-0334 J9 STAT METHODS MED RES JI Stat. Methods Med. Res. PD OCT PY 2016 VL 25 IS 5 BP 1991 EP 2013 DI 10.1177/0962280213509720 PG 23 WC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Statistics & Probability SC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Mathematics GA DZ0UO UT WOS:000385555400015 PM 24334284 ER PT J AU Mulatya, CM McLain, AC Cai, B Hardin, JW Albert, PS AF Mulatya, Caroline M. McLain, Alexander C. Cai, Bo Hardin, James W. Albert, Paul S. TI Estimating time to event characteristics via longitudinal threshold regression models - an application to cervical dilation progression SO STATISTICS IN MEDICINE LA English DT Article DE first hitting time; threshold regression; Weiner process ID NULLIPAROUS WOMEN; LABOR CURVE; INTERVAL; OUTCOMES AB In longitudinal studies, it is sometimes of interest to estimate the distribution of the time a longitudinal process takes to traverse from one threshold to another. For example, the distribution of the time it takes a woman's cervical dilation to progress from 3 to 4cm can aid the decision-making of obstetricians as to whether a stalled labor should be allowed to proceed or stopped in favor of other options. Often researchers treat this type of data structure as interval censored and employ traditional survival analysis methods. However, the traditional interval censoring approaches are inefficient in that they do not use all of the available data. In this paper, we propose utilizing a longitudinal threshold model to estimate the distribution of the elapsed time between two thresholds of the longitudinal process from repeated measurements. We extend this modeling framework to be used with multiple thresholds. A Wiener process under the first hitting time framework is used to represent survival distribution. We demonstrate our model through simulation studies and an analysis of data from the Consortium on Safe Labor study. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. C1 [Mulatya, Caroline M.; McLain, Alexander C.; Cai, Bo; Hardin, James W.] Univ South Carolina, Dept Epidemiol & Biostat, 915 Greene St, Columbia, SC 29208 USA. [Albert, Paul S.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, 6100 Execut Blvd, Rockville, MD 20852 USA. RP McLain, AC (reprint author), Univ South Carolina, Dept Epidemiol & Biostat, 915 Greene St, Columbia, SC 29208 USA. EM mclaina@mailbox.sc.edu RI Hardin, James/Q-7617-2016 OI Hardin, James/0000-0003-0506-5500 FU Intramural Research Program of the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development; Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development FX We thank the editor, associate editor, and two anonymous referees for their helpful comments, which greatly improved this manuscript. We thank the Intramural Research Program of the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for allowing us to use these data from the CSL study. The research by Dr. Albert was supported by the Intramural Research Program of the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development. The research by Dr. McLain was supported, in part, by an Interpersonal Agreement with the Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 28 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD OCT PY 2016 VL 35 IS 24 BP 4368 EP 4379 DI 10.1002/sim.7031 PG 12 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA DY9XQ UT WOS:000385490200006 PM 27405611 ER PT J AU Follmann, D Huang, CY Gabriel, E AF Follmann, Dean Huang, Chiung-Yu Gabriel, Erin TI Who really gets strep sore throat? Confounding and effect modification of a time-varying exposure on recurrent events SO STATISTICS IN MEDICINE LA English DT Article DE attributable fraction; case-crossover design; pattern mixture models; probability of causation; self-controlled case series ID CASE-CROSSOVER DESIGN; CAUSAL INFERENCE; CASE SERIES; TESTS; RISK; BIAS AB Unmeasured confounding is the fundamental obstacle to drawing causal conclusions about the impact of an intervention from observational data. Typically, covariates are measured to eliminate or ameliorate confounding, but they may be insufficient or unavailable. In the special setting where a transient intervention or exposure varies over time within each individual and confounding is time constant, a different tack is possible. The key idea is to condition on either the overall outcome or the proportion of time in the intervention. These measures can eliminate the unmeasured confounding either by conditioning or by use of a proxy covariate. We evaluate existing methods and develop new models from which causal conclusions can be drawn from such observational data even if no baseline covariates are measured. Our motivation for this work was to determine the causal effect of Streptococcus bacteria in the throat on pharyngitis (sore throat) in Indian schoolchildren. Using our models, we show that existing methods can be badly biased and that sick children who are rarely colonized have a high probability that the Streptococcus bacteria are causing their disease. Published 2016. This article is a U.S. Government work and is in the public domain in the USA C1 [Follmann, Dean; Gabriel, Erin] NIAID, Biostat Res Branch, NIH, 5601 Fishers Lane Room 4C11, Rockville, MD 20852 USA. [Huang, Chiung-Yu] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA. [Huang, Chiung-Yu] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA. RP Follmann, D (reprint author), NIAID, Biostat Res Branch, NIH, 5601 Fishers Lane Room 4C11, Rockville, MD 20852 USA. EM dean.follmann@nih.gov OI Gabriel, Erin/0000-0002-0504-8404 FU National Institutes of Health [1R01CA193888] FX Huang's work was sponsored by the National Institutes of Health grant 1R01CA193888. NR 26 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD OCT PY 2016 VL 35 IS 24 BP 4398 EP 4412 DI 10.1002/sim.7000 PG 15 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA DY9XQ UT WOS:000385490200008 PM 27313096 ER PT J AU Asdaghi, N Romano, JG Wang, KF Ciliberti-Vargas, MA Koch, S Gardener, H Dong, CH Rose, DZ Waddy, SP Robichaux, M Garcia, EJ Gonzalez-Sanchez, JA Burgin, WS Sacco, RL Rundek, T AF Asdaghi, Negar Romano, Jose G. Wang, Kefeng Ciliberti-Vargas, Maria A. Koch, Sebastian Gardener, Hannah Dong, Chuanhui Rose, David Z. Waddy, Salina P. Robichaux, Mary Garcia, Enid J. Gonzalez-Sanchez, Juan A. Burgin, W. Scott Sacco, Ralph L. Rundek, Tatjana TI Sex Disparities in Ischemic Stroke Care FL-PR CReSD Study (Florida-Puerto Rico Collaboration to Reduce Stroke Disparities) SO STROKE LA English DT Article DE Get With The Guidelines; National Institute of Neurological Disorders and Stroke; sex characteristics; stroke ID AMERICAN-HEART-ASSOCIATION; IN-HOSPITAL MORTALITY; EMERGENCY-DEPARTMENT; GENDER-DIFFERENCES; WOMEN; IMPROVEMENT; OUTCOMES; REGISTRY; PROGRAM; FUTURE AB Background and Purpose-Sex-specific disparities in stroke care including thrombolytic therapy and early hospital admission are reported. In a large registry of Florida and Puerto Rico hospitals participating in the Get With The GuidelinesStroke program, we sought to determine sex-specific differences in ischemic stroke performance metrics and overall thrombolytic treatment. Methods-Around 51317 (49% women) patients were included from 73 sites from 2010 to 2014. Multivariable logistic regression with generalized estimating equations evaluated sex-specific differences in the prespecified Get With The GuidelinesStroke metrics for defect-free care in ischemic stroke, adjusting for age, race-ethnicity, insurance status, hospital characteristics, individual risk factors, and the presenting stroke severity. Results-As compared with men, women were older (7315 versus 69 +/- 14 years; P<0.0001), more hypertensive (67% versus 63%, P<0.0001), and had more atrial fibrillation (19% versus 16%; P<0.0001). Defect-free care was slightly lower in women than in men (odds ratio, 0.96; 95% confidence interval, 0.93-1.00). Temporal trends in defect-free care improved substantially and similarly for men and women, with a 29% absolute improvement in women (P<0.0001) and 28% in men (P<0.0001), with P value of 0.13 for time-by-sex interaction. Women were less likely to receive thrombolysis (odds ratio, 0.92; 95% confidence interval, 0.86-0.99; P=0.02) and less likely to have a door-to-needle time <1 hour (odds ratio, 0.83; 95% confidence interval, 0.71-0.97; P=0.02) as compared with men. Conclusions-Women received comparable stroke care to men in this registry as measured by prespecified Get With The Guidelines metrics. However, women less likely received thrombolysis and had door-to-needle time <1 hour, an observation that calls for the implementation of interventions to reduce sex disparity in these measures. C1 [Asdaghi, Negar; Romano, Jose G.; Wang, Kefeng; Ciliberti-Vargas, Maria A.; Koch, Sebastian; Gardener, Hannah; Dong, Chuanhui; Sacco, Ralph L.; Rundek, Tatjana] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA. [Rose, David Z.; Burgin, W. Scott] Univ S Florida, Sch Med, Dept Neurol, Tampa, FL USA. [Waddy, Salina P.] NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Robichaux, Mary] Amer Heart Assoc, Greater Southeast Affiliate, Marietta, GA USA. [Garcia, Enid J.] Univ Puerto Rico, Sch Med, Endowed Hlth Serv Res Ctr, San Juan, PR 00936 USA. [Gonzalez-Sanchez, Juan A.] Univ Puerto Rico, Sch Med, Dept Emergency Med, San Juan, PR 00936 USA. RP Asdaghi, N (reprint author), 1120 NW 14th St,Clin Res Bldg,13th Floor, Miami, FL 33136 USA. EM nasdaghi@med.miami.edu FU National Institute of Health (NIH)/National Institute of Neurological Disorders (NINDs) and Stroke Prevention and Intervention Research Program (SPIRP) cooperative grant [U54NS081763]; Office of Research on Women's Health [3U54NS081763-01S1] FX The Florida Puerto Rico Collaboration to Reduce Stroke Disparities Study is supported by the National Institute of Health (NIH)/National Institute of Neurological Disorders (NINDs) and Stroke Prevention and Intervention Research Program (SPIRP) cooperative grant (grant number: U54NS081763). The women's supplement is awarded from the Office of Research on Women's Health (Grant Number: 3U54NS081763-01S1). NR 29 TC 1 Z9 1 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD OCT PY 2016 VL 47 IS 10 BP 2618 EP 2626 DI 10.1161/STROKEAHA.116.013059 PG 9 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA DY8VV UT WOS:000385410700037 PM 27553032 ER PT J AU Allen, ES Klein, HG AF Allen, Elizabeth S. Klein, Harvey G. TI In a digital age, a relic of manual transfusion records SO TRANSFUSION LA English DT Editorial Material C1 [Allen, Elizabeth S.; Klein, Harvey G.] NIH, Dept Transfus Med, Ctr Clin, 10 Ctr Dr,MSC 1184,Bldg 10,Room 1C-711, Bethesda, MD 20892 USA. RP Allen, ES (reprint author), NIH, Dept Transfus Med, Ctr Clin, 10 Ctr Dr,MSC 1184,Bldg 10,Room 1C-711, Bethesda, MD 20892 USA. EM elizabeth.allen@nih.gov OI Allen, Elizabeth/0000-0002-1004-3851 NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2016 VL 56 IS 10 BP 2405 EP 2405 DI 10.1111/trf.13665 PG 1 WC Hematology SC Hematology GA DZ4NG UT WOS:000385834800003 PM 27739156 ER PT J AU Srivastava, K Polin, H Sheldon, SL Wagner, FF Grabmer, C Gabriel, C Denomme, GA Flegel, WA AF Srivastava, Kshitij Polin, Helene Sheldon, Sherry Lynne Wagner, Franz Friedrich Grabmer, Christoph Gabriel, Christian Denomme, Gregory Andrew Flegel, Willy Albert TI The DAU cluster: a comparative analysis of 18 RHD alleles, some forming partial D antigens SO TRANSFUSION LA English DT Article ID SICKLE-CELL-DISEASE; AMINO-ACID SUBSTITUTIONS; PROTEIN-STRUCTURE; TRANSFUSION THERAPY; CLINICALLY RELEVANT; MOLECULAR-GENETICS; RHESUS-BOX; D VARIANTS; PHENOTYPE; ENCODES AB BACKGROUNDThe Rh system is the most complex and polymorphic blood group system in humans with more than 460 alleles known for the RHD gene. The DAU cluster of RHD alleles is characterized by the single-nucleotide change producing the p.Thr379Met amino acid substitution. It is called the DAU-0 allele and has been postulated to be the primordial allele, from which all other alleles of the DAU cluster have eventually evolved. STUDY DESIGN AND METHODSFor two novel DAU alleles, the nucleotide sequences of all 10 exons as well as adjacent intronic regions, including the 5 and 3 untranslated regions (UTR), were determined for the RHD and RHCE genes. A phylogenetic tree for all DAU alleles was established using the neighbor-joining method with Pan troglodytes as root. Standard hemagglutination and flow cytometry tests were performed. RESULTSWe characterized two DAU alleles, DAU-11 and DAU-5.1, closely related to DAU-3 and DAU-5, respectively. A phylogenetic analysis of the 18 known DAU alleles indicated point mutations and interallelic recombination contributing to diversification of the DAU cluster. CONCLUSIONSThe DAU alleles encode a group of RhD protein variants, some forming partial D antigens known to permit anti-D in carriers; all are expected to cause anti-D alloimmunization in recipients of red blood cell transfusions. The DAU alleles evolved through genomic point mutations and recombination. These results suggest that the cluster of DAU alleles represent a clade, which is concordant with our previous postulate that they derived from the primordial DAU-0 allele. C1 [Srivastava, Kshitij; Sheldon, Sherry Lynne; Flegel, Willy Albert] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA. [Polin, Helene; Gabriel, Christian] Red Cross Transfus Serv Upper Austria, Linz, Austria. [Wagner, Franz Friedrich] Inst Springe, Red Cross Blood Serv NSTOB, Springe, Germany. [Grabmer, Christoph] SALK Paracelsus Med Univ, Dept Blood Grp Serol & Transfus Med, Salzburg, Austria. [Gabriel, Christian] Med Univ Graz, Dept Blood Grp Serol & Transfus Med, Graz, Austria. [Denomme, Gregory Andrew] BloodCtr Wisconsin, Diagnost Labs, Milwaukee, WI USA. RP Flegel, WA (reprint author), NIH, Lab Serv Sect, Dept Transfus Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA. EM waf@nih.gov OI Denomme, Gregory/0000-0001-8727-1679 NR 67 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2016 VL 56 IS 10 BP 2520 EP 2531 DI 10.1111/trf.13739 PG 12 WC Hematology SC Hematology GA DZ4NG UT WOS:000385834800018 PM 27480171 ER PT J AU Rooney, MR Pankow, JS Sibley, SD Selvin, E Reis, JP Michos, ED Lutsey, PL AF Rooney, Mary R. Pankow, James S. Sibley, Shalamar D. Selvin, Elizabeth Reis, Jared P. Michos, Erin D. Lutsey, Pamela L. TI Serum calcium and incident type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE calcium-sensing receptor polymorphism; cohort study; diabetes mellitus; race; serum calcium ID GENOME-WIDE ASSOCIATION; CYTOSOLIC-FREE CALCIUM; PARATHYROID-HORMONE; INSULIN-RESISTANCE; RACIAL-DIFFERENCES; VITAMIN-D; CARDIOVASCULAR RISK; 25-HYDROXYVITAMIN D; BLACK-WOMEN; GLUCOSE AB Background: Elevated serum calcium has been associated with a variety of metabolic abnormalities and may be associated with a greater risk of diabetes. Objective: The purpose of this study was to test the hypothesis that serum calcium concentration is positively and independently associated with the incidence of diabetes and to evaluate the association of calcium-sensing receptor (CaSR) gene single nucleotide polymorphism (SNP) rs1801725 with incident diabetes. Design: Atherosclerosis Risk in Communities study participants free of diabetes at baseline (n = 12,800; mean age: 53.9 y; 22.6% black) were studied for incident diabetes. Serum calcium was measured at baseline and corrected for serum albumin. Diabetes was defined by use of glucose concentrations, self-report, or medication use. Cox proportional hazards regression was used. Results: During a mean 8.8 y of follow-up, 1516 cases of diabetes were reported. Participants in the highest compared with lowest calcium quintile were at greater risk of incident diabetes after adjustment for demographic and lifestyle factors [BR (95% CI): 1.34 (1.14, 1.57); P-trend across quintiles <0.0001] and with further adjustment for waist circumference and body mass index [1.26 (1.07, 1.48); P-trend = 0.004]. Additional adjustment for biomarkers on the metabolic pathway (e.g., 25-hydroxyvitamin D, parathyroid hormone, phosphorus) had little impact. The calcium-diabetes association was statistically significant in blacks [1.48 (1.11, 1.98); P-trend = 0.002] but not whites [1.17 (0.96, 1.43); P-trend = 0.17] after adjustment for adiposity. In whites, CaSR gene SNP rs1801725 was associated with serum calcium but not with risk of diabetes. Conclusions: Consistent with 3 previous cohort studies, elevated serum calcium was found to be associated with a greater risk of type 2 diabetes. Further research is needed to understand the role, if any, that calcium plays in the pathogenesis of diabetes. C1 [Rooney, Mary R.; Pankow, James S.; Lutsey, Pamela L.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA. [Sibley, Shalamar D.] Univ Minnesota, Div Endocrinol & Diabet, Minneapolis, MN 55455 USA. [Selvin, Elizabeth; Michos, Erin D.] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21205 USA. [Selvin, Elizabeth; Michos, Erin D.] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA. [Michos, Erin D.] Johns Hopkins Univ, Div Cardiol, Baltimore, MD 21205 USA. [Reis, Jared P.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. RP Rooney, MR (reprint author), Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA. EM roone166@umn.edu FU NIH National Heart, Lung, and Blood Institute [R01 HL103706]; NIH Office of Dietary Supplements [R01 HL103706-S1]; National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK089174]; National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; NHLBI Candidate Gene Resource grant [N01-HC-65226] FX The research was supported by grants from the NIH National Heart, Lung, and Blood Institute (R01 HL103706 to PLL), the NIH Office of Dietary Supplements (R01 HL103706-S1 to PLL), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK089174 to ES). The Atherosclerosis Risk in Communities study is a collaborative study supported by National Heart, Lung, and Blood Institute contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C. Reagents for the serum albumin assays were donated by the manufacturers. Genotyping was supported through NHLBI Candidate Gene Resource grant no. N01-HC-65226. NR 42 TC 1 Z9 1 U1 5 U2 5 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2016 VL 104 IS 4 BP 1023 EP 1029 DI 10.3945/ajcn.115.130021 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DY1SO UT WOS:000384874900013 PM 27510541 ER PT J AU Ahluwalia, N Herrick, KA Rossen, LM Rhodes, D Kit, B Moshfegh, A Dodd, KW AF Ahluwalia, Namanjeet Herrick, Kirsten A. Rossen, Lauren M. Rhodes, Donna Kit, Brian Moshfegh, Alanna Dodd, Kevin W. TI Usual nutrient intakes of US infants and toddlers generally meet or exceed Dietary Reference Intakes: findings from NHANES 2009-2012 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article DE infants and toddlers; nationally representative sample; nutrient adequacy; recommended intakes; usual nutrient intake ID NATIONAL-HEALTH; PRESCHOOL-CHILDREN; FEEDING INFANTS; TOTAL-ENERGY; NUTRITION; COLLECTION; AMERICA; BIRTH; FOODS; B-24 AB Background: To our knowledge, few studies have described the usual nutrient intakes of US children aged <2 y or assessed the nutrient adequacy of their diets relative to the recommended Dietary Reference Intakes (DRIs). Objective: We estimated the usual nutrient intake of US children aged 6-23 mo examined in NHANES 2009-2012 and compared them to age-specific DRIs as applicable. Design: Dietary intake was assessed with two 24-h recalls for infants aged 6-11 mo (n = 381) and toddlers aged 12-23 mo (n = 516) with the use of the USDA's Automated Multiple-Pass Method. Estimates of usual nutrient intakes from food and beverages were obtained with the use of the National Cancer Institute method. The proportions of children with intakes below and above the DRI were also estimated. Results: The estimated usual intakes of infants were adequate for most nutrients; however, 10% had an iron intake below the Estimated Average Requirement (EAR), and only 21% had a vitamin D intake that met or exceeded the recommended Adequate Intake (AI). More nutrient inadequacies were noted among toddlers; 1 in 4 had a lower-than-recommended fat intake (percentage of energy), and most had intakes that were below the EAR for vitamins E (82%) and D (74%). Few toddlers (<1%) met or exceeded the AI for fiber and potassium. In contrast, 1 in 2 had sodium intakes that exceeded the Tolerable Upper Intake Level (UL); >= 16% and 41% of the children had excessive intakes (greater than the ULs) of vitamin A and zinc, respectively. Conclusions: The estimated usual intakes of infants were adequate for most nutrients. Most toddlers were at risk for inadequate intakes of vitamins D and E and had diets low in fiber and potassium. The sources contributing to excessive intakes of vitamin A and zinc among infants and toddlers may need further evaluation. C1 [Ahluwalia, Namanjeet; Herrick, Kirsten A.; Kit, Brian] CDC, Div Hlth & Nutr Examinat Survey, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Rossen, Lauren M.] CDC, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Rhodes, Donna; Moshfegh, Alanna] USDA, Food Surveys Res Grp, Beltsville, MD 20705 USA. [Dodd, Kevin W.] NCI, NIH, Rockville, MD USA. RP Ahluwalia, N (reprint author), CDC, Div Hlth & Nutr Examinat Survey, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM n.ahluwalia@cdc.gov NR 40 TC 2 Z9 2 U1 8 U2 8 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2016 VL 104 IS 4 BP 1167 EP 1174 DI 10.3945/ajcn.116.137752 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DY1SO UT WOS:000384874900029 PM 27629049 ER PT J AU Yanik, EL Nogueira, LM Koch, L Copeland, G Lynch, CF Pawlish, KS Finch, JL Kahn, AR Hernandez, BY Segev, DL Pfeiffer, RM Snyder, JJ Kasiske, BL Engels, EA AF Yanik, E. L. Nogueira, L. M. Koch, L. Copeland, G. Lynch, C. F. Pawlish, K. S. Finch, J. L. Kahn, A. R. Hernandez, B. Y. Segev, D. L. Pfeiffer, R. M. Snyder, J. J. Kasiske, B. L. Engels, E. A. TI Comparison of Cancer Diagnoses Between the US Solid Organ Transplant Registry and Linked Central Cancer Registries SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID RECIPIENTS; RISK; MALIGNANCIES AB US transplant centers are required to report cancers in transplant recipients to the transplant network. The accuracy and completeness of these data, collected in the Scientific Registry of Transplant Recipients (SRTR), are unknown. We compared diagnoses in the SRTR and 15 linked cancer registries for colorectal, liver, lung, breast, prostate and kidney cancers; melanoma; and non-Hodgkin lymphoma (NHL). Among 187 384 transplants, 9323 cancers were documented in the SRTR or cancer registries. Only 36.8% of cancers were in both, with 47.5% and 15.7% of cases additionally documented solely in cancer registries or the SRTR, respectively. Agreement between the SRTR and cancer registries varied (kappa = 0.28 for liver cancer and kappa = 0.52-0.66 for lung, prostate, kidney, colorectum, and breast cancers). Upon evaluation, some NHLs documented only in cancer registries were identified in the SRTR as another type of posttransplant lymphoproliferative disorder. Some SRTR-only cases were explained by miscoding (colorectal cancer instead of anal cancer, metastases as lung or liver cancers) or missed matches with cancer registries, partly due to recipients' outmigration from catchment areas. Estimated sensitivity for identifying cancer was 52.5% for the SRTR and 84.3% for cancer registries. In conclusion, SRTR cancer data are substantially incomplete, limiting their usefulness for surveillance and research. C1 [Yanik, E. L.; Pfeiffer, R. M.; Engels, E. A.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Nogueira, L. M.] Texas Dept State Hlth Serv, Texas Canc Registry, Austin, TX USA. [Koch, L.] Illinois Dept Publ Hlth, Illinois State Canc Registry, Springfield, IL 62761 USA. [Copeland, G.] Michigan Dept Hlth & Human Serv, Michigan Canc Surveillance Program, Lansing, MI USA. [Lynch, C. F.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Pawlish, K. S.] New Jersey Dept Hlth, Canc Epidemiol Serv, New Jersey State Canc Registry, Trenton, NJ USA. [Finch, J. L.] Colorado Dept Publ Hlth & Environm, Colorado Cent Canc Registry, Denver, CO USA. [Kahn, A. R.] New York State Dept Hlth, New York State Canc Registry, Albany, NY USA. [Hernandez, B. Y.] Univ Hawaii, Ctr Canc, Honolulu, HI USA. [Segev, D. L.] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA. [Snyder, J. J.; Kasiske, B. L.] Minneapolis Med Res Fdn Inc, Sci Registry Transplant Recipients, Minneapolis, MN USA. RP Engels, EA (reprint author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. EM engelse@exchange.nih.gov OI Yanik, Elizabeth/0000-0002-5835-0201 FU Intramural Research Program of the National Cancer Institute; Minneapolis Medical Research Foundation, Minneapolis, MN [HHSH250201500009C]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: California [HHSN261201000036C, HHSN261201000035C, HHSN261201000034C]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: Connecticut [HHSN 261201000024C]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: Hawaii [HHSN261201000037C, N01-PC-35137, N01-PC-35139]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: Iowa [HSN261201000032C, N01-PC-35143]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: New Jersey [HHSN261201300021I, N01-PC-2013-00021]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: Seattle-Puget Sound [N01-PC-35142]; Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: Utah [HHSN2612013000171]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: California [1U58 DP000807-01]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Colorado [U58 DP000848-04]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Georgia [5U58DP003875-01]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Illinois [5U58DP003883-03]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Maryland [U58DP12-1205 3919-03]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Michigan [5U58DP003921-03]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: New Jersey [5U58/DP003931-02]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: New York [U58DP003879]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: North Carolina [U58DP00 0832]; National Program of Cancer Registries of the Centers for Disease Control and Prevention: Texas [5U58DP000824-04]; state of California; state of Colorado; state of Connecticut; state of Illinois; state of Iowa; state of Massachusetts [5458DP003920] FX This research was supported in part by the Intramural Research Program of the National Cancer Institute. The authors gratefully acknowledge the support and assistance provided by individuals at the Health Resources and Services Administration (Monica Lin), the SRTR (Ajay Israni and Paul Newkirk) and the following cancer registries: the states of California (Tina Clarke), Colorado, Connecticut (Lou Gonsalves), Georgia, Hawaii (Brenda Hernandez), Iowa, Illinois, Michigan, New Jersey (Xiaoling Niu), New York, North Carolina (Chandrika Rao), Texas, Utah (Janna Harrell), and the Seattle-Puget Sound area of Washington (Margaret Madeleine). We also thank analysts at Information Management Services for programming support (David Castenson, Matthew Chaloux, Michael Curry, and Ruth Parsons). The SRTR is currently operated under contract number HHSH250201500009C (Health Resources and Services Administration) by the Minneapolis Medical Research Foundation, Minneapolis, MN. Previously, the SRTR was managed under contracts HHSH250201000018C and HHSH234200537009C. The following cancer registries were supported by the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute: California (contracts HHSN261201000036C, HHSN261201000035C and HHSN261201000034C); Connecticut (HHSN 261201000024C); Hawaii (HHSN261201000037C, N01-PC-35137 and N01-PC-35139); Iowa (HSN261201000032C and N01-PC-35143); New Jersey (HHSN261201300021I and N01-PC-2013-00021); Seattle-Puget Sound (N01-PC-35142); and Utah (HHSN2612013000171). The following cancer registries were supported by the National Program of Cancer Registries of the Centers for Disease Control and Prevention: California (agreement 1U58 DP000807-01), Colorado (U58 DP000848-04), Georgia (5U58DP003875-01), Illinois (5U58DP003883-03), Maryland (U58DP12-1205 3919-03), Michigan (5U58DP003921-03), New Jersey (5U58/DP003931-02), New York (U58DP003879), North Carolina (U58DP00 0832), and Texas (5U58DP000824-04). Additional support was provided by the states of California, Colorado, Connecticut, Illinois, Iowa, Massachusetts (Massachusetts Cancer Prevention and Control Cooperative Agreement 5458DP003920), New Jersey, New York (including the Cancer Surveillance Improvement Initiative), Texas, Utah, and Washington, as well as the University of Utah and the Fred Hutchinson Cancer Research Center in Seattle, WA. NR 12 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2016 VL 16 IS 10 BP 2986 EP 2993 DI 10.1111/ajt.13818 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA DY0UA UT WOS:000384810500025 ER PT J AU Ferrer, RA Klein, WMP Persoskie, A Avishai-Yitshak, A Sheeran, P AF Ferrer, Rebecca A. Klein, William M. P. Persoskie, Alexander Avishai-Yitshak, Aya Sheeran, Paschal TI The Tripartite Model of Risk Perception (TRIRISK): Distinguishing Deliberative, Affective, and Experiential Components of Perceived Risk SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE Risk perception; Vulnerability; Susceptibility; Behavior; Cancer ID HEALTH BELIEF MODEL; BREAST-CANCER; DECISION-MAKING; MECHANICAL TURK; BEHAVIOR; METAANALYSIS; INTENTIONS; JUDGMENT; WORRY; VACCINATION AB Although risk perception is a key predictor in health behavior theories, current conceptions of risk comprise only one (deliberative) or two (deliberative vs. affective/experiential) dimensions. This research tested a tripartite model that distinguishes among deliberative, affective, and experiential components of risk perception. In two studies, and in relation to three common diseases (cancer, heart disease, diabetes), we used confirmatory factor analyses to examine the factor structure of the tripartite risk perception (TRIRISK) model and compared the fit of the TRIRISK model to dual-factor and single-factor models. In a third study, we assessed concurrent validity by examining the impact of cancer diagnosis on (a) levels of deliberative, affective, and experiential risk perception, and (b) the strength of relations among risk components, and tested predictive validity by assessing relations with behavioral intentions to prevent cancer. The tripartite factor structure was supported, producing better model fit across diseases (studies 1 and 2). Inter-correlations among the components were significantly smaller among participants who had been diagnosed with cancer, suggesting that affected populations make finer-grained distinctions among risk perceptions (study 3). Moreover, all three risk perception components predicted unique variance in intentions to engage in preventive behavior (study 3). The TRIRISK model offers both a novel conceptualization of health-related risk perceptions, and new measures that enhance predictive validity beyond that engendered by unidimensional and bidimensional models. The present findings have implications for the ways in which risk perceptions are targeted in health behavior change interventions, health communications, and decision aids. C1 [Ferrer, Rebecca A.; Klein, William M. P.] NCI, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD 20850 USA. [Persoskie, Alexander] NCI, Behav Res Program, Div Canc Control & Populat Sci, Silver Spring, MD USA. [Avishai-Yitshak, Aya; Sheeran, Paschal] Univ North Carolina Chapel Hill, Chapel Hill, NC USA. RP Ferrer, RA (reprint author), NCI, Behav Res Program, Div Canc Control & Populat Sci, Rockville, MD 20850 USA. EM ferrerra@mail.nih.gov NR 61 TC 0 Z9 0 U1 11 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD OCT PY 2016 VL 50 IS 5 BP 653 EP 663 DI 10.1007/s12160-016-9790-z PG 11 WC Psychology, Multidisciplinary SC Psychology GA DY5ZI UT WOS:000385184000003 PM 26961206 ER PT J AU Shomaker, LB Kelly, NR Pickworth, CK Cassidy, OL Radin, RM Shank, LM Vannucci, A Thompson, KA Armaiz-Flores, SA Brady, SM Demidowich, AP Galescu, OA Courville, AB Olsen, C Chen, KY Stice, E Tanofsky-Kraff, M Yanovski, JA AF Shomaker, Lauren B. Kelly, Nichole R. Pickworth, Courtney K. Cassidy, Omni L. Radin, Rachel M. Shank, Lisa M. Vannucci, Anna Thompson, Katherine A. Armaiz-Flores, Sara A. Brady, Sheila M. Demidowich, Andrew P. Galescu, Ovidiu A. Courville, Amber B. Olsen, Cara Chen, Kong Y. Stice, Eric Tanofsky-Kraff, Marian Yanovski, Jack A. TI A Randomized Controlled Trial to Prevent Depression and Ameliorate Insulin Resistance in Adolescent Girls at Risk for Type 2 Diabetes SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE Adolescence; Depression; Insulin resistance; Type 2 diabetes; Randomized controlled trial ID EXCESS WEIGHT-GAIN; BETA-CELL FUNCTION; CARDIORESPIRATORY FITNESS; RECIPROCAL RELATIONS; SENSITIVITY INDEXES; FEMALE ADOLESCENTS; OBESE ADOLESCENTS; HISPANIC CHILDREN; PLASMA-GLUCOSE; EFFICACY TRIAL AB Prospective data suggest depressive symptoms worsen insulin resistance and accelerate type 2 diabetes (T2D) onset. We sought to determine whether reducing depressive symptoms in overweight/obese adolescents at risk for T2D would increase insulin sensitivity and mitigate T2D risk. We conducted a parallel-group, randomized controlled trial comparing a 6-week cognitive-behavioral (CB) depression prevention group with a 6-week health education (HE) control group in 119 overweight/obese adolescent girls with mild-to-moderate depressive symptoms (Center for Epidemiological Studies-Depression Scale [CES-D] aeyen16) and T2D family history. Primary outcomes were baseline to post-intervention changes in CES-D and whole body insulin sensitivity index (WBISI), derived from 2-h oral glucose tolerance tests. Outcome changes were compared between groups using ANCOVA, adjusting for respective baseline outcome, puberty, race, facilitator, T2D family history degree, baseline age, adiposity, and adiposity change. Multiple imputation was used for missing data. Depressive symptoms decreased (p < 0.001) in CB and HE from baseline to posttreatment, but did not differ between groups (Delta CESD = -12 vs. -11, 95 % CI difference = -4 to +1, p = 0.31). Insulin sensitivity was stable (p > 0.29) in CB and HE (Delta WBISI = 0.1 vs. 0.2, 95 % CI difference = -0.6 to +0.4, p = 0.63). Among all participants, reductions in depressive symptoms were associated with improvements in insulin sensitivity (p = 0.02). Girls at risk for T2D displayed reduced depressive symptoms following 6 weeks of CB or HE. Decreases in depressive symptoms related to improvements in insulin sensitivity. Longer-term follow-up is needed to determine whether either program causes sustained decreases in depressive symptoms and improvements in insulin sensitivity. The trial was registered with clinicaltrials.gov (NCT01425905). C1 [Shomaker, Lauren B.; Kelly, Nichole R.; Pickworth, Courtney K.; Cassidy, Omni L.; Radin, Rachel M.; Shank, Lisa M.; Vannucci, Anna; Thompson, Katherine A.; Armaiz-Flores, Sara A.; Brady, Sheila M.; Demidowich, Andrew P.; Galescu, Ovidiu A.; Courville, Amber B.; Olsen, Cara; Tanofsky-Kraff, Marian; Yanovski, Jack A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Growth & Obes, NIH, Hatfield Clin Res Ctr, 10 Ctr Dr,Bldg 10,Room 1-3330,MSC 1103, Bethesda, MD 20892 USA. [Shomaker, Lauren B.; Kelly, Nichole R.; Cassidy, Omni L.; Radin, Rachel M.; Shank, Lisa M.; Vannucci, Anna; Tanofsky-Kraff, Marian] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. [Shomaker, Lauren B.; Kelly, Nichole R.] Colorado State Univ, Dept Human Dev & Family Studies, 303A Behav Sci Bldg,410 Pitkin St, Ft Collins, CO 80523 USA. [Courville, Amber B.] NIH, Dept Nutr, Mark O Hatfield Clin Ctr, Bldg 10, Bethesda, MD 20892 USA. [Olsen, Cara] Uniformed Serv Univ Hlth Sci, Dept Prevent Med, Biostat, Bethesda, MD 20814 USA. [Chen, Kong Y.] NIDDK, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD 20892 USA. [Stice, Eric] Oregon Res Inst, Eugene, OR 97403 USA. RP Shomaker, LB; Tanofsky-Kraff, M; Yanovski, JA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Growth & Obes, NIH, Hatfield Clin Res Ctr, 10 Ctr Dr,Bldg 10,Room 1-3330,MSC 1103, Bethesda, MD 20892 USA.; Shomaker, LB; Tanofsky-Kraff, M (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Shomaker, LB (reprint author), Colorado State Univ, Dept Human Dev & Family Studies, 303A Behav Sci Bldg,410 Pitkin St, Ft Collins, CO 80523 USA. EM lauren.shomaker@colostate.edu; marian.tanofsky-kraff@usuhs.edu; jy15i@nih.gov OI Chen, Kong/0000-0002-0306-1904; Shank, Lisa/0000-0002-6922-7946 FU Intramural NIH HHS [Z01 HD000641-12, Z01 HD000641-13, Z99 HD999999, ZIA HD000641-21]; NICHD NIH HHS [R00 HD069516, K99 HD069516, ZIA HD000641] NR 48 TC 0 Z9 0 U1 11 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD OCT PY 2016 VL 50 IS 5 BP 762 EP 774 DI 10.1007/s12160-016-9801-0 PG 13 WC Psychology, Multidisciplinary SC Psychology GA DY5ZI UT WOS:000385184000013 PM 27333897 ER PT J AU Deligiannidis, KM Kroll-Desrosiers, AR Svenson, A Jaitly, N Barton, BA Hall, JE Rothschild, AJ AF Deligiannidis, Kristina M. Kroll-Desrosiers, Aimee R. Svenson, Abby Jaitly, Nina Barton, Bruce A. Hall, Janet E. Rothschild, Anthony J. TI Cortisol response to the Trier Social Stress Test in pregnant women at risk for postpartum depression SO ARCHIVES OF WOMENS MENTAL HEALTH LA English DT Article DE Postpartum; Cortisol; Depression; Anxiety ID CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; POSTNATAL DEPRESSION; SALIVARY CORTISOL; PSYCHOSOCIAL STRESS; AWAKENING RESPONSE; MATERNAL CORTISOL; PHYSICAL ABUSE; REACTIVITY; SYMPTOMS AB Antepartum depression and anxiety are risk factors for postpartum depression (PPD). Postpartum abnormalities in hypothalamic-pituitary-adrenal (HPA) reactivity are associated with PPD. It is not known if antepartum HPA abnormalities exist in women at risk for PPD (AR-PPD). We measured salivary cortisol response to the Trier Social Stress Test (TSST) in 44 (24 AR-PPD, 20 healthy comparison) pregnant women. Depression and anxiety were measured using the Edinburgh Postnatal Depression Scale (EPDS) and Spielberger State-Trait Anxiety Inventory-State (STAI-S). We analyzed longitudinal changes in cortisol using generalized estimating equation methods to control for the correlation within subjects at the six TSST time points. Group differences in area under the curve (AUC) were examined. A majority (70.8 %) of the AR-PPD had prior depression. EPDS total score was higher in AR-PPD vs. comparison women (mean EPDS = 9.8 +/- 4.9 vs. mean EPDS = 2.4 +/- 2.0 respectively, p < 0.001). Mean STAI-S total score was higher in AR-PPD vs. comparison women at all TSST time points and over time (z = 2.71, df = 1, p = 0.007). There was no significant difference in cortisol concentration over time between groups. We observed no detectable difference in cortisol response to psychosocial stress induced by the TSST despite clinically significant between-group differences in current/past depression and current symptomatology. C1 [Deligiannidis, Kristina M.; Svenson, Abby; Jaitly, Nina; Rothschild, Anthony J.] Univ Massachusetts, Sch Med, Ctr Psychopharmacol Res & Treatment, Dept Psychiat, Worcester, MA 01605 USA. [Deligiannidis, Kristina M.] Univ Massachusetts, Dept Psychiat, Womens Mental Hlth Program, Med Sch,UMass Mem Med Ctr, 55 Lake Ave North, Worcester, MA 01605 USA. [Deligiannidis, Kristina M.] Univ Massachusetts, Dept Obstet & Gynecol, Womens Mental Hlth Program, Med Sch,UMass Mem Med Ctr, 55 Lake Ave North, Worcester, MA 01605 USA. [Kroll-Desrosiers, Aimee R.; Barton, Bruce A.] Univ Massachusetts, Dept Quantitat Hlth Sci, Sch Med, Worcester, MA 01605 USA. [Jaitly, Nina; Hall, Janet E.] NIEHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA. [Hall, Janet E.] Harvard Med Sch, Reprod Endocrine Unit, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Deligiannidis, KM (reprint author), Univ Massachusetts, Sch Med, Ctr Psychopharmacol Res & Treatment, Dept Psychiat, Worcester, MA 01605 USA.; Deligiannidis, KM (reprint author), Univ Massachusetts, Dept Psychiat, Womens Mental Hlth Program, Med Sch,UMass Mem Med Ctr, 55 Lake Ave North, Worcester, MA 01605 USA.; Deligiannidis, KM (reprint author), Univ Massachusetts, Dept Obstet & Gynecol, Womens Mental Hlth Program, Med Sch,UMass Mem Med Ctr, 55 Lake Ave North, Worcester, MA 01605 USA. EM Kristina.Deligiannidis@umassmemorial.org; aimee.kroll@umassmed.edu; abbysve@gmail.com; nina.jaitly@nih.gov; bruce.barton@umassmed.edu; janet.hall@nih.gov; anthony.rothschild@umassmemorial.org OI Deligiannidis, Kristina/0000-0001-7439-2236; Barton, Bruce/0000-0001-7878-8895; Hall, Janet/0000-0003-4644-3061 FU National Center for Advancing Translational Sciences, National Institutes of Health [UL1 TR000161]; National Institutes of Health [5K23MH097794] FX This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health Grant (UL1 TR000161), and National Institutes of Health Grant (5K23MH097794) awarded to Dr. Deligiannidis. The sponsoring agency had no further role in the study design and analysis, the writing of the report, or the decision to submit the paper for publication. The authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily reflect the position of the NIH. NR 58 TC 0 Z9 0 U1 5 U2 5 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 1434-1816 EI 1435-1102 J9 ARCH WOMEN MENT HLTH JI Arch. Womens Ment. Health PD OCT PY 2016 VL 19 IS 5 BP 789 EP 797 DI 10.1007/s00737-016-0615-7 PG 9 WC Psychiatry SC Psychiatry GA DW4JW UT WOS:000383610000008 PM 26951216 ER PT J AU Musset, L Allenbach, Y Benveniste, O Boyer, O Bossuyt, X Bentow, C Phillips, J Mammen, A Van Damme, P Westhovens, R Ghirardello, A Doria, A Choi, MY Fritzler, MJ Schmeling, H Muro, Y Garcia-De la Torre, I Ortiz-Villalvazo, MA Bizzaro, N Infantino, M Imbastaro, T Peng, QL Wang, GC Vencovsky, J Klein, M Krystufkova, O Franceschini, F Fredi, M Hue, S Belmondo, T Danko, K Mahler, M AF Musset, Lucile Allenbach, Yves Benveniste, Olivier Boyer, Olivier Bossuyt, Xavier Bentow, Chelsea Phillips, Joe Mammen, Andrew Van Damme, Philip Westhovens, Rene Ghirardello, Anna Doria, Andrea Choi, May Y. Fritzler, Marvin J. Schmeling, Heinrike Muro, Yoshinao Garcia-De la Torre, Ignacio Ortiz-Villalvazo, Miguel A. Bizzaro, Nicola Infantino, Maria Imbastaro, Tiziana Peng, Qinglin Wang, Guochun Vencovsky, Jiri Klein, Martin Krystufkova, Olga Franceschini, Franco Fredi, Micaela Hue, Sophie Belmondo, Thibaut Danko, Katalin Mahler, Michael TI Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study SO AUTOIMMUNITY REVIEWS LA English DT Review DE Autoimmune myositis; Autoantibodies; Immune-mediated necrotizing myopathy; HMGCR; Statins ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; IDIOPATHIC INFLAMMATORY MYOPATHIES; CLASSIFICATION CRITERIA; AUTOIMMUNE MYOPATHY; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; REDUCTASE AUTOANTIBODIES; RISK-ASSESSMENT; MYOSITIS; DIAGNOSIS AB In an effort to find naturally occurring substances that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), statins were first discovered by Endo in 1972. With the widespread prescription and use of statins to decrease morbidity from myocardial infarction and stroke, it was noted that approximately 5% of all statin users experienced muscle pain and weakness during treatment In a smaller proportion of patients, the myopathy progressed to severe morbidity marked by proximal weakness and severe muscle wasting. Remarkably, Mammen and colleagues were the first to discover that the molecular target of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), is an autoantibody target in patients that develop an immune-mediated necrotizing myopathy (IMNM). These observations have been confirmed in a number of studies but, until today, a multi-center, international study of IMNM, related idiopathic inflammatory myopathies (IIM), other auto-inflammatory conditions and controls has not been published. Accordingly, an international, multi-center study investigated the utility of anti-HMGCR antibodies in the diagnosis of statin-associated IMNM in comparison to different forms of IIM and controls. This study included samples from patients with different forms of IIM (n = 1250) and patients with other diseases (n = 656) that were collected from twelve sites and tested for anti-HMGCR antibodies by ELISA. This study confirmed that anti-HMGCR autoantibodies, when found in conjunction with statin use, characterize a subset of IIM who are older and have necrosis on muscle biopsy. Taken together, the data to date indicates that testing for anti-HMGCR antibodies is important in the differential diagnosis of IIM and might be considered for future classification criteria. (C) 2016 Published by Elsevier B.V. C1 [Musset, Lucile] Pitie Salpetriere Univ Hosp Paris, AP HP, Dept Immunol, Immunochem & Autoimmun Lab, Paris, France. [Allenbach, Yves; Benveniste, Olivier] Pitie Salpetriere Univ Hosp, AP HP, Dept Internal Med & Clin Immunol, Hosp Univ Dept Inflammat Immunopathol & Biotherap, Paris, France. [Allenbach, Yves; Benveniste, Olivier] Univ Paris 06, Sorbonne Univ, INSERM, U974, Paris, France. [Boyer, Olivier] Rouen Univ Hosp, Dept Immunol, Rouen, France. [Boyer, Olivier] INSERM, U905, Rouen, France. [Boyer, Olivier] Normandie Univ, IRIB, Rouen, France. [Bossuyt, Xavier] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium. [Bossuyt, Xavier] Katholieke Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium. [Bentow, Chelsea; Phillips, Joe; Mahler, Michael] Inova Diagnost, Dept Res, San Diego, CA USA. [Mammen, Andrew] NIAMSD, NIH, Bethesda, MD 20892 USA. [Van Damme, Philip] Univ Leuven, KU Leuven, Dept Neurosci, VIB Vesalius Res Ctr,Expt Neurol Lab Neurobiol, Leuven, Belgium. [Van Damme, Philip] Univ Hosp Leuven, Dept Neurol, Leuven, Belgium. [Westhovens, Rene] Katholieke Univ Leuven, Skeletal Biol & Engn Res Ctr, Dept Dev & Regenerat, Leuven, Belgium. [Westhovens, Rene] Univ Hosp Leuven, Rheumatol, Leuven, Belgium. [Ghirardello, Anna; Doria, Andrea] Univ Padua, Dept Med, Div Rheumatol, Padua, Italy. [Choi, May Y.; Fritzler, Marvin J.] Univ Calgary, Dept Med, Calgary, AB, Canada. [Schmeling, Heinrike] Univ Calgary, Dept Pediat, Alberta Childrens Hosp, Calgary, AB, Canada. [Muro, Yoshinao] Nagoya Univ, Div Connect Tissue Dis & Autoimmun, Dept Dermatol, Grad Sch Med, Nagoya, Aichi, Japan. [Garcia-De la Torre, Ignacio] Hosp Gen Occidente Seguro Social, Dept Immunol & Rheumatol, Zapopan, Jalisco, Mexico. [Garcia-De la Torre, Ignacio] Univ Guadalajara, Zapopan, Jalisco, Mexico. [Ortiz-Villalvazo, Miguel A.] Hosp Civil Dr Juan I Menchaca, Dept Internal Med, Guadalajara, Jalisco, Mexico. [Bizzaro, Nicola] San Antonio Hosp, Clin Pathol Lab, Tolmezzo, Italy. [Infantino, Maria] S Giovanni di Dio Hosp, Lab Immunol & Allergol, Florence, Italy. [Imbastaro, Tiziana] Lab Autoimmune Dis Diagnost, PO Spirit Santo, Pescara, Italy. [Peng, Qinglin; Wang, Guochun] China Japan Friendship Hosp, Dept Rheumatol, Beijing, Peoples R China. [Vencovsky, Jiri; Klein, Martin; Krystufkova, Olga] Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic. [Vencovsky, Jiri; Klein, Martin; Krystufkova, Olga] Charles Univ Prague, Dept Rheumatol, Prague, Czech Republic. [Franceschini, Franco; Fredi, Micaela] Univ Brescia, Rheumatol & Clin Immunol, Spedali Civili Brescia, I-25121 Brescia, Italy. [Franceschini, Franco; Fredi, Micaela] Univ Pavia, I-27100 Pavia, Italy. [Hue, Sophie; Belmondo, Thibaut] Henri Mondor Univ Hosp, Dept Immunohematol, Creteil, France. [Danko, Katalin] Univ Debrecen, Div Immunol, Dept Internal Med 3, Med & Hlth Sci Ctr, Debrecen, Hungary. RP Mahler, M (reprint author), Inova Diagnost, 9900 Old Grove Rd, San Diego, CA 92131 USA. EM mmahler@inovadx.com RI Van Damme, Philip/A-6464-2009 OI Van Damme, Philip/0000-0001-6384-0611 FU Ministry of Health [00023728] FX The work of Jiri Vencovsky in myositis is supported by project from Ministry of Health No. 00023728. We acknowledge Laurent Drouot and Fabienne Jouen (Rouen University Hospital, Department of Immunology, Rouen, France) as well as Jean-Luc Charuel and Laurent Dufat (Pitie-Salpetriere Hospital University, Paris, France) for their help during the study. We acknowledge Lisa Christopher-Stine for proofreading the draft manuscript and providing valuable suggestions. The local ethics committees who approved the study for the various centers involved included the local ethics committee of the University Hospital Leuven (ML9544, Leuven, Belgium), the local ethics committee of CPP-Ile-de-France VI GH Pitie-Salpetriere/Ch Foix (President: Dr Laurent Capelle, Paris, France), the Italian Local Ethics Committee (Comitato Etico per la Sperimentazione dell'Azienda Ospedaliera di Padova, Prot. N. 2542P), the Conjoint Health Research Ethics Board (CHREB) of the University of Calgary (Calgary, Canada), the local ethics committees of the Nagoya University Graduate School of Medicine (Nagoya, Japan), the Human Ethics Board of China-Japan Friendship Hospital (Beijing, China), and the local ethics committee at the Institute of Rheumatology (Prague, Czech Republic). Where no ethics committee was required per institution guidelines, informed consent was obtained from the patients involved in the study. NR 72 TC 1 Z9 2 U1 9 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-9972 EI 1873-0183 J9 AUTOIMMUN REV JI Autoimmun. Rev. PD OCT PY 2016 VL 15 IS 10 BP 983 EP 993 DI 10.1016/j.autrev.2016.07.023 PG 11 WC Immunology SC Immunology GA DY1RM UT WOS:000384872100009 PM 27491568 ER PT J AU Alousi, AM Anasetti, C Antin, JH Appelbaum, FR Bashey, A Confer, DL Devine, SM DiFronzo, N Giralt, SA Grupp, SN Hari, PN Heslop, HE Horowitz, MM Jones, RJ Kurtzberg, J Lazarus, HM Lowsky, R Mendizabal, AM Merritt, W Nakamura, R Pulsipher, MA Ratanatharathorn, V Stadtmauer, EA Stiff, PJ Vose, JM Weisdorf, DJ Westervelt, P Wingard, JR Yanik, GA AF Alousi, Amin M. Anasetti, Claudio Antin, Joseph H. Appelbaum, Frederick R. Bashey, Asad Confer, Dennis L. Devine, Steven M. DiFronzo, Nancy Giralt, Sergio A. Grupp, Stephan N. Hari, Parameswaran N. Heslop, Helen E. Horowitz, Mary M. Jones, Richard J. Kurtzberg, Joanne Lazarus, Hillard M. Lowsky, Robert Mendizabal, Adam M. Merritt, William Nakamura, Ryotaro Pulsipher, Michael A. Ratanatharathorn, Voravit Stadtmauer, Edward A. Stiff, Patrick J. Vose, Julie M. Weisdorf, Daniel J. Westervelt, Peter Wingard, John R. Yanik, Gregory A. CA Blood Marrow Transplant Clinical TI The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Review DE Hematopoietic cell transplantation; Blood and Marrow Transplant; Clinical Trials Network; Infrastructure; Review ID VERSUS-HOST-DISEASE; UMBILICAL-CORD BLOOD; COST-EFFECTIVENESS ANALYSIS; COOPERATIVE-ONCOLOGY-GROUP; INVASIVE FUNGAL-INFECTION; ACUTE MYELOID-LEUKEMIA; SCIENCE SYMPOSIUM 2007; BMT CTN 0902; BONE-MARROW; MULTIPLE-MYELOMA AB Hematopoietic cell transplantation (HCT) is a rapidly evolving field with active preclinical and clinical development of new strategies for patient assessment, graft selection and manipulation, and pre- and post transplantation drug and cell therapy. New strategies require evaluation in definitive clinical trials; however, HCT trials face unique challenges, including the relatively small number of transplantations performed at any single center, the diverse indications for HCT requiring dissimilar approaches, the complex nature of the intervention itself, the risk of multiple complications in the immediate post-transplantation period, and the risk of important, though infrequent, late effects. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) was established by the US National Heart Lung and Blood Institute and the National Cancer Institute to meet these challenges. In its 15 years as a network, the BMT CTN has proven to be a successful infrastructure for planning, implementing, and completing such trials and for providing definitive answers to questions leading to improvements in the understanding and practice of HCT. It has opened 37 trials, about one-half phase 2 and one-half phase 3, enrolled more than 8000 patients, and published 57 papers addressing important issues in the treatment of patients with life-threatening malignant and nonmalignant blood disorders. This review describes the network's accomplishments, key components of its success, lessons learned over the past 15 years, and challenges for the future. (C) 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. C1 [Blood Marrow Transplant Clinical] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Alousi, Amin M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Anasetti, Claudio] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Bashey, Asad] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA. [Confer, Dennis L.] Natl Marrow Donor Program, Minneapolis, MN USA. [Devine, Steven M.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [DiFronzo, Nancy] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Giralt, Sergio A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Grupp, Stephan N.; Horowitz, Mary M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Hari, Parameswaran N.; Horowitz, Mary M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Heslop, Helen E.] Baylor Coll Med, Houston, TX 77030 USA. [Jones, Richard J.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Kurtzberg, Joanne] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Lazarus, Hillard M.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Lowsky, Robert] Stanford Hosp & Clin, Palo Alto, CA USA. [Mendizabal, Adam M.] Emmes Corp, Rockville, MD USA. [Merritt, William] NCI, NIH, Bethesda, MD 20892 USA. [Nakamura, Ryotaro] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Pulsipher, Michael A.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Ratanatharathorn, Voravit] Karmanos Canc Inst, Detroit, MI USA. [Stadtmauer, Edward A.] Univ Penn, Philadelphia, PA 19104 USA. [Stiff, Patrick J.] Loyola Univ, Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. [Vose, Julie M.] Univ Nebraska Med Ctr, Omaha, NE USA. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Westervelt, Peter] Washington Univ, St Louis, MO USA. [Wingard, John R.] Univ Florida, Gainesville, FL USA. [Yanik, Gregory A.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Horowitz, MM (reprint author), Med Coll Wisconsin, Milwaukee, WI 53226 USA. FU National Institutes of Health; Health Resources and Services Administration FX This work was supported by the National Institutes of Health and the Health Resources and Services Administration. The views expressed do not necessarily represent the views of the National Institutes of Health, the Health Resources and Services Administration, or the United States government. NR 68 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD OCT PY 2016 VL 22 IS 10 BP 1747 EP 1757 DI 10.1016/j.bbmt.2016.07.003 PG 11 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA DY3BG UT WOS:000384965200004 ER PT J AU Khan, NE Rosenberg, PS Alter, BP AF Khan, Nicholas E. Rosenberg, Philip S. Alter, Blanche P. TI Preemptive Bone Marrow Transplantation and Event-Free Survival in Fanconi Anemia SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Preemptive transplantation; Fanconi anemia; Markov model; Decision analysis ID STEM-CELL TRANSPLANTATION; DIAMOND-BLACKFAN ANEMIA; DECISION-MAKING; FAILURE SYNDROMES; CANCER; REGISTRY AB Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome associated with high risks of severe bone marrow failure (BMF), acute myeloid leukemia (AML), and solid tumors (ST). Bone marrow transplantation (BMT) provides a theoretical cure for hematologic risks (BMF, AML), but it introduces uncertain risks of transplantation-related mortality (TRM) and carcinogenicity. We developed a mathematical (Markov) decision model to estimate event-free survival (EFS) conditional on age based on per-year cause-specific hazard rates. We assumed that preemptive (PE) BMT eliminates the risks of BMF and AML, but it may introduce independent risks of TRM or influence the trajectory to ST. Our model suggested that the expected mean EFS in FA is higher for PE-BMT at young ages, with minimal risk of TRM and with little carcinogenicity. PE-BMT in adults decreased expected EFS because of the greater competing risk of ST in adulthood. Estimates of EFS conditioned on attained age may be used in shared decision-making when clinicians must counsel patients using limited data. Our methods may be used to model early transplantation in other blood disorders for which hematopoietic stem cell transplantation mitigates some but not all of the risks. Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation. C1 [Khan, Nicholas E.; Alter, Blanche P.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,Room 6E452, Bethesda, MD 20850 USA. [Rosenberg, Philip S.] NCI, Biostat Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Alter, BP (reprint author), NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,Room 6E452, Bethesda, MD 20850 USA. EM alterb@mail.nih.gov FU Intramural Research Program of the National Cancer Institute of the National Institutes of Health FX This research was supported in part by the Intramural Research Program of the National Cancer Institute of the National Institutes of Health. NR 23 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD OCT PY 2016 VL 22 IS 10 BP 1888 EP 1892 DI 10.1016/j.bbmt.2016.06.018 PG 5 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA DY3BG UT WOS:000384965200022 PM 27345141 ER PT J AU Doyle, M Pohost, GM Merz, CNB Shaw, LJ Sopko, G Rogers, WJ Sharaf, BL Pepine, CJ Thompson, DV Rayarao, G Tauxe, L Kelsey, SF Biederman, RWW AF Doyle, Mark Pohost, Gerald M. Merz, C. Noel Bairey Shaw, Leslee J. Sopko, George Rogers, William J. Sharaf, Barry L. Pepine, Carl J. Thompson, Diane V. Rayarao, Geetha Tauxe, Lindsey Kelsey, Sheryl F. Biederman, Robert W. W. TI Use of bio-informatics assessment schema (BIAS) to improve diagnosis and prognosis of myocardial perfusion data: results from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) SO CARDIOVASCULAR DIAGNOSIS AND THERAPY LA English DT Article DE Modeling; prognosis; diagnosis; myocardial perfusion imaging (MPI); women ID CARDIOVASCULAR MAGNETIC-RESONANCE; CORONARY-ARTERY-DISEASE; FEASIBILITY; RESERVE; SPECT; FLOW AB Background: We introduce an algorithmic approach to optimize diagnostic and prognostic value of gated cardiac single photon emission computed tomography (SPECT) and magnetic resonance (MR) myocardial perfusion imaging (MPI) modalities in women with suspected myocardial ischemia. The novel approach: bioinformatics assessment schema (BIAS) forms a mathematical model utilizing MPI data and cardiac metrics generated by one modality to predict the MPI status of another modality. The model identifies cardiac features that either enhance or mask the image-based evidence of ischemia. For each patient, the BIAS model value is used to set an appropriate threshold for the detection of ischemia. Methods: Women (n=130), with symptoms and signs of suspected myocardial ischemia, underwent MPI assessment for regional perfusion defects using two different modalities: gated SPECT and MR. To determine perfusion status, MR data were evaluated qualitatively (MRIQL) and semi-quantitatively (MRISQ) while SPECT data were evaluated using conventional clinical criteria. Evaluators were masked to results of the alternate modality. These MPI status readings were designated "original". Two regression models designated "BIAS" models were generated to model MPI status obtained with one modality (e.g., MRI) compared with a second modality (e.g., SPECT), but importantly, the BIAS models did not include the primary Original MPI reading of the predicting modality. Instead, the BIAS models included auxiliary measurements like left ventricular chamber volumes and myocardial wall thickness. For each modality, the BIAS model was used to set a progressive threshold for interpretation of MPI status. Women were then followed for 38 +/- 14 months for the development of a first major adverse cardiovascular event [MACE: CV death, nonfatal myocardial infarction (MI) or hospitalization for heart failure]. Original and BIAS-augmented perfusion status were compared in their ability to detect coronary artery disease (CAD) and for prediction of MACE. Results: Adverse events occurred in 14 (11%) women and CAD was present in 13 (10%). There was a positive correlation of maximum coronary artery stenosis and BIAS score for MRI and SPECT (P<0.001). Receiver operator characteristic (ROC) analysis was conducted and showed an increase in the area under the curve of the BIAS-augmented MPI interpretation of MACE vs. the original for MRISQ (0.78 vs. 0.54), MRIQL (0.78 vs. 0.64), SPECT (0.82 vs. 0.63) and the average of the three readings (0.80 +/- 0.02 vs. 0.60 +/- 0.05, P<0.05). Conclusions: Increasing values of the BIAS score generated by both MRI and SPECT corresponded to the increasing prevalence of CAD and MACE. The BIAS-augmented detection of ischemia better predicted MACE compared with the Original reading for the MPI data for both MRI and SPECT. C1 [Doyle, Mark; Thompson, Diane V.; Rayarao, Geetha; Biederman, Robert W. W.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Pohost, Gerald M.] Univ Southern Calif, Keck Med Ctr, Los Angeles, CA USA. [Merz, C. Noel Bairey; Shaw, Leslee J.] Cedars Sinai Heart Inst, Barbra Streisand Womens Heart Ctr, Los Angeles, CA USA. [Sopko, George] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Rogers, William J.; Tauxe, Lindsey] Univ Alabama Birmingham, Birmingham, AL USA. [Sharaf, Barry L.] Brown Univ, Providence, RI 02912 USA. [Pepine, Carl J.] Univ Florida, Gainesville, FL USA. [Kelsey, Sheryl F.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Doyle, M (reprint author), Allegheny Gen Hosp, Div Cardiol, CV MRI Ctr, 320 East North Ave, Pittsburgh, PA 15212 USA. EM mdoyle@wpahs.org FU NHLBI NIH HHS [N01 HV068161, N01 HV068164, N01HV68162, N01HV68163, R01 HL073412] NR 16 TC 0 Z9 0 U1 2 U2 2 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2223-3652 EI 2223-3660 J9 CARDIOVASC DIAGN THE JI Cardiovisc. Diagn. Ther. PD OCT PY 2016 VL 6 IS 5 BP 424 EP U9 DI 10.21037/cdt.2016.03.11 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DX6KS UT WOS:000384493200003 PM 27747165 ER PT J AU Morkl, S Muller, NJ Blesl, C Wilkinson, L Tmava, A Wurm, W Holl, AK Painold, A AF Moerkl, Sabrina Mueller, Nicole J. Blesl, Claudia Wilkinson, Leonora Tmava, Adelina Wurm, Walter Holl, Anna K. Painold, Annamaria TI Problem solving, impulse control and planning in patients with early- and late-stage Huntington's disease SO EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE LA English DT Article DE Huntington's disease; Executive function; Tower of London; Neuropsychology; Disease severity ID DECISION-MAKING; LONDON TASK; SCHIZOPHRENIA; COMPENSATION; PROGRESSION; DIAGNOSIS; PATHOLOGY; MEMORY; TOWER; HD AB Sub-domains of executive functions, including problems with planning, accuracy, impulsivity, and inhibition, are core features of Huntington's disease. It is known that the decline of cognitive function in Huntington's disease is related to the anatomical progression of pathology in the basal ganglia. However, it remains to be determined whether the severity of executive dysfunction depends on the stage of the disease. To examine the severity of sub-domains of executive dysfunction in early- and late-stage Huntington's disease, we studied performance in the Tower of London task of two groups of Huntington's disease patients (Group 1: early, n = 23, and Group 2: late stage, n = 29), as well as a third group of age, education, and IQ matched healthy controls (n = 34). During the task, we measured the total number of problems solved, total planning time, and total number of breaks taken. One aspect of executive function indexed by the number of solved problems seems to progress in the course of the disease. Late-stage Huntington's disease patients scored significantly worse than early-stage patients and controls, and early-stage patients scored significantly worse than controls on this measure of accuracy. In contrast, late- and early-stage HD patients did not differ in terms of planning time and number of breaks. Early- and late-stage HD pathology has a different impact on executive sub-domains. While accuracy differs between early- and late-stage HD patients, other domains like planning time and number of breaks do not. Striatal degeneration, which is a characteristic feature of the disease, might not affect all aspects of executive function in HD. C1 [Moerkl, Sabrina; Mueller, Nicole J.; Blesl, Claudia; Tmava, Adelina; Wurm, Walter; Holl, Anna K.; Painold, Annamaria] Med Univ Graz, Dept Psychiat, Auenbruggerpl 31-1, A-8036 Graz, Austria. [Wilkinson, Leonora] NINDS, Behav Neurol Unit, NIH, 10 Ctr Dr,MSC 1440, Bethesda, MD 20892 USA. RP Blesl, C (reprint author), Med Univ Graz, Dept Psychiat, Auenbruggerpl 31-1, A-8036 Graz, Austria. EM claudia.blesl@medunigraz.at FU Medical University of Graz FX Open access funding provided by Medical University of Graz. We express our kind appreciation to all the participants of the study. NR 36 TC 0 Z9 0 U1 8 U2 8 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0940-1334 EI 1433-8491 J9 EUR ARCH PSY CLIN N JI Eur. Arch. Psych. Clin. Neurosci. PD OCT PY 2016 VL 266 IS 7 BP 663 EP 671 DI 10.1007/s00406-016-0707-4 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DY5TY UT WOS:000385167700009 PM 27372072 ER PT J AU Li, DX Ferrada, MA Avdic, E Tamma, PD Cosgrove, SE AF Li, David X. Ferrada, Marcela A. Avdic, Edina Tamma, Pranita D. Cosgrove, Sara E. TI Sustained Impact of an Antibiotic Stewardship Intervention for Community-Acquired Pneumonia SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID IMPLEMENTATION AB Antibiotic stewardship interventions targeting community-acquired pneumonia have been successful in reducing antibiotic overuse in the short term, but the sustainability of their effects has not been investigated. We report that improvements in antibiotic use due to a syndrome-focused intervention for community-acquired pneumonia were sustained 3 years later without additional intervention. C1 [Li, David X.; Ferrada, Marcela A.; Cosgrove, Sara E.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Ferrada, Marcela A.] NIH, Dept Crit Care Med, Bldg 10, Bethesda, MD 20892 USA. [Avdic, Edina] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA. [Tamma, Pranita D.] Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, Baltimore, MD USA. RP Cosgrove, SE (reprint author), Johns Hopkins Univ Hosp, 600 N Wolfe St,Halsted 827, Baltimore, MD 21287 USA. EM scosgro1@jhmi.edu FU Pfizer Grants for Learning and Change; Joint Commission FX Pfizer Grants for Learning and Change and the Joint Commission (grant to P.D.T., E.A., and S.E.C.). NR 9 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2016 VL 37 IS 10 BP 1243 EP 1246 DI 10.1017/ice.2016.165 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DY4GS UT WOS:000385057600016 PM 27498601 ER PT J AU Sy, AA Kim, WS Chen, J Shen, Y Tao, C Lee, JS AF Sy, A. A. Kim, W. S. Chen, J. Shen, Y. Tao, C. Lee, J. S. TI Acculturation levels and personalizing orthognathic surgery for the Asian American patient SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article DE facial aesthetics; ethnic variation; Suinn-Lew survey; Western aesthetics; customized orthognathic treatment planning ID HEALTH-CARE; ATTRACTIVENESS; QUALITY AB This study was performed to investigate whether the level of acculturation among Asians living in the USA plays a significant role in their opinion of facial profiles. One hundred and ninety-eight Asian American subjects were asked to complete a pre-validated survey to measure their level of acculturation and to evaluate four sets of pictures that displayed a class II male, class II female, class III male, and class III female. Each set consisted of three lateral profile pictures: an initial unaltered photo, a picture simulating a flatter profile (orthodontic camouflage in class II; mandibular setback in class III), and a picture simulating a fuller profile (mandibular advancement in class II; maxillary advancement in class III). For the class II male, subjects who were more acculturated indicated that a flatter profile (orthodontic camouflage) was less attractive. For the class II female, higher acculturated subjects chose expansive treatment (mandibular advancement) as more aesthetic compared to the less acculturated subjects. Each of these scenarios had statistically significant odds ratios. In general, highly acculturated subjects preferred a fuller facial profile, while low acculturated subjects preferred a flatter facial profile appearance, except for the class III female profile, which did not follow this trend. C1 [Sy, A. A.; Lee, J. S.] UCSF Oral & Maxillofacial Surg, Box 0440,521 Parnassus Ave,Clin Sci Room 522C, San Francisco, CA 94143 USA. [Kim, W. S.] Columbia Univ, Oral & Maxillofacial Surg, New York, NY USA. [Shen, Y.] Washington St, Daly City, CA USA. [Lee, J. S.] NIDCR, NIH, Bethesda, MD USA. RP Sy, AA (reprint author), UCSF Oral & Maxillofacial Surg, Box 0440,521 Parnassus Ave,Clin Sci Room 522C, San Francisco, CA 94143 USA. EM Aldrich.sy@ucsf.edu OI Kim, William/0000-0001-7693-3454 FU Oral and Maxillofacial Surgery Foundation Student Research Fund FX This research was supported by the Oral and Maxillofacial Surgery Foundation Student Research Fund. NR 26 TC 0 Z9 0 U1 3 U2 3 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0901-5027 EI 1399-0020 J9 INT J ORAL MAX SURG JI Int. J. Oral Maxillofac. Surg. PD OCT PY 2016 VL 45 IS 10 BP 1201 EP 1208 DI 10.1016/j.ijom.2016.04.013 PG 8 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA DY1MB UT WOS:000384858000003 PM 27197783 ER PT J AU Yoneyama, K Donekal, S Venkatesh, BA Wu, CO Liu, CY Nacif, MS Armstrong, A Gomes, AS Hundley, WG McClelland, RL Bluemke, DA Lima, JAG AF Yoneyama, Kihei Donekal, Sirisha Venkatesh, Bharath A. Wu, Colin O. Liu, Chia-Ying Nacif, Marcelo Souto Armstrong, Anderson Gomes, Antoinette S. Hundley, W. Gregory McClelland, Robyn L. Bluemke, David A. Lima, Joao A. G. TI Natural History of Myocardial Function in an Adult Human Population Serial Longitudinal Observations From MESA SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE aging; heart failure; hypertension; left ventricular; torsion ID LEFT-VENTRICULAR HYPERTROPHY; HYPERTENSIVE HEART-DISEASE; CARDIAC MAGNETIC-RESONANCE; ASYMPTOMATIC INDIVIDUALS; CARDIOVASCULAR EVENTS; ATHEROSCLEROSIS MESA; PROGNOSTIC VALUE; BLOOD-PRESSURE; MIDDLE-AGE; DYSFUNCTION AB OBJECTIVES The aim of this longitudinal study was to define the determinants of aging-related left ventricular (LV) remodeling and function in a large multiethnic population. BACKGROUND The influence of risk factor exposure on myocardial remodeling and function in humans across adult life remains incompletely understood. MESA (Multi-Ethnic Study of Atherosclerosis) is a Longitudinal population-based cohort of asymptomatic adults at baseline. METHODS We examined 757 participants who were free of clinical cardiovascular disease and underwent tagged cardiac magnetic resonance both at baseline and at the 10-year follow-up as part of the MESA study. LV remodeling, circumferential shortening (CS), and torsion were assessed by tagged cardiac magnetic resonance. Multivariable linear regression was used to determine the association of changes in risk factors with changes in cardiac geometry and function. RESULTS The mean age of participants was 63 9 years at baseline; 50% were women. Overall, the LV mass-to volume ratio increased by 10% over 10 years (p < 0.01). CS was unchanged (17.8% to 17.9%, p = 0.246), whereas torsion increased by 13% (3.8 degrees/cm to 4.3 degrees/cm, p < 0.001). Increased systolic blood pressure was associated with reduced CS (-0.02%/mm Hg, p < 0.01). Participants who remained on antihypertensive therapy during the whole study had a greater decrease in LV mass-to-volume ratio (-0.045 vs. no medication, p < 0.05) with a greater increase in CS (0.78% vs. no medication, p < 0.01). Moreover, greater LV mass at baseline was significantly associated with reduced CS (-0.02%/g, p < 0.01) and torsion (-0.02 degrees/cm/g, p < 0.01) independently of risk factors. CONCLUSIONS Longitudinal observation demonstrates that LV mass and worsening risk factors are fundamental determinants of reduced regional myocardial shortening over 10 years. Increased torsion of the myocardial wall is seen with progressive concentric remodeling and may explain why systolic function is maintained with aging. (C) 2016 by the American College of Cardiology Foundation. C1 [Yoneyama, Kihei; Donekal, Sirisha; Venkatesh, Bharath A.; Nacif, Marcelo Souto; Armstrong, Anderson; Lima, Joao A. G.] Johns Hopkins Univ, Dept Cardiol, Baltimore, MD USA. [Yoneyama, Kihei] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan. [Wu, Colin O.] NHLBI, Off Biostat Res, Bldg 10, Bethesda, MD 20892 USA. [Liu, Chia-Ying; Nacif, Marcelo Souto; Bluemke, David A.] Natl Inst Biomed Imaging & Bioengn, NIH, Ctr Clin, Bethesda, MD USA. [Gomes, Antoinette S.] Univ Calif Los Angeles, Sch Med, Dept Radiol, Los Angeles, CA 90024 USA. [Hundley, W. Gregory] Wake Forest Univ Hlth Sci, Dept Internal Med Cardiol, Winston Salem, NC USA. [McClelland, Robyn L.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Lima, JAG (reprint author), Johns Hopkins Univ, Johns Hopkins Hosp, Div Cardiol, Blalock 524D1,600 North Wolfe St, Baltimore, MD 21287 USA. EM jlima@jhmi.edu OI Bluemke, David/0000-0002-8323-8086 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; National Center for Research Resources [UL1-TR-000040, UL1-TR-001079] FX This research was supported by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 37 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD OCT PY 2016 VL 9 IS 10 BP 1164 EP 1173 DI 10.1016/j.jcmg.2016.01.038 PG 10 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DY6JO UT WOS:000385212400005 PM 27639760 ER PT J AU Lancaster, C Pristatsky, P Hoang, VM Casimiro, DR Schwartz, RM Rustandi, R Ha, S AF Lancaster, Catherine Pristatsky, Pavlo Hoang, Van M. Casimiro, Danilo R. Schwartz, Richard M. Rustandi, Richard Ha, Sha TI Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES LA English DT Article DE Chikungunya; Vaccine; VLP; Glycosylation; HILIC ID PARTICLE VACCINE; NEUTRALIZING ANTIBODIES; VIRAL HEMAGGLUTININ; AEDES-ALBOPICTUS; VIRUS; CULTURE; IMMUNOGENICITY; GLYCOPROTEINS; PATTERNS; MOSQUITO AB Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes severe arthralgia. The envelope of CHIKV is composed of 240 copies of two glycoproteins: El and E2. In this work, we have characterized the N-glycosylation patterns of CHIKV virus-like particles (VLP5), containing both El and E2 proteins, derived from mammalian and insect cells using hydrophilic interaction liquid chromatography (HILIC) with fluorescence (FL) and mass spectrometry (MS) detection. While HEK293 derived CHIKV VLPs contain oligomannose, hybrid and complex glycans, VLPs derived from SfBasic predominantly contain oligomannose glycans. This strong host dependence of N-glycosylation pattern resembles other alphaviruses such as SINV. The VLPs from HEK293 and SfBasic, with significantly different N-glycosylation profiles, are valuable reagents enabling future in-depth correlation studies between immunogenicity and glycosylation. In addition, the characterization tools presented here allow one to monitor glycosylation during vaccine process development and ensure process consistency. (C) 2016 Published by Elsevier B.V. C1 [Lancaster, Catherine; Pristatsky, Pavlo; Hoang, Van M.; Casimiro, Danilo R.; Rustandi, Richard; Ha, Sha] Merck Res Labs, Vaccine Bioproc Res & Dev, West Point, PA 19486 USA. [Schwartz, Richard M.] NIAID, Vaccine Prod Program, Vaccine Res Ctr, NIH, Gaithersburg, MD 20878 USA. RP Ha, S (reprint author), Merck Res Labs, Vaccine Bioproc Res & Dev, West Point, PA 19486 USA. EM sha_ha@merck.com NR 30 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-0232 EI 1873-376X J9 J CHROMATOGR B JI J. Chromatogr. B PD OCT 1 PY 2016 VL 1032 SI SI BP 218 EP 223 DI 10.1016/j.jchromb.2016.04.025 PG 6 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA DY1LV UT WOS:000384857400024 PM 27157808 ER PT J AU Gordon, SN Liyanage, NPM Doster, MN Vaccari, M Vargas-Inchaustegui, DA Pegu, P Schifanella, L Shen, XY Tomaras, GD Rao, M Billings, EA Schwartz, J Prado, I Bobb, K Zhang, WL Montefiori, DC Foulds, KE Ferrari, G Robert-Guroff, M Roederer, M Phan, TB Forthal, DN Stablein, DM Phogat, S Venzon, DJ Fouts, T Franchini, G AF Gordon, Shari N. Liyanage, Namal P. M. Doster, Melvin N. Vaccari, Monica Vargas-Inchaustegui, Diego A. Pegu, Poonam Schifanella, Luca Shen, Xiaoying Tomaras, Georgia D. Rao, Mangala Billings, Erik A. Schwartz, Jennifer Prado, Ilia Bobb, Kathryn Zhang, Wenlei Montefiori, David C. Foulds, Kathryn E. Ferrari, Guido Robert-Guroff, Marjorie Roederer, Mario Phan, Tran B. Forthal, Donald N. Stablein, Donald M. Phogat, Sanjay Venzon, David J. Fouts, Timothy Franchini, Genoveffa TI Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition SO JOURNAL OF IMMUNOLOGY LA English DT Article ID DEPENDENT CELLULAR CYTOTOXICITY; IMMUNODEFICIENCY VIRUS SIV; SIMIAN IMMUNODEFICIENCY; RHESUS MACAQUES; HIV-1 VACCINE; MEDIATED CYTOTOXICITY; SHIV CHALLENGE; GAG/POL/NEF VACCINE; ENVELOPE PROTEIN; EFFICACY TRIAL AB The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acquisition. Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques. We hypothesized that the breadth and functional profile of Abs induced by an ALVAC/envelope protein regimen could be improved by substituting the monomeric gp120 boost, with the full-length single-chain (FLSC) protein. FLSC is a CD4-gp120 fusion immunogen that exposes cryptic gp120 epitopes to the immune system. We compared the immunogenicity and relative efficiency of an ALVAC-SIV vaccine boosted either with bivalent FLSC proteins or with monomeric gp120 in alum. FLSC was superior to monomeric gp120 in directing Abs to the C3 alpha 2 helix, the V5 loop, and the V3 region that contains the putative CCR5 binding site. In addition, FLSC boosting elicited significantly higher binding Abs to V2 and increased both the Ab-dependent cellular cytotoxicity activity and the breadth of neutralizing Abs. However, the FLSC vaccine regimen demonstrated only a trend in vaccine efficacy, whereas the monomeric gp120 regimen significantly decreased the risk of SIVmac251 acquisition. In both vaccine regimens, anti-V2 Abs correlated with a decreased risk of virus acquisition but differed with regard to systemic or mucosal origin. In the FLSC regimen, serum Abs to V2 correlated, whereas in the monomeric gp120 regimen, V2 Abs in rectal secretions, the site of viral challenge, were associated with efficacy. C1 [Gordon, Shari N.; Liyanage, Namal P. M.; Doster, Melvin N.; Vaccari, Monica; Pegu, Poonam; Schifanella, Luca; Franchini, Genoveffa] NCI, Anim Models & Vaccine Sect, NIH, 41 Lib Dr,Bldg 41,Room D804, Bethesda, MD 20892 USA. [Vargas-Inchaustegui, Diego A.; Robert-Guroff, Marjorie] NCI, Immune Biol Retroviral Infect Sect, Vaccine Branch, Bethesda, MD 20892 USA. [Shen, Xiaoying; Tomaras, Georgia D.; Montefiori, David C.; Ferrari, Guido] Duke Univ, Med Ctr, Durham, NC 27710 USA. [Rao, Mangala; Billings, Erik A.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA. [Schwartz, Jennifer; Prado, Ilia; Bobb, Kathryn; Zhang, Wenlei; Fouts, Timothy] Profectus BioSci Inc, Baltimore, MD 21224 USA. [Foulds, Kathryn E.; Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Phan, Tran B.; Forthal, Donald N.] Univ Calif Irvine, Div Infect Dis, Dept Med, Sch Med, Irvine, CA 92868 USA. [Stablein, Donald M.] Emmes Corp, Rockville, MD 20850 USA. [Phogat, Sanjay] Sanofi Pasteur, Swiftwater, PA 18370 USA. [Venzon, David J.] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA. RP Franchini, G (reprint author), NCI, Anim Models & Vaccine Sect, NIH, 41 Lib Dr,Bldg 41,Room D804, Bethesda, MD 20892 USA. EM franchig@mail.nih.gov FU Intramural NIH HHS [Z01 BC005688-17] NR 53 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD OCT 1 PY 2016 VL 197 IS 7 BP 2726 EP 2737 DI 10.4049/jimmunol.1600674 PG 12 WC Immunology SC Immunology GA DY3OX UT WOS:000385004600022 PM 27591322 ER PT J AU Roberts, LM Crane, DD Wehrly, TD Fletcher, JR Jones, BD Bosio, CM AF Roberts, Lydia M. Crane, Deborah D. Wehrly, Tara D. Fletcher, Joshua R. Jones, Bradley D. Bosio, Catharine M. TI Inclusion of Epitopes That Expand High-Avidity CD4(+) T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis SO JOURNAL OF IMMUNOLOGY LA English DT Article ID RESPIRATORY VIRUS-INFECTIONS; TULAREMIA VACCINES; PROTECTIVE IMMUNITY; INTERFERON-GAMMA; C57BL/6 MICE; IFN-GAMMA; LVS; PULMONARY; LIVE; IDENTIFICATION AB T cells are the immunological cornerstone in host defense against infections by intracellular bacterial pathogens, such as virulent Francisella tularensis spp. tularensis (Ftt). The general paucity of novel vaccines for Ftt during the past 60 y can, in part, be attributed to the poor understanding of immune parameters required to survive infection. Thus, we developed a strategy utilizing classical immunological tools to elucidate requirements for effective adaptive immune responses directed against Ftt. Following generation of various Francisella strains expressing well-characterized lymphocytic choriomeningitis virus epitopes, we found that survival correlated with persistence of Ag-specific CD4(+) T cells. Function of these cells was confirmed in their ability to more effectively control Ftt replication in vitro. The importance of understanding the Ag-specific response was underscored by our observation that inclusion of an epitope that elicits high-avidity CD4(+) T cells converted a poorly protective vaccine to one that engenders 100% protection. Taken together, these data suggest that improved efficacy of current tularemia vaccine platforms will require targeting appropriate Ag-specific CD4(+) T cell responses and that elucidation of Francisella epitopes that elicit high-avidity CD4(+) T cell responses, specifically in humans, will be required for successful vaccine development. C1 [Roberts, Lydia M.; Crane, Deborah D.; Wehrly, Tara D.; Bosio, Catharine M.] NIAID, Immun Pulm Pathogens Sect, Bacteriol Lab, Rocky Mt Labs,NIH, 903 S 4th St, Hamilton, MT 59840 USA. [Fletcher, Joshua R.; Jones, Bradley D.] Univ Iowa, Carver Coll Med, Dept Microbiol, Iowa City, IA 52242 USA. RP Bosio, CM (reprint author), NIAID, Immun Pulm Pathogens Sect, Bacteriol Lab, Rocky Mt Labs,NIH, 903 S 4th St, Hamilton, MT 59840 USA. EM bosioc@niaid.nih.gov FU Intramural NIH HHS [Z01 AI001013-02]; NIAID NIH HHS [HHSN272201300006C] NR 38 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD OCT 1 PY 2016 VL 197 IS 7 BP 2738 EP 2747 DI 10.4049/jimmunol.1600879 PG 10 WC Immunology SC Immunology GA DY3OX UT WOS:000385004600023 PM 27543611 ER PT J AU Gazzinelli-Guimaraes, PH Bonne-Annee, S Fujiwara, RT Santiago, HC Nutman, TB AF Gazzinelli-Guimaraes, Pedro H. Bonne-Annee, Sandra Fujiwara, Ricardo T. Santiago, Helton C. Nutman, Thomas B. TI Allergic Sensitization Underlies Hyperreactive Antigen-Specific CD4(+) T Cell Responses in Coincident Filarial Infection SO JOURNAL OF IMMUNOLOGY LA English DT Article ID TROPICAL PULMONARY EOSINOPHILIA; SPIRALIS NEWBORN LARVAE; ASCARIS-LUMBRICOIDES; IGE RESPONSES; LYMPHATIC FILARIASIS; HELMINTH INFECTIONS; SCHISTOSOMA-MANSONI; NECATOR-AMERICANUS; IMMUNOGLOBULIN-E; SCHOOL-CHILDREN AB Among the various hypotheses put forward to explain the modulatory influence of helminth infection on allergic effector responses in humans, the IL-10-induced suppression of Th2-associated responses has been the leading candidate. To explore this helminth/allergy interaction more fully, parasite-and allergen-specific CD4(+) T cell responses in 12 subjects with filarial infections, and coincident allergic sensitization (filarial [Fil](+)allergy [A](+)) were compared with the responses to three appropriate control groups (Fil(-)A(-) [n = 13], Fil(-)A(+) [n = 12], Fil(+)A(-) [n = 11]). The most important findings revealed that Fil(+)A(+) had marked (p < 0.0001 for all cytokines) increases in parasite Ag-driven Th2 (IL-4, IL-5, IL-13), Th9 (IL-9), and the regulatory (IL-10) cytokines when compared with Fil(+)A(-). Moreover, using multiparameter flow cytometry, filarial parasite Ag induced a marked increase in not only the frequency of CD4(+) T cells producing IL-4, IL-5, IL-2, and TNF-alpha in Fil(+)A(+) when compared with Fil(+)A(-) patients, but also in the frequencies of polyfunctional Th2-like (CD4(+)IL-4(+)IL-5(+) and CD4(+)IL-2(+)IL-4(+)IL-5(+)TNF-alpha(+)) cells. The Th2-associated responses seen in the Fil(+)A(+) group were correlated with serum IgE levels (p < 0.01, r = 0.5165 for IL-4; p < 0.001, r = 0.5544 for IL-5; and p < 0.001, r = 0.4901 for IL-13) and levels of circulating eosinophils (p < 0.0116, r = 0.5656) and their degranulation/activation products (major basic protein [p < 0.001, r = 0.7353] and eosinophil-derived neurotoxin [p < 0.01, r = 0.7059]). CD4(+) responses to allergen were not different (to a large extent) among the groups. Taken together, our data suggest that allergic sensitization coincident with filarial infection drives parasite Ag-specific T cell hyperresponsiveness, which is characterized largely by an augmented Th2-dominated immune response. C1 [Gazzinelli-Guimaraes, Pedro H.; Bonne-Annee, Sandra; Nutman, Thomas B.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Gazzinelli-Guimaraes, Pedro H.; Fujiwara, Ricardo T.] Univ Fed Minas Gerais, Inst Biol Sci, Dept Parasitol, BR-31270901 Belo Horizonte, MG, Brazil. [Santiago, Helton C.] Univ Fed Minas Gerais, Inst Biol Sci, Dept Immunol & Biochem, BR-31270901 Belo Horizonte, MG, Brazil. RP Nutman, TB (reprint author), NIAID, Parasit Dis Lab, NIH, 4 Ctr Dr,Bldg 4,Room B1-03, Bethesda, MD 20892 USA. EM tnutman@niaid.nih.gov RI Gazzinelli-Guimaraes, Pedro Henrique/E-7693-2013; Fujiwara, Ricardo/J-7579-2012 OI Gazzinelli-Guimaraes, Pedro Henrique/0000-0003-4932-2206; Fujiwara, Ricardo/0000-0002-4713-575X FU Intramural NIH HHS [Z01 AI000197-28] NR 76 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD OCT 1 PY 2016 VL 197 IS 7 BP 2772 EP 2779 DI 10.4049/jimmunol.1600829 PG 8 WC Immunology SC Immunology GA DY3OX UT WOS:000385004600026 PM 27566825 ER PT J AU Chan, YN Boesch, AW Osei-Owusu, NY Emileh, A Crowley, AR Cocklin, SL Finstad, SL Linde, CH Howell, RA Zentner, I Cocklin, S Miles, AR Eckman, JW Alter, G Schmitz, JE Ackerman, ME AF Chan, Ying N. Boesch, Austin W. Osei-Owusu, Nana Y. Emileh, Ali Crowley, Andrew R. Cocklin, Sarah L. Finstad, Samantha L. Linde, Caitlyn H. Howell, Rebecca A. Zentner, Isaac Cocklin, Simon Miles, Adam R. Eckman, Joshua W. Alter, Galit Schmitz, Joern E. Ackerman, Margaret E. TI IgG Binding Characteristics of Rhesus Macaque Fc gamma R SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HIGH-THROUGHPUT; PROTECTIVE EFFICACY; ANTIBODY; AFFINITY; RECEPTOR; HIV; COMPLEMENT; CHALLENGES; SUBCLASSES; VACCINES AB Indian rhesus macaques (Macaca mulatta) are routinely used in preclinical studies to evaluate therapeutic Abs and candidate vaccines. The efficacy of these interventions in many cases is known to rely heavily on the ability of Abs to interact with a set of Ab Fc gamma R expressed on innate immune cells. Yet, despite their presumed functional importance, M. mulatta Ab receptors are largely uncharacterized, posing a fundamental limit to ensuring accurate interpretation and translation of results from studies in this model. In this article, we describe the binding characteristics of the most prevalent allotypic variants of M. mulatta FcgR for binding to both human and M. mulatta IgG of varying subclasses. The resulting determination of the affinity, specificity, and glycan sensitivity of these receptors promises to be useful in designing and evaluating studies of candidate vaccines and therapeutic Abs in this key animal model and exposes significant evolutionary divergence between humans and macaques. C1 [Chan, Ying N.; Boesch, Austin W.; Emileh, Ali; Ackerman, Margaret E.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Osei-Owusu, Nana Y.; Crowley, Andrew R.; Ackerman, Margaret E.] Dartmouth Coll, Mol & Cellular Biol Program, Hanover, NH 03755 USA. [Cocklin, Sarah L.; Finstad, Samantha L.; Linde, Caitlyn H.; Howell, Rebecca A.; Schmitz, Joern E.] Harvard Med Sch, Ctr Virol & Vaccine Res, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Zentner, Isaac; Cocklin, Simon] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA. [Miles, Adam R.; Eckman, Joshua W.] Wasatch Microfluid, Salt Lake City, UT 84103 USA. [Linde, Caitlyn H.; Alter, Galit] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA. [Finstad, Samantha L.] NIH, Off AIDS Res, Bldg 10, Bethesda, MD 20892 USA. [Schmitz, Joern E.] Fraunhofer Inst Mol Biol & Appl Ecol, Dept Immunotherapy, Aachen, Germany. RP Ackerman, ME (reprint author), Dartmouth Coll, 14 Engn Dr, Hanover, NH 03755 USA. EM margaret.e.ackerman@dartmouth.edu FU NIAID NIH HHS [HHSN272201100023C, P01 AI120756, R01 AI102691, R56 AI097315, UM1 AI100645] NR 30 TC 1 Z9 1 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD OCT 1 PY 2016 VL 197 IS 7 BP 2936 EP 2947 DI 10.4049/jimmunol.1502252 PG 12 WC Immunology SC Immunology GA DY3OX UT WOS:000385004600042 PM 27559046 ER PT J AU Absinta, M Reich, DS Filippi, M AF Absinta, Martina Reich, Daniel S. Filippi, Massimo TI Spring cleaning: time to rethink imaging research lines in MS? SO JOURNAL OF NEUROLOGY LA English DT Review DE Multiple sclerosis; Neuroimaging; Biomarkers ID MULTIPLE-SCLEROSIS LESIONS; OPTICAL COHERENCE TOMOGRAPHY; REGIONAL HIPPOCAMPAL ATROPHY; WHITE-MATTER LESIONS; BLOOD-BRAIN-BARRIER; CORTICAL-LESIONS; IN-VIVO; 7 TESLA; COGNITIVE IMPAIRMENT; SPINAL-CORD AB Together with recently advanced MRI technological capability, new needs and updated questions are emerging in imaging research in multiple sclerosis (MS), especially with respect to the identification of novel in vivo biomarkers of MS-relevant pathological processes. Expected benefits will involve approaches to diagnosis and clinical classification. In detail, three main points of discussion are addressed in this review: (1) new imaging biomarkers (centrifugal/centripetal lesion enhancement, central vein, paramagnetic rims at the lesion edge, subpial cortical demyelination); (2) thinking about high-resolution MR from a pathological perspective (from postmortem to in vivo staging); and (3) the clinical utility of quantitative MRI. In this context, research efforts should increasingly be focused on the direct in vivo visualization of "hidden" inflammation, beyond what can be detected with conventional gadolinium-based methods, as well as remyelination and repair, since these are likely to represent critical pathological processes and potential therapeutic targets. Concluding remarks concern the limitations, challenges, and ultimately clinical role of non-conventional MRI techniques. C1 [Absinta, Martina; Filippi, Massimo] Univ Vita Salute San Raffaele, Inst Expt Neurol, San Raffaele Sci Inst, Hosp San Raffaele,Neuroimaging Res Unit,Div Neuro, Via Olgettina 60, I-20132 Milan, Italy. [Absinta, Martina; Reich, Daniel S.] NINDS, Translat Neuroradiol Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. RP Filippi, M (reprint author), Univ Vita Salute San Raffaele, Inst Expt Neurol, San Raffaele Sci Inst, Hosp San Raffaele,Neuroimaging Res Unit,Div Neuro, Via Olgettina 60, I-20132 Milan, Italy. EM filippi.massimo@hsr.it OI Filippi, Massimo/0000-0002-5485-0479 FU Intramural Research Program of NINDS, NIH FX Special thanks to Prof. Andrea Falini (Head of the Department of Neuroradiology, San Raffaele Hospital), Dr. Vittorio Martinelli (Head of Clinical Trials Unit, Division of Neuroscience, San Raffaele Hospital), and Dr. Pascal Sati and Dr. Govind Nair (staff scientists, NINDS, NIH) for valuable advice, assistance with MRI data acquisition/post-processing, and help in figures' preparation. This work was supported in part by the Intramural Research Program of NINDS, NIH. NR 116 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0340-5354 EI 1432-1459 J9 J NEUROL JI J. Neurol. PD OCT PY 2016 VL 263 IS 10 BP 1893 EP 1902 DI 10.1007/s00415-016-8060-0 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DY5WA UT WOS:000385173900001 PM 26886204 ER PT J AU Buch, S Chivero, ET Hoare, J Jumare, J Nakasujja, N Mudenda, V Paul, R Kanmogne, GD Sacktor, N Wood, C Royal, W Joseph, J AF Buch, Shilpa Chivero, Ernest T. Hoare, Jackie Jumare, Jibreel Nakasujja, Noeline Mudenda, Victor Paul, Robert Kanmogne, Georgette D. Sacktor, Ned Wood, Charles Royal, Walter Joseph, Jeymohan TI Proceedings from the NIMH symposium on "NeuroAIDS in Africa: neurological and neuropsychiatric complications of HIV" SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE Human immunodeficiency virus (HIV); HIV-associated neurocognitive disorders (HAND); NeuroAIDS ID COGNITIVE IMPAIRMENT; TAT; DISORDERS; THERAPY; DISEASE; HAART AB Despite major advances in HIV-1 treatment, the prevalence of HIV-associated neurocognitive disorders (HAND) remains a problem, particularly as individuals on suppressive treatment continue to live longer. To facilitate discussion on emerging and future directions in HAND research, a meeting was held in Durban, South Africa in March 2015 as part of the Society of Neuroscientists of Africa (SONA) conference. The objective of the meeting was to assess the impact of HIV subtype diversity on HAND and immunological dysfunction. The meeting brought together international leaders in the area of neurological complications of HIV-1 infection with special focus on the African population. Research presentations indicated that HAND was highly prevalent and that inflammatory cytokines and immune-activation played important roles in progression of neurocognitive impairment. Furthermore, children on antiretroviral therapy were also at risk for developing neurocognitive impairment. With respect to the effect of HIV-1 subtype diversity, analyses of HIV-1 clade C infection among South Africans revealed that clade C infection induced cognitive impairment that was independent of the substitution in HIV-1 Trans-Activator of Transcription (Tat; C31S). At the cellular level, a Zambian study showed that clade C infection resulted in reduced brain cell death compared with clade B infection suggesting clade specific variations in mediating brain cell injury. Furthermore, ex vivo Tat protein from clade CRF02_AG, prevalent in West/ Central Africa, exhibited reduced disruption of brain endothelium compared with clade B Tat protein. Discussions shed light on future research directions aimed at understanding biomarkers and disease mechanisms critical for HAND. C1 [Buch, Shilpa; Chivero, Ernest T.; Kanmogne, Georgette D.] Univ Nebraska Med Ctr, Omaha, NE 68198 USA. [Hoare, Jackie] Univ Cape Town, Cape Town, South Africa. [Jumare, Jibreel; Royal, Walter] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Nakasujja, Noeline] Makerere Univ, Kampala, Uganda. [Mudenda, Victor] Univ Zambia, Lusaka, Zambia. [Paul, Robert] Univ Missouri, St Louis, MO 63121 USA. [Sacktor, Ned] Johns Hopkins Univ, Baltimore, MD USA. [Wood, Charles] Univ Nebraska, Lincoln, NE USA. [Joseph, Jeymohan] NIMH, Div AIDS Res, NIH, Bethesda, MD 20892 USA. RP Buch, S (reprint author), Univ Nebraska Med Ctr, Omaha, NE 68198 USA.; Joseph, J (reprint author), NIMH, Div AIDS Res, NIH, Bethesda, MD 20892 USA. EM sbuch@unmc.edu; jjeymoha@mail.nih.gov FU National Institutes of Health [MH094160, DA036157] FX The authors acknowledge funding from National Institutes of Health: MH094160 (to GDK); DA036157 (to SB). NR 16 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2016 VL 22 IS 5 BP 699 EP 702 DI 10.1007/s13365-016-0467-y PG 4 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA DY4JM UT WOS:000385064800020 PM 27473196 ER PT J AU Lindenberg, L Ahlman, M Turkbey, B Mena, E Choyke, P AF Lindenberg, Liza Ahlman, Mark Turkbey, Baris Mena, Esther Choyke, Peter TI Evaluation of Prostate Cancer with PET/MRI SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE multiparametric MRI; PET/MRI; prostate cancer ID SEMINAL-VESICLE INVASION; PLANAR BONE-SCINTIGRAPHY; INTEGRATED WHOLE-BODY; FUSION-GUIDED BIOPSY; EXTRACAPSULAR EXTENSION; INITIAL-EXPERIENCE; F-18-DCFBC PET/CT; CHOLINE-PET/CT; METASTASES; MRI AB In the ongoing effort to understand and cure prostate cancer, imaging modalities are constantly evolving to assist in clinical decisions. Multiparametric MRI can be used to direct prostate biopsies, improve diagnostic yield, and help clinicians make more accurate decisions. PET is superior in providing biologic information about the cancer and is sensitive and highly specific. Integrated PET/MRI is a welcome technical advance with great potential to influence the diagnosis and management of prostate cancer in clinical practice. C1 [Lindenberg, Liza; Turkbey, Baris; Choyke, Peter] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bldg 10,Room B3B402 MS 1088,10 Ctr Dr, Bethesda, MD 20892 USA. [Ahlman, Mark] NIH, Dept Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA. [Mena, Esther] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, 600 N Wolfe St, Baltimore, MD 21205 USA. RP Lindenberg, L (reprint author), NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bldg 10,Room B3B402 MS 1088,10 Ctr Dr, Bethesda, MD 20892 USA. EM liza.lindenberg@mail.nih.gov NR 51 TC 2 Z9 2 U1 3 U2 3 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD OCT PY 2016 VL 57 SU 3 BP 111S EP 116S DI 10.2967/jnumed.115.169763 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DY3AB UT WOS:000384962100019 PM 27694163 ER PT J AU Kiess, AP Minn, I Vaidyanathan, G Hobbs, RF Josefsson, A Shen, C Brummet, M Chen, Y Choi, J Koumarianou, E Baidoo, K Brechbiel, MW Mease, RC Sgouros, G Zalutsky, MR Pomper, MG AF Kiess, Ana P. Minn, Il Vaidyanathan, Ganesan Hobbs, Robert F. Josefsson, Anders Shen, Colette Brummet, Mary Chen, Ying Choi, Jaeyeon Koumarianou, Eftychia Baidoo, Kwamena Brechbiel, Martin W. Mease, Ronnie C. Sgouros, George Zalutsky, Michael R. Pomper, Martin G. TI (2S)-2-(3-(1-Carboxy-5-(4-At-211-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted alpha-Particle Radiopharmaceutical Therapy SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE oncology: GU; radionuclide therapy; radiopharmaceuticals; alpha emitter; astatine; prostate cancer; prostate-specific membrane antigen; radiation dosimetry ID METASTATIC PROSTATE-CANCER; MALIGNANT HUMAN TISSUES; MEMBRANE ANTIGEN PSMA; SURVIVAL; RADIOIMMUNOTHERAPY; EXPRESSION; INHIBITORS; F-18-DCFBC; DOSIMETRY; SERIES AB Alpha-particle emitters have a high linear energy transfer and short range, offering the potential for treating micrometastases while sparing normal tissues. We developed a urea-based, At-211-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of micrometastases due to prostate cancer (PC). Methods: PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-At-211-astatobenzami do) pentyl)ureido)-pentanedioic acid (At-211-6) was synthesized. Cellular uptake and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after At-211-6 treatment. The antitumor efficacy of At-211-6 was evaluated in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice bearing PSMA+, luciferase-expressing PC3-ML micrometastases. Biodistribution was determined in mice bearing PSMA+ PC3 PIP and PSMA(-) PC3 flu flank xenografts. Suborgan distribution was evaluated using alpha-camera images, and microscale dosimetry was modeled. Longterm toxicity was assessed in mice for 12 mo. Results: At-211-6 treatment resulted in PSMA-specific cellular uptake and decreased clonogenic survival in PSMA+ PC3 PIP cells and caused significant tumor growth delay in PSMA+ PC3 PIP flank tumors. Significantly improved survival was achieved in the newly developed PSMA+ micrometastatic PC model. Biodistribution showed uptake of At-211-6 in PSMA+ PC3 PIP tumors and in kidneys. Microscale kidney dosimetry based on alpha-camera images and a nephron model revealed hot spots in the proximal renal tubules. Long-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy. Conclusion: PSMA-targeted At-211-6 alpha-particle radiotherapy yielded significantly improved survival in mice bearing PC micrometastases after systemic administration. At-211-6 also showed uptake in renal proximal tubules resulting in late nephrotoxicity, highlighting the importance of long-term toxicity studies and microscale dosimetry. C1 [Kiess, Ana P.; Hobbs, Robert F.; Shen, Colette; Sgouros, George; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA. [Minn, Il; Josefsson, Anders; Brummet, Mary; Chen, Ying; Mease, Ronnie C.; Sgouros, George; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA. [Vaidyanathan, Ganesan; Choi, Jaeyeon; Koumarianou, Eftychia; Zalutsky, Michael R.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA. [Baidoo, Kwamena; Brechbiel, Martin W.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA. RP Pomper, MG (reprint author), Johns Hopkins Med Sch, 1550 Orleans St,492 CRB 2, Baltimore, MD 21287 USA. EM mpomper@jhmi.edu FU NIH [CA116477, CA184228, CA134675, CA183031, CA157542, EB005324]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported by NIH CA116477, CA184228, CA134675, CA183031, CA157542, and EB005324 and in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. No other potential conflict of interest relevant to this article was reported. NR 32 TC 2 Z9 2 U1 15 U2 15 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD OCT PY 2016 VL 57 IS 10 BP 1569 EP 1575 DI 10.2967/jnumed.116.174300 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DY2ZZ UT WOS:000384961900022 PM 27230930 ER PT J AU Von Korff, M Scher, AI Helmick, C Carter-Pokras, O Dodick, DW Goulet, J Hamill-Ruth, R LeResche, L Porter, L Tait, R Terman, G Veasley, C Mackey, S AF Von Korff, Michael Scher, Ann I. Helmick, Charles Carter-Pokras, Olivia Dodick, David W. Goulet, Joseph Hamill-Ruth, Robin LeResche, Linda Porter, Linda Tait, Raymond Terman, Gregory Veasley, Christin Mackey, Sean TI United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data SO JOURNAL OF PAIN LA English DT Article DE Chronic pain; epidemiology; health services research; prevalence; electronic databases ID CROSS-SECTIONAL SURVEY; CHRONIC BACK-PAIN; SEVERITY; MODERATE; PATIENT; MILD; COMORBIDITY; PREVALENCE; DISABILITY; ARTHRITIS AB National Pain Strategy population research objectives include: estimating chronic pain prevalence, studying pain treatment with electronic health care data, and developing metrics to assess progress in reducing chronic pain impact. In this article, the National Pain Strategy Population Research Workgroup reviews concepts relevant to achieving these aims. High-impact chronic pain was defined as persistent pain with substantial restriction of life activities lasting 6 months or more. In pilot work, we tested a brief assessment of high-impact chronic pain, and used electronic health records data to describe pain-related health care. A mail survey of adult health plan enrollees (N = 770) reported that 14% had high-impact chronic pain. Relative to persons with lower-impact chronic pain, those with high-impact chronic pain were more often frequent users of health care for pain, reported lower quality of life, greater pain-related interference with activities, and more often reported pain at multiple anatomic locations. Analyses of health care data (N = 289,464) reported that pain patients had higher health care costs compared with others and that pain services were typically delivered in primary care. These results support the feasibility of developing data on chronic pain through national health interview surveys and large electronic health care databases. Perspective: Pilot analyses supported the feasibility of brief chronic pain assessments suitable for national health surveys and use of electronic health care databases to develop data regarding trends in the delivery of pain treatments, costs, and effectiveness. These methods are relevant to achieving the aims of the US National Pain Strategy. (C) 2016 by the American Pain Society C1 [Von Korff, Michael] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. [Scher, Ann I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA. [Helmick, Charles] Ctr Dis Control & Prevent, Atlanta, GA USA. [Carter-Pokras, Olivia] Univ Maryland, Sch Publ Hlth, College Pk, MD 20742 USA. [Dodick, David W.] Mayo Clin, Coll Med, Phoenix, AZ USA. [Goulet, Joseph] Yale Univ, Sch Med, New Haven, CT USA. [Hamill-Ruth, Robin] Univ Virginia Hlth Syst, Charlottesville, VA USA. [LeResche, Linda] Univ Washington, Sch Dent, Seattle, WA 98195 USA. [Porter, Linda] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Tait, Raymond] St Louis Univ, Sch Med, Dept Psychiat, St Louis, MO 63103 USA. [Terman, Gregory] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Veasley, Christin] Chron Pain Res Alliance, Milwaukee, WI USA. [Mackey, Sean] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. RP Von Korff, M (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM vonkorff.m@ghc.org OI Goulet, Joseph/0000-0002-0842-804X FU NINDS; IH Inter-Agency Pain Research Coordinating Committee [AG034181]; Pfizer Inc.; Healthlogix; Haymarket Media Group, Ltd.; SAGE Publishing; Synergy; Allergan; Lippincott Williams Wilkins; Oxford University Press; Cambridge University Press FX The pilot data collection reported in this paper was supported by a supplemental award from NINDS and the NIH Inter-Agency Pain Research Coordinating Committee to a National Institute on Aging grant (AG034181, Von Korff, Principal Investigator).; Dr. Von Korff is the Principal Investigator of grants to GHRI from Pfizer Inc. that concern opioids. Dr. Scher is an advisory board member and consultant for Allergan. Dr. Tait's spouse serves on the speaker's bureau for Lilly Pharmaceuticals. David W. Dodick, MD, in the past 12 months, has served on advisory boards and has consulted for Allergan, Amgen, Alder, CoLucid, Merck, ENeura, Eli Lilly & Company, Autonomic Technologies, Teva, Tonix, Novartis, Supernus, ScionNeurostim, Boston Scientific. Within the past 12 months, Dr. Dodick has received royalties, funding for travel, speaking, or editorial activities from the following: Healthlogix, Haymarket Media Group, Ltd., SAGE Publishing, Synergy, Allergan, Lippincott Williams & Wilkins, Oxford University Press, and Cambridge University Press; he serves as Editor-in-Chief of Cephalalgia and on the editorial boards of The Neurologist, Lancet Neurology, and Postgraduate Medicine. The remaining authors report no conflicts. NR 41 TC 1 Z9 1 U1 4 U2 4 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD OCT PY 2016 VL 17 IS 10 BP 1068 EP 1080 DI 10.1016/j.jpain.2016.06.009 PG 13 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY1SF UT WOS:000384874000003 PM 27377620 ER PT J AU Ruiz-Rodado, V Nicoli, ER Probert, F Smith, DA Morris, L Wassif, CA Platt, FM Grootveld, M AF Ruiz-Rodado, Victor Nicoli, Elena-Raluca Probert, Fay Smith, David A. Morris, Lauren Wassif, Christopher A. Platt, Frances M. Grootveld, Martin TI H-1 NMR-Linked Metabolomics Analysis of Liver from a Mouse Model of NP-C1 Disease SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE NP-Cl disease; liver damage/dysfunction; fibrosis-cirrhosis; NMR-based metabolomics; biomarkers; amino acid biosynthesis and metabolism; nicotinate and niacinamide metabolism; 3-hydroxyphenylacetate; metabolic pathway analysis ID NIEMANN-PICK-DISEASE; CHAIN AMINO-ACIDS; C DISEASE; GLUTATHIONE METABOLISM; METABONOMIC APPROACH; URINARY-EXCRETION; STORAGE DISORDER; PHENOLIC-ACIDS; RANDOM FORESTS; MURINE MODEL AB Clinical manifestations of Niemann-Pick type Cl (NP-C1) disease include neonatal hepatosplenomegaly and in some patients progressive liver dysfunction and failure. This study involved a H-1 NMR-linked metabolomics analysis of liver samples collected from a NP-C1 disease mutant mouse model in order to explore time-dependent imbalances in metabolic pathways associated with NP-C1 liver dysfunction, including fibrosis. NP-Cl mutant (Npc1(-/-); NP-C1), control (Npcl(+/+); WT), and NP-C1 heterozygous mice (Npc1(+/-); HET) were generated from heterozygote matings. Aqueous extracts of these liver samples collected at time points of 3, 6, 9, and 11 weeks were subjected to high-resolution NMR analysis, and multivariate (MV) metabolomics analyses of data sets acquired were performed. A MV random forests (RFs) model effectively discriminated between NP-C1 and a combined WT/HET hepatic NMR profiles with very high predictive accuracy and reliability. Key distinguishing features included significant upregulations in the hepatic concentrations of phenylalanine, tyrosine, glutamate, lysine/ornithine, valine, threonine, and hypotaurine/methionine, and diminished levels of nicotinate/niacinamide, inosine, phosphoenolpyruvate, and 3-hydroxyphenylacetate. Quantitative pathway topological analysis confirmed that imbalances in tyrosine biosynthesis, and hepatic phenylalanine, tyrosine, glutamate/glutamine, and nicotinate/niacinamide metabolism were involved in the pathogenesis of NP-C1 disease-associated liver dysfunction/damage. H-1 NMR-linked metabolomics analysis provides valuable biomarker information regarding hepatic dysfunction or damage in NP-C1 disease. C1 [Ruiz-Rodado, Victor; Probert, Fay; Grootveld, Martin] De Montfort Univ, Leicester Sch Pharm, Leicester LE1 9BH, Leics, England. [Nicoli, Elena-Raluca; Smith, David A.; Morris, Lauren; Wassif, Christopher A.; Platt, Frances M.] Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England. [Wassif, Christopher A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA. RP Grootveld, M (reprint author), De Montfort Univ, Leicester Sch Pharm, Leicester LE1 9BH, Leics, England. EM mgrootveld@dmu.ac.uk FU SPARKS Medical Charity for Children's Health; Action Medical research; Niemann-Pick Research Foundation FX We are very grateful to the SPARKS Medical Charity for Children's Health for providing funding for a Research Fellowship to F.P. and the Hope Against Cancer Charity and De Montfort University, Leicester, for the provision of doctoral training bursaries to V.R-R. E.-R.N. is supported by Action Medical research, and D.S. is supported by the Niemann-Pick Research Foundation. F.M.P. is a Royal Society Wolfson Research Merit Award holder. NR 90 TC 0 Z9 0 U1 3 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 EI 1535-3907 J9 J PROTEOME RES JI J. Proteome Res. PD OCT PY 2016 VL 15 IS 10 BP 3511 EP 3527 DI 10.1021/acs.jproteome.6b00238 PG 17 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA DY4FJ UT WOS:000385054100007 PM 27503774 ER PT J AU Park, S Thompson, FE McGuire, LC Pan, LP Galuska, DA Blanck, HM AF Park, Sohyun Thompson, Frances E. McGuire, Lisa C. Pan, Liping Galuska, Deborah A. Blanck, Heidi M. TI Sociodemographic and Behavioral Factors Associated with Added Sugars Intake among US Adults SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Added sugars; Sugar-sweetened beverages; Sweet food; Sociodemographic characteristics; Behaviors ID SWEETENED BEVERAGE INTAKE; FAMILY-HISTORY; CIGARETTE-SMOKING; TASTE INTENSITY; YOUNG-ADULTS; HEALTH; ALCOHOLISM; STATES; CONSUMPTION; ADDICTION AB Background Reducing added sugars intake is one, of the Healthy People 2020 objectives. High added sugars intake may be associated with adverse health consequences. Objective This cross-sectional study identified sociodemographic and behavioral characteristics associated With added sugars intake among US adults (18 years and older) using the 2010 National Health Interview Survey data (n=24,967). Methods The outcome variable was added sugars intake from foods and beverages using scoring algorithms to convert dietary screener frequency responses on nine items to estimates of individual dietary intake of added sugars in teaspoons per day. Added sugars intake was categorized into tertiles (lowest, middle, highest) stratified by sex. The explanatory variables were sociodemographic and behavioral characteristics. Multinomial logistic regression was used to estimate the adjusted odds ratios for the highest and middle tertile added sugars intake groups as compared with the lowest tertile group. Results Estimated median added sugars intake was 17.6 tsp/d for men and 11.7 tsp/d for women. For men and women, those who had significantly greater odds for being in the highest tertile of added sugars intake (men: >= 22.0 tsp/d; women: >= 14.6 tsp/d) were younger, less educated, had lower income, were less physically active, were current smokers, and were former or current infrequent/light drinkers, whereas non-Hispanic other/multiracial and those living in the West had significantly lower odds for being in the highest tertile of added sugars intake. Different patterns were found by sex. Non-Hispanic black men had lower odds for being in the highest tertile of added sugars intake, whereas non-Hispanic black women had greater odds for being in the highest tertile. Conclusions One in three men consumed >= 22.0 tsp added sugars and one in three women consumed >= 14.6 tsp added sugars daily. Higher added sugars intake was associated with various sociodemographic and behavioral characteristics; this information can inform efforts to design programs and policies specific to high-intake populations. C1 [Park, Sohyun; Pan, Liping; Galuska, Deborah A.; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F77, Atlanta, GA 30341 USA. [McGuire, Lisa C.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Thompson, Frances E.] NCI, Risk Factor Assessment Branch, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci,NIH, Bethesda, MD 20892 USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F77, Atlanta, GA 30341 USA. EM spark3@cdc.gov FU Intramural CDC HHS [CC999999] NR 36 TC 0 Z9 0 U1 8 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 EI 2212-2680 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD OCT PY 2016 VL 116 IS 10 BP 1589 EP 1598 DI 10.1016/j.jand.2016.04.012 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DY4GI UT WOS:000385056600008 PM 27236642 ER PT J AU Lu, GY Ren, L Kolagunda, A Wang, XL Turkbey, IB Choyke, PL Kambhamettu, C AF Lu, Guoyu Ren, Li Kolagunda, Abhishek Wang, Xiaolong Turkbey, Ismail B. Choyke, Peter L. Kambhamettu, Chandra TI Representing 3D shapes based on implicit surface functions learned from RBF neural networks SO JOURNAL OF VISUAL COMMUNICATION AND IMAGE REPRESENTATION LA English DT Article DE 3D shape presentation; Radial basis function; Neural network; 3D reconstruction ID RECONSTRUCTION; KERNELS AB We propose to represent the shape of 3D objects using a neural network classifier. The 3D shape is learned from a neural network, where Radial Basis Function (RBF) is applied as the activation function for each perceptron. The implicit functions derived from the neural network is a combination of radial basis functions, which can represent complex shapes. The use of RBF provides a rotation, translation and scaling invariant feature to represent the shape. We conduct experiments on a new prostate dataset and public datasets. Our testing results show that our neural network -based method can accurately represent various shapes. (C) 2016 Elsevier Inc. All rights reserved. C1 [Lu, Guoyu; Ren, Li; Kolagunda, Abhishek; Wang, Xiaolong; Kambhamettu, Chandra] Univ Delaware, Dept Comp & Informat Sci, Newark, DE 19716 USA. [Turkbey, Ismail B.; Choyke, Peter L.] NCI, NIH, Bethesda, MD 20892 USA. RP Lu, GY (reprint author), Univ Delaware, Dept Comp & Informat Sci, Newark, DE 19716 USA. EM luguoyu@udel.edu NR 35 TC 0 Z9 0 U1 5 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1047-3203 EI 1095-9076 J9 J VIS COMMUN IMAGE R JI J. Vis. Commun. Image Represent. PD OCT PY 2016 VL 40 BP 852 EP 860 DI 10.1016/j.jvcir.2016.08.014 PN B PG 9 WC Computer Science, Information Systems; Computer Science, Software Engineering SC Computer Science GA DX5CY UT WOS:000384398600039 ER PT J AU Brown, P AF Brown, Patricia TI A Word from OLAW SO LAB ANIMAL LA English DT Editorial Material C1 [Brown, Patricia] NIH, OLAW, OER, OD,HHS, Bethesda, MD 20892 USA. RP Brown, P (reprint author), NIH, OLAW, OER, OD,HHS, Bethesda, MD 20892 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0093-7355 EI 1548-4475 J9 LAB ANIMAL JI Lab Anim. PD OCT PY 2016 VL 45 IS 10 BP 356 EP 356 PG 1 WC Veterinary Sciences SC Veterinary Sciences GA DY4FU UT WOS:000385055200016 PM 27654683 ER PT J AU Blankenship-Paris, TL Dutton, JW Goulding, DR Mcgee, CA Kissling, GE Myers, PH AF Blankenship-Paris, Terry L. Dutton, John W. Goulding, David R. McGee, Christopher A. Kissling, Grace E. Myers, Page H. TI Evaluation of buprenorphine hydrochloride Pluronica (R) gel formulation in male C57BL/6NCrl mice SO LAB ANIMAL LA English DT Article ID SUSTAINED-RELEASE BUPRENORPHINE; RATS RATTUS-NORVEGICUS; ORALLY-ADMINISTERED BUPRENORPHINE; CORTICOSTERONE LEVELS; POSTOPERATIVE ANALGESICS; VOLUNTARY INGESTION; INCISIONAL PAIN; DRUG-RELEASE; BODY-WEIGHT; 2 STRAINS AB Providing adequate analgesia while minimizing handling and stress post-surgery can be challenging. Recently, there have been commercial products made available for providing long acting analgesia in rodents. However, we find there are limitations for use in mice due to the viscosity of the product and the small dosing volumes needed. This project evaluated an in-house compounded formulation of buprenorphine easily made in the laboratory using pharmaceutical. grade products. The release of buprenorphine was evaluated when compounded with two types of hydrogels (Pluronic (R) F-127 and F-68). Mice given buprenorphine in hydrogel (BP) demonstrated higher serum levels of buprenorphine for a longer period of time compared to mice given standard buprenorphine (Bup). However, the rate of decline in serum levels between the groups was similar; thus, it is more likely that the higher buprenorphine concentration seen in the BP group is due to the higher dose of buprenorphine given, rather than a slower release of product. Feed consumption was decreased in both groups one day after dosing; however, there was no difference in body weights. Increased activity in the open field was observed with both buprenorphine formulations, and lipemia was observed in mice given BP which persisted to at least 96 h. Based on our results, we conclude that this formulation did not sustain the release of buprenorphine or eliminate the increased activity commonly seen in mice given buprenorphine. In addition, the lipemia may confound research parameters, especially in cardiac studies and lipid metabolism studies. Therefore, we cannot recommend this formulation for use. C1 [Blankenship-Paris, Terry L.; Goulding, David R.; McGee, Christopher A.; Myers, Page H.] NIEHS, Vet Med Sect, Comparat Med Branch, NIH,DHHS, POB 12233, Res Triangle Pk, NC 27709 USA. [Dutton, John W.] Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, San Antonio, TX USA. [Kissling, Grace E.] NIEHS, Biostat & Computat Biol Branch, NIH, DHHS, Res Triangle Pk, NC USA. RP Blankenship-Paris, TL (reprint author), NIEHS, Vet Med Sect, Comparat Med Branch, NIH,DHHS, POB 12233, Res Triangle Pk, NC 27709 USA. EM blanken1@niehs.nih.gov FU Intramural Research Program of the National Institutes of Health; National Institute of Environmental Health Sciences FX This research was supported by the Intramural Research Program of the National Institutes of Health and the National Institute of Environmental Health Sciences. This article may be the work product of an employee or group of employees of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), however, the statements, opinions or conclusions contained herein do not necessarily represent the statements, opinions or conclusions of NIEHS, NIH or the United States government. NR 66 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0093-7355 EI 1548-4475 J9 LAB ANIMAL JI Lab Anim. PD OCT PY 2016 VL 45 IS 10 BP 370 EP 379 PG 10 WC Veterinary Sciences SC Veterinary Sciences GA DY4FU UT WOS:000385055200021 PM 27654688 ER PT J AU Johnson, C Pinal-Fernandez, I Parikh, R Paik, J Albayda, J Mammen, AL Christopher-Stine, L Danoff, S AF Johnson, Cheilonda Pinal-Fernandez, Iago Parikh, Radhika Paik, Julie Albayda, Jemima Mammen, Andrew L. Christopher-Stine, Lisa Danoff, Sonye TI Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease SO LUNG LA English DT Article DE Survival; Interstitial lung disease; Idiopathic inflammatory myopathy; Dermatomyositis; Polymyositis; Clinically amyopathic dermatomyositis ID IDIOPATHIC INFLAMMATORY MYOPATHIES; AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; SURVIVAL; TERM AB Among patients with autoimmune myositis, associated interstitial lung disease (MA-ILD) is a known contributor of excess morbidity and mortality. Recent data on survival in idiopathic inflammatory myopathies originate primarily in Asia and Europe and vary widely. We sought to examine mortality in a large U.S. myositis cohort focusing in particular on the impact of associated ILD. A cross-sectional analysis of participants from the Johns Hopkins Myositis Center with autoimmune myositis (polymyositis [PM], dermatomyositis [DM], or clinically amyopathic dermatomyositis [CADM]) was conducted. The primary outcome assessed was all-cause mortality. Cumulative mortality rates were estimated using the Kaplan-Meier test; the Cox proportional hazards model was used to compare group differences in survival. Eight hundred and thirty-one participants were included with a median follow-up time of 4.5 years. Four hundred thirty-eight (53 %) had PM, 362 (43 %) had DM, and 31 (4 %) had CADM. Ninety-four (11 %) participants had clinically evident ILD. Overall, 51 participants died (6 %). In those without ILD, the survival rates at 1, 5, and 10 years were 99, 95, and 90 %, respectively. In those with ILD, the survival rates at 1, 5, and 10 years were 97, 91, and 81 %, respectively. The risk of death was statistically significantly higher among participants with ILD compared to those without ILD (HR 2.13. 95 % CI 1.06-4.25; p = 0.03). We analyzed one of the largest known cohorts of patients with autoimmune myositis and found significantly higher mortality rates among those with clinically evident ILD compared to those without clinically evident ILD. Our results suggest that ILD remains an important and significant source of mortality in patients with inflammatory myopathies and as such should be screened for and treated aggressively. C1 [Johnson, Cheilonda; Danoff, Sonye] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 E Monument St Suite 500, Baltimore, MD 21224 USA. [Pinal-Fernandez, Iago; Mammen, Andrew L.] NIAMSD, Muscle Dis Unit, Lab Muscle Stem Cells & Gene Express, NIH, Bethesda, MD 20892 USA. [Parikh, Radhika] Univ Vermont, Div Pulm & Crit Care Med, Med Ctr, Burlington, VT 05401 USA. [Paik, Julie; Albayda, Jemima; Christopher-Stine, Lisa] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD 21224 USA. [Mammen, Andrew L.] Johns Hopkins Univ, Dept Neurol, Sch Med, Baltimore, MD 21224 USA. RP Danoff, S (reprint author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 E Monument St Suite 500, Baltimore, MD 21224 USA. EM sdanoff@jhmi.edu FU Huayi and Siuling Zhang Discovery Fund FX This study was financially supported by The Huayi and Siuling Zhang Discovery Fund. NR 25 TC 2 Z9 2 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0341-2040 EI 1432-1750 J9 LUNG JI Lung PD OCT PY 2016 VL 194 IS 5 BP 733 EP 737 DI 10.1007/s00408-016-9896-x PG 5 WC Respiratory System SC Respiratory System GA DY5OG UT WOS:000385148500004 PM 27166633 ER PT J AU Fulton, JE Carlson, SA Ainsworth, BE Berrigan, D Carlson, C Dorn, JM Heath, GW Kohl, HW Lee, IM Lee, SM Masse, LC Morrow, JR Gabriel, KP Pivarnik, JM Pronk, NP Rodgers, AB Saelens, BE Sallis, JF Troiano, RP Tudor-Locke, C Wendel, A AF Fulton, Janet E. Carlson, Susan A. Ainsworth, Barbara E. Berrigan, David Carlson, Cynthia Dorn, Joan M. Heath, Gregory W. Kohl, Harold W., III Lee, I-Min Lee, Sarah M. Masse, Louise C. Morrow, James R., Jr. Gabriel, Kelley Pettee Pivarnik, James M. Pronk, Nicolaas P. Rodgers, Anne B. Saelens, Brian E. Sallis, James F. Troiano, Richard P. Tudor-Locke, Catrine Wendel, Arthur TI Strategic Priorities for Physical Activity Surveillance in the United States SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE POPULATION HEALTH; MONITORING; EPIDEMIOLOGY; RECOMMENDATIONS; EXERCISE ID GOOGLE STREET VIEW; NEIGHBORHOOD ENVIRONMENTS; SELF-REPORT; SEDENTARY BEHAVIOR; ADULTS; ACCELEROMETER; PREVALENCE; FITNESS; TRENDS; AUDIT AB Purpose Develop strategic priorities to guide future physical activity surveillance in the United States. Methods The Centers for Disease Control and Prevention and the American College of Sports Medicine convened a scientific roundtable of physical activity and measurement experts. Participants summarized the current state of aerobic physical activity surveillance for adults, focusing on practice and research needs in three areas: 1) behavior, 2) human movement, and 3) community supports. Needs and challenges for each area were identified. At the conclusion of the meeting, experts identified one overarching strategy and five strategic priorities to guide future surveillance. Results The identified overarching strategy was to develop a national plan for physical activity surveillance similar to the U.S. National Physical Activity Plan for promotion. The purpose of the plan would be to enhance coordination and collaboration within and between sectors, such as transportation and public health, and to address specific strategic priorities identified at the roundtable. These strategic priorities were used 1) to identify and prioritize physical activity constructs; 2) to assess the psychometric properties of instruments for physical activity surveillance; 3) to provide training and technical assistance for those collecting, analyzing, or interpreting surveillance data; 4) to explore accessing data from alternative sources; and 5) to improve communication, translation, and dissemination about estimates of physical activity from surveillance systems. Conclusion This roundtable provided strategic priorities for physical activity surveillance in the United States. A first step is to develop a national plan for physical activity surveillance that would provide an operating framework from which to execute these priorities. C1 [Fulton, Janet E.; Carlson, Susan A.; Dorn, Joan M.; Lee, Sarah M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ainsworth, Barbara E.] Arizona State Univ, Phoenix, AZ USA. [Berrigan, David; Troiano, Richard P.] NCI, Bethesda, MD 20892 USA. [Carlson, Cynthia] Merrimack Coll, N Andover, MA 01845 USA. [Carlson, Cynthia] MA England Coll, Henniker, NH USA. [Heath, Gregory W.] Univ Tennessee, Chattanooga, TN USA. [Kohl, Harold W., III; Gabriel, Kelley Pettee] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Austin Reg Campus, Austin, TX USA. [Kohl, Harold W., III] Univ Texas Austin, Austin, TX 78712 USA. [Lee, I-Min; Pronk, Nicolaas P.] Harvard Univ, Boston, MA 02115 USA. [Masse, Louise C.] Univ British Columbia, Vancouver, BC, Canada. [Masse, Louise C.] British Columbia Childrens Hosp, Child & Family Res Inst, Vancouver, BC, Canada. [Morrow, James R., Jr.] Univ North Texas, Denton, TX USA. [Pivarnik, James M.] Michigan State Univ, E Lansing, MI 48824 USA. [Pronk, Nicolaas P.] HealthPartners, Minneapolis, MN USA. [Rodgers, Anne B.] Ctr Dis Control & Prevent, Falls Church, VA USA. [Saelens, Brian E.] Univ Washington, Seattle, WA 98195 USA. [Saelens, Brian E.] Seattle Childrens Res Inst, Seattle, WA USA. [Sallis, James F.] Univ Calif Calif, La Jolla, CA USA. [Tudor-Locke, Catrine] Univ Massachusetts, Amherst, MA 01003 USA. [Wendel, Arthur] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Fulton, JE (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Highway NE,MS F-77, Atlanta, GA 30341 USA. EM jkf2@cdc.gov FU Child and Family Research Institute at the British Columbia Children's Hospital FX LCM received salary support from the Child and Family Research Institute at the British Columbia Children's Hospital. NR 68 TC 1 Z9 1 U1 7 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD OCT PY 2016 VL 48 IS 10 BP 2057 EP 2069 DI 10.1249/MSS.0000000000000989 PG 13 WC Sport Sciences SC Sport Sciences GA DX3TZ UT WOS:000384298800024 PM 27187094 ER PT J AU Esmail, H Lai, RP Lesosky, M Wilkinson, KA Graham, CM Coussens, AK Oni, T Warwick, JM Said-Hartley, Q Koegelenberg, CF Walzl, G Flynn, JL Young, DB Barry, CE O'Garra, A Wilkinson, RJ AF Esmail, Hanif Lai, Rachel P. Lesosky, Maia Wilkinson, Katalin A. Graham, Christine M. Coussens, Anna K. Oni, Tolu Warwick, James M. Said-Hartley, Qonita Koegelenberg, Coenraad F. Walzl, Gerhard Flynn, JoAnne L. Young, Douglas B. Barry, Clifton E., III O'Garra, Anne Wilkinson, Robert J. TI Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[F-18] fluoro-D-glucose positron emission and computed tomography SO NATURE MEDICINE LA English DT Article ID PULMONARY TUBERCULOSIS; ACTIVE TUBERCULOSIS; FUTURE-PROSPECTS; INFECTION; PREVALENCE; STRATEGIES; DISEASE; ADULTS; LUNG AB Tuberculosis is classically divided into states of latent infection and active disease. Using combined positron emission and computed tomography in 35 asymptomatic, antiretroviral-therapy-naive, HIV-1-infected adults with latent tuberculosis, we identified ten individuals with pulmonary abnormalities suggestive of subclinical, active disease who were substantially more likely to progress to clinical disease. Our findings challenge the conventional two-state paradigm and may aid future identification of biomarkers that are predictive of progression. C1 [Esmail, Hanif; Young, Douglas B.; Wilkinson, Robert J.] Imperial Coll London, Dept Med, London, England. [Esmail, Hanif; Lesosky, Maia; Wilkinson, Katalin A.; Coussens, Anna K.; Oni, Tolu; Barry, Clifton E., III; Wilkinson, Robert J.] Univ Cape Town, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, Cape Town, South Africa. [Esmail, Hanif] Univ Oxford, Radcliffe Dept Med, Oxford, England. [Lai, Rachel P.; Wilkinson, Katalin A.; Graham, Christine M.; Young, Douglas B.; O'Garra, Anne; Wilkinson, Robert J.] Francis Crick Inst Mill Hill Lab, London, England. [Lesosky, Maia] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Cape Town, South Africa. [Warwick, James M.] Univ Stellenbosch, Dept Med Imaging & Clin Oncol, Cape Town, South Africa. [Said-Hartley, Qonita] Groote Schuur Hosp, Dept Radiol, Cape Town, South Africa. [Koegelenberg, Coenraad F.; Walzl, Gerhard] Univ Stellenbosch, Dept Med, Cape Town, South Africa. [Walzl, Gerhard; Barry, Clifton E., III] Univ Stellenbosch, Dept Biomed Sci, Fac Med & Hlth Sci, Cape Town, South Africa. [Flynn, JoAnne L.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA. [Barry, Clifton E., III] NIAID, TB Res Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Barry, Clifton E., III] Univ Cape Town, Dept Pathol, Cape Town, South Africa. [O'Garra, Anne] Imperial Coll London, Natl Heart & Lung Inst, London, England. RP Esmail, H; Wilkinson, RJ (reprint author), Imperial Coll London, Dept Med, London, England.; Esmail, H; Wilkinson, RJ (reprint author), Univ Cape Town, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, Cape Town, South Africa.; Esmail, H (reprint author), Univ Oxford, Radcliffe Dept Med, Oxford, England.; Wilkinson, RJ (reprint author), Francis Crick Inst Mill Hill Lab, London, England. EM hanif.esmail@ndcls.ox.ac.uk; r.j.wilkinson@imperial.ac.uk OI Esmail, Hanif/0000-0002-4278-9316; Lesosky, Maia/0000-0002-2026-958X; Coussens, Anna/0000-0002-7086-2621 FU Wellcome Trust [090170, 104803]; Bill and Melinda Gates Foundation-Wellcome Trust Grand challenges in Global Health [37822]; US National Institutes of Health (NIH) [R01 HL106804]; intramural research program of the NIH-NIAID; European Union [FP& HEALTH F3-2012-305578]; National Research Foundation of South Africa [96841]; Research Councils of the UK via the Francis Crick Institute [10218, U117565642]; Medical Research Council of South Africa (Strategic Health Innovations partnership) FX This work was funded by the Wellcome Trust (grant no. 090170 (H.E.) and 104803 (R.J.W.)), the Bill and Melinda Gates Foundation-Wellcome Trust Grand challenges in Global Health (grant no. 37822; D.B.Y.), the US National Institutes of Health (NIH) (grant no. R01 HL106804; J.L.F.) and the intramural research program of the NIH-NIAID (C.E.B.). R.J.W. also received support from the European Union (grant no. FP& HEALTH F3-2012-305578), the National Research Foundation of South Africa (grant no. 96841), the Research Councils of the UK via the Francis Crick Institute (grant no. 10218 and U117565642) and the Medical Research Council of South Africa (Strategic Health Innovations partnership). NR 20 TC 5 Z9 5 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD OCT PY 2016 VL 22 IS 10 BP 1090 EP 1093 DI 10.1038/nm.4161 PG 4 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA DY1RQ UT WOS:000384872500011 PM 27595321 ER PT J AU Malherbe, ST Shenai, S Ronacher, K Loxton, AG Dolganov, G Kriel, M Van, T Chen, RY Warwick, J Via, LE Song, T Lee, M Schoolnik, G Tromp, G Alland, D Barry, CE Winter, J Walzl, G AF Malherbe, Stephanus T. Shenai, Shubhada Ronacher, Katharina Loxton, Andre G. Dolganov, Gregory Kriel, Magdalena Tran Van Chen, Ray Y. Warwick, James Via, Laura E. Song, Taeksun Lee, Myungsun Schoolnik, Gary Tromp, Gerard Alland, David Barry, Clifton E., III Winter, Jill Walzl, Gerhard CA Catalysis TB-Biomarker Consortium TI Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure SO NATURE MEDICINE LA English DT Article ID PULMONARY TUBERCULOSIS; RECURRENT TUBERCULOSIS; THERAPEUTIC RESPONSE; SHORTENING TREATMENT; COMPUTED-TOMOGRAPHY; CULTURE CONVERSION; RISK-FACTORS; RELAPSE; REINFECTION; IMPAIRMENT AB The absence of a gold standard to determine when antibiotics induce a sterilizing cure has confounded the development of new approaches to treat pulmonary tuberculosis (PTB). We detected positron emission tomography and computerized tomography (PET-CT) imaging response patterns consistent with active disease, along with the presence of Mycobacterium tuberculosis (MTB) mRNA in sputum and bronchoalveolar lavage samples, in a substantial proportion of adult, HIV-negative patients with PTB after a standard 6-month treatment plus 1 year follow-up, including patients with a durable cure and others who later developed recurrent disease. The presence of MTB mRNA in the context of nonresolving and intensifying lesions on PET-CT images might indicate ongoing transcription, suggesting that even apparently curative treatment for PTB may not eradicate all of the MTB bacteria in most patients. This suggests an important complementary role for the immune response in maintaining a disease-free state. Sterilizing drugs or host-directed therapies, and better treatment response markers, are probably needed for the successful development of improved and shortened PTB-treatment strategies. C1 [Malherbe, Stephanus T.; Ronacher, Katharina; Loxton, Andre G.; Kriel, Magdalena; Tromp, Gerard; Barry, Clifton E., III; Walzl, Gerhard] Univ Stellenbosch, Natl Res Fdn Ctr Excellence Biomed TB Res, Dept Sci & Technol, Cape Town, South Africa. [Malherbe, Stephanus T.; Ronacher, Katharina; Loxton, Andre G.; Kriel, Magdalena; Tromp, Gerard; Barry, Clifton E., III; Walzl, Gerhard] Univ Stellenbosch, Fac Med & Hlth Sci, Div Mol Biol & Human Genet, South African Med Res Council,Ctr TB Res, Cape Town, South Africa. [Shenai, Shubhada] Rutgers New Jersey Med Sch, Dept Med, Ctr Emerging Pathogens, Newark, NJ USA. [Dolganov, Gregory; Tran Van] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA. [Chen, Ray Y.; Via, Laura E.] NIAID, TB Res Sect, Lab Clin Infect Dis, Div Intramural Res,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Warwick, James] Tygerberg Acad Hosp, Western Cape Acad Positron Emiss Tomog Computed T, Cape Town, South Africa. [Warwick, James] Univ Stellenbosch, Div Nucl Med, Dept Med Imaging & Clin Oncol, Fac Med & Hlth Sci, Cape Town, South Africa. [Via, Laura E.; Barry, Clifton E., III] Univ Cape Town, Inst Infect Dis & Mol Med, Dept Clin Lab Sci, Cape Town, South Africa. [Song, Taeksun; Lee, Myungsun] Int TB Res Ctr, Seoul, South Korea. [Winter, Jill] Catalysis Fdn Hlth, Emeryville, CA USA. Natl Med Ctr, Seoul, South Korea. NIAID, Biostat Res Branch, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. Univ Stellenbosch, Divis Pulmonol, Fac Med & Hlth Sci, Cape Town, South Africa. Univ Stellenbosch, Fac Med & Hlth Sci, Med Imaging & Clin Oncol, Div Radiodiag, Cape Town, South Africa. RP Malherbe, ST (reprint author), Univ Stellenbosch, Natl Res Fdn Ctr Excellence Biomed TB Res, Dept Sci & Technol, Cape Town, South Africa.; Malherbe, ST (reprint author), Univ Stellenbosch, Fac Med & Hlth Sci, Div Mol Biol & Human Genet, South African Med Res Council,Ctr TB Res, Cape Town, South Africa. EM malherbe@sun.ac.za FU Catalysis Foundation for Health (CFH); Division of Intramural Research, National Institute of Allergy and Infectious Diseases; National Institute of Allergy and Infectious Diseases, International Collaborations in Infectious Disease Research FX Funding was provided by grants from the Catalysis Foundation for Health (CFH) (G.W., C.E.B. and D.A.) the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (C.E.B.) and the National Institute of Allergy and Infectious Diseases, International Collaborations in Infectious Disease Research (G.W.), as well as by a bursary from the South African National Research Fund and the Medical Research Council's Clinician Scholarship Program (S.T.M.). We thank our participants for their willingness to take part in this study. We acknowledge R. Thayer and M. Urdea of CFH, the staff at the Stellenbosch University Immunology Research Group, the International TB Research Center (Seoul), the Western Cape Academic PET-CT Centre, Ithemba LABS, Tygerberg Academic Hospital's Nuclear Medicine Department and Pulmonology Unit, as well as the managers and healthcare providers from the City of Cape Town Health Department for assistance with the recruitment of participants and sample collection. NR 52 TC 3 Z9 3 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD OCT PY 2016 VL 22 IS 10 BP 1094 EP 1100 DI 10.1038/nm.4177 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA DY1RQ UT WOS:000384872500012 PM 27595324 ER PT J AU Xu, M Lee, EM Wen, ZX Cheng, YC Huang, WK Qian, XY Julia, TCW Kouznetsova, J Ogden, SC Hammack, C Jacob, F Nguyen, HN Itkin, M Hanna, C Shinn, P Allen, C Michael, SG Simeonov, A Huang, WW Christian, KM Goate, A Brennand, KJ Huang, RL Xia, MH Ming, GL Zheng, W Song, HJ Tang, HL AF Xu, Miao Lee, Emily M. Wen, Zhexing Cheng, Yichen Huang, Wei-Kai Qian, Xuyu Julia, T. C. W. Kouznetsova, Jennifer Ogden, Sarah C. Hammack, Christy Jacob, Fadi Ha Nam Nguyen Itkin, Misha Hanna, Catherine Shinn, Paul Allen, Chase Michael, Samuel G. Simeonov, Anton Huang, Wenwei Christian, Kimberly M. Goate, Alison Brennand, Kristen J. Huang, Ruili Xia, Menghang Ming, Guo-li Zheng, Wei Song, Hongjun Tang, Hengli TI Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen SO NATURE MEDICINE LA English DT Article ID CDK9 INHIBITORS; APPROVED DRUGS; MICE; TRANSMISSION; REPLICATION; ORGANOIDS; NICLOSAMIDE; THERAPY; FIT-039; BIOLOGY AB In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurological conditions, we performed a drug repurposing screen of similar to 6,000 compounds that included approved drugs, clinical trial drug candidates and pharmacologically active compounds; we identified compounds that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells. A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures. Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication. Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication. Finally, combination treatments using one compound from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death. Our results demonstrate the efficacy of this screening strategy and identify lead compounds for anti-ZIKV drug development. C1 [Xu, Miao; Kouznetsova, Jennifer; Itkin, Misha; Shinn, Paul; Michael, Samuel G.; Simeonov, Anton; Huang, Wenwei; Huang, Ruili; Xia, Menghang; Zheng, Wei] NIH, Natl Ctr Adv Translat, Bldg 10, Bethesda, MD 20892 USA. [Xu, Miao] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China. [Lee, Emily M.; Cheng, Yichen; Ogden, Sarah C.; Hammack, Christy; Hanna, Catherine; Allen, Chase; Tang, Hengli] Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA. [Wen, Zhexing] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. [Wen, Zhexing] Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA USA. [Wen, Zhexing] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Wen, Zhexing; Huang, Wei-Kai; Qian, Xuyu; Jacob, Fadi; Ha Nam Nguyen; Christian, Kimberly M.; Ming, Guo-li; Song, Hongjun] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21218 USA. [Huang, Wei-Kai] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. [Qian, Xuyu; Ming, Guo-li; Song, Hongjun] Johns Hopkins Univ, Sch Med, Biomed Engn Grad Program, Baltimore, MD 21218 USA. [Julia, T. C. W.; Goate, Alison] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Jacob, Fadi; Ming, Guo-li; Song, Hongjun] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21218 USA. [Ha Nam Nguyen; Christian, Kimberly M.; Ming, Guo-li; Song, Hongjun] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Brennand, Kristen J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Ming, Guo-li] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Ming, Guo-li; Song, Hongjun] Johns Hopkins Univ, Sch Med, Kavli Neurosci Discovery Inst, Baltimore, MD 21218 USA. RP Zheng, W (reprint author), NIH, Natl Ctr Adv Translat, Bldg 10, Bethesda, MD 20892 USA.; Tang, HL (reprint author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.; Ming, GL; Song, HJ (reprint author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21218 USA.; Ming, GL; Song, HJ (reprint author), Johns Hopkins Univ, Sch Med, Biomed Engn Grad Program, Baltimore, MD 21218 USA.; Song, HJ (reprint author), Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD 21218 USA.; Ming, GL; Song, HJ (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.; Ming, GL (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.; Ming, GL; Song, HJ (reprint author), Johns Hopkins Univ, Sch Med, Kavli Neurosci Discovery Inst, Baltimore, MD 21218 USA. EM gming1@jhmi.edu; wzheng@mail.nih.gov; shongju1@jhmi.edu; tang@bio.fsu.edu RI Brennand, Kristen/J-8704-2012; Zheng, Wei/J-8889-2014; OI Brennand, Kristen/0000-0003-0993-5956; Zheng, Wei/0000-0003-1034-0757; Qian, Xuyu/0000-0001-5944-3816 FU Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health (NIH); Florida State University; Emory University; Brain and Behavior Research Foundation; New York Stem Cell Foundation; Maryland Stem Cell Research Fund; Simons Foundation Autism Research Initiative [308988]; NIH [NS048271, NS095348, MH105128, NS047344, NS097206, MH106434, MH101454, MH106056, AG005138, AG046170, AI119530] FX We thank R. Tesh and P.-Y. Shi (University of Texas Medical Branch) and the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) for the FSS-13025 isolate of ZIKV, and D. Meckes (Florida State University) for the glioblastoma SNB-19 cell line. We also thank L. Liu and Y. Cai for technical support. This work was supported by the Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) (W.Z.), ZIKV seed funding from Florida State University (H.T.), a start-up fund from Emory University (Z.W.), the Brain and Behavior Research Foundation (K.J.B.), the New York Stem Cell Foundation (K.J.B.), the Maryland Stem Cell Research Fund (G.M. and H.S.), the Simons Foundation Autism Research Initiative (award no. 308988; H.S.), and partially by NIH grants NS048271 (G.M.), NS095348 (G.M.), MH105128 (G.M.), NS047344 (H.S.), NS097206 (H.S.), MH106434 (H.S.), MH101454 (K.J.B.), MH106056 (K.J.B.), AG005138 (K.J.B.), AG046170 (K.J.B.) and AI119530 (H.T.). NR 59 TC 23 Z9 23 U1 121 U2 121 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD OCT PY 2016 VL 22 IS 10 BP 1101 EP 1107 DI 10.1038/nm.4184 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA DY1RQ UT WOS:000384872500013 PM 27571349 ER PT J AU Blackshaw, S Venkataraman, A Irizarry, J Yang, K Anderson, S Campbell, E Gatlin, CL Freeman, NL Basavappa, R Stewart, R Loss, MA Pino, I Zhu, H Bader, JS AF Blackshaw, Seth Venkataraman, Anand Irizarry, Jose Yang, Kun Anderson, Stephen Campbell, Elliot Gatlin, Christine L. Freeman, Nancy L. Basavappa, Ravi Stewart, Randall Loss, Michael A. Pino, Ignacio Zhu, Heng Bader, Joel S. TI The NIH Protein Capture Reagents Program (PCRP): a standardized protein affinity reagent toolbox SO NATURE METHODS LA English DT Letter ID ANTIBODIES C1 [Blackshaw, Seth; Venkataraman, Anand] Johns Hopkins Univ, Solomon H Snyder Dept Neurosci, Baltimore, MD 21218 USA. [Blackshaw, Seth] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA. [Blackshaw, Seth] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD 21218 USA. [Blackshaw, Seth; Zhu, Heng; Bader, Joel S.] Johns Hopkins Univ, Ctr Human Syst Biol, Baltimore, MD 21218 USA. [Blackshaw, Seth] Johns Hopkins Univ, Inst Cell Engn, Baltimore, MD 21218 USA. [Irizarry, Jose; Pino, Ignacio] CDI Labs, Guanajibo Res & Innovat Pk, Mayaguez, PR USA. [Yang, Kun] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA. [Anderson, Stephen; Campbell, Elliot] Rutgers State Univ, Dept Mol Biol & Biochem, New Brunswick, NJ USA. [Anderson, Stephen; Campbell, Elliot] Ctr Adv Biotechnol & Med, Piscataway, NJ USA. [Gatlin, Christine L.] NHGRI, Bethesda, MD 20892 USA. [Gatlin, Christine L.; Freeman, Nancy L.; Basavappa, Ravi; Stewart, Randall] NIH, Bldg 10, Bethesda, MD 20892 USA. [Freeman, Nancy L.] NIDCD, Div Sci Programs, Bethesda, MD USA. [Basavappa, Ravi] NIH, Off Strateg Coordinat, Off Director, Bldg 10, Bethesda, MD 20892 USA. [Stewart, Randall] NINDS, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Loss, Michael A.] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Adv Biomed Comp Ctr, Frederick, MD USA. [Zhu, Heng] Johns Hopkins Univ, Dept Pharmacol, Baltimore, MD USA. [Bader, Joel S.] Ctr Neurosci, Bethesda, MD USA. RP Blackshaw, S (reprint author), Johns Hopkins Univ, Solomon H Snyder Dept Neurosci, Baltimore, MD 21218 USA.; Blackshaw, S (reprint author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.; Blackshaw, S (reprint author), Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD 21218 USA.; Blackshaw, S (reprint author), Johns Hopkins Univ, Ctr Human Syst Biol, Baltimore, MD 21218 USA.; Blackshaw, S (reprint author), Johns Hopkins Univ, Inst Cell Engn, Baltimore, MD 21218 USA. EM sblack@jhmi.edu NR 6 TC 0 Z9 0 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD OCT PY 2016 VL 13 IS 10 BP 805 EP 806 DI 10.1038/nmeth.4013 PG 2 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA DY6CV UT WOS:000385194600005 PM 27684578 ER PT J AU Uhlen, M Bandrowski, A Carr, S Edwards, A Ellenberg, J Lundberg, E Rimm, DL Rodriguez, H Hiltke, T Snyder, M Yamamoto, T AF Uhlen, Mathias Bandrowski, Anita Carr, Steven Edwards, Aled Ellenberg, Jan Lundberg, Emma Rimm, David L. Rodriguez, Henry Hiltke, Tara Snyder, Michael Yamamoto, Tadashi TI A proposal for validation of antibodies SO NATURE METHODS LA English DT Article ID ASSAYS; LOCALIZATION; MICROARRAYS; PROTEINS; CELLS AB We convened an ad hoc International Working Group for Antibody Validation in order to formulate the best approaches for validating antibodies used in common research applications and to provide guidelines that ensure antibody reproducibility. We recommend five conceptual 'pillars' for antibody validation to be used in an application-specific manner. C1 [Uhlen, Mathias; Lundberg, Emma] KTH Royal Inst Technol, Sch Biotechnol, Sci Life Lab, Stockholm, Sweden. [Bandrowski, Anita] Univ Calif San Diego, Ctr Res Biol Syst, San Diego, CA 92103 USA. [Carr, Steven] Broad Inst Massachusetts Inst Technol & Harvard U, Prote Platform, Cambridge, MA USA. [Edwards, Aled] Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada. [Ellenberg, Jan] European Mol Biol Lab, Cell Biol & Biophys Unit, Heidelberg, Germany. [Rimm, David L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Rodriguez, Henry; Hiltke, Tara] NCI, Off Canc Clin Prote Res, NIH, Bethesda, MD 20892 USA. [Snyder, Michael] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA. [Yamamoto, Tadashi] Niigata Univ, Biofluid Biomarker Ctr, Niigata, Japan. RP Uhlen, M (reprint author), KTH Royal Inst Technol, Sch Biotechnol, Sci Life Lab, Stockholm, Sweden. EM mathias.uhlen@scilifelab.se OI Bandrowski, Anita/0000-0002-5497-0243; Ellenberg, Jan/0000-0001-5909-701X; Uhlen, Mathias/0000-0002-4858-8056 NR 20 TC 7 Z9 7 U1 14 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1548-7091 EI 1548-7105 J9 NAT METHODS JI Nat. Methods PD OCT PY 2016 VL 13 IS 10 BP 823 EP + DI 10.1038/NMETH.3995 PG 6 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA DY6CV UT WOS:000385194600015 PM 27595404 ER PT J AU Arveson, I Shelton, M Tonkura, F Bendixen, R Meilleur, K AF Arveson, I. Shelton, M. Tonkura, F. Bendixen, R. Meilleur, K. TI Development of a proxy motor outcome measurement scale in young children with neuromuscular disorders SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Arveson, I.; Shelton, M.; Tonkura, F.; Meilleur, K.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Bendixen, R.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.207 BP S148 EP S148 DI 10.1016/j.nmd.2016.06.227 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100217 ER PT J AU Arveson, I Witherspoon, J Drinkard, B Waite, M Razaqyar, M Tounkara, E Elliott, J Shelton, M Jain, M Bonnemann, C Meilleur, K AF Arveson, I. Witherspoon, J. Drinkard, B. Waite, M. Razaqyar, M. Tounkara, E. Elliott, J. Shelton, M. Jain, M. Bonnemann, C. Meilleur, K. TI Antioxidant therapy in RYR1-related myopathies SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Arveson, I.; Witherspoon, J.; Drinkard, B.; Waite, M.; Razaqyar, M.; Tounkara, E.; Elliott, J.; Shelton, M.; Jain, M.; Bonnemann, C.; Meilleur, K.] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.166 BP S137 EP S137 DI 10.1016/j.nmd.2016.06.186 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100176 ER PT J AU Bharucha-Goebel, D Collins, J Hu, Y Foley, AR Donkervoort, S Leach, M Dastgir, N Vuillerot, C Meilleur, K Jain, M Waite, M Jacobson, S Gordish, H Rutkowski, A Hoffman, E Hathout, Y Bonnemann, C AF Bharucha-Goebel, D. Collins, J. Hu, Y. Foley, A. Reghan Donkervoort, S. Leach, M. Dastgir, N. Vuillerot, C. Meilleur, K. Jain, M. Waite, M. Jacobson, S. Gordish, H. Rutkowski, A. Hoffman, E. Hathout, Y. Bonnemann, C. TI Serum biomarker discovery for congenital muscular dystrophies SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Bharucha-Goebel, D.; Hu, Y.; Foley, A. Reghan; Donkervoort, S.; Leach, M.; Meilleur, K.; Jain, M.; Waite, M.; Bonnemann, C.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Bharucha-Goebel, D.; Leach, M.] Natl Inst Childrens Natl Hlth Syst, Bethesda, MD USA. [Collins, J.] Mercy Clin, Springfield, MO USA. [Dastgir, N.] Columbia Univ, Med Ctr, New York, NY USA. [Vuillerot, C.] Hosp Civils Lyon, Lyon, France. [Jacobson, S.] Cincinnati Childrens Hosp Ctr, Cincinnati, OH USA. [Gordish, H.] Childrens Natl Hlth Syst, Washington, DC USA. [Rutkowski, A.] Cure CMD, Torrance, CA USA. [Hoffman, E.; Hathout, Y.] Childrens Natl Hlth Syst CRI, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.345 BP S189 EP S189 DI 10.1016/j.nmd.2016.06.374 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100363 ER PT J AU Butterfield, R Dunn, D Hu, Y Bonnernann, C Weiss, R AF Butterfield, R. Dunn, D. Hu, Y. Bonnernann, C. Weiss, R. TI Transcriptome profiling identifies key pathways important in collagen VI related muscular dystrophies including differences between patients with dominant negative vs. null mutations SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Butterfield, R.; Dunn, D.; Weiss, R.] Univ Utah, Salt Lake City, UT USA. [Hu, Y.; Bonnernann, C.] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.342 BP S188 EP S189 DI 10.1016/j.nmd.2016.06.371 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100360 ER PT J AU Carrillo, N Huizing, M Quintana, M Slota, C Malicdan, M Khatami, H Berry, S Gahl, W AF Carrillo, N. Huizing, M. Quintana, M. Slota, C. Malicdan, M. Khatami, H. Berry, S. Gahl, W. TI Therapeutic development of ManNAc for GNE myopathy SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Carrillo, N.; Huizing, M.; Slota, C.; Malicdan, M.; Gahl, W.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Quintana, M.; Berry, S.] Berry Consultants, Austin, TX USA. [Khatami, H.] Escala Therapeut, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.283 BP S172 EP S172 DI 10.1016/j.nmd.2016.06.313 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100302 ER PT J AU Rubio, RD Martinez, A Poza, J Bragado, FG Jerico, I van der Ven, P Furst, D Romero, N Goldfarb, L Olive, M AF Dominguez Rubio, R. Martinez, A. Poza, J. Garcia Bragado, F. Jerico, I. van der Ven, P. Fuerst, D. Romero, N. Goldfarb, L. Olive, M. TI Intranuclear protein aggregation in myofibrillar myopathies SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Dominguez Rubio, R.; Martinez, A.; Olive, M.] IDIBELL Hosp Bellvitge, Lhospitalet De Llobregat, Spain. [Poza, J.] Hosp Donostia, San Sebastian, Spain. [Garcia Bragado, F.] Hosp Virgen del Camino, Pamplona, Spain. [Jerico, I.] Complejo Hosp Navarra, Pamplona, Spain. [van der Ven, P.; Fuerst, D.] Univ Bonn, Inst Cell Biol, Bonn, Germany. [Romero, N.] GHU Pitie Salpetriere, Inst Myol, Paris, France. [Goldfarb, L.] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 1 Z9 1 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.352 BP S191 EP S191 DI 10.1016/j.nmd.2016.06.381 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100370 ER PT J AU Foley, AR Cocanougher, B Flynn, L Yun, P Jain, M Waite, M Vasavada, R de Chastonay, S Donkervoort, S Bonnemann, C AF Foley, A. Reghan Cocanougher, B. Flynn, L. Yun, P. Jain, M. Waite, M. Vasavada, R. de Chastonay, S. Donkervoort, S. Bonnemann, C. TI MTM1-related myopathy carrier females manifest significant skeletal asymmetries and a spectrum of muscle involvement SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Foley, A. Reghan; Flynn, L.; Yun, P.; Donkervoort, S.; Bonnemann, C.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Cocanougher, B.] Howard Hughes Med Inst, Ashburn, VA USA. [Jain, M.; Waite, M.; Vasavada, R.] NIH, Bethesda, MD USA. [de Chastonay, S.] Cure CMD, Torrance, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.93 BP S117 EP S117 DI 10.1016/j.nmd.2016.06.115 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100105 ER PT J AU Korinthenberg, R Schorling, D Rost, S Krueger, M Beytia, M Mueller, C Bonnemann, C Kirschner, J AF Korinthenberg, R. Schorling, D. Rost, S. Krueger, M. Beytia, M. Mueller, C. Bonnemann, C. Kirschner, J. TI Severe congenital myopathy with myasthenic features and lethal neurodegeneration - A new ALG14-related phenotype? SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Korinthenberg, R.; Schorling, D.; Krueger, M.; Kirschner, J.] Univ Med Ctr Freiburg, Freiburg, Germany. [Rost, S.; Beytia, M.; Mueller, C.] Univ Wurzburg, D-97070 Wurzburg, Germany. [Bonnemann, C.] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.77 BP S112 EP S112 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100089 ER PT J AU Malicdan, M Leoyklang, P Ciccone, C Carrillo, N Huizing, M Gahl, W AF Malicdan, M. Leoyklang, P. Ciccone, C. Carrillo, N. Huizing, M. Gahl, W. TI GNE myopathy biomarkers: Essential for diagnosis and response to therapy SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Malicdan, M.; Leoyklang, P.; Ciccone, C.; Carrillo, N.; Huizing, M.; Gahl, W.] NHGRI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.276 BP S170 EP S170 DI 10.1016/j.nmd.2016.06.306 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100295 ER PT J AU Miyakawa, M Cho, A Malicdan, M Nishino, I Noguchi, S AF Miyakawa, M. Cho, A. Malicdan, M. Nishino, I. Noguchi, S. TI S-nitrosylation of muscle contractile proteins and metabolic enzymes causes muscle atrophy and weakness in GNE myopathy SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Miyakawa, M.; Nishino, I.; Noguchi, S.] Natl Inst Neurosci, Kodaira, Tokyo, Japan. [Cho, A.] Ewha Womans Univ, Sch Med, Seoul, South Korea. [Malicdan, M.] NHGRI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.281 BP S171 EP S172 DI 10.1016/j.nmd.2016.06.311 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100300 ER PT J AU Oates, E Yau, K Donkervoort, S Swanson, L Brammah, S Topf, A Richard, I Ferreiro, A Hoffman, E Bushby, K Straub, V Udd, B Lek, M MacArthur, D Granzier, H Beggs, A Bonnemann, C North, K Davis, M Laing, N AF Oates, E. Yau, K. Donkervoort, S. Swanson, L. Brammah, S. Topf, A. Richard, I. Ferreiro, A. Hoffman, E. Bushby, K. Straub, V. Udd, B. Lek, M. MacArthur, D. Granzier, H. Beggs, A. Bonnemann, C. North, K. Davis, M. Laing, N. TI Analysis of a large international cohort confirms that recessively inherited loss-of-function TTN mutations cause prenatal or infant-onset muscle disease, often complicated by early cardiorespiratory involvement SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Oates, E.] Inst Neurosci & Muscle Res, Sydney, NSW, Australia. [Yau, K.; Laing, N.] Univ Western Australia, Perth, WA, Australia. [Donkervoort, S.; Bonnemann, C.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Swanson, L.; Beggs, A.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA. [Brammah, S.] Concord Repatriat Gen Hosp, Sydney, NSW, Australia. [Topf, A.; Bushby, K.; Straub, V.] Univ Newcastle, Newcastle Upon Tyne, Tyne & Wear, England. [Richard, I.] Genethon, Evry, France. [Ferreiro, A.] Univ Paris, Sorbonne, Diderot, Paris, France. [Hoffman, E.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Hoffman, E.] George Washington Univ, Washington, DC USA. [Udd, B.] Tampere Univ, Tampere, Finland. [Udd, B.] Univ Hosp, Tampere, Finland. [Lek, M.; MacArthur, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lek, M.; MacArthur, D.] Broad Inst Harvard & MIT, Boston, MA USA. [Granzier, H.] Univ Arizona, Tucson, AZ USA. [North, K.] Royal Childrens Hosp, Melbourne, Vic, Australia. [Davis, M.] Royal Perth Hosp, Perth, WA, Australia. RI North, Kathryn/K-6476-2012 OI North, Kathryn/0000-0003-0841-8009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA S.O.2 BP S89 EP S89 DI 10.1016/j.nmd.2016.06.018 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100008 ER PT J AU Punetha, J Kesari, A Hoffman, E Gos, M Kaminska, A Kostera-Pruszczyk, A Hu, Y Zou, Y Bonnemann, C Jedrzejowska, M AF Punetha, J. Kesari, A. Hoffman, E. Gos, M. Kaminska, A. Kostera-Pruszczyk, A. Hu, Y. Zou, Y. Bonnemann, C. Jedrzejowska, M. TI A novel COL12A1 variant expands the clinical picture for a collagen XII-related myopathy SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Punetha, J.; Kesari, A.; Hoffman, E.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Gos, M.] Inst Mother & Child Hlth, Warsaw, Poland. [Kaminska, A.; Kostera-Pruszczyk, A.] Med Univ Warsaw, Warsaw, Poland. [Hu, Y.; Zou, Y.; Bonnemann, C.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Jedrzejowska, M.] Mossakowski Med Res Ctr, Warsaw, Poland. NR 0 TC 0 Z9 0 U1 3 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.344 BP S189 EP S189 DI 10.1016/j.nmd.2016.06.373 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100362 ER PT J AU Razaqyar, M Butrum, J Witherspoon, J Tounkara, F Shelton, M Elliott, J Arveson, I Meilleur, K AF Razaqyar, M. Butrum, J. Witherspoon, J. Tounkara, F. Shelton, M. Elliott, J. Arveson, I. Meilleur, K. TI Qualitative comparison of healthy versus affected muscles by ultrasound imaging in RYR1-related myopathies SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Razaqyar, M.; Butrum, J.; Witherspoon, J.; Tounkara, F.; Shelton, M.; Elliott, J.; Arveson, I.; Meilleur, K.] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.28 BP S98 EP S98 DI 10.1016/j.nmd.2016.06.050 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100040 ER PT J AU Witherspoon, J Drinkard, B Arveson, I Stockman, M Jain, M Meilleur, K AF Witherspoon, J. Drinkard, B. Arveson, I. Stockman, M. Jain, M. Meilleur, K. TI Skeletal muscle oxygenation in adults with RYR1-related myopathies: Exploratory study SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Witherspoon, J.; Drinkard, B.; Arveson, I.; Stockman, M.; Jain, M.; Meilleur, K.] NIH, Bldg 10, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA P.160 BP S135 EP S135 DI 10.1016/j.nmd.2016.06.180 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100170 ER PT J AU Zou, Y Donkervoort, S Salo, A Barnes, A Hu, Y Foley, AR Makareeva, E Leach, M Dastgir, J Cohn, R DiNonno, W Leikin, S Marini, J Myllyharju, J Bonnemann, C AF Zou, Y. Donkervoort, S. Salo, A. Barnes, A. Hu, Y. Foley, A. Reghan Makareeva, E. Leach, M. Dastgir, J. Cohn, R. DiNonno, W. Leikin, S. Marini, J. Myllyharju, J. Bonnemann, C. TI P4HA1 mutations cause a unique congenital disorder of connective tissue involving tendon, bone, muscle and the eye SO NEUROMUSCULAR DISORDERS LA English DT Meeting Abstract CT 21st International Congress of the World-Muscle-Society CY OCT 04-08, 2016 CL Granada, SPAIN SP World Muscle Soc C1 [Zou, Y.; Donkervoort, S.; Hu, Y.; Foley, A. Reghan; Leach, M.; Dastgir, J.; Bonnemann, C.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Salo, A.; Myllyharju, J.] Bioctr Oulu, Oulu Ctr Cell Matrix Res, Oulu, Finland. [Barnes, A.; Makareeva, E.; Leikin, S.; Marini, J.] NICHD, NIH, Bethesda, MD USA. [Cohn, R.] Hosp Sick Children, Toronto, ON, Canada. [DiNonno, W.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-8966 EI 1873-2364 J9 NEUROMUSCULAR DISORD JI Neuromusc. Disord. PD OCT PY 2016 VL 26 SU 2 MA G.O.21 BP S211 EP S212 DI 10.1016/j.nmd.2016.06.455 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DY0ME UT WOS:000384790100444 ER PT J AU de Jesus, AA Goldbach-Mansky, R AF de Jesus, A. A. Goldbach-Mansky, R. TI Genetically defined autoinflammatory diseases SO ORAL DISEASES LA English DT Review DE autoinflammatory diseases; inflammatory diseases; immune defects; immunology; rheumatology; IL-1; Type I interferon ID FAMILIAL MEDITERRANEAN FEVER; SINGLETON-MERTEN SYNDROME; RECURRENT MULTIFOCAL OSTEOMYELITIS; PEDIATRIC GRANULOMATOUS ARTHRITIS; CONGENITAL SIDEROBLASTIC ANEMIA; MACROPHAGE ACTIVATION SYNDROME; JUVENILE IDIOPATHIC ARTHRITIS; INFLAMMATORY-BOWEL-DISEASE; STEM-CELL TRANSPLANTATION; DEVELOPMENTAL DELAY SIFD AB Autoinflammatory diseases are hyperinflammatory, immune dysregulatory conditions that typically present in early childhood with fever and rashes and disease-specific patterns of organ inflammation. This review provides a historic background of autoinflammatory disease research, an overview of the currently genetically defined autoinflammatory diseases, and insights into treatment strategies derived from understanding of the disease pathogenesis. The integrative assessment of autoinflammatory conditions led to the identification of innate pro-inflammatory cytokine amplification loops' as the cause of the systemic and organ-specific disease manifestations, which initially centered around increased IL-1 production and signaling. More recently, additional innate pro-inflammatory cytokine amplification loops resulting in increased Type I IFN, IL-17, IL-18, or IL-36 signaling or production have led to the successful use of targeted therapies in some of these conditions. Clinical findings such as fever patterns, type of skin lesions, genetic mutation testing, and the prevalent cytokine abnormalities can be used to group autoinflammatory diseases. C1 [de Jesus, A. A.; Goldbach-Mansky, R.] Natl Inst Arthrit Musculoskeletal & Skin Dis NIAM, Translat Autoinflammatory Dis Sect, NIH, Bethesda, MD USA. RP Goldbach-Mansky, R (reprint author), Natl Inst Arthrit Musculoskeletal & Skin Dis NIAM, Translat Autoinflammatory Dis Sect, Ctr Clin, NIH, Bldg 10 Room 6D47-B,10 Ctr Dr, Bethesda, MD 20814 USA. EM goldbacr@arb.niams.nih.gov FU Intramural NIH HHS [Z01 AR041138-06] NR 82 TC 0 Z9 0 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1354-523X EI 1601-0825 J9 ORAL DIS JI Oral Dis. PD OCT PY 2016 VL 22 IS 7 BP 591 EP 604 DI 10.1111/odi.12448 PG 14 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DW4MS UT WOS:000383617900003 PM 26837051 ER PT J AU Shaikh, N Hoberman, A Keren, R Ivanova, A Ziessman, HA Cui, G Mattoo, TK Bhatnagar, S Nadkarni, MD Moxey-Mims, M Primack, WA AF Shaikh, Nader Hoberman, Alejandro Keren, Ron Ivanova, Anastasia Ziessman, Harvey A. Cui, Gang Mattoo, Tej K. Bhatnagar, Sonika Nadkarni, Milan D. Moxey-Mims, Marva Primack, William A. TI Utility of sedation for young children undergoing dimercaptosuccinic acid renal scans SO PEDIATRIC RADIOLOGY LA English DT Article DE Anxiolytic; Children; Dimercaptosuccinic acid; Renal scintigraphy; Sedation; Ultrasound; Voiding cystourethrogram ID VOIDING CYSTOURETHROGRAPHY; ORAL MIDAZOLAM; VESICOURETERAL REFLUX; NITROUS-OXIDE; DOUBLE-BLIND; DISTRESS; EFFICACY; PREMEDICATION; SAFETY AB No studies have examined whether use of sedation during a Tc-99 m dimercaptosuccinic acid (DMSA) renal scan reduces patient discomfort. To compare discomfort level during a DMSA scan to the discomfort level during other frequently performed uroradiologic tests, and to determine whether use of sedation during a DMSA scan modifies the level of discomfort. We examined the discomfort level in 798 children enrolled in the Randomized Intervention for children with Vesicoureteral Reflux (RIVUR) and Careful Urinary Tract Infection Evaluation (CUTIE) studies by asking parents to rate their child's discomfort level with each procedure on a scale from 0 to 10. We compared discomfort during the DMSA scan and the DMSA image quality between centers in which sedation was used > 90% of the time (sedation centers), centers in which sedation was used < 10% of the time (non-sedation centers), and centers in which sedation was used on a case-by-case basis (selective centers). Mean discomfort level was highest for voiding cystourethrogram (6.4), followed by DMSA (4.0), followed by ultrasound (2.4; P < 0.0001). Mean discomfort level during the DMSA scan was significantly higher at non-sedation centers than at selective centers (P < 0.001). No difference was apparent in discomfort level during the DMSA scan between sedation centers and selective centers (P=0.12), or between the sedation centers and non-sedation centers (P=0.80). There were no differences in the proportion with uninterpretable DMSA scans according to sedation use. Selective use of sedation in children 12-36 months of age can reduce the discomfort level experienced during a DMSA scan. C1 [Shaikh, Nader; Hoberman, Alejandro; Bhatnagar, Sonika] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh UPMC, Div Gen Acad Pediat, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA. [Keren, Ron] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Div Gen Pediat, Philadelphia, PA 19104 USA. [Ivanova, Anastasia] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Ziessman, Harvey A.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA. [Cui, Gang] Univ N Carolina, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA. [Mattoo, Tej K.] Wayne State Univ, Sch Med, Childrens Hosp Michigan, Div Nephrol & Hypertens, Detroit, MI USA. [Nadkarni, Milan D.] Wake Forest Sch Med, Brenner Childrens Hosp, Pediat Emergency Dept, Winston Salem, NC USA. [Moxey-Mims, Marva] NIDDK, NIH, Bethesda, MD 20892 USA. [Primack, William A.] Univ N Carolina, Kidney Ctr, Chapel Hill, NC USA. RP Shaikh, N (reprint author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh UPMC, Div Gen Acad Pediat, One Childrens Hosp Dr,4401 Penn Ave, Pittsburgh, PA 15224 USA. EM nader.shaikh@chp.edu FU NIDDK NIH HHS [U01 DK074059] NR 15 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 EI 1432-1998 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD OCT PY 2016 VL 46 IS 11 BP 1573 EP 1578 DI 10.1007/s00247-016-3649-0 PG 6 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA DY5WX UT WOS:000385176200011 PM 27287454 ER PT J AU Lopez, G Bayulkem, K Hallett, M AF Lopez, G. Bayulkem, K. Hallett, M. TI Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants SO ACTA NEUROLOGICA SCANDINAVICA LA English DT Review DE atypical parkinsonism; phenomenology; progressive supranuclear palsy; Richardson syndrome; tauopathy ID PRIMARY LATERAL SCLEROSIS; CORTICOBASAL DEGENERATION; FRONTOTEMPORAL DEMENTIA; ESSENTIAL TREMOR; NONFLUENT APHASIA; PARKINSONISM; DIAGNOSIS; CRITERIA; APRAXIA; SPEECH AB Phenotypic heterogeneity of progressive supranuclear palsy (PSP) has been increasingly reported in the literature and can be the source of incorrect clinical diagnosis particularly in the early stages of the disease when the classically associated symptoms of early falls and supranuclear gaze palsy may not be apparent. In addition to Richardson syndrome (RS), several atypical clinical phenotypes have been described. Advances in genetic, neuroimaging, and biochemical/molecular technologies contribute to the identification of these clinical subtypes in the context of typical PSP pathological findings. Our goal is to review the phenomenology reported in the literature that is associated with confirmed histopathological changes consistent with a PSP diagnosis and to highlight the clinical spectrum of PSP. A systematic review of the literature in PubMed through July 2015 using MeSH terms and key words related to PSP was conducted. Articles describing PSP classifications, diagnostic criteria, and case reports were reviewed and summarized. Additional PSP phenotypes not seen in recent clinicopathological studies are included. These include primary lateral sclerosis, pallido-nigro-luysian degeneration, axonal dystrophy, and multiple system atrophy in the spectrum of atypical PSP variants beyond the traditionally classified PSP subtypes. This review is intended to help with the diagnostic challenges of atypical PSP variants. We believe that large multicenter clinicopathological studies will help expand our understanding of etiology and specific mechanisms of neurodegeneration and will aid in the appropriate interpretation of outcomes when conducting clinical and basic science research. C1 [Lopez, G.] NHGRI, Sect Mol Neurogenet, Med Genet Branch, Intramural Res Program,NIH, Bethesda, MD 20892 USA. [Bayulkem, K.; Hallett, M.] NINDS, Human Motor Control Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. RP Lopez, G (reprint author), NHGRI, Sect Mol Neurogenet, Med Genet Branch, Intramural Res Program,NIH, Bethesda, MD 20892 USA. EM glopez@mail.nih.gov NR 45 TC 0 Z9 0 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-6314 EI 1600-0404 J9 ACTA NEUROL SCAND JI Acta Neurol. Scand. PD OCT PY 2016 VL 134 IS 4 BP 242 EP 249 DI 10.1111/ane.12546 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DW4OI UT WOS:000383622300001 PM 27070344 ER PT J AU Doussau, A Grady, C AF Doussau, Adelaide Grady, Christine TI The Ethics of Studying Financial Incentives in Public Health Implementation: Study Design Challenges SO AMERICAN JOURNAL OF BIOETHICS LA English DT Editorial Material ID CLUSTER RANDOMIZED-TRIAL C1 [Doussau, Adelaide; Grady, Christine] NIH, 10 Ctr Dr,Bldg 10, Bethesda, MD 20892 USA. RP Doussau, A (reprint author), NIH, Dept Bioeth, Ctr Clin, Bioeth, 10 Ctr Dr,Bldg 10, Bethesda, MD 20892 USA. EM adelaide.doussau@gmail.com NR 10 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1526-5161 EI 1536-0075 J9 AM J BIOETHICS JI Am. J. Bioeth. PD OCT PY 2016 VL 16 IS 10 BP 78 EP 80 DI 10.1080/15265161.2016.1214322 PG 3 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA DX6ZU UT WOS:000384536000031 PM 27653414 ER PT J AU Rosenkrantz, AB Oto, A Turkbey, B Westphalen, AC AF Rosenkrantz, Andrew B. Oto, Aytekin Turkbey, Baris Westphalen, Antonio C. TI Reply to "Standardizing Biparametric MRI to Simplify and Improve Prostate Imaging Reporting and Data System, Version 2, in Prostate Cancer Management" SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Letter ID PI-RADS; BIOPSY C1 [Rosenkrantz, Andrew B.] NYU, Langone Med Ctr, Sch Med, New York, NY 10012 USA. [Oto, Aytekin] Univ Chicago, Chicago, IL 60637 USA. [Turkbey, Baris] NCI, NIH, Bethesda, MD 20892 USA. [Westphalen, Antonio C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Rosenkrantz, AB (reprint author), NYU, Langone Med Ctr, Sch Med, New York, NY 10012 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD OCT PY 2016 VL 207 IS 4 BP W76 EP W76 DI 10.2214/AJR.16.16563 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DX7LF UT WOS:000384568100008 ER PT J AU Costa, VD Kakalios, LC Averbeck, BB AF Costa, Vincent D. Kakalios, Laura C. Averbeck, Bruno B. TI Blocking Serotonin but Not Dopamine Reuptake Alters Neural Processing During Perceptual Decision Making SO BEHAVIORAL NEUROSCIENCE LA English DT Article DE serotonin; dopamine; impulsivity; perceptual inference; drift diffusion model ID CENTRAL 5-HT DEPLETION; PARKINSONS-DISEASE; DELAYED REWARDS; REACTION-TIME; IMPULSIVITY; NEURONS; PERFORMANCE; ACTIVATION; BEHAVIOR; RATS AB Dopamine and serotonin have opponent interactions on aspects of impulsivity. Therefore we wanted to test the hypothesis that dopamine and serotonin would have opposing effects on speed-accuracy trade offs in a perceptual decision making task. Unlike other behavioral measures of impulsivity, perceptual decision making allows us to determine whether decreasing premature responses, often interpreted as decreased impulsivity, corresponds to increased behavioral performance. We administered GBR-12909 (a dopamine transporter blocker), escitalopram (a serotonin transporter blocker), or saline in separate sessions to 3 rhesus macaques. We found that animals had slower reaction times (RTs) on escitalopram than on GBR-12909 or saline. However, they were also least accurate on escitalopram. Animals were faster, although nonsignificantly, on GBR than saline and had equivalent accuracy. Administration of GBR-12909 did cause animals to be faster in error trials than correct trials. Therefore, from the point of view of RTs the animals were less impulsive on escitalopram. However, the decreased accuracy of the monkeys shows that they were not able to make use of their slower response times to make more accurate decisions. Therefore, impulsivity was reduced on escitalopram, but at the expense of a slower information-processing rate in the perceptual inference task. C1 [Costa, Vincent D.; Kakalios, Laura C.; Averbeck, Bruno B.] NIMH, Neuropsychol Lab, NIH, Bldg 49,Room 1B80,49 Convent Dr,MSC 4415, Bethesda, MD 20892 USA. RP Averbeck, BB (reprint author), NIMH, Neuropsychol Lab, NIH, Bldg 49,Room 1B80,49 Convent Dr,MSC 4415, Bethesda, MD 20892 USA. EM bruno.averbeck@nih.gov OI Costa, Vincent/0000-0002-5412-8945 FU Intramural Research Program of the National Institute of Mental Health FX This work was supported by the Intramural Research Program of the National Institute of Mental Health. NR 37 TC 0 Z9 0 U1 4 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7044 EI 1939-0084 J9 BEHAV NEUROSCI JI Behav. Neurosci. PD OCT PY 2016 VL 130 IS 5 BP 461 EP 468 DI 10.1037/bne0000162 PG 8 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA DX6XR UT WOS:000384529900001 PM 27513807 ER PT J AU Castillo, JJ Garcia-Sanz, R Hatjiharissi, E Kyle, RA Leleu, X McMaster, M Merlini, G Minnema, MC Morra, E Owen, RG Poulain, S Stone, MJ Tam, C Varettoni, M Dimopoulos, MA Treon, SP Kastritis, E AF Castillo, Jorge J. Garcia-Sanz, Ramon Hatjiharissi, Evdoxia Kyle, Robert A. Leleu, Xavier McMaster, Mary Merlini, Giampaolo Minnema, Monique C. Morra, Enrica Owen, Roger G. Poulain, Stephanie Stone, Marvin J. Tam, Constantine Varettoni, Marzia Dimopoulos, Meletios A. Treon, Steven P. Kastritis, Efstathios TI Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE Waldenstrom macroglobulinaemia; anaemia; neuropathy; hyperviscosity; Bing-Neel syndrome; amyloidosis ID CONSENSUS PANEL RECOMMENDATIONS; IGM MONOCLONAL GAMMOPATHY; END RESULTS DATABASE; BING-NEEL SYNDROME; MYD88 L265P; LYMPHOPLASMACYTIC LYMPHOMA; CXCR4 MUTATIONS; HYPERVISCOSITY SYNDROME; GENOMIC LANDSCAPE; LIGHT-CHAIN AB The diagnosis of Waldenstrom macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM. C1 [Castillo, Jorge J.; Treon, Steven P.] Harvard Med Sch, Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, 450 Brookline Ave,M221, Boston, MA 02215 USA. [Garcia-Sanz, Ramon] Hosp Univ Salamanca, Salamanca, Spain. [Hatjiharissi, Evdoxia] Theagene Hosp Thessaloniki, Dept Haematol, Thessaloniki, Greece. [Kyle, Robert A.] Mayo Clin, Div Hematol, Rochester, MN USA. [Leleu, Xavier] CHU Poitiers, La Mil Hosp, Poitiers, France. [McMaster, Mary] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Merlini, Giampaolo] Univ Pavia, Fdn IRCCS Policlin San Matteo, Amyloidosis Res & Treatment Ctr, Pavia, Italy. [Minnema, Monique C.] UMC Utrecht Canc Ctr, Dept Haematol, Utrecht, Netherlands. [Morra, Enrica] Osped Niguarda Ca Granda, Div Haematol, Milan, Italy. [Owen, Roger G.] Leeds Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England. [Poulain, Stephanie] Ctr Hosp Valenciennes, Serv Hematol Immunol Cytogenet, Valenciennes, France. [Stone, Marvin J.] Baylor Charles Sammons Canc Ctr, Dept Oncol, Dallas, TX USA. [Tam, Constantine] Univ Melbourne, Dept Haematol, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Varettoni, Marzia] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Haematol Oncol, Pavia, Italy. [Dimopoulos, Meletios A.; Kastritis, Efstathios] Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece. RP Castillo, JJ (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, 450 Brookline Ave,M221, Boston, MA 02215 USA. EM jorgej_castillo@dfci.harvard.edu RI Garcia-Sanz, Ramon/B-7986-2017; OI Garcia-Sanz, Ramon/0000-0003-4120-2787; Castillo, Jorge/0000-0001-9490-7532 FU Abbvie; Gilead; Millennium; Pharmacyclics; Celgene; Janssen; Roche; Onyx FX JJC received honoraria from Celgene and Pharmacyclics, and research funding from Abbvie, Gilead, Millennium and Pharmacyclics. RGS received honoraria from Bristol-Myers Squibb, Janssen and Takeda and. EH received honoraria from Amgen, Gilead and Janssen. GM received honoraria from GlaxoSmithKline, Janssen and Millennium-Takeda. RGO received honoraria from Celgene, Janssen, Pharmacyclics and Roche, and research funding from Celgene. CT received honoraria and research funding from Janssen and Roche. MAD received honoraria from Amgen, Celgene, Janssen and Novartis. SPT received research funding and/or honoraria from Gilead, Janssen, Onyx and Pharmacyclics. EK received honoraria from Amgen, Janssen and Takeda and. RAK, XL, MM, MCM, EM, SP, MJS, MV have no conflict of interest to disclose. NR 58 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD OCT PY 2016 VL 175 IS 1 BP 77 EP 86 DI 10.1111/bjh.14196 PG 10 WC Hematology SC Hematology GA DY0TE UT WOS:000384808300011 PM 27378193 ER PT J AU Schinasi, LH Brown, EE Camp, NJ Wang, SS Hofmann, JN Chiu, BC Miligi, L Freeman, LEB de Sanjose, S Bernstein, L Monnereau, A Clavel, J Tricot, GJ Atanackovic, D Cocco, P Orsi, L Dosman, JA McLaughlin, JR Purdue, MP Cozen, W Spinelli, JJ de Roos, AJ AF Schinasi, Leah H. Brown, Elizabeth E. Camp, Nicola J. Wang, Sophia S. Hofmann, Jonathan N. Chiu, Brian C. Miligi, Lucia Freeman, Laura E. Beane de Sanjose, Silvia Bernstein, Leslie Monnereau, Alain Clavel, Jacqueline Tricot, Guido J. Atanackovic, Djordje Cocco, Pierluigi Orsi, Laurent Dosman, James A. McLaughlin, John R. Purdue, Mark P. Cozen, Wendy Spinelli, John J. de Roos, Anneclaire J. TI Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE multiple myeloma; epidemiology; lympho-haematopoietic malignancies; family history; lymphoma ID CHRONIC LYMPHOCYTIC-LEUKEMIA; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; HEMATOLOGIC MALIGNANCIES; 1ST-DEGREE RELATIVES; LYMPHOID NEOPLASMS; RISK; OCCUPATION; VARIANTS; EXPOSURE AB Family clusters of multiple myeloma (MM) suggest disease heritability. Nevertheless, patterns of inheritance and the importance of genetic versus environmental risk factors in MM aetiology remain unclear. We pooled data from eleven case-control studies from the International Multiple Myeloma Consortium to characterize the association of MM risk with having a first-degree relative with a history of a lympho-haematapoietic cancer. Unconditional logistic regression models, adjusted for study, sex, age and education level, were used to estimate associations between MM risk and having a first-degree relative with a history of non-Hodgkin lymphoma, Hodgkin lymphoma, leukaemia or MM. Sex, African American race/ethnicity and age were explored as effect modifiers. A total of 2843 cases and 11470 controls were included. MM risk was elevated in association with having a first-degree relative with any lympho-haematapoietic cancer (Odds Ratio (OR)=129, 95% Confidence Interval (CI): 108-155). The association was particularly strong for having a first-degree relative with MM (OR=190, 95% CI: 126-287), especially among men (OR=413, 95% CI: 217-785) and African Americans (OR=552, 95% CI: 187-1627).These results support the hypothesis that genetic inheritance plays a role in MM aetiology. Future studies are warranted to characterize interactions of genetic markers with environmental exposures. C1 [Schinasi, Leah H.; de Roos, Anneclaire J.] Drexel Univ, Dornsife Sch Publ Hlth, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USA. [Brown, Elizabeth E.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Pathol, Birmingham, AL 35294 USA. [Brown, Elizabeth E.] Univ Alabama Birmingham, Sch Publ Hlth, Ctr Comprehens Canc, Sch Med, Birmingham, AL 35294 USA. [Camp, Nicola J.; Atanackovic, Djordje] Univ Utah, Sch Med, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA. [Wang, Sophia S.; Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA. [Hofmann, Jonathan N.; Freeman, Laura E. Beane; Purdue, Mark P.] NCI, Occupat & Environm Epidemiol Branch, Div Canc & Genet, Rockville, MD USA. [Chiu, Brian C.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA. [Miligi, Lucia] Inst Study & Prevent Canc, Unit Environm & Occupat Hlth, Florence, Italy. [de Sanjose, Silvia] Catalan Inst Oncol, Canc Epidemiol Res Programme, Barcelona, Spain. [Monnereau, Alain; Clavel, Jacqueline; Orsi, Laurent] INSERM, U1153, Epidemiol & Biostat Sorbonne Paris Cite Ctr CRESS, Epidemiol Childhood & Adolescent Canc Team EPICEA, Villejuif, France. [Monnereau, Alain; Clavel, Jacqueline; Orsi, Laurent] Paris Descartes Univ, UMRS 1153, Epidemiol & Biostat Sorbonne Paris Cite Ctr CRESS, Paris, France. [Tricot, Guido J.] Univ Iowa, Internal Med, Iowa City, IA USA. [Cocco, Pierluigi] Univ Cagliari, Dept Publ Hlth Clin & Mol Med, Occupat Hlth Sect, Cagliari, Italy. [Dosman, James A.] Univ Saskatchewan, Canadian Ctr Hlth & Safety Agr, Saskatoon, SK, Canada. [McLaughlin, John R.] Publ Hlth Ontario, Toronto, ON, Canada. [Cozen, Wendy] Univ Southern Calif, USC Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Cozen, Wendy] Univ Southern Calif, USC Keck Sch Med, Dept Pathol, Los Angeles, CA USA. [Spinelli, John J.] Univ British Columbia, Sch Populat & Publ Hlth, Canc Control Res, BC Canc Agcy, Vancouver, BC, Canada. RP Schinasi, LH (reprint author), Drexel Univ, Sch Publ Hlth, Dept Environm & Occupat Hlth, Nesbitt Hall,3215 Market St, Philadelphia, PA 19104 USA. EM lhs36@drexel.edu RI Clavel, Jacqueline/Q-2750-2016; Beane Freeman, Laura/C-4468-2015 OI Clavel, Jacqueline/0000-0002-3616-7676; Beane Freeman, Laura/0000-0003-1294-4124 FU National Institute of Environmental Health Sciences [R21 ES021592]; Intramural Research Program of the NIH; Association pour la Recherche contre le Cancer; Fondation de France; AFSSET; NCI [U54CA118948, R21CA155951, R25CA76023, R01CA186646]; NCI (University of Alabama at Birmingham Comprehensive Cancer Center Support grant) [P30CA13148]; American Cancer Society [IRG60-001-47] FX This study was supported by the National Institute of Environmental Health Sciences grant R21 ES021592 (A.J.D.). The Connecticut Study and the Population Health Study were supported in part by the Intramural Research Program of the NIH. The ENGELA study (JC) was supported by grants from the Association pour la Recherche contre le Cancer, the Fondation de France, AFSSET and a donation from Faberge employees. The work conducted by E.E. Brown was supported, in part, by grants from the NCI (U54CA118948, R21CA155951, R25CA76023, R01CA186646, and the University of Alabama at Birmingham Comprehensive Cancer Center Support grant P30CA13148) and the American Cancer Society (IRG60-001-47). NR 47 TC 0 Z9 0 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD OCT PY 2016 VL 175 IS 1 BP 87 EP 101 DI 10.1111/bjh.14199 PG 15 WC Hematology SC Hematology GA DY0TE UT WOS:000384808300012 PM 27330041 ER PT J AU Lewis, MD Francisco, AF Taylor, MC Jayawardhana, S Kelly, JM AF Lewis, Michael D. Francisco, Amanda Fortes Taylor, Martin C. Jayawardhana, Shiromani Kelly, John M. TI Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy SO CELLULAR MICROBIOLOGY LA English DT Article ID CHRONIC-CHAGAS-CARDIOMYOPATHY; HEART-DISEASE; IMMUNE-SYSTEM; LOOKING-BACK; INBRED MICE; AUTOIMMUNITY; PATHOGENESIS; MYOCARDITIS; LESIONS; CLONES AB Host and parasite diversity are suspected to be key factors in Chagas disease pathogenesis. Experimental investigation of underlying mechanisms is hampered by a lack of tools to detect scarce, pleiotropic infection foci. We developed sensitive imaging models to track Trypanosoma cruzi infection dynamics and quantify tissue-specific parasite loads, with minimal sampling bias. We used this technology to investigate cardiomyopathy caused by highly divergent parasite strains in BALB/c, C3H/HeN and C57BL/6 mice. The gastrointestinal tract was unexpectedly found to be the primary site of chronic infection in all models. Immunosuppression induced expansion of parasite loads in the gut and was followed by widespread dissemination. These data indicate that differential immune control of T. cruzi occurs between tissues and shows that the large intestine and stomach provide permissive niches for active infection. The end-point frequency of heart-specific infections ranged from 0% in TcVI-CLBR-infected C57BL/6 to 88% in TcI-JR-infected C3H/HeN mice. Nevertheless, infection led to fibrotic cardiac pathology in all models. Heart disease severity was associated with the model-dependent frequency of dissemination outside the gut and inferred cumulative heart-specific parasite loads. We propose a model of cardiac pathogenesis driven by periodic trafficking of parasites into the heart, occurring at a frequency determined by host and parasite genetics. C1 [Lewis, Michael D.; Francisco, Amanda Fortes; Taylor, Martin C.; Jayawardhana, Shiromani; Kelly, John M.] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, Keppel St, London WC1E 7HT, England. [Lewis, Michael D.] NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA. RP Lewis, MD (reprint author), London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, Keppel St, London WC1E 7HT, England.; Lewis, MD (reprint author), NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA. EM michael.lewis@lshtm.ac.uk FU Wellcome Trust [084175]; British Heart Foundation [PG/13/88/30556]; Bill and Melinda Gates Foundation [OPPGH5337]; Drugs for Neglected Diseases initiative (DNDi); EU Marie Curie Fellowship; NIAID, NIH FX This work was supported by Wellcome Trust Grant 084175, British Heart Foundation Grant PG/13/88/30556, Bill and Melinda Gates Foundation Grant OPPGH5337 and the Drugs for Neglected Diseases initiative (DNDi). MDL is currently supported by an EU Marie Curie Fellowship and the intramural research programme of the NIAID, NIH. The authors thank LSHTM Biological Services Facility staff for technical support, Bruce Branchini for the PpyRE9h luciferase gene, Hernan Carrasco for the JR parasite stock, Laura Muller and Monica Campos for experimental assistance, Cheryl Whitehorn and Louisa Messenger for triatomine samples and Michael Miles for valuable support, discussions and advice. NR 61 TC 3 Z9 3 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-5814 EI 1462-5822 J9 CELL MICROBIOL JI Cell Microbiol. PD OCT PY 2016 VL 18 IS 10 BP 1429 EP 1443 DI 10.1111/cmi.12584 PG 15 WC Cell Biology; Microbiology SC Cell Biology; Microbiology GA DW4KS UT WOS:000383612400009 PM 26918803 ER PT J AU Roudnitzky, N Risso, D Drayna, D Behrens, M Meyerhof, W Wooding, SP AF Roudnitzky, Natacha Risso, Davide Drayna, Dennis Behrens, Maik Meyerhof, Wolfgang Wooding, Stephen P. TI Copy Number Variation in TAS2R Bitter Taste Receptor Genes: Structure, Origin, and Population Genetics SO CHEMICAL SENSES LA English DT Article DE bitter; evolution; genetic; genomic; natural selection; taste receptor ID CELL-LINE PANEL; HUMAN GENOME; DEVELOPMENTAL DELAY; POSITIVE SELECTION; ALLELIC VARIATION; EVOLUTION; SENSITIVITY; HUMANS; DIVERSITY; VARIABILITY AB Bitter taste receptor genes (TAS2Rs) harbor extensive diversity, which is broadly distributed across human populations and strongly associated with taste response phenotypes. The majority of TAS2R variation is composed of single-nucleotide polymorphisms. However, 2 closely positioned loci at 12p13, TAS2R43 and -45, harbor high-frequency deletion (Delta) alleles in which genomic segments are absent, resulting in copy number variation (CNV). To resolve their chromosomal structure and organization, we generated maps using long-range contig alignments and local sequencing across the TAS2R43-45 region. These revealed that the deletion alleles (43 Delta and 45 Delta) are 37.8 and 32.2 kb in length, respectively and span the complete coding region of each gene (similar to 1 kb) along with extensive up-and downstream flanking sequence, producing separate CNVs at the 2 loci. Comparisons with a chimpanzee genome, which contained intact homologs of TAS2R43, -45, and nearby TAS2Rs, indicated that the deletions evolved recently, through unequal recombination in a cluster of closely related loci. Population genetic analyses in 946 subjects from 52 worldwide populations revealed that copy number ranged from 0 to 2 at both TAS2R43 and TAS2R45, with 43 Delta and 45 Delta occurring at high global frequencies (0.33 and 0.18). Estimated recombination rates between the loci were low (rho = 2.7 x 10(-4); r = 6.6 x 10(-9)) and linkage disequilibrium was high (D' = 1.0), consistent with their adjacent genomic positioning and recent origin. Geographic variation pointed to an African origin for the deletions. However, no signatures of natural selection were found in population structure or integrated haplotype scores spanning the region, suggesting that patterns of diversity at TAS2R43 and -45 are primarily due to genetic drift. C1 [Roudnitzky, Natacha; Behrens, Maik; Meyerhof, Wolfgang] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Genet, Arthur Scheunert Allee 114-116, D-14558 Nuthetal, Germany. [Risso, Davide; Drayna, Dennis] NIDCD, NIH, Bethesda, MD 20892 USA. [Wooding, Stephen P.] Univ Calif Merced, Hlth Sci Res Inst, 5200 North Lake Rd, Merced, CA 95343 USA. RP Wooding, SP (reprint author), Univ Calif Merced, Hlth Sci Res Inst, 5200 North Lake Rd, Merced, CA 95343 USA. EM swooding@ucmerced.edu NR 64 TC 0 Z9 0 U1 18 U2 18 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0379-864X EI 1464-3553 J9 CHEM SENSES JI Chem. Senses PD OCT PY 2016 VL 41 IS 8 BP 3 EP 13 DI 10.1093/chemse/bjw067 PG 11 WC Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology SC Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology GA DX5FZ UT WOS:000384406500001 PM 27340135 ER PT J AU Papadakis, GZ Millo, C Sadowski, SM Bagci, U Patronas, NJ AF Papadakis, Georgios Z. Millo, Corina Sadowski, Samira M. Bagci, Ulas Patronas, Nicholas J. TI Epididymal Cystadenomas in von Hippel-Lindau Disease Showing Increased Activity on Ga-68 DOTATATE PET/CT SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE von Hippel-Lindau (VHL) disease; Ga-68 DOTATATE PET/CT; epididymal; cystadenomas; somatostatin receptors imaging ID CEREBELLAR HEMANGIOBLASTOMA; IMAGING FEATURES AB von Hippel-Lindau (VHL) disease is a familial cancer syndrome characterized by the development of a variety of malignant and benign tumors, including epididymal cystadenomas. We report a case of a VHL patient with bilateral epididymal cystadenomas who was evaluated with Ga-68 DOTATATE PET/CT, showing intensely increased activity (SUVmax, 21.6) associated with the epididymal cystadenomas, indicating cell-surface overexpression of somatostatin receptors. The presented case supports the usefulness of somatostatin receptor imaging using Ga-68 DOTA-conjugated peptides for detection and follow-up of VHL manifestations, as well as surveillance of asymptomatic gene carriers. C1 [Papadakis, Georgios Z.; Patronas, Nicholas J.] NCI, Radiol & Imaging Sci, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA. [Millo, Corina] NCI, Div Nucl Med, RADIS, Ctr Clin,NIH, Bethesda, MD 20892 USA. [Sadowski, Samira M.] NCI, Endocrine Oncol Branch, NIH, Bethesda, MD 20892 USA. [Sadowski, Samira M.] Univ Hosp Geneva, Endocrine & Thorac Surg, Geneva, Switzerland. [Bagci, Ulas] Univ Cent Florida, Dept Elect & Comp Sci, Ctr Comp Vis Res, Orlando, FL 32816 USA. RP Patronas, NJ (reprint author), NIH, Radiol & Imaging Sci, Warren Grant Magnuson Clin Ctr, Bldg 10,Room 1C361X 10,Ctr Dr, Bethesda, MD 20814 USA. EM NPatronas@cc.nih.gov FU Intramural NIH HHS [Z99 CL999999] NR 10 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD OCT PY 2016 VL 41 IS 10 BP 781 EP 782 DI 10.1097/RLU.0000000000001314 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DX5WD UT WOS:000384452500023 PM 27454594 ER PT J AU Papadakis, GZ Millo, C Sadowski, SM Bagci, U Patronas, NJ AF Papadakis, Georgios Z. Millo, Corina Sadowski, Samira M. Bagci, Ulas Patronas, Nicholas J. TI Endolymphatic Sac Tumor Showing Increased Activity on Ga-68 DOTATATE PET/CT SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE endolymphatic sac tumors; von Hippel-Lindau disease; Ga-68-DOTATATE PET/CT; somatostatin receptors-imaging ID HIPPEL-LINDAU-DISEASE AB Endolymphatic sac tumors (ELSTs) are rare tumors arising from the epithelium of the endolymphatic sac and duct that can be either sporadic or associated with von Hippel-Lindau (VHL) disease. We report a case of a VHL patient with histologically proven residual ELST who underwent Ga-68 DOTATATE PET/CT showing increased activity (SUVmax, 6.29) by the ELST. The presented case of a VHL-associated ELST with increased Ga-68 DOTATATE uptake indicates cell-surface expression of somatostatin receptors by this tumor, suggesting the potential application of somatostatin receptor imaging using Ga-68 DOTA-conjugated peptides in the workup and management of these patients. C1 [Papadakis, Georgios Z.; Patronas, Nicholas J.] NCI, Radiol & Imaging Sci, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA. [Millo, Corina] NCI, Div Nucl Med, RAD&IS, Ctr Clin,NIH, Bethesda, MD 20892 USA. [Sadowski, Samira M.] NCI, Endocrine Oncol Branch, NIH, Bethesda, MD 20892 USA. [Sadowski, Samira M.] Univ Hosp Geneva, Endocrine & Thorac Surg, Geneva, Switzerland. [Bagci, Ulas] Univ Cent Florida, Dept Elect & Comp Sci, Ctr Comp Vis Res, Orlando, FL 32816 USA. RP Patronas, NJ (reprint author), NIH, Neuroradiol Sect, Warren Grant Magnuson Clin Ctr, Bldg 10,Room 1C361X 10,Ctr Dr, Bethesda, MD 20814 USA. EM NPatronas@cc.nih.gov FU Intramural NIH HHS [Z99 CL999999] NR 12 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD OCT PY 2016 VL 41 IS 10 BP 783 EP 784 DI 10.1097/RLU.0000000000001315 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DX5WD UT WOS:000384452500024 PM 27454593 ER PT J AU Knickelbein, JE Abbott, AB Chew, EY AF Knickelbein, Jared E. Abbott, Akshar B. Chew, Emily Y. TI Fenofibrate and Diabetic Retinopathy SO CURRENT DIABETES REPORTS LA English DT Review DE Diabetic retinopathy; Diabetic macular edema; Fenofibrate ID CONTROL-CARDIOVASCULAR-RISK; RANDOMIZED CONTROLLED-TRIAL; MACULAR EDEMA; MELLITUS; PREVALENCE; COMPLICATIONS; RANIBIZUMAB; PROGRESSION; DYSLIPIDEMIA; ASSOCIATION AB Diabetic retinopathy, a common and sight-threatening microvascular complication of diabetes mellitus, is a leading cause of blindness among working-aged adults. Medical therapies including intensive control of hyperglycemia and hypertension have been shown to reduce the incidence and progression of diabetic retinopathy. The association of dyslipidemia and treatment with statins with diabetic retinopathy is inconsistent in epidemiologic studies. However, two recent randomized clinical trials have demonstrated beneficial effects of systemic fenofibrate therapy in reducing the progression of diabetic retinopathy independently of serum lipid levels. These findings suggest that fenofibrate may be an effective strategy for reducing the progression of diabetic retinopathy, thus reducing the large and growing public health burden of treating the sight-threatening complications of diabetic retinopathy. C1 [Knickelbein, Jared E.; Abbott, Akshar B.; Chew, Emily Y.] NEI, NIH, 10 Ctr Dr,10-10D45, Bethesda, MD 20892 USA. [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, Clin Trials Branch, NIH, Bldg 10 Clin Res Ctr,Room3-2531,10 Ctr Dr, Bethesda, MD 20892 USA. RP Chew, EY (reprint author), NEI, NIH, 10 Ctr Dr,10-10D45, Bethesda, MD 20892 USA.; Chew, EY (reprint author), NEI, Div Epidemiol & Clin Applicat, Clin Trials Branch, NIH, Bldg 10 Clin Res Ctr,Room3-2531,10 Ctr Dr, Bethesda, MD 20892 USA. EM Knickelbeinje@nei.nih.gov; akshar.abbott@nih.gov; echew@nei.nih.gov FU Intramural Research Program of the NIH, NEI FX This research was supported by the Intramural Research Program of the NIH, NEI. NR 45 TC 1 Z9 1 U1 2 U2 2 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 EI 1539-0829 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD OCT PY 2016 VL 16 IS 10 AR 90 DI 10.1007/s11892-016-0786-7 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DX7CG UT WOS:000384543100002 PM 27525681 ER PT J AU Robinson, C Collins, MT Boyce, AM AF Robinson, Cemre Collins, Michael T. Boyce, Alison M. TI Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives SO CURRENT OSTEOPOROSIS REPORTS LA English DT Review DE Fibrous dysplasia; McCune-Albright syndrome; GNAS gene; G(s)alpha; FGF23 ID MARROW STROMAL CELLS; DENOSUMAB TREATMENT; ACTIVATING MUTATIONS; INTRAVENOUS PAMIDRONATE; MONOZYGOTIC TWINS; SKELETAL LESIONS; RANK-LIGAND; STEM-CELLS; G-PROTEIN; BONE AB Fibrous dysplasia (FD) is an uncommon and debilitating skeletal disorder resulting in fractures, deformity, functional impairment, and pain. It arises from post-zygotic somatic activating mutations in GNAS, in the cAMP-regulating transcript alpha-subunit, G(s)alpha. Constitutive G(s) signaling results in activation of adenylyl cyclase and dysregulated cAMP production. In the skeleton, this leads to the development of FD lesions with abnormal bone matrix, trabeculae, and collagen, produced by undifferentiated mesenchymal cells. FD may occur in isolation or in combination with extraskeletal manifestations, including hyperfunctioning endocrinopathies and cafc-au-lait macules, termed McCune-Albright syndrome (MAS). This review summarizes current clinical and translational perspectives in FD/MAS, with an emphasis on FD pathogenesis, natural history, pre-clinical and clinical investigation, and future directions. C1 [Robinson, Cemre; Collins, Michael T.; Boyce, Alison M.] Natl Inst Dent & Craniofacial Res, Sect Skeletal Disorders andMineral Homeostasis, Craniofacial & Skeletal Dis Branch, NIH, 30 Convent Dr Room 228 MSC 4320, Bethesda, MD 20892 USA. [Boyce, Alison M.] Childrens Natl Hlth Syst, Div Endocrinol & Diabet, Washington, DC 20010 USA. [Boyce, Alison M.] Childrens Natl Hlth Syst, Div Orthopaed & Sports Med, Bone Hlth Program, Washington, DC 20010 USA. RP Boyce, AM (reprint author), Natl Inst Dent & Craniofacial Res, Sect Skeletal Disorders andMineral Homeostasis, Craniofacial & Skeletal Dis Branch, NIH, 30 Convent Dr Room 228 MSC 4320, Bethesda, MD 20892 USA.; Boyce, AM (reprint author), Childrens Natl Hlth Syst, Div Endocrinol & Diabet, Washington, DC 20010 USA.; Boyce, AM (reprint author), Childrens Natl Hlth Syst, Div Orthopaed & Sports Med, Bone Hlth Program, Washington, DC 20010 USA. EM boyceam@mail.nih.gov FU Intramural Research Program of the National Institute of Dental and Craniofacial Research FX This research was supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research NR 72 TC 1 Z9 1 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1544-2241 J9 CURR OSTEOPOROS REP JI Curr. Osteoporos. Rep. PD OCT PY 2016 VL 14 IS 5 BP 178 EP 186 DI 10.1007/s11914-016-0317-0 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DX7DH UT WOS:000384546100003 PM 27492469 ER PT J AU Provinciali, N Suen, C Dunn, BK DeCensi, A AF Provinciali, Nicoletta Suen, Chen Dunn, Barbara K. DeCensi, Andrea TI Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY LA English DT Article DE Clinical trials; raloxifene; breast cancer risk; cancer prevention; pharmacology ID ESTROGEN-RECEPTOR MODULATOR; RANDOMIZED CONTROLLED-TRIAL; SURGICAL ADJUVANT BREAST; CORONARY-HEART-DISEASE; BONE-MINERAL DENSITY; STAR P-2 TRIAL; PREMENOPAUSAL WOMEN; HORMONE-THERAPY; CLINICAL-TRIAL; CARDIOVASCULAR EVENTS AB Introduction: Raloxifene is an estrogen receptor modulator which competes with estrogens for binding to the estrogen receptor. Based on the results of the STAR (Study of Tamoxifen And Raloxifene) trial, raloxifene has been approved by the U.S. Food and Drug Administration for the reduction of breast cancer (BC) risk in postmenopausal women at increased risk. Areas covered: This analysis reviews the activity of raloxifene and the clinical trials for non-BC indications which led to investigate its use as BC preventive agent. We review the trial establishing its efficacy for BC prevention and the meta-analyses including different SERMs for BC prevention. Expert commentary: Compared with tamoxifen, raloxifene has shown a slightly lower efficacy in reducing BC risk and a better safety profile. Raloxifene also offers to postmenopausal women a benefit in terms of osteoporosis. Future research should investigate its use in premenopausal women and in association with other preventive agents. C1 [Provinciali, Nicoletta; DeCensi, Andrea] EO Osped Galliera, Div Med Oncol, Mura Cappuccine 14, I-16128 Genoa, Italy. [Suen, Chen; Dunn, Barbara K.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA. [DeCensi, Andrea] European Inst Oncol, Div Canc Prevent & Genet, Milan, Italy. RP Provinciali, N (reprint author), EO Osped Galliera, Div Med Oncol, Mura Cappuccine 14, I-16128 Genoa, Italy. EM nicoletta.provinciali@galliera.it NR 67 TC 0 Z9 0 U1 5 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1751-2433 EI 1751-2441 J9 EXPERT REV CLIN PHAR JI Expert Rev. Clin. Pharmacol. PD OCT PY 2016 VL 9 IS 10 BP 1263 EP 1272 DI 10.1080/17512433.2016.1231575 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DX8MR UT WOS:000384643500002 ER PT J AU Lynch, JA Berse, B Petkov, V Filipski, K Zhou, YJ Khoury, MJ Hassett, M Freedman, AN AF Lynch, Julie A. Berse, Brygida Petkov, Valentina Filipski, Kelly Zhou, Yingjun Khoury, Muin J. Hassett, Michael Freedman, Andrew N. TI Implementation of the 21-gene recurrence score test in the United States in 2011 SO GENETICS IN MEDICINE LA English DT Article DE breast cancer; cancer genomics; dissemination; equity; implementation ID NEGATIVE BREAST-CANCER; GENE-EXPRESSION; ASSAY; POPULATION; ESTROGEN; SUBTYPES; RISK; CHEMOTHERAPY; PATTERNS; WOMEN AB Purpose: We examined hospital use of the 21-gene breast cancer test in the United States. We report state-level differences in utilization and propose a model for predicting implementation of -guideline-recommended genomic testing. Methods: Genomic Health provided test orders for calendar year 2011. We summarized utilization at the hospital and state levels. Using logistic regression, we analyzed the association between the likelihood to order the test and the hospital's institutional and regional characteristics. Results: In 2011, 45% of 4,712 acute-care hospitals ordered the test, which suggests that 25% of newly diagnosed invasive female breast cancer cases were tested. Significant predictors of testing included participation in National Cancer Institute (NCI) clinical research cooperative groups (odds ratio (OR) 3.73; 95% confidence interval, 2.96-4.70), advanced imaging (OR, 2.19; CI, 1.78-2.68), high-complexity laboratory (OR, 2.15; CI, 1.24-3.70), affiliation with a medical school (OR, 1.57; CI, 1.31-1.88), and reconstructive surgery (OR, 1.23; CI, 1.01-1.50). Significant regional predictors included metropolitan county (OR, 3.77; CI, 2.83-5.03), above-mean income (OR, 1.37; CI, 1.11-1.69), and education (OR, 1.26; CI, 1.03-1.54). Negative predictors included designation as a critical-access hospital (OR, 0.10; CI, 0.07-0.14) and distance from an NCI cancer center (OR, 0.998; CI, 0.997-0.999), with a 15% decrease in likelihood for every 100 miles. Conclusion: Despite considerable market penetration of the test, there are significant regional and site-of-care differences in implementation, particularly in rural states. C1 [Lynch, Julie A.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA. [Lynch, Julie A.; Berse, Brygida] RTI Int, Durham, NC 27709 USA. [Berse, Brygida] Boston Univ, Sch Med, Boston, MA 02118 USA. [Berse, Brygida] Vet Hlth Adm, Bedford, MA USA. [Petkov, Valentina; Filipski, Kelly; Zhou, Yingjun; Freedman, Andrew N.] NCI, NIH, Bethesda, MD 20892 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, NIH, Bethesda, MD 20892 USA. [Hassett, Michael] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hassett, Michael] Harvard Med Sch, Boston, MA USA. RP Lynch, JA (reprint author), VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA.; Lynch, JA (reprint author), RTI Int, Durham, NC 27709 USA. EM Julie.Lynch@va.gov OI Lynch, Julie/0000-0003-0108-2127 FU National Cancer Institute FX This research was conducted while J.A.L. was a postdoctoral fellow within the Center for Healthcare Organization and Implementation Research (CHOIR), a Veterans Administration Health Services Research & Development Center of Excellence. She and B.B. are funded by the National Cancer Institute through an Interagency Agreement. Preliminary results were previously presented as a poster at the 49th American Society of Clinical Oncology Annual Meeting, 31 May 20. NR 34 TC 2 Z9 2 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD OCT PY 2016 VL 18 IS 10 BP 982 EP 990 DI 10.1038/gim.2015.218 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA DX8CN UT WOS:000384615800013 PM 26890451 ER PT J AU Kelly, NR Tanofsky-Kraff, M Vannucci, A Ranzenhofer, LM Altschul, AM Schvey, NA Shank, LM Brady, SM Galescu, O Kozlosky, M Yanovski, SZ Yanovski, JA AF Kelly, Nichole R. Tanofsky-Kraff, Marian Vannucci, Anna Ranzenhofer, Lisa M. Altschul, Annie M. Schvey, Natasha A. Shank, Lisa M. Brady, Sheila M. Galescu, Ovidiu Kozlosky, Merel Yanovski, Susan Z. Yanovski, Jack A. TI Emotion Dysregulation and Loss-of-Control Eating in Children and Adolescents SO HEALTH PSYCHOLOGY LA English DT Article DE emotion regulation; loss-of-control eating; binge eating; body mass; fat mass ID HANDLING MISSING DATA; BODY-MASS INDEX; SELF-REGULATION; ADULT OBESITY; OVERWEIGHT CHILDREN; BEHAVIOR CHECKLIST; PUBERTAL STAGE; MEDIATING ROLE; ENERGY-INTAKE; HIGH-RISK AB Objective: To examine the associations among self-reported loss-of-control (LOC) eating, emotion dysregulation, body mass, and objective energy intake among youth. Emotion dysregulation may be 1 individual factor that promotes excess energy intake and increases in body mass among youth with LOC eating. Method: Children and adolescents (N = 230; 8 to 17 years) enrolled in a nonintervention study completed a structured interview to determine the presence or absence of self-reported LOC eating. Children's emotion dysregulation was assessed via parent-report with the Child Behavior Checklist. Youth also completed 2 test meals to capture "binge" and "normal" eating. Body composition was examined using air displacement plethysmography. Results: After controlling for relevant covariates, youth with self-reported LOC eating had higher parent-reported emotion dysregulation than those without LOC. Parent-reported emotion dysregulation was also associated with greater observed energy intake (after accounting for body mass), as well as higher fat mass. Emotion dysregulation also moderated associations between LOC status/gender and body mass variables; among youth with self-reported LOC eating and girls, those with high parent-described emotion dysregulation (vs. low) had significantly higher fat mass and BMIz. Conclusions: Data from the current study suggest that emotion dysregulation may play a role in energy intake and obesity, particularly among youth with self-reported LOC eating and girls. Additional studies are needed to identify the prospective mechanisms linking poor emotion regulation and LOC eating. These mechanisms, in turn, may inform future interventions targeting excess energy intake and obesity in pediatric samples. C1 [Kelly, Nichole R.; Tanofsky-Kraff, Marian; Vannucci, Anna; Altschul, Annie M.; Schvey, Natasha A.; Shank, Lisa M.; Brady, Sheila M.; Galescu, Ovidiu; Kozlosky, Merel; Yanovski, Susan Z.; Yanovski, Jack A.] NIH, US Dept HHS, Bldg 10, Bethesda, MD 20892 USA. [Kelly, Nichole R.; Tanofsky-Kraff, Marian; Vannucci, Anna; Schvey, Natasha A.; Shank, Lisa M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Ranzenhofer, Lisa M.] Brown Univ, Miriam Hosp, Alpert Med Sch, Providence, RI USA. RP Tanofsky-Kraff, M (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM marian.tanofsky-kraff@usuhs.edu OI Shank, Lisa/0000-0002-6922-7946 FU USUHS [R072IC]; Intramural Research Program, NIH from the NICHD [1ZIAHD000641]; NIMHD; Bench to Bedside Program; Office of Behavioral and Social Sciences Research (OBSSR) of the NIH; NIMH [5F31MH095348]; Division of Nutrition Research Coordination, NIH FX USUHS Grant R072IC (to Marian Tanofsky-Kraff). Intramural Research Program, NIH, Grant 1ZIAHD000641 from the NICHD with supplemental funding from NIMHD, the Bench to Bedside Program, the Office of Behavioral and Social Sciences Research (OBSSR) of the NIH (to Jack A. Yanovski), and NIMH 5F31MH095348 (to Lisa M. Ranzenhofer). Annie M. Altschul is supported by the Division of Nutrition Research Coordination, NIH. NR 59 TC 0 Z9 0 U1 7 U2 7 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD OCT PY 2016 VL 35 IS 10 BP 1110 EP 1119 DI 10.1037/hea0000389 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA DX6XU UT WOS:000384530200007 PM 27505194 ER PT J AU Xu, Y Li, F Zalzala, M Xu, JS Gonzalez, FJ Adorini, L Lee, YK Yin, LY Zhang, YQ AF Xu, Yang Li, Fei Zalzala, Munaf Xu, Jiesi Gonzalez, Frank J. Adorini, Luciano Lee, Yoon-Kwang Yin, Liya Zhang, Yanqiao TI Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice SO HEPATOLOGY LA English DT Article ID NEGATIVE FEEDBACK-REGULATION; FATTY LIVER-DISEASE; E-KNOCKOUT MICE; NUCLEAR RECEPTOR; LIPID HOMEOSTASIS; IN-VIVO; METABOLISM; PATHWAYS; FXR; ATHEROSCLEROSIS AB Activation of farnesoid X receptor (FXR) markedly attenuates development of atherosclerosis in animal models. However, the underlying mechanism is not well elucidated. Here, we show that the FXR agonist, obeticholic acid (OCA), increases fecal cholesterol excretion and macrophage reverse cholesterol transport (RCT) dependent on activation of hepatic FXR. OCA does not increase biliary cholesterol secretion, but inhibits intestinal cholesterol absorption. OCA markedly inhibits hepatic cholesterol 7-alpha hydroxylase (Cyp7a1) and sterol 12 alpha-hydroxylase (Cyp8b1) partly through inducing small heterodimer partner, leading to reduced bile acid pool size and altered bile acid composition, with the alpha/beta-muricholic acid proportion in bile increased by 2.6-fold and taurocholic acid (TCA) level reduced by 71%. Overexpression of Cyp8b1 or concurrent overexpression of Cyp7a1 and Cyp8b1 normalizes TCA level, bile acid composition, and intestinal cholesterol absorption. Conclusion: Activation of FXR inhibits intestinal cholesterol absorption by modulation of bile acid pool size and composition, thus leading to increased RCT. Targeting hepatic FXR and/or bile acids may be useful for boosting RCT and preventing the development of atherosclerosis. C1 [Xu, Yang; Zalzala, Munaf; Xu, Jiesi; Lee, Yoon-Kwang; Yin, Liya; Zhang, Yanqiao] Northeast Ohio Med Univ, Dept Integrat Med Sci, 4209 St,Route 44,POB 95, Rootstown, OH 44272 USA. [Li, Fei; Gonzalez, Frank J.] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Zalzala, Munaf] Univ Baghdad, Coll Pharm, Dept Pharmacol & Toxicol, Baghdad, Iraq. [Adorini, Luciano] Intercept Pharmaceut, New York, NY USA. RP Yin, LY; Zhang, YQ (reprint author), Northeast Ohio Med Univ, Dept Integrat Med Sci, 4209 St,Route 44,POB 95, Rootstown, OH 44272 USA. EM lyin@neomed.edu; yzhang@neomed.edu FU NIH [R01HL103227, R01DK095895, R01DK102619] FX This work was supported by NIH grants R01HL103227, R01DK095895, and R01DK102619 (to Y.Z.). NR 43 TC 2 Z9 2 U1 13 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 IS 4 BP 1072 EP 1085 DI 10.1002/hep.28712 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DX7FP UT WOS:000384552300010 PM 27359351 ER PT J AU Bae, HR Leung, PSC Tsuneyama, K Valencia, JC Hodge, DL Kim, S Back, T Karwan, M Merchant, AS Baba, N Feng, DC Park, O Gao, B Yang, GX Gershwin, ME Young, HA AF Bae, Heekyong R. Leung, Patrick S. C. Tsuneyama, Koichi Valencia, Julio C. Hodge, Deborah L. Kim, Seohyun Back, Tim Karwan, Megan Merchant, Anand S. Baba, Nobuyuki Feng, Dechun Park, Ogyi Gao, Bin Yang, Guo-Xiang Gershwin, M. Eric Young, Howard A. TI Chronic Expression of Interferon-Gamma Leads to Murine Autoimmune Cholangitis With a Female Predominance SO HEPATOLOGY LA English DT Article ID PRIMARY BILIARY-CIRRHOSIS; GENOME-WIDE ASSOCIATION; DIFFERENTIAL GENE-EXPRESSION; ANTIMITOCHONDRIAL ANTIBODIES; T-CELLS; SUSCEPTIBILITY LOCI; IMMUNE-RESPONSES; EPITHELIAL-CELLS; ANIMAL-MODELS; RISK-FACTORS AB In most autoimmune diseases the serologic hallmarks of disease precede clinical pathology by years. Therefore, the use of animal models in defining early disease events becomes critical. We took advantage of a "designer" mouse with dysregulation of interferon gamma (IFN gamma) characterized by prolonged and chronic expression of IFN through deletion of the IFN gamma 3-untranslated region adenylate uridylate-rich element (ARE). The ARE-Del(-/-) mice develop primary biliary cholangitis (PBC) with a female predominance that mimics human PBC that is characterized by up-regulation of total bile acids, spontaneous production of anti-mitochondrial antibodies, and portal duct inflammation. Transfer of CD4 T cells from ARE-Del(-/-) to B6/Rag1(-/-) mice induced moderate portal inflammation and parenchymal inflammation, and RNA sequencing of liver gene expression revealed that up-regulated genes potentially define early stages of cholangitis. Interestingly, up-regulated genes specifically overlap with the gene expression signature of biliary epithelial cells in PBC, implying that IFN gamma may play a pathogenic role in biliary epithelial cells in the initiation stage of PBC. Moreover, differentially expressed genes in female mice have stronger type 1 and type 2 IFN gamma signaling and lymphocyte-mediated immune responses and thus may drive the female bias of the disease. Conclusion: Changes in IFN expression are critical for the pathogenesis of PBC. C1 [Bae, Heekyong R.; Valencia, Julio C.; Hodge, Deborah L.; Kim, Seohyun; Back, Tim; Young, Howard A.] NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA. [Leung, Patrick S. C.; Yang, Guo-Xiang; Gershwin, M. Eric] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA. [Tsuneyama, Koichi] Univ Tokushima, Inst Biomed Sci, Dept Pathol & Lab Med, Grad Sch, Tokushima, Japan. [Karwan, Megan] NCI, Lab Anim Sci, Frederick, MD 21701 USA. [Merchant, Anand S.] NCI, CCR Collaborat Bioinformat Core, Bethesda, MD 20892 USA. [Baba, Nobuyuki] Kagawa Prefectural Cent Hosp, Cent Lab, Takamatsu, Kagawa, Japan. [Feng, Dechun; Gao, Bin] NIAAA, Lab Liver Dis, Rockville, MD 20852 USA. [Park, Ogyi] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA. RP Young, HA (reprint author), NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21702 USA.; Gershwin, ME (reprint author), Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA. FU National Institutes of Health grant [DK090019] FX Supported in part by National Institutes of Health grant DK090019 (to M.E.G.). NR 44 TC 3 Z9 3 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 IS 4 BP 1189 EP 1201 DI 10.1002/hep.28641 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DX7FP UT WOS:000384552300018 PM 27178326 ER PT J AU Porat-Shliom, N Tietgens, AJ Van Itallie, CM Vitale-Cross, L Jarnik, M Harding, OJ Anderson, JM Gutkind, JS Weigert, R Arias, IM AF Porat-Shliom, Natalie Tietgens, Amber J. Van Itallie, Christina M. Vitale-Cross, Lynn Jarnik, Michal Harding, Olivia J. Anderson, James M. Gutkind, J. Silvio Weigert, Roberto Arias, Irwin M. TI Liver Kinase B1 Regulates Hepatocellular Tight Junction Distribution and Function In Vivo SO HEPATOLOGY LA English DT Article ID ACTIVATED PROTEIN-KINASE; HEPATOCYTE POLARIZATION; MITOCHONDRIAL FISSION; CELL POLARITY; LKB1; AMPK; PERMEABILITY; CINGULIN; PHOSPHORYLATION; BARRIER AB Liver kinase B1 (LKB1) and its downstream effector AMP-activated protein kinase (AMPK) play critical roles in polarity establishment by regulating membrane trafficking and energy metabolism. In collagen sandwich-cultured hepatocytes, loss of LKB1 or AMPK impaired apical ABCB11 (Bsep) trafficking and bile canalicular formation. In the present study, we used liver-specific (albumin-Cre) LKB1 knockout mice (LKB1(-/-)) to investigate the role of LKB1 in the maintenance of functional tight junction (TJ) in vivo. Transmission electron microscopy examination revealed that hepatocyte apical membrane with microvilli substantially extended into the basolateral domain of LKB1(-/-) livers. Immunofluorescence studies revealed that loss of LKB1 led to longer and wider canalicular structures correlating with mislocalization of the junctional protein, cingulin. To test junctional function, we used intravital microscopy to quantify the transport kinetics of 6-carboxyfluorescein diacetate (6-CFDA), which is processed in hepatocytes into its fluorescent derivative 6-carboxyfluorescein (6-CF) and secreted into the canaliculi. In LKB1(-/-) mice, 6-CF remained largely in hepatocytes, canalicular secretion was delayed, and 6-CF appeared in the blood. To test whether 6-CF was transported through permeable TJ, we intravenously injected low molecular weight (3 kDa) dextran in combination with 6-CFDA. In wild-type mice, 3 kDa dextran remained in the vasculature, whereas it rapidly appeared in the abnormal bile canaliculi in LKB1(-/-) mice, confirming that junctional disruption resulted in paracellular exchange between the blood stream and the bile canaliculus. Conclusion: LKB1 plays a critical role in regulating the maintenance of TJ and paracellular permeability, which may explain how various drugs, chemicals, and metabolic states that inhibit the LKB1/AMPK pathway result in cholestasis. C1 [Porat-Shliom, Natalie; Vitale-Cross, Lynn; Harding, Olivia J.; Gutkind, J. Silvio; Weigert, Roberto] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA. [Porat-Shliom, Natalie; Weigert, Roberto] NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA. [Tietgens, Amber J.; Van Itallie, Christina M.; Anderson, James M.] NHLBI, Lab Tight Junct Struct & Funct, Bldg 10, Bethesda, MD 20892 USA. [Jarnik, Michal; Arias, Irwin M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Cell Biol & Metab Program, NIH, Bethesda, MD USA. RP Porat-Shliom, N (reprint author), NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bldg 37,Room 2050B, Bethesda, MD 20892 USA. EM poratshliomn@mail.nih.gov FU Intramural Research Program of the National Institutes of Health, National Institute of Dental and Craniofacial Research FX This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Dental and Craniofacial Research. NR 48 TC 3 Z9 3 U1 10 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 IS 4 BP 1317 EP 1329 DI 10.1002/hep.28724 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DX7FP UT WOS:000384552300027 PM 27396550 ER PT J AU Mandrekar, P Bataller, R Tsukamoto, H Gao, B AF Mandrekar, Pranoti Bataller, Ramon Tsukamoto, Hidekazu Gao, Bin TI Alcoholic Hepatitis: Translational Approaches to Develop Targeted Therapies SO HEPATOLOGY LA English DT Article ID INDUCED LIVER-INJURY; TUMOR-NECROSIS-FACTOR; MACROPHAGE ACTIVATION; BINGE ETHANOL; MICE; DISEASE; INFLAMMATION; STEATOSIS; CELL; STEATOHEPATITIS AB Alcoholic liver disease is a leading cause of liver-related mortality worldwide. In contrast to recent advances in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel therapeutic options for patients with alcoholic liver disease. In particular, there is an urgent need to focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoholic liver disease. AH is characterized by an abrupt development of jaundice and complications related to liver insufficiency and portal hypertension in patients with heavy alcohol intake. The mortality of patients with AH is very high (20%-50% at 3 months). Available therapies are not effective in many patients, and targeted approaches are imminently needed. The development of such therapies requires translational studies in human samples and suitable animal models that reproduce the clinical and histological features of AH. In recent years, new animal models that simulate some of the features of human AH have been developed, and translational studies using human samples have identified potential pathogenic factors and histological parameters that predict survival. Conclusion: This review summarizes the unmet needs for translational studies on the pathogenesis of AH, preclinical translational tools, and emerging drug targets to benefit the AH patient. C1 [Mandrekar, Pranoti] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Bataller, Ramon] Univ N Carolina, Div Gastroenterol & Hepatol, Dept Med, Chapel Hill, NC USA. [Bataller, Ramon] Univ N Carolina, Div Gastroenterol & Hepatol, Dept Nutr, Chapel Hill, NC USA. [Tsukamoto, Hidekazu] Univ Southern Calif, Greater Los Angeles Dept Vet Affairs Healthcare S, Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. [Tsukamoto, Hidekazu] Univ Southern Calif, Greater Los Angeles Dept Vet Affairs Healthcare S, Dept Pathol, Los Angeles, CA USA. [Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD USA. RP Gao, B (reprint author), NIAAA, Lab Liver Dis, NIH, Bethesda, MD USA.; Mandrekar, P (reprint author), Univ Massachusetts, Med Ctr, Gastrointestinal Div, Dept Med, LRB Rm 221 364 Plantat St, Worcester, MA 01605 USA.; Bataller, R (reprint author), Univ North Carlina, Chapel Hill, NC 27599 USA.; Tsukamoto, H (reprint author), Univ South Calif, Los Angeles, CA 90089 USA. EM Pranoti.Mandrekar@umassmed.edu; ramon_bataller@med.unc.edu; htsukamo@med.usc.edu; bgao@mail.nih.gov FU Department of Defense [W81XWH-11-1-0420, W81XWH-13-1-0498]; National Institute on Alcohol Abuse and Alcoholism [5P50AA011999, 1U01AA018663, 5R24AA012885]; Department of Veterans Affairs Merit Review award [5I01BX001991]; National Institute on Alcohol Abuse and Alcoholism Intramural Program; [2AA017986-01]; [1U01AA021908-01]; [1U01AA020821] FX Supported by RO1 #2AA017986-01 and Department of Defense grants PRMRP #W81XWH-11-1-0420 and PRMRP#W81XWH-13-1-0498 (to P.M.); grants 1U01AA021908-01 and 1U01AA020821 (to R.B.); National Institute on Alcohol Abuse and Alcoholism grants 5P50AA011999, 1U01AA018663, and 5R24AA012885 and Department of Veterans Affairs Merit Review award 5I01BX001991 (to H.T.); and the National Institute on Alcohol Abuse and Alcoholism Intramural Program (to B.G.). NR 61 TC 6 Z9 6 U1 9 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 IS 4 BP 1343 EP 1355 DI 10.1002/hep.28530 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DX7FP UT WOS:000384552300029 PM 26940353 ER PT J AU Tang, DM Heller, T Koh, C AF Tang, Derek M. Heller, Theo Koh, Christopher TI The Many Faces of Positive Hepatitis B Surface Antigen SO HEPATOLOGY LA English DT Letter C1 [Tang, Derek M.; Koh, Christopher] NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA. [Heller, Theo; Koh, Christopher] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA. RP Tang, DM (reprint author), NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA. FU Intramural NIH HHS [Z99 DK999999] NR 5 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD OCT PY 2016 VL 64 IS 4 BP 1379 EP 1381 DI 10.1002/hep.28503 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DX7FP UT WOS:000384552300043 PM 26890893 ER PT J AU Peng, GCY AF Peng, Grace C. Y. TI Moving Toward Model Reproducibility and Reusability SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE Biological system modeling; biomedical computing; biomedical engineering; computational biology; computational modeling; computer simulation; reproducibility of results AB This paper provides a brief history of the U.S. funding initiatives associated with promoting multiscale modeling of the physiome since 2003. An effort led in the United States is the Interagency Modeling and Analysis Group (IMAG) Multiscale Modeling (MSM) Consortium. Though IMAG and the MSM Consortium have generated much interest in developing MSM models of the physiome, challenges associated with model and data sharing in biomedical, biological, and behavioral systems still exist. Since 2013, the IEEE EMBS Technical Committee on Computational Biology and the Physiome (CBaP TC) has supported discussions on promoting model reproducibility through publications. This special issue on model sharing and reproducibility is a realization of the CBaP TC discussions. Though open questions remain on how we can further facilitate model reproducibility, accessibility, and reuse by the worldwide community for different biomedical domain applications, this special issue provides a unique demonstration of both the challenges and opportunities for publishing reproducible computational models. C1 [Peng, Grace C. Y.] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA. RP Peng, GCY (reprint author), Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA. EM grace.peng@nih.gov FU Intramural NIH HHS [Z99 EB999999] NR 8 TC 0 Z9 0 U1 3 U2 3 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 0018-9294 EI 1558-2531 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD OCT PY 2016 VL 63 IS 10 BP 1997 EP 1998 DI 10.1109/TBME.2016.2603418 PG 2 WC Engineering, Biomedical SC Engineering GA DX7LZ UT WOS:000384570200002 PM 27576241 ER PT J AU Chan, JL Mazilu, D Miller, JG Hunt, T Horvath, KA Li, M AF Chan, Joshua L. Mazilu, Dumitru Miller, Justin G. Hunt, Timothy Horvath, Keith A. Li, Ming TI Robotic-assisted real-time MRI-guided TAVR: from system deployment to in vivo experiment in swine model SO INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY LA English DT Article DE Robotic assistance; MRI; Magnetic resonance; TAVR; Valve replacement; Cardiac surgery ID AORTIC-VALVE-REPLACEMENT; IMPLANTATION; STENOSIS; SURGERY; SAFETY; PROSTHESIS; PLACEMENT AB Real-time magnetic resonance imaging (rtMRI) guidance provides significant advantages during transcatheter aortic valve replacement (TAVR) as it provides superior real-time visualization and accurate device delivery tracking. However, performing a TAVR within an MRI scanner remains difficult due to a constrained procedural environment. To address these concerns, a magnetic resonance (MR)-compatible robotic system to assist in TAVR deployments was developed. This study evaluates the technical design and interface considerations of an MR-compatible robotic-assisted TAVR system with the purpose of demonstrating that such a system can be developed and executed safely and precisely in a preclinical model. An MR-compatible robotic surgical assistant system was built for TAVR deployment. This system integrates a 5-degrees of freedom (DoF) robotic arm with a 3-DoF robotic valve delivery module. A user interface system was designed for procedural planning and real-time intraoperative manipulation of the robot. The robotic device was constructed of plastic materials, pneumatic actuators, and fiber-optical encoders. The mechanical profile and MR compatibility of the robotic system were evaluated. The system-level error based on a phantom model was 1.14 +/- 0.33 mm. A self-expanding prosthesis was successfully deployed in eight Yorkshire swine under rtMRI guidance. Post-deployment imaging and necropsy confirmed placement of the stent within 3 mm of the aortic valve annulus. These phantom and in vivo studies demonstrate the feasibility and advantages of robotic-assisted TAVR under rtMRI guidance. This robotic system increases the precision of valve deployments, diminishes environmental constraints, and improves the overall success of TAVR. C1 [Chan, Joshua L.; Mazilu, Dumitru; Miller, Justin G.; Hunt, Timothy; Horvath, Keith A.; Li, Ming] NHLBI, Cardiothorac Surg Res Program, NIH, Bldg 10,Room B1D47,MSC 1550,10 Ctr Dr, Bethesda, MD 20892 USA. RP Li, M (reprint author), NHLBI, Cardiothorac Surg Res Program, NIH, Bldg 10,Room B1D47,MSC 1550,10 Ctr Dr, Bethesda, MD 20892 USA. EM Joshua.Chan@nih.gov; horvathka@nhlbi.nih.gov; lim2@mail.nih.gov OI Chan, Joshua/0000-0001-7220-561X FU Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), US Department of Health and Human Services (DHHS) FX This research was made possible by funding from the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), US Department of Health and Human Services (DHHS) NR 39 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1861-6410 EI 1861-6429 J9 INT J COMPUT ASS RAD JI Int. J. Comput. Assist. Radiol. Surg. PD OCT PY 2016 VL 11 IS 10 BP 1905 EP 1918 DI 10.1007/s11548-016-1421-4 PG 14 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery SC Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery GA DX7EP UT WOS:000384549700012 PM 27246950 ER PT J AU Lansford, JE Godwin, J Alampay, LP Tirado, LMU Zelli, A Al-Hassan, SM Bacchini, D Bombi, AS Bornstein, MH Chang, L Deater-Deckard, K Di Giunta, L Dodge, KA Malone, PS Oburu, P Pastorelli, C Skinner, AT Sorbring, E Tapanya, S AF Lansford, Jennifer E. Godwin, Jennifer Pena Alampay, Liane Uribe Tirado, Liliana Maria Zelli, Arnaldo Al-Hassan, Suha M. Bacchini, Dario Bombi, Anna Silvia Bornstein, Marc H. Chang, Lei Deater-Deckard, Kirby Di Giunta, Laura Dodge, Kenneth A. Malone, Patrick S. Oburu, Paul Pastorelli, Concetta Skinner, Ann T. Sorbring, Emma Tapanya, Sombat TI Mothers', fathers' and children's perceptions of parents' expectations about children's family obligations in nine countries SO INTERNATIONAL JOURNAL OF PSYCHOLOGY LA English DT Article DE Culture; Family obligations; Parent-child relationships; Parental attitudes ID EUROPEAN BACKGROUNDS; CULTURAL-VALUES; LATIN-AMERICAN; ADOLESCENTS; IMMIGRANT; ATTITUDES; PARENTIFICATION; ACCULTURATION; ADAPTATION; STUDENTS AB Children's family obligations involve assistance and respect that children are expected to provide to immediate and extended family members and reflect beliefs related to family life that may differ across cultural groups. Mothers, fathers and children (N = 1432 families) in 13 cultural groups in 9 countries (China, Colombia, Italy, Jordan, Kenya, Philippines, Sweden, Thailand and United States) reported on their expectations regarding children's family obligations and parenting attitudes and behaviours. Within families, mothers and fathers had more concordant expectations regarding children's family obligations than did parents and children. Parenting behaviours that were warmer, less neglectful and more controlling as well as parenting attitudes that were more authoritarian were related to higher expectations regarding children's family obligations between families within cultures as well as between cultures. These international findings advance understanding of children's family obligations by contextualising them both within families and across a number of diverse cultural groups in 9 countries. C1 [Lansford, Jennifer E.; Godwin, Jennifer; Dodge, Kenneth A.; Malone, Patrick S.; Skinner, Ann T.] Duke Univ, Ctr Child & Family Policy, Box 90545, Durham, NC 27708 USA. [Pena Alampay, Liane] Ateneo Manila Univ, Dept Psychol, Quezon City, Philippines. [Uribe Tirado, Liliana Maria] Univ San Buenaventura, Consultorio Psicol Popular, Medellin, Colombia. [Zelli, Arnaldo] Univ Rome Foro Italico, Dept Educ Sci, Rome, Italy. [Al-Hassan, Suha M.] Hashemite Univ, Queen Rania Fac Childhood, Zarqa, Jordan. [Al-Hassan, Suha M.] Emirates Coll Adv Educ, Hlth & Special Educ Div, Abu Dhabi, U Arab Emirates. [Bacchini, Dario] Univ Naples 2, Dept Psychol, Caserta, Italy. [Bombi, Anna Silvia; Di Giunta, Laura; Pastorelli, Concetta] Univ Roma La Sapienza, Fac Psychol, Rome, Italy. [Bornstein, Marc H.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Child & Family Res Program Dev Neurosci, Bethesda, MD USA. [Chang, Lei] Hong Kong Inst Educ, Dept Psychol Studies, Hong Kong, Hong Kong, Peoples R China. [Deater-Deckard, Kirby] Virginia Polytech Inst & State Univ, Dept Psychol, Blacksburg, VA 24061 USA. [Oburu, Paul] Maseno Univ, Dept Educ Psychol, Maseno, Kenya. [Sorbring, Emma] Univ West, Dept Psychol, Trollhattan, Sweden. [Tapanya, Sombat] Chiang Mai Univ, Dept Psychiat, Chiang Mai, Thailand. RP Lansford, JE (reprint author), Duke Univ, Ctr Child & Family Policy, Box 90545, Durham, NC 27708 USA. EM lansford@duke.edu OI ZELLI, Arnaldo/0000-0003-4020-8159 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [RO1-HD054805]; Fogarty International Center [RO3-TW008141]; Intramural Research Program of the NIH/NICHD FX This research has been funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant RO1-HD054805 and Fogarty International Center grant RO3-TW008141. This research was also supported by the Intramural Research Program of the NIH/NICHD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or NICHD. Lansford designed the study and drafted the Introduction and Discussion sections of this article. Godwin conducted the statistical analyses and drafted the Methods and Results sections. All other authors contributed to the overall study design and data collection, provided critical feedback on the manuscript and approved the final submitted version. NR 25 TC 1 Z9 1 U1 5 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0020-7594 EI 1464-066X J9 INT J PSYCHOL JI Int. J. Psychol. PD OCT PY 2016 VL 51 IS 5 BP 366 EP 374 DI 10.1002/ijop.12185 PG 9 WC Psychology, Multidisciplinary SC Psychology GA DW4NV UT WOS:000383620900006 PM 26104262 ER PT J AU O'Brien, F Gormley, M AF O'Brien, Fearghal Gormley, Michael TI Risk-perception and dangerous driving among adolescents: Outcome- and behavior-focused questions yield opposite results SO JOURNAL OF ADOLESCENCE LA English DT Article DE Dangerous driving; Adolescence; Risk taking; Risk perception; Question focus ID YOUNG-ADULTS; SMOKING; AGE AB While some studies have found that those who perceive a behavior to be more risky are less likely to engage in it, others have found that those who engage in more risky behaviors see themselves as being more at-risk. Using an online questionnaire we investigated whether such conflicting findings may be due to the types of risk-questions employed in past studies. We assessed risk-perception using outcome-focused questions (e.g. the likelihood of being in an accident) and a behavior-focused question (the riskiness of speeding). Participants who reported engaging in more risky driving gave higher estimates of their chances of experiencing a negative outcome. However, those same participants gave lower estimates of the general riskiness of risky driving. Drivers may think about the risks of risky driving in different ways depending on the focus of the questions. Published by Elsevier Ltd on behalf of The Foundation for Professionals in Services for Adolescents. C1 [O'Brien, Fearghal] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, 6100 Execut Blvd, Bethesda, MD 20892 USA. [Gormley, Michael] Trinity Coll Dublin, Sch Psychol, Dublin 2, Ireland. RP O'Brien, F (reprint author), NICHHD, Div Intramural Populat Hlth Res, 6100 Execut Blvd,Room 7B13L, Bethesda, MD 20892 USA. EM obrienfk@tcd.ie FU School of Psychology, Trinity College, Dublin; Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development FX This research was supported by the School of Psychology, Trinity College, Dublin and by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 21 TC 0 Z9 0 U1 6 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0140-1971 EI 1095-9254 J9 J ADOLESCENCE JI J. Adolesc. PD OCT PY 2016 VL 52 BP 89 EP 94 DI 10.1016/j.adolescence.2016.07.010 PG 6 WC Psychology, Developmental SC Psychology GA DY0IO UT WOS:000384780700010 PM 27518903 ER PT J AU Yeboah, J Rodriguez, CJ Qureshi, W Liu, ST Carr, JJ Lima, JA Hundley, WG Herrington, DM AF Yeboah, Joseph Rodriguez, Carlos J. Qureshi, Waqas Liu, Songtao Carr, J. Jeffrey Lima, Joao A. Hundley, W. Gregory Herrington, David M. TI Prognosis of Low Normal Left Ventricular Ejection Fraction in an Asymptomatic Population-Based Adult Cohort: The Multiethnic Study of Atherosclerosis SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Low normal left ventricular ejection fraction; congestive heart failure; death; prognosis; prevalence ID HEART-FAILURE; MYOCARDIAL-INFARCTION; SYSTOLIC DYSFUNCTION; ETHNIC-MINORITIES; MANAGEMENT; TRIAL AB Background: Reduced left ventricular systolic function predicts worse outcomes. However, the optimal threshold for "normal" left ventricular ejection fraction (LVEF) is uncertain. In general, LVEF >= 55% is considered to be "normal" by guidelines, with a low normal designation for LVEF being 50%-55%. We assessed the prognosis of participants with low normal LVEF in the Multiethnic Study of Atherosclerosis. All participants were asymptomatic and had no known clinical cardiovascular disease at baseline. Methods and Results: A total of 4926 out of 6814 had LVEF assessed with the use of cardiac magnetic resonance imaging (MRI), had no significant valvular disease, did not have myocardial infarction during follow-up, had complete data, and were included in this analysis. A total of 83/4926 (1.7%) had LVEF <50% (low LVEF) and 101/4926 (2.1%) had low normal LVEF. Cox proportional hazard and cubic spline analyses were used to evaluate the association between LVEF category and 10 years of adjudicated incident congestive heart failure (CHF) and all-cause mortality adjusting for (model 1) age, sex, and race and (model 2) model 1 and diabetes mellitus, smoking, systolic blood pressure (BP), BP medications, body mass index, estimated glomerular filtration rate, low-density lipoprotein, family history of coronary heart disease, educational status, and LV mass. Mean age was 61 +/- 10 years, 47% were men, 35% were on BP medications, 9% had diabetes. After 10.2 years of follow-up, 109 (2.2%) had CHF and 427 (8.7%) died. Compared with normal LVEF (>= 55%), low normal LVEF and low LVEF were associated with an increased risk for incident CHF during follow-up in our multivariable Cox models: hazard ratios (HRs) 3.64 (95% CI 1.76-7.52) and 9.52 (5.63-17.52), respectively. Unlike low LVEF, low normal LVEF was not associated with increased risk of death compared with normal LVEF in our fully adjusted models: HRs 3.03 (1.94-1.73) and 1.32 (0.72-2.41), respectively. In the adjusted spline analysis HR of LVEF 55% as reference, LVEF had a U-shape association of future CHF risk and LVEF. Conclusion: Low normal LVEF is as prevalent as low LVEF in asymptomatic community-dwelling adults. We observed a gradient-response association between the 3 categories of LVEF (low, low normal, and normal) and incident CHF but not for all-cause death. C1 [Yeboah, Joseph; Rodriguez, Carlos J.; Qureshi, Waqas; Hundley, W. Gregory; Herrington, David M.] Wake Forest Univ, Sch Med, Heart & Vasc Ctr Excellence, Winston Salem, NC 27109 USA. [Yeboah, Joseph; Rodriguez, Carlos J.] Wake Forest Sch Med, Epidemiol & Prevent, Winston Salem, NC USA. [Liu, Songtao] NIH, Bldg 10, Bethesda, MD 20892 USA. [Carr, J. Jeffrey] Vanderbilt Univ, Sch Med, Cardiol & Radiol, Nashville, TN 37212 USA. [Lima, Joao A.] Johns Hopkins Univ, Cardiol & Radiol, Baltimore, MD USA. RP Yeboah, J (reprint author), Wake Forest Sch Med, Heart & Vasc C